Name,Term,ES,NES,NOM p-val,FDR q-val,FWER p-val,Tag %,Gene %,Lead_genes
prerank,GO_Biological_Process_2021__negative regulation of ATP metabolic process (GO:1903579),0.998075769520196,1.8666552714838482,0.04878048780487805,0.02696175065994407,0.024,1/16,0.20%,PPARA
prerank,GO_Biological_Process_2021__maturation of 5.8S rRNA (GO:0000460),-0.9866942985748978,-1.8346355277980246,0.13953488372093023,0.18343938860199419,0.204,1/17,1.34%,RRP15
prerank,GO_Biological_Process_2021__establishment of apical/basal cell polarity (GO:0035089),0.9857719774055174,1.7947205696232165,0.14814814814814814,0.41341351011914246,0.52,1/15,1.43%,CAMSAP3
prerank,GO_Biological_Process_2021__base conversion or substitution editing (GO:0016553),0.9853864902507585,1.7899754455783476,0.1721311475409836,0.3445112584326187,0.608,1/15,1.46%,A1CF
prerank,Reactome_2022__Metabolism Of Nitric Oxide: NOS3 Activation And Regulation R-HSA-202131,-0.9905020814004455,-1.7798954430455665,0.09848484848484848,0.45683463122996626,0.668,1/15,0.96%,ZDHHC21
prerank,Reactome_2022__cGMP Effects R-HSA-418457,-0.9758163447007295,-1.7702865556281253,0.328125,0.37628592533742394,0.748,3/15,2.43%,PDE5A;PDE11A;IRAG1
prerank,GO_Biological_Process_2021__regulation of voltage-gated calcium channel activity (GO:1901385),0.9790044639082836,1.7627026563790786,0.28888888888888886,0.5527158885288534,0.836,3/18,2.11%,DRD4;GNB5;GPR35
prerank,TRRUST_Transcription_Factors_2019__GLI1 human,-0.996960153163671,-1.7440036901656282,0.03125,0.5282701623682429,0.912,1/16,0.31%,TNFRSF10B
prerank,Elsevier_Pathway_Collection__Myocyte Dysfunction in Hypoparathyroidism,0.9914248003721626,1.7330621613109718,0.08870967741935484,0.8591811210302177,0.98,1/15,0.86%,PTK2
prerank,GO_Biological_Process_2021__positive regulation of alpha-beta T cell proliferation (GO:0046641),0.9874631530153852,1.7313469574528835,0.16,0.7534311434417704,0.988,1/16,1.26%,SYK
prerank,WikiPathway_2021_Human__Nephrogenesis WP5052,-0.9861957414274617,-1.7285810278003084,0.2196969696969697,0.7013028933476239,0.988,1/15,1.39%,MEIS1
prerank,Elsevier_Pathway_Collection__Aldosterone Renal Effects,-0.9911170209639134,-1.7283331940672972,0.08547008547008547,0.5054662273840664,0.988,2/17,0.90%,NR3C1;WNK3
prerank,Elsevier_Pathway_Collection__Aldosterone Signaling in Arterial Hypertension,-0.9911170209639134,-1.7283331940672972,0.08547008547008547,0.5054662273840664,0.988,2/17,0.90%,NR3C1;WNK3
prerank,GO_Biological_Process_2021__response to nutrient levels (GO:0031667),0.9890021113242176,1.72575194816869,0.1417910447761194,0.7671260009198373,0.992,1/15,1.10%,PRKAA2
prerank,TRRUST_Transcription_Factors_2019__ATF3 human,-0.9807737501914646,-1.7208051857967834,0.25757575757575757,0.5441447248434154,0.992,1/15,1.93%,MMP2
prerank,Reactome_2022__GRB2 Events In ERBB2 Signaling R-HSA-1963640,-0.9848114508504071,-1.719303431259761,0.2125984251968504,0.498186886566527,0.992,1/15,1.53%,NRG1
prerank,Elsevier_Pathway_Collection__NO Synthesis in Early Vasospasm,-0.9864659309338241,-1.7141045543710682,0.1440677966101695,0.5160996644706106,0.992,2/15,1.36%,PDE5A;HRH2
prerank,Elsevier_Pathway_Collection__Wolfram Syndrome Progression (Hypothesis),0.9989213428329222,1.7136399561893558,0.008928571428571428,0.9414144605430472,0.996,1/17,0.11%,ERN1
prerank,GO_Biological_Process_2021__negative regulation of cytokine production involved in immune response (GO:0002719),-0.9765034731703787,-1.7109260817754781,0.31932773109243695,0.5028548274963757,0.992,1/17,2.36%,IRAK3
prerank,Elsevier_Pathway_Collection__BMP2 and Canonical WNT Signaling in Pulmonary Artery Endothelial Cells,0.9956914149140816,1.7054380933030946,0.05511811023622047,1.0,0.996,1/19,0.43%,LRP5
prerank,Elsevier_Pathway_Collection__IL33 Signaling Related Eosinophilia in Asthma,-0.9978066247741119,-1.6974658897920574,0.017241379310344827,0.6329246853527138,1.0,1/16,0.23%,MAP2K6
prerank,Elsevier_Pathway_Collection__AGER -> CREB/SP1 Signaling,0.9957686018584814,1.6972072738540056,0.06779661016949153,1.0,1.0,1/17,0.43%,CREB1
prerank,GO_Biological_Process_2021__embryonic axis specification (GO:0000578),0.9765809459564716,1.6963020569449239,0.36065573770491804,1.0,1.0,1/16,2.34%,TBX3
prerank,Reactome_2022__Activation Of IRF3/IRF7 Mediated By TBK1/IKK Epsilon R-HSA-936964,0.9979219942002935,1.6898889353259712,0.0,1.0,1.0,1/16,0.21%,TRAF3
prerank,GO_Biological_Process_2021__positive regulation of fatty acid metabolic process (GO:0045923),0.998075505593879,1.689484246445814,0.022556390977443608,1.0,1.0,1/17,0.20%,PPARA
prerank,GO_Biological_Process_2021__retrograde axonal transport (GO:0008090),-0.9812713124931827,-1.687252943790537,0.23357664233576642,0.7261594732232788,1.0,1/16,1.88%,DLG2
prerank,Elsevier_Pathway_Collection__DNA Replication in DNA Machinery,0.9981147579083345,1.6858437855127328,0.024193548387096774,1.0,1.0,1/15,0.19%,CDC45
prerank,Elsevier_Pathway_Collection__WNT Signaling in Hepatocellular Carcinoma,0.9956926579627332,1.6855892552811316,0.058823529411764705,0.9915932742712765,1.0,1/15,0.43%,LRP5
prerank,Elsevier_Pathway_Collection__TGFBR -> AP-1 Signaling,-0.9978069769757166,-1.684015531108234,0.023255813953488372,0.7256942845793176,1.0,1/16,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of ATP biosynthetic process (GO:2001169),0.9980757656958468,1.6830710193732816,0.022556390977443608,0.9936528524466889,1.0,1/15,0.20%,PPARA
prerank,WikiPathway_2021_Human__Transcription co-factors SKI and SKIL protein partners WP4533,0.9814620136048651,1.6820663243395013,0.3170731707317073,0.9560848248727226,1.0,1/18,1.86%,TEAD4
prerank,WikiPathway_2021_Human__Mammary gland development pathway - Embryonic development (Stage 1 of 4) WP2813,0.9829649239353843,1.6813882464886214,0.2727272727272727,0.9176981057958742,1.0,1/15,1.71%,CDH1
prerank,GO_Biological_Process_2021__detection of mechanical stimulus (GO:0050982),0.9914634553829915,1.6812398360045115,0.14393939393939395,0.874601350355028,1.0,2/16,0.86%,CDH2;PTK2
prerank,Reactome_2022__Signaling By Activin R-HSA-1502540,-0.9851182616287375,-1.680674994909929,0.2204724409448819,0.7344630905179844,1.0,1/15,1.49%,INHBB
prerank,GO_Biological_Process_2021__peptidyl-tyrosine autophosphorylation (GO:0038083),-0.9941166846388503,-1.6801046699351596,0.046511627906976744,0.6971578687013289,1.0,2/15,0.60%,PTK2B;TEC
prerank,GO_Biological_Process_2021__cellular response to sterol (GO:0036315),-0.9806959516908457,-1.67844983812091,0.3055555555555556,0.6903878347045641,1.0,1/15,1.94%,RORC
prerank,GO_Biological_Process_2021__regulation of tissue remodeling (GO:0034103),-0.976427623949853,-1.6778356869699647,0.36220472440944884,0.6602642096155112,1.0,2/18,2.37%,THBS4;SYT7
prerank,TRRUST_Transcription_Factors_2019__ESR2 human,0.9793492873945129,1.6770699935679958,0.28448275862068967,0.9160254786715999,1.0,1/16,2.07%,SERPINE1
prerank,KEGG_2021_Human__Primary bile acid biosynthesis,-0.9978833199153636,-1.6766026294407168,0.05511811023622047,0.6435231992859431,1.0,1/17,0.22%,CYP39A1
prerank,GO_Biological_Process_2021__basement membrane organization (GO:0071711),-0.9918866487467151,-1.6748172622437372,0.10569105691056911,0.6339241948418916,1.0,2/16,0.82%,FLRT2;NTN4
prerank,Reactome_2022__KSRP (KHSRP) Binds And Destabilizes mRNA R-HSA-450604,0.9919623578574093,1.6739961567448312,0.08547008547008547,0.9329621656933027,1.0,1/17,0.81%,PARN
prerank,Elsevier_Pathway_Collection__Myeloid Progenitor Cell -> GEMM - CFU Surface Expression Markers,0.9965374875286539,1.6735178583934787,0.02564102564102564,0.8995420447454068,1.0,1/17,0.35%,CD33
prerank,Elsevier_Pathway_Collection__AHR in Intestinal Cell Antimicrobial Barrier Maintenance,-0.9806948030180672,-1.67298084062876,0.25984251968503935,0.6378382404045531,1.0,1/16,1.94%,RORC
prerank,Elsevier_Pathway_Collection__NCAM1 -> CREB/ELK/SRF/MYC Signaling,0.9914639054771652,1.6703708571735052,0.09322033898305085,0.914355022380712,1.0,2/15,0.86%,CREB1;PTK2
prerank,GO_Biological_Process_2021__detection of visible light (GO:0009584),0.9820034612031459,1.6698627831813053,0.2833333333333333,0.8854313810477467,1.0,1/15,1.80%,CACNA2D4
prerank,GO_Biological_Process_2021__regulation of presynapse assembly (GO:1905606),-0.9803902802784362,-1.6698323376689947,0.30952380952380953,0.6290007798133597,1.0,2/16,1.97%,APP;SLITRK3
prerank,GO_Biological_Process_2021__regulation of presynapse organization (GO:0099174),-0.9803902802784362,-1.6698323376689947,0.30952380952380953,0.6290007798133597,1.0,2/16,1.97%,APP;SLITRK3
prerank,GO_Biological_Process_2021__positive regulation of endothelial cell apoptotic process (GO:2000353),0.9878860362439104,1.6696670458913432,0.13559322033898305,0.8530697908806304,1.0,1/16,1.21%,ITGA4
prerank,Reactome_2022__Vitamin B5 (Pantothenate) Metabolism R-HSA-199220,-0.9932693896636351,-1.6693183956475273,0.07377049180327869,0.6101417484670495,1.0,1/17,0.68%,VNN1
prerank,WikiPathway_2021_Human__ACE Inhibitor Pathway WP554,-0.9799265193657115,-1.6688081512180002,0.26229508196721313,0.5923681179624396,1.0,1/15,2.01%,BDKRB2
prerank,GO_Biological_Process_2021__diol metabolic process (GO:0034311),-0.9946924423091367,-1.6680843002683818,0.08148148148148149,0.5811175306082405,1.0,2/19,0.54%,PLPP1;SGPP1
prerank,Reactome_2022__Phase 4 - Resting Membrane Potential R-HSA-5576886,-0.9836940858363236,-1.667774086728113,0.205607476635514,0.5641675783357628,1.0,1/16,1.64%,KCNK6
prerank,GO_Biological_Process_2021__regulation of phospholipase C activity (GO:1900274),-0.982004599905767,-1.6676886539398748,0.2727272727272727,0.5454046107541435,1.0,1/15,1.81%,NTF3
prerank,WikiPathway_2021_Human__TCA Cycle and Deficiency of Pyruvate Dehydrogenase complex (PDHc) WP2453,-0.9987291750487388,-1.6675464928723498,0.013793103448275862,0.5281789292505694,1.0,1/16,0.13%,SUCLG2
prerank,Elsevier_Pathway_Collection__BMP2 and WNT Signaling in Pulmonary Artery Smooth Muscle Cells,0.9773883899540385,1.6656631897499738,0.3620689655172414,0.8914660891281507,1.0,2/19,2.27%,LRP5;FN1
prerank,Reactome_2022__Acetylcholine Neurotransmitter Release Cycle R-HSA-264642,0.9765073762217527,1.6651061111393581,0.3652173913043478,0.8667703545493131,1.0,2/15,2.36%,PPFIA4;STX1A
prerank,GO_Biological_Process_2021__nucleobase-containing small molecule catabolic process (GO:0034656),-0.9789679830190999,-1.6634356982666105,0.26229508196721313,0.5614891542144373,1.0,2/15,2.11%,ENTPD8;ENTPD3
prerank,GO_Biological_Process_2021__regulation of hippo signaling (GO:0035330),0.9918472332755541,1.6610712165040824,0.10526315789473684,0.9081937320513305,1.0,3/19,0.83%,WWC2;VGLL4;NEK8
prerank,Elsevier_Pathway_Collection__RNA and DNA Metabolism Dysregulation,0.9912328096497824,1.659235549821392,0.15315315315315314,0.9061627463181202,1.0,1/15,0.88%,DROSHA
prerank,Elsevier_Pathway_Collection__Myostatin in Skeletal Muscles in Muscular Dystrophies,-0.9764246628725939,-1.6578566669724575,0.36054421768707484,0.6140440080002237,1.0,1/17,2.36%,FBXO32
prerank,GO_Biological_Process_2021__regulation of extracellular matrix disassembly (GO:0010715),0.976123268875691,1.657237249007484,0.4016393442622951,0.908461209736449,1.0,2/15,2.39%,CARMIL2;MELTF
prerank,GO_Biological_Process_2021__aromatic amino acid family catabolic process (GO:0009074),-0.9796570805450308,-1.6565696406179535,0.2971014492753623,0.6124935355004084,1.0,1/16,2.04%,AADAT
prerank,TRRUST_Transcription_Factors_2019__WT1 mouse,0.9835791644536569,1.6564748678738515,0.1875,0.89075246131912,1.0,1/16,1.64%,AMH
prerank,GO_Biological_Process_2021__negative regulation of release of cytochrome c from mitochondria (GO:0090201),0.9772350891960373,1.6540576353364496,0.368,0.8967590610125148,1.0,1/15,2.28%,HGF
prerank,GO_Biological_Process_2021__glutamine family amino acid catabolic process (GO:0009065),0.984770606435176,1.6533339474029005,0.2248062015503876,0.8784356237742384,1.0,1/16,1.53%,GLS
prerank,GO_Biological_Process_2021__regulation of telomere maintenance via telomere lengthening (GO:1904356),-0.9865031522477132,-1.6531637834748687,0.17037037037037037,0.6365859901660113,1.0,2/17,1.36%,TNKS;SMG6
prerank,TRRUST_Transcription_Factors_2019__FOXM1 human,0.9801592214493163,1.653118597760976,0.33613445378151263,0.8569607415641047,1.0,3/17,1.99%,BRIP1;CDH1;APOE
prerank,GO_Biological_Process_2021__neuron projection organization (GO:0106027),-0.9919242451628011,-1.6513848486599962,0.1968503937007874,0.6422453707275703,1.0,1/15,0.81%,APP
prerank,WikiPathway_2021_Human__ERK Pathway in Huntington's Disease WP3853,0.9901180365798274,1.6505784931658398,0.13432835820895522,0.8647018604510633,1.0,2/15,1.00%,CREB1;CASP7
prerank,Elsevier_Pathway_Collection__Frizzled Receptors -> ARRB1/ARRB2 Canonical Signaling,0.9956921788061469,1.6479999605687323,0.09090909090909091,0.8733859692945771,1.0,1/16,0.43%,LRP5
prerank,Elsevier_Pathway_Collection__Vascularization in Hepatocellular Carcinoma,0.9772337600502041,1.6476995894701567,0.375,0.8552461628257935,1.0,1/17,2.28%,HGF
prerank,Elsevier_Pathway_Collection__Disorders of Phenylalanine and Tyrosine Metabolism,0.9831189636935301,1.6461818569006639,0.28205128205128205,0.849768158957711,1.0,1/15,1.69%,PAH
prerank,Elsevier_Pathway_Collection__Glutamate Mediated Excitotoxicity in Amyotrophic Lateral Sclerosis,-0.9903097299111457,-1.6452085531434404,0.1076923076923077,0.709769326667716,1.0,1/15,0.98%,SOD2
prerank,WikiPathway_2021_Human__Deregulation of Rab and Rab Effector Genes in Bladder Cancer WP2291,-0.9926543431723093,-1.6446570071028344,0.12403100775193798,0.6977948110228637,1.0,1/16,0.74%,MYRIP
prerank,TRRUST_Transcription_Factors_2019__FOXA2 human,0.9829641194584116,1.6440760170084174,0.31896551724137934,0.8544800978382274,1.0,1/15,1.71%,CDH1
prerank,Elsevier_Pathway_Collection__Adipose Tissue Inflammation Provokes Insulin Resistance,-0.9854263833791687,-1.6432437303946528,0.17699115044247787,0.7023898003279061,1.0,1/15,1.46%,LIPE
prerank,GO_Biological_Process_2021__snRNA processing (GO:0016180),-0.9763509797357427,-1.6430482735692635,0.3893129770992366,0.6867837028732555,1.0,1/16,2.37%,INTS7
prerank,Reactome_2022__Synthesis Of Bile Acids And Bile Salts Via 27-Hydroxycholesterol R-HSA-193807,-0.9922706868432604,-1.6425219885940352,0.07317073170731707,0.6763196787855574,1.0,1/15,0.78%,NCOA1
prerank,Reactome_2022__Early Phase Of HIV Life Cycle R-HSA-162594,0.9776227169453481,1.6413715568913605,0.375,0.8660338993229535,1.0,2/15,2.24%,CD4;LRIG1
prerank,Elsevier_Pathway_Collection__Exocytosis: Vesicle Fusion,0.9764661482072187,1.6411180830460717,0.4017857142857143,0.848966343950922,1.0,1/16,2.36%,STX1A
prerank,Elsevier_Pathway_Collection__P-cell Activation,-0.9864265842120563,-1.6383335485195072,0.22142857142857142,0.7200877922765782,1.0,1/15,1.36%,HRH2
prerank,GO_Biological_Process_2021__negative regulation of tumor necrosis factor-mediated signaling pathway (GO:0010804),0.9943079526296844,1.6382649380696421,0.05217391304347826,0.8614921282296416,1.0,1/15,0.57%,PTPN2
prerank,Elsevier_Pathway_Collection__NTRK1/2/3 -> Acetylcholine Production,-0.9820443111795272,-1.6381127463680267,0.23529411764705882,0.7049338230844927,1.0,2/15,1.81%,PTK2B;NTF3
prerank,GO_Biological_Process_2021__positive regulation of exosomal secretion (GO:1903543),0.991616434374372,1.6379523783305345,0.16153846153846155,0.8453240352259209,1.0,1/15,0.84%,RAB7A
prerank,GO_Biological_Process_2021__negative regulation of double-strand break repair via homologous recombination (GO:2000042),0.9888476355957297,1.6374314389001827,0.10714285714285714,0.8335674579032709,1.0,1/18,1.12%,SMCHD1
prerank,GO_Biological_Process_2021__telomere capping (GO:0016233),0.9785441060893558,1.6350970348763263,0.328,0.8466988290580214,1.0,2/17,2.15%,DCLRE1C;ACD
prerank,GO_Biological_Process_2021__cellular biogenic amine biosynthetic process (GO:0042401),0.9831594130291699,1.6347087212650802,0.25203252032520324,0.8352281454439195,1.0,2/15,1.69%,SMOX;PAH
prerank,GO_Biological_Process_2021__ruffle organization (GO:0031529),-0.9982670999917419,-1.6339719698912154,0.04838709677419355,0.7517319267343625,1.0,1/17,0.18%,CARMIL1
prerank,Reactome_2022__CRMPs In Sema3A Signaling R-HSA-399956,0.9779299054155576,1.6329612996085627,0.35537190082644626,0.8424112945559121,1.0,2/15,2.21%,DPYSL2;DPYSL3
prerank,Elsevier_Pathway_Collection__TLR3 Role in Retinal Pigment Epithelial Cell,-0.9903094767664745,-1.6328937969686683,0.13846153846153847,0.749919253672106,1.0,1/15,0.98%,SOD2
prerank,Reactome_2022__Initiation Of Nuclear Envelope (NE) Reformation R-HSA-2995383,-0.9998442294130052,-1.6328575963900298,0.0,0.7334368561761552,1.0,1/19,0.02%,VRK2
prerank,Elsevier_Pathway_Collection__Somatostatin Receptors Signaling,0.9818501442383463,1.6321128109400809,0.30597014925373134,0.8362823564072236,1.0,2/18,1.82%,CREB1;PTGS2
prerank,Reactome_2022__Triglyceride Catabolism R-HSA-163560,-0.9854239794218019,-1.6316363487077015,0.21428571428571427,0.7354821982324399,1.0,1/18,1.46%,LIPE
prerank,GO_Biological_Process_2021__hyaluronan catabolic process (GO:0030214),-0.9824247202684167,-1.6311899359511886,0.2764227642276423,0.7257819288165858,1.0,1/17,1.76%,CD44
prerank,GO_Biological_Process_2021__regulation of NLRP3 inflammasome complex assembly (GO:1900225),0.9883488308267107,1.6307243861899916,0.19008264462809918,0.8370064567119372,1.0,1/15,1.17%,MEFV
prerank,GO_Biological_Process_2021__mitochondrial fusion (GO:0008053),-0.9994214738626402,-1.6292365358275702,0.007462686567164179,0.7402875162771968,1.0,1/18,0.07%,CHCHD3
prerank,Reactome_2022__Fertilization R-HSA-1187000,-0.9775839769041184,-1.6282556609392416,0.36923076923076925,0.7384611284746945,1.0,3/16,2.26%,CATSPER3;ADAM20;CD9
prerank,Elsevier_Pathway_Collection__RET1 Mutation in Hyperparathyroidism,0.9914616392877357,1.628105862375021,0.05128205128205128,0.8553166034356257,1.0,2/21,0.86%,CREB1;PTK2
prerank,Elsevier_Pathway_Collection__Insulin Secretion,0.9798118691636959,1.6280710978278952,0.3492063492063492,0.8385456896427703,1.0,2/18,2.02%,CREB1;CPE
prerank,Elsevier_Pathway_Collection__IFNLR1-> STAT/NFKB Signaling,-0.9802742123868313,-1.627928021800325,0.2966101694915254,0.7279980759589345,1.0,2/16,1.98%,STAT5A;IL10RA
prerank,Elsevier_Pathway_Collection__IFN-gamma/TNF-alpha Mediated Cell Proliferation in Psoriasis,-0.9795752604979701,-1.6267009431757133,0.36585365853658536,0.7321348213549591,1.0,1/21,2.05%,KLF4
prerank,GO_Biological_Process_2021__response to ATP (GO:0033198),0.9796923858366354,1.6265191165628607,0.3284671532846715,0.8426411239907521,1.0,1/18,2.03%,TRPV1
prerank,Reactome_2022__Processing Of SMDT1 R-HSA-8949664,0.997191758939329,1.624722337432576,0.04310344827586207,0.8544670539336991,1.0,1/15,0.28%,MICU1
prerank,TRRUST_Transcription_Factors_2019__MYB mouse,0.9818106740325013,1.6246727789558435,0.3238095238095238,0.8390596663710372,1.0,1/15,1.82%,PTGS2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Cryptorchidism,0.9835802820119528,1.6241892828045665,0.26666666666666666,0.8295231953042793,1.0,1/15,1.64%,AMH
prerank,GO_Biological_Process_2021__chromatin disassembly (GO:0031498),-0.9906169181186967,-1.6231819874388143,0.12698412698412698,0.7538381975389643,1.0,1/16,0.95%,ARID2
prerank,GO_Biological_Process_2021__nucleosome disassembly (GO:0006337),-0.9906169181186967,-1.6231819874388143,0.12698412698412698,0.7538381975389643,1.0,1/16,0.95%,ARID2
prerank,GO_Biological_Process_2021__negative regulation of cation transmembrane transport (GO:1904063),0.9767366267089682,1.6226553043320622,0.4247787610619469,0.8359747570693373,1.0,2/17,2.33%,CAB39;SLC43A1
prerank,Reactome_2022__Constitutive Signaling By NOTCH1 HD Domain Mutants R-HSA-2691232,-0.9965380040527867,-1.6224947276749155,0.061068702290076333,0.7484007566911547,1.0,1/15,0.35%,ADAM10
prerank,Elsevier_Pathway_Collection__Leptin in Insulin Synthesis and Secretion,-0.9803859055084987,-1.6205282085138504,0.3106060606060606,0.7664865906222215,1.0,1/17,1.97%,SH2B2
prerank,Elsevier_Pathway_Collection__Sperm Motility Impairement in Testicular Male Infertility,-0.9976144484950243,-1.6194549334882122,0.022058823529411766,0.7679439859201665,1.0,1/15,0.25%,CATSPER3
prerank,GO_Biological_Process_2021__protein localization to microtubule organizing center (GO:1905508),-0.9974222246525047,-1.618894904961201,0.025,0.7612860615573832,1.0,1/16,0.27%,CCDC14
prerank,WikiPathway_2021_Human__MFAP5 effect on permeability and motility of endothelial cells via cytoskeleton rearrangement WP4560,0.9915019769816238,1.6178203735251115,0.1171875,0.8913933178713087,1.0,3/17,0.86%,TJP1;CREB1;PTK2
prerank,Elsevier_Pathway_Collection__Complement Cascade Activation by Pentraxins,-0.9919627042665764,-1.6170868849073885,0.07317073170731707,0.7733047100478804,1.0,2/18,0.81%,C4BPA;APP
prerank,GO_Biological_Process_2021__mesenchyme development (GO:0060485),-0.9850421602721665,-1.6158188713475439,0.24806201550387597,0.7771845184205177,1.0,1/15,1.50%,BMP4
prerank,KEGG_2021_Human__Pantothenate and CoA biosynthesis,-0.9929230295732836,-1.6154162315819145,0.0873015873015873,0.7703497662151542,1.0,2/21,0.72%,VNN1;DPYS
prerank,MSigDB_Oncogenic_Signatures__HINATA NFKB IMMU INF,-0.9790058404952536,-1.6150856368339546,0.3418803418803419,0.7619789988082835,1.0,2/16,2.11%,TNFAIP2;CD83
prerank,GO_Biological_Process_2021__myoblast differentiation (GO:0045445),-0.9848511344385753,-1.6144291230325802,0.22764227642276422,0.7585091490869343,1.0,2/15,1.53%,RB1;NRG1
prerank,Elsevier_Pathway_Collection__Hedgehog Family -> ARRB1/ARRB2 Canonical Signaling,-0.985849837935949,-1.6143188607734047,0.24615384615384617,0.7478113785347426,1.0,2/16,1.43%,SUFU;SHH
prerank,GO_Biological_Process_2021__sphingolipid catabolic process (GO:0030149),-0.9792754702256821,-1.6131014224311835,0.3225806451612903,0.7544196833439157,1.0,2/16,2.08%,SGPL1;SMPD1
prerank,GO_Biological_Process_2021__neutrophil activation (GO:0042119),0.9875039974326063,1.6130953431015915,0.20689655172413793,0.9551277647580186,1.0,2/15,1.26%,LILRA2;SYK
prerank,GO_Biological_Process_2021__synaptic vesicle transport along microtubule (GO:0099517),-0.9888497311918162,-1.6127052862983131,0.1590909090909091,0.736362610814159,1.0,2/15,1.13%,AP3B1;DTNBP1
prerank,GO_Biological_Process_2021__anterograde synaptic vesicle transport (GO:0048490),-0.9888497311918162,-1.6127052862983131,0.1590909090909091,0.736362610814159,1.0,2/15,1.13%,AP3B1;DTNBP1
prerank,GO_Biological_Process_2021__aflatoxin metabolic process (GO:0046222),-0.9803135684972006,-1.6123880453614534,0.328125,0.7091675458680037,1.0,2/15,1.98%,AKR7A3;CYP1A2
prerank,GO_Biological_Process_2021__mycotoxin metabolic process (GO:0043385),-0.9803135684972006,-1.6123880453614534,0.328125,0.7091675458680037,1.0,2/15,1.98%,AKR7A3;CYP1A2
prerank,GO_Biological_Process_2021__organic heteropentacyclic compound metabolic process (GO:1901376),-0.9803135684972006,-1.6123880453614534,0.328125,0.7091675458680037,1.0,2/15,1.98%,AKR7A3;CYP1A2
prerank,GO_Biological_Process_2021__purine ribonucleotide transport (GO:0015868),0.9853890633903672,1.6123876200141365,0.24615384615384617,0.9496781609571825,1.0,2/15,1.47%,SLC19A1;LRRC8C
prerank,Elsevier_Pathway_Collection__Insulin Influence on Lipogenesis,-0.9913860140270532,-1.6123627356856178,0.09836065573770492,0.6991453843735425,1.0,1/15,0.87%,TBC1D4
prerank,GO_Biological_Process_2021__snRNA 3'-end processing (GO:0034472),-0.9763456003674176,-1.6121660224601446,0.4032258064516129,0.6914253878075166,1.0,1/20,2.37%,INTS7
prerank,Elsevier_Pathway_Collection__Retinal Ganglion and Suprachiasmatic Nucleus in Melatonin Synthesis Regulation,0.9848125060398956,1.6119914741625936,0.2719298245614035,0.9405906292728823,1.0,2/15,1.53%,CREB1;GLS
prerank,GO_Biological_Process_2021__regulation of smooth muscle cell migration (GO:0014910),0.9793865694767052,1.6118578717178031,0.3305084745762712,0.9272337583516832,1.0,2/20,2.07%,IGFBP3;SERPINE1
prerank,Reactome_2022__Apoptotic Factor-Mediated Response R-HSA-111471,0.9770030047184708,1.611592278154443,0.39655172413793105,0.9169894337355172,1.0,2/20,2.31%,CASP7;UACA
prerank,WikiPathway_2021_Human__Metabolism of Spingolipids in ER and Golgi apparatus WP4142,-0.9899241982455036,-1.611505588067717,0.18461538461538463,0.6905807319011693,1.0,2/19,1.02%,SGPP1;SGPL1
prerank,GO_Biological_Process_2021__positive regulation of lymphocyte chemotaxis (GO:0140131),-0.9965771307451977,-1.6109466252034839,0.03816793893129771,0.6880446939470631,1.0,2/15,0.35%,PTK2B;ADAM10
prerank,TRRUST_Transcription_Factors_2019__BCL3 mouse,-0.9764289548275018,-1.6097934135718464,0.39316239316239315,0.6933100390602768,1.0,1/15,2.36%,FBXO32
prerank,GO_Biological_Process_2021__positive regulation of cytokine production involved in inflammatory response (GO:1900017),0.9910393870473572,1.6096739874991794,0.13194444444444445,0.9341747311991733,1.0,1/16,0.90%,NOD2
prerank,Elsevier_Pathway_Collection__SWI/SNF BRG1/BAF in Chromatin Remodeling,-0.9968462005563411,-1.6092600149367338,0.06569343065693431,0.6902812751966932,1.0,1/15,0.32%,NR3C1
prerank,KEGG_2021_Human__Folate biosynthesis,0.9831092986599352,1.608678270850692,0.24193548387096775,0.9346740228780612,1.0,1/24,1.69%,PAH
prerank,GO_Biological_Process_2021__nucleoside diphosphate metabolic process (GO:0009132),-0.9789670467532741,-1.6080147302655465,0.27049180327868855,0.6958937831708986,1.0,2/16,2.11%,ENTPD8;ENTPD3
prerank,GO_Biological_Process_2021__acyl-CoA biosynthetic process (GO:0071616),0.9965765481276552,1.6056812028998555,0.08130081300813008,0.970000829511988,1.0,1/17,0.35%,ACACA
prerank,WikiPathway_2021_Human__Cells and molecules involved in local acute inflammatory response  WP4493,0.9863493935992029,1.6053404036871028,0.2283464566929134,0.9612272621643696,1.0,2/16,1.37%,ITGA4;ITGAL
prerank,GO_Biological_Process_2021__preassembly of GPI anchor in ER membrane (GO:0016254),-0.9853120113663524,-1.6047515879653629,0.24822695035460993,0.7266557764585575,1.0,2/16,1.48%,PIGX;PIGZ
prerank,GO_Biological_Process_2021__regulation of adaptive immune response (GO:0002819),0.982885382746169,1.6045082574250262,0.21487603305785125,0.9613004283805432,1.0,1/18,1.71%,SAMSN1
prerank,Reactome_2022__Processing Of Capped Intron-Containing Pre-mRNA R-HSA-72203,0.986419338659972,1.6036083470525995,0.0,0.9631556761487374,1.0,4/239,1.36%,PRPF40A;CDC5L;NUP210;SF3A2
prerank,GO_Biological_Process_2021__acetyl-CoA metabolic process (GO:0006084),0.9965765126885843,1.6034197753103898,0.06015037593984962,0.9524531483132417,1.0,1/15,0.35%,ACACA
prerank,GO_Biological_Process_2021__negative regulation of telomere maintenance (GO:0032205),-0.9865043398791026,-1.6027868982300661,0.22900763358778625,0.7413168698723446,1.0,2/15,1.36%,TNKS;SMG6
prerank,GO_Biological_Process_2021__regulation of ERBB signaling pathway (GO:1901184),-0.976352635169359,-1.6024530082869282,0.4132231404958678,0.7356118480304328,1.0,2/16,2.37%,PTPN18;IFI6
prerank,GO_Biological_Process_2021__positive regulation of neural precursor cell proliferation (GO:2000179),0.9856935072176198,1.6023685152943568,0.1794871794871795,0.9554088930284466,1.0,2/20,1.44%,CX3CL1;PROX1
prerank,WikiPathway_2021_Human__Regulation of sister chromatid separation at the metaphase-anaphase transition WP4240,0.9961536846129015,1.6021285005166217,0.09016393442622951,0.9453701164497291,1.0,1/15,0.39%,CENPE
prerank,GO_Biological_Process_2021__negative regulation of peptide hormone secretion (GO:0090278),-0.985118110232688,-1.6020738647265529,0.16153846153846155,0.7309443408047817,1.0,1/16,1.49%,INHBB
prerank,GO_Biological_Process_2021__NLS-bearing protein import into nucleus (GO:0006607),-0.9959600533561855,-1.6017803702090398,0.07692307692307693,0.7249383530328809,1.0,1/18,0.41%,KPNA3
prerank,GO_Biological_Process_2021__regulation of nuclear-transcribed mRNA poly(A) tail shortening (GO:0060211),-0.9982293172072476,-1.6017244478976838,0.015625,0.7166417709985314,1.0,1/15,0.18%,CPEB3
prerank,GO_Biological_Process_2021__insulin secretion (GO:0030073),0.9836543655365895,1.601721021865525,0.23684210526315788,0.9375449500316664,1.0,1/18,1.64%,ANXA1
prerank,Elsevier_Pathway_Collection__Alternative Lengthening of Telomeres in Cancer,0.9898480755316169,1.6013715062309362,0.15315315315315314,0.9298726152262904,1.0,1/16,1.02%,ATR
prerank,GO_Biological_Process_2021__water transport (GO:0006833),-0.9791574440965485,-1.6010436913604225,0.35833333333333334,0.715344782756557,1.0,1/16,2.09%,AQP3
prerank,GO_Biological_Process_2021__negative regulation of anoikis (GO:2000811),0.9911559622105685,1.6007773029878185,0.16279069767441862,0.92526170001254,1.0,2/16,0.89%,PTK2;ZNF304
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hutchinson-Gilford Progeria Sindrome,-0.9885405967797504,-1.6006968870665104,0.152,0.7114014101993,1.0,1/16,1.15%,RB1
prerank,Elsevier_Pathway_Collection__Deacetylases Activation in Histone Deacetylation in Cancer,0.996845795424253,1.6006606873205373,0.041666666666666664,0.9147223273897025,1.0,1/15,0.32%,HDAC8
prerank,GO_Biological_Process_2021__protein heterooligomerization (GO:0051291),-0.989309627586535,-1.6005732575896894,0.17886178861788618,0.7044022126880147,1.0,1/16,1.08%,GRIN2B
prerank,GO_Biological_Process_2021__cellular modified amino acid catabolic process (GO:0042219),-0.9915788720088289,-1.5998138699192759,0.15384615384615385,0.7056606163800242,1.0,2/16,0.85%,GGACT;GGT5
prerank,Elsevier_Pathway_Collection__WHIM Syndrome,0.9830432176966919,1.5991611868000877,0.25862068965517243,0.9252728861347912,1.0,2/16,1.70%,PTK2;GRK3
prerank,Reactome_2022__Peroxisomal Lipid Metabolism R-HSA-390918,0.9895725117522972,1.5991305860131364,0.1,0.9140150191256364,1.0,1/28,1.05%,SLC27A2
prerank,GO_Biological_Process_2021__negative regulation of protein localization to nucleus (GO:1900181),-0.985846359609,-1.598963031175927,0.19083969465648856,0.7082844192733975,1.0,1/19,1.42%,SUFU
prerank,GO_Biological_Process_2021__response to progesterone (GO:0032570),-0.9976139020713287,-1.5989512576988525,0.03076923076923077,0.7003054112610614,1.0,1/18,0.25%,CATSPER3
prerank,GO_Biological_Process_2021__intracellular estrogen receptor signaling pathway (GO:0030520),0.988078352867434,1.5987550498362675,0.19548872180451127,0.9065600606514527,1.0,1/16,1.20%,PADI2
prerank,GO_Biological_Process_2021__regulation of mitotic sister chromatid separation (GO:0010965),0.9826592269401098,1.598121418545586,0.2971014492753623,0.9031617657776202,1.0,3/16,1.74%,NEK6;CENPE;UBE2C
prerank,Elsevier_Pathway_Collection__Double Strand DNA non-Homologous Repair,0.9926533075562141,1.597672968795296,0.14285714285714285,0.8874077439433443,1.0,1/20,0.74%,DCLRE1C
prerank,Elsevier_Pathway_Collection__Persistent Double Strand DNA non-Homologous Repair in Cancer,0.9926533075562141,1.597672968795296,0.14285714285714285,0.8874077439433443,1.0,1/20,0.74%,DCLRE1C
prerank,GO_Biological_Process_2021__positive regulation of monocyte chemotaxis (GO:0090026),0.9793901103996638,1.5970567226167378,0.3464566929133858,0.8858469500365771,1.0,2/16,2.07%,MOSPD2;SERPINE1
prerank,GO_Biological_Process_2021__regulation of nervous system process (GO:0031644),-0.9919235405858282,-1.5969940483846836,0.11851851851851852,0.7152372315202754,1.0,1/18,0.81%,APP
prerank,Reactome_2022__SHC-mediated cascade:FGFR1 R-HSA-5654688,0.9763129476943928,1.595334624683676,0.42748091603053434,0.9027855266155972,1.0,1/15,2.37%,FGF1
prerank,GO_Biological_Process_2021__fluid transport (GO:0042044),-0.9791572108213276,-1.5952129617163635,0.3629032258064516,0.729357862935457,1.0,1/16,2.09%,AQP3
prerank,GO_Biological_Process_2021__regulation of delayed rectifier potassium channel activity (GO:1902259),-0.9756186369164723,-1.5949514828089222,0.42105263157894735,0.7250559423845488,1.0,1/17,2.44%,KCNE1
prerank,GO_Biological_Process_2021__negative regulation of amyloid-beta formation (GO:1902430),0.9800788102957617,1.5944293258576727,0.3458646616541353,0.9055189552001455,1.0,1/17,1.99%,APOE
prerank,GO_Biological_Process_2021__peptide cross-linking (GO:0018149),0.9773850390878693,1.5943276461157856,0.366412213740458,0.8966632410653166,1.0,2/21,2.27%,ANXA1;FN1
prerank,Reactome_2022__SHC-mediated cascade:FGFR2 R-HSA-5654699,0.9763125436693126,1.5942305529122758,0.4122137404580153,0.887961222316065,1.0,1/16,2.37%,FGF1
prerank,KEGG_2021_Human__Terpenoid backbone biosynthesis,-0.996574768975025,-1.5938928143346611,0.025210084033613446,0.7298034509343074,1.0,1/21,0.35%,PDSS2
prerank,Reactome_2022__Defects Of Contact Activation System (CAS) And Kallikrein/Kinin System (KKS) R-HSA-9651496,-0.9937701675774918,-1.5938118281204379,0.11267605633802817,0.7225993474507902,1.0,1/15,0.63%,TPST1
prerank,Elsevier_Pathway_Collection__Oxytocin Signaling in Brain Nerve Cell (Hypothesis),-0.9757724455020662,-1.593746496092947,0.4358974358974359,0.7158915593642342,1.0,1/17,2.43%,FOSB
prerank,GO_Biological_Process_2021__mitochondrial membrane organization (GO:0007006),-0.9994192855650673,-1.5931419872147605,0.0,0.715143410229051,1.0,1/31,0.07%,CHCHD3
prerank,Elsevier_Pathway_Collection__SERPINA1 Associated Liver Damage,0.99891966895509,1.5927210720247602,0.0,0.9007910565314646,1.0,1/25,0.11%,ERN1
prerank,Elsevier_Pathway_Collection__Neonatal Diabetes Mellitus,0.9989216852433022,1.5925713061926636,0.016666666666666666,0.8930058627672385,1.0,1/15,0.11%,ERN1
prerank,Reactome_2022__NOTCH4 Intracellular Domain Regulates Transcription R-HSA-9013695,-0.9878468565725936,-1.5924326958166781,0.1865671641791045,0.7164533529730518,1.0,1/19,1.22%,CREBBP
prerank,GO_Biological_Process_2021__positive regulation of triglyceride metabolic process (GO:0090208),-0.9926148832887304,-1.5924303088066318,0.11666666666666667,0.709027043885312,1.0,1/19,0.75%,AADAC
prerank,GO_Biological_Process_2021__regulation of phosphate metabolic process (GO:0019220),-0.9864641675035006,-1.5922056866783902,0.17037037037037037,0.7043723391045645,1.0,1/15,1.36%,SMG6
prerank,Reactome_2022__Synthesis Of Prostaglandins (PG) And Thromboxanes (TX) R-HSA-2162123,0.981810646340875,1.591808071809439,0.3333333333333333,0.8948877690952224,1.0,1/15,1.82%,PTGS2
prerank,GO_Biological_Process_2021__snRNA metabolic process (GO:0016073),-0.9763498008470782,-1.5915210125235644,0.4251968503937008,0.7042042306163289,1.0,1/17,2.37%,INTS7
prerank,GO_Biological_Process_2021__regulation of histone H3-K4 methylation (GO:0051569),0.9969601216652246,1.5914265769865907,0.046511627906976744,0.8915352218221506,1.0,1/19,0.31%,BCOR
prerank,Reactome_2022__TRAF6-mediated Induction Of TAK1 Complex Within TLR4 Complex R-HSA-937072,0.9936158840601003,1.5912979636567253,0.06504065040650407,0.8842071562581658,1.0,1/15,0.64%,IRAK2
prerank,GO_Biological_Process_2021__epithelial cell morphogenesis (GO:0003382),0.99484618166888,1.5908236633807364,0.08396946564885496,0.880848209060564,1.0,1/16,0.52%,SIPA1L3
prerank,GO_Biological_Process_2021__establishment of melanosome localization (GO:0032401),-0.9768117297846535,-1.5901248243614787,0.42105263157894735,0.7140880628562478,1.0,2/19,2.33%,MREG;BBS5
prerank,WikiPathway_2021_Human__Regulation of Wnt/B-catenin Signaling by Small Molecule Compounds WP3664,-0.9903859006486346,-1.5890057341660349,0.22935779816513763,0.7192587873473192,1.0,1/17,0.97%,TNKS
prerank,KEGG_2021_Human__Maturity onset diabetes of the young,0.9778487112899268,1.5889385828111884,0.35555555555555557,0.8976620139076004,1.0,2/20,2.22%,PKLR;FOXA3
prerank,GO_Biological_Process_2021__histone H3 deacetylation (GO:0070932),0.9817749332567254,1.5888648744627432,0.30434782608695654,0.8888772903741137,1.0,2/15,1.83%,HDAC8;HDAC9
prerank,Elsevier_Pathway_Collection__Proteins Involved in Friedreich Ataxia,-0.9954222504299667,-1.588613501250673,0.09016393442622951,0.7160492965973883,1.0,1/17,0.46%,TTPA
prerank,WikiPathway_2021_Human__TGF-B Signaling in Thyroid Cells for Epithelial-Mesenchymal Transition WP3859,0.9774280395279269,1.588478039633981,0.39344262295081966,0.8857644611545836,1.0,3/18,2.27%,CDH2;CDH1;FN1
prerank,Reactome_2022__Regulation Of FZD By Ubiquitination R-HSA-4641263,0.9956906252830874,1.5880974719619074,0.06837606837606838,0.8818739278356705,1.0,1/19,0.43%,LRP5
prerank,GO_Biological_Process_2021__dorsal/ventral pattern formation (GO:0009953),-0.9778890362922394,-1.5878066766725778,0.3884297520661157,0.7171221196573057,1.0,2/18,2.22%,SHH;DSCAML1
prerank,GO_Biological_Process_2021__DNA strand elongation (GO:0022616),0.9930390709320099,1.5877241882310704,0.17272727272727273,0.8780636116985909,1.0,1/18,0.70%,GINS1
prerank,GO_Biological_Process_2021__response to fatty acid (GO:0070542),0.9845410969441862,1.5877226584198862,0.3252032520325203,0.8691037789261563,1.0,1/15,1.55%,PDK3
prerank,GO_Biological_Process_2021__adrenergic receptor signaling pathway (GO:0071875),-0.9905020207332715,-1.5871923366727074,0.18518518518518517,0.7171466314296409,1.0,1/15,0.96%,ZDHHC21
prerank,GO_Biological_Process_2021__positive regulation of small molecule metabolic process (GO:0062013),0.9980758847821077,1.5870862068251337,0.04,0.8697661046226401,1.0,1/15,0.20%,PPARA
prerank,Elsevier_Pathway_Collection__Mast-Cell Activation without Degranulation through IL1R1 and TLR Signaling,-0.9978063263351165,-1.5870588338358176,0.015625,0.7117434709755259,1.0,1/17,0.23%,MAP2K6
prerank,Reactome_2022__Deregulated CDK5 Triggers Neurodegenerative Pathways In Alzheimers Disease Models R-HSA-8862803,-0.9919226467871541,-1.586810192684149,0.1282051282051282,0.7084254483629395,1.0,1/20,0.81%,APP
prerank,Reactome_2022__Interleukin-20 Family Signaling R-HSA-8854691,-0.9829602889208103,-1.5862107075155045,0.27586206896551724,0.7081985104227931,1.0,1/20,1.71%,STAT5A
prerank,GO_Biological_Process_2021__positive regulation of response to cytokine stimulus (GO:0060760),-0.9955384477377192,-1.5861822479406127,0.07751937984496124,0.7018435845721157,1.0,1/15,0.45%,TRIM44
prerank,GO_Biological_Process_2021__T cell mediated immunity (GO:0002456),0.980504950006165,1.5856565103520561,0.384,0.8815144378268713,1.0,1/15,1.95%,CTSH
prerank,WikiPathway_2021_Human__MAPK pathway in congenital thyroid cancer WP4928,0.9893099097784449,1.585177139145676,0.11206896551724138,0.8795492554396607,1.0,1/16,1.07%,KSR1
prerank,GO_Biological_Process_2021__histone H2A ubiquitination (GO:0033522),0.9969605160265607,1.5849231920645919,0.05384615384615385,0.8741863044857356,1.0,1/17,0.31%,BCOR
prerank,Reactome_2022__Recycling Of Bile Acids And Salts R-HSA-159418,-0.9873111294358872,-1.5844842432015387,0.1532258064516129,0.7122648340197801,1.0,2/16,1.28%,NCOA1;SLCO1A2
prerank,GO_Biological_Process_2021__positive regulation of peptidyl-lysine acetylation (GO:2000758),0.9889995294831745,1.5844548212879623,0.168,0.8724176827619767,1.0,1/20,1.10%,PRKAA2
prerank,GO_Biological_Process_2021__cellular response to arsenic-containing substance (GO:0071243),0.980234535023619,1.5842908121492887,0.3089430894308943,0.8659734082157037,1.0,1/15,1.98%,MAPK13
prerank,WikiPathway_2021_Human__Nanomaterial induced apoptosis WP2507,0.9900758980055506,1.58264090854455,0.13043478260869565,0.8804937429804592,1.0,1/20,1.00%,CASP7
prerank,WikiPathway_2021_Human__Cell Differentiation - Index expanded WP2023,-0.97958151964255,-1.582557434112257,0.32592592592592595,0.7248574429285222,1.0,1/15,2.05%,KLF4
prerank,GO_Biological_Process_2021__cardiac atrium morphogenesis (GO:0003209),0.981427370892839,1.582507085186529,0.3828125,0.8738829058240363,1.0,2/17,1.86%,PROX1;ZFPM1
prerank,Elsevier_Pathway_Collection__Osteoblast Function Decline in Osteoporosis,0.9773353637584211,1.5822300603740385,0.36585365853658536,0.8690754955714683,1.0,1/30,2.27%,FN1
prerank,GO_Biological_Process_2021__dendrite self-avoidance (GO:0070593),-0.977851251444835,-1.5816375714475994,0.3629032258064516,0.7278567069424581,1.0,1/15,2.22%,DSCAML1
prerank,Elsevier_Pathway_Collection__Circadian Clock Genes Mutations Cause Insomnia,0.9957677743492593,1.5816049847740077,0.028985507246376812,0.8617041472387631,1.0,1/18,0.43%,CREB1
prerank,Elsevier_Pathway_Collection__Circadian Clock and Sleep Regulation by Melatonin,0.9957677743492593,1.5816049847740077,0.028985507246376812,0.8617041472387631,1.0,1/18,0.43%,CREB1
prerank,GO_Biological_Process_2021__melanosome transport (GO:0032402),-0.9768127613511406,-1.5812876499986677,0.4198473282442748,0.7193003635823731,1.0,2/18,2.33%,MREG;BBS5
prerank,GO_Biological_Process_2021__pigment granule transport (GO:0051904),-0.9768127613511406,-1.5812876499986677,0.4198473282442748,0.7193003635823731,1.0,2/18,2.33%,MREG;BBS5
prerank,Elsevier_Pathway_Collection__B-Cell Receptor -> NF-kB Signaling,0.9874612235056401,1.5810818704636822,0.224,0.8611419756236682,1.0,1/19,1.26%,SYK
prerank,Elsevier_Pathway_Collection__G2/M Damage Checkpoint,0.9898474527889832,1.580980243864542,0.18461538461538463,0.8547198824075062,1.0,1/17,1.02%,ATR
prerank,Elsevier_Pathway_Collection__Werner Syndrome (Adult Progeria),0.9898455130022942,1.5809659157693863,0.14074074074074075,0.8472088198443141,1.0,1/21,1.02%,ATR
prerank,TRRUST_Transcription_Factors_2019__NFE2L2 human,-0.9903487898347044,-1.5808885666763575,0.15671641791044777,0.7176800722551472,1.0,2/16,0.98%,GSTA1;SOD2
prerank,GO_Biological_Process_2021__positive regulation of translational initiation (GO:0045948),0.9987677408678849,1.580814613992484,0.0,0.8414213601972811,1.0,1/16,0.13%,YTHDF3
prerank,Reactome_2022__mRNA Splicing - Major Pathway R-HSA-72163,0.9864115061707226,1.5806390030293627,0.0,0.8362478658636161,1.0,3/180,1.36%,PRPF40A;CDC5L;SF3A2
prerank,GO_Biological_Process_2021__regulation of calcium ion transmembrane transport (GO:1903169),-0.9987673532488627,-1.5806300090910865,0.03731343283582089,0.713674530925741,1.0,1/20,0.13%,PTK2B
prerank,GO_Biological_Process_2021__regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis (GO:1903587),0.9891176987123016,1.5804291660309464,0.18796992481203006,0.8308517453367983,1.0,1/15,1.09%,PPP1R16B
prerank,GO_Biological_Process_2021__rRNA processing (GO:0006364),-0.9865951167148259,-1.5803490669178524,0.00819672131147541,0.7103521608455484,1.0,1/173,1.34%,RRP15
prerank,GO_Biological_Process_2021__regulation of oligodendrocyte differentiation (GO:0048713),0.9904623321113926,1.5792567114682259,0.16923076923076924,0.8382160356032612,1.0,1/17,0.96%,TNFRSF21
prerank,"Reactome_2022__Synthesis, Secretion, And Deacylation Of Ghrelin R-HSA-422085",-0.9795784954415995,-1.5791912377074782,0.3548387096774194,0.7159062743832136,1.0,1/17,2.05%,KLF4
prerank,Elsevier_Pathway_Collection__SWI/SNF BRG1/PBAF in Chromatin Remodeling,-0.9906565776729972,-1.5790800484763787,0.10852713178294573,0.7108728575064459,1.0,2/16,0.95%,NR3C1;ARID2
prerank,GO_Biological_Process_2021__pyroptosis (GO:0070269),0.9809611481366259,1.5787778917243187,0.27906976744186046,0.8363519691893763,1.0,1/19,1.91%,NAIP
prerank,Reactome_2022__mRNA Splicing R-HSA-72172,0.9864071042036389,1.5787299584176668,0.0,0.830102035148956,1.0,3/188,1.36%,PRPF40A;CDC5L;SF3A2
prerank,GO_Biological_Process_2021__regulation of protein sumoylation (GO:0033233),0.999075598935856,1.5783475702298857,0.015267175572519083,0.828224197793492,1.0,1/16,0.10%,RWDD3
prerank,TRRUST_Transcription_Factors_2019__USF1 mouse,-0.9773534458501584,-1.577333883109154,0.3951612903225806,0.7236528423239685,1.0,2/15,2.27%,LIPE;CIITA
prerank,Reactome_2022__TP53 Regulates Transcription Of Genes Involved In G2 Cell Cycle Arrest R-HSA-6804114,0.9909245373763373,1.57723356306192,0.125,0.8358142704582662,1.0,2/18,0.91%,RBL1;TFDP2
prerank,Elsevier_Pathway_Collection__Proteins Involved in HPV Infection,-0.9791608192073982,-1.5770608739433025,0.4049586776859504,0.7203286528183349,1.0,2/15,2.09%,RB1;PML
prerank,Elsevier_Pathway_Collection__Keratinocyte Proliferation in Acne Vulgaris,-0.9978057091168907,-1.5769107910396707,0.014705882352941176,0.7157957809406982,1.0,1/19,0.23%,MAP2K6
prerank,WikiPathway_2021_Human__Fatty acid transporters WP5061,0.9777746235453542,1.5765797478032764,0.3828125,0.8366684306031404,1.0,1/15,2.22%,ACSL5
prerank,Elsevier_Pathway_Collection__BDKRB1/2 -> Interleukins Production,-0.9799260802112246,-1.5761156107570486,0.3389830508474576,0.718043341048715,1.0,1/17,2.01%,BDKRB2
prerank,GO_Biological_Process_2021__ribosome biogenesis (GO:0042254),0.9974606151109908,1.5751977946927522,0.0,0.8478218260800446,1.0,1/191,0.25%,EIF2A
prerank,GO_Biological_Process_2021__positive regulation of excitatory postsynaptic potential (GO:2000463),-0.9987677188686946,-1.5751497155590508,0.03968253968253968,0.7225094582279364,1.0,1/16,0.13%,PTK2B
prerank,GO_Biological_Process_2021__early endosome to late endosome transport (GO:0045022),0.9916541971971463,1.574839712588331,0.13385826771653545,0.8458975268026355,1.0,2/20,0.84%,LMTK2;RAB7A
prerank,GO_Biological_Process_2021__regulation of cellular response to growth factor stimulus (GO:0090287),0.9983834355321713,1.574342664405494,0.0234375,0.8455262989217944,1.0,1/15,0.17%,ITGA3
prerank,Reactome_2022__Tie2 Signaling R-HSA-210993,-0.9811201371679432,-1.574328326523377,0.2631578947368421,0.725612340780246,1.0,2/17,1.90%,PIK3CB;TEK
prerank,TRRUST_Transcription_Factors_2019__RBPJ mouse,0.9989603343772752,1.574275403159483,0.016260162601626018,0.8394810685480186,1.0,1/16,0.11%,CDH2
prerank,Reactome_2022__Pre-NOTCH Processing In Golgi R-HSA-1912420,0.9873079060931248,1.5740135110816789,0.20437956204379562,0.8365988716679471,1.0,1/18,1.27%,NOTCH3
prerank,WikiPathway_2021_Human__Hereditary leiomyomatosis and renal cell carcinoma pathway WP4206,0.9965757596344866,1.5739182267720595,0.1111111111111111,0.8311437309738663,1.0,1/19,0.35%,ACACA
prerank,Reactome_2022__Regulation Of KIT Signaling R-HSA-1433559,-0.9803883338970312,-1.5733391979405167,0.33793103448275863,0.7290919123901841,1.0,1/16,1.97%,SH2B2
prerank,GO_Biological_Process_2021__negative regulation of receptor signaling pathway via JAK-STAT (GO:0046426),0.9943082541652903,1.573235619541216,0.06140350877192982,0.8327600096413195,1.0,1/16,0.57%,PTPN2
prerank,Elsevier_Pathway_Collection__Hutchinson-Gilford Progeria Syndrome,-0.9769652671277531,-1.5728888899476943,0.3888888888888889,0.7274641723067083,1.0,1/16,2.31%,SYNE1
prerank,Reactome_2022__Response Of EIF2AK1 (HRI) To Heme Deficiency R-HSA-9648895,-0.9842730572352881,-1.5719378296914623,0.3157894736842105,0.731209785121838,1.0,1/15,1.58%,GRB10
prerank,Reactome_2022__Signaling By FLT3 Fusion Proteins R-HSA-9703465,-0.9829621161569027,-1.571795835509234,0.2459016393442623,0.7269799634299503,1.0,1/18,1.71%,STAT5A
prerank,Elsevier_Pathway_Collection__Apoptosis of Thyroid Cell in Hashimoto's Thyroiditis,0.9877683460508032,1.5710481078415577,0.17557251908396945,0.8551124744190014,1.0,1/19,1.23%,CD4
prerank,Reactome_2022__Digestion And Absorption R-HSA-8963743,-0.9786965779482304,-1.5707720610782097,0.3968253968253968,0.7319110341200661,1.0,1/16,2.14%,PIR
prerank,GO_Biological_Process_2021__histone mRNA catabolic process (GO:0071044),0.9932702209025199,1.570645976132337,0.1206896551724138,0.8543418324502279,1.0,1/15,0.68%,TENT2
prerank,GO_Biological_Process_2021__peptidyl-lysine dimethylation (GO:0018027),0.9947314189365022,1.5705635193531977,0.12096774193548387,0.8486433986348808,1.0,2/18,0.53%,SETD3;ASH1L
prerank,TRRUST_Transcription_Factors_2019__ATF1 human,0.9928845637564085,1.5703109904552168,0.1076923076923077,0.8451419468229437,1.0,1/19,0.71%,PLAUR
prerank,GO_Biological_Process_2021__positive regulation of collagen biosynthetic process (GO:0032967),-0.9850425257744289,-1.5702385563672885,0.29365079365079366,0.7314331137354709,1.0,1/15,1.50%,BMP4
prerank,GO_Biological_Process_2021__cellular response to alkaloid (GO:0071312),0.9797356679616864,1.5700229915107362,0.3382352941176471,0.8422337349011102,1.0,2/17,2.03%,CASP7;TRPV1
prerank,WikiPathway_2021_Human__Fatty Acid Omega Oxidation WP206,-0.980273724087117,-1.5700099298449501,0.3643410852713178,0.7281404015321464,1.0,1/15,1.98%,CYP1A2
prerank,GO_Biological_Process_2021__regulation of establishment or maintenance of cell polarity (GO:0032878),-0.9811968080916299,-1.5695546301765964,0.26865671641791045,0.7272676993502727,1.0,4/18,1.90%,PTK2B;RAP1B;BCAS3;TEK
prerank,WikiPathway_2021_Human__Hypertrophy Model WP516,-0.99573133694171,-1.5693381105980473,0.0851063829787234,0.7245642050957556,1.0,2/17,0.44%,ADAM10;ZEB1
prerank,GO_Biological_Process_2021__response to purine-containing compound (GO:0014074),-0.991731572108663,-1.5675336613260034,0.16176470588235295,0.7354816088121309,1.0,1/16,0.83%,NDUFS4
prerank,Elsevier_Pathway_Collection__BDNF Upregulation Triggered by Seizures,0.9957667258641474,1.5673844863395092,0.06451612903225806,0.8701536145823742,1.0,1/22,0.43%,CREB1
prerank,Reactome_2022__Response Of Mtb To Phagocytosis R-HSA-9637690,0.9916140035936367,1.5668274566574707,0.08396946564885496,0.8716634130024141,1.0,1/21,0.84%,RAB7A
prerank,GO_Biological_Process_2021__heparan sulfate proteoglycan biosynthetic process (GO:0015012),0.9976143441730556,1.5665826780768504,0.0390625,0.8684921765890072,1.0,1/17,0.24%,HS2ST1
prerank,GO_Biological_Process_2021__positive regulation of telomere capping (GO:1904355),-0.9904250595577331,-1.5665767319164163,0.14285714285714285,0.7394702908210986,1.0,2/17,0.97%,NEK7;TNKS
prerank,GO_Biological_Process_2021__regulation of isotype switching (GO:0045191),-0.9766213364788704,-1.5660659010365603,0.4264705882352941,0.7394802361891502,1.0,1/15,2.34%,PARP3
prerank,GO_Biological_Process_2021__myeloid cell activation involved in immune response (GO:0002275),0.9875016010689719,1.5660010686528643,0.24107142857142858,0.869172056858708,1.0,2/19,1.26%,LILRA2;SYK
prerank,Elsevier_Pathway_Collection__NO Effect on Vasodilation and Vasoconstriction,-0.9864252953942072,-1.5659303742723358,0.18620689655172415,0.7352620064072579,1.0,1/16,1.36%,HRH2
prerank,WikiPathway_2021_Human__Apoptosis Modulation by HSP70 WP384,0.9900762143612934,1.5658909227105333,0.16030534351145037,0.8642087711532798,1.0,1/19,1.00%,CASP7
prerank,Reactome_2022__Beta-catenin Independent WNT Signaling R-HSA-3858494,0.976623052293776,1.5657426513565456,0.037383177570093455,0.859801823203684,1.0,4/137,2.34%,PSMB9;GNB5;AXIN2;GNG2
prerank,TRRUST_Transcription_Factors_2019__PPARGC1A mouse,0.9808903244439819,1.564744033201267,0.3474576271186441,0.8664351158506313,1.0,2/16,1.92%,PPARA;NR1I2
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Asthma,-0.9853466958440452,-1.5643392885272316,0.19008264462809918,0.7453963252737966,1.0,1/19,1.47%,ADAM33
prerank,WikiPathway_2021_Human__Major receptors targeted by epinephrine and norepinephrine WP4589,-0.9844266355758682,-1.5643351344663112,0.21428571428571427,0.7400715913344947,1.0,1/15,1.56%,ADCY3
prerank,Reactome_2022__Metabolism Of Cofactors R-HSA-8978934,-0.9965753548234959,-1.5640141023151708,0.07692307692307693,0.7378181938900353,1.0,1/19,0.35%,PDSS2
prerank,GO_Biological_Process_2021__modulation by symbiont of entry into host (GO:0052372),-0.9993828989944449,-1.5636466831648572,0.008130081300813009,0.7365796988480074,1.0,1/18,0.07%,EXOC2
prerank,GO_Biological_Process_2021__necroptotic process (GO:0070266),-0.9815789774929393,-1.563300630066186,0.28346456692913385,0.7343830296828062,1.0,1/16,1.85%,TICAM2
prerank,GO_Biological_Process_2021__cellular response to copper ion (GO:0071280),-0.9783480151202222,-1.562993218618045,0.4,0.732490570548456,1.0,1/17,2.17%,AOC1
prerank,Elsevier_Pathway_Collection__Fatty Acid Synthase (FASN) Signaling,-0.9829643698467121,-1.5628137843274246,0.2857142857142857,0.7291197645939403,1.0,1/16,1.71%,STAT5A
prerank,Elsevier_Pathway_Collection__Vitamin C Related Norepinephrine Synthesis,-0.997960381342164,-1.561804316927557,0.04065040650406504,0.733316594339222,1.0,1/16,0.21%,SLC23A2
prerank,GO_Biological_Process_2021__nucleotide biosynthetic process (GO:0009165),0.9762749874135505,1.5617289039917979,0.4380165289256198,0.8981194980471442,1.0,2/17,2.38%,HPRT1;RRM2
prerank,"Reactome_2022__GABA Synthesis, Release, Reuptake And Degradation R-HSA-888590",0.9764659563686992,1.5615269094394946,0.452991452991453,0.8945478493606795,1.0,1/16,2.36%,STX1A
prerank,Elsevier_Pathway_Collection__IL1R -> NF-kB Signaling,-0.9978056451071549,-1.5613075787558555,0.022727272727272728,0.7334656084314218,1.0,1/19,0.23%,MAP2K6
prerank,Reactome_2022__FRS-mediated FGFR2 Signaling R-HSA-5654700,0.9763096678287124,1.560165060902836,0.4264705882352941,0.9050726602653953,1.0,1/18,2.37%,FGF1
prerank,GO_Biological_Process_2021__T cell proliferation (GO:0042098),-0.9776977063153318,-1.5598058804291233,0.4180327868852459,0.7421659984587532,1.0,1/15,2.24%,TNFSF14
prerank,Elsevier_Pathway_Collection__Frizzled Receptors -> ARRB1/ARRB2 non-Canonical Signaling,0.9956911230669455,1.5596096796610812,0.06504065040650407,0.9065264544807584,1.0,1/17,0.43%,LRP5
prerank,Elsevier_Pathway_Collection__GALR1/2/3 -> POMC/NPY Production,0.9957679973889823,1.5588287703759836,0.038461538461538464,0.9099125989961124,1.0,1/20,0.43%,CREB1
prerank,Reactome_2022__Removal Of Flap Intermediate From C-strand R-HSA-174437,0.9785023956159219,1.5576958113546084,0.36363636363636365,0.9174074222841929,1.0,1/17,2.15%,ACD
prerank,GO_Biological_Process_2021__positive regulation of regulated secretory pathway (GO:1903307),0.9764645433599759,1.557389193102822,0.42342342342342343,0.9147431142269461,1.0,1/17,2.36%,STX1A
prerank,GO_Biological_Process_2021__stress granule assembly (GO:0034063),0.9987674749166024,1.5572620943677762,0.01818181818181818,0.9099894471049366,1.0,1/20,0.13%,YTHDF3
prerank,GO_Biological_Process_2021__negative regulation of interleukin-1 beta production (GO:0032691),0.9858858592353233,1.556892165913023,0.1984732824427481,0.9078329064492577,1.0,3/21,1.42%,CD33;MEFV;CX3CL1
prerank,GO_Biological_Process_2021__detection of chemical stimulus involved in sensory perception of taste (GO:0050912),-0.975850676177232,-1.5565249314388363,0.45528455284552843,0.7701622577712977,1.0,1/16,2.42%,RTP4
prerank,Reactome_2022__Impaired BRCA2 Binding To PALB2 R-HSA-9709603,0.9884975332525362,1.5563100578879587,0.1743119266055046,0.9089405297481812,1.0,1/24,1.15%,BRIP1
prerank,GO_Biological_Process_2021__positive regulation of collagen metabolic process (GO:0010714),-0.985041751194379,-1.5559909231121956,0.30708661417322836,0.7699401157252619,1.0,1/16,1.50%,BMP4
prerank,Elsevier_Pathway_Collection__FBLN5 Potentiates Migration and Proliferation of Endothelial Cells in Cancer,-0.9810764821527123,-1.5552984583185043,0.2748091603053435,0.7720411748738292,1.0,1/19,1.90%,TEK
prerank,TRRUST_Transcription_Factors_2019__NKX2-5 mouse,0.9859659270380003,1.5552504814851427,0.25892857142857145,0.916104340304325,1.0,2/15,1.41%,GJC1;MYCN
prerank,GO_Biological_Process_2021__neural tube development (GO:0021915),0.9856567496324853,1.5550513298668116,0.2556390977443609,0.9127676004668566,1.0,1/15,1.44%,PROX1
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Polycystic Ovary Syndrome,0.9788124037254429,1.554114120181896,0.41605839416058393,0.9176981057958741,1.0,2/17,2.12%,AMH;RBP4
prerank,GO_Biological_Process_2021__GTP metabolic process (GO:0046039),0.9906173155266864,1.5540820407464726,0.1796875,0.9120600004089522,1.0,1/15,0.94%,RHOQ
prerank,GO_Biological_Process_2021__endocardial cushion development (GO:0003197),-0.9850384144957087,-1.5540648871487,0.26229508196721313,0.7781828114681264,1.0,1/20,1.50%,BMP4
prerank,GO_Biological_Process_2021__activation of protein kinase A activity (GO:0034199),-0.9844259674383515,-1.5539976986801338,0.23404255319148937,0.7737301466007954,1.0,1/16,1.56%,ADCY3
prerank,GO_Biological_Process_2021__cell surface receptor signaling pathway involved in heart development (GO:0061311),-0.9850400714883283,-1.5537658562636838,0.25,0.7710534928547638,1.0,1/17,1.50%,BMP4
prerank,GO_Biological_Process_2021__regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway (GO:1902235),0.9813429333899174,1.5533157672200917,0.336,0.9159167619350679,1.0,1/22,1.87%,BOK
prerank,GO_Biological_Process_2021__negative regulation of intrinsic apoptotic signaling pathway by p53 class mediator (GO:1902254),-0.9824258411343563,-1.552932251786691,0.2440944881889764,0.7732306857914124,1.0,1/16,1.76%,CD44
prerank,TRRUST_Transcription_Factors_2019__SRF mouse,-0.9808127988572741,-1.5517681840987934,0.3409090909090909,0.7787927489623625,1.0,2/16,1.93%,TGFB1I1;MMP2
prerank,Reactome_2022__Cell-extracellular Matrix Interactions R-HSA-446353,0.9771595473325665,1.5514675687517685,0.4316546762589928,0.9326576526363985,1.0,2/16,2.29%,FBLIM1;FLNA
prerank,GO_Biological_Process_2021__nucleotide catabolic process (GO:0009166),-0.9948474155963835,-1.551463324994873,0.06870229007633588,0.7767269794303794,1.0,2/15,0.53%,NT5C1B;DERA
prerank,Elsevier_Pathway_Collection__Ethanol Induced Efects in Hyperprolactinemia,0.9957687354444634,1.5511412223543486,0.064,0.9307242122718273,1.0,1/18,0.43%,CREB1
prerank,GO_Biological_Process_2021__adenine nucleotide transport (GO:0051503),0.9853883692525591,1.5505316515686804,0.2824427480916031,0.9329107016323686,1.0,2/16,1.47%,SLC19A1;LRRC8C
prerank,Reactome_2022__FRS-mediated FGFR3 Signaling R-HSA-5654706,0.976313396541164,1.5505301706383898,0.4146341463414634,0.927071600522165,1.0,1/15,2.37%,FGF1
prerank,Elsevier_Pathway_Collection__Mitochondrial Protein Transport,-0.9927302386542602,-1.549187746159152,0.1,0.7951753773176189,1.0,1/19,0.73%,TOMM70
prerank,GO_Biological_Process_2021__endocardial cushion morphogenesis (GO:0003203),-0.9850395620984643,-1.5487472746792026,0.28695652173913044,0.7952785056564161,1.0,1/18,1.50%,BMP4
prerank,GO_Biological_Process_2021__positive regulation of protein export from nucleus (GO:0046827),-0.9846193917756341,-1.548540103866641,0.24603174603174602,0.7922768627728534,1.0,1/15,1.54%,RAPGEF3
prerank,GO_Biological_Process_2021__interleukin-27-mediated signaling pathway (GO:0070106),-0.9784691734649102,-1.548129836127087,0.3629032258064516,0.7914207100655218,1.0,2/15,2.16%,OAS1;OASL
prerank,GO_Biological_Process_2021__maintenance of protein location in nucleus (GO:0051457),-0.9770018729222073,-1.547949514483303,0.4146341463414634,0.7884145549301335,1.0,2/20,2.31%,PML;SYNE1
prerank,WikiPathway_2021_Human__miR-509-3p alteration of YAP1/ECM axis WP3967,0.9774289349050064,1.547753427267299,0.41353383458646614,0.9560468273074543,1.0,3/17,2.27%,BCAR1;TEAD4;FN1
prerank,GO_Biological_Process_2021__glycerolipid catabolic process (GO:0046503),0.9944610062647488,1.5476922446528985,0.07936507936507936,0.9506110411252952,1.0,1/18,0.56%,PNPLA6
prerank,Reactome_2022__Signaling By FLT3 ITD And TKD Mutants R-HSA-9703648,-0.9829646000152417,-1.547321003848907,0.29508196721311475,0.7897403109629332,1.0,1/15,1.71%,STAT5A
prerank,TRRUST_Transcription_Factors_2019__ESR2 mouse,-0.9829630295303733,-1.5466393008007566,0.33043478260869563,0.7911150270548966,1.0,1/17,1.71%,STAT5A
prerank,GO_Biological_Process_2021__regulation of metal ion transport (GO:0010959),0.9786988948039441,1.5463682371957805,0.3793103448275862,0.9615525582581906,1.0,3/16,2.14%,DLG1;CD4;SLC30A10
prerank,GO_Biological_Process_2021__potassium ion homeostasis (GO:0055075),-0.9761901093929082,-1.5463581350366022,0.424,0.7892698280941631,1.0,1/21,2.39%,SLC12A8
prerank,TRRUST_Transcription_Factors_2019__NOTCH1 mouse,-0.9761180580703328,-1.5460332311191558,0.42063492063492064,0.7877482750213686,1.0,2/20,2.40%,EFNB2;SPI1
prerank,GO_Biological_Process_2021__miRNA metabolic process (GO:0010586),0.9913092627866658,1.5459115854886925,0.1652892561983471,0.9616909100424222,1.0,3/18,0.88%,DIS3L2;PARN;DROSHA
prerank,GO_Biological_Process_2021__cellular response to misfolded protein (GO:0071218),-0.9923450370403223,-1.545463256616569,0.05970149253731343,0.7887038514600893,1.0,1/20,0.77%,DNAJB14
prerank,GO_Biological_Process_2021__medium-chain fatty acid metabolic process (GO:0051791),-0.9931161307238224,-1.5452209013166665,0.1206896551724138,0.7861414854672812,1.0,1/15,0.70%,ABHD3
prerank,Elsevier_Pathway_Collection__Leptin and CCK8 Activate Nodose Ganglia Neuron,0.9957668699522475,1.5451361059176718,0.043478260869565216,0.9655265952795826,1.0,1/23,0.43%,CREB1
prerank,GO_Biological_Process_2021__synaptic vesicle membrane organization (GO:0048499),0.9764630314681975,1.5450884231940263,0.46846846846846846,0.9601651325929174,1.0,1/17,2.36%,STX1A
prerank,GO_Biological_Process_2021__positive regulation of protein autophosphorylation (GO:0031954),0.9951905852321334,1.5450092886363371,0.06299212598425197,0.95551794658103,1.0,1/22,0.48%,TOM1L1
prerank,GO_Biological_Process_2021__positive regulation of protein processing (GO:0010954),0.9760803473335858,1.5448135134283212,0.44715447154471544,0.9522449042961685,1.0,1/17,2.39%,MELTF
prerank,GO_Biological_Process_2021__epithelial cell development (GO:0002064),0.9940769897372874,1.5445885387704605,0.11403508771929824,0.9489573312633887,1.0,2/20,0.60%,SIPA1L3;SLC4A7
prerank,Elsevier_Pathway_Collection__HIF1 Signaling,0.9990744736565563,1.5443810039641241,0.0,0.9458150224111149,1.0,1/24,0.10%,RWDD3
prerank,Elsevier_Pathway_Collection__Insulin Influence on Glycogenesis,-0.9913826470655932,-1.5440077418528197,0.08661417322834646,0.7929254180047278,1.0,1/23,0.87%,TBC1D4
prerank,Elsevier_Pathway_Collection__Bone Resorption in Hyperparathyroidism,0.995730354072691,1.5436704513806498,0.0625,0.949106489407796,1.0,2/21,0.43%,CREB1;LRP5
prerank,GO_Biological_Process_2021__interleukin-6-mediated signaling pathway (GO:0070102),-0.9760798356230875,-1.5436297039101161,0.43636363636363634,0.7913133424297334,1.0,1/18,2.40%,SPI1
prerank,GO_Biological_Process_2021__error-prone translesion synthesis (GO:0042276),-0.9959226173806752,-1.5430875946488645,0.03816793893129771,0.7917659819142286,1.0,2/21,0.42%,REV3L;POLK
prerank,Elsevier_Pathway_Collection__Melatonin Effects on Circadian Cycle,0.9957674692280565,1.5418364368317032,0.072,0.9673644885905078,1.0,1/21,0.43%,CREB1
prerank,GO_Biological_Process_2021__inositol phosphate-mediated signaling (GO:0048016),0.9780819805991097,1.5416795449099372,0.3709677419354839,0.963699706001315,1.0,2/17,2.20%,NFATC2;GPR62
prerank,TRRUST_Transcription_Factors_2019__BCL6 mouse,-0.9806960089322958,-1.541663334314173,0.3826086956521739,0.8003892146795835,1.0,1/15,1.94%,RORC
prerank,GO_Biological_Process_2021__regulation of collagen biosynthetic process (GO:0032965),-0.9773511554296351,-1.5415172719930599,0.3984375,0.7971939151762102,1.0,2/18,2.27%,BMP4;CIITA
prerank,GO_Biological_Process_2021__positive regulation of cellular protein catabolic process (GO:1903364),0.9801185139294,1.5414151784692143,0.3656716417910448,0.9613500517102023,1.0,2/19,1.99%,VGLL4;APOE
prerank,Reactome_2022__Synthesis Of Glycosylphosphatidylinositol (GPI) R-HSA-162710,-0.9853113420922048,-1.5410751573730932,0.2727272727272727,0.7970507066022695,1.0,2/17,1.48%,PIGX;PIGZ
prerank,KEGG_2021_Human__Selenocompound metabolism,0.9796978782317232,1.5406658345374298,0.33884297520661155,0.9652255085396644,1.0,3/17,2.04%,PAPSS1;SCLY;TXNRD2
prerank,Reactome_2022__MET Activates PTK2 Signaling R-HSA-8874081,0.9845041116875428,1.539917423833311,0.2601626016260163,0.9689282851450759,1.0,3/17,1.56%,ITGA3;PTK2;ITGA2
prerank,WikiPathway_2021_Human__Phytochemical activity on NRF2 transcriptional activation WP3,-0.987387852380995,-1.5397824831653673,0.20491803278688525,0.804841337052102,1.0,1/15,1.27%,GSTA2
prerank,GO_Biological_Process_2021__cellular modified amino acid biosynthetic process (GO:0042398),0.9931154118097166,1.5395213769996625,0.096,0.9683506792421389,1.0,2/20,0.70%,PLOD2;MTHFS
prerank,GO_Biological_Process_2021__porphyrin-containing compound catabolic process (GO:0006787),-0.9998061283912709,-1.5393044038623287,0.0,0.800521428589274,1.0,1/16,0.03%,GSTA1
prerank,GO_Biological_Process_2021__heme catabolic process (GO:0042167),-0.9998061283912709,-1.5393044038623287,0.0,0.800521428589274,1.0,1/16,0.03%,GSTA1
prerank,Elsevier_Pathway_Collection__IL4R -> ELK/SRF/HMGY Signaling,0.9844588366473767,1.539303048804686,0.21774193548387097,0.9657993583856801,1.0,1/21,1.56%,PKMYT1
prerank,Elsevier_Pathway_Collection__Ca2+ Overload in Muscular Dystrophies,0.991422219497969,1.5391904379292474,0.14634146341463414,0.9617872440473307,1.0,1/21,0.86%,PTK2
prerank,WikiPathway_2021_Human__Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex WP3657,-0.9878460540572924,-1.5385094747130392,0.18796992481203006,0.8036898125845894,1.0,1/20,1.22%,CREBBP
prerank,Elsevier_Pathway_Collection__TGFBR -> ATF/GADD/MAX/TP53 Signaling,-0.9978068755241775,-1.5382109800245973,0.0364963503649635,0.8020191695711483,1.0,1/17,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__response to organophosphorus (GO:0046683),-0.9917323313527564,-1.5379687732382419,0.16666666666666666,0.8003078425373519,1.0,1/15,0.83%,NDUFS4
prerank,Elsevier_Pathway_Collection__Luteinizing Hormone in Oocyte Meiotic Resumption,0.9957683840478693,1.5378856740707492,0.07079646017699115,0.9740120706286499,1.0,1/18,0.43%,CREB1
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Endometrial Cancer,0.982958447180688,1.537835746801172,0.26495726495726496,0.9692000424731563,1.0,1/22,1.71%,CDH1
prerank,GO_Biological_Process_2021__extrinsic apoptotic signaling pathway in absence of ligand (GO:0097192),0.9813862312490809,1.5375923796151612,0.27350427350427353,0.9663776652286583,1.0,2/20,1.87%,ERBB3;BOK
prerank,"GO_Biological_Process_2021__synaptic transmission, glutamatergic (GO:0035249)",-0.9855419052679317,-1.5374024121292449,0.2992125984251969,0.8012761776729567,1.0,1/15,1.45%,GRIK5
prerank,GO_Biological_Process_2021__negative regulation of protein transport (GO:0051224),0.9801944415866277,1.536985190173427,0.31666666666666665,0.9681046184765632,1.0,4/21,1.99%,WWP2;PKDCC;DRD4;APOE
prerank,Reactome_2022__FRS-mediated FGFR4 Signaling R-HSA-5654712,0.9763516627000395,1.5368505099403293,0.4453125,0.9644350809835732,1.0,2/17,2.37%,KLB;FGF1
prerank,GO_Biological_Process_2021__positive regulation of epithelial cell apoptotic process (GO:1904037),0.987882289667354,1.5362822425550848,0.20634920634920634,0.9671306955475046,1.0,1/22,1.21%,ITGA4
prerank,GO_Biological_Process_2021__programmed necrotic cell death (GO:0097300),-0.9815768406476916,-1.5362213409643084,0.2992125984251969,0.8089559447996275,1.0,1/18,1.85%,TICAM2
prerank,GO_Biological_Process_2021__leukotriene biosynthetic process (GO:0019370),-0.9915395025745525,-1.536047327565055,0.15079365079365079,0.8058118913885944,1.0,1/16,0.85%,GGT5
prerank,GO_Biological_Process_2021__regulation of insulin-like growth factor receptor signaling pathway (GO:0043567),0.9881928196513247,1.5358725826677575,0.2028985507246377,0.9675625007101011,1.0,1/17,1.18%,IGFBP3
prerank,Reactome_2022__HS-GAG Degradation R-HSA-2024096,-0.9827658682817886,-1.5356801052971656,0.23255813953488372,0.8055129027389766,1.0,1/21,1.73%,SDC3
prerank,Reactome_2022__Interleukin Receptor SHC Signaling R-HSA-912526,-0.9945748143018508,-1.5356290984238767,0.07246376811594203,0.8014581778600788,1.0,1/25,0.55%,PIK3CB
prerank,GO_Biological_Process_2021__regulation of membrane depolarization (GO:0003254),0.9774283639772666,1.5355479828201228,0.43410852713178294,0.9659844429992865,1.0,1/15,2.26%,GPD1L
prerank,GO_Biological_Process_2021__regulation of receptor recycling (GO:0001919),0.978887677014115,1.535531499902922,0.3875968992248062,0.9610350215179528,1.0,1/17,2.11%,OPTN
prerank,GO_Biological_Process_2021__gastrulation (GO:0007369),0.9957310998042032,1.5353821334475337,0.10317460317460317,0.9578114117422685,1.0,2/17,0.43%,MEGF8;LRP5
prerank,GO_Biological_Process_2021__regulation of spindle organization (GO:0090224),-0.9766187740128207,-1.5353444923315538,0.40869565217391307,0.7999782534288054,1.0,1/18,2.34%,PARP3
prerank,KEGG_2021_Human__RNA transport,0.9895113108521774,1.5347216306040328,0.008695652173913044,0.9604469838263675,1.0,2/163,1.05%,UPF2;NUP210
prerank,Elsevier_Pathway_Collection__MUC5AC Expression by NTHi and S. Pneumoniae,-0.9978055035482214,-1.5346877113420014,0.031007751937984496,0.8031670527979204,1.0,1/21,0.23%,MAP2K6
prerank,WikiPathway_2021_Human__BMP Signaling Pathway in Eyelid Development WP3927,-0.9851179757611332,-1.5344148127737274,0.2786885245901639,0.8016748880084462,1.0,3/19,1.50%,SHH;INHBB;BMP4
prerank,GO_Biological_Process_2021__determination of bilateral symmetry (GO:0009855),0.9759218311079859,1.5342590671237168,0.44,0.9611864110270061,1.0,1/21,2.41%,KIF3B
prerank,GO_Biological_Process_2021__regulation of protein kinase A signaling (GO:0010738),-0.9909624720297565,-1.5342542041022227,0.18045112781954886,0.7991422644958533,1.0,1/17,0.91%,AKAP7
prerank,Reactome_2022__Na+/Cl- Dependent Neurotransmitter Transporters R-HSA-442660,-0.9986530412846415,-1.5341431567159622,0.023255813953488372,0.7959985990062598,1.0,1/15,0.14%,SLC22A1
prerank,Reactome_2022__Negative Regulation Of FLT3 R-HSA-9706369,-0.9902329268903124,-1.5333794697275422,0.1937984496124031,0.7994956014832946,1.0,1/15,0.98%,PTPRJ
prerank,GO_Biological_Process_2021__hepaticobiliary system development (GO:0061008),0.9856938704657757,1.5331333250695758,0.1984126984126984,0.970364228594584,1.0,2/20,1.44%,PHF2;PROX1
prerank,GO_Biological_Process_2021__negative regulation of G protein-coupled receptor signaling pathway (GO:0045744),0.9829952299974689,1.5328004169974694,0.3037037037037037,0.969476213183041,1.0,1/22,1.70%,GRK3
prerank,Elsevier_Pathway_Collection__Chromosome Condensation,0.9940772857245002,1.5326686830258782,0.13953488372093023,0.966152681679654,1.0,1/15,0.60%,NCAPG
prerank,Reactome_2022__Chondroitin Sulfate Biosynthesis R-HSA-2022870,0.9921139675277043,1.532653350931794,0.13178294573643412,0.9613114913135729,1.0,1/20,0.79%,CHST11
prerank,GO_Biological_Process_2021__protein localization to chromatin (GO:0071168),0.9923063794538939,1.5324177723005559,0.1484375,0.959123952322677,1.0,1/21,0.77%,MSH2
prerank,TRRUST_Transcription_Factors_2019__TRP73 mouse,-0.9968448990510813,-1.5323987116106927,0.03968253968253968,0.8052766358750701,1.0,1/18,0.32%,NR3C1
prerank,GO_Biological_Process_2021__regulation of cartilage development (GO:0061035),-0.985039628738303,-1.53219846585001,0.288,0.8028520724063718,1.0,1/18,1.50%,BMP4
prerank,Reactome_2022__FOXO-mediated Transcription Of Cell Death Genes R-HSA-9614657,-0.9878488230796232,-1.5318402966850198,0.25757575757575757,0.8024003384441396,1.0,1/16,1.22%,CREBBP
prerank,GO_Biological_Process_2021__regulation of synapse organization (GO:0050807),-0.9889205027607231,-1.5316234708632341,0.19130434782608696,0.8003996439698412,1.0,1/24,1.11%,NEDD4
prerank,GO_Biological_Process_2021__mitochondrial RNA metabolic process (GO:0000959),-0.9970763743145837,-1.5314462515452207,0.04918032786885246,0.7984013912914113,1.0,1/15,0.30%,FASTKD1
prerank,Elsevier_Pathway_Collection__Dopamine Mediated Glutamate Release and Glutamate Uptake Circle,0.9765825019732878,1.5310005841772452,0.4032258064516129,0.9716547234005866,1.0,4/18,2.36%,SLC38A3;GLS;SLC38A1;STX1A
prerank,GO_Biological_Process_2021__regulation of transposition (GO:0010528),-0.9836153483373442,-1.5307865391810296,0.2746478873239437,0.8008739382061423,1.0,1/18,1.64%,PIWIL4
prerank,Reactome_2022__IL-6-type Cytokine Receptor Ligand Interactions R-HSA-6788467,-0.9828108551867919,-1.530092622620604,0.3064516129032258,0.8038792045250656,1.0,1/16,1.73%,IL11RA
prerank,GO_Biological_Process_2021__lipid droplet organization (GO:0034389),0.9837694707497344,1.5300744885128512,0.2796610169491525,0.9788575347463452,1.0,2/22,1.63%,RAB3GAP1;PNPLA3
prerank,GO_Biological_Process_2021__negative regulation of osteoclast differentiation (GO:0045671),-0.9873470087117029,-1.529624436303151,0.20161290322580644,0.804669305566108,1.0,1/18,1.27%,GPR137B
prerank,GO_Biological_Process_2021__production of small RNA involved in gene silencing by RNA (GO:0070918),0.9912307874161485,1.5294067875767137,0.1889763779527559,0.9822202077539726,1.0,1/19,0.88%,DROSHA
prerank,GO_Biological_Process_2021__regulation of monocyte differentiation (GO:0045655),0.9878114055404804,1.5293415322920887,0.23728813559322035,0.9783908983199805,1.0,2/15,1.23%,CDK6;CD4
prerank,Reactome_2022__PINK1-PRKN Mediated Mitophagy R-HSA-5205685,-0.9927293686383915,-1.529202716424772,0.06504065040650407,0.8046674967774344,1.0,1/21,0.73%,TOMM70
prerank,Reactome_2022__Gastrin-CREB Signaling Pathway Via PKC And MAPK R-HSA-881907,0.9957694709390972,1.5289475198606477,0.06299212598425197,0.9787564852070696,1.0,1/15,0.43%,CREB1
prerank,KEGG_2021_Human__Proximal tubule bicarbonate reclamation,0.9848073711361046,1.528762939143135,0.24666666666666667,0.97659216756081,1.0,2/22,1.53%,SLC38A3;GLS
prerank,GO_Biological_Process_2021__regulation of establishment of cell polarity (GO:2000114),-0.9898106553240404,-1.5285373029727947,0.13709677419354838,0.8070411292514871,1.0,3/16,1.03%,PTK2B;RAP1B;BCAS3
prerank,GO_Biological_Process_2021__regulation of transferase activity (GO:0051338),-0.9865418803361927,-1.5284201343086985,0.21138211382113822,0.8042229733949928,1.0,3/17,1.36%,HMBOX1;LDB2;SMG6
prerank,Elsevier_Pathway_Collection__IL6 and Insulin Resistance in Muscular Dystrophies,-0.9854612237891514,-1.5281989240415947,0.216,0.802661404355492,1.0,2/23,1.46%,TBC1D4;LIPE
prerank,Elsevier_Pathway_Collection__Corneodesmosomes in Atopic Dermatitis,0.9830056664644657,1.5281878707011545,0.3275862068965517,0.978831675567821,1.0,2/15,1.71%,PKP4;CDH1
prerank,GO_Biological_Process_2021__steroid hormone mediated signaling pathway (GO:0043401),-0.9851205228202526,-1.5281343153969722,0.23387096774193547,0.7992292097648767,1.0,3/15,1.50%,PLPP1;NR3C1;BMP4
prerank,GO_Biological_Process_2021__RNA interference (GO:0016246),0.9912318152619833,1.5280189615356172,0.2230769230769231,0.9760020922394039,1.0,1/17,0.88%,DROSHA
prerank,WikiPathway_2021_Human__Globo Sphingolipid Metabolism WP1424,0.9968056483027963,1.5271047413726733,0.06060606060606061,0.9821214174217863,1.0,1/20,0.32%,ST3GAL1
prerank,GO_Biological_Process_2021__cellular response to glucagon stimulus (GO:0071377),-0.984424530914814,-1.5266392440692977,0.22695035460992907,0.8094549754718537,1.0,1/18,1.56%,ADCY3
prerank,GO_Biological_Process_2021__positive regulation of response to endoplasmic reticulum stress (GO:1905898),0.9813882797853791,1.5265206345487528,0.3548387096774194,0.983884697863081,1.0,2/18,1.87%,ERN1;BOK
prerank,GO_Biological_Process_2021__negative regulation of calcium ion transport (GO:0051926),0.9851584882142471,1.5259695445029005,0.21212121212121213,0.98608894707344,1.0,2/15,1.49%,CD33;PACSIN3
prerank,GO_Biological_Process_2021__regulation of centriole replication (GO:0046599),0.9914622649867009,1.5257087479364282,0.14655172413793102,0.9846031907668464,1.0,1/17,0.86%,CEP295
prerank,Reactome_2022__RHO GTPase Effectors R-HSA-195258,0.9108662462102823,1.525541018432515,0.0,0.9819218984335881,1.0,17/252,2.29%,ABI2;CENPE;ACTR3;YWHAQ;NDC80;PTK2;PPP1R12A;RHOQ;MRTFA;ARHGEF7;CENPA;IQGAP3;ERCC6L;FMNL2;CYBA;RHPN2;FLNA
prerank,Elsevier_Pathway_Collection__Proteins Involved in Pathogenesis of Arrhythmogenic Right Ventricular Cardiomyopathy,0.9814247066013064,1.525172633614853,0.2975206611570248,0.982168845212843,1.0,1/18,1.86%,PPP1R13L
prerank,GO_Biological_Process_2021__positive regulation of membrane protein ectodomain proteolysis (GO:0051044),0.9801211446730443,1.5249892772318097,0.3591549295774648,0.9797814596964438,1.0,2/15,1.99%,PACSIN3;APOE
prerank,Elsevier_Pathway_Collection__Telomere Maintenance,-0.9903846221342821,-1.52497594398812,0.18705035971223022,0.8216383022280498,1.0,1/20,0.97%,TNKS
prerank,Elsevier_Pathway_Collection__NURD in Chromatin Remodeling,-0.9910384880100854,-1.5242980498617973,0.11851851851851852,0.8238424699174927,1.0,1/19,0.90%,MTA3
prerank,GO_Biological_Process_2021__regulation of exosomal secretion (GO:1903541),0.9916145150245474,1.5242774581241934,0.14634146341463414,0.9831881366247851,1.0,1/19,0.84%,RAB7A
prerank,Elsevier_Pathway_Collection__Proteins Involved in Vasospasm,-0.9995369728513628,-1.5238033450129198,0.0,0.8248607608458604,1.0,1/17,0.05%,PDE5A
prerank,Elsevier_Pathway_Collection__ER Stress in Huntington Disease,0.9989200571506395,1.523688064568287,0.008130081300813009,0.9858631957112096,1.0,1/23,0.11%,ERN1
prerank,Elsevier_Pathway_Collection__PI3K/AKT/MTOR Signaling Activation in Cancer,-0.99534604714101,-1.5236146408348163,0.07575757575757576,0.8225971616898604,1.0,1/17,0.47%,AKT3
prerank,Reactome_2022__Serotonin Neurotransmitter Release Cycle R-HSA-181429,0.9765053882761849,1.5236025578756631,0.43119266055045874,0.9820575064322351,1.0,2/17,2.36%,PPFIA4;STX1A
prerank,Reactome_2022__Conversion From APC/C:Cdc20 To APC/C:Cdh1 In Late Anaphase R-HSA-176407,0.9825755276556415,1.5235896228892287,0.28888888888888886,0.9775734439047479,1.0,1/20,1.74%,UBE2C
prerank,Reactome_2022__Eicosanoid Ligand-Binding Receptors R-HSA-391903,-0.9773512639869384,-1.5228871903531156,0.373134328358209,0.8252228486693076,1.0,1/15,2.27%,GPR17
prerank,Elsevier_Pathway_Collection__UrokinaseR -> ELK/SRF Signaling,0.9928822878726584,1.5221893802563915,0.06349206349206349,0.9898724596942723,1.0,1/23,0.71%,PLAUR
prerank,GO_Biological_Process_2021__regulation of lipoprotein lipase activity (GO:0051004),0.9817704946869303,1.5217097838390885,0.2971014492753623,0.9911147864123422,1.0,2/21,1.83%,SORT1;HDAC9
prerank,Elsevier_Pathway_Collection__Familial Partial Lipodystrophy Type 2 Progression (Hypothesis),0.996616097680924,1.5217007256741089,0.05343511450381679,0.9866302689654648,1.0,2/15,0.35%,PPARA;ACACA
prerank,Elsevier_Pathway_Collection__Apoptosis of Renal Tubule Epithelial Cell in Pyelonephritis,0.9989185943556256,1.521600342480216,0.0,0.9836710269443357,1.0,1/30,0.11%,ERN1
prerank,Reactome_2022__N-glycan Antennae Elongation In medial/trans-Golgi R-HSA-975576,0.9832636554391402,1.5215693718794687,0.23728813559322035,0.9794666421251372,1.0,1/24,1.68%,MOGAT2
prerank,Reactome_2022__SHC-mediated cascade:FGFR4 R-HSA-5654719,0.9763540082081003,1.521534109081156,0.4462809917355372,0.9754230323982039,1.0,2/15,2.37%,KLB;FGF1
prerank,Reactome_2022__Expression And Translocation Of Olfactory Receptors R-HSA-9752946,-0.9895780491131826,-1.5211462609355597,0.16666666666666666,0.8392166361143863,1.0,1/17,1.05%,LDB2
prerank,GO_Biological_Process_2021__transepithelial transport (GO:0070633),-0.9979603567986057,-1.5207422419920529,0.03669724770642202,0.839604769387937,1.0,1/16,0.21%,SLC23A2
prerank,Elsevier_Pathway_Collection__Sister Chromatid Cohesion,-0.9957299544842036,-1.5205788565903873,0.10144927536231885,0.8368795147522258,1.0,1/18,0.43%,PDS5B
prerank,GO_Biological_Process_2021__nuclear-transcribed mRNA poly(A) tail shortening (GO:0000289),0.9919603023234961,1.520420777605107,0.1328125,0.9846122277203103,1.0,1/21,0.81%,PARN
prerank,GO_Biological_Process_2021__pulmonary valve development (GO:0003177),-0.9850397026677314,-1.5203755928733724,0.2824427480916031,0.8350618902034177,1.0,1/18,1.50%,BMP4
prerank,Elsevier_Pathway_Collection__ER Associated Protein Degradation in Vesicular Transport,-0.9967289239866868,-1.5201808493737121,0.02459016393442623,0.8330957137466154,1.0,1/19,0.33%,AMFR
prerank,GO_Biological_Process_2021__regulation of Arp2/3 complex-mediated actin nucleation (GO:0034315),0.9820807928575476,1.5199750742966476,0.3114754098360656,0.9851362183699834,1.0,2/17,1.80%,ABI2;FCHSD2
prerank,Elsevier_Pathway_Collection__Glutamate Mediated Excitotoxicity in Glaucoma,0.9788840110427901,1.5197573530282322,0.375,0.9831366613961222,1.0,1/20,2.11%,OPTN
prerank,Reactome_2022__Regulation Of Pyruvate Dehydrogenase (PDH) Complex R-HSA-204174,0.9845402997329386,1.5196153405448296,0.3181818181818182,0.980312402901404,1.0,1/15,1.55%,PDK3
prerank,Reactome_2022__SUMOylation Of DNA Methylation Proteins R-HSA-4655427,0.9868867281935367,1.5195668236033908,0.248,0.9766544672389518,1.0,1/15,1.31%,CBX2
prerank,Elsevier_Pathway_Collection__ECL-cell: CHGA and Histamine Synthesis,0.9957686773594712,1.5194803759940847,0.04716981132075472,0.9735061018152815,1.0,1/17,0.43%,CREB1
prerank,GO_Biological_Process_2021__negative regulation of GTPase activity (GO:0034260),-0.989729371994123,-1.5194225994600965,0.16535433070866143,0.8370658441607354,1.0,1/22,1.03%,BCAS3
prerank,GO_Biological_Process_2021__negative regulation of telomere maintenance via telomerase (GO:0032211),0.9774262853224881,1.5188749892918065,0.40310077519379844,0.9768190795263878,1.0,2/19,2.26%,ACD;PIF1
prerank,GO_Biological_Process_2021__positive regulation of oxidoreductase activity (GO:0051353),0.99103898204755,1.5187446983323454,0.1276595744680851,0.9740917870007862,1.0,1/17,0.90%,NOD2
prerank,Reactome_2022__PI-3K cascade:FGFR1 R-HSA-5654689,0.9763110087728321,1.51850546402299,0.4444444444444444,0.9726245510995545,1.0,1/16,2.37%,FGF1
prerank,Elsevier_Pathway_Collection__B-Cell Receptor -> NFATC Signaling,0.9800806266957285,1.5183952807994598,0.3627450980392157,0.9697047612355102,1.0,2/18,2.00%,SYK;NFATC2
prerank,GO_Biological_Process_2021__regulation of telomere capping (GO:1904353),-0.9865386107249827,-1.5183518585373659,0.2714285714285714,0.8444446845966219,1.0,3/23,1.36%,NEK7;TNKS;SMG6
prerank,"GO_Biological_Process_2021__RNA splicing, via endonucleolytic cleavage and ligation (GO:0000394)",0.9989222720770126,1.5183000571957634,0.008130081300813009,0.9668491567824966,1.0,1/15,0.11%,ERN1
prerank,Elsevier_Pathway_Collection__Histone Acetylation,-0.9878859829575576,-1.5182231730928952,0.2413793103448276,0.8416784482721129,1.0,2/20,1.22%,NCOA1;CREBBP
prerank,GO_Biological_Process_2021__regulation of interferon-gamma-mediated signaling pathway (GO:0060334),0.9943061405217665,1.5179712218579486,0.07874015748031496,0.9661875058692457,1.0,1/21,0.57%,PTPN2
prerank,GO_Biological_Process_2021__negative regulation of insulin secretion (GO:0046676),-0.9851180117100619,-1.51789111388413,0.1953125,0.8410998340020008,1.0,1/16,1.49%,INHBB
prerank,Reactome_2022__PI-3K cascade:FGFR2 R-HSA-5654695,0.9763106046766871,1.5175182293868787,0.4496124031007752,0.9676529882775634,1.0,1/17,2.37%,FGF1
prerank,GO_Biological_Process_2021__stress fiber assembly (GO:0043149),0.9820797565200698,1.5171201034552164,0.3442622950819672,0.9639112688064686,1.0,1/15,1.79%,ITGB5
prerank,GO_Biological_Process_2021__contractile actin filament bundle assembly (GO:0030038),0.9820797565200698,1.5171201034552164,0.3442622950819672,0.9639112688064686,1.0,1/15,1.79%,ITGB5
prerank,Elsevier_Pathway_Collection__EGFR/ERBB -> STAT Signaling,-0.9830017173631748,-1.5168300660104417,0.2846153846153846,0.8474038869901755,1.0,2/20,1.71%,NRG1;STAT5A
prerank,Reactome_2022__FRS-mediated FGFR1 Signaling R-HSA-5654693,0.9763100719949148,1.5167451880073333,0.45925925925925926,0.9641491570741016,1.0,1/17,2.37%,FGF1
prerank,GO_Biological_Process_2021__cellular response to steroid hormone stimulus (GO:0071383),-0.9851167375293705,-1.516586609995062,0.2733812949640288,0.8460151149249506,1.0,3/21,1.50%,NR3C1;TFPI;BMP4
prerank,GO_Biological_Process_2021__Arp2/3 complex-mediated actin nucleation (GO:0034314),0.9938469751593186,1.5164993448018995,0.12213740458015267,0.9633990947836977,1.0,1/15,0.62%,ACTR3
prerank,Reactome_2022__SUMOylation Of Transcription Factors R-HSA-3232118,-0.9857713959441324,-1.51606800091817,0.2421875,0.8473328332076205,1.0,1/17,1.43%,HIC1
prerank,Reactome_2022__VxPx Cargo-Targeting To Cilium R-HSA-5620916,-0.9993824828608348,-1.5158321632356007,0.01680672268907563,0.8453184565085108,1.0,1/20,0.07%,EXOC2
prerank,GO_Biological_Process_2021__regulation of lymphocyte activation (GO:0051249),0.9877712299930848,1.5157571153506382,0.23076923076923078,0.9679041917586644,1.0,1/15,1.23%,CD4
prerank,GO_Biological_Process_2021__organelle fusion (GO:0048284),-0.999420625040311,-1.5157565298587394,0.0,0.8421940051893357,1.0,1/22,0.07%,CHCHD3
prerank,Reactome_2022__Defective B3GALT6 Causes EDSP2 And SEMDJL1 R-HSA-4420332,-0.9827665816530418,-1.5156308395566276,0.2903225806451613,0.8395721517138356,1.0,1/20,1.73%,SDC3
prerank,WikiPathway_2021_Human__TCA Cycle (aka Krebs or citric acid cycle) WP78,-0.9987283104000476,-1.5153264539870157,0.013513513513513514,0.8386588050499654,1.0,1/18,0.13%,SUCLG2
prerank,Reactome_2022__PI-3K cascade:FGFR4 R-HSA-5654720,0.9763525849342927,1.5151406881079756,0.464,0.971074266446856,1.0,2/16,2.37%,KLB;FGF1
prerank,Reactome_2022__Telomere Extension By Telomerase R-HSA-171319,0.9774623548055225,1.5150762603558137,0.39622641509433965,0.9676459971226178,1.0,3/22,2.26%,WRAP53;ACD;PIF1
prerank,Reactome_2022__mRNA Decay By 5 To 3 Exoribonuclease R-HSA-430039,-0.9934622656651507,-1.5149085158905462,0.10833333333333334,0.8386315775155613,1.0,1/15,0.66%,EDC3
prerank,Elsevier_Pathway_Collection__Oxidized LDL/OLR1 Activates Cell Proliferation in Cancer,-0.9808112760313891,-1.5146519517930803,0.328,0.837043670335427,1.0,2/18,1.93%,CCND2;MMP2
prerank,Reactome_2022__Cyclin A/B1/B2 Associated Events During G2/M Transition R-HSA-69273,0.9844574857996788,1.5144689803300724,0.29914529914529914,0.9710705216942511,1.0,1/24,1.56%,PKMYT1
prerank,WikiPathway_2021_Human__Follicle Stimulating Hormone (FSH) signaling pathway WP2035,0.9957662426948827,1.5141317329607944,0.031496062992125984,0.9704930428663753,1.0,1/24,0.43%,CREB1
prerank,GO_Biological_Process_2021__response to ketone (GO:1901654),-0.9807669948522175,-1.514032168659912,0.25,0.8389663531910587,1.0,2/25,1.93%,CATSPER3;SLIT3
prerank,KEGG_2021_Human__Renin-angiotensin system,0.9970746897665567,1.5139173181491365,0.040983606557377046,0.9690696718681131,1.0,1/20,0.30%,NLN
prerank,GO_Biological_Process_2021__regulation of cellular biosynthetic process (GO:0031326),0.9889949396756553,1.5137791001435088,0.12,0.966608227553159,1.0,1/30,1.10%,PRKAA2
prerank,GO_Biological_Process_2021__interleukin-7-mediated signaling pathway (GO:0038111),-0.9829604187838344,-1.5137573835894114,0.3274336283185841,0.834273343006231,1.0,1/19,1.71%,STAT5A
prerank,GO_Biological_Process_2021__cellular response to interleukin-7 (GO:0098761),-0.9829604187838344,-1.5137573835894114,0.3274336283185841,0.834273343006231,1.0,1/19,1.71%,STAT5A
prerank,Elsevier_Pathway_Collection__BMP Signaling Impairment in Granulosa Cell in POF,0.9818475435543471,1.5136794610520052,0.37209302325581395,0.9636533195057563,1.0,2/20,1.82%,SMAD9;PTGS2
prerank,Elsevier_Pathway_Collection__B-Cell Receptor -> AP-1 Signaling,0.9874599975028946,1.5135994392162897,0.2,0.9607224351010153,1.0,1/21,1.26%,SYK
prerank,GO_Biological_Process_2021__regulation of cholesterol storage (GO:0010885),0.9980757004556025,1.5135010819156898,0.03076923076923077,0.9578152825538025,1.0,1/16,0.20%,PPARA
prerank,Elsevier_Pathway_Collection__CD8+ T-Cell Response to Self-Determinants in Diabetes,-0.9757308543876785,-1.5134129405259342,0.4420289855072464,0.8340510462197193,1.0,2/23,2.44%,PTK2B;ZAP70
prerank,KEGG_2021_Human__Other glycan degradation,0.9979986761845285,1.5132730133432768,0.018018018018018018,0.9565804452892657,1.0,1/17,0.20%,MANBA
prerank,Reactome_2022__Defective HDR Thru Homologous Recombination (HRR) Due To BRCA1 Loss-Of-Function R-HSA-9701192,0.988496900480025,1.5130966072655547,0.20909090909090908,0.9548141257806699,1.0,1/25,1.15%,BRIP1
prerank,WikiPathway_2021_Human__Cytokines and Inflammatory Response WP530,0.9877684676611741,1.512930736908074,0.2116788321167883,0.9529720643259432,1.0,1/20,1.23%,CD4
prerank,Reactome_2022__Plasma Lipoprotein Assembly R-HSA-8963898,0.9800814649530792,1.5128627505928935,0.3969465648854962,0.9500705073186667,1.0,1/15,1.99%,APOE
prerank,GO_Biological_Process_2021__histone monoubiquitination (GO:0010390),0.9969585569470364,1.5127107541784865,0.05673758865248227,0.9477625976031927,1.0,1/24,0.31%,BCOR
prerank,GO_Biological_Process_2021__regulation of B cell activation (GO:0050864),0.9829199698622193,1.5124620971660583,0.2894736842105263,0.9467517504464155,1.0,2/26,1.71%,NOD2;SAMSN1
prerank,GO_Biological_Process_2021__cellular response to nitrogen compound (GO:1901699),-0.9783477065740311,-1.5120395008209826,0.4206896551724138,0.8433752643134975,1.0,1/19,2.17%,AOC1
prerank,GO_Biological_Process_2021__regulation of cell-cell adhesion mediated by cadherin (GO:2000047),0.9978829317091941,1.5119412185718888,0.015873015873015872,0.9486325670189376,1.0,1/19,0.22%,TJP1
prerank,GO_Biological_Process_2021__copper ion homeostasis (GO:0055070),-0.9919238135566931,-1.5111276839283638,0.15328467153284672,0.8478901846174071,1.0,1/17,0.81%,APP
prerank,TRRUST_Transcription_Factors_2019__CREB1 mouse,0.9817994793204059,1.5109404636034558,0.3037037037037037,0.9551860998507244,1.0,1/28,1.82%,PTGS2
prerank,GO_Biological_Process_2021__negative regulation of Rho protein signal transduction (GO:0035024),0.9832730275489698,1.51091258977391,0.31007751937984496,0.951735755717557,1.0,2/17,1.68%,ITGA3;DLC1
prerank,Elsevier_Pathway_Collection__TNF-alpha/TNFRSF1B Signaling,0.9958069373045192,1.5106317956299378,0.04477611940298507,0.9511972747416456,1.0,2/22,0.43%,TRAF3;CREB1
prerank,GO_Biological_Process_2021__membrane lipid metabolic process (GO:0006643),-0.9823093057412384,-1.5099498795187125,0.3445378151260504,0.8552278593562931,1.0,3/21,1.78%,AGK;ARV1;CYP1B1
prerank,Elsevier_Pathway_Collection__FGFR -> RUNX2 Signaling,0.9763055277059086,1.5097875813608168,0.47368421052631576,0.9566718853351086,1.0,1/22,2.37%,FGF1
prerank,GO_Biological_Process_2021__ear morphogenesis (GO:0042471),-0.9843063164687873,-1.5097794576170074,0.2827586206896552,0.8532313508141901,1.0,1/20,1.58%,PAX8
prerank,Reactome_2022__Heme Degradation R-HSA-189483,-0.9998060254143812,-1.509432688694484,0.0,0.8525428148013957,1.0,1/16,0.03%,GSTA1
prerank,Elsevier_Pathway_Collection__Angiotensin-Aldosterone System Activation Scheme,0.9957682702630273,1.5091885294934457,0.06451612903225806,0.959831383532449,1.0,1/17,0.43%,CREB1
prerank,Elsevier_Pathway_Collection__ALK Associated Neuroblastoma,-0.9879594891849611,-1.5089315923444897,0.21374045801526717,0.853384789331523,1.0,1/24,1.21%,RAP1A
prerank,GO_Biological_Process_2021__outflow tract septum morphogenesis (GO:0003148),-0.985036990016577,-1.508694510480821,0.2595419847328244,0.8518232173738172,1.0,1/22,1.50%,BMP4
prerank,GO_Biological_Process_2021__negative regulation of phagocytosis (GO:0050765),0.9969987698470034,1.5085831064847361,0.031496062992125984,0.9623443836515038,1.0,1/16,0.30%,CD300A
prerank,GO_Biological_Process_2021__regulation of fatty acid oxidation (GO:0046320),0.9980753803728658,1.5084744230740021,0.047619047619047616,0.9600518137291196,1.0,1/16,0.20%,PPARA
prerank,Reactome_2022__Depolymerisation Of Nuclear Lamina R-HSA-4419969,0.9770438012899281,1.5080989769212991,0.472,0.9607782114941139,1.0,1/15,2.30%,LPIN3
prerank,GO_Biological_Process_2021__negative regulation of intracellular protein transport (GO:0090317),-0.9756569222744347,-1.5080826099799045,0.4409448818897638,0.8536097599861705,1.0,2/20,2.44%,SUFU;KCNE1
prerank,Elsevier_Pathway_Collection__Protein Degradation Dysregulation in Dementia (Hypothesis),-0.996728904680416,-1.5078895451483894,0.02608695652173913,0.8517503507134435,1.0,1/19,0.33%,AMFR
prerank,GO_Biological_Process_2021__postsynaptic membrane organization (GO:0001941),0.9801187963135779,1.5078680447766448,0.36220472440944884,0.9596367083750055,1.0,2/18,1.99%,LRRC4;APOE
prerank,GO_Biological_Process_2021__adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains (GO:0002460),0.9923069238651194,1.5073153404268769,0.12396694214876033,0.9614485391584222,1.0,1/20,0.77%,MSH2
prerank,Reactome_2022__Deadenylation Of mRNA R-HSA-429947,0.9919589575917163,1.507252946689674,0.11940298507462686,0.9584987144989552,1.0,1/24,0.81%,PARN
prerank,GO_Biological_Process_2021__fatty-acyl-CoA metabolic process (GO:0035337),0.9965753794742493,1.506937772469649,0.06870229007633588,0.9583246813516962,1.0,1/22,0.35%,ACACA
prerank,Elsevier_Pathway_Collection__Proteins Involved in Chronic Bronchitis,-0.9822263327494263,-1.5068527677220205,0.3023255813953488,0.8582258831484966,1.0,1/22,1.78%,CYP1B1
prerank,GO_Biological_Process_2021__cellular response to inorganic substance (GO:0071241),-0.9783452039525882,-1.506614929901564,0.42748091603053434,0.8569043447294401,1.0,1/20,2.17%,AOC1
prerank,GO_Biological_Process_2021__protein import into mitochondrial matrix (GO:0030150),-0.9927301642154768,-1.506511005385442,0.11764705882352941,0.8544275527270573,1.0,1/19,0.73%,TOMM70
prerank,GO_Biological_Process_2021__amyloid-beta metabolic process (GO:0050435),-0.9786183477210417,-1.5060970380450525,0.3669064748201439,0.8546858629751349,1.0,1/17,2.14%,MGAT3
prerank,WikiPathway_2021_Human__Mitochondrial Gene Expression WP391,0.9957674852206938,1.5060075659216636,0.058823529411764705,0.9653047258750013,1.0,1/19,0.43%,CREB1
prerank,GO_Biological_Process_2021__melanosome localization (GO:0032400),-0.976809808566555,-1.5056978952379485,0.4573643410852713,0.8548408519758914,1.0,2/21,2.33%,MREG;BBS5
prerank,GO_Biological_Process_2021__cellular response to gamma radiation (GO:0071480),0.989887081423203,1.5052586200459166,0.16260162601626016,0.9693990139332502,1.0,2/17,1.02%,TLK2;ATR
prerank,WikiPathway_2021_Human__SREBF and miR33 in cholesterol and lipid homeostasis WP2011,0.9980756700639798,1.5052040767038077,0.051470588235294115,0.9664300873170658,1.0,1/16,0.20%,PPARA
prerank,GO_Biological_Process_2021__meiosis I (GO:0007127),0.9972691917610532,1.5051183207348198,0.04201680672268908,0.9638825860930005,1.0,2/19,0.28%,SYCP3;FOXJ3
prerank,GO_Biological_Process_2021__sphingosine metabolic process (GO:0006670),-0.9946926740947545,-1.5043513857343889,0.0625,0.8636625908261235,1.0,2/19,0.54%,PLPP1;SGPP1
prerank,Elsevier_Pathway_Collection__Leukotriene Effect on Airway Smooth Muscle Response,-0.9978056634744016,-1.5041849571338728,0.022222222222222223,0.8616144640996106,1.0,1/19,0.23%,MAP2K6
prerank,Elsevier_Pathway_Collection__DNMT and MBD Families Activation in DNA Methylation in Cancer,0.9829630337216837,1.5041271891505903,0.29411764705882354,0.972297769647688,1.0,1/17,1.71%,CDH1
prerank,Reactome_2022__ABC Transporters In Lipid Homeostasis R-HSA-1369062,-0.9759673925100276,-1.5040374237558398,0.45454545454545453,0.8596543319326247,1.0,3/18,2.42%,ABCD3;ABCA6;ABCA10
prerank,Elsevier_Pathway_Collection__PGF2-alpha Effect on Treatment,-0.9807720846483458,-1.5036587701048152,0.29838709677419356,0.85963031725995,1.0,1/17,1.93%,MMP2
prerank,GO_Biological_Process_2021__defense response to fungus (GO:0050832),-0.9762751729418503,-1.5035717838275169,0.46017699115044247,0.8568013519063022,1.0,2/17,2.38%,FAM3A;HRG
prerank,TRRUST_Transcription_Factors_2019__POU2F1 mouse,-0.9969987058968982,-1.5034034377286805,0.0743801652892562,0.8549968795516948,1.0,1/18,0.31%,ATP11C
prerank,GO_Biological_Process_2021__dopaminergic neuron differentiation (GO:0071542),-0.9858108190115441,-1.5030269037366797,0.27007299270072993,0.8546825084021201,1.0,1/15,1.43%,SHH
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hirschsprung Disease,-0.9848472131215175,-1.5028607037090091,0.2982456140350877,0.8527327805777226,1.0,2/20,1.53%,SHH;NRG1
prerank,GO_Biological_Process_2021__negative regulation of cell communication (GO:0010648),0.9881942456018109,1.5028127512054048,0.21323529411764705,0.9834430718659011,1.0,2/18,1.19%,IGFBP3;ERBB3
prerank,"Reactome_2022__Defective B4GALT7 Causes EDS, Progeroid Type R-HSA-3560783",-0.9827665174932916,-1.502756102201189,0.2926829268292683,0.8502686163689273,1.0,1/20,1.73%,SDC3
prerank,GO_Biological_Process_2021__regulation of nuclear division (GO:0051783),0.9845010666327672,1.5027413450397762,0.28225806451612906,0.9806637245532038,1.0,2/20,1.56%,MKI67;PKMYT1
prerank,GO_Biological_Process_2021__cardiac muscle cell contraction (GO:0086003),-0.9756170646970411,-1.5024151112047865,0.4957983193277311,0.8498793539310895,1.0,1/18,2.44%,KCNE1
prerank,GO_Biological_Process_2021__regulation of SMAD protein signal transduction (GO:0060390),-0.9850765896026208,-1.502343506662835,0.2608695652173913,0.8472105277054847,1.0,2/23,1.50%,SLC2A10;BMP4
prerank,Reactome_2022__G Beta:Gamma Signaling Thru CDC42 R-HSA-8964616,0.976658121723175,1.5023020181656972,0.4925373134328358,0.9820538876326708,1.0,2/18,2.34%,GNB5;GNG2
prerank,Elsevier_Pathway_Collection__Gap Junction Assembly,0.9880014399294708,1.50165664238254,0.2231404958677686,0.98513334774952,1.0,2/19,1.21%,TJP1;GJC1
prerank,GO_Biological_Process_2021__histone H3-K4 methylation (GO:0051568),-0.9991507696932146,-1.501488338412255,0.0,0.8505430726172541,1.0,1/28,0.09%,KDM6A
prerank,Reactome_2022__NOTCH2 Activation And Transmission Of Signal To Nucleus R-HSA-2979096,-0.9965366210469812,-1.5011650396054645,0.07194244604316546,0.8500474751080737,1.0,1/21,0.35%,ADAM10
prerank,GO_Biological_Process_2021__in utero embryonic development (GO:0001701),-0.996536240516699,-1.5011336677794485,0.05303030303030303,0.847053527421999,1.0,1/24,0.35%,ADAM10
prerank,Elsevier_Pathway_Collection__Axonal Transport Impairment in Hungtington Disease,0.9899230118114322,1.5010999440954211,0.15625,0.9876369304244369,1.0,1/19,1.01%,SORT1
prerank,Reactome_2022__Mitochondrial Calcium Ion Transport R-HSA-8949215,0.9971903425598891,1.5008451708652892,0.03278688524590164,0.987056389232429,1.0,1/21,0.28%,MICU1
prerank,Elsevier_Pathway_Collection__HMGB1 and IL1B in Neuroinflammation,-0.9815724477342235,-1.5006281597248803,0.319672131147541,0.8481960562667499,1.0,1/23,1.85%,TICAM2
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA gap filling (GO:0006297)",-0.9958819082028612,-1.500571521558751,0.03361344537815126,0.8454493478230372,1.0,1/24,0.42%,POLK
prerank,Elsevier_Pathway_Collection__I-cell: CCK-8 Secretion and Regulation of Eating Behavior,0.995766663434013,1.5005303490568227,0.07142857142857142,0.9870942611215855,1.0,1/24,0.43%,CREB1
prerank,GO_Biological_Process_2021__response to copper ion (GO:0046688),-0.9783450145291916,-1.5004130209587707,0.4253731343283582,0.8436292601216234,1.0,1/20,2.17%,AOC1
prerank,Reactome_2022__ATF4 Activates Genes In Response To Endoplasmic Reticulum Stress R-HSA-380994,0.9919580719795519,1.500239735505979,0.08490566037735849,0.9865037203832583,1.0,1/27,0.81%,PARN
prerank,GO_Biological_Process_2021__nucleotide-sugar biosynthetic process (GO:0009226),0.9823456129627034,1.5000781022530005,0.3228346456692913,0.9847939915155643,1.0,1/19,1.77%,UAP1L1
prerank,GO_Biological_Process_2021__ERK1 and ERK2 cascade (GO:0070371),0.9804961117868412,1.500045017045909,0.3611111111111111,0.9814972766931954,1.0,1/21,1.95%,CTSH
prerank,Elsevier_Pathway_Collection__Estrogen Effects in Mitochondria in Alzheimer Disease,-0.9823140827885922,-1.4995347003600663,0.33884297520661155,0.8472088380515765,1.0,3/15,1.78%,APP;SOD2;CYP1B1
prerank,TRRUST_Transcription_Factors_2019__NR1H4 human,0.980846720098266,1.4992174985773346,0.3609022556390977,0.9873546066143349,1.0,1/18,1.92%,NR1I2
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Asthma,-0.9765443146491959,-1.4990620962557064,0.4380165289256198,0.84774321719971,1.0,2/17,2.36%,ADAM33;IRAK3
prerank,TRRUST_Transcription_Factors_2019__DDIT3 human,-0.9969603445542518,-1.49904756629118,0.04477611940298507,0.8445988807813409,1.0,1/18,0.31%,TNFRSF10B
prerank,GO_Biological_Process_2021__zinc ion transport (GO:0006829),0.9786135694046483,1.4989987044557238,0.375,0.9859458090270361,1.0,1/20,2.14%,SLC30A10
prerank,WikiPathway_2021_Human__DNA Mismatch Repair WP531,0.9915377311018951,1.4988701291883995,0.13076923076923078,0.983850737109931,1.0,2/23,0.85%,MSH2;POLE4
prerank,GO_Biological_Process_2021__pulmonary valve morphogenesis (GO:0003184),-0.985040456381832,-1.4986691430646228,0.27906976744186046,0.8443936036584246,1.0,1/17,1.50%,BMP4
prerank,Reactome_2022__Presynaptic Function Of Kainate Receptors R-HSA-500657,0.976657177607387,1.4983719597584173,0.4645669291338583,0.9855544728076749,1.0,2/19,2.34%,GNB5;GNG2
prerank,GO_Biological_Process_2021__cell migration involved in sprouting angiogenesis (GO:0002042),-0.9769240549110573,-1.4982859991878548,0.43609022556390975,0.844561204767264,1.0,1/18,2.31%,EFNB2
prerank,GO_Biological_Process_2021__regulation of lymphocyte proliferation (GO:0050670),0.9795009754646848,1.4969897280667348,0.3712121212121212,0.9974747905865673,1.0,1/18,2.05%,LGALS3
prerank,GO_Biological_Process_2021__regulation of telomerase RNA localization to Cajal body (GO:1904872),0.9919613588305795,1.4969494342643668,0.15315315315315314,0.994422013887554,1.0,1/18,0.81%,PARN
prerank,GO_Biological_Process_2021__regulation of lymphocyte differentiation (GO:0045619),-0.9841916918414015,-1.496947666219799,0.2932330827067669,0.8515450903764857,1.0,1/19,1.59%,CD2
prerank,Elsevier_Pathway_Collection__Epigenetic Alterations Triggers Genomic Instability,0.9946154731500322,1.4968850907310438,0.10091743119266056,0.9916088771362417,1.0,1/18,0.54%,SLC19A1
prerank,GO_Biological_Process_2021__response to exogenous dsRNA (GO:0043330),-0.9765011194903586,-1.496818360082377,0.4573643410852713,0.8495391891771459,1.0,1/19,2.36%,IRAK3
prerank,TRRUST_Transcription_Factors_2019__CEBPD human,0.9818110429633946,1.496792525191925,0.3135593220338983,0.9891728326030346,1.0,1/16,1.82%,PTGS2
prerank,GO_Biological_Process_2021__mitotic sister chromatid cohesion (GO:0007064),-0.9885805178243344,-1.496756666245989,0.23015873015873015,0.8470105255237061,1.0,2/15,1.15%,PDS5B;RB1
prerank,GO_Biological_Process_2021__regulation of fatty acid biosynthetic process (GO:0042304),0.9889957240507159,1.4965387648658954,0.19008264462809918,0.9889539151549486,1.0,1/28,1.10%,PRKAA2
prerank,WikiPathway_2021_Human__Regulation of apoptosis by parathyroid hormone-related protein WP3872,0.9813441845871277,1.4965342881787684,0.3951612903225806,0.9856326581459965,1.0,1/22,1.87%,BOK
prerank,Elsevier_Pathway_Collection__IL17F Signaling in Bronchial Epithelial Cell in Asthma,0.9957674081544495,1.4963339949292653,0.04065040650406504,0.9847040750444301,1.0,1/20,0.43%,CREB1
prerank,Reactome_2022__Nitric Oxide Stimulates Guanylate Cyclase R-HSA-392154,-0.9758113911543087,-1.496201656378121,0.45901639344262296,0.8480936006797754,1.0,3/20,2.43%,PDE5A;PDE11A;IRAG1
prerank,Reactome_2022__Dopamine Neurotransmitter Release Cycle R-HSA-212676,0.9765400021013245,1.4957091949366617,0.40869565217391307,0.988689543824775,1.0,3/22,2.36%,LIN7A;PPFIA4;STX1A
prerank,Reactome_2022__Lewis Blood Group Biosynthesis R-HSA-9037629,0.9806168375897474,1.4955046011654316,0.3798449612403101,0.9876346045315227,1.0,1/17,1.94%,FUT6
prerank,GO_Biological_Process_2021__DNA replication checkpoint signaling (GO:0000076),0.9981143174458422,1.4953329303876643,0.00819672131147541,0.986586817369072,1.0,1/17,0.19%,CDC45
prerank,Elsevier_Pathway_Collection__Proteins Involved in Mantle Cell Lymphoma,-0.9858078639769365,-1.4951661133648009,0.2677165354330709,0.8531910195245888,1.0,1/19,1.43%,SHH
prerank,GO_Biological_Process_2021__mesoderm formation (GO:0001707),0.9844642814054176,1.4949425556618194,0.2809917355371901,0.9877170165750456,1.0,2/18,1.56%,ITGA3;ITGA2
prerank,KEGG_2021_Human__Spliceosome,0.9864375414343691,1.494784603180169,0.0,0.9858135948368777,1.0,3/134,1.36%,PRPF40A;CDC5L;SF3A2
prerank,GO_Biological_Process_2021__protein-DNA complex disassembly (GO:0032986),-0.9906158013836589,-1.494369360110101,0.13821138211382114,0.8554755027980868,1.0,1/18,0.95%,ARID2
prerank,KEGG_2021_Human__Pentose and glucuronate interconversions,-0.9989573448617222,-1.494068500857761,0.0,0.8546678361175329,1.0,1/30,0.11%,CRPPA
prerank,Reactome_2022__Gap Junction Trafficking R-HSA-190828,-0.9849219471577624,-1.49376531921559,0.22764227642276422,0.8540205617726052,1.0,1/21,1.51%,GJB5
prerank,GO_Biological_Process_2021__positive regulation of glucose import (GO:0046326),0.9906126374106833,1.4934437732213028,0.1111111111111111,0.997901439274675,1.0,1/23,0.94%,RHOQ
prerank,GO_Biological_Process_2021__regulation of superoxide anion generation (GO:0032928),0.987503939624803,1.493240001647863,0.22727272727272727,0.9966078993940195,1.0,2/15,1.26%,AATF;SYK
prerank,Reactome_2022__Defective B3GAT3 Causes JDSSDHD R-HSA-3560801,-0.9827663160903762,-1.4929029325572802,0.2846153846153846,0.8575855556789592,1.0,1/20,1.73%,SDC3
prerank,TRRUST_Transcription_Factors_2019__E2F4 human,-0.9801124092106187,-1.4928838906660788,0.3233082706766917,0.854670083405668,1.0,1/23,1.99%,LTBP4
prerank,Elsevier_Pathway_Collection__TNFRSF5/6 -> RB1/E2F Signaling,-0.9885798000948408,-1.4927096884061448,0.23529411764705882,0.8531765454466397,1.0,2/16,1.15%,MAP2K6;RB1
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Amyotrophic Lateral Sclerosis,0.9858075463349482,1.4926911594152605,0.20930232558139536,0.9990077557027609,1.0,1/19,1.42%,CX3CL1
prerank,GO_Biological_Process_2021__DNA strand elongation involved in DNA replication (GO:0006271),0.993038865879076,1.492552594314017,0.18421052631578946,0.9973309816376321,1.0,1/18,0.70%,GINS1
prerank,Reactome_2022__Scavenging By Class A Receptors R-HSA-3000480,0.9800781297653197,1.49177422167664,0.3382352941176471,1.0,1.0,1/18,1.99%,APOE
prerank,Reactome_2022__Processive Synthesis On C-strand Of Telomere R-HSA-174414,0.977618232670916,1.4917543153690662,0.40336134453781514,0.9994682410481908,1.0,2/19,2.24%,ACD;LRIG1
prerank,TRRUST_Transcription_Factors_2019__LEF1 human,0.9964206698055144,1.4916497423491857,0.07086614173228346,0.9973630494947403,1.0,1/25,0.36%,HERC2
prerank,GO_Biological_Process_2021__polyol biosynthetic process (GO:0046173),0.9833107360436495,1.4911729227982067,0.3382352941176471,0.9991612265056978,1.0,1/16,1.67%,CYP27B1
prerank,GO_Biological_Process_2021__chondroitin sulfate biosynthetic process (GO:0030206),0.9921135331904177,1.491154765069799,0.15447154471544716,0.996072214331888,1.0,1/21,0.79%,CHST11
prerank,GO_Biological_Process_2021__regulation of myotube differentiation (GO:0010830),0.981727936734448,1.490927248617829,0.35384615384615387,0.9951842711018445,1.0,1/22,1.83%,HDAC9
prerank,WikiPathway_2021_Human__15q13.3 copy number variation syndrome WP4942,-0.9878469906099224,-1.4898987693951602,0.19548872180451127,0.8723776347267499,1.0,1/18,1.22%,CREBBP
prerank,GO_Biological_Process_2021__membrane repolarization (GO:0086009),-0.9756205457909668,-1.4894083360996118,0.5,0.8731704782241877,1.0,1/15,2.44%,KCNE1
prerank,WikiPathway_2021_Human__Effect of progerin on genes involved in Hutchinson-Gilford progeria syndrome WP4320,-0.9885770449955176,-1.4893738169736839,0.17073170731707318,0.8703165882717827,1.0,2/22,1.15%,MTA3;RB1
prerank,Elsevier_Pathway_Collection__Cochlear Hair Cell Stereocilia Proteins Mutations (Age-Related),0.9769297926143988,1.4891513250017787,0.4552238805970149,1.0,1.0,2/16,2.31%,ESPN;MYO7A
prerank,GO_Biological_Process_2021__positive regulation of axon extension (GO:0045773),0.9971522728802598,1.48913629292794,0.04201680672268908,1.0,1.0,1/21,0.29%,MEGF8
prerank,Reactome_2022__Chaperone Mediated Autophagy R-HSA-9613829,0.9836918221332079,1.488726745202423,0.2992125984251969,1.0,1.0,1/19,1.63%,LAMP2
prerank,GO_Biological_Process_2021__positive regulation of synapse assembly (GO:0051965),-0.9775688855404259,-1.488590807362404,0.39568345323741005,0.873031889006288,1.0,1/26,2.25%,SEMA4D
prerank,GO_Biological_Process_2021__endoplasmic reticulum mannose trimming (GO:1904380),-0.9967291917395319,-1.4884769699236868,0.04580152671755725,0.8707741681121258,1.0,1/19,0.33%,AMFR
prerank,WikiPathway_2021_Human__Hedgehog Signaling Pathway Netpath WP47,-0.9793523813681156,-1.488368198120966,0.4351145038167939,0.8683703539127969,1.0,3/16,2.08%,SUFU;SHH;GLI3
prerank,Reactome_2022__Assembly Of ORC Complex At Origin Of Replication R-HSA-68616,-0.9920727376904227,-1.48822689736692,0.1076923076923077,0.8665175886291383,1.0,1/27,0.80%,ORC4
prerank,GO_Biological_Process_2021__proteoglycan metabolic process (GO:0006029),0.9921529616038778,1.48805702563498,0.152,1.0,1.0,2/24,0.79%,FAM20B;CHST11
prerank,GO_Biological_Process_2021__3'-UTR-mediated mRNA destabilization (GO:0061158),-0.9982292733624549,-1.4875431141092073,0.008,0.8688739083876912,1.0,1/15,0.18%,CPEB3
prerank,Reactome_2022__Signaling By FGFR3 In Disease R-HSA-5655332,0.9763112307920422,1.4871780955249752,0.4806201550387597,1.0,1.0,1/17,2.37%,FGF1
prerank,Elsevier_Pathway_Collection__IL36 Receptor Antagonist (IL1F5) Deficiency (DITRA),-0.9978046126046549,-1.4870673032910877,0.015748031496062992,0.8693635682790314,1.0,1/26,0.23%,MAP2K6
prerank,KEGG_2021_Human__Protein export,-0.9862279566000953,-1.4870529363711804,0.17692307692307693,0.8664450510548896,1.0,1/23,1.38%,SEC61A2
prerank,GO_Biological_Process_2021__negative regulation of protein localization to plasma membrane (GO:1903077),0.9875396370571177,1.4864548908306021,0.22950819672131148,1.0,1.0,2/20,1.25%,RHOQ;PKDCC
prerank,GO_Biological_Process_2021__mitochondrial cytochrome c oxidase assembly (GO:0033617),-0.9957679080503463,-1.4863224776560182,0.1016949152542373,0.8688995665905224,1.0,1/20,0.43%,COX16
prerank,GO_Biological_Process_2021__regulation of granulocyte chemotaxis (GO:0071622),0.991422617750594,1.486308464867195,0.1592920353982301,1.0,1.0,1/19,0.86%,PTK2
prerank,Elsevier_Pathway_Collection__KIT -> MITF Signaling,-0.9987671966771874,-1.486204875549807,0.015873015873015872,0.866649797135546,1.0,1/21,0.13%,PTK2B
prerank,TRRUST_Transcription_Factors_2019__FOXO3 human,-0.9846556684190384,-1.4861254679428553,0.2824427480916031,0.8643303924221549,1.0,1/18,1.54%,CCND2
prerank,TRRUST_Transcription_Factors_2019__SIRT1 mouse,0.9808436737407655,1.4859737277390535,0.3865546218487395,1.0,1.0,1/22,1.92%,NR1I2
prerank,GO_Biological_Process_2021__negative regulation of RNA splicing (GO:0033119),0.9839621779000015,1.4857549214549985,0.31007751937984496,1.0,1.0,1/19,1.61%,PCBP4
prerank,Elsevier_Pathway_Collection__EphrinR -> STAT Signaling,-0.9769685568176123,-1.4856617067165327,0.47107438016528924,0.8644878191901539,1.0,2/15,2.31%,STAT5A;EFNB2
prerank,GO_Biological_Process_2021__heparan sulfate proteoglycan metabolic process (GO:0030201),0.997613665285162,1.4855070467414577,0.047244094488188976,1.0,1.0,1/21,0.24%,HS2ST1
prerank,GO_Biological_Process_2021__negative regulation of protein localization to cell periphery (GO:1904376),0.9803099397793654,1.485312688494155,0.34959349593495936,1.0,1.0,2/20,1.98%,RHOQ;SAPCD2
prerank,GO_Biological_Process_2021__filopodium assembly (GO:0046847),0.981887564373516,1.4852802274464547,0.3008130081300813,1.0,1.0,1/16,1.81%,SPATA13
prerank,GO_Biological_Process_2021__vesicle transport along actin filament (GO:0030050),0.9768864320417655,1.4845609245239353,0.46825396825396826,1.0,1.0,1/19,2.31%,MYO7A
prerank,GO_Biological_Process_2021__regulation of execution phase of apoptosis (GO:1900117),0.9813875159927931,1.4845173729612724,0.3969465648854962,1.0,1.0,2/18,1.87%,DLC1;BOK
prerank,Reactome_2022__Translesion Synthesis By POLH R-HSA-110320,0.9946146752045332,1.4843548257308306,0.1016949152542373,1.0,1.0,1/19,0.54%,SLC19A1
prerank,GO_Biological_Process_2021__nuclear membrane organization (GO:0071763),0.9963835785710083,1.484272076165069,0.034782608695652174,1.0,1.0,1/19,0.37%,UBXN2A
prerank,Reactome_2022__Abortive Elongation Of HIV-1 Transcript In Absence Of Tat R-HSA-167242,-0.9930370045063172,-1.4840334516655402,0.11428571428571428,0.8734512879699406,1.0,1/22,0.70%,NELFA
prerank,Reactome_2022__RHO GTPases Activate CIT R-HSA-5625900,0.9911920698822002,1.483453312195854,0.17391304347826086,1.0,1.0,1/19,0.88%,PPP1R12A
prerank,GO_Biological_Process_2021__NAD biosynthetic process (GO:0009435),0.9818492260763831,1.4834085080474109,0.38095238095238093,1.0,1.0,2/19,1.82%,QPRT;PTGS2
prerank,GO_Biological_Process_2021__positive regulation of B cell proliferation (GO:0030890),0.9800325946057162,1.483348104242947,0.35398230088495575,1.0,1.0,1/25,2.00%,NFATC2
prerank,GO_Biological_Process_2021__negative regulation of mRNA processing (GO:0050686),0.9839654798482933,1.4828675687225858,0.3559322033898305,1.0,1.0,1/15,1.61%,PCBP4
prerank,Reactome_2022__Defective Intrinsic Pathway For Apoptosis R-HSA-9734009,-0.9919215499726101,-1.4828031129656487,0.13675213675213677,0.8794880847071719,1.0,1/23,0.81%,APP
prerank,Reactome_2022__Signaling To RAS R-HSA-167044,0.980231548924818,1.4815966135217415,0.41732283464566927,1.0,1.0,1/19,1.98%,MAPK13
prerank,GO_Biological_Process_2021__fatty acid transport (GO:0015908),0.980078527063684,1.4815634700482339,0.4,1.0,1.0,1/18,1.99%,APOE
prerank,GO_Biological_Process_2021__cardiac ventricle development (GO:0003231),0.9874233625056765,1.4812224725162364,0.25547445255474455,1.0,1.0,1/19,1.26%,SALL1
prerank,Reactome_2022__Phosphorylation Of APC/C R-HSA-176412,0.9825753733083166,1.4810737240591558,0.3082706766917293,1.0,1.0,1/20,1.74%,UBE2C
prerank,Elsevier_Pathway_Collection__EctodysplasinR -> AP-1 Signaling,0.9795390985092192,1.4810495996476434,0.37398373983739835,1.0,1.0,1/19,2.05%,EDA2R
prerank,GO_Biological_Process_2021__positive regulation of phospholipase activity (GO:0010518),-0.9819972682624342,-1.4809256626005531,0.34615384615384615,0.8902113866935212,1.0,1/23,1.81%,NTF3
prerank,Reactome_2022__Prostacyclin Signaling Thru Prostacyclin Receptor R-HSA-392851,0.976659199241523,1.4804648347063558,0.4765625,1.0,1.0,2/17,2.34%,GNB5;GNG2
prerank,GO_Biological_Process_2021__positive regulation of transforming growth factor beta receptor signaling pathway (GO:0030511),-0.9855392798960424,-1.4801263843896846,0.25735294117647056,0.8902864609762324,1.0,3/22,1.46%,SLC2A10;CREBBP;TGFB1I1
prerank,GO_Biological_Process_2021__positive regulation of cellular response to transforming growth factor beta stimulus (GO:1903846),-0.9855392798960424,-1.4801263843896846,0.25735294117647056,0.8902864609762324,1.0,3/22,1.46%,SLC2A10;CREBBP;TGFB1I1
prerank,Reactome_2022__Cellular Response To Starvation R-HSA-9711097,0.99353741554118,1.4797365010346193,0.0,1.0,1.0,2/148,0.65%,FNIP2;FNIP1
prerank,Elsevier_Pathway_Collection__IL6 Expression Targets -> Nociception,0.9818011743007173,1.479605196108658,0.33858267716535434,1.0,1.0,1/26,1.82%,PTGS2
prerank,GO_Biological_Process_2021__negative regulation of amyloid precursor protein catabolic process (GO:1902992),0.9800770283511824,1.4795576151804517,0.38461538461538464,1.0,1.0,1/19,1.99%,APOE
prerank,GO_Biological_Process_2021__positive regulation of cellular component movement (GO:0051272),0.9801071436209026,1.4794751097303158,0.34782608695652173,1.0,1.0,1/26,1.99%,CAVIN1
prerank,GO_Biological_Process_2021__regulation of vacuole organization (GO:0044088),-0.9914603603591543,-1.4794457596318817,0.1297709923664122,0.8927407334054963,1.0,1/21,0.86%,TBC1D12
prerank,Reactome_2022__Influenza Viral RNA Transcription And Replication R-HSA-168273,0.9894768133857186,1.4793855051239098,0.008264462809917356,1.0,1.0,1/135,1.05%,NUP210
prerank,GO_Biological_Process_2021__sterol transport (GO:0015918),-0.9857301265485798,-1.4789925434429787,0.20491803278688525,0.8931187475778299,1.0,1/21,1.43%,ARV1
prerank,Elsevier_Pathway_Collection__Apoptosis Block in Melanoma Cell,0.9914140856537129,1.478690475155474,0.07086614173228346,1.0,1.0,1/39,0.86%,PTK2
prerank,GO_Biological_Process_2021__phosphate ion transport (GO:0006817),0.9985368113663909,1.477932665584102,0.016129032258064516,1.0,1.0,1/17,0.15%,SLC20A2
prerank,GO_Biological_Process_2021__negative regulation of cellular carbohydrate metabolic process (GO:0010677),0.998074886066965,1.477889413665555,0.03418803418803419,1.0,1.0,1/22,0.20%,PPARA
prerank,GO_Biological_Process_2021__cell communication by electrical coupling involved in cardiac conduction (GO:0086064),0.9879626668672052,1.47744208574246,0.22535211267605634,1.0,1.0,1/16,1.21%,GJC1
prerank,Elsevier_Pathway_Collection__TLR -> AP-1 Signaling,-0.9978052788477072,-1.4774113618806486,0.046875,0.9018945962761926,1.0,1/23,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__DNA packaging (GO:0006323),0.981308396670431,1.477359786176619,0.3798449612403101,1.0,1.0,1/18,1.87%,NAA10
prerank,GO_Biological_Process_2021__regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway (GO:1900739),0.990921465058664,1.4771611266583484,0.14814814814814814,1.0,1.0,2/26,0.91%,YWHAQ;TFDP2
prerank,GO_Biological_Process_2021__positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway (GO:1900740),0.990921465058664,1.4771611266583484,0.14814814814814814,1.0,1.0,2/26,0.91%,YWHAQ;TFDP2
prerank,Elsevier_Pathway_Collection__HPV E6 and E7 Induced Block of Apoptosis in Keratinocytes,-0.9885384076421988,-1.4767047010469183,0.16,0.9041327660396623,1.0,1/19,1.15%,RB1
prerank,GO_Biological_Process_2021__positive regulation of response to wounding (GO:1903036),0.983689106325387,1.4764750903011863,0.2773109243697479,1.0,1.0,2/27,1.64%,PTK2;ANXA1
prerank,Reactome_2022__G Beta:Gamma Signaling Thru BTK R-HSA-8964315,0.9766602000157881,1.4763749765011538,0.484375,1.0,1.0,2/16,2.34%,GNB5;GNG2
prerank,GO_Biological_Process_2021__protein K63-linked deubiquitination (GO:0070536),-0.9883011548128745,-1.4761526490409422,0.10344827586206896,0.9054301945972185,1.0,1/31,1.18%,BRCC3
prerank,Elsevier_Pathway_Collection__Dentin and Enamel Dysruprion in Bloch-Sulzberger Syndrome,0.9834229115832246,1.4761218218875962,0.29310344827586204,1.0,1.0,1/18,1.66%,TUFT1
prerank,GO_Biological_Process_2021__microtubule depolymerization (GO:0007019),0.9824658191186453,1.4760552797743098,0.3458646616541353,1.0,1.0,2/17,1.76%,CCSAP;STMN3
prerank,Reactome_2022__PKA-mediated Phosphorylation Of CREB R-HSA-111931,0.9957683271785592,1.476017233916412,0.0847457627118644,1.0,1.0,1/18,0.43%,CREB1
prerank,GO_Biological_Process_2021__endoplasmic reticulum calcium ion homeostasis (GO:0032469),-0.9791562642491473,-1.475992604777197,0.38524590163934425,0.9034249715911126,1.0,2/20,2.09%,THADA;PML
prerank,GO_Biological_Process_2021__artery development (GO:0060840),-0.990152233537148,-1.475765393522843,0.16296296296296298,0.9021897475347251,1.0,1/23,0.99%,SLC2A10
prerank,WikiPathway_2021_Human__Nicotine Activity on Dopaminergic Neurons WP1602,0.976657229762149,1.4755710452084643,0.43902439024390244,1.0,1.0,2/19,2.34%,DRD4;GNG2
prerank,Elsevier_Pathway_Collection__Lactate as a Signaling Molecule in Cancer Cells,-0.9824179247046994,-1.475345879242809,0.2734375,0.9024711975560279,1.0,1/24,1.76%,CD44
prerank,GO_Biological_Process_2021__negative regulation of interleukin-2 production (GO:0032703),0.9846120234263763,1.474894621152272,0.29545454545454547,1.0,1.0,1/22,1.54%,HOMER3
prerank,GO_Biological_Process_2021__regulation of DNA recombination at telomere (GO:0072695),0.9784988647050589,1.4747770540352096,0.43333333333333335,1.0,1.0,1/21,2.15%,ACD
prerank,GO_Biological_Process_2021__negative regulation of DNA recombination at telomere (GO:0048239),0.9784988647050589,1.4747770540352096,0.43333333333333335,1.0,1.0,1/21,2.15%,ACD
prerank,Reactome_2022__Sema3A PAK Dependent Axon Repulsion R-HSA-399954,0.9893481648405065,1.4736977611121767,0.225,1.0,1.0,1/16,1.07%,ARHGEF7
prerank,GO_Biological_Process_2021__protein N-linked glycosylation via asparagine (GO:0018279),0.9880339353291394,1.4736857864595294,0.1510791366906475,1.0,1.0,2/30,1.20%,DAD1;ASGR2
prerank,GO_Biological_Process_2021__respiratory chain complex IV assembly (GO:0008535),-0.9957670210526421,-1.473507270914018,0.0967741935483871,0.9135304684710785,1.0,1/23,0.43%,COX16
prerank,GO_Biological_Process_2021__sodium ion import across plasma membrane (GO:0098719),-0.9817714085363538,-1.473384508598342,0.37593984962406013,0.911421230736869,1.0,1/16,1.83%,SLC9A9
prerank,Reactome_2022__Nef-mediated Downmodulation Of Cell Surface Receptors By Recruitment To Clathrin Adapters R-HSA-164938,0.9877682350367203,1.4733725791430776,0.23300970873786409,1.0,1.0,1/20,1.23%,CD4
prerank,GO_Biological_Process_2021__phosphatidylserine acyl-chain remodeling (GO:0036150),-0.9881929363740516,-1.4732926427298954,0.18518518518518517,0.9091533717232385,1.0,1/19,1.19%,PLAAT3
prerank,GO_Biological_Process_2021__myoblast fusion (GO:0007520),-0.9775461216257924,-1.4732340367856949,0.46218487394957986,0.9065909943432973,1.0,2/15,2.26%,ADAMTS5;CD9
prerank,WikiPathway_2021_Human__Urea cycle and metabolism of amino groups WP497,0.9761547510868318,1.4730054654543971,0.472,1.0,1.0,2/21,2.39%,SMS;PYCR1
prerank,Reactome_2022__G Beta:Gamma Signaling Thru PLC Beta R-HSA-418217,0.976658300801197,1.4730004324964727,0.47107438016528924,1.0,1.0,2/18,2.34%,GNB5;GNG2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Photoaging,-0.9807668385813809,-1.4728192369320476,0.3333333333333333,0.9068193973142271,1.0,1/21,1.93%,MMP2
prerank,WikiPathway_2021_Human__SARS coronavirus and innate immunity WP4912,0.9979217496728418,1.4725525062576652,0.04411764705882353,1.0,1.0,1/17,0.21%,TRAF3
prerank,Elsevier_Pathway_Collection__EGFR and PTAFR Signaling in Ovarian Cancer,-0.9879615851074924,-1.4724731020552706,0.25757575757575757,0.9065342440571131,1.0,1/21,1.21%,RAP1A
prerank,Elsevier_Pathway_Collection__Proteins Involved in Sleep Disorders,0.984619306162597,1.4724094909843677,0.3333333333333333,1.0,1.0,2/16,1.54%,MAOA;SLC6A4
prerank,GO_Biological_Process_2021__regulation of macrophage derived foam cell differentiation (GO:0010743),0.9980731434967567,1.4722445171048637,0.02631578947368421,1.0,1.0,1/29,0.20%,PPARA
prerank,"Reactome_2022__Antigen Presentation: Folding, Assembly, Peptide Loading Of Class I MHC R-HSA-983170",-0.9780667750509008,-1.4721707759421125,0.36585365853658536,0.9062168955101731,1.0,1/28,2.20%,HLA-B
prerank,GO_Biological_Process_2021__oligodendrocyte differentiation (GO:0048709),-0.9858074640845067,-1.4719529052775637,0.23943661971830985,0.9048274477479776,1.0,1/20,1.43%,SHH
prerank,GO_Biological_Process_2021__regulation of interleukin-1 production (GO:0032652),0.9836966947092859,1.471694460537914,0.30833333333333335,1.0,1.0,2/16,1.64%,MEFV;ANXA1
prerank,GO_Biological_Process_2021__RNA destabilization (GO:0050779),0.9987675485644337,1.4701572542507844,0.008264462809917356,1.0,1.0,1/17,0.13%,YTHDF3
prerank,MSigDB_Oncogenic_Signatures__SINGH KRAS DEPENDENCY SIGNATURE ,0.9813128740797801,1.4699802936784927,0.34306569343065696,1.0,1.0,2/16,1.88%,MAOA;DAPP1
prerank,WikiPathway_2021_Human__Extracellular vesicle-mediated signaling in recipient cells WP2870,0.9772201176421074,1.4697542253863676,0.4444444444444444,1.0,1.0,1/29,2.28%,HGF
prerank,"GO_Biological_Process_2021__RNA phosphodiester bond hydrolysis, endonucleolytic (GO:0090502)",-0.9810829300004488,-1.4697470700459365,0.37593984962406013,0.9179746106072637,1.0,2/15,1.90%,LACTB2;NYNRIN
prerank,GO_Biological_Process_2021__negative regulation of signal transduction by p53 class mediator (GO:1901797),-0.9824240359070874,-1.469397331650978,0.2558139534883721,0.9174104013872025,1.0,1/17,1.76%,CD44
prerank,GO_Biological_Process_2021__negative regulation of phosphate metabolic process (GO:0045936),-0.9850373258007851,-1.4693836807603287,0.24031007751937986,0.9146211762591493,1.0,1/22,1.50%,BMP4
prerank,GO_Biological_Process_2021__protein autoprocessing (GO:0016540),-0.9774653515368433,-1.4690760183639942,0.43859649122807015,0.9143948929528203,1.0,1/16,2.26%,TMPRSS2
prerank,Elsevier_Pathway_Collection__Tight Junction Assembly (Occludin),0.9978823631954786,1.4689580253340677,0.02702702702702703,1.0,1.0,1/24,0.22%,TJP1
prerank,Reactome_2022__Inactivation Of APC/C Via Direct Inhibition Of APC/C Complex R-HSA-141430,0.9825743574738253,1.4689235091276613,0.35074626865671643,1.0,1.0,1/21,1.74%,UBE2C
prerank,Reactome_2022__Golgi-to-ER Retrograde Transport R-HSA-8856688,0.9759951914295752,1.468797086546854,0.09174311926605505,1.0,1.0,5/110,2.41%,CENPE;RAB3GAP1;AGPAT3;KIF23;KIF3B
prerank,Elsevier_Pathway_Collection__Nicotine anti-Inflammatory Effect in Ulcerative Colitis,-0.9815684650196638,-1.4685932063564702,0.312,0.915238356963262,1.0,1/28,1.85%,TICAM2
prerank,Elsevier_Pathway_Collection__T-Cell Genetic Rearrangements in Acute Lymphoblastic Leukemia,-0.9846573563177107,-1.4685452774534447,0.24166666666666667,0.9127374223146394,1.0,1/16,1.54%,CCND2
prerank,GO_Biological_Process_2021__regulation of cardiac muscle cell proliferation (GO:0060043),0.9788104145040581,1.468325455702997,0.4444444444444444,1.0,1.0,2/20,2.12%,VGLL4;RBP4
prerank,Reactome_2022__APC/C:Cdc20 Mediated Degradation Of Cyclin B R-HSA-174048,0.9825719791210361,1.468218176359172,0.3333333333333333,1.0,1.0,1/24,1.74%,UBE2C
prerank,GO_Biological_Process_2021__modulation of excitatory postsynaptic potential (GO:0098815),-0.9919598714669166,-1.468149763610429,0.09230769230769231,0.9125855236075697,1.0,2/25,0.81%,PTK2B;APP
prerank,GO_Biological_Process_2021__negative regulation of protein dephosphorylation (GO:0035308),0.9891146074447771,1.4678526687493174,0.22727272727272727,1.0,1.0,1/21,1.09%,PPP1R16B
prerank,TRRUST_Transcription_Factors_2019__LEF1 mouse,0.9818847835474354,1.4676662630331527,0.3170731707317073,1.0,1.0,3/23,1.82%,LRP5;CDH1;PTGS2
prerank,Elsevier_Pathway_Collection__Autophagic-Lysosomal System Decline Associated with Aging,0.9837259868536912,1.4673601363173843,0.2413793103448276,1.0,1.0,2/29,1.63%,ERN1;LAMP2
prerank,TRRUST_Transcription_Factors_2019__RXRA human,0.9910771908168005,1.467352262139094,0.1721311475409836,1.0,1.0,1/18,0.90%,PLD1
prerank,Elsevier_Pathway_Collection__beta-Catenin/Androgen Receptor Signaling in Prostate Cancer,0.9803849510059534,1.4672073682521893,0.424,1.0,1.0,3/23,1.97%,LRP5;CDH1;AXIN2
prerank,TRRUST_Transcription_Factors_2019__HDAC9 human,-0.9919634392433743,-1.4671110362907551,0.10218978102189781,0.9168772469601237,1.0,2/16,0.81%,TNFRSF10B;APP
prerank,Elsevier_Pathway_Collection__Genes with Mutations in Cancer Metabolic Reprogramming,-0.9885391344267359,-1.466899089726937,0.208955223880597,0.9156803700632256,1.0,1/19,1.15%,RB1
prerank,Reactome_2022__Aflatoxin Activation And Detoxification R-HSA-5423646,-0.980349759687426,-1.4667669496555191,0.4090909090909091,0.9137569066972006,1.0,3/19,1.98%,GGT5;AKR7A3;CYP1A2
prerank,Elsevier_Pathway_Collection__TRPM7/8 in Pancreatic Adenocarcinoma,0.9957678302820754,1.466493841851544,0.06086956521739131,1.0,1.0,1/21,0.43%,CREB1
prerank,GO_Biological_Process_2021__mitochondrion localization (GO:0051646),0.9991905269377195,1.4660120299190125,0.01652892561983471,1.0,1.0,1/18,0.08%,TRAK1
prerank,TRRUST_Transcription_Factors_2019__NRF1 human,-0.9770823927621857,-1.4660007006790752,0.453125,0.9165853327598095,1.0,1/15,2.30%,GALNT3
prerank,WikiPathway_2021_Human__Glutathione metabolism WP100,-0.9915774357933774,-1.4659080908024245,0.1794871794871795,0.9147362769472899,1.0,2/20,0.85%,GSTA1;GGT5
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Dysregulated DNA Repair,0.9923051057868362,1.4656838936757284,0.12096774193548387,1.0,1.0,1/25,0.77%,MSH2
prerank,TRRUST_Transcription_Factors_2019__ETS2 mouse,0.9877668680353842,1.4655637274232676,0.2109375,1.0,1.0,1/23,1.23%,CD4
prerank,GO_Biological_Process_2021__negative regulation of reactive oxygen species metabolic process (GO:2000378),0.9786939788277805,1.4653591575093967,0.3728813559322034,1.0,1.0,3/22,2.14%,AATF;PPARA;SLC30A10
prerank,Elsevier_Pathway_Collection__OPTN Effects on NF-kB Signaling in Glaucoma,0.9788769736016231,1.4653335986627727,0.4380165289256198,1.0,1.0,1/26,2.11%,OPTN
prerank,GO_Biological_Process_2021__chaperone cofactor-dependent protein refolding (GO:0051085),-0.9923429784436004,-1.4652258487233671,0.13178294573643412,0.9172729238218179,1.0,1/25,0.77%,DNAJB14
prerank,Elsevier_Pathway_Collection__CHRM1/2/3/5 -> Ion Channels,0.9797301945742524,1.464840615039694,0.4094488188976378,1.0,1.0,2/23,2.03%,KCNC1;TRPV1
prerank,GO_Biological_Process_2021__endoplasmic reticulum tubular network organization (GO:0071786),-0.9912323036338853,-1.4647978632823517,0.16546762589928057,0.9175648606133492,1.0,1/15,0.88%,ATL2
prerank,GO_Biological_Process_2021__ribonucleoprotein complex assembly (GO:0022618),0.9863435967215758,1.4647666115667441,0.03389830508474576,1.0,1.0,1/133,1.36%,SF3A2
prerank,Elsevier_Pathway_Collection__Cryopyrin (NLPR3) Associated Periodic Syndromes,-0.9815695783102077,-1.4646044695052423,0.3488372093023256,0.9161181416185219,1.0,1/26,1.85%,TICAM2
prerank,Reactome_2022__Miscellaneous Transport And Binding Events R-HSA-5223345,0.985342957042286,1.4645585638990748,0.304,1.0,1.0,1/23,1.47%,LRRC8C
prerank,WikiPathway_2021_Human__Galanin receptor pathway WP4970,0.9957684954055084,1.4640462240020526,0.072992700729927,1.0,1.0,1/18,0.43%,CREB1
prerank,WikiPathway_2021_Human__TP53 network WP1742,0.9813471240269729,1.4638466905985892,0.3684210526315789,1.0,1.0,1/18,1.87%,BOK
prerank,Reactome_2022__Downstream Signaling Of Activated FGFR3 R-HSA-5654708,0.9763077431827838,1.4634339955920863,0.46923076923076923,1.0,1.0,1/20,2.37%,FGF1
prerank,Reactome_2022__MicroRNA (miRNA) Biogenesis R-HSA-203927,0.9912281645587632,1.463234235133019,0.1732283464566929,1.0,1.0,1/24,0.88%,DROSHA
prerank,GO_Biological_Process_2021__negative regulation of cation channel activity (GO:2001258),0.9789998929789487,1.4629537670318835,0.41379310344827586,1.0,1.0,3/23,2.11%,DRD4;GNB5;GPR35
prerank,Reactome_2022__LDL Clearance R-HSA-8964038,0.9850772776113115,1.4626593979875184,0.30708661417322836,1.0,1.0,1/17,1.49%,SOAT2
prerank,GO_Biological_Process_2021__negative regulation of transposition (GO:0010529),-0.9836105184953183,-1.4626510852309746,0.2867647058823529,0.9282639652233534,1.0,1/23,1.64%,PIWIL4
prerank,KEGG_2021_Human__Fatty acid biosynthesis,0.9778516780080831,1.4625416915658422,0.4666666666666667,1.0,1.0,3/18,2.22%,ACSF3;ACACA;ACSL5
prerank,GO_Biological_Process_2021__mitochondrial fission (GO:0000266),-0.9924234208052987,-1.4624942165998835,0.08823529411764706,0.9267935207980692,1.0,1/18,0.76%,MTFR1
prerank,WikiPathway_2021_Human__Complement Activation WP545,-0.9837653624467217,-1.4624333849247608,0.28448275862068967,0.924626452047173,1.0,1/22,1.63%,C1R
prerank,GO_Biological_Process_2021__monovalent inorganic cation homeostasis (GO:0055067),-0.9761890230478707,-1.4620342503925974,0.461038961038961,0.9247318981425302,1.0,1/23,2.39%,SLC12A8
prerank,GO_Biological_Process_2021__peptidyl-asparagine modification (GO:0018196),0.9880334476728077,1.4618046181435547,0.16058394160583941,1.0,1.0,2/31,1.20%,DAD1;ASGR2
prerank,GO_Biological_Process_2021__histone H2A monoubiquitination (GO:0035518),0.9969601780673465,1.461804378720167,0.0625,1.0,1.0,1/17,0.31%,BCOR
prerank,Reactome_2022__Metalloprotease DUBs R-HSA-5689901,-0.9883052579142255,-1.461483422087596,0.1864406779661017,0.9266218003831157,1.0,1/24,1.18%,BRCC3
prerank,GO_Biological_Process_2021__nitric oxide mediated signal transduction (GO:0007263),0.9800805049101902,1.4613873993622783,0.4098360655737705,1.0,1.0,1/16,1.99%,APOE
prerank,GO_Biological_Process_2021__regulation of protein ubiquitination (GO:0031396),0.9763409989188154,1.4612039335831513,0.14912280701754385,1.0,1.0,3/107,2.37%,HDAC8;SH3RF2;PRR7
prerank,WikiPathway_2021_Human__Blood Clotting Cascade WP272,0.9793849207556686,1.4609906666833592,0.417910447761194,1.0,1.0,2/22,2.07%,F7;SERPINE1
prerank,Elsevier_Pathway_Collection__ADRA2C/ADRB2 -> Vasoconstriction,-0.9879590805068088,-1.460918097252899,0.24305555555555555,0.9282249173420728,1.0,1/24,1.21%,RAP1A
prerank,Elsevier_Pathway_Collection__Amyloid beta Traffic and Degradation in Extracellular Matrix in Alzheimer's Disease,0.9801132112626407,1.4608013833524682,0.3870967741935484,1.0,1.0,2/24,1.99%,A2M;APOE
prerank,Reactome_2022__APC-Cdc20 Mediated Degradation Of Nek2A R-HSA-179409,0.9825696671868097,1.4607758499836432,0.3435114503816794,1.0,1.0,1/26,1.74%,UBE2C
prerank,GO_Biological_Process_2021__regulation of T cell migration (GO:2000404),-0.9781573552417262,-1.4607150437074854,0.4621212121212121,0.926977278906185,1.0,2/19,2.19%,APP;TNFRSF14
prerank,WikiPathway_2021_Human__NRF2-ARE regulation WP4357,-0.98738286932024,-1.4604517281144849,0.18604651162790697,0.9262741389327562,1.0,1/23,1.27%,GSTA2
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Psoriasis,-0.9796136192073017,-1.4601661469838607,0.392,0.9257641672029212,1.0,2/24,2.05%,RORC;KLF4
prerank,GO_Biological_Process_2021__translational termination (GO:0006415),-0.9842609256616387,-1.4599143356800797,0.032520325203252036,0.9249117814829035,1.0,3/95,1.58%,MRPS28;MRPS9;MRRF
prerank,GO_Biological_Process_2021__carbohydrate biosynthetic process (GO:0016051),0.9806112605820301,1.4597888434476067,0.3805970149253731,1.0,1.0,1/23,1.94%,FUT6
prerank,GO_Biological_Process_2021__regulation of monocyte chemotaxis (GO:0090025),0.9793838670956301,1.4597729046120507,0.376,1.0,1.0,2/23,2.07%,MOSPD2;SERPINE1
prerank,WikiPathway_2021_Human__Vitamin D in inflammatory diseases WP4482,-0.9782706373713244,-1.4595420740198433,0.43703703703703706,0.9252333750322476,1.0,3/22,2.19%,MAP2K6;NR3C1;VDR
prerank,GO_Biological_Process_2021__autonomic nervous system development (GO:0048483),0.977391128153469,1.4594049560333546,0.4297520661157025,1.0,1.0,2/16,2.27%,ISX;FN1
prerank,Elsevier_Pathway_Collection__Fatty Acids in Hypertension and Atherosclerosis Development,0.9793506365855198,1.4593406179106923,0.4222222222222222,1.0,1.0,1/15,2.07%,SERPINE1
prerank,WikiPathway_2021_Human__7-oxo-C and 7beta-HC pathways WP5064,0.9896130895623839,1.4593207748589305,0.14492753623188406,1.0,1.0,2/27,1.05%,EPHX2;SLC27A2
prerank,GO_Biological_Process_2021__oligodendrocyte development (GO:0014003),0.9866177904999348,1.4592533396792338,0.2336448598130841,1.0,1.0,1/16,1.34%,CNTNAP1
prerank,KEGG_2021_Human__Arginine biosynthesis,0.9847666359718247,1.4590026287059867,0.26356589147286824,1.0,1.0,1/21,1.53%,GLS
prerank,GO_Biological_Process_2021__positive regulation of interleukin-17 production (GO:0032740),0.991038155847582,1.4583738221621443,0.15,1.0,1.0,1/20,0.90%,NOD2
prerank,GO_Biological_Process_2021__negative regulation of cytokine production involved in inflammatory response (GO:1900016),0.9883862650921267,1.4583138599660221,0.2595419847328244,1.0,1.0,2/19,1.17%,PPARA;MEFV
prerank,Reactome_2022__Signaling By KIT In Disease R-HSA-9669938,-0.9829616564163509,-1.4582724521111827,0.31851851851851853,0.9323794973536463,1.0,1/19,1.71%,STAT5A
prerank,TRRUST_Transcription_Factors_2019__ING4 human,0.9818111168032035,1.4580444271050705,0.35294117647058826,1.0,1.0,1/15,1.82%,PTGS2
prerank,WikiPathway_2021_Human__Estrogen signaling pathway WP712,0.9957674572378385,1.4579240835122664,0.05454545454545454,1.0,1.0,1/22,0.43%,CREB1
prerank,GO_Biological_Process_2021__N-acetylglucosamine metabolic process (GO:0006044),-0.9786196223220953,-1.4571450593227118,0.3798449612403101,0.93816589122064,1.0,1/15,2.14%,MGAT3
prerank,Elsevier_Pathway_Collection__ADRA2C/ADRB2 -> Synaptic Endocytosis,-0.9879581454406221,-1.4570252648704325,0.16778523489932887,0.9364595271277757,1.0,1/26,1.21%,RAP1A
prerank,GO_Biological_Process_2021__female gamete generation (GO:0007292),0.9919591875045513,1.4565659776963888,0.16806722689075632,1.0,1.0,1/24,0.81%,PARN
prerank,GO_Biological_Process_2021__response to steroid hormone (GO:0048545),-0.9914966790039642,-1.4561113653694011,0.11538461538461539,0.9408592213192924,1.0,3/31,0.86%,CATSPER3;NR3C1;TFPI
prerank,TRRUST_Transcription_Factors_2019__IRF1 mouse,-0.9773038672433187,-1.4560274216756908,0.4152542372881356,0.9387435632791555,1.0,1/22,2.27%,CIITA
prerank,GO_Biological_Process_2021__translational elongation (GO:0006414),-0.9902730865945278,-1.4560002837288288,0.008130081300813009,0.9361787357370669,1.0,2/102,0.98%,MRPS28;MRPS9
prerank,TRRUST_Transcription_Factors_2019__IRF8 mouse,-0.9761173465598292,-1.4558709489267734,0.46017699115044247,0.9345285909297246,1.0,2/21,2.40%,GAS2;SPI1
prerank,GO_Biological_Process_2021__positive regulation of peptidase activity (GO:0010952),0.980498218495265,1.4558562172113214,0.42735042735042733,1.0,1.0,1/21,1.95%,CTSH
prerank,Reactome_2022__Regulation Of mRNA Stability By Proteins That Bind AU-rich Elements R-HSA-450531,0.9880432246035691,1.4556321413163749,0.05084745762711865,1.0,1.0,2/86,1.20%,PARN;PSMB9
prerank,GO_Biological_Process_2021__regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway (GO:1901028),0.9813472120791685,1.4556015671910427,0.38738738738738737,1.0,1.0,1/18,1.87%,BOK
prerank,Elsevier_Pathway_Collection__IL6 Promotes Inflammation in Muscular Dystrophies,-0.9766870226681015,-1.4553774397456654,0.38461538461538464,0.9357121680934093,1.0,2/29,2.34%,ADAM10;VAV1
prerank,GO_Biological_Process_2021__regulation of viral release from host cell (GO:1902186),-0.9791126827290557,-1.4552469748911014,0.4322033898305085,0.9340322138770127,1.0,1/22,2.09%,PML
prerank,KEGG_2021_Human__Steroid biosynthesis,0.9833482099229371,1.4552404574671427,0.34328358208955223,1.0,1.0,2/19,1.67%,SOAT2;CYP27B1
prerank,WikiPathway_2021_Human__Urea cycle and associated pathways WP4595,0.9761099617447768,1.4549650737102098,0.4883720930232558,1.0,1.0,1/24,2.39%,PYCR1
prerank,GO_Biological_Process_2021__dendritic spine organization (GO:0097061),0.9983809823322062,1.4549119233551822,0.008130081300813009,1.0,1.0,1/27,0.17%,ITGA3
prerank,GO_Biological_Process_2021__regulation of chromosome segregation (GO:0051983),0.9868107308940244,1.454784329717458,0.21666666666666667,1.0,1.0,2/17,1.33%,SMC5;MKI67
prerank,Elsevier_Pathway_Collection__Desmosome Assembly,0.9830043718518924,1.4547716117916352,0.3416666666666667,1.0,1.0,2/17,1.71%,PKP4;CDH1
prerank,GO_Biological_Process_2021__positive regulation of release of cytochrome c from mitochondria (GO:0090200),0.9928824646069883,1.4545097915318823,0.14166666666666666,1.0,1.0,1/23,0.71%,PLAUR
prerank,GO_Biological_Process_2021__negative regulation of lipid biosynthetic process (GO:0051055),-0.9770381854859262,-1.4543217617829183,0.4745762711864407,0.9381704230617794,1.0,1/21,2.30%,ASXL3
prerank,GO_Biological_Process_2021__receptor catabolic process (GO:0032801),-0.9889603953444926,-1.4540227395409473,0.17073170731707318,0.9377262243770996,1.0,2/24,1.11%,UVRAG;NEDD4
prerank,GO_Biological_Process_2021__establishment of protein localization to endoplasmic reticulum (GO:0072599),0.9826966721137096,1.4538258828575932,0.25806451612903225,1.0,1.0,2/17,1.74%,RAB3GAP1;MAN1A1
prerank,GO_Biological_Process_2021__tail-anchored membrane protein insertion into ER membrane (GO:0071816),0.9962683231446727,1.4536544175889965,0.07258064516129033,1.0,1.0,1/17,0.38%,GET3
prerank,WikiPathway_2021_Human__Nucleotide metabolism WP404,0.9762734849858097,1.4528361772034524,0.5169491525423728,1.0,1.0,2/18,2.38%,HPRT1;RRM2
prerank,GO_Biological_Process_2021__blood vessel endothelial cell migration (GO:0043534),-0.9769184785103966,-1.4527349765790152,0.42028985507246375,0.9452470429264188,1.0,1/23,2.31%,EFNB2
prerank,GO_Biological_Process_2021__regulation of oxidative stress-induced intrinsic apoptotic signaling pathway (GO:1902175),-0.990348083950544,-1.4526710818371413,0.15827338129496402,0.9429962477733569,1.0,2/17,0.98%,VNN1;SOD2
prerank,GO_Biological_Process_2021__regulation of epidermal cell differentiation (GO:0045604),-0.9792323159439689,-1.452454503414567,0.40476190476190477,0.9418506195812617,1.0,3/22,2.09%,SGPP1;BMP4;AQP3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Fragile X Syndrome,-0.9919627545288957,-1.4522844105895039,0.18803418803418803,0.940611547907251,1.0,2/18,0.81%,ADAM10;APP
prerank,GO_Biological_Process_2021__leukocyte adhesion to vascular endothelial cell (GO:0061756),0.9878839297133558,1.4520864584743334,0.21904761904761905,1.0,1.0,1/19,1.21%,ITGA4
prerank,GO_Biological_Process_2021__positive regulation of calcium ion transmembrane transport (GO:1904427),0.9858441157526097,1.452053844026471,0.18181818181818182,1.0,1.0,2/25,1.42%,THY1;CX3CL1
prerank,KEGG_2021_Human__Mismatch repair,0.9923055109707386,1.451810835388494,0.16793893129770993,1.0,1.0,1/23,0.77%,MSH2
prerank,Reactome_2022__Synthesis Of IP3 And IP4 In Cytosol R-HSA-1855204,-0.9809562215037828,-1.4516450077067728,0.3023255813953488,0.9428174703945715,1.0,1/26,1.91%,PLCB4
prerank,Reactome_2022__Mismatch Repair R-HSA-5358508,0.9776226989569277,1.451553774333251,0.4418604651162791,1.0,1.0,2/15,2.24%,MSH2;LRIG1
prerank,GO_Biological_Process_2021__regulation of mitotic spindle assembly (GO:1901673),0.9936526000636485,1.451449483621212,0.12295081967213115,1.0,1.0,1/19,0.64%,CCSAP
prerank,GO_Biological_Process_2021__positive regulation of epithelial cell differentiation (GO:0030858),-0.9850410452126367,-1.4514066005931838,0.30578512396694213,0.9420397637848887,1.0,1/16,1.50%,BMP4
prerank,GO_Biological_Process_2021__leukocyte tethering or rolling (GO:0050901),0.9878847069821485,1.4513352986218868,0.22115384615384615,1.0,1.0,1/18,1.21%,ITGA4
prerank,GO_Biological_Process_2021__activin receptor signaling pathway (GO:0032924),-0.9851166576470121,-1.4508484228718475,0.28346456692913385,0.9437040932103995,1.0,1/17,1.49%,INHBB
prerank,GO_Biological_Process_2021__chondroitin sulfate proteoglycan biosynthetic process (GO:0050650),0.9921110408418766,1.4508279445972936,0.14049586776859505,1.0,1.0,1/27,0.79%,CHST11
prerank,Elsevier_Pathway_Collection__CFL1 in Cancer Cell Motility,-0.982423764958932,-1.4504826956284453,0.3188405797101449,0.9437484209874304,1.0,1/18,1.76%,CD44
prerank,GO_Biological_Process_2021__organophosphate ester transport (GO:0015748),0.9882669052662406,1.450054056543178,0.21052631578947367,1.0,1.0,1/24,1.18%,PRELID3A
prerank,GO_Biological_Process_2021__regulation of stem cell differentiation (GO:2000736),0.9879973255668852,1.4498969865332014,0.06504065040650407,1.0,1.0,1/86,1.20%,PSMB9
prerank,GO_Biological_Process_2021__peptidyl-threonine dephosphorylation (GO:0035970),-0.9811110908561007,-1.449768472150407,0.34074074074074073,0.9465023116016305,1.0,1/22,1.89%,DUSP4
prerank,GO_Biological_Process_2021__peptidyl-lysine trimethylation (GO:0018023),0.9955347649089527,1.4497483015884929,0.056910569105691054,1.0,1.0,1/28,0.45%,SETD3
prerank,Elsevier_Pathway_Collection__Apoptosis of Chondrocyte,-0.9978048395044967,-1.44973451238293,0.02586206896551724,0.9440918223009318,1.0,1/22,0.23%,MAP2K6
prerank,Reactome_2022__RAF-independent MAPK1/3 Activation R-HSA-112409,-0.9811104736998001,-1.4496726884285862,0.3228346456692913,0.9418809077476004,1.0,1/23,1.89%,DUSP4
prerank,Elsevier_Pathway_Collection__Antiphospholipid Antibodies in Platelets and Coagulation Cascade,-0.9869983499127246,-1.4496622716683614,0.19858156028368795,0.9367648505913992,1.0,1/23,1.31%,PROS1
prerank,Elsevier_Pathway_Collection__Platelet and Coagulation Cascade Activation by Antiphospholipid Antibodies,-0.9869983499127246,-1.4496622716683614,0.19858156028368795,0.9367648505913992,1.0,1/23,1.31%,PROS1
prerank,Reactome_2022__RNA Polymerase III Transcription Initiation From Type 3 Promoter R-HSA-76071,-0.9909197051136545,-1.4494293179225377,0.1322314049586777,0.9359237761227088,1.0,1/27,0.91%,POU2F1
prerank,KEGG_2021_Human__Glycosylphosphatidylinositol (GPI)-anchor biosynthesis,-0.9853061527960976,-1.4494223357841,0.2518518518518518,0.9334107055380318,1.0,2/25,1.48%,PIGX;PIGZ
prerank,Elsevier_Pathway_Collection__Postsynaptic Neuron Activation,0.9797678885956251,1.4494011558962596,0.4090909090909091,1.0,1.0,3/25,2.03%,CREB1;PTGS2;TRPV1
prerank,GO_Biological_Process_2021__regulation of phosphatase activity (GO:0010921),0.9792271534561524,1.4485943066094564,0.3305785123966942,1.0,1.0,1/24,2.08%,SH3RF2
prerank,GO_Biological_Process_2021__actin nucleation (GO:0045010),0.980578439565833,1.4483703661776484,0.408,1.0,1.0,2/21,1.95%,ACTR3;SPIRE2
prerank,Reactome_2022__ER Quality Control Compartment (ERQC) R-HSA-901032,-0.9967286000020891,-1.4481826381908307,0.046875,0.9410305326987232,1.0,1/21,0.33%,AMFR
prerank,GO_Biological_Process_2021__regulation of transcription by RNA polymerase I (GO:0006356),0.9771178410279129,1.4478270114690683,0.4661016949152542,1.0,1.0,1/18,2.29%,FLNA
prerank,Elsevier_Pathway_Collection__Genes with Susceptibility for Crohn's Disease and Ulcerative Colitis,0.9910379183417584,1.4476288782831837,0.13432835820895522,1.0,1.0,1/19,0.90%,NOD2
prerank,GO_Biological_Process_2021__regulation of vasoconstriction (GO:0019229),-0.9799560076307962,-1.4474617018510865,0.34615384615384615,0.9441557476505645,1.0,2/29,2.01%,ZDHHC21;BDKRB2
prerank,GO_Biological_Process_2021__regulation of cardiac muscle cell action potential (GO:0098901),0.9945743843975102,1.4472852034813801,0.07086614173228346,1.0,1.0,1/24,0.55%,DLG1
prerank,GO_Biological_Process_2021__regulation of ubiquitin protein ligase activity (GO:1904666),0.9826165631272847,1.4472349730438128,0.2627118644067797,1.0,1.0,2/21,1.74%,CDC14B;UBE2C
prerank,Elsevier_Pathway_Collection__Microglia Activation in Parkinson's Disease,0.981809728578352,1.447159010362212,0.40298507462686567,1.0,1.0,1/16,1.82%,PTGS2
prerank,Elsevier_Pathway_Collection__Androgen Deficiency in Male Obesity,-0.9854220754768951,-1.44689991796274,0.24074074074074073,0.9453991629931112,1.0,1/22,1.46%,LIPE
prerank,GO_Biological_Process_2021__dolichol-linked oligosaccharide biosynthetic process (GO:0006488),-0.9937315439971479,-1.4468204611748852,0.10317460317460317,0.943577858427649,1.0,2/17,0.64%,ALG6;ALG13
prerank,GO_Biological_Process_2021__granulocyte differentiation (GO:0030851),-0.9761179858488263,-1.4464629897132228,0.46825396825396826,0.9439748108166307,1.0,2/20,2.40%,PML;SPI1
prerank,GO_Biological_Process_2021__cellular response to hexose stimulus (GO:0071331),0.9846147841467718,1.4461642036989983,0.288,1.0,1.0,3/24,1.55%,ERN1;PRKAA2;PDK3
prerank,Elsevier_Pathway_Collection__ActivinR -> SMAD2/3 Signaling,-0.9851126549656597,-1.4458647665059758,0.2887323943661972,0.9460095122592029,1.0,1/22,1.49%,INHBB
prerank,Elsevier_Pathway_Collection__CRH Secretion Regulation,0.9865770239906576,1.4454653304214045,0.24390243902439024,1.0,1.0,2/22,1.35%,CREB1;KCNJ10
prerank,Reactome_2022__Initial Triggering Of Complement R-HSA-166663,-0.9837672364202792,-1.4454164121821442,0.288135593220339,0.9468066390553064,1.0,1/21,1.63%,C1R
prerank,GO_Biological_Process_2021__rRNA transcription (GO:0009303),0.9801576373240499,1.4452581426098876,0.36065573770491804,1.0,1.0,2/18,1.99%,TAF1B;CAVIN1
prerank,GO_Biological_Process_2021__positive regulation of glucose transmembrane transport (GO:0010828),0.9906100751367206,1.445225312076425,0.11023622047244094,1.0,1.0,1/28,0.94%,RHOQ
prerank,Reactome_2022__PCNA-Dependent Long Patch Base Excision Repair R-HSA-5651801,0.9776563999255649,1.4451054025794454,0.448,1.0,1.0,3/21,2.24%,SLC19A1;POLE4;LRIG1
prerank,TRRUST_Transcription_Factors_2019__NANOG human,0.9933455100422893,1.4446825874039988,0.088,1.0,1.0,1/21,0.67%,CDK6
prerank,Reactome_2022__Negative Regulation Of FGFR2 Signaling R-HSA-5654727,0.9762979246339968,1.4445593678047814,0.4728682170542636,1.0,1.0,1/28,2.37%,FGF1
prerank,TRRUST_Transcription_Factors_2019__RARA human,-0.9783474955230286,-1.4445422385080844,0.4274193548387097,0.9512030248713622,1.0,2/21,2.17%,HCK;MAOB
prerank,Elsevier_Pathway_Collection__OipA Signaling in Helicobacter Pylori Infection,0.9830326237218459,1.4443802379301924,0.2966101694915254,1.0,1.0,3/32,1.71%,CREB1;PTK2;CDH1
prerank,Elsevier_Pathway_Collection__Peroxisome Protein Import and Peroxisome Division,-0.9941117881226661,-1.4440884263151021,0.07801418439716312,0.9523224270926585,1.0,1/27,0.60%,ABCD3
prerank,GO_Biological_Process_2021__'de novo' posttranslational protein folding (GO:0051084),-0.9923405672282011,-1.4440574865210092,0.13333333333333333,0.9499553241604608,1.0,1/30,0.77%,DNAJB14
prerank,GO_Biological_Process_2021__negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway (GO:1902176),-0.9903476874976714,-1.4437353489948401,0.13043478260869565,0.9501689972176628,1.0,2/18,0.98%,VNN1;SOD2
prerank,GO_Biological_Process_2021__positive regulation of phosphate metabolic process (GO:0045937),-0.9919195523627551,-1.4436816444097587,0.13380281690140844,0.9480641478228065,1.0,1/26,0.81%,APP
prerank,WikiPathway_2021_Human__Photodynamic therapy-induced unfolded protein response WP3613,0.9975370777425383,1.4434399762446055,0.008064516129032258,1.0,1.0,2/25,0.25%,ERN1;EIF2A
prerank,KEGG_2021_Human__Citrate cycle (TCA cycle),-0.9987269195896455,-1.4433876878847998,0.007874015748031496,0.9479167712481033,1.0,1/29,0.13%,SUCLG2
prerank,GO_Biological_Process_2021__regulation of transforming growth factor beta production (GO:0071634),0.9773886411816983,1.4433380067045738,0.4782608695652174,1.0,1.0,2/18,2.27%,PTGS2;FN1
prerank,"Elsevier_Pathway_Collection__Apoptosis of Cochlear Hair Cells (Noise-Induced, Mouse Model)",-0.9903056270590002,-1.4431463459064995,0.152,0.9472102251499798,1.0,1/22,0.98%,SOD2
prerank,GO_Biological_Process_2021__positive regulation of cytokinesis (GO:0032467),0.9785376300506539,1.4426193089396078,0.4444444444444444,1.0,1.0,4/25,2.16%,PKP4;SVIL;CDC14B;KIF23
prerank,GO_Biological_Process_2021__regulation of peptidase activity (GO:0052547),0.9805007113212622,1.4423348660920536,0.4188034188034188,1.0,1.0,1/19,1.95%,CTSH
prerank,Reactome_2022__Other Interleukin Signaling R-HSA-449836,0.9764984143400712,1.4423148968952648,0.4634146341463415,1.0,1.0,2/24,2.36%,CD4;STX1A
prerank,GO_Biological_Process_2021__cobalamin metabolic process (GO:0009235),0.987193129376203,1.4422288450755378,0.24166666666666667,1.0,1.0,1/17,1.28%,AMN
prerank,"Reactome_2022__FOXO-mediated Transcription Of Oxidative Stress, Metabolic And Neuronal Genes R-HSA-9615017",-0.9765366314523548,-1.4421530285498458,0.43333333333333335,0.95274367657355,1.0,4/26,2.36%,NR3C1;GLYAT;ABCA6;FBXO32
prerank,Elsevier_Pathway_Collection__Axonal Transport,0.9899197281389135,1.441668325009433,0.15384615384615385,1.0,1.0,1/25,1.01%,SORT1
prerank,GO_Biological_Process_2021__chondrocyte differentiation (GO:0002062),-0.9850716284716081,-1.4415827226220845,0.2605633802816901,0.9547481741281424,1.0,2/31,1.50%,CREB3L2;BMP4
prerank,GO_Biological_Process_2021__membrane protein ectodomain proteolysis (GO:0006509),-0.9965362892799569,-1.4414938389315386,0.03787878787878788,0.9529552167219082,1.0,1/22,0.35%,ADAM10
prerank,GO_Biological_Process_2021__mRNA metabolic process (GO:0016071),0.9865020043442141,1.4414062727804395,0.0390625,1.0,1.0,4/90,1.36%,ZNF473;ERN1;DIS3L2;SF3A2
prerank,Reactome_2022__Estrogen-dependent Gene Expression R-HSA-9018519,-0.9758038123055148,-1.441360817590333,0.13178294573643412,0.9514486895023591,1.0,4/108,2.43%,NCOA1;POU2F1;CREBBP;FOSB
prerank,GO_Biological_Process_2021__mitochondrial calcium ion transmembrane transport (GO:0006851),0.9960762415933289,1.4409164681886848,0.0603448275862069,1.0,1.0,2/21,0.40%,MICU1;SLC25A23
prerank,Elsevier_Pathway_Collection__G1/S Damage Checkpoint,0.9898845516747751,1.440574593937307,0.2,1.0,1.0,2/22,1.02%,CDK6;ATR
prerank,"WikiPathway_2021_Human__Oligodendrocyte specification and differentiation, leading to myelin components for CNS WP4304",-0.9850749800736224,-1.4402674462135374,0.3135593220338983,0.957300131299441,1.0,2/25,1.50%,SHH;BMP4
prerank,GO_Biological_Process_2021__pore complex assembly (GO:0046931),-0.996537097843278,-1.4402542182028304,0.07086614173228346,0.9549541488971001,1.0,1/19,0.35%,ADAM10
prerank,Elsevier_Pathway_Collection__Androgen Receptor and Cell Cycle in Prostate Cancer,-0.9885408188715721,-1.4400294388103658,0.2076923076923077,0.9540497512495923,1.0,1/16,1.15%,RB1
prerank,Reactome_2022__Interleukin-6 Family Signaling R-HSA-6783589,-0.9828048514905385,-1.440029366374725,0.30578512396694213,0.9515781197696711,1.0,1/23,1.73%,IL11RA
prerank,TRRUST_Transcription_Factors_2019__ARNT human,-0.9822300963963659,-1.439762409914091,0.359375,0.951133776828557,1.0,1/20,1.78%,CYP1B1
prerank,Reactome_2022__tRNA Processing In Nucleus R-HSA-6784531,0.989518698837784,1.4395049389378676,0.0743801652892562,1.0,1.0,1/56,1.05%,NUP210
prerank,MSigDB_Oncogenic_Signatures__EIF4E UP,0.9781006361408833,1.4383516321710625,0.14184397163120568,1.0,1.0,2/81,2.19%,SNTB1;MAPK8IP1
prerank,Elsevier_Pathway_Collection__Hypertrophic Cardiomyopathy,-0.9808009813247391,-1.4379411452875914,0.07936507936507936,0.962038490620252,1.0,3/81,1.93%,PTK2B;MAP2K6;MMP2
prerank,GO_Biological_Process_2021__sulfur compound catabolic process (GO:0044273),-0.9915290499830753,-1.437827426531191,0.08130081300813008,0.9604359683636543,1.0,1/39,0.85%,GGT5
prerank,GO_Biological_Process_2021__regulation of cardiac muscle cell contraction (GO:0086004),0.9945736536103587,1.4376539966809043,0.056,1.0,1.0,1/26,0.55%,DLG1
prerank,GO_Biological_Process_2021__calcium-mediated signaling using intracellular calcium source (GO:0035584),-0.990229769327837,-1.437309248410581,0.125,0.9620889393428949,1.0,1/20,0.98%,PTPRJ
prerank,"Reactome_2022__Cobalamin (Cbl, Vitamin B12) Transport And Metabolism R-HSA-196741",0.9871930425210149,1.4370711433896084,0.2396694214876033,1.0,1.0,1/17,1.28%,AMN
prerank,GO_Biological_Process_2021__positive regulation of viral transcription (GO:0050434),-0.9930355408659894,-1.4369516914563443,0.10569105691056911,0.9624342582986981,1.0,1/25,0.70%,NELFA
prerank,KEGG_2021_Human__Ribosome,-0.9902152701127214,-1.4368727741535412,0.015384615384615385,0.9605460175240902,1.0,1/129,0.98%,MRPS9
prerank,GO_Biological_Process_2021__regulation of cardiac muscle contraction (GO:0055117),0.9954563927984756,1.4366817044163593,0.05303030303030303,1.0,1.0,1/31,0.46%,ASB3
prerank,GO_Biological_Process_2021__positive regulation of immune effector process (GO:0002699),-0.9902246482229927,-1.4366721795585975,0.16806722689075632,0.9598881610659058,1.0,1/30,0.98%,PTPRJ
prerank,GO_Biological_Process_2021__cellular zinc ion homeostasis (GO:0006882),0.9786072112991921,1.4363174979242848,0.3709677419354839,1.0,1.0,1/26,2.14%,SLC30A10
prerank,Elsevier_Pathway_Collection__TSLP Signaling in Bronchial Epithelial Cell in Asthma,-0.9782200289404607,-1.4359231205979508,0.3898305084745763,0.9629762086250626,1.0,2/33,2.19%,STAT5A;VDR
prerank,Elsevier_Pathway_Collection__MYOC Associated Glaucoma,0.9789199690600852,1.4358647813450027,0.42016806722689076,1.0,1.0,2/26,2.11%,ERN1;OPTN
prerank,Elsevier_Pathway_Collection__Hyperglycemia and Hyperlipidemia Trigger beta-Cell Apoptosis,0.9798051985255292,1.4357329531178025,0.3925233644859813,1.0,1.0,2/26,2.02%,ERN1;CPE
prerank,Reactome_2022__Interleukin-7 Signaling R-HSA-1266695,-0.9829571594103166,-1.4356119944010657,0.31451612903225806,0.9629228276079362,1.0,1/23,1.71%,STAT5A
prerank,GO_Biological_Process_2021__calcium ion transport (GO:0006816),0.9797403189638683,1.4355788817628898,0.06896551724137931,1.0,1.0,4/105,2.03%,MICU1;CYP27B1;CACNA2D4;TRPV1
prerank,GO_Biological_Process_2021__cellular response to pH (GO:0071467),0.9796949705189875,1.4354856452260658,0.4700854700854701,1.0,1.0,1/16,2.03%,TRPV1
prerank,"GO_Biological_Process_2021__positive regulation of DNA-templated transcription, initiation (GO:2000144)",0.9823824939763153,1.4354262271949196,0.3233082706766917,1.0,1.0,1/21,1.76%,FOSL1
prerank,GO_Biological_Process_2021__positive regulation of T cell mediated cytotoxicity (GO:0001916),-0.9780703706256564,-1.4353878380924883,0.41353383458646614,0.9621570534545253,1.0,1/25,2.20%,HLA-B
prerank,Reactome_2022__Activation Of Matrix Metalloproteinases R-HSA-1592389,-0.9807604737070825,-1.4353579204235667,0.27611940298507465,0.9600178310972122,1.0,1/28,1.93%,MMP2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Autistic Disorder,0.9845743392767117,1.4350585337578858,0.28346456692913385,1.0,1.0,1/21,1.54%,SLC6A4
prerank,Elsevier_Pathway_Collection__Lipogenesis Regulation in Adipocyte,0.9966142780838404,1.4349278151243445,0.08064516129032258,1.0,1.0,2/24,0.35%,PPARA;ACACA
prerank,GO_Biological_Process_2021__regulation of amyloid-beta clearance (GO:1900221),0.9800805418331044,1.4348659275592222,0.3983050847457627,1.0,1.0,1/15,1.99%,APOE
prerank,WikiPathway_2021_Human__1q21.1 copy number variation syndrome WP4905,0.9890371967756523,1.4346585482927756,0.19008264462809918,1.0,1.0,2/25,1.10%,TJP1;PRKAA2
prerank,GO_Biological_Process_2021__phosphatidylethanolamine biosynthetic process (GO:0006646),0.9770439479236535,1.434620040265285,0.504,1.0,1.0,1/15,2.30%,LPIN3
prerank,GO_Biological_Process_2021__negative regulation of fibroblast proliferation (GO:0048147),0.9969982916831596,1.4341257951452158,0.06666666666666667,1.0,1.0,1/18,0.30%,CD300A
prerank,Reactome_2022__Negative Regulation Of FGFR3 Signaling R-HSA-5654732,0.9763016554432197,1.4341167598169584,0.4921875,1.0,1.0,1/25,2.37%,FGF1
prerank,TRRUST_Transcription_Factors_2019__CREBBP human,0.9818859032257412,1.434084229537327,0.38392857142857145,1.0,1.0,3/22,1.82%,PPARA;CREB1;PTGS2
prerank,GO_Biological_Process_2021__negative regulation of small GTPase mediated signal transduction (GO:0051058),0.9888467398685085,1.4340820103276855,0.24603174603174602,1.0,1.0,2/21,1.12%,CD2AP;ARHGAP12
prerank,GO_Biological_Process_2021__aspartate family amino acid metabolic process (GO:0009066),0.9816927213431389,1.4340583642301057,0.3533834586466165,1.0,1.0,1/19,1.83%,SMS
prerank,GO_Biological_Process_2021__carbohydrate derivative transport (GO:1901264),-0.9840772075838443,-1.4333414993491929,0.3448275862068966,0.9733561992035463,1.0,1/18,1.60%,SLC15A3
prerank,Reactome_2022__tRNA Modification In Nucleus And Cytosol R-HSA-6782315,-0.9788303433865595,-1.4332441188622502,0.3383458646616541,0.9717654752276067,1.0,3/42,2.13%,TYW1;THADA;TRMT9B
prerank,GO_Biological_Process_2021__proteasomal ubiquitin-independent protein catabolic process (GO:0010499),0.9880383018287763,1.4332170895426641,0.25,1.0,1.0,1/20,1.20%,PSMB9
prerank,GO_Biological_Process_2021__tetrapyrrole metabolic process (GO:0033013),0.9871926052547499,1.4331231875229513,0.21929824561403508,1.0,1.0,1/18,1.28%,AMN
prerank,Reactome_2022__Condensation Of Prophase Chromosomes R-HSA-2299718,-0.9885309369576439,-1.4329389504291221,0.18604651162790697,0.9718759915355654,1.0,1/32,1.15%,RB1
prerank,GO_Biological_Process_2021__regulation of chondrocyte differentiation (GO:0032330),0.9874973324715807,1.432744863616682,0.2076923076923077,1.0,1.0,1/24,1.25%,PKDCC
prerank,Reactome_2022__Resolution Of AP Sites Via Multiple-Nucleotide Patch Replacement Pathway R-HSA-110373,0.977652776671625,1.4325761418039116,0.43902439024390244,1.0,1.0,3/25,2.24%,SLC19A1;POLE4;LRIG1
prerank,GO_Biological_Process_2021__skeletal muscle tissue development (GO:0007519),0.9891861231120561,1.4324376660608182,0.15079365079365079,1.0,1.0,1/31,1.08%,SVIL
prerank,Elsevier_Pathway_Collection__Proteins Involved in Antiphospholipid Syndrome,0.979347324741187,1.4323847047355425,0.45,1.0,1.0,1/18,2.07%,SERPINE1
prerank,WikiPathway_2021_Human__BDNF-TrkB Signaling WP3676,0.995764615636387,1.432184088669785,0.02459016393442623,1.0,1.0,1/33,0.43%,CREB1
prerank,GO_Biological_Process_2021__striated muscle tissue development (GO:0014706),0.9788023929627842,1.4321006588160023,0.38461538461538464,1.0,1.0,2/29,2.12%,SVIL;RBP4
prerank,GO_Biological_Process_2021__inner ear morphogenesis (GO:0042472),-0.9843477736433494,-1.4319348198907293,0.3115942028985507,0.977968058320856,1.0,2/20,1.58%,TTC39C;PAX8
prerank,Reactome_2022__RHOB GTPase Cycle R-HSA-9013026,0.9781937104750015,1.4318451248637805,0.18181818181818182,1.0,1.0,7/67,2.20%,DEPDC1B;ARHGAP39;IQGAP3;ANLN;DLC1;CAVIN1;RHPN2
prerank,TRRUST_Transcription_Factors_2019__BCL6 human,-0.9846552331819607,-1.4313981733462766,0.2781954887218045,0.979598277316744,1.0,1/17,1.54%,CCND2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Celiac Disease,0.9877694126739373,1.431159585068736,0.2777777777777778,1.0,1.0,1/19,1.23%,CD4
prerank,GO_Biological_Process_2021__protein depolymerization (GO:0051261),0.9803802947699758,1.4311442282853426,0.3700787401574803,1.0,1.0,2/27,1.97%,STMN3;MICAL3
prerank,Elsevier_Pathway_Collection__Neutrophil Activation via LTB4/Polyisoprenyl Phosphate Signaling,-0.9766504699125791,-1.430733046988587,0.5072463768115942,0.9827697842018748,1.0,1/23,2.34%,VAV1
prerank,TRRUST_Transcription_Factors_2019__CIITA human,-0.9781106861953155,-1.4307098019464217,0.4032258064516129,0.9804768958469212,1.0,2/28,2.20%,CREBBP;HLA-B
prerank,Elsevier_Pathway_Collection__Apoptosis Block by BCL2 Family Proteins in Cancer,0.9813269095389691,1.4306204948936432,0.2642857142857143,1.0,1.0,1/39,1.87%,BOK
prerank,GO_Biological_Process_2021__positive regulation of interleukin-2 production (GO:0032743),0.9771524152460553,1.4305772720468035,0.4444444444444444,1.0,1.0,3/25,2.29%,CD4;ANXA1;CD86
prerank,GO_Biological_Process_2021__regulation of cholesterol biosynthetic process (GO:0045540),0.976351464681886,1.4303114188969939,0.49166666666666664,1.0,1.0,2/17,2.37%,APOE;FGF1
prerank,Reactome_2022__PERK Regulates Gene Expression R-HSA-381042,0.991955983879753,1.4302460593630462,0.05714285714285714,1.0,1.0,1/32,0.81%,PARN
prerank,TRRUST_Transcription_Factors_2019__SREBF1 human,0.9780716204315039,1.430051589077543,0.4881889763779528,1.0,1.0,1/26,2.19%,HK2
prerank,GO_Biological_Process_2021__oligosaccharide biosynthetic process (GO:0009312),0.9806122470588641,1.4299021128371596,0.3828125,1.0,1.0,1/22,1.94%,FUT6
prerank,Elsevier_Pathway_Collection__Histone Sumoylation,-0.9791162779570599,-1.4296839029116775,0.3893129770992366,0.9864091643694888,1.0,1/19,2.09%,PML
prerank,GO_Biological_Process_2021__regulation of microtubule cytoskeleton organization (GO:0070507),0.9824912116107898,1.4289913511926042,0.30357142857142855,1.0,1.0,3/36,1.76%,PRKAA2;CAMSAP3;STMN3
prerank,GO_Biological_Process_2021__antigen processing and presentation of exogenous peptide antigen (GO:0002478),0.9760054545106103,1.4288150576166911,0.15079365079365079,1.0,1.0,5/99,2.41%,CENPE;RAB7A;SPTBN2;KIF23;KIF3B
prerank,GO_Biological_Process_2021__negative regulation of signaling (GO:0023057),0.9789627902727682,1.4286633688625554,0.46206896551724136,1.0,1.0,3/22,2.11%,IGFBP3;ERBB3;OPTN
prerank,Reactome_2022__Resolution Of D-loop Structures Thru Synthesis-Dependent Strand Annealing (SDSA) R-HSA-5693554,0.9884956831326613,1.4286331086105815,0.2222222222222222,1.0,1.0,1/27,1.15%,BRIP1
prerank,Reactome_2022__Glutamate Neurotransmitter Release Cycle R-HSA-210500,0.9765014448701002,1.428534470362348,0.4921875,1.0,1.0,2/21,2.36%,PPFIA4;STX1A
prerank,TRRUST_Transcription_Factors_2019__FLI1 human,0.9881901232826394,1.4283514651575435,0.1968503937007874,1.0,1.0,1/22,1.18%,IGFBP3
prerank,Reactome_2022__FLT3 Signaling In Disease R-HSA-9682385,-0.9829536812439346,-1.427944514102485,0.256198347107438,0.9975602863777164,1.0,1/27,1.71%,STAT5A
prerank,GO_Biological_Process_2021__negative regulation of intracellular steroid hormone receptor signaling pathway (GO:0033144),0.9894170986547842,1.4278378752472995,0.1875,1.0,1.0,1/30,1.06%,STRN3
prerank,Reactome_2022__Mitochondrial Translation Initiation R-HSA-5368286,-0.9902386933226243,-1.427831803321279,0.016129032258064516,0.9959673627611958,1.0,1/81,0.98%,MRPS9
prerank,WikiPathway_2021_Human__Statin inhibition of cholesterol production WP430,0.9800672524241647,1.4276742966696465,0.3851851851851852,1.0,1.0,1/29,1.99%,APOE
prerank,Reactome_2022__Blood Group Systems Biosynthesis R-HSA-9033658,0.9806132597541841,1.4273217265469333,0.40145985401459855,1.0,1.0,1/21,1.94%,FUT6
prerank,WikiPathway_2021_Human__Notch Signaling Pathway Netpath WP61,0.9872825681053274,1.4273016358850552,0.11764705882352941,1.0,1.0,1/59,1.27%,NOTCH3
prerank,Reactome_2022__Stabilization Of P53 R-HSA-69541,0.9880172076480777,1.4270957060529519,0.16260162601626016,1.0,1.0,1/54,1.20%,PSMB9
prerank,KEGG_2021_Human__Glyoxylate and dicarboxylate metabolism,-0.9820285539661641,-1.426972619101369,0.2734375,1.0,1.0,1/29,1.80%,HAO1
prerank,Elsevier_Pathway_Collection__Th17-Cell Numbers Reduction in HIV,-0.9783426677668616,-1.4268313915392545,0.42063492063492064,0.9992392349218654,1.0,3/27,2.18%,IL12RB2;RORC;IL21R
prerank,GO_Biological_Process_2021__chromosome organization (GO:0051276),0.9804005456006523,1.4268272651520653,0.12096774193548387,1.0,1.0,5/102,1.97%,HDAC8;MSH2;NDC80;PADI2;AXIN2
prerank,GO_Biological_Process_2021__divalent inorganic cation homeostasis (GO:0072507),0.9833468712625597,1.4268014259406168,0.296875,1.0,1.0,2/21,1.67%,TMTC2;CYP27B1
prerank,WikiPathway_2021_Human__Type II diabetes mellitus WP1584,0.9765801859138459,1.4265787004257036,0.4740740740740741,1.0,1.0,2/20,2.35%,PHKA2;GK
prerank,GO_Biological_Process_2021__regulation of microtubule-based process (GO:0032886),0.9857999890096063,1.426555613146575,0.23684210526315788,1.0,1.0,2/36,1.43%,PRKAA2;CAMSAP3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Bronchiectasis,0.9773476584285633,1.4264700665153744,0.4878048780487805,1.0,1.0,1/17,2.27%,FN1
prerank,Reactome_2022__RHO GTPases Activate ROCKs R-HSA-5627117,0.9911919720088812,1.4264164002192303,0.20535714285714285,1.0,1.0,1/19,0.88%,PPP1R12A
prerank,GO_Biological_Process_2021__transferrin transport (GO:0033572),0.9948786899004731,1.4263932412471665,0.08461538461538462,1.0,1.0,1/33,0.51%,LMTK2
prerank,Elsevier_Pathway_Collection__AHR Signaling in Th17 Cells Function,-0.9807339282332391,-1.4263384080581547,0.4608695652173913,1.0,1.0,2/18,1.94%,STAT5A;RORC
prerank,GO_Biological_Process_2021__negative regulation of synaptic transmission (GO:0050805),-0.9953054383534509,-1.4262799848163008,0.07142857142857142,0.9987455875499085,1.0,1/20,0.48%,ATAD1
prerank,GO_Biological_Process_2021__negative regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032435),0.99257153134958,1.4262434316215908,0.1079136690647482,1.0,1.0,1/29,0.75%,TLK2
prerank,Reactome_2022__G1/S DNA Damage Checkpoints R-HSA-69615,0.9839704012763331,1.4261884977185735,0.15447154471544716,1.0,1.0,2/64,1.61%,PSMB9;PCBP4
prerank,Elsevier_Pathway_Collection__Apoptosis Block by Inhibitor of Apoptosis Proteins (IAPs) in Cancer,-0.9892305264000681,-1.4258319192014801,0.13333333333333333,0.9999005023129331,1.0,1/19,1.08%,BIRC6
prerank,GO_Biological_Process_2021__cytoskeleton-dependent intracellular transport (GO:0030705),0.9785358064499124,1.425721234488282,0.408,1.0,1.0,1/23,2.15%,TUBA1A
prerank,GO_Biological_Process_2021__clathrin-dependent endocytosis (GO:0072583),0.9820320702238643,1.4255744378067878,0.33858267716535434,1.0,1.0,1/25,1.80%,FCHSD2
prerank,Reactome_2022__Mitochondrial Translation R-HSA-5368287,-0.9842248297658021,-1.425503564853722,0.032520325203252036,1.0,1.0,2/87,1.58%,MRPS9;MRRF
prerank,GO_Biological_Process_2021__positive regulation of cell growth (GO:0030307),-0.9775883092686178,-1.4251066400182548,0.14615384615384616,1.0,1.0,3/95,2.25%,ADAM10;SYT2;SEMA4D
prerank,Elsevier_Pathway_Collection__Histone Phosphorylation,0.9898476550870955,1.425054056567371,0.19327731092436976,1.0,1.0,1/16,1.02%,ATR
prerank,Reactome_2022__Acyl Chain Remodelling Of PS R-HSA-1482801,-0.9881927187070273,-1.4249600309615393,0.2,0.9996256617900238,1.0,1/19,1.19%,PLAAT3
prerank,Elsevier_Pathway_Collection__GNRH Signaling Impairment in Hypogonadotrophic Hypogonadism,0.9957653026214128,1.4248181941161702,0.058333333333333334,1.0,1.0,1/30,0.43%,CREB1
prerank,WikiPathway_2021_Human__PPAR-alpha pathway WP2878,0.9980736361085846,1.4247372592792302,0.008928571428571428,1.0,1.0,1/25,0.20%,PPARA
prerank,Reactome_2022__Mitophagy R-HSA-5205647,-0.9927267527477569,-1.424596146199895,0.09090909090909091,0.9998260758935615,1.0,1/27,0.73%,TOMM70
prerank,GO_Biological_Process_2021__antigen processing and presentation of peptide antigen via MHC class II (GO:0002495),0.9760083442248096,1.4243514407634221,0.1532258064516129,1.0,1.0,5/96,2.41%,CENPE;RAB7A;SPTBN2;KIF23;KIF3B
prerank,Reactome_2022__Cardiac Conduction R-HSA-5576891,-0.9755589852196648,-1.4239504162554786,0.09848484848484848,1.0,1.0,2/110,2.44%,KCNK6;KCNE1
prerank,WikiPathway_2021_Human__Host-pathogen interaction of human coronaviruses - autophagy WP4863,-0.9894616620884235,-1.423844599238753,0.18699186991869918,1.0,1.0,1/19,1.06%,ATG10
prerank,Reactome_2022__Mitotic Spindle Checkpoint R-HSA-69618,0.9823258245934281,1.4238328343769229,0.04,1.0,1.0,5/107,1.78%,CENPE;NDC80;CENPA;UBE2C;ERCC6L
prerank,WikiPathway_2021_Human__Wnt signaling in kidney disease WP4150,0.9956868753173655,1.4237360858619823,0.058333333333333334,1.0,1.0,1/35,0.43%,LRP5
prerank,GO_Biological_Process_2021__regulation of keratinocyte proliferation (GO:0010837),-0.9781892386853595,-1.4236778698945114,0.4444444444444444,1.0,1.0,1/22,2.19%,VDR
prerank,GO_Biological_Process_2021__regulation of protein export from nucleus (GO:0046825),-0.9846134011672609,-1.423529534039665,0.2698412698412698,0.9989971355738365,1.0,1/23,1.54%,RAPGEF3
prerank,Reactome_2022__Class I Peroxisomal Membrane Protein Import R-HSA-9603798,-0.9941538675107691,-1.423494283903529,0.08029197080291971,0.9968253236917154,1.0,2/20,0.60%,ATAD1;ABCD3
prerank,Elsevier_Pathway_Collection__TNFRSF1A -> AP-1/ATF/TP53 Signaling,-0.9978041319127287,-1.4231190794631425,0.035398230088495575,0.9972385099924762,1.0,1/28,0.23%,MAP2K6
prerank,Reactome_2022__p53-Dependent G1 DNA Damage Response R-HSA-69563,0.9839718085735008,1.4229166433281963,0.15833333333333333,1.0,1.0,2/62,1.61%,PSMB9;PCBP4
prerank,GO_Biological_Process_2021__primary neural tube formation (GO:0014020),0.9832204278439257,1.4228729850904556,0.256,1.0,1.0,1/30,1.68%,DLC1
prerank,GO_Biological_Process_2021__cellular response to acid chemical (GO:0071229),-0.9982271676348428,-1.4228643622072397,0.00847457627118644,0.9968074359902691,1.0,1/26,0.18%,CPEB3
prerank,GO_Biological_Process_2021__lysosome localization (GO:0032418),0.996110307313759,1.422581545929232,0.023622047244094488,1.0,1.0,1/35,0.39%,PIK3CD
prerank,Reactome_2022__TRAF6 Mediated NF-kB Activation R-HSA-933542,-0.9919204859850547,-1.42228763701926,0.12096774193548387,0.9989742357607418,1.0,1/24,0.81%,APP
prerank,Elsevier_Pathway_Collection__Myostatin-IGF1 Crosstalk in Skeletal Muscles in Muscular Dystrophies,-0.9764109736160638,-1.422241925702409,0.417910447761194,0.9969806264146029,1.0,1/29,2.36%,FBXO32
prerank,Reactome_2022__Infection With Mycobacterium Tuberculosis R-HSA-9635486,0.9916121708855706,1.4221657331763202,0.07874015748031496,1.0,1.0,1/25,0.84%,RAB7A
prerank,MSigDB_Oncogenic_Signatures__RAPA EARLY UP.V1 DN,0.9019755456588154,1.4220815710630303,0.03076923076923077,1.0,1.0,16/173,2.30%,TAF4;ZNF175;YTHDF3;MICU1;COG5;SNTB1;NUP210;IGFBP3;SF3A2;MYCN;PCBP4;SMAD9;MID1;SNTA1;LRIG1;COL9A2
prerank,GO_Biological_Process_2021__organelle transport along microtubule (GO:0072384),0.9991880907241755,1.4218374566131287,0.01680672268907563,1.0,1.0,1/31,0.08%,TRAK1
prerank,GO_Biological_Process_2021__ncRNA catabolic process (GO:0034661),0.9919973649953716,1.4216169045457487,0.1532258064516129,1.0,1.0,2/28,0.81%,DIS3L2;PARN
prerank,Reactome_2022__RAF Activation R-HSA-5673000,0.9893021599798498,1.4213545847031839,0.14912280701754385,1.0,1.0,1/30,1.07%,KSR1
prerank,GO_Biological_Process_2021__cristae formation (GO:0042407),-0.9994195611122159,-1.4209628158518317,0.0,1.0,1.0,1/28,0.07%,CHCHD3
prerank,Reactome_2022__Defective CFTR Causes Cystic Fibrosis R-HSA-5678895,0.9880144807872223,1.420936888113495,0.13114754098360656,1.0,1.0,1/58,1.20%,PSMB9
prerank,GO_Biological_Process_2021__prostaglandin biosynthetic process (GO:0001516),0.9818087602851656,1.4208392502100509,0.425,1.0,1.0,1/18,1.82%,PTGS2
prerank,Reactome_2022__SIRT1 Negatively Regulates rRNA Expression R-HSA-427359,0.9922272727451725,1.4208110933556737,0.07751937984496124,1.0,1.0,1/27,0.78%,TAF1B
prerank,GO_Biological_Process_2021__positive regulation of protein targeting to membrane (GO:0090314),0.9842642731502459,1.4204545460266935,0.34210526315789475,1.0,1.0,1/24,1.58%,MTCL1
prerank,GO_Biological_Process_2021__negative regulation of natural killer cell mediated cytotoxicity (GO:0045953),-0.9780824110709507,-1.4204253499726447,0.46774193548387094,1.0,1.0,1/15,2.20%,HLA-B
prerank,Elsevier_Pathway_Collection__Genes with Mutation in Cancer-Associated Dysregulated DNA Repair,0.992301557044709,1.4201213445072687,0.125,1.0,1.0,1/34,0.77%,MSH2
prerank,GO_Biological_Process_2021__keratinocyte differentiation (GO:0030216),0.983642959335397,1.4200591635705266,0.25806451612903225,1.0,1.0,1/29,1.64%,ANXA1
prerank,GO_Biological_Process_2021__organelle disassembly (GO:1903008),-0.9842167952561336,-1.4196138411400745,0.19696969696969696,1.0,1.0,1/34,1.58%,MRRF
prerank,GO_Biological_Process_2021__protein import into peroxisome membrane (GO:0045046),-0.9941532816366536,-1.418877859153191,0.06338028169014084,1.0,1.0,2/22,0.60%,ATAD1;ABCD3
prerank,GO_Biological_Process_2021__negative regulation of viral entry into host cell (GO:0046597),-0.9773122320610002,-1.4188607603583117,0.4409448818897638,1.0,1.0,1/16,2.27%,CIITA
prerank,WikiPathway_2021_Human__Endothelin Pathways WP2197,0.9834898653949985,1.418793476709745,0.2578125,1.0,1.0,1/29,1.65%,GNB5
prerank,Elsevier_Pathway_Collection__Dectin-1 (CLEC7A) Signaling,0.980073594489918,1.4187662899270863,0.375,1.0,1.0,2/26,2.00%,SYK;NFATC2
prerank,GO_Biological_Process_2021__mitochondrial translational termination (GO:0070126),-0.9842654912541217,-1.4187550480710875,0.034782608695652174,1.0,1.0,3/88,1.58%,MRPS28;MRPS9;MRRF
prerank,Elsevier_Pathway_Collection__Antiphospholipid Antibodies and Endothelial Cell Interaction,-0.9978049967668474,-1.418730078781585,0.024793388429752067,1.0,1.0,1/23,0.23%,MAP2K6
prerank,Elsevier_Pathway_Collection__Antiphospholipid Antibodies in Endothelial Cell,-0.9978049967668474,-1.418730078781585,0.024793388429752067,1.0,1.0,1/23,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__aminoglycan catabolic process (GO:0006026),-0.9827570153580041,-1.4186519008997815,0.26515151515151514,1.0,1.0,1/31,1.73%,SDC3
prerank,Reactome_2022__Signaling By NTRK3 (TRKC) R-HSA-9034015,-0.9820030997979287,-1.4185193791256405,0.368,1.0,1.0,1/16,1.81%,NTF3
prerank,Elsevier_Pathway_Collection__IL23A and IL17A Provoke Cancer-Associated Inflammation,0.9818012192395695,1.4182259002126592,0.3937007874015748,1.0,1.0,1/25,1.82%,PTGS2
prerank,GO_Biological_Process_2021__positive regulation of receptor internalization (GO:0002092),-0.9820395482086989,-1.417879058454799,0.3170731707317073,1.0,1.0,2/21,1.81%,ATAD1;NTF3
prerank,Reactome_2022__CaM Pathway R-HSA-111997,0.9957644612375764,1.4178468805863988,0.05,1.0,1.0,1/31,0.43%,CREB1
prerank,Reactome_2022__ADP Signaling Thru P2Y Purinoceptor 12 R-HSA-392170,0.9766573546958324,1.4176429550508514,0.532258064516129,1.0,1.0,2/19,2.34%,GNB5;GNG2
prerank,Elsevier_Pathway_Collection__Complement Activation in Glomerulonephritis,-0.983767482534025,-1.417609801910207,0.36666666666666664,1.0,1.0,1/20,1.63%,C1R
prerank,Elsevier_Pathway_Collection__ER Stress in Macular Degeneration,0.9989200930435052,1.4175038398261932,0.0,1.0,1.0,1/25,0.11%,ERN1
prerank,MSigDB_Hallmark_2020__Notch Signaling,0.9872991308240632,1.4174919442788267,0.18421052631578946,1.0,1.0,1/32,1.27%,NOTCH3
prerank,"GO_Biological_Process_2021__negative regulation of gene expression, epigenetic (GO:0045814)",-0.9760653210072201,-1.4174788620505825,0.5121951219512195,1.0,1.0,1/30,2.40%,SPI1
prerank,Elsevier_Pathway_Collection__Nitric Oxide Effects on beta-Cell,0.9989206059521777,1.4173541094008697,0.008264462809917356,1.0,1.0,1/25,0.11%,ERN1
prerank,GO_Biological_Process_2021__zinc ion homeostasis (GO:0055069),0.9786048832563808,1.4173020158706326,0.36885245901639346,1.0,1.0,1/28,2.14%,SLC30A10
prerank,WikiPathway_2021_Human__NAD Metabolism in Oncogene-Induced Senescence and Mitochondrial Dysfunction-Associated Senescence WP5046,-0.9885371262479598,-1.4170943228743405,0.16393442622950818,1.0,1.0,1/23,1.15%,RB1
prerank,GO_Biological_Process_2021__entrainment of circadian clock by photoperiod (GO:0043153),-0.9791084207275698,-1.4169206354608959,0.41025641025641024,1.0,1.0,1/26,2.09%,PML
prerank,GO_Biological_Process_2021__photoperiodism (GO:0009648),-0.9791071833952043,-1.4166048444142478,0.41025641025641024,1.0,1.0,1/27,2.09%,PML
prerank,Elsevier_Pathway_Collection__AHR Signaling in Treg and Dendritic Cells Function,-0.9829591980524501,-1.4165019177324518,0.3902439024390244,1.0,1.0,1/21,1.71%,STAT5A
prerank,GO_Biological_Process_2021__lymphocyte proliferation (GO:0046651),-0.9776900007330154,-1.416324692944915,0.4672131147540984,1.0,1.0,1/22,2.24%,TNFSF14
prerank,GO_Biological_Process_2021__negative regulation of cell death (GO:0060548),-0.9849847102535074,-1.4162685037551568,0.078125,1.0,1.0,1/90,1.50%,BMP4
prerank,Reactome_2022__Adherens Junctions Interactions R-HSA-418990,0.9793048179651115,1.4162497027505907,0.4230769230769231,1.0,1.0,2/26,2.07%,CDH2;CDH15
prerank,"GO_Biological_Process_2021__regulation of mRNA splicing, via spliceosome (GO:0048024)",0.9839093341384434,1.4162375040159974,0.08196721311475409,1.0,1.0,1/81,1.61%,PCBP4
prerank,Elsevier_Pathway_Collection__Complement System Defects in Systemic Lupus Erythematosis,-0.9837656264174909,-1.4161430655448646,0.30327868852459017,1.0,1.0,1/23,1.63%,C1R
prerank,Elsevier_Pathway_Collection__Aqueous Humor Production,-0.9834618974929736,-1.4160721874987576,0.325,0.998649979566686,1.0,2/22,1.66%,SLC23A2;KCNS3
prerank,Reactome_2022__JNK (c-Jun Kinases) Phosphorylation And Activation Mediated By Activated Human TAK1 R-HSA-450321,0.9910783370870907,1.4160707108354944,0.13934426229508196,1.0,1.0,2/18,0.90%,IRAK2;NOD2
prerank,Reactome_2022__Metabolism Of Steroid Hormones R-HSA-196071,0.9830719393652158,1.4157817704613067,0.3597122302158273,1.0,1.0,2/29,1.70%,HSD17B11;FDXR
prerank,GO_Biological_Process_2021__cellular response to vascular endothelial growth factor stimulus (GO:0035924),0.9836839633496042,1.4151542287824546,0.2743362831858407,1.0,1.0,2/34,1.64%,ERN1;ANXA1
prerank,GO_Biological_Process_2021__positive regulation of interleukin-4 production (GO:0032753),0.9771198694433665,1.4151107154083025,0.4673913043478261,1.0,1.0,2/18,2.29%,SYK;CD86
prerank,GO_Biological_Process_2021__positive regulation of lamellipodium assembly (GO:0010592),0.9812313044755929,1.4149843338916839,0.3360655737704918,1.0,1.0,3/23,1.89%,ABI2;ACTR3;CARMIL2
prerank,WikiPathway_2021_Human__Zinc homeostasis WP3529,0.9785987005249132,1.4149288889520248,0.33620689655172414,1.0,1.0,1/34,2.14%,SLC30A10
prerank,GO_Biological_Process_2021__maturation of LSU-rRNA (GO:0000470),-0.986688791055053,-1.4149213661719071,0.2619047619047619,1.0,1.0,1/26,1.34%,RRP15
prerank,GO_Biological_Process_2021__endosome transport via multivesicular body sorting pathway (GO:0032509),0.9899191302412151,1.414744365547878,0.1640625,1.0,1.0,1/25,1.01%,SORT1
prerank,Reactome_2022__Gluconeogenesis R-HSA-70263,-0.9979197109203107,-1.414204983453127,0.031007751937984496,1.0,1.0,1/27,0.22%,ALDOB
prerank,GO_Biological_Process_2021__establishment of mitotic spindle orientation (GO:0000132),0.9803457900720891,1.4140870090784499,0.38405797101449274,1.0,1.0,3/24,1.98%,NDC80;CENPA;SAPCD2
prerank,Elsevier_Pathway_Collection__Aldosterone Synthesis Acute Regulation,0.9957666627867594,1.4139369402565105,0.0603448275862069,1.0,1.0,1/24,0.43%,CREB1
prerank,GO_Biological_Process_2021__renal water homeostasis (GO:0003091),-0.9791891154370146,-1.4135997423207514,0.3698630136986301,1.0,1.0,2/26,2.09%,ADCY3;AQP3
prerank,GO_Biological_Process_2021__actin filament polymerization (GO:0030041),0.9805291541851409,1.4134589073309185,0.32407407407407407,1.0,1.0,1/29,1.95%,SPIRE2
prerank,WikiPathway_2021_Human__Glycosylation and related congenital defects WP4521,-0.9937291082945958,-1.4131873252079605,0.09558823529411764,1.0,1.0,2/25,0.64%,ALG6;ALG13
prerank,Reactome_2022__Mitochondrial Translation Termination R-HSA-5419276,-0.984228930722106,-1.4130230091487663,0.03389830508474576,1.0,1.0,2/81,1.58%,MRPS9;MRRF
prerank,GO_Biological_Process_2021__regulation of hematopoietic stem cell differentiation (GO:1902036),0.9880083904375301,1.4130027608140598,0.10852713178294573,1.0,1.0,1/68,1.20%,PSMB9
prerank,GO_Biological_Process_2021__mitotic intra-S DNA damage checkpoint signaling (GO:0031573),-0.9830419403820798,-1.4129710607881067,0.35036496350364965,1.0,1.0,1/15,1.70%,NEK11
prerank,Reactome_2022__Vif-mediated Degradation Of APOBEC3G R-HSA-180585,0.9880186531935917,1.4128796107135857,0.17886178861788618,1.0,1.0,1/51,1.20%,PSMB9
prerank,GO_Biological_Process_2021__calcium-ion regulated exocytosis (GO:0017156),-0.9764216554257525,-1.4127458135118007,0.463768115942029,1.0,1.0,2/24,2.37%,SYT2;SYT7
prerank,GO_Biological_Process_2021__morphogenesis of an epithelium (GO:0002009),0.9888037840092591,1.4126833479120293,0.20388349514563106,1.0,1.0,1/27,1.12%,ARHGAP12
prerank,Elsevier_Pathway_Collection__B-Cell Acute Lymphoblastic Leukemia,-0.983082911007445,-1.4125121069312114,0.1532258064516129,1.0,1.0,5/72,1.71%,RB1;CREBBP;HCK;CCND2;STAT5A
prerank,Reactome_2022__Interaction Between L1 And Ankyrins R-HSA-445095,0.986032761741908,1.4123575668028676,0.29457364341085274,1.0,1.0,1/27,1.40%,SPTBN2
prerank,GO_Biological_Process_2021__positive regulation of intrinsic apoptotic signaling pathway (GO:2001244),0.9813692223013546,1.4123561516217429,0.264,1.0,1.0,2/40,1.87%,MSX1;BOK
prerank,Reactome_2022__Defective Pyroptosis R-HSA-9710421,-0.9904161987377976,-1.412316967747169,0.1452991452991453,1.0,1.0,1/32,0.96%,PRIM2
prerank,GO_Biological_Process_2021__negative regulation of dephosphorylation (GO:0035305),0.9792727979125856,1.4122491279271596,0.415929203539823,1.0,1.0,2/19,2.08%,PPP1R16B;SH3RF2
prerank,"GO_Biological_Process_2021__base-excision repair, AP site formation (GO:0006285)",0.9785008878349152,1.412247669222569,0.4409448818897638,1.0,1.0,1/19,2.15%,ACD
prerank,WikiPathway_2021_Human__Eicosanoid Synthesis WP167,0.9818432673356476,1.4120448394896332,0.425,1.0,1.0,2/25,1.82%,PNPLA3;PTGS2
prerank,Reactome_2022__Autodegradation Of E3 Ubiquitin Ligase COP1 R-HSA-349425,0.9880202267228939,1.4118231424044636,0.17829457364341086,1.0,1.0,1/49,1.20%,PSMB9
prerank,Elsevier_Pathway_Collection__TGFB2 Signaling Impairement in Osteoarthritis,0.981537849212226,1.4118002861338974,0.35398230088495575,1.0,1.0,2/22,1.85%,SMAD9;TIMP3
prerank,Reactome_2022__Downstream Signaling Of Activated FGFR2 R-HSA-5654696,0.9763040134218184,1.4117458352817827,0.48854961832061067,1.0,1.0,1/23,2.37%,FGF1
prerank,Reactome_2022__Formation Of Early Elongation Complex R-HSA-113418,-0.9930332991404467,-1.4116294895925896,0.13286713286713286,1.0,1.0,1/32,0.70%,NELFA
prerank,WikiPathway_2021_Human__Nanoparticle triggered autophagic cell death WP2509,-0.9894996538538109,-1.41143037410823,0.14615384615384616,1.0,1.0,2/22,1.06%,UVRAG;ATG10
prerank,WikiPathway_2021_Human__Acute viral myocarditis WP4298,0.986428466738727,1.4112991681787728,0.05084745762711865,1.0,1.0,5/84,1.37%,CREB1;NOD2;CASP7;CD4;ITGAL
prerank,GO_Biological_Process_2021__production of miRNAs involved in gene silencing by miRNA (GO:0035196),0.9912272760805562,1.4112395598434135,0.16666666666666666,1.0,1.0,1/26,0.88%,DROSHA
prerank,GO_Biological_Process_2021__mitochondrial calcium ion homeostasis (GO:0051560),0.9960763004400437,1.4112285900155124,0.07563025210084033,1.0,1.0,2/21,0.40%,MICU1;SLC25A23
prerank,Reactome_2022__RNA Pol II CTD Phosphorylation And Interaction With CE R-HSA-77075,-0.9916117603186535,-1.4110554607346277,0.1678832116788321,1.0,1.0,1/27,0.85%,RNGTT
prerank,GO_Biological_Process_2021__cellular response to catecholamine stimulus (GO:0071870),0.9766126830320718,1.4110438621039652,0.47580645161290325,1.0,1.0,1/22,2.34%,GNG2
prerank,Reactome_2022__Defects In Vitamin And Cofactor Metabolism R-HSA-3296482,0.9872325587634769,1.4108295564498268,0.2543859649122807,1.0,1.0,2/19,1.28%,ACACA;AMN
prerank,GO_Biological_Process_2021__purine ribonucleotide catabolic process (GO:0009154),0.9816125638526774,1.4107270594471384,0.36507936507936506,1.0,1.0,1/22,1.84%,HPRT1
prerank,Reactome_2022__Mitochondrial Translation Elongation R-HSA-5389840,-0.9902388072212629,-1.4104188788889613,0.016666666666666666,1.0,1.0,1/81,0.98%,MRPS9
prerank,GO_Biological_Process_2021__positive regulation of RNA splicing (GO:0033120),0.9989198577728099,1.4101529346327009,0.008620689655172414,1.0,1.0,1/29,0.11%,ERN1
prerank,GO_Biological_Process_2021__positive regulation of cell adhesion mediated by integrin (GO:0033630),0.9874620810425188,1.4099351900404367,0.2677165354330709,1.0,1.0,1/18,1.26%,SYK
prerank,Elsevier_Pathway_Collection__Mast-Cell Related Chemokines Signaling in Asthma,-0.9767239292579526,-1.4098261064658595,0.40425531914893614,1.0,1.0,3/30,2.34%,STAT5A;GNA14;VAV1
prerank,KEGG_2021_Human__alpha-Linolenic acid metabolism,-0.9881919094241628,-1.4098215456919765,0.2619047619047619,1.0,1.0,1/21,1.19%,PLAAT3
prerank,GO_Biological_Process_2021__mitochondrial translational elongation (GO:0070125),-0.9902790302984159,-1.4097312854954005,0.008547008547008548,1.0,1.0,2/88,0.98%,MRPS28;MRPS9
prerank,Elsevier_Pathway_Collection__beta-Cell Recovery in Diabetes Mellitus,0.9957671493885246,1.4095756548364542,0.08,1.0,1.0,1/22,0.43%,CREB1
prerank,TRRUST_Transcription_Factors_2019__MITF human,0.9964204438208868,1.4094812615639563,0.08148148148148149,1.0,1.0,1/24,0.36%,HERC2
prerank,TRRUST_Transcription_Factors_2019__REL mouse,-0.980732098908598,-1.4092922408830395,0.37209302325581395,1.0,1.0,2/21,1.94%,SOD2;RORC
prerank,GO_Biological_Process_2021__antigen processing and presentation of peptide antigen via MHC class I (GO:0002474),-0.9780618629242044,-1.4092764122753605,0.3484848484848485,1.0,1.0,1/33,2.20%,HLA-B
prerank,GO_Biological_Process_2021__positive regulation of receptor signaling pathway via STAT (GO:1904894),-0.9802668179167607,-1.409082600959058,0.38636363636363635,1.0,1.0,2/25,1.98%,CYP1B1;IL10RA
prerank,Elsevier_Pathway_Collection__TNFR/NF-kB Alternative Pathway in Multiple Myeloma Plasma Cells,0.9979208585810302,1.4090588452055255,0.017699115044247787,1.0,1.0,1/21,0.21%,TRAF3
prerank,Reactome_2022__Diseases Associated With TLR Signaling Cascade R-HSA-5602358,0.997918451468436,1.4087344082572915,0.045454545454545456,1.0,1.0,1/31,0.21%,TRAF3
prerank,Elsevier_Pathway_Collection__PTPRC -> BCL6 Signaling,-0.9766567761559273,-1.4085701413369396,0.525,1.0,1.0,1/17,2.34%,VAV1
prerank,Elsevier_Pathway_Collection__AHR Signaling in Tr1 Cells Function,-0.9783025672699529,-1.4085696233576954,0.36363636363636365,1.0,1.0,2/28,2.18%,RORC;IL21R
prerank,GO_Biological_Process_2021__positive regulation of leukocyte migration (GO:0002687),0.9795737097252439,1.4085659496449296,0.3644067796610169,1.0,1.0,3/27,2.05%,THY1;F7;LGALS3
prerank,GO_Biological_Process_2021__negative regulation of peptidyl-serine phosphorylation (GO:0033137),0.9774224278983985,1.4085553814638039,0.48695652173913045,1.0,1.0,1/20,2.26%,GPD1L
prerank,Elsevier_Pathway_Collection__Mutations in Krebs Cycle Enzymes in Cancer,-0.9866512424749927,-1.4081856414004725,0.24242424242424243,1.0,1.0,1/24,1.34%,DEPTOR
prerank,Elsevier_Pathway_Collection__Macroautophagy Decline,-0.9913052878537314,-1.408163109292498,0.14516129032258066,1.0,1.0,1/23,0.88%,UVRAG
prerank,GO_Biological_Process_2021__phospholipid translocation (GO:0045332),-0.9969956406198429,-1.4080020883086133,0.022222222222222223,1.0,1.0,1/29,0.31%,ATP11C
prerank,GO_Biological_Process_2021__heterochromatin assembly (GO:0031507),0.9888441469710192,1.407868590368829,0.23076923076923078,1.0,1.0,1/24,1.12%,SMCHD1
prerank,Elsevier_Pathway_Collection__PI3K/AKT/MTOR Signaling Activation by Blocking of Tumor Suppressors,-0.9889602852741664,-1.4076424792661502,0.19310344827586207,1.0,1.0,2/25,1.11%,AKT3;NEDD4
prerank,Elsevier_Pathway_Collection__Hereditary Hemorrhagic Telangiectasia,0.9831480157430116,1.4072489982793555,0.319672131147541,1.0,1.0,1/25,1.69%,SMAD9
prerank,GO_Biological_Process_2021__regulation of reactive oxygen species biosynthetic process (GO:1903426),0.9785362974516583,1.407154567344622,0.40601503759398494,1.0,1.0,3/26,2.16%,PPARA;SLC30A10;CYBA
prerank,WikiPathway_2021_Human__Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway WP3670,0.9773489581359974,1.407029789456078,0.48872180451127817,1.0,1.0,1/18,2.27%,FN1
prerank,Elsevier_Pathway_Collection__Toll-like Receptors (TLR) in Antiviral Innate Immune Response,-0.9815759068562526,-1.4067569485347957,0.34959349593495936,1.0,1.0,1/20,1.85%,TICAM2
prerank,GO_Biological_Process_2021__response to gamma radiation (GO:0010332),0.9898838608609373,1.406520064846907,0.140625,1.0,1.0,2/24,1.02%,TLK2;ATR
prerank,Elsevier_Pathway_Collection__NF-kB non-Canonical Signaling,0.9979188231742889,1.4065049052657492,0.017543859649122806,1.0,1.0,1/28,0.21%,TRAF3
prerank,Reactome_2022__Regulation Of APC/C Activators Between G1/S And Early Anaphase R-HSA-176408,0.9825733258524518,1.4063209708660904,0.15873015873015872,1.0,1.0,2/77,1.74%,PSMB9;UBE2C
prerank,GO_Biological_Process_2021__cyclic purine nucleotide metabolic process (GO:0052652),-0.9844235339079827,-1.406137927564634,0.28125,1.0,1.0,1/19,1.56%,ADCY3
prerank,GO_Biological_Process_2021__antigen processing and presentation of exogenous peptide antigen via MHC class II (GO:0019886),0.9760102613648531,1.406059916080954,0.1774193548387097,1.0,1.0,5/94,2.41%,CENPE;RAB7A;SPTBN2;KIF23;KIF3B
prerank,Reactome_2022__Selenoamino Acid Metabolism R-HSA-2408522,0.9890721785639707,1.4057347347694056,0.016260162601626018,1.0,1.0,2/111,1.10%,PAPSS1;SCLY
prerank,GO_Biological_Process_2021__negative regulation of DNA metabolic process (GO:0051053),0.992111839525815,1.4055959632443265,0.125,1.0,1.0,2/30,0.80%,MSH2;NIBAN2
prerank,Reactome_2022__Regulation Of TP53 Activity Thru Phosphorylation R-HSA-6804756,0.9885458325893299,1.4054050556368234,0.008849557522123894,1.0,1.0,3/88,1.15%,TAF4;PRKAA2;BRIP1
prerank,GO_Biological_Process_2021__regulation of macrophage activation (GO:0043030),-0.9873419327819327,-1.4053330015330825,0.24242424242424243,1.0,1.0,1/27,1.27%,GPR137B
prerank,Reactome_2022__Calnexin/calreticulin Cycle R-HSA-901042,-0.996727555942249,-1.405274131729125,0.032,1.0,1.0,1/26,0.33%,AMFR
prerank,GO_Biological_Process_2021__positive regulation of protein modification by small protein conjugation or removal (GO:1903322),0.9990639021845941,1.4052428594225284,0.0,1.0,1.0,1/76,0.10%,RWDD3
prerank,WikiPathway_2021_Human__Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling WP3612,0.9802287222358175,1.4051431752213326,0.38461538461538464,1.0,1.0,1/22,1.98%,MAPK13
prerank,Reactome_2022__Ubiquitin-dependent Degradation Of Cyclin D R-HSA-75815,0.9880205225175944,1.4050848159280793,0.19008264462809918,1.0,1.0,1/49,1.20%,PSMB9
prerank,Elsevier_Pathway_Collection__Ketogenic Diet Mechanism (Hypothesis),0.99807405596843,1.4046395268910432,0.015625,1.0,1.0,1/25,0.20%,PPARA
prerank,GO_Biological_Process_2021__negative regulation of endocytosis (GO:0045806),0.9796143467370889,1.4043936674049429,0.38848920863309355,1.0,1.0,4/25,2.05%,CD300A;PACSIN3;MCTP1;LGALS3
prerank,Elsevier_Pathway_Collection__Advanced Glycation End Products Pathway in Diabetic Microangiopathy,0.9793428021443242,1.4042060831553747,0.42990654205607476,1.0,1.0,1/22,2.07%,SERPINE1
prerank,MSigDB_Oncogenic_Signatures__RPS14 DN.V1 DN,0.8856151338357783,1.4041823756710228,0.03508771929824561,1.0,1.0,15/167,2.39%,CENPE;FOXRED2;MSH2;PKLR;LRRC20;MKI67;CBS;DEPDC1;PBK;ERCC6L;CNN3;CLCN4;KIF23;SLC43A1;PYCR1
prerank,Elsevier_Pathway_Collection__CD8+ T-Cell Action Impairment in HIV Type 1 Infection,-0.9757268752109592,-1.4041193453648393,0.5073529411764706,1.0,1.0,2/27,2.44%,PTK2B;ZAP70
prerank,Reactome_2022__Citric Acid Cycle (TCA Cycle) R-HSA-71403,-0.9987280324194512,-1.4039732040583108,0.016260162601626018,1.0,1.0,1/21,0.13%,SUCLG2
prerank,GO_Biological_Process_2021__regulation of bicellular tight junction assembly (GO:2000810),0.9978828005846703,1.4039203758443377,0.05172413793103448,1.0,1.0,1/19,0.22%,TJP1
prerank,Reactome_2022__TRP Channels R-HSA-3295583,0.979688079070271,1.4038753268321136,0.512,1.0,1.0,1/23,2.03%,TRPV1
prerank,GO_Biological_Process_2021__negative regulation of viral life cycle (GO:1903901),-0.9773087383587649,-1.4037345291728707,0.4365079365079365,1.0,1.0,1/19,2.27%,CIITA
prerank,GO_Biological_Process_2021__regulation of calcineurin-NFAT signaling cascade (GO:0070884),0.9826500891140266,1.403555565333155,0.37398373983739835,1.0,1.0,2/26,1.74%,HOMER3;FHL2
prerank,GO_Biological_Process_2021__bile acid and bile salt transport (GO:0015721),-0.9873050509686649,-1.4032275902381175,0.17054263565891473,1.0,1.0,2/27,1.28%,NCOA1;SLCO1A2
prerank,Elsevier_Pathway_Collection__Vascular Reactivity in Raynaud Disease,-0.9995347205616714,-1.4032152793740174,0.0,1.0,1.0,1/30,0.05%,PDE5A
prerank,GO_Biological_Process_2021__nucleobase-containing compound catabolic process (GO:0034655),-0.9789458505000084,-1.4031716652367072,0.2903225806451613,1.0,1.0,2/39,2.11%,ENTPD8;ENTPD3
prerank,TRRUST_Transcription_Factors_2019__PML human,-0.9791578785109155,-1.4031274726984961,0.4393939393939394,1.0,1.0,2/18,2.09%,HCK;PML
prerank,GO_Biological_Process_2021__regulation of monooxygenase activity (GO:0032768),-0.9782308370534126,-1.40268770441451,0.4583333333333333,1.0,1.0,2/23,2.19%,ZDHHC21;VDR
prerank,GO_Biological_Process_2021__negative regulation of lipid storage (GO:0010888),0.9943460541207059,1.4024928547676874,0.12844036697247707,1.0,1.0,2/20,0.57%,PPARA;PTPN2
prerank,GO_Biological_Process_2021__establishment of spindle orientation (GO:0051294),0.9803417339208524,1.4024487900896148,0.3695652173913043,1.0,1.0,3/29,1.98%,NDC80;CENPA;SAPCD2
prerank,GO_Biological_Process_2021__zinc ion transmembrane transport (GO:0071577),0.9786126339437659,1.4019360827401297,0.40384615384615385,1.0,1.0,1/21,2.14%,SLC30A10
prerank,Elsevier_Pathway_Collection__Double Strand DNA Homologous Repair,-0.9883085519553639,-1.401917517714846,0.22900763358778625,1.0,1.0,1/19,1.18%,BRCC3
prerank,TRRUST_Transcription_Factors_2019__RUNX3 human,0.9900726283685605,1.4019081728417553,0.12903225806451613,1.0,1.0,1/29,1.00%,CASP7
prerank,Reactome_2022__RUNX2 Regulates Osteoblast Differentiation R-HSA-8940973,-0.9793093628817637,-1.4017069408903373,0.4067796610169492,1.0,1.0,2/21,2.08%,RB1;GLI3
prerank,Elsevier_Pathway_Collection__Skeletal Muscle Wasting in Cancer Cachexia,-0.9763960590195453,-1.4016078790461066,0.40707964601769914,1.0,1.0,1/42,2.36%,FBXO32
prerank,Reactome_2022__PCP/CE Pathway R-HSA-4086400,0.9879979392375725,1.4015575242260185,0.10619469026548672,1.0,1.0,1/85,1.20%,PSMB9
prerank,Elsevier_Pathway_Collection__Immune System Role in Otitis Media,-0.9978020703720966,-1.4014241526453506,0.056451612903225805,1.0,1.0,1/37,0.23%,MAP2K6
prerank,Reactome_2022__ERK/MAPK Targets R-HSA-198753,-0.9811124429562565,-1.4013105877485184,0.38571428571428573,1.0,1.0,1/22,1.89%,DUSP4
prerank,Reactome_2022__Unattached Kinetochores Signal Amplification Via A MAD2 Inhibitory Signal R-HSA-141444,0.9822989839884135,1.4012865855321257,0.08064516129032258,1.0,1.0,4/90,1.78%,CENPE;NDC80;CENPA;ERCC6L
prerank,GO_Biological_Process_2021__regulation of mRNA polyadenylation (GO:1900363),-0.9982295694971144,-1.4009776307716302,0.064,1.0,1.0,1/18,0.18%,CPEB3
prerank,GO_Biological_Process_2021__regulation of dendrite extension (GO:1903859),-0.9850792563471718,-1.4006703962383469,0.3277310924369748,1.0,1.0,1/16,1.50%,SYT2
prerank,Reactome_2022__PIWI-interacting RNA (piRNA) Biogenesis R-HSA-5601884,-0.9836093892599261,-1.4004762014858667,0.2835820895522388,1.0,1.0,1/26,1.64%,PIWIL4
prerank,GO_Biological_Process_2021__calcium ion transport into cytosol (GO:0060402),-0.9893064421070942,-1.400414978057075,0.2222222222222222,1.0,1.0,1/21,1.08%,GRIN2B
prerank,GO_Biological_Process_2021__glycoprotein biosynthetic process (GO:0009101),0.9806896368788789,1.400226719456162,0.1810344827586207,1.0,1.0,4/77,1.94%,FAM20B;CHST11;DAD1;FUT6
prerank,GO_Biological_Process_2021__myeloid cell development (GO:0061515),-0.991922601847847,-1.3999671084788914,0.16666666666666666,1.0,1.0,1/20,0.81%,APP
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA incision (GO:0033683)",-0.9958778853872388,-1.3997502169886293,0.031746031746031744,1.0,1.0,1/39,0.42%,POLK
prerank,Elsevier_Pathway_Collection__Toll-like Receptors (TLR) in Periodontitis,-0.981570307792921,-1.3997369560622488,0.3333333333333333,1.0,1.0,1/26,1.85%,TICAM2
prerank,GO_Biological_Process_2021__synapse assembly (GO:0007416),0.9830116190008439,1.3996541757760579,0.13559322033898305,1.0,1.0,3/61,1.71%,CDH2;LRRC4;CDH1
prerank,KEGG_2021_Human__Linoleic acid metabolism,-0.9803451777664774,-1.3992106908020001,0.4098360655737705,1.0,1.0,3/25,1.98%,CYP2C8;PLAAT3;CYP1A2
prerank,GO_Biological_Process_2021__regulation of protein autophosphorylation (GO:0031952),0.9951859772694598,1.3991929363525077,0.07964601769911504,1.0,1.0,1/35,0.48%,TOM1L1
prerank,GO_Biological_Process_2021__negative regulation of phosphoprotein phosphatase activity (GO:0032515),0.9794971602200198,1.399087231575727,0.41739130434782606,1.0,1.0,1/22,2.05%,LGALS3
prerank,GO_Biological_Process_2021__actin filament-based transport (GO:0099515),0.9768838304053643,1.3989986018964875,0.5040650406504065,1.0,1.0,1/21,2.31%,MYO7A
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Medulloblastoma,-0.9846919674704321,-1.3989379421571275,0.3619047619047619,1.0,1.0,2/23,1.54%,NRG1;CCND2
prerank,GO_Biological_Process_2021__negative regulation of interleukin-1 production (GO:0032692),0.9858834825122151,1.3987048606516823,0.2558139534883721,1.0,1.0,3/25,1.42%,CD33;MEFV;CX3CL1
prerank,Reactome_2022__Negative Regulation Of FGFR4 Signaling R-HSA-5654733,0.9763412510725722,1.3984601319597052,0.5121951219512195,1.0,1.0,2/27,2.37%,KLB;FGF1
prerank,GO_Biological_Process_2021__regulation of intracellular protein transport (GO:0033157),-0.9798399489277262,-1.3983642087905954,0.3893805309734513,1.0,1.0,3/31,2.03%,BCAS3;BMP4;PRR5L
prerank,TRRUST_Transcription_Factors_2019__PGR human,0.9818843768246248,1.3982141961811183,0.3644067796610169,1.0,1.0,3/24,1.82%,YWHAQ;PLD1;PTGS2
prerank,GO_Biological_Process_2021__regulation of extracellular matrix organization (GO:1903053),-0.9886193549055085,-1.3980053431813437,0.23134328358208955,1.0,1.0,3/15,1.15%,RIC1;SLC2A10;RB1
prerank,GO_Biological_Process_2021__regulation of striated muscle contraction (GO:0006942),0.9954585759951116,1.397941563531294,0.05223880597014925,1.0,1.0,1/24,0.46%,ASB3
prerank,Elsevier_Pathway_Collection__Osteoclast Activation in Psoriatic Arthritis,-0.9987624989017813,-1.3979076040055083,0.016129032258064516,1.0,1.0,1/45,0.13%,PTK2B
prerank,GO_Biological_Process_2021__protein K48-linked deubiquitination (GO:0071108),-0.9921520745080865,-1.397865028583999,0.14285714285714285,1.0,1.0,1/23,0.79%,USP37
prerank,GO_Biological_Process_2021__cardiac muscle cell differentiation (GO:0055007),-0.984805909208471,-1.3975664645433283,0.3208955223880597,1.0,1.0,1/22,1.53%,NRG1
prerank,Elsevier_Pathway_Collection__PARK2/PINK1/UCHL1 in Young Onset Parkinson's Disease,0.9836919305151524,1.39755033313958,0.32142857142857145,1.0,1.0,1/18,1.63%,LAMP2
prerank,GO_Biological_Process_2021__negative regulation of cellular component movement (GO:0051271),-0.9775055286215081,-1.397449870122378,0.46825396825396826,1.0,1.0,1/15,2.26%,CD9
prerank,GO_Biological_Process_2021__protein insertion into mitochondrial membrane (GO:0051204),-0.9894605035255125,-1.3973741932191817,0.1984732824427481,1.0,1.0,2/24,1.06%,TOMM70;AGK
prerank,GO_Biological_Process_2021__telomere maintenance via telomerase (GO:0007004),0.9774557180439651,1.397350848004234,0.46551724137931033,1.0,1.0,3/29,2.26%,WRAP53;ACD;PIF1
prerank,Reactome_2022__HSF1 Activation R-HSA-3371511,0.990457467235716,1.397194788900285,0.16666666666666666,1.0,1.0,1/27,0.96%,TNFRSF21
prerank,GO_Biological_Process_2021__cellular response to unfolded protein (GO:0034620),0.9789195037380269,1.39695167352583,0.4358974358974359,1.0,1.0,2/27,2.11%,ERN1;OPTN
prerank,Elsevier_Pathway_Collection__Proteins Involved in non-Alcoholic Fatty Liver Disease,0.8926468024621558,1.3968463558432385,0.046875,1.0,1.0,18/177,2.28%,PPARA;ACACA;SLC27A2;SLC13A5;IL1RN;PNPLA3;FOSL1;PTGS2;TIMP3;NR1I2;ELOVL6;FOSL2;APOE;TRPV1;LGALS3;SERPINE1;RBP4;HGF
prerank,Elsevier_Pathway_Collection__TNF Receptor Associated Periodic Syndrome,-0.9815574053435382,-1.3967840860634457,0.31666666666666665,1.0,1.0,1/37,1.85%,TICAM2
prerank,KEGG_2021_Human__SNARE interactions in vesicular transport,0.976445477961336,1.396663489098121,0.47058823529411764,1.0,1.0,1/33,2.36%,STX1A
prerank,Elsevier_Pathway_Collection__Lamellipodia and Filopodia Formation in Cancer,-0.9766429531773074,-1.3966555138228274,0.44,1.0,1.0,1/29,2.34%,VAV1
prerank,GO_Biological_Process_2021__regulation of immunoglobulin production (GO:0002637),0.977113348092403,1.3965138055237327,0.4846153846153846,1.0,1.0,2/24,2.29%,RBP4;CD86
prerank,Reactome_2022__Interconversion Of Nucleotide Di- And Triphosphates R-HSA-499943,0.9762215998904337,1.3964441193812958,0.49230769230769234,1.0,1.0,1/28,2.38%,RRM2
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA incision, 5'-to lesion (GO:0006296)",-0.9958785300655919,-1.3962538194921434,0.046875,1.0,1.0,1/37,0.42%,POLK
prerank,Elsevier_Pathway_Collection__Glutamate Toxiicity Effects on Striatum Medium Spiny Neurons in Hantington's Disease,-0.9903037475439005,-1.396181376283857,0.15267175572519084,1.0,1.0,1/27,0.98%,SOD2
prerank,GO_Biological_Process_2021__regulation of cholesterol transport (GO:0032374),-0.9838824525877379,-1.3958487348566635,0.30097087378640774,1.0,1.0,2/25,1.62%,ARV1;LIPG
prerank,GO_Biological_Process_2021__regulation of protein localization to nucleus (GO:1900180),-0.9798656059823502,-1.3957811847601587,0.23357664233576642,1.0,1.0,3/46,2.02%,SHH;BMP4;CARD10
prerank,WikiPathway_2021_Human__Cell migration and invasion through p75NTR WP4561,-0.9770327649598342,-1.3957269874911595,0.45038167938931295,1.0,1.0,4/30,2.31%,AKT3;PARD3;MMP2;EFNB2
prerank,Elsevier_Pathway_Collection__Steroidogenesis Impairement in Polycystic Ovary Syndrome,0.978833526663908,1.3947914198703673,0.3953488372093023,1.0,1.0,3/38,2.12%,CREB1;AMH;RBP4
prerank,GO_Biological_Process_2021__nuclear membrane reassembly (GO:0031468),0.9963739004118797,1.3943840824091223,0.021739130434782608,1.0,1.0,1/54,0.37%,UBXN2A
prerank,Reactome_2022__ERCC6 (CSB) And EHMT2 (G9a) Positively Regulate rRNA Expression R-HSA-427389,-0.9910305470404449,-1.3941674780024569,0.12,1.0,1.0,1/35,0.90%,MTA3
prerank,GO_Biological_Process_2021__inner mitochondrial membrane organization (GO:0007007),-0.9894883772095566,-1.3940293270158588,0.07142857142857142,1.0,1.0,3/49,1.06%,CHCHD3;TOMM70;AGK
prerank,GO_Biological_Process_2021__stress-activated protein kinase signaling cascade (GO:0031098),0.980223331841045,1.3940215120746544,0.4112903225806452,1.0,1.0,1/27,1.98%,MAPK13
prerank,Elsevier_Pathway_Collection__Macrophage Related Iron Uptake and Release,-0.9821929566435285,-1.3939164617546975,0.3548387096774194,1.0,1.0,1/19,1.79%,CD163
prerank,Reactome_2022__HCMV Late Events R-HSA-9610379,0.9895067605788153,1.3937396281774577,0.023622047244094488,1.0,1.0,1/77,1.05%,NUP210
prerank,Reactome_2022__Resolution Of D-loop Structures Thru Holliday Junction Intermediates R-HSA-5693568,0.9884930985970267,1.3936575381635288,0.19130434782608696,1.0,1.0,1/32,1.15%,BRIP1
prerank,GO_Biological_Process_2021__protein localization to cell surface (GO:0034394),0.9771049469649573,1.393528416248701,0.5,1.0,1.0,1/28,2.29%,FLNA
prerank,WikiPathway_2021_Human__Purine metabolism and related disorders WP4224,0.9816137249545249,1.3932438716433804,0.432,1.0,1.0,1/20,1.84%,HPRT1
prerank,Elsevier_Pathway_Collection__High Level of Homocystine Effects (Methylation Cycle),0.9863074003252938,1.3932121891820766,0.2777777777777778,1.0,1.0,2/23,1.38%,SLC19A1;CBS
prerank,GO_Biological_Process_2021__protein targeting to ER (GO:0045047),0.9826320273133802,1.3931614492319393,0.07751937984496124,1.0,1.0,2/103,1.74%,GET3;MAN1A1
prerank,GO_Biological_Process_2021__cholesterol efflux (GO:0033344),0.9801133992504805,1.3929502568160332,0.45161290322580644,1.0,1.0,2/24,1.99%,SOAT2;APOE
prerank,GO_Biological_Process_2021__positive regulation of BMP signaling pathway (GO:0030513),-0.985034034674845,-1.3927494053869018,0.3088235294117647,1.0,1.0,1/25,1.50%,BMP4
prerank,Elsevier_Pathway_Collection__T-Cell Positive Selection and Neglect Induced Death,-0.9757227097499956,-1.3927218410068343,0.4661016949152542,1.0,1.0,2/30,2.44%,RORC;ZAP70
prerank,Elsevier_Pathway_Collection__Nuclear Envelope in Cell Division,-0.977001977537583,-1.3925779864626127,0.4852941176470588,1.0,1.0,2/21,2.31%,RB1;SYNE1
prerank,Elsevier_Pathway_Collection__Toll-like Receptors in beta-Cell,-0.9820895589565238,-1.3924561026913058,0.2222222222222222,1.0,1.0,1/45,1.79%,IL12RB2
prerank,"Reactome_2022__Adrenaline,noradrenaline Inhibits Insulin Secretion R-HSA-400042",0.9766498561088542,1.3923300275716253,0.504,1.0,1.0,2/26,2.34%,GNB5;GNG2
prerank,Elsevier_Pathway_Collection__T-Cell Acute Lymphoblastic Leukemia,-0.97581050375616,-1.3920439556056217,0.16666666666666666,1.0,1.0,6/102,2.44%,PTK2B;RB1;CCND2;STAT5A;VAV1;ZAP70
prerank,Elsevier_Pathway_Collection__Plasmacytoid Dendritic Cell in Diabetes Mellitus Type 1,-0.9775220027813097,-1.3920358490819646,0.4186046511627907,1.0,1.0,1/34,2.25%,CD274
prerank,WikiPathway_2021_Human__Nucleotide-binding Oligomerization Domain (NOD) pathway WP1433,0.9810654256963983,1.3920171551680427,0.26666666666666666,1.0,1.0,4/39,1.91%,NOD2;CASP7;MEFV;NAIP
prerank,GO_Biological_Process_2021__energy derivation by oxidation of organic compounds (GO:0015980),-0.9917281524113963,-1.3918652463027843,0.0967741935483871,1.0,1.0,1/24,0.83%,NDUFS4
prerank,GO_Biological_Process_2021__positive regulation of nuclear division (GO:0051785),0.9956903246549246,1.3918271431491918,0.06451612903225806,1.0,1.0,1/21,0.43%,LRP5
prerank,Reactome_2022__ABC Transporter Disorders R-HSA-5619084,0.988003908683559,1.3915269550896519,0.05785123966942149,1.0,1.0,1/75,1.20%,PSMB9
prerank,Elsevier_Pathway_Collection__mTOR/NF-kB/BCR Signaling Disregulation in Mantle Cell Lymphoma,0.9874850969596207,1.3913855520113345,0.11666666666666667,1.0,1.0,2/49,1.26%,TRAF3;SYK
prerank,Reactome_2022__RHO GTPases Activate PAKs R-HSA-5627123,0.9771949256873667,1.3913758692295788,0.49193548387096775,1.0,1.0,3/21,2.29%,PPP1R12A;ARHGEF7;FLNA
prerank,GO_Biological_Process_2021__regulation of androgen receptor signaling pathway (GO:0060765),0.9958790651194718,1.391020437699806,0.0390625,1.0,1.0,1/36,0.41%,PRMT2
prerank,TRRUST_Transcription_Factors_2019__FOS mouse,-0.9761330673691841,-1.3909293300017869,0.3888888888888889,1.0,1.0,3/45,2.40%,NR3C1;MMP2;SPI1
prerank,GO_Biological_Process_2021__second-messenger-mediated signaling (GO:0019932),0.9781786943061338,1.3908272024638344,0.2074074074074074,1.0,1.0,6/84,2.20%,PPP1R9A;MCTP2;MCTP1;APOE;RCAN3;GPR62
prerank,Reactome_2022__AUF1 (hnRNP D0) Binds And Destabilizes mRNA R-HSA-450408,0.9880184828004389,1.3907566608267412,0.192,1.0,1.0,1/52,1.20%,PSMB9
prerank,GO_Biological_Process_2021__negative regulation of response to DNA damage stimulus (GO:2001021),-0.9824117344994313,-1.3906347543492588,0.2647058823529412,1.0,1.0,1/30,1.76%,CD44
prerank,WikiPathway_2021_Human__Histone Modifications WP2369,0.9947257756541779,1.3905163560949017,0.07518796992481203,1.0,1.0,2/38,0.53%,SETD3;ASH1L
prerank,GO_Biological_Process_2021__regulation of ruffle assembly (GO:1900027),0.9811494835968099,1.3904779067872048,0.31092436974789917,1.0,1.0,1/23,1.89%,CARMIL2
prerank,GO_Biological_Process_2021__liver development (GO:0001889),0.9837651860700664,1.390063670930291,0.2923076923076923,1.0,1.0,4/30,1.64%,PHF2;CCDC40;PROX1;ANXA1
prerank,GO_Biological_Process_2021__positive regulation of transcription from RNA polymerase II promoter in response to stress (GO:0036003),-0.9966898067372095,-1.3898896177383102,0.08823529411764706,1.0,1.0,1/24,0.34%,CHD6
prerank,WikiPathway_2021_Human__Alpha 6 Beta 4 signaling pathway WP244,0.9914167895855652,1.3898542807698224,0.12903225806451613,1.0,1.0,1/33,0.86%,PTK2
prerank,Reactome_2022__COPI-mediated Anterograde Transport R-HSA-6807878,0.9860424089189672,1.3897280869130166,0.08130081300813008,1.0,1.0,2/79,1.40%,COG5;SPTBN2
prerank,Reactome_2022__COPI-dependent Golgi-to-ER Retrograde Traffic R-HSA-6811434,0.9759480227210723,1.3895643627945138,0.1981981981981982,1.0,1.0,3/76,2.41%,CENPE;KIF23;KIF3B
prerank,GO_Biological_Process_2021__positive regulation of dendrite extension (GO:1903861),-0.9850801203624409,-1.3894872097142197,0.336283185840708,1.0,1.0,1/15,1.50%,SYT2
prerank,GO_Biological_Process_2021__dicarboxylic acid transport (GO:0006835),0.9816129619435336,1.3893941955125826,0.31297709923664124,1.0,1.0,3/27,1.85%,SLC19A1;SLC13A5;SLC13A3
prerank,Elsevier_Pathway_Collection__Adiponectin Synthesis Declines in Insulin Resistance,0.9957620613041206,1.389232167173049,0.034782608695652174,1.0,1.0,1/42,0.43%,CREB1
prerank,GO_Biological_Process_2021__protein targeting to peroxisome (GO:0006625),-0.9941511601661905,-1.3892123870869604,0.05442176870748299,1.0,1.0,2/29,0.60%,ATAD1;ABCD3
prerank,GO_Biological_Process_2021__regulation of muscle contraction (GO:0006937),0.9825327977774114,1.3891780861488192,0.3884297520661157,1.0,1.0,1/24,1.75%,TNNC2
prerank,Elsevier_Pathway_Collection__TNF and IL1B Induce Metalloproteinase Synthesis in Osteoarthritis,-0.997801879723438,-1.3889382101888192,0.0,1.0,1.0,1/37,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__phagosome acidification (GO:0090383),0.9916523713898802,1.3889172269590857,0.15126050420168066,1.0,1.0,2/25,0.84%,RAB20;RAB7A
prerank,TRRUST_Transcription_Factors_2019__TCF3 mouse,0.9829496119084168,1.3889131714462661,0.2975206611570248,1.0,1.0,1/31,1.71%,CDH1
prerank,GO_Biological_Process_2021__cellular response to cAMP (GO:0071320),-0.9757242630707725,-1.3881746501642096,0.46825396825396826,1.0,1.0,4/31,2.44%,RAP1B;RAP1A;RAPGEF3;KCNE1
prerank,WikiPathway_2021_Human__Host-pathogen interaction of human coronaviruses - apoptosis WP4864,0.9802704791209382,1.3880549636551667,0.3942307692307692,1.0,1.0,2/21,1.98%,CASP7;MAPK13
prerank,GO_Biological_Process_2021__peroxisomal membrane transport (GO:0015919),-0.9941517365028797,-1.3879325769292539,0.06206896551724138,1.0,1.0,2/27,0.60%,ATAD1;ABCD3
prerank,Elsevier_Pathway_Collection__Mevalonate Kinase Deficiency,-0.9815686122646531,-1.3879273039655953,0.3333333333333333,1.0,1.0,1/28,1.85%,TICAM2
prerank,GO_Biological_Process_2021__regulation of lipid storage (GO:0010883),0.9943059895636399,1.3877829951032437,0.11607142857142858,1.0,1.0,1/21,0.57%,PTPN2
prerank,GO_Biological_Process_2021__regulation of vasculature development (GO:1901342),-0.9848425807369487,-1.3875485679716908,0.29914529914529914,1.0,1.0,1/26,1.52%,ADGRA2
prerank,Elsevier_Pathway_Collection__Splenic Marginal Zone Lymphoma,0.9874875259564961,1.3874719559224375,0.11570247933884298,1.0,1.0,2/45,1.26%,TRAF3;SYK
prerank,GO_Biological_Process_2021__positive regulation of type I interferon production (GO:0032481),-0.9808832782392242,-1.3872984235383783,0.15827338129496402,1.0,1.0,4/76,1.93%,OAS1;TOMM70;CREBBP;LRRFIP1
prerank,Elsevier_Pathway_Collection__Rett Syndrome,0.9881921665739014,1.3871800212241343,0.19491525423728814,1.0,1.0,1/19,1.18%,IGFBP3
prerank,Reactome_2022__Downstream Signaling Of Activated FGFR4 R-HSA-5654716,0.9763465659190935,1.3871340104345016,0.5275590551181102,1.0,1.0,2/22,2.37%,KLB;FGF1
prerank,Elsevier_Pathway_Collection__Estrogens/ESR1 Genomic Canonical Signaling,-0.9878848569612703,-1.3870522444094258,0.25,1.0,1.0,2/22,1.22%,NCOA1;CREBBP
prerank,GO_Biological_Process_2021__artery morphogenesis (GO:0048844),-0.985072348024582,-1.3868964327512943,0.3333333333333333,1.0,1.0,2/29,1.50%,ADAMTS9;BMP4
prerank,Reactome_2022__Signaling By FGFR2 IIIa TM R-HSA-8851708,0.976309505207705,1.3866212963876539,0.5175438596491229,1.0,1.0,1/19,2.37%,FGF1
prerank,GO_Biological_Process_2021__negative regulation of proteasomal protein catabolic process (GO:1901799),0.9925695393450711,1.3864827587197612,0.144,1.0,1.0,1/35,0.75%,TLK2
prerank,Reactome_2022__Signaling By NTRK2 (TRKB) R-HSA-9006115,-0.9820388394981083,-1.3864007075077036,0.4180327868852459,1.0,1.0,2/22,1.81%,GRIN2B;NTF3
prerank,Reactome_2022__CLEC7A (Dectin-1) Signaling R-HSA-5607764,0.9800546444415423,1.386384976476114,0.13821138211382114,1.0,1.0,3/97,2.00%,PSMB9;SYK;NFATC2
prerank,GO_Biological_Process_2021__regulation of spindle assembly (GO:0090169),0.9936505096296111,1.3861178084979002,0.088,1.0,1.0,1/25,0.64%,CCSAP
prerank,Elsevier_Pathway_Collection__CFTR Misfolding and Degradation (Class II Mutations),0.9906502294874626,1.38602298148245,0.16666666666666666,1.0,1.0,2/30,0.94%,ERN1;RHOQ
prerank,Reactome_2022__SRP-dependent Cotranslational Protein Targeting To Membrane R-HSA-1799339,-0.9861701145980661,-1.3855159758531583,0.048,1.0,1.0,1/106,1.38%,SEC61A2
prerank,Elsevier_Pathway_Collection__Lipolysis Regulation in Adipocyte,-0.985493526077932,-1.3853846122852154,0.25,1.0,1.0,3/34,1.46%,NR3C1;PLAAT3;LIPE
prerank,Reactome_2022__RNA Polymerase II Transcription Termination R-HSA-73856,0.9998388571103483,1.385328542261513,0.0,1.0,1.0,1/66,0.02%,ZNF473
prerank,GO_Biological_Process_2021__glycerophospholipid catabolic process (GO:0046475),0.9944586118036823,1.3851515897304345,0.10084033613445378,1.0,1.0,1/25,0.56%,PNPLA6
prerank,GO_Biological_Process_2021__negative regulation of lipid metabolic process (GO:0045833),-0.9770369200785693,-1.3850214690253493,0.4838709677419355,1.0,1.0,1/21,2.30%,ASXL3
prerank,Elsevier_Pathway_Collection__TGFBR Signaling in Pancreatic Neoplasms,0.9957600980395329,1.384996143296686,0.03278688524590164,1.0,1.0,1/47,0.43%,CREB1
prerank,Reactome_2022__Activation Of APC/C And APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins R-HSA-176814,0.9825764642784549,1.384864094993483,0.18253968253968253,1.0,1.0,2/73,1.74%,PSMB9;UBE2C
prerank,Reactome_2022__Ca-dependent Events R-HSA-111996,0.9957638419378035,1.3848069474229696,0.0603448275862069,1.0,1.0,1/33,0.43%,CREB1
prerank,GO_Biological_Process_2021__regulation of amyloid-beta formation (GO:1902003),0.9800607583142017,1.384651315146974,0.3364485981308411,1.0,1.0,1/34,1.99%,APOE
prerank,GO_Biological_Process_2021__regulation of synapse assembly (GO:0051963),-0.9803677535354166,-1.3841721129350548,0.2809917355371901,1.0,1.0,2/43,1.97%,APP;SLITRK3
prerank,Reactome_2022__Lysosome Vesicle Biogenesis R-HSA-432720,-0.9919158351426868,-1.3840111035464597,0.12781954887218044,1.0,1.0,1/34,0.81%,APP
prerank,GO_Biological_Process_2021__positive regulation of p38MAPK cascade (GO:1900745),-0.9760722538074361,-1.3839952795305268,0.512,1.0,1.0,1/24,2.40%,SPI1
prerank,TRRUST_Transcription_Factors_2019__HNF4A mouse,0.9877665731776393,1.3838684699912047,0.22137404580152673,1.0,1.0,2/27,1.23%,PPARA;PKLR
prerank,GO_Biological_Process_2021__protein ADP-ribosylation (GO:0006471),-0.9766885181509102,-1.383866683938853,0.4765625,1.0,1.0,3/28,2.34%,PARP8;TNKS;PARP3
prerank,GO_Biological_Process_2021__lipopolysaccharide-mediated signaling pathway (GO:0031663),-0.9851536630763824,-1.383856885643966,0.304,1.0,1.0,1/20,1.49%,HCK
prerank,GO_Biological_Process_2021__axon extension (GO:0048675),-0.9807268878123845,-1.3838103849687107,0.3597122302158273,1.0,1.0,1/23,1.93%,SLIT3
prerank,Reactome_2022__Resolution Of D-Loop Structures R-HSA-5693537,0.9884924946829554,1.3835263906121886,0.20353982300884957,1.0,1.0,1/33,1.15%,BRIP1
prerank,Elsevier_Pathway_Collection__Osteoclast Activation in Postmenopause,-0.9978421276237057,-1.383510962953263,0.016260162601626018,1.0,1.0,2/41,0.23%,PTK2B;MAP2K6
prerank,GO_Biological_Process_2021__internal peptidyl-lysine acetylation (GO:0018393),-0.9878416111082876,-1.3834734532391997,0.1889763779527559,1.0,1.0,1/28,1.22%,CREBBP
prerank,GO_Biological_Process_2021__positive regulation of release of sequestered calcium ion into cytosol (GO:0051281),0.9858404911968475,1.383458747613326,0.16279069767441862,1.0,1.0,2/31,1.42%,THY1;CX3CL1
prerank,Reactome_2022__SCF(Skp2)-mediated Degradation Of P27/P21 R-HSA-187577,0.9880148702811961,1.383337429775229,0.1810344827586207,1.0,1.0,1/58,1.20%,PSMB9
prerank,Reactome_2022__SCF-beta-TrCP Mediated Degradation Of Emi1 R-HSA-174113,0.9880183576890381,1.383250165261365,0.18584070796460178,1.0,1.0,1/52,1.20%,PSMB9
prerank,WikiPathway_2021_Human__Amyotrophic lateral sclerosis (ALS) WP2447,-0.9978024412322613,-1.3832438530490756,0.0234375,1.0,1.0,1/36,0.23%,MAP2K6
prerank,Elsevier_Pathway_Collection__ADRA1 -> Prostaglandin Generation,-0.9978057218147178,-1.382887402595112,0.03968253968253968,1.0,1.0,1/22,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__phosphatidylethanolamine acyl-chain remodeling (GO:0036152),-0.9881911946956172,-1.3814936878862847,0.22580645161290322,1.0,1.0,1/22,1.19%,PLAAT3
prerank,GO_Biological_Process_2021__RNA-dependent DNA biosynthetic process (GO:0006278),0.9774547588171902,1.3812695827294685,0.4661016949152542,1.0,1.0,3/30,2.26%,WRAP53;ACD;PIF1
prerank,TRRUST_Transcription_Factors_2019__REL human,-0.9903069014394937,-1.3812256118169346,0.16666666666666666,1.0,1.0,1/21,0.98%,SOD2
prerank,GO_Biological_Process_2021__lipid translocation (GO:0034204),-0.9969969187226124,-1.381174809821809,0.031496062992125984,1.0,1.0,1/24,0.31%,ATP11C
prerank,Reactome_2022__Cristae Formation R-HSA-8949613,-0.9994193580142725,-1.3811190415194046,0.0,1.0,1.0,1/29,0.07%,CHCHD3
prerank,Reactome_2022__Downregulation Of TGF-beta Receptor Signaling R-HSA-2173788,0.9768815716325874,1.3811055396418925,0.5203252032520326,1.0,1.0,2/26,2.32%,USP15;ZFYVE9
prerank,GO_Biological_Process_2021__positive regulation of antigen receptor-mediated signaling pathway (GO:0050857),0.9865761761079164,1.3810936270108063,0.2283464566929134,1.0,1.0,1/21,1.34%,NFAM1
prerank,"KEGG_2021_Human__Alanine, aspartate and glutamate metabolism",0.9804502188527731,1.381085792673798,0.3089430894308943,1.0,1.0,2/35,1.96%,GLS;ASRGL1
prerank,GO_Biological_Process_2021__positive regulation of growth (GO:0045927),-0.9965239342555574,-1.3809374271064352,0.008403361344537815,1.0,1.0,1/67,0.35%,ADAM10
prerank,GO_Biological_Process_2021__negative regulation of actin filament polymerization (GO:0030837),-0.983570886921958,-1.3805551549300443,0.33858267716535434,1.0,1.0,1/25,1.65%,KANK3
prerank,GO_Biological_Process_2021__acylglycerol homeostasis (GO:0055090),0.9800720918915373,1.380548129675023,0.3969465648854962,1.0,1.0,1/24,1.99%,APOE
prerank,Reactome_2022__Nucleotide Catabolism R-HSA-8956319,-0.9789927212845406,-1.3804835502644712,0.3700787401574803,1.0,1.0,3/32,2.11%,DPYS;ENTPD8;ENTPD3
prerank,Elsevier_Pathway_Collection__Familial Cold Autoinflammatory Syndrome 2,-0.9815671583372466,-1.3804471366634972,0.36,1.0,1.0,1/28,1.85%,TICAM2
prerank,Elsevier_Pathway_Collection__TGFBR -> MEF/MYOD/MYOG Signaling,-0.9936524753987452,-1.3800682437766694,0.09090909090909091,1.0,1.0,2/25,0.65%,MAP2K6;MAP2K5
prerank,TRRUST_Transcription_Factors_2019__ERG human,-0.9775363244722657,-1.3800635214431425,0.464,1.0,1.0,3/26,2.26%,ZEB1;KCNN2;TMPRSS2
prerank,Elsevier_Pathway_Collection__SCF/BTRC Complex,-0.9866862113047308,-1.3799761612694939,0.25384615384615383,1.0,1.0,2/34,1.34%,RB1;DEPTOR
prerank,GO_Biological_Process_2021__neural tube closure (GO:0001843),0.9832171622690224,1.3799094155483962,0.248,1.0,1.0,1/34,1.68%,DLC1
prerank,GO_Biological_Process_2021__amide transport (GO:0042886),0.9946120285329189,1.3798778803536091,0.1111111111111111,1.0,1.0,1/28,0.54%,SLC19A1
prerank,GO_Biological_Process_2021__positive regulation of proteolysis involved in cellular protein catabolic process (GO:1903052),0.9914187490189077,1.3795617467715522,0.0962962962962963,1.0,1.0,1/29,0.86%,PTK2
prerank,GO_Biological_Process_2021__response to glucose (GO:0009749),0.9846013708914378,1.3795056611076586,0.21705426356589147,1.0,1.0,3/45,1.55%,ERN1;PRKAA2;PDK3
prerank,WikiPathway_2021_Human__Pathogenic Escherichia coli infection WP2272,0.9785901467860829,1.379309067293208,0.33884297520661155,1.0,1.0,3/52,2.15%,YWHAQ;CDH1;TUBA1A
prerank,Elsevier_Pathway_Collection__Sertoli Cells Dysfunction Causes Male Infertility,0.9818821015594427,1.3792610006604993,0.33064516129032256,1.0,1.0,3/27,1.82%,TJP1;CREB1;PTGS2
prerank,Elsevier_Pathway_Collection__Hedgehog Family Signaling,-0.9793836744225491,-1.3790435747955125,0.4435483870967742,1.0,1.0,4/25,2.08%,SUFU;SHH;BOC;GLI3
prerank,GO_Biological_Process_2021__lytic vacuole organization (GO:0080171),0.9768697019343529,1.3788339770975455,0.4523809523809524,1.0,1.0,1/33,2.31%,MYO7A
prerank,TRRUST_Transcription_Factors_2019__FOXM1 mouse,0.9804631180784671,1.3786371417633516,0.4424778761061947,1.0,1.0,5/22,1.97%,BRIP1;MYCN;CDH1;PTGS2;AXIN2
prerank,GO_Biological_Process_2021__cellular response to virus (GO:0098586),-0.9763778145525944,-1.3786358216097547,0.40714285714285714,1.0,1.0,3/31,2.37%,OAS1;TOMM70;IFI6
prerank,Reactome_2022__NIK To Noncanonical NF-kB Signaling R-HSA-5676590,0.9880158333408402,1.3785714879072766,0.17796610169491525,1.0,1.0,1/56,1.20%,PSMB9
prerank,GO_Biological_Process_2021__COPII-coated vesicle budding (GO:0090114),-0.9760566224587864,-1.378494631368179,0.2558139534883721,1.0,1.0,1/70,2.39%,COL7A1
prerank,Reactome_2022__Mitochondrial tRNA Aminoacylation R-HSA-379726,0.9840748450656044,1.3782834539162916,0.31851851851851853,1.0,1.0,1/21,1.59%,SARS2
prerank,GO_Biological_Process_2021__regulation of insulin secretion involved in cellular response to glucose stimulus (GO:0061178),0.9956888041322781,1.3782760867255897,0.07042253521126761,1.0,1.0,1/27,0.43%,LRP5
prerank,Reactome_2022__Dectin-1 Mediated Noncanonical NF-kB Signaling R-HSA-5607761,0.9880138188044394,1.3780139779371858,0.17355371900826447,1.0,1.0,1/59,1.20%,PSMB9
prerank,GO_Biological_Process_2021__tube closure (GO:0060606),0.9832196976956867,1.377954852628581,0.2601626016260163,1.0,1.0,1/31,1.68%,DLC1
prerank,GO_Biological_Process_2021__RNA catabolic process (GO:0006401),0.9978031933520585,1.3779091528728873,0.024,1.0,1.0,2/46,0.23%,ERN1;DIS3L2
prerank,Reactome_2022__APC/C:Cdc20 Mediated Degradation Of Mitotic Proteins R-HSA-176409,0.9825772781555095,1.3777176234421908,0.19047619047619047,1.0,1.0,2/72,1.74%,PSMB9;UBE2C
prerank,GO_Biological_Process_2021__regulation of receptor internalization (GO:0002090),-0.9820293430365986,-1.3776983819567767,0.3178294573643411,1.0,1.0,2/34,1.81%,ATAD1;NTF3
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Early Diabetic Nephropathy,0.9957665958381301,1.3776640108057046,0.08928571428571429,1.0,1.0,1/24,0.43%,CREB1
prerank,GO_Biological_Process_2021__actin-myosin filament sliding (GO:0033275),0.9825272040058051,1.377545472954488,0.33858267716535434,1.0,1.0,1/31,1.75%,TNNC2
prerank,GO_Biological_Process_2021__muscle filament sliding (GO:0030049),0.9825272040058051,1.377545472954488,0.33858267716535434,1.0,1.0,1/31,1.75%,TNNC2
prerank,GO_Biological_Process_2021__positive regulation of ion transmembrane transporter activity (GO:0032414),-0.9910739253308762,-1.3774698928948863,0.0873015873015873,1.0,1.0,1/25,0.90%,WNK3
prerank,Reactome_2022__Olfactory Signaling Pathway R-HSA-381753,-0.989574817090371,-1.377311046811722,0.140625,1.0,1.0,1/23,1.05%,LDB2
prerank,GO_Biological_Process_2021__purine ribonucleoside monophosphate metabolic process (GO:0009167),0.9816141423994452,1.3772738382200287,0.4017857142857143,1.0,1.0,1/20,1.84%,HPRT1
prerank,GO_Biological_Process_2021__positive regulation of telomere maintenance (GO:0032206),-0.9791862181034547,-1.3771864707952168,0.41007194244604317,1.0,1.0,3/31,2.09%,NEK7;TNKS;PML
prerank,GO_Biological_Process_2021__negative regulation of cell-substrate adhesion (GO:0010812),0.9761410581708261,1.376812695895886,0.4166666666666667,1.0,1.0,3/37,2.39%,TBCD;CX3CL1;MELTF
prerank,Reactome_2022__Regulation Of Activated PAK-2p34 By Proteasome Mediated Degradation R-HSA-211733,0.9880213135756271,1.3767352273472129,0.20168067226890757,1.0,1.0,1/47,1.20%,PSMB9
prerank,GO_Biological_Process_2021__ribosomal large subunit biogenesis (GO:0042273),-0.9866707328772903,-1.3766880280957892,0.14754098360655737,1.0,1.0,1/56,1.34%,RRP15
prerank,Elsevier_Pathway_Collection__Persistent Double Strand DNA Homologous Repair in Cancer,-0.9883079345625403,-1.3765365735696806,0.23255813953488372,1.0,1.0,1/20,1.18%,BRCC3
prerank,GO_Biological_Process_2021__histone mRNA metabolic process (GO:0008334),0.9933056134179232,1.3764250893938983,0.14912280701754385,1.0,1.0,2/28,0.68%,ZNF473;TENT2
prerank,Reactome_2022__APC:Cdc20 Mediated Degradation Of Cell Cycle Proteins Before Cycle Checkpoint Satisfied R-HSA-179419,0.9825787107162096,1.376402717542958,0.208,1.0,1.0,2/70,1.74%,PSMB9;UBE2C
prerank,GO_Biological_Process_2021__telomere maintenance via telomere lengthening (GO:0010833),0.9774501218415086,1.3759524165968227,0.4634146341463415,1.0,1.0,3/35,2.26%,WRAP53;ACD;PIF1
prerank,Reactome_2022__DAG And IP3 Signaling R-HSA-1489509,0.9957625162387855,1.3758982969988023,0.06086956521739131,1.0,1.0,1/37,0.43%,CREB1
prerank,GO_Biological_Process_2021__positive regulation of viral genome replication (GO:0045070),0.9980734825473978,1.375853969698852,0.015151515151515152,1.0,1.0,1/28,0.20%,PPARA
prerank,GO_Biological_Process_2021__regulation of supramolecular fiber organization (GO:1902903),0.9801158590225303,1.37556577341069,0.42857142857142855,1.0,1.0,2/22,1.99%,CAMSAP3;APOE
prerank,GO_Biological_Process_2021__negative regulation of signal transduction in absence of ligand (GO:1901099),-0.9763468905098208,-1.3754189666168115,0.5234375,1.0,1.0,2/22,2.37%,MAP2K5;IFI6
prerank,GO_Biological_Process_2021__negative regulation of extrinsic apoptotic signaling pathway in absence of ligand (GO:2001240),-0.9763468905098208,-1.3754189666168115,0.5234375,1.0,1.0,2/22,2.37%,MAP2K5;IFI6
prerank,WikiPathway_2021_Human__PPAR signaling pathway WP3942,0.9778116754369738,1.3753510350104177,0.2777777777777778,1.0,1.0,3/62,2.22%,PPARA;SLC27A2;ACSL5
prerank,"GO_Biological_Process_2021__Wnt signaling pathway, calcium modulating pathway (GO:0007223)",0.976596525043928,1.3752908043588874,0.38461538461538464,1.0,1.0,1/36,2.34%,GNG2
prerank,Elsevier_Pathway_Collection__Replication Stress Triggers Genomic Instability,0.9898813540644904,1.3751080371888824,0.23333333333333334,1.0,1.0,2/29,1.02%,MMS22L;ATR
prerank,GO_Biological_Process_2021__positive regulation of cholesterol efflux (GO:0010875),0.9800744648734533,1.375033521919717,0.4126984126984127,1.0,1.0,1/22,1.99%,APOE
prerank,GO_Biological_Process_2021__protein transmembrane import into intracellular organelle (GO:0044743),-0.9927245019023948,-1.375024686869754,0.09836065573770492,1.0,1.0,1/32,0.73%,TOMM70
prerank,Reactome_2022__Recycling Pathway Of L1 R-HSA-437239,0.9794528192336502,1.3750122962679057,0.40869565217391307,1.0,1.0,1/27,2.06%,DPYSL2
prerank,GO_Biological_Process_2021__regulation of exit from mitosis (GO:0007096),0.9826427661520887,1.374927730046556,0.30158730158730157,1.0,1.0,3/38,1.74%,CDC14B;ANLN;UBE2C
prerank,GO_Biological_Process_2021__negative regulation of cellular metabolic process (GO:0031324),0.9789505462805713,1.3749123017775764,0.33076923076923076,1.0,1.0,3/36,2.11%,AATF;APOE;OPTN
prerank,Elsevier_Pathway_Collection__IL6/IGF1/VEGFA Signaling in Multiple Myeloma,-0.9807416065591555,-1.3748928902975444,0.2746478873239437,1.0,1.0,1/47,1.93%,MMP2
prerank,GO_Biological_Process_2021__regulation of dendrite development (GO:0050773),-0.9776405267945589,-1.3747968270594695,0.427536231884058,1.0,1.0,3/38,2.25%,NEDD4;KNDC1;SEMA4D
prerank,Reactome_2022__Intra-Golgi And Retrograde Golgi-to-ER Traffic R-HSA-6811442,0.8427155234114783,1.3747389880815943,0.01680672268907563,1.0,1.0,8/178,2.41%,COG5;IGF2R;CENPE;RAB3GAP1;AGPAT3;MAN1A1;KIF23;KIF3B
prerank,Reactome_2022__Signaling By PDGFR In Disease R-HSA-9671555,-0.9800417481720003,-1.3744291618272082,0.41935483870967744,1.0,1.0,2/19,2.01%,PIK3CB;BIN2
prerank,TRRUST_Transcription_Factors_2019__CEBPB human,0.9818240294951344,1.3743867751171295,0.24369747899159663,1.0,1.0,2/51,1.82%,SLC19A1;PTGS2
prerank,GO_Biological_Process_2021__histone H4 acetylation (GO:0043967),0.9950701655855219,1.3740106763020505,0.05785123966942149,1.0,1.0,2/47,0.50%,NAA60;ING5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Endometrioid Ovarian Carcinoma,-0.9847877844486441,-1.373729939611614,0.19327731092436976,1.0,1.0,1/47,1.53%,NRG1
prerank,GO_Biological_Process_2021__epidermal cell differentiation (GO:0009913),0.9836349418703542,1.3735984773496355,0.2396694214876033,1.0,1.0,1/39,1.64%,ANXA1
prerank,GO_Biological_Process_2021__regulation of proteasomal protein catabolic process (GO:0061136),0.9800421216923307,1.3735579293266367,0.2535211267605634,1.0,1.0,1/52,1.99%,APOE
prerank,Reactome_2022__Post-chaperonin Tubulin Folding Pathway R-HSA-389977,0.9785792708453143,1.3734911011747648,0.48201438848920863,1.0,1.0,2/20,2.15%,TBCD;TUBA1A
prerank,Reactome_2022__RUNX2 Regulates Bone Development R-HSA-8941326,-0.9793030229056789,-1.373438570449303,0.3858267716535433,1.0,1.0,2/28,2.08%,RB1;GLI3
prerank,GO_Biological_Process_2021__mesenchymal cell differentiation (GO:0048762),0.9771980252344186,1.3732714205316847,0.3559322033898305,1.0,1.0,1/49,2.28%,HGF
prerank,Reactome_2022__Ubiquitin Mediated Degradation Of Phosphorylated Cdc25A R-HSA-69601,0.98802016713826,1.3732551718880324,0.20491803278688525,1.0,1.0,1/49,1.20%,PSMB9
prerank,GO_Biological_Process_2021__metal ion export (GO:0070839),-0.9756477766648756,-1.3730983965477714,0.49206349206349204,1.0,1.0,2/29,2.44%,KCNT2;KCNE1
prerank,GO_Biological_Process_2021__negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage (GO:1902230),-0.9824166890698038,-1.3730363075129801,0.32,1.0,1.0,1/25,1.76%,CD44
prerank,GO_Biological_Process_2021__actin filament bundle assembly (GO:0051017),0.9779918829808155,1.3728470708130187,0.4222222222222222,1.0,1.0,4/33,2.21%,ESPN;BAIAP2L2;SHROOM1;DPYSL3
prerank,GO_Biological_Process_2021__calcium ion import (GO:0070509),0.9960751023994113,1.372633071273363,0.06299212598425197,1.0,1.0,2/27,0.40%,MICU1;SLC25A23
prerank,Reactome_2022__Degradation Of DVL R-HSA-4641258,0.9880176419173193,1.371977243773338,0.15748031496062992,1.0,1.0,1/53,1.20%,PSMB9
prerank,GO_Biological_Process_2021__hematopoietic progenitor cell differentiation (GO:0002244),-0.9850717953150806,-1.3719415933499477,0.23529411764705882,1.0,1.0,2/30,1.50%,SHH;BMP4
prerank,Reactome_2022__Signaling By SCF-KIT R-HSA-1433557,-0.9768299830249607,-1.3718599199984465,0.37142857142857144,1.0,1.0,6/42,2.34%,TEC;GRB10;GRAP2;STAT5A;SH2B2;VAV1
prerank,Reactome_2022__Keratan Sulfate Biosynthesis R-HSA-2022854,0.9937673073018838,1.3717458156921585,0.1297709923664122,1.0,1.0,2/26,0.63%,ST3GAL1;SLC35D2
prerank,GO_Biological_Process_2021__keratan sulfate biosynthetic process (GO:0018146),0.9937673073018838,1.3717458156921585,0.1297709923664122,1.0,1.0,2/26,0.63%,ST3GAL1;SLC35D2
prerank,Reactome_2022__mRNA Capping R-HSA-72086,-0.9916111103225466,-1.3716864059241756,0.15671641791044777,1.0,1.0,1/29,0.85%,RNGTT
prerank,MSigDB_Hallmark_2020__Myc Targets V2,0.9780830586020903,1.371447073513954,0.27906976744186046,1.0,1.0,2/58,2.19%,SLC19A1;HK2
prerank,Elsevier_Pathway_Collection__Airway Smooth Muscle Cell Contraction,-0.9766302520049771,-1.3714139771382934,0.3939393939393939,1.0,1.0,1/40,2.34%,VAV1
prerank,GO_Biological_Process_2021__cellular response to glucose starvation (GO:0042149),0.9890278069128504,1.3714059076705032,0.15441176470588236,1.0,1.0,2/43,1.10%,BRSK1;PRKAA2
prerank,Elsevier_Pathway_Collection__Chronic Myeloid Leukemia,-0.982965913001367,-1.371265258979501,0.11764705882352941,1.0,1.0,2/69,1.71%,RB1;STAT5A
prerank,GO_Biological_Process_2021__regulation of neuron death (GO:1901214),-0.9769043090575645,-1.3712184870355684,0.20512820512820512,1.0,1.0,2/82,2.31%,GRIN2B;EFNB2
prerank,WikiPathway_2021_Human__IL-9 signaling pathway WP22,-0.9829638270397855,-1.3711799642416005,0.3448275862068966,1.0,1.0,1/16,1.71%,STAT5A
prerank,GO_Biological_Process_2021__GPI anchor metabolic process (GO:0006505),-0.9772659794444439,-1.3711265220048134,0.48091603053435117,1.0,1.0,2/26,2.28%,PIGZ;PGAP4
prerank,Reactome_2022__Negative Regulation Of FGFR1 Signaling R-HSA-5654726,0.9762971075358454,1.3710691775874864,0.5365853658536586,1.0,1.0,1/28,2.37%,FGF1
prerank,GO_Biological_Process_2021__exonucleolytic catabolism of deadenylated mRNA (GO:0043928),-0.9934555028498493,-1.3709527642216053,0.08270676691729323,1.0,1.0,1/33,0.66%,EDC3
prerank,GO_Biological_Process_2021__negative regulation of Ras protein signal transduction (GO:0046580),0.9824919555523483,1.3708263030644638,0.2764227642276423,1.0,1.0,3/34,1.76%,ITGA3;DLC1;STMN3
prerank,TRRUST_Transcription_Factors_2019__MITF mouse,0.9878813858068897,1.3707473076352892,0.19469026548672566,1.0,1.0,1/24,1.21%,ITGA4
prerank,"GO_Biological_Process_2021__DNA-templated transcription, termination (GO:0006353)",0.9801549731661026,1.3707013142005264,0.1557377049180328,1.0,1.0,3/70,1.99%,ZNF473;TAF1B;CAVIN1
prerank,Elsevier_Pathway_Collection__WNT Signaling Activation by Blocking of Tumor Suppressors,0.9804144411987975,1.3705667756574649,0.3671875,1.0,1.0,4/35,1.97%,AATF;LRP5;CDH1;AXIN2
prerank,GO_Biological_Process_2021__negative regulation of binding (GO:0051100),0.9813720683220486,1.3705362818145124,0.11538461538461539,1.0,1.0,2/86,1.86%,ZNF304;ZFPM1
prerank,GO_Biological_Process_2021__positive regulation of extrinsic apoptotic signaling pathway (GO:2001238),-0.9791492619126295,-1.3704279877180163,0.4580152671755725,1.0,1.0,2/28,2.09%,PAK2;PML
prerank,Elsevier_Pathway_Collection__NOD-like Receptors,0.9810319399504738,1.3703623203804578,0.33070866141732286,1.0,1.0,3/32,1.91%,TRAF3;NOD2;NAIP
prerank,GO_Biological_Process_2021__aortic valve morphogenesis (GO:0003180),-0.9808015684872677,-1.370252100989856,0.3435114503816794,1.0,1.0,3/31,1.93%,RB1;BMP4;SLIT3
prerank,Reactome_2022__Surfactant Metabolism R-HSA-5683826,0.9805345140617814,1.370197612510107,0.38095238095238093,1.0,1.0,2/27,1.95%,CKAP4;CTSH
prerank,Reactome_2022__Regulation Of RUNX3 Expression And Activity R-HSA-8941858,0.9880171765820546,1.3701450619921791,0.20175438596491227,1.0,1.0,1/54,1.20%,PSMB9
prerank,Elsevier_Pathway_Collection__IGF1 Role in Muscle Hypertrophy,-0.9764111409900755,-1.3700528855506917,0.46616541353383456,1.0,1.0,1/31,2.36%,FBXO32
prerank,GO_Biological_Process_2021__membrane protein intracellular domain proteolysis (GO:0031293),-0.9965360238388365,-1.3700499488801365,0.07142857142857142,1.0,1.0,1/21,0.35%,ADAM10
prerank,"Reactome_2022__Inactivation, Recovery And Regulation Of Phototransduction Cascade R-HSA-2514859",0.9834939315503296,1.3698404887685942,0.3391304347826087,1.0,1.0,1/25,1.65%,GNB5
prerank,GO_Biological_Process_2021__regulation of histone acetylation (GO:0035065),-0.9761057350813928,-1.36983007390409,0.45901639344262296,1.0,1.0,2/32,2.40%,RAPGEF3;SPI1
prerank,GO_Biological_Process_2021__regulation of regulated secretory pathway (GO:1903305),-0.9764533704862084,-1.3698008126961565,0.42105263157894735,1.0,1.0,3/32,2.37%,DTNBP1;SYT2;SYT7
prerank,Reactome_2022__RNA Polymerase III Transcription Initiation R-HSA-76046,-0.9909157335422647,-1.3697330727227224,0.128,1.0,1.0,1/35,0.91%,POU2F1
prerank,GO_Biological_Process_2021__positive regulation of defense response to virus by host (GO:0002230),-0.9927669736231473,-1.3697035335550163,0.1171875,1.0,1.0,2/27,0.73%,TRIM44;TOMM70
prerank,Elsevier_Pathway_Collection__EGFR -> SMAD1 Signaling,-0.9766921000511943,-1.3696431754467688,0.4915254237288136,1.0,1.0,2/23,2.34%,NRG1;VAV1
prerank,GO_Biological_Process_2021__negative regulation of DNA biosynthetic process (GO:2000279),0.977455564541721,1.3696368746845051,0.41935483870967744,1.0,1.0,3/30,2.26%,NIBAN2;ACD;PIF1
prerank,WikiPathway_2021_Human__TNF related weak inducer of apoptosis (TWEAK) Signaling Pathway WP2036,0.9901063840520096,1.3691592413077012,0.13008130081300814,1.0,1.0,2/42,1.00%,TRAF3;CASP7
prerank,GO_Biological_Process_2021__mRNA catabolic process (GO:0006402),0.9978034555134434,1.368970887484408,0.016666666666666666,1.0,1.0,2/43,0.23%,ERN1;DIS3L2
prerank,Reactome_2022__Cleavage Of Damaged Purine R-HSA-110331,0.9784914125901158,1.3688736279621947,0.4306569343065693,1.0,1.0,1/27,2.15%,ACD
prerank,Reactome_2022__Negative Regulation Of NOTCH4 Signaling R-HSA-9604323,0.9880183451456901,1.368757607416005,0.15966386554621848,1.0,1.0,1/53,1.20%,PSMB9
prerank,GO_Biological_Process_2021__regulation of transcription initiation from RNA polymerase II promoter (GO:0060260),-0.9899002384863246,-1.368503557620925,0.07758620689655173,1.0,1.0,1/63,1.01%,ZNF451
prerank,Elsevier_Pathway_Collection__Coagulation Factors and PAR1/2 Receptors (F2R/F2RL1) in Endometriosis,0.9818390982261551,1.368495606826092,0.3135593220338983,1.0,1.0,2/32,1.82%,F7;PTGS2
prerank,GO_Biological_Process_2021__negative regulation of immune effector process (GO:0002698),0.9795452359342816,1.3684673045515328,0.472,1.0,1.0,2/15,2.05%,CD300A;LGALS3
prerank,GO_Biological_Process_2021__cellular response to interleukin-6 (GO:0071354),-0.9760674187863928,-1.3682593994670007,0.512396694214876,1.0,1.0,1/28,2.40%,SPI1
prerank,Elsevier_Pathway_Collection__Lipid Metabolism Impairement in non-Alcoholic Fatty Liver Disease,0.976608753069977,1.3682076148726865,0.4857142857142857,1.0,1.0,3/31,2.35%,ACACA;CREB1;GK
prerank,GO_Biological_Process_2021__cellular polysaccharide biosynthetic process (GO:0033692),0.9850773181087276,1.3681765787029228,0.3409090909090909,1.0,1.0,2/21,1.50%,HS2ST1;HAS3
prerank,GO_Biological_Process_2021__COPII vesicle coating (GO:0048208),-0.9760648930739059,-1.3681258568594168,0.2890625,1.0,1.0,1/63,2.39%,COL7A1
prerank,"GO_Biological_Process_2021__vesicle targeting, rough ER to cis-Golgi (GO:0048207)",-0.9760648930739059,-1.3681258568594168,0.2890625,1.0,1.0,1/63,2.39%,COL7A1
prerank,GO_Biological_Process_2021__vesicle coating (GO:0006901),-0.9760648930739059,-1.3681258568594168,0.2890625,1.0,1.0,1/63,2.39%,COL7A1
prerank,Reactome_2022__GAG Synthesis Requires Tetrasaccharide Linker Sequence R-HSA-1971475,-0.982761367967077,-1.3681042308449438,0.3125,1.0,1.0,1/26,1.73%,SDC3
prerank,Elsevier_Pathway_Collection__APC/C-CDC20 Complex,0.9961485950178506,1.3680469696959692,0.05785123966942149,1.0,1.0,1/33,0.39%,CENPE
prerank,GO_Biological_Process_2021__blood vessel diameter maintenance (GO:0097746),-0.9799112940156137,-1.3679335030112374,0.368,1.0,1.0,1/31,2.01%,BDKRB2
prerank,Elsevier_Pathway_Collection__Myeloid Cell Differentiation Block in Leukemia,-0.9760707294818418,-1.3677370295849212,0.5483870967741935,1.0,1.0,1/25,2.40%,SPI1
prerank,GO_Biological_Process_2021__inorganic anion transport (GO:0015698),0.9788119477394694,1.367597074408528,0.28,1.0,1.0,1/52,2.12%,CLCN4
prerank,GO_Biological_Process_2021__positive regulation of mononuclear cell migration (GO:0071677),0.9794197040322212,1.3674749056886706,0.45,1.0,1.0,3/27,2.07%,MOSPD2;LGALS3;SERPINE1
prerank,Reactome_2022__GSK3B And BTRC:CUL1-mediated-degradation Of NFE2L2 R-HSA-9762114,0.9880191306929889,1.3673107908280615,0.16521739130434782,1.0,1.0,1/51,1.20%,PSMB9
prerank,GO_Biological_Process_2021__negative regulation of signaling receptor activity (GO:2000272),0.9927292080210662,1.3670742647903242,0.140625,1.0,1.0,2/26,0.73%,PPARA;ZGPAT
prerank,GO_Biological_Process_2021__positive regulation of innate immune response (GO:0045089),-0.9760612986453384,-1.3669244898571604,0.5,1.0,1.0,1/33,2.40%,SPI1
prerank,GO_Biological_Process_2021__glycosaminoglycan catabolic process (GO:0006027),-0.9824348139856363,-1.366916259958653,0.1984732824427481,1.0,1.0,2/54,1.76%,SDC3;CD44
prerank,Reactome_2022__Cdc20:Phospho-APC/C Mediated Degradation Of Cyclin A R-HSA-174184,0.982579551213296,1.3666768090915966,0.21428571428571427,1.0,1.0,2/69,1.74%,PSMB9;UBE2C
prerank,Reactome_2022__Vpu Mediated Degradation Of CD4 R-HSA-180534,0.9877930059208797,1.3664601547044457,0.1864406779661017,1.0,1.0,2/49,1.23%,PSMB9;CD4
prerank,Elsevier_Pathway_Collection__Majeed Syndrome,-0.9815666987955082,-1.3664377214067238,0.3220338983050847,1.0,1.0,1/29,1.85%,TICAM2
prerank,Reactome_2022__Activation Of NF-kappaB In B Cells R-HSA-1169091,0.9880109265274777,1.3664002412622005,0.1111111111111111,1.0,1.0,1/64,1.20%,PSMB9
prerank,Reactome_2022__Regulation Of TP53 Degradation R-HSA-6804757,-0.9953404022923064,-1.3663001542597308,0.047619047619047616,1.0,1.0,1/35,0.47%,AKT3
prerank,Elsevier_Pathway_Collection__Immunoglobulin Class-Switch Recombination Activation,0.981958653526437,1.3662281418064564,0.40707964601769914,1.0,1.0,2/26,1.81%,TRAF3;IL13RA1
prerank,Reactome_2022__Regulation Of TP53 Expression And Degradation R-HSA-6806003,-0.9953401839562963,-1.3660273798915186,0.04918032786885246,1.0,1.0,1/36,0.47%,AKT3
prerank,TRRUST_Transcription_Factors_2019__AHR human,-0.9803095198092071,-1.3658517297425268,0.4108527131782946,1.0,1.0,2/20,1.98%,CYP1B1;CYP1A2
prerank,Reactome_2022__APC/C:Cdc20 Mediated Degradation Of Securin R-HSA-174154,0.982582830697591,1.365672918057297,0.21875,1.0,1.0,2/65,1.74%,PSMB9;UBE2C
prerank,GO_Biological_Process_2021__negative regulation of mitochondrion organization (GO:0010823),0.9772592968724061,1.3656546827655822,0.45161290322580644,1.0,1.0,2/33,2.28%,ADCK1;HGF
prerank,Reactome_2022__Role Of GTSE1 In G2/M Progression After G2 Checkpoint R-HSA-8852276,0.9880148392818663,1.365433287205385,0.15833333333333333,1.0,1.0,1/57,1.20%,PSMB9
prerank,Elsevier_Pathway_Collection__Podocyte Dysfunction in Glomerulonephritis,0.9976110370510978,1.36539353352414,0.05,1.0,1.0,3/48,0.25%,PPARA;TJP1;CD2AP
prerank,GO_Biological_Process_2021__regulation of release of cytochrome c from mitochondria (GO:0090199),0.9772556188639274,1.3650871864041676,0.38333333333333336,1.0,1.0,2/37,2.28%,PLAUR;HGF
prerank,WikiPathway_2021_Human__Base Excision Repair WP4752,0.9914941734513669,1.3650092503023545,0.15625,1.0,1.0,1/31,0.85%,POLE4
prerank,Elsevier_Pathway_Collection__Focal Junction Assembly,0.977494587485797,1.3644597396909839,0.48333333333333334,1.0,1.0,5/30,2.27%,PTK2;BCAR1;DLC1;FBLIM1;FN1
prerank,TRRUST_Transcription_Factors_2019__JUND human,0.981879262747983,1.3643147405975,0.32786885245901637,1.0,1.0,3/30,1.82%,PLAUR;FOSL1;PTGS2
prerank,GO_Biological_Process_2021__establishment of mitotic spindle localization (GO:0040001),0.9803418395627749,1.3641736147792143,0.4142857142857143,1.0,1.0,3/29,1.98%,NDC80;CENPA;SAPCD2
prerank,Elsevier_Pathway_Collection__mTOR Signaling,-0.9842675757617162,-1.3641590443448692,0.09243697478991597,1.0,1.0,2/80,1.58%,DEPTOR;GRB10
prerank,Reactome_2022__Transcriptional Regulation By VENTX R-HSA-8853884,0.9825574435048858,1.363855525217445,0.2578125,1.0,1.0,1/39,1.74%,UBE2C
prerank,Reactome_2022__Acyl Chain Remodelling Of PE R-HSA-1482839,-0.9881894649226869,-1.3637499413739427,0.23809523809523808,1.0,1.0,1/25,1.19%,PLAAT3
prerank,"Reactome_2022__Glutamate Binding, Activation Of AMPA Receptors And Synaptic Plasticity R-HSA-399721",0.9945730991317507,1.3637246541408559,0.058333333333333334,1.0,1.0,1/26,0.55%,DLG1
prerank,Reactome_2022__Activation Of GABAB Receptors R-HSA-991365,0.9766780638650661,1.3636940705513918,0.4365079365079365,1.0,1.0,3/38,2.34%,KCNJ10;GNB5;GNG2
prerank,Reactome_2022__Metabolism Of Polyamines R-HSA-351202,0.9812450944216224,1.3636021031883219,0.23076923076923078,1.0,1.0,3/55,1.88%,SMOX;PSMB9;SLC38A1
prerank,GO_Biological_Process_2021__mRNA splice site selection (GO:0006376),0.9864167997752926,1.363252471084383,0.2831858407079646,1.0,1.0,1/29,1.36%,SF3A2
prerank,Reactome_2022__FBXL7 Down-Regulates AURKA During Mitotic Entry And In Early Mitosis R-HSA-8854050,0.9880184623200643,1.3630725979716307,0.1694915254237288,1.0,1.0,1/52,1.20%,PSMB9
prerank,Reactome_2022__Cell Cycle Checkpoints R-HSA-69620,0.812282223548385,1.3630431539546901,0.03508771929824561,1.0,1.0,12/258,1.78%,CDC45;HERC2;CENPE;YWHAQ;NDC80;BRIP1;CENPA;PSMB9;PKMYT1;PCBP4;UBE2C;ERCC6L
prerank,GO_Biological_Process_2021__peroxisome organization (GO:0007031),-0.988229314852997,-1.3629451781733712,0.18181818181818182,1.0,1.0,2/25,1.19%,ABCD3;PLAAT3
prerank,Elsevier_Pathway_Collection__Adherens Junction Assembly (Cadherins),0.9829941880044268,1.362396610035054,0.3484848484848485,1.0,1.0,2/30,1.71%,CDH2;CDH1
prerank,Reactome_2022__Packaging Of Telomere Ends R-HSA-171306,0.9784956596162843,1.362375480355518,0.453125,1.0,1.0,1/23,2.15%,ACD
prerank,Elsevier_Pathway_Collection__Cochlear Hair Cell Stereocilia Proteins Mutations (Congenital Deafness),0.9769128588639424,1.3622189212440547,0.43548387096774194,1.0,1.0,2/33,2.31%,ESPN;MYO7A
prerank,GO_Biological_Process_2021__tRNA methylation (GO:0030488),-0.9869143970151559,-1.362140304642191,0.17164179104477612,1.0,1.0,1/34,1.31%,THADA
prerank,GO_Biological_Process_2021__regulation of cell size (GO:0008361),-0.9766923217873528,-1.3620184640012731,0.4957983193277311,1.0,1.0,2/23,2.34%,DEPTOR;VAV1
prerank,GO_Biological_Process_2021__regulation of microtubule polymerization or depolymerization (GO:0031110),0.9824578106476916,1.3619788584700712,0.4224137931034483,1.0,1.0,2/27,1.76%,CAMSAP3;STMN3
prerank,GO_Biological_Process_2021__fat cell differentiation (GO:0045444),-0.9795876107467574,-1.3618746342659132,0.2713178294573643,1.0,1.0,2/54,2.05%,INHBB;KLF4
prerank,GO_Biological_Process_2021__response to cAMP (GO:0051591),-0.9757572440871001,-1.3617078165800618,0.4645669291338583,1.0,1.0,5/37,2.44%,RAP1B;NDUFS4;RAP1A;RAPGEF3;KCNE1
prerank,Elsevier_Pathway_Collection__Adiponectin in Insulin Resistance Prevention,0.998074143747958,1.361676483167853,0.024390243902439025,1.0,1.0,1/23,0.20%,PPARA
prerank,GO_Biological_Process_2021__negative regulation of catalytic activity (GO:0043086),0.9790366815237213,1.3615668668848286,0.45038167938931295,1.0,1.0,2/25,2.10%,PPP1R12A;SERPINA5
prerank,GO_Biological_Process_2021__positive regulation of lipid metabolic process (GO:0045834),0.9801543489639504,1.3614235900463818,0.4017857142857143,1.0,1.0,3/23,1.99%,PPARA;CREB1;APOE
prerank,GO_Biological_Process_2021__positive regulation of ERBB signaling pathway (GO:1901186),0.9928815233138375,1.3613581777712533,0.13333333333333333,1.0,1.0,1/24,0.71%,PLAUR
prerank,Elsevier_Pathway_Collection__EGFR -> NCOR2 Signaling,-0.984842701747475,-1.361338227422349,0.2283464566929134,1.0,1.0,2/28,1.53%,PTK2B;NRG1
prerank,GO_Biological_Process_2021__response to amino acid (GO:0043200),-0.9982265222733847,-1.3612379331583961,0.01694915254237288,1.0,1.0,1/29,0.18%,CPEB3
prerank,GO_Biological_Process_2021__protein modification process (GO:0036211),0.9799205887804991,1.36115066281868,0.15702479338842976,1.0,1.0,6/76,2.02%,PLOD2;MANBA;ST3GAL1;PHKA2;WWP2;CPE
prerank,Elsevier_Pathway_Collection__NF-kB Canonical Signaling,0.9874844207078977,1.36105429220921,0.152,1.0,1.0,2/50,1.26%,TRAF3;SYK
prerank,Reactome_2022__Autodegradation Of Cdh1 By Cdh1:APC/C R-HSA-174084,0.9825842530860966,1.3607026120189136,0.21705426356589147,1.0,1.0,2/63,1.74%,PSMB9;UBE2C
prerank,Reactome_2022__Metabolism Of Porphyrins R-HSA-189445,-0.9998044394188259,-1.3606700587679066,0.0,1.0,1.0,1/28,0.03%,GSTA1
prerank,GO_Biological_Process_2021__positive regulation of T cell migration (GO:2000406),-0.978192624490749,-1.3604856293032161,0.484375,1.0,1.0,3/23,2.19%,ADAM10;APP;TNFRSF14
prerank,Reactome_2022__Activation Of G Protein Gated Potassium Channels R-HSA-1296041,0.9766896191436062,1.3603757630197346,0.53125,1.0,1.0,3/26,2.34%,KCNJ10;GNB5;GNG2
prerank,GO_Biological_Process_2021__lysosome organization (GO:0007040),0.9768652585090747,1.360349816101107,0.46774193548387094,1.0,1.0,1/37,2.31%,MYO7A
prerank,WikiPathway_2021_Human__Peptide GPCRs WP24,-0.9798912628845794,-1.360279108287439,0.24031007751937986,1.0,1.0,1/50,2.01%,BDKRB2
prerank,GO_Biological_Process_2021__positive regulation of proteolysis (GO:0045862),0.9801278743284227,1.3602691712943435,0.2713178294573643,1.0,1.0,3/54,1.99%,PACSIN3;CTSH;APOE
prerank,GO_Biological_Process_2021__cytosolic calcium ion transport (GO:0060401),0.9960745508084531,1.3601945456765816,0.056910569105691054,1.0,1.0,2/28,0.40%,MICU1;SLC25A23
prerank,Elsevier_Pathway_Collection__Alveolar Macrophage Negative Regulation Declined in COPD,-0.9802530617636896,-1.3598876551686865,0.312,1.0,1.0,2/42,1.98%,RASA2;IL10RA
prerank,GO_Biological_Process_2021__regulation of RNA splicing (GO:0043484),0.9953721186822594,1.359550550011834,0.03389830508474576,1.0,1.0,2/70,0.47%,ERN1;ZNF326
prerank,WikiPathway_2021_Human__IL-6 signaling pathway WP364,-0.9767517345629008,-1.3595335352878404,0.373015873015873,1.0,1.0,4/43,2.34%,NCOA1;CREBBP;HCK;VAV1
prerank,GO_Biological_Process_2021__regulation of nervous system development (GO:0051960),0.9848740108309191,1.359525926792187,0.3008130081300813,1.0,1.0,2/37,1.52%,CX3CL1;NKX6-2
prerank,Reactome_2022__RND2 GTPase Cycle R-HSA-9696270,0.9877212959387196,1.359481373888436,0.16793893129770993,1.0,1.0,4/42,1.24%,DEPDC1B;PKP4;FNBP1;CKAP4
prerank,Elsevier_Pathway_Collection__DNA Damage Checkpoint Impairment in Cancer,0.9899191557074934,1.3594483472565226,0.1724137931034483,1.0,1.0,3/32,1.02%,AATF;CDK6;ATR
prerank,GO_Biological_Process_2021__cytoskeleton-dependent cytokinesis (GO:0061640),0.9785777345507102,1.3594059866000765,0.232,1.0,1.0,6/68,2.16%,CENPA;SEPTIN6;ANLN;SEPTIN9;SPIRE2;KIF23
prerank,Reactome_2022__Disassembly Of Destruction Complex And Recruitment Of AXIN To Membrane R-HSA-4641262,0.9956887174811523,1.3593881132113728,0.07936507936507936,1.0,1.0,1/27,0.43%,LRP5
prerank,GO_Biological_Process_2021__regulation of mononuclear cell migration (GO:0071675),0.9795386781486244,1.3593865988536873,0.44537815126050423,1.0,1.0,2/22,2.05%,PTK2;LGALS3
prerank,Reactome_2022__COPI-independent Golgi-to-ER Retrograde Traffic R-HSA-6811436,0.9941500994946035,1.359341676044082,0.1076923076923077,1.0,1.0,2/34,0.59%,RAB3GAP1;AGPAT3
prerank,Reactome_2022__Processing Of Capped Intronless Pre-mRNA R-HSA-75067,0.9998433711081572,1.358917528514101,0.0,1.0,1.0,1/29,0.02%,ZNF473
prerank,Elsevier_Pathway_Collection__TLR2 Induced Synovial Fibroblast Activation in Rheumatoid Arthritis,-0.9815631779316918,-1.3586697509247263,0.296875,1.0,1.0,1/33,1.85%,TICAM2
prerank,TRRUST_Transcription_Factors_2019__SMAD3 mouse,0.9774061432336084,1.3586065110243326,0.39090909090909093,1.0,1.0,3/41,2.27%,CDH1;SERPINE1;FN1
prerank,TRRUST_Transcription_Factors_2019__SMAD4 mouse,0.9772572961741837,1.35852994651234,0.4830508474576271,1.0,1.0,2/34,2.28%,CDH1;HGF
prerank,GO_Biological_Process_2021__regulation of cellular component size (GO:0032535),-0.9766415819014763,-1.3584479712964166,0.48717948717948717,1.0,1.0,1/31,2.34%,VAV1
prerank,Elsevier_Pathway_Collection__Adipocyte Hypertrophy and Hyperplasia,0.9966136549876023,1.3583547987332203,0.0859375,1.0,1.0,2/28,0.35%,PPARA;ACACA
prerank,GO_Biological_Process_2021__negative regulation of endothelial cell proliferation (GO:0001937),0.9801035853494436,1.3580483864429889,0.3383458646616541,1.0,1.0,2/35,1.99%,PTPRM;APOE
prerank,GO_Biological_Process_2021__inositol phosphate metabolic process (GO:0043647),-0.9809356104235407,-1.3580152906820258,0.2231404958677686,1.0,1.0,1/47,1.91%,PLCB4
prerank,"GO_Biological_Process_2021__regulation of DNA-templated transcription, initiation (GO:2000142)",0.9823445090608401,1.3579947114328177,0.18705035971223022,1.0,1.0,1/61,1.76%,FOSL1
prerank,GO_Biological_Process_2021__mitochondrion disassembly (GO:0061726),-0.9985720074091463,-1.3579892233503983,0.0234375,1.0,1.0,1/36,0.15%,FUNDC2
prerank,GO_Biological_Process_2021__oligosaccharide metabolic process (GO:0009311),0.9806375204219222,1.357890520552697,0.3253968253968254,1.0,1.0,2/42,1.94%,MANBA;FUT6
prerank,Elsevier_Pathway_Collection__Enterocyte Mediated Mucosal Damage in Celiac Disease,0.9978819991040838,1.3578113998002685,0.046296296296296294,1.0,1.0,1/24,0.22%,TJP1
prerank,GO_Biological_Process_2021__type I interferon signaling pathway (GO:0060337),-0.9763961063675853,-1.35780845765069,0.3157894736842105,1.0,1.0,4/52,2.37%,OAS1;OASL;HLA-B;IFI6
prerank,GO_Biological_Process_2021__cellular response to type I interferon (GO:0071357),-0.9763961063675853,-1.35780845765069,0.3157894736842105,1.0,1.0,4/52,2.37%,OAS1;OASL;HLA-B;IFI6
prerank,GO_Biological_Process_2021__protein targeting to mitochondrion (GO:0006626),-0.9894458472507593,-1.357628385453897,0.08870967741935484,1.0,1.0,2/55,1.06%,TOMM70;AGK
prerank,Elsevier_Pathway_Collection__Vascular Smooth Muscle Cell Vasodilation in Brain,-0.9799151728591379,-1.3575467907054175,0.32592592592592595,1.0,1.0,1/28,2.01%,BDKRB2
prerank,GO_Biological_Process_2021__tRNA processing (GO:0008033),-0.9787250896413273,-1.3574023681294531,0.21875,1.0,1.0,1/62,2.13%,TRMT9B
prerank,GO_Biological_Process_2021__amyloid fibril formation (GO:1990000),-0.991947121040508,-1.357055601725876,0.0761904761904762,1.0,1.0,2/60,0.81%,ADAM10;APP
prerank,WikiPathway_2021_Human__SARS-CoV-2 innate immunity evasion and cell-specific immune response WP5039,0.9979119310847101,1.3569440673987578,0.0,1.0,1.0,1/65,0.21%,TRAF3
prerank,Elsevier_Pathway_Collection__Apoptosis Block in Infected Cells,-0.9978030050185726,-1.3569040645651669,0.03571428571428571,1.0,1.0,1/31,0.23%,MAP2K6
prerank,Reactome_2022__Ca2+ Pathway R-HSA-4086398,0.9766570628262631,1.356619578271261,0.2980769230769231,1.0,1.0,3/59,2.34%,GNB5;AXIN2;GNG2
prerank,Reactome_2022__PKMTs Methylate Histone Lysines R-HSA-3214841,0.9947236386109917,1.3564397514841064,0.11290322580645161,1.0,1.0,2/45,0.53%,SETD3;ASH1L
prerank,Reactome_2022__Regulation Of MECP2 Expression And Activity R-HSA-9022692,0.9846494760151444,1.3563788766901346,0.3275862068965517,1.0,1.0,3/30,1.54%,TBL1X;CREB1;SLC6A4
prerank,KEGG_2021_Human__Ribosome biogenesis in eukaryotes,0.9912469183731367,1.3562037156042026,0.05042016806722689,1.0,1.0,2/76,0.88%,REXO5;DROSHA
prerank,GO_Biological_Process_2021__actin filament bundle organization (GO:0061572),0.9779918887040129,1.3561663847904302,0.4453125,1.0,1.0,4/33,2.21%,ESPN;BAIAP2L2;SHROOM1;DPYSL3
prerank,GO_Biological_Process_2021__proteoglycan biosynthetic process (GO:0030166),0.9921506631567016,1.3561205296587966,0.14634146341463414,1.0,1.0,2/30,0.79%,FAM20B;CHST11
prerank,Elsevier_Pathway_Collection__Toll-like Receptors Act through MYD88-TIRAP Signaling,-0.9978021920972685,-1.356092877285473,0.03389830508474576,1.0,1.0,1/38,0.23%,MAP2K6
prerank,Reactome_2022__Transport Of Mature mRNA Derived From An Intron-Containing Transcript R-HSA-159236,0.989510799302781,1.3560405795242403,0.04918032786885246,1.0,1.0,1/72,1.05%,NUP210
prerank,KEGG_2021_Human__Nicotine addiction,-0.989301998231543,-1.3558700892582016,0.2,1.0,1.0,1/30,1.08%,GRIN2B
prerank,Reactome_2022__Impaired BRCA2 Binding To RAD51 R-HSA-9709570,0.9884916607550522,1.3557062070448318,0.20689655172413793,1.0,1.0,1/35,1.15%,BRIP1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Ichthyosis,-0.9841517379339847,-1.3556755625489076,0.3586206896551724,1.0,1.0,1/21,1.59%,CYP4F22
prerank,GO_Biological_Process_2021__negative regulation of cellular biosynthetic process (GO:0031327),0.977859205758394,1.3555986933214765,0.4049586776859504,1.0,1.0,2/50,2.22%,PROX1;GFI1
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Testicular Male Infertility,0.9836124883374253,1.3555218518459125,0.36666666666666664,1.0,1.0,2/26,1.64%,CBX2;AMH
prerank,Elsevier_Pathway_Collection__Hippo/YAP1 Signaling Deregulation in Cancer,0.9815261425255641,1.3554018618818005,0.3644067796610169,1.0,1.0,3/40,1.86%,LRP5;PPP1R12A;TEAD4
prerank,GO_Biological_Process_2021__positive regulation of macrophage migration (GO:1905523),0.9858478336684084,1.355400895950994,0.3220338983050847,1.0,1.0,2/19,1.42%,PTK2;CX3CL1
prerank,Reactome_2022__COPII-mediated Vesicle Transport R-HSA-204005,-0.9760624165880795,-1.3551614972293864,0.26515151515151514,1.0,1.0,1/65,2.39%,COL7A1
prerank,GO_Biological_Process_2021__RNA 3'-end processing (GO:0031123),0.9932507471838643,1.3547896269406192,0.075,1.0,1.0,1/67,0.68%,TENT2
prerank,Elsevier_Pathway_Collection__Inflammatory Reaction in Acne Vulgaris,-0.9807855234800009,-1.354681787220717,0.256,1.0,1.0,2/49,1.93%,MAP2K6;MMP2
prerank,Reactome_2022__Activated NOTCH1 Transmits Signal To Nucleus R-HSA-2122948,-0.996534200736937,-1.3544872068663394,0.0546875,1.0,1.0,1/31,0.35%,ADAM10
prerank,GO_Biological_Process_2021__peptidyl-lysine methylation (GO:0018022),0.9955355257827313,1.354333976669386,0.1111111111111111,1.0,1.0,1/25,0.45%,SETD3
prerank,Elsevier_Pathway_Collection__Mineralcorticoids Secretion Regulation,0.9957635533230274,1.3541265229087773,0.08108108108108109,1.0,1.0,1/34,0.43%,CREB1
prerank,Reactome_2022__Formation Of Cornified Envelope R-HSA-6809371,0.9964950729570867,1.3541158556288657,0.03968253968253968,1.0,1.0,1/33,0.35%,PKP4
prerank,Reactome_2022__Diseases Associated With Glycosaminoglycan Metabolism R-HSA-3560782,-0.9827489385590518,-1.3540064804823224,0.25196850393700787,1.0,1.0,1/39,1.73%,SDC3
prerank,Reactome_2022__Negative Epigenetic Regulation Of rRNA Expression R-HSA-5250941,0.992211092199527,1.354001236548077,0.05084745762711865,1.0,1.0,1/67,0.78%,TAF1B
prerank,GO_Biological_Process_2021__sterol biosynthetic process (GO:0016126),-0.9857185613942647,-1.353933800596533,0.21929824561403508,1.0,1.0,1/37,1.43%,ARV1
prerank,GO_Biological_Process_2021__regulation of actin polymerization or depolymerization (GO:0008064),0.9773387369799722,1.3538759429773382,0.48333333333333334,1.0,1.0,2/29,2.27%,FCHSD2;COTL1
prerank,KEGG_2021_Human__Cardiac muscle contraction,0.9819509694675994,1.3538669511674457,0.14634146341463414,1.0,1.0,1/70,1.80%,CACNA2D4
prerank,Elsevier_Pathway_Collection__AngiopoietinR -> AP-1 Signaling,-0.981148050580587,-1.353856053584084,0.35714285714285715,1.0,1.0,3/31,1.90%,PTK2B;MAP2K6;TEK
prerank,MSigDB_Oncogenic_Signatures__YAP1 UP,0.9829525161278871,1.3538456637419871,0.2719298245614035,1.0,1.0,3/36,1.71%,RAB40C;RHOQ;SAMSN1
prerank,GO_Biological_Process_2021__chondroitin sulfate metabolic process (GO:0030204),0.9921098544882354,1.3538167514835233,0.17073170731707318,1.0,1.0,1/30,0.79%,CHST11
prerank,Reactome_2022__RNA Polymerase III Abortive And Retractive Initiation R-HSA-749476,-0.9909140897951941,-1.3535429714324103,0.13178294573643412,1.0,1.0,1/39,0.91%,POU2F1
prerank,GO_Biological_Process_2021__positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway (GO:1901030),0.9814153726450545,1.3534997278127163,0.3412698412698413,1.0,1.0,3/34,1.87%,YWHAQ;TFDP2;BOK
prerank,Elsevier_Pathway_Collection__Cyclosporine Induced Nephrotoxicity,0.9818054934528126,1.3533011978630998,0.41739130434782606,1.0,1.0,1/22,1.82%,PTGS2
prerank,Reactome_2022__Transcriptional Regulation By Small RNAs R-HSA-5578749,0.989512980127471,1.3532476590972569,0.0625,1.0,1.0,1/66,1.05%,NUP210
prerank,GO_Biological_Process_2021__regulation of regulatory T cell differentiation (GO:0045589),0.9800318816405557,1.3532323947109361,0.47619047619047616,1.0,1.0,1/25,2.00%,NFATC2
prerank,Elsevier_Pathway_Collection__Hyperseborrhea in Acne Vulgaris,0.9958059575876984,1.3526906258661477,0.0703125,1.0,1.0,2/26,0.43%,PPARA;CREB1
prerank,Reactome_2022__Cross-presentation Of Soluble Exogenous Antigens (Endosomes) R-HSA-1236978,0.9880219275087957,1.3526819645726529,0.22033898305084745,1.0,1.0,1/46,1.20%,PSMB9
prerank,GO_Biological_Process_2021__iron ion homeostasis (GO:0055072),-0.9954488408194812,-1.3525165431592348,0.031496062992125984,1.0,1.0,1/59,0.46%,NEO1
prerank,GO_Biological_Process_2021__triglyceride homeostasis (GO:0070328),0.9800662463379092,1.3524041751723432,0.3969465648854962,1.0,1.0,1/30,1.99%,APOE
prerank,GO_Biological_Process_2021__positive regulation of protein import (GO:1904591),0.9771456772630567,1.3523109954521415,0.4921875,1.0,1.0,2/30,2.29%,CDH1;FLNA
prerank,GO_Biological_Process_2021__regulation of dopamine secretion (GO:0014059),-0.9764629714373942,-1.3522990599438003,0.5114503816793893,1.0,1.0,3/22,2.37%,DTNBP1;SYT2;SYT7
prerank,Elsevier_Pathway_Collection__CFTR Related Ion-Channel Dysfunction in Cystic Fibrosis Airway Epithelium (Class III Mutations),-0.9791444393056842,-1.3522174763296075,0.4122137404580153,1.0,1.0,1/28,2.09%,AQP3
prerank,GO_Biological_Process_2021__positive regulation of immunoglobulin production (GO:0002639),0.9771064725109002,1.35216415591985,0.4666666666666667,1.0,1.0,2/31,2.29%,RBP4;CD86
prerank,GO_Biological_Process_2021__intra-Golgi vesicle-mediated transport (GO:0006891),0.9967647146844351,1.3521033626252703,0.044642857142857144,1.0,1.0,1/31,0.33%,COG5
prerank,WikiPathway_2021_Human__DNA IR-double strand breaks and cellular response via ATM WP3959,0.9898702527249317,1.3520906469230813,0.10434782608695652,1.0,1.0,2/54,1.02%,DCLRE1C;ATR
prerank,Reactome_2022__Mitochondrial Protein Import R-HSA-1268020,-0.9927549427256522,-1.3517381370576487,0.04,1.0,1.0,2/62,0.73%,CHCHD3;TOMM70
prerank,GO_Biological_Process_2021__7-methylguanosine RNA capping (GO:0009452),-0.9916094731380511,-1.3516223151248632,0.14925373134328357,1.0,1.0,1/32,0.85%,RNGTT
prerank,GO_Biological_Process_2021__7-methylguanosine mRNA capping (GO:0006370),-0.9916094731380511,-1.3516223151248632,0.14925373134328357,1.0,1.0,1/32,0.85%,RNGTT
prerank,GO_Biological_Process_2021__autophagosome assembly (GO:0000045),0.991640573783733,1.3514451575676296,0.09917355371900827,1.0,1.0,2/56,0.84%,UBXN2A;RAB7A
prerank,WikiPathway_2021_Human__IL-7 signaling pathway WP205,-0.9829982492710492,-1.3513651064643826,0.34146341463414637,1.0,1.0,2/25,1.71%,PTK2B;STAT5A
prerank,Elsevier_Pathway_Collection__Androgen Receptor non-Genomic Signaling,-0.9854562734367541,-1.3512469889171277,0.2426470588235294,1.0,1.0,1/28,1.46%,TGFB1I1
prerank,GO_Biological_Process_2021__response to metal ion (GO:0010038),-0.9791520709439068,-1.35119151575979,0.16793893129770993,1.0,1.0,2/68,2.09%,NEDD4;AQP3
prerank,GO_Biological_Process_2021__spermatid development (GO:0007286),0.9996890528813691,1.3511145503727575,0.0,1.0,1.0,1/31,0.03%,SYCP3
prerank,GO_Biological_Process_2021__vesicle transport along microtubule (GO:0047496),0.9760006782422782,1.3510195214661718,0.544,1.0,1.0,3/23,2.41%,TRAK1;KIF13A;KIF3B
prerank,Reactome_2022__Regulation Of Ornithine Decarboxylase (ODC) R-HSA-350562,0.9880210210260537,1.3509536224063539,0.18584070796460178,1.0,1.0,1/48,1.20%,PSMB9
prerank,Reactome_2022__Cell Recruitment (Pro-Inflammatory Response) R-HSA-9664424,0.9883434014535147,1.3509283150258742,0.23275862068965517,1.0,1.0,1/24,1.17%,MEFV
prerank,Elsevier_Pathway_Collection__SIRT3 Signaling in Aging,-0.990304332859113,-1.3508945638036458,0.216,1.0,1.0,1/26,0.98%,SOD2
prerank,Reactome_2022__Cytosolic Sensors Of Pathogen-Associated DNA R-HSA-1834949,-0.980814888767673,-1.3508552859804863,0.256,1.0,1.0,2/61,1.93%,CREBBP;LRRFIP1
prerank,Reactome_2022__Recognition Of DNA Damage By PCNA-containing Replication Complex R-HSA-110314,0.9915350834378913,1.3506777092648297,0.15079365079365079,1.0,1.0,2/30,0.85%,SLC19A1;POLE4
prerank,KEGG_2021_Human__African trypanosomiasis,-0.9809470353431922,-1.3504109130153135,0.3305084745762712,1.0,1.0,1/34,1.91%,PLCB4
prerank,GO_Biological_Process_2021__secondary alcohol metabolic process (GO:1902652),0.9800943131210553,1.350120188693269,0.2558139534883721,1.0,1.0,2/46,1.99%,SOAT2;APOE
prerank,GO_Biological_Process_2021__positive regulation of protein import into nucleus (GO:0042307),0.9771477144886948,1.3500114673018564,0.49206349206349204,1.0,1.0,2/28,2.29%,CDH1;FLNA
prerank,Reactome_2022__Inositol Phosphate Metabolism R-HSA-1483249,-0.9809351300582203,-1.3498297521297782,0.2222222222222222,1.0,1.0,1/48,1.91%,PLCB4
prerank,WikiPathway_2021_Human__Development and heterogeneity of the ILC family WP3893,0.9778402008967965,1.3497481572810455,0.46923076923076923,1.0,1.0,1/26,2.22%,GFI1
prerank,Reactome_2022__Transport Of Mature Transcript To Cytoplasm R-HSA-72202,0.9895066023053282,1.3497373099461543,0.06837606837606838,1.0,1.0,1/81,1.05%,NUP210
prerank,GO_Biological_Process_2021__negative regulation of double-strand break repair (GO:2000780),0.988840136292125,1.349684395247365,0.19827586206896552,1.0,1.0,1/32,1.12%,SMCHD1
prerank,GO_Biological_Process_2021__regulation of megakaryocyte differentiation (GO:0045652),0.9813490150375284,1.3496279640042377,0.22580645161290322,1.0,1.0,1/54,1.86%,ZFPM1
prerank,Reactome_2022__Oxygen-dependent Proline Hydroxylation Of Hypoxia-inducible Factor Alpha R-HSA-1234176,0.9880120382716914,1.3493535435831499,0.18181818181818182,1.0,1.0,1/62,1.20%,PSMB9
prerank,TRRUST_Transcription_Factors_2019__PARP1 human,0.9774223889157763,1.3492839593231667,0.5234375,1.0,1.0,3/24,2.27%,CDH1;SERPINE1;FN1
prerank,Reactome_2022__Interferon Alpha/Beta Signaling R-HSA-909733,-0.9763904759749281,-1.34916899188809,0.3135593220338983,1.0,1.0,4/58,2.37%,OAS1;OASL;HLA-B;IFI6
prerank,Elsevier_Pathway_Collection__Adipokines Production by Adipocyte Impaired in Obesity,0.9787447842867774,1.349122532904309,0.3541666666666667,1.0,1.0,1/42,2.12%,RBP4
prerank,GO_Biological_Process_2021__positive regulation of nitrogen compound metabolic process (GO:0051173),-0.9796955009435826,-1.3489215908556702,0.4406779661016949,1.0,1.0,4/20,2.05%,MAP2K5;APP;PAX8;KLF4
prerank,Reactome_2022__Plasma Lipoprotein Clearance R-HSA-8964043,0.9801447236758811,1.348901710796261,0.4351145038167939,1.0,1.0,3/34,1.99%,AMN;SOAT2;APOE
prerank,Reactome_2022__Fanconi Anemia Pathway R-HSA-6783310,0.9951088150907543,1.348844061817752,0.08396946564885496,1.0,1.0,1/36,0.49%,FANCL
prerank,KEGG_2021_Human__Bile secretion,-0.9766764451030628,-1.3488347917960573,0.20930232558139536,1.0,1.0,5/83,2.35%,SLC22A1;KCNN2;SLCO1A2;ADCY3;SLC4A5
prerank,Reactome_2022__Synthesis Of Active Ubiquitin: Roles Of E1 And E2 Enzymes R-HSA-8866652,0.9826097057924139,1.348530278093943,0.373134328358209,1.0,1.0,2/30,1.74%,UBE2H;UBE2C
prerank,Reactome_2022__CDK-mediated Phosphorylation And Removal Of Cdc6 R-HSA-69017,0.982579613208602,1.348427240492802,0.2231404958677686,1.0,1.0,2/69,1.74%,PSMB9;UBE2C
prerank,GO_Biological_Process_2021__DNA geometric change (GO:0032392),0.9774189433806555,1.3484192727090096,0.4778761061946903,1.0,1.0,2/26,2.26%,ANXA1;PIF1
prerank,MSigDB_Oncogenic_Signatures__KRAS.KIDNEY UP.V1 DN,-0.9074991289860529,-1.3484116699518691,0.1206896551724138,1.0,1.0,9/105,2.38%,OAS1;IFI44L;AADAC;LIPE;BMP4;VILL;APBB3;ADAMTSL2;HRG
prerank,Reactome_2022__Other Semaphorin Interactions R-HSA-416700,-0.9776192413008632,-1.3482710702104628,0.475,1.0,1.0,2/19,2.25%,ITGA1;SEMA4D
prerank,KEGG_2021_Human__Intestinal immune network for IgA production,0.9770963511178238,1.3482451896583587,0.39316239316239315,1.0,1.0,2/42,2.29%,ITGA4;CD86
prerank,Reactome_2022__Cargo Concentration In ER R-HSA-5694530,-0.9761035676690464,-1.3481844757134274,0.4744525547445255,1.0,1.0,1/30,2.39%,COL7A1
prerank,GO_Biological_Process_2021__transition metal ion homeostasis (GO:0055076),-0.9954572652109969,-1.348042362634069,0.0703125,1.0,1.0,1/29,0.46%,NEO1
prerank,GO_Biological_Process_2021__regulation of interleukin-4 production (GO:0032673),0.9771541556628225,1.3477745076780518,0.5151515151515151,1.0,1.0,3/23,2.29%,SYK;ZFPM1;CD86
prerank,WikiPathway_2021_Human__Exercise-induced Circadian Regulation WP410,0.9766994432585198,1.3476583489473823,0.373015873015873,1.0,1.0,1/46,2.33%,GSTM3
prerank,Elsevier_Pathway_Collection__Polycystic Ovary Syndrome,0.978824139471005,1.347652485726544,0.35537190082644626,1.0,1.0,3/49,2.12%,CREB1;AMH;RBP4
prerank,GO_Biological_Process_2021__regulation of dendrite morphogenesis (GO:0048814),-0.9776460614781157,-1.3475551479989787,0.4244604316546763,1.0,1.0,3/32,2.25%,NEDD4;KNDC1;SEMA4D
prerank,GO_Biological_Process_2021__mismatch repair (GO:0006298),0.9923035479198177,1.3475294447904236,0.16312056737588654,1.0,1.0,1/27,0.77%,MSH2
prerank,GO_Biological_Process_2021__regulation of neuroinflammatory response (GO:0150077),0.9818089607853979,1.347517729564355,0.4132231404958678,1.0,1.0,1/18,1.82%,PTGS2
prerank,GO_Biological_Process_2021__regulation of blood circulation (GO:1903522),-0.979909001248859,-1.3475152951646496,0.38345864661654133,1.0,1.0,1/33,2.01%,BDKRB2
prerank,KEGG_2021_Human__Synaptic vesicle cycle,0.9764542035943815,1.3474668445201303,0.3333333333333333,1.0,1.0,2/67,2.36%,SLC6A4;STX1A
prerank,Reactome_2022__Resolution Of Abasic Sites (AP Sites) R-HSA-73933,0.9776409484131666,1.3474297329100053,0.40310077519379844,1.0,1.0,3/38,2.24%,SLC19A1;POLE4;LRIG1
prerank,GO_Biological_Process_2021__positive regulation of protein targeting to mitochondrion (GO:1903955),-0.9826029659461611,-1.3473491304217657,0.33070866141732286,1.0,1.0,1/31,1.74%,ABLIM3
prerank,GO_Biological_Process_2021__regulation of tumor necrosis factor-mediated signaling pathway (GO:0010803),0.987481266281881,1.3473326552109564,0.16071428571428573,1.0,1.0,2/55,1.26%,PTPN2;SYK
prerank,Reactome_2022__EGFR Downregulation R-HSA-182971,0.9893401290309096,1.3472645089683137,0.19047619047619047,1.0,1.0,1/30,1.07%,ARHGEF7
prerank,GO_Biological_Process_2021__regulation of B cell proliferation (GO:0030888),0.9776001048401372,1.347162652452203,0.41379310344827586,1.0,1.0,4/41,2.25%,CD300A;TNFRSF21;NFATC2;MNDA
prerank,Elsevier_Pathway_Collection__PDGFR -> AP-1/MYC Signaling,-0.9978430663270628,-1.3469290922147497,0.022727272727272728,1.0,1.0,2/37,0.23%,PTK2B;MAP2K6
prerank,GO_Biological_Process_2021__intraciliary transport involved in cilium assembly (GO:0035735),0.9758985624987119,1.3467388383715067,0.47244094488188976,1.0,1.0,1/40,2.41%,KIF3B
prerank,GO_Biological_Process_2021__regulation of carbohydrate catabolic process (GO:0043470),0.9775579961022638,1.3465251518287114,0.4263565891472868,1.0,1.0,2/43,2.25%,NUP210;SLC2A6
prerank,Elsevier_Pathway_Collection__Kinetochore Assembly,0.9884919568995494,1.3462829634938327,0.14035087719298245,1.0,1.0,3/40,1.16%,CENPE;NDC80;CENPA
prerank,GO_Biological_Process_2021__cellular response to amino acid stimulus (GO:0071230),-0.998225840762528,-1.3461270131691534,0.017241379310344827,1.0,1.0,1/32,0.18%,CPEB3
prerank,KEGG_2021_Human__Leishmaniasis,0.9785344927402968,1.3460426439286068,0.21052631578947367,1.0,1.0,4/72,2.16%,ITGA4;PTGS2;MAPK13;CYBA
prerank,Elsevier_Pathway_Collection__EGFR/ERBB2 -> TP53 Signaling,-0.9767535642433692,-1.3460367993027835,0.4098360655737705,1.0,1.0,4/41,2.34%,PTK2B;MAP2K6;NRG1;VAV1
prerank,GO_Biological_Process_2021__secondary alcohol biosynthetic process (GO:1902653),-0.9857213825351114,-1.346028269604972,0.2523364485981308,1.0,1.0,1/33,1.43%,ARV1
prerank,Elsevier_Pathway_Collection__Thrombopoietin Receptors Signaling in Platelet Maturation,-0.9761476662331078,-1.3458231389390811,0.5118110236220472,1.0,1.0,3/30,2.40%,MAP2K6;STAT5A;SPI1
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Retinitis Pigmentosa,-0.9859826557663862,-1.3456368447699372,0.17424242424242425,1.0,1.0,2/50,1.41%,CYP4V2;IMPG2
prerank,GO_Biological_Process_2021__stem cell differentiation (GO:0048863),-0.9857959900463722,-1.3456297217186315,0.19696969696969696,1.0,1.0,1/37,1.43%,SHH
prerank,Reactome_2022__Endogenous Sterols R-HSA-211976,-0.8573470485044538,-1.3455954544898296,0.4122137404580153,1.0,1.0,4/23,1.78%,CYP39A1;NCOA1;CYP4V2;CYP1B1
prerank,WikiPathway_2021_Human__EPO Receptor Signaling WP581,-0.9829547249773898,-1.345412898873755,0.36496350364963503,1.0,1.0,1/26,1.71%,STAT5A
prerank,GO_Biological_Process_2021__keratan sulfate metabolic process (GO:0042339),0.9937658629968253,1.3452815211715443,0.12878787878787878,1.0,1.0,2/31,0.63%,ST3GAL1;SLC35D2
prerank,Reactome_2022__tRNA Aminoacylation R-HSA-379724,0.9840563751244035,1.3451704531001005,0.2302158273381295,1.0,1.0,1/42,1.59%,SARS2
prerank,GO_Biological_Process_2021__positive regulation of ubiquitin-protein transferase activity (GO:0051443),0.9826103199398198,1.3449910443599542,0.29770992366412213,1.0,1.0,2/29,1.74%,CDC14B;UBE2C
prerank,GO_Biological_Process_2021__SRP-dependent cotranslational protein targeting to membrane (GO:0006614),-0.986181760718676,-1.344929109718238,0.075,1.0,1.0,1/90,1.38%,SEC61A2
prerank,GO_Biological_Process_2021__regulation of cellular ketone metabolic process (GO:0010565),0.9880570429872741,1.34477258929717,0.10909090909090909,1.0,1.0,2/61,1.20%,PPARA;PSMB9
prerank,GO_Biological_Process_2021__regulation of membrane protein ectodomain proteolysis (GO:0051043),0.980154567753087,1.3447321172800606,0.41353383458646614,1.0,1.0,3/22,1.99%,PACSIN3;TIMP3;APOE
prerank,Elsevier_Pathway_Collection__FOXO1 and SREBP-1C Role in beta-Cell Suppression (Rodent Model),-0.9803733077868969,-1.3447029178423298,0.33076923076923076,1.0,1.0,1/31,1.97%,SH2B2
prerank,WikiPathway_2021_Human__Ethanol effects on histone modifications WP3996,0.9818412233980565,1.3446608197553829,0.362962962962963,1.0,1.0,4/31,1.83%,HDAC8;SLC19A1;ELP3;HDAC9
prerank,GO_Biological_Process_2021__canonical Wnt signaling pathway (GO:0060070),0.995678195133349,1.3444811222409028,0.022556390977443608,1.0,1.0,1/66,0.43%,LRP5
prerank,GO_Biological_Process_2021__regulation of cilium assembly (GO:1902017),-0.9773149624701392,-1.3443624633515594,0.24561403508771928,1.0,1.0,5/59,2.29%,EVI5;SDCCAG8;CEP120;RABGAP1;CROCC
prerank,Reactome_2022__N-glycan Trimming In ER And Calnexin/Calreticulin Cycle R-HSA-532668,-0.9967249076166945,-1.3442589681074126,0.02564102564102564,1.0,1.0,1/35,0.33%,AMFR
prerank,Elsevier_Pathway_Collection__Autocrine Cytokine/Chemokine Loops in Systemic Scleroderma,-0.9978035197964809,-1.344241643596726,0.042735042735042736,1.0,1.0,1/32,0.23%,MAP2K6
prerank,Reactome_2022__FGFR2 Mutant Receptor Activation R-HSA-1839126,0.9763000255993445,1.343855641406714,0.5041322314049587,1.0,1.0,1/27,2.37%,FGF1
prerank,GO_Biological_Process_2021__membrane fusion (GO:0061025),0.982836871928053,1.3437156610974468,0.30158730158730157,1.0,1.0,2/35,1.72%,UBXN2A;MYOF
prerank,GO_Biological_Process_2021__protein K11-linked ubiquitination (GO:0070979),0.9826100235177606,1.3436528575932136,0.3203125,1.0,1.0,2/29,1.74%,UBE2H;UBE2C
prerank,GO_Biological_Process_2021__negative regulation of Notch signaling pathway (GO:0045746),0.9873816228698531,1.3436172563608053,0.23357664233576642,1.0,1.0,3/29,1.27%,NIBAN2;WWP2;NOTCH3
prerank,GO_Biological_Process_2021__protein localization to cilium (GO:0061512),0.9851803407589238,1.3435202148398058,0.232,1.0,1.0,1/33,1.48%,TUB
prerank,GO_Biological_Process_2021__regulation of viral transcription (GO:0046782),-0.9930294750993092,-1.3433229185718012,0.078125,1.0,1.0,1/40,0.70%,NELFA
prerank,GO_Biological_Process_2021__tRNA-containing ribonucleoprotein complex export from nucleus (GO:0071431),0.9895302819757043,1.3432596655492384,0.128,1.0,1.0,1/34,1.05%,NUP210
prerank,GO_Biological_Process_2021__tRNA export from nucleus (GO:0006409),0.9895302819757043,1.3432596655492384,0.128,1.0,1.0,1/34,1.05%,NUP210
prerank,GO_Biological_Process_2021__CENP-A containing chromatin organization (GO:0061641),0.9884170623037389,1.3432429745616128,0.13157894736842105,1.0,1.0,1/30,1.16%,CENPA
prerank,GO_Biological_Process_2021__CENP-A containing nucleosome assembly (GO:0034080),0.9884170623037389,1.3432429745616128,0.13157894736842105,1.0,1.0,1/30,1.16%,CENPA
prerank,GO_Biological_Process_2021__regulation of actin filament bundle assembly (GO:0032231),0.9858029579060905,1.3432152285437176,0.20869565217391303,1.0,1.0,1/26,1.42%,CX3CL1
prerank,GO_Biological_Process_2021__positive regulation of lipid biosynthetic process (GO:0046889),0.9801462153034168,1.3431564983683406,0.3984375,1.0,1.0,3/33,1.99%,PPARA;CREB1;APOE
prerank,Reactome_2022__Formation Of Tubulin Folding Intermediates By CCT/TriC R-HSA-389960,0.9785342441319597,1.3429192495459281,0.43283582089552236,1.0,1.0,1/23,2.15%,TUBA1A
prerank,GO_Biological_Process_2021__negative regulation of organelle assembly (GO:1902116),-0.9852963893060949,-1.3428258836018483,0.14285714285714285,1.0,1.0,1/34,1.48%,FEZ1
prerank,Reactome_2022__Diseases Of DNA Repair R-HSA-9675135,0.9885241241879779,1.3427851624985079,0.13114754098360656,1.0,1.0,2/51,1.15%,MSH2;BRIP1
prerank,Reactome_2022__Transport Of Mature mRNAs Derived From Intronless Transcripts R-HSA-159234,0.9895262627072231,1.3427687110087907,0.1349206349206349,1.0,1.0,1/43,1.05%,NUP210
prerank,Elsevier_Pathway_Collection__NGFR -> MEF Signaling,-0.9820780626691245,-1.3426916154372215,0.3898305084745763,1.0,1.0,3/22,1.81%,MAP2K6;MAP2K5;NTF3
prerank,GO_Biological_Process_2021__transcription by RNA polymerase I (GO:0006360),0.9801448434283173,1.3424766305268083,0.36220472440944884,1.0,1.0,2/34,1.99%,TAF1B;CAVIN1
prerank,WikiPathway_2021_Human__Photodynamic therapy-induced HIF-1 survival signaling WP3614,0.9794111603575253,1.342458847307871,0.3359375,1.0,1.0,3/37,2.07%,IGFBP3;PTGS2;SERPINE1
prerank,Elsevier_Pathway_Collection__WNT Signaling in Cystic Kidney Disease,0.995684089968305,1.3420317238091708,0.06557377049180328,1.0,1.0,1/43,0.43%,LRP5
prerank,KEGG_2021_Human__Endocrine and other factor-regulated calcium reabsorption,-0.9782470951863129,-1.3417888568588963,0.3230769230769231,1.0,1.0,3/47,2.19%,PLCB4;BDKRB2;VDR
prerank,WikiPathway_2021_Human__Circadian rhythm related genes WP3594,0.8366359201102654,1.3417385348725388,0.05,1.0,1.0,8/177,2.07%,PPARA;CREB1;PRKAA2;F7;PROX1;SLC6A4;DRD4;SERPINE1
prerank,GO_Biological_Process_2021__positive regulation of neurogenesis (GO:0050769),0.985775026801495,1.3416873540368037,0.136,1.0,1.0,1/66,1.42%,CX3CL1
prerank,KEGG_2021_Human__Basal transcription factors,0.9910698141273102,1.3413438134230704,0.16666666666666666,1.0,1.0,3/41,0.90%,TAF4;GTF2I;GTF2E2
prerank,Reactome_2022__Regulation Of HSF1-mediated Heat Shock Response R-HSA-3371453,0.9895502769176239,1.3412548688718502,0.05785123966942149,1.0,1.0,2/79,1.05%,TNFRSF21;NUP210
prerank,GO_Biological_Process_2021__regulation of defense response to virus by host (GO:0050691),-0.9927645530062577,-1.3412087634786853,0.11194029850746269,1.0,1.0,2/34,0.73%,TRIM44;TOMM70
prerank,GO_Biological_Process_2021__negative regulation of interferon-gamma production (GO:0032689),-0.9775301731492648,-1.3408011049785027,0.43089430894308944,1.0,1.0,1/27,2.25%,CD274
prerank,Reactome_2022__Intraflagellar Transport R-HSA-5620924,0.9759012047695188,1.3405964440037061,0.48333333333333334,1.0,1.0,1/38,2.41%,KIF3B
prerank,GO_Biological_Process_2021__microtubule polymerization (GO:0046785),-0.9759539848016638,-1.3405771135070579,0.5158730158730159,1.0,1.0,2/30,2.41%,HDGFL3;TPPP2
prerank,Reactome_2022__Senescence-Associated Secretory Phenotype (SASP) R-HSA-2559582,0.9825802009497209,1.3405593909575346,0.16541353383458646,1.0,1.0,2/69,1.74%,CDK6;UBE2C
prerank,GO_Biological_Process_2021__autophagosome organization (GO:1905037),0.9916413229535388,1.3405423190311987,0.10714285714285714,1.0,1.0,2/54,0.84%,UBXN2A;RAB7A
prerank,WikiPathway_2021_Human__Type 2 papillary renal cell carcinoma WP4241,-0.987838238964111,-1.3404690865494866,0.22388059701492538,1.0,1.0,1/34,1.22%,CREBBP
prerank,WikiPathway_2021_Human__Modulators of TCR signaling and T cell activation WP5072,-0.9758492400220264,-1.3404599447887673,0.3106060606060606,1.0,1.0,6/61,2.44%,RASA2;GRAP2;RHOH;VAV1;MAP4K1;ZAP70
prerank,Elsevier_Pathway_Collection__Catecholamines Secretion from Adrenal Gland,0.9760495557615048,1.3403084761447628,0.3813559322033898,1.0,1.0,5/53,2.41%,CREB1;RHOQ;TRPV1;STX1A;KIF3B
prerank,Reactome_2022__Asymmetric Localization Of PCP Proteins R-HSA-4608870,0.9880132525977526,1.340274620649076,0.19469026548672566,1.0,1.0,1/60,1.20%,PSMB9
prerank,Reactome_2022__Sensory Processing Of Sound By Inner Hair Cells Of Cochlea R-HSA-9662360,0.9765021885329341,1.3402010523859085,0.3017241379310345,1.0,1.0,3/61,2.36%,ESPN;MYO7A;STX1A
prerank,Elsevier_Pathway_Collection__NFKB Non-Canonical Signaling Activation in Cancer,0.9979189044400675,1.3401740893857828,0.017699115044247787,1.0,1.0,1/29,0.21%,TRAF3
prerank,GO_Biological_Process_2021__calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules (GO:0016339),-0.9848750752708695,-1.3400420362785084,0.3,1.0,1.0,1/32,1.52%,DCHS1
prerank,GO_Biological_Process_2021__vesicle cytoskeletal trafficking (GO:0099518),0.9769076304110564,1.3396761550182916,0.42276422764227645,1.0,1.0,2/39,2.31%,TRAK1;MYO7A
prerank,GO_Biological_Process_2021__tRNA transport (GO:0051031),0.9895286044611059,1.3393952630077555,0.12605042016806722,1.0,1.0,1/37,1.05%,NUP210
prerank,KEGG_2021_Human__Salivary secretion,-0.9809583571249477,-1.3392510472340833,0.1366906474820144,1.0,1.0,2/73,1.91%,ADCY3;PLCB4
prerank,GO_Biological_Process_2021__polyol metabolic process (GO:0019751),-0.9809358678129345,-1.3391286198040306,0.24166666666666667,1.0,1.0,1/47,1.91%,PLCB4
prerank,Elsevier_Pathway_Collection__T-Cell Cytotoxic Activation,-0.9978007502941805,-1.339051804683189,0.0078125,1.0,1.0,1/42,0.23%,MAP2K6
prerank,WikiPathway_2021_Human__Parkin-Ubiquitin Proteasomal System pathway WP2359,0.9784884449611352,1.3389394461193667,0.2601626016260163,1.0,1.0,1/66,2.15%,TUBA1A
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Ovarian Cancer,0.9772644660572016,1.33886426936758,0.5,1.0,1.0,2/28,2.28%,NOTCH3;HGF
prerank,Reactome_2022__Signaling By FGFR2 In Disease R-HSA-5655253,0.9762896196459938,1.338535362369186,0.4740740740740741,1.0,1.0,1/36,2.37%,FGF1
prerank,Reactome_2022__Diseases Of Programmed Cell Death R-HSA-9645723,-0.9904450702714963,-1.3384897021590432,0.06363636363636363,1.0,1.0,2/60,0.96%,APP;PRIM2
prerank,GO_Biological_Process_2021__nucleobase-containing small molecule interconversion (GO:0015949),0.9762224659941627,1.3384474999063785,0.5317460317460317,1.0,1.0,1/27,2.38%,RRM2
prerank,GO_Biological_Process_2021__tRNA aminoacylation for protein translation (GO:0006418),0.9840551267308336,1.3383839720057598,0.22302158273381295,1.0,1.0,1/43,1.59%,SARS2
prerank,GO_Biological_Process_2021__regulation of gene silencing by RNA (GO:0060966),0.98951896002301,1.3381073123141973,0.09302325581395349,1.0,1.0,1/55,1.05%,NUP210
prerank,GO_Biological_Process_2021__regulation of posttranscriptional gene silencing (GO:0060147),0.98951896002301,1.3381073123141973,0.09302325581395349,1.0,1.0,1/55,1.05%,NUP210
prerank,WikiPathway_2021_Human__Cannabinoid receptor signaling WP3869,0.9802222004718265,1.3379671663496062,0.4318181818181818,1.0,1.0,1/28,1.98%,MAPK13
prerank,Elsevier_Pathway_Collection__Alveolar Epithelial Cell Dysfunction in COPD,-0.9808905458714052,-1.337783510859957,0.1984732824427481,1.0,1.0,5/67,1.93%,PTK2B;MAP2K6;SOD2;GSTA2;MMP2
prerank,Reactome_2022__Formation Of TC-NER Pre-Incision Complex R-HSA-6781823,0.9925254470256686,1.3377807275623925,0.096,1.0,1.0,1/51,0.75%,TCEA1
prerank,KEGG_2021_Human__Proteasome,0.9880232273743282,1.3377800212409325,0.2542372881355932,1.0,1.0,1/44,1.20%,PSMB9
prerank,GO_Biological_Process_2021__activation of adenylate cyclase activity (GO:0007190),-0.9844147853112517,-1.337563972881778,0.265625,1.0,1.0,1/30,1.56%,ADCY3
prerank,Reactome_2022__Transport Of SLBP Independent Mature mRNA R-HSA-159227,0.9895300259435224,1.3375535951195454,0.13821138211382114,1.0,1.0,1/35,1.05%,NUP210
prerank,Elsevier_Pathway_Collection__Skin Fibrosis,-0.9808121481063774,-1.3375521405245205,0.17073170731707318,1.0,1.0,3/67,1.93%,PTK2B;MAP2K6;MMP2
prerank,GO_Biological_Process_2021__regulation of B cell receptor signaling pathway (GO:0050855),0.986614959325449,1.3374268727172236,0.23015873015873015,1.0,1.0,2/23,1.34%,CD300A;NFAM1
prerank,TRRUST_Transcription_Factors_2019__SPI1 mouse,-0.9940711277435768,-1.3373439690473345,0.0859375,1.0,1.0,1/32,0.60%,TEC
prerank,"GO_Biological_Process_2021__positive regulation of gene expression, epigenetic (GO:0045815)",0.9881782187567583,1.337003624722629,0.14285714285714285,1.0,1.0,4/53,1.20%,ARID1B;TAF1B;PHF2;PADI2
prerank,GO_Biological_Process_2021__negative regulation of plasma membrane bounded cell projection assembly (GO:0120033),-0.9762216169937133,-1.3369681999282936,0.512,1.0,1.0,1/27,2.38%,HRG
prerank,GO_Biological_Process_2021__positive regulation of calcium ion transport into cytosol (GO:0010524),0.9858396925303539,1.3368206775985516,0.21138211382113822,1.0,1.0,2/32,1.42%,THY1;CX3CL1
prerank,GO_Biological_Process_2021__positive regulation of protein tyrosine kinase activity (GO:0061098),0.9881826928440758,1.336721719252326,0.22033898305084745,1.0,1.0,2/40,1.19%,DLG3;ERBB3
prerank,GO_Biological_Process_2021__C21-steroid hormone metabolic process (GO:0008207),0.9830357399237395,1.3367180655573236,0.31496062992125984,1.0,1.0,1/21,1.70%,FDXR
prerank,WikiPathway_2021_Human__Eicosanoid metabolism via cyclooxygenases (COX) WP4719,0.9818406111612278,1.3364754510817298,0.3275862068965517,1.0,1.0,2/30,1.82%,PTGR1;PTGS2
prerank,Reactome_2022__Translation R-HSA-72766,-0.8023259948159549,-1.3364124068789478,0.03875968992248062,1.0,1.0,3/277,1.58%,MRPS9;SEC61A2;MRRF
prerank,Reactome_2022__Defective TPR May Confer Susceptibility Towards Thyroid Papillary Carcinoma (TPC) R-HSA-5619107,0.9895719704696923,1.3362484422999445,0.175,1.0,1.0,2/32,1.05%,MAP4K5;NUP210
prerank,GO_Biological_Process_2021__monocarboxylic acid transport (GO:0015718),-0.975585266343925,-1.336165316704725,0.3697478991596639,1.0,1.0,4/55,2.46%,NCOA1;SLCO1A2;SLCO3A1;SLC16A2
prerank,GO_Biological_Process_2021__negative regulation of cellular protein localization (GO:1903828),-0.9761048332859886,-1.3360949529651662,0.46564885496183206,1.0,1.0,2/34,2.40%,TTBK2;SPI1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hypertrophic Cardiomyopathy,-0.9757260818478406,-1.3359575878180032,0.30357142857142855,1.0,1.0,1/57,2.43%,FOSB
prerank,GO_Biological_Process_2021__aortic valve development (GO:0003176),-0.9807984741634306,-1.3358083410148738,0.328125,1.0,1.0,3/35,1.93%,RB1;BMP4;SLIT3
prerank,GO_Biological_Process_2021__termination of RNA polymerase I transcription (GO:0006363),0.9801481012114855,1.3356152652263074,0.3884297520661157,1.0,1.0,2/30,1.99%,TAF1B;CAVIN1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Clear Cell Ovarian Carcinoma,0.9772019635435538,1.335610458184269,0.4230769230769231,1.0,1.0,1/46,2.28%,HGF
prerank,Elsevier_Pathway_Collection__Proteins Involved in Otitis Media,0.981797728350413,1.335475623397103,0.3435114503816794,1.0,1.0,1/29,1.82%,PTGS2
prerank,KEGG_2021_Human__Mitophagy,0.9789243342730803,1.335346792201606,0.2773109243697479,1.0,1.0,3/67,2.11%,USP15;RAB7A;OPTN
prerank,GO_Biological_Process_2021__centromere complex assembly (GO:0034508),0.9884538489777706,1.3353105378997274,0.1271186440677966,1.0,1.0,2/37,1.16%,CENPE;CENPA
prerank,GO_Biological_Process_2021__cholesterol biosynthetic process (GO:0006695),-0.9857205336119408,-1.3352087529839023,0.24770642201834864,1.0,1.0,1/34,1.43%,ARV1
prerank,GO_Biological_Process_2021__Golgi to plasma membrane protein transport (GO:0043001),0.9789560256821068,1.3351208496276272,0.4566929133858268,1.0,1.0,3/30,2.11%,KIF13A;AMN;OPTN
prerank,Elsevier_Pathway_Collection__Synovial Fibroblast Activation by Citokines in Rheumatoid Arthritis,-0.9978000630462662,-1.3351167395471635,0.0,1.0,1.0,1/48,0.23%,MAP2K6
prerank,Reactome_2022__Phototransduction Cascade R-HSA-2514856,0.9834932849662579,1.3349291690383682,0.35714285714285715,1.0,1.0,1/26,1.65%,GNB5
prerank,Reactome_2022__HDR Thru Single Strand Annealing (SSA) R-HSA-5685938,0.9884903978909367,1.3347395434107738,0.18032786885245902,1.0,1.0,1/37,1.15%,BRIP1
prerank,GO_Biological_Process_2021__positive regulation of lymphocyte activation (GO:0051251),0.9867625691991042,1.3346624411428536,0.25,1.0,1.0,2/34,1.33%,NOD2;THY1
prerank,Elsevier_Pathway_Collection__AXL Receptor Inhibits Macrophages and Dendritic Cells Function,-0.9816023528113972,-1.3345458611849166,0.30578512396694213,1.0,1.0,2/39,1.85%,PROS1;TICAM2
prerank,GO_Biological_Process_2021__regulation of response to DNA damage stimulus (GO:2001020),0.9924900753100653,1.3344665642398499,0.06779661016949153,1.0,1.0,1/41,0.75%,NEK4
prerank,Elsevier_Pathway_Collection__Vitiligo,-0.976721056155378,-1.3344335736810868,0.2421875,1.0,1.0,4/75,2.34%,PTK2B;C1R;STAT5A;VAV1
prerank,Reactome_2022__Sealing Of Nuclear Envelope (NE) By ESCRT-III R-HSA-9668328,0.9785299388519945,1.3344158718902361,0.4413793103448276,1.0,1.0,1/27,2.15%,TUBA1A
prerank,Elsevier_Pathway_Collection__RARA Signaling in Acute Myeloid Leukemia (M3),-0.9761111587092829,-1.3343933873598834,0.5307692307692308,1.0,1.0,2/27,2.40%,STAT5A;SPI1
prerank,GO_Biological_Process_2021__nucleic acid phosphodiester bond hydrolysis (GO:0090305),-0.9934837911835911,-1.3343841604604825,0.04032258064516129,1.0,1.0,2/73,0.66%,POLK;EDC3
prerank,GO_Biological_Process_2021__negative regulation of JNK cascade (GO:0046329),0.9781448877764063,1.3343564245094601,0.488,1.0,1.0,2/32,2.19%,SH3RF2;MAPK8IP1
prerank,GO_Biological_Process_2021__regulation of cellular amine metabolic process (GO:0033238),0.9880210727561165,1.3342861428095232,0.18421052631578946,1.0,1.0,1/48,1.20%,PSMB9
prerank,GO_Biological_Process_2021__positive regulation of T cell mediated immunity (GO:0002711),-0.9780590280491221,-1.3339553269248108,0.42748091603053434,1.0,1.0,1/35,2.20%,HLA-B
prerank,TRRUST_Transcription_Factors_2019__RUNX2 mouse,0.9795574926965254,1.3339469814104876,0.358974358974359,1.0,1.0,3/45,2.05%,ASRGL1;AXIN2;LGALS3
prerank,Reactome_2022__RHO GTPases Activate WASPs And WAVEs R-HSA-5663213,0.9914958095732366,1.333874559272428,0.12598425196850394,1.0,1.0,3/34,0.86%,ABI2;ACTR3;PTK2
prerank,Elsevier_Pathway_Collection__Synovial Fibroblast Activation in Psoriatic Arthritis,-0.9977998494891868,-1.3338709090735366,0.017699115044247787,1.0,1.0,1/47,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of intracellular transport (GO:0032388),-0.9798335273328381,-1.33370786586494,0.3984375,1.0,1.0,3/39,2.03%,BCAS3;NEDD4;PRR5L
prerank,GO_Biological_Process_2021__pattern recognition receptor signaling pathway (GO:0002221),0.9911011184129705,1.3335246767877496,0.1015625,1.0,1.0,3/60,0.90%,TRAF3;IRAK2;NOD2
prerank,TRRUST_Transcription_Factors_2019__STAT5A mouse,-0.984308112046457,-1.3334145483520508,0.33064516129032256,1.0,1.0,2/22,1.58%,NR3C1;GRB10
prerank,GO_Biological_Process_2021__regulation of multicellular organismal development (GO:2000026),0.9936500873547359,1.333405412795576,0.14049586776859505,1.0,1.0,1/26,0.64%,CCSAP
prerank,Reactome_2022__RND3 GTPase Cycle R-HSA-9696264,0.9871835348326468,1.3333068680567548,0.1984732824427481,1.0,1.0,4/40,1.29%,DEPDC1B;PKP4;CKAP4;PLEKHG5
prerank,Elsevier_Pathway_Collection__Apoptosis of Melanocyte in Vitiligo,-0.9987651901186093,-1.333294786522379,0.03361344537815126,1.0,1.0,1/29,0.13%,PTK2B
prerank,Elsevier_Pathway_Collection__Low-Density Lipoproteins and Chemokines in Atherosclerosis,0.985846007932538,1.3327028995956236,0.30327868852459017,1.0,1.0,2/22,1.42%,ITGAL;CX3CL1
prerank,Elsevier_Pathway_Collection__SNS Related Adrenal Cortex Response,-0.9846117259152802,-1.3323873429118969,0.2755905511811024,1.0,1.0,1/25,1.54%,RAPGEF3
prerank,Reactome_2022__Sialic Acid Metabolism R-HSA-4085001,0.9968034081038217,1.3322828651803802,0.025423728813559324,1.0,1.0,1/31,0.32%,ST3GAL1
prerank,GO_Biological_Process_2021__DNA replication-independent nucleosome assembly (GO:0006336),0.9884529524542123,1.3322008706402229,0.12096774193548387,1.0,1.0,2/39,1.16%,HIRA;CENPA
prerank,Elsevier_Pathway_Collection__EGFR/ERBB2 -> HIF1A Signaling,-0.9766833869272916,-1.3321083994014522,0.4573643410852713,1.0,1.0,2/32,2.34%,NRG1;VAV1
prerank,GO_Biological_Process_2021__positive regulation of locomotion (GO:0040017),0.9801027958266578,1.3320488585829744,0.40336134453781514,1.0,1.0,1/30,1.99%,CAVIN1
prerank,Reactome_2022__Energy Dependent Regulation Of mTOR By LKB1-AMPK R-HSA-380972,0.9890348835914531,1.3319556342670156,0.16822429906542055,1.0,1.0,2/29,1.10%,CAB39;PRKAA2
prerank,GO_Biological_Process_2021__positive regulation of leukocyte mediated cytotoxicity (GO:0001912),-0.9760961187504531,-1.3319286927499154,0.44680851063829785,1.0,1.0,2/41,2.40%,HLA-B;SPI1
prerank,GO_Biological_Process_2021__intracellular pH reduction (GO:0051452),0.9916496457322361,1.3319214793016712,0.16521739130434782,1.0,1.0,2/32,0.84%,RAB20;RAB7A
prerank,GO_Biological_Process_2021__negative regulation of receptor-mediated endocytosis (GO:0048261),-0.9919200817226319,-1.3318275782592226,0.19696969696969696,1.0,1.0,1/25,0.81%,APP
prerank,Elsevier_Pathway_Collection__RAGE/AGER and S100 Proteins in Cardiovascular Injury,0.9793343247256174,1.331742457903547,0.3828125,1.0,1.0,1/30,2.07%,SERPINE1
prerank,Reactome_2022__Complement Cascade R-HSA-166658,-0.9838637163902196,-1.331459171112482,0.17647058823529413,1.0,1.0,4/55,1.63%,C4BPA;PROS1;C5AR2;C1R
prerank,TRRUST_Transcription_Factors_2019__HNF1A human,-0.9803074028019825,-1.33136129455766,0.453781512605042,1.0,1.0,2/23,1.98%,GPR39;CYP1A2
prerank,Reactome_2022__Rev-mediated Nuclear Export Of HIV RNA R-HSA-165054,0.9895296759820726,1.3308991012750446,0.1487603305785124,1.0,1.0,1/35,1.05%,NUP210
prerank,Elsevier_Pathway_Collection__MTOR/TP53 Regulates Cell Metabolism,0.9780694764352814,1.3303901414407888,0.4605263157894737,1.0,1.0,1/27,2.19%,HK2
prerank,GO_Biological_Process_2021__cellular response to glucose stimulus (GO:0071333),0.984610341440266,1.330305497091254,0.2956521739130435,1.0,1.0,3/31,1.55%,ERN1;PRKAA2;PDK3
prerank,GO_Biological_Process_2021__cellular glucose homeostasis (GO:0001678),0.9773696432327008,1.3297012712392347,0.44166666666666665,1.0,1.0,6/41,2.28%,ERN1;PRKAA2;PDK3;HK2;FOXA3;HKDC1
prerank,Elsevier_Pathway_Collection__Dendritic Spine Morphogenesis and Stabilization,0.9893760205569428,1.3293223077758771,0.16030534351145037,1.0,1.0,2/40,1.07%,PPP1R12A;ARHGEF7
prerank,Reactome_2022__RUNX1 Regulates Genes Involved In Megakaryocyte Differentiation And Platelet Function R-HSA-8936459,0.9813475575309628,1.3291935723738495,0.208,1.0,1.0,1/56,1.86%,ZFPM1
prerank,GO_Biological_Process_2021__positive regulation of reactive oxygen species metabolic process (GO:2000379),0.9784755076343018,1.3291127873413435,0.3359375,1.0,1.0,2/49,2.16%,SYK;CYBA
prerank,GO_Biological_Process_2021__negative regulation of protein-containing complex assembly (GO:0031333),0.9883308465233277,1.3287462116056805,0.15,1.0,1.0,1/47,1.17%,MEFV
prerank,KEGG_2021_Human__ABC transporters,-0.9759428050573383,-1.3287373526546684,0.39344262295081966,1.0,1.0,3/43,2.42%,ABCD3;ABCA6;ABCA10
prerank,TRRUST_Transcription_Factors_2019__MYCN human,-0.9773643594516356,-1.3285778013852434,0.41025641025641024,1.0,1.0,3/44,2.27%,CD44;HLA-B;CIITA
prerank,KEGG_2021_Human__Taste transduction,-0.9809316367931729,-1.3285295270894675,0.30578512396694213,1.0,1.0,1/50,1.91%,PLCB4
prerank,GO_Biological_Process_2021__smoothened signaling pathway (GO:0007224),-0.9793362909704673,-1.3285093154686125,0.3870967741935484,1.0,1.0,3/35,2.08%,TTBK2;SHH;GLI3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Atopic Dermatitis,0.9877562798618446,1.3284435767131062,0.1746031746031746,1.0,1.0,1/39,1.23%,CD4
prerank,WikiPathway_2021_Human__CAMKK2  Pathway WP4874,0.9801069546562917,1.3281020178643366,0.4418604651162791,1.0,1.0,3/34,2.00%,CREB1;ARHGEF7;NFATC2
prerank,GO_Biological_Process_2021__GPI anchor biosynthetic process (GO:0006506),-0.9773018263488906,-1.3280956016936456,0.47368421052631576,1.0,1.0,3/30,2.28%,PIGX;PIGZ;PGAP4
prerank,GO_Biological_Process_2021__chromatin remodeling at centromere (GO:0031055),0.9884158306656963,1.327993377839972,0.16666666666666666,1.0,1.0,1/32,1.16%,CENPA
prerank,WikiPathway_2021_Human__Nucleotide Excision Repair WP4753,0.9914883504956109,1.3278867932065535,0.056,1.0,1.0,1/44,0.85%,POLE4
prerank,GO_Biological_Process_2021__autophagy of mitochondrion (GO:0000422),-0.998571160742562,-1.3277089132968714,0.029197080291970802,1.0,1.0,1/40,0.15%,FUNDC2
prerank,Elsevier_Pathway_Collection__Cytokines Trigger Otitis Media,-0.9766907370915185,-1.3275997542877422,0.3130434782608696,1.0,1.0,3/66,2.34%,MAP2K6;NR3C1;VAV1
prerank,GO_Biological_Process_2021__receptor clustering (GO:0043113),0.882066430605409,1.3272559996711901,0.4369747899159664,1.0,1.0,6/28,2.29%,DLG1;DLG3;ITGA4;THY1;ITGAL;FLNA
prerank,Reactome_2022__NoRC Negatively Regulates rRNA Expression R-HSA-427413,0.9922121386608429,1.327194834736605,0.05785123966942149,1.0,1.0,1/64,0.78%,TAF1B
prerank,WikiPathway_2021_Human__Myometrial relaxation and contraction pathways WP289,0.8403340659580336,1.3271862978231344,0.09302325581395349,1.0,1.0,6/145,2.34%,CREB1;YWHAQ;LPAR1;IGFBP3;GNB5;GNG2
prerank,GO_Biological_Process_2021__regulation of mitochondrial membrane potential (GO:0051881),0.9760898372666886,1.3268436206193128,0.47058823529411764,1.0,1.0,1/41,2.39%,PYCR1
prerank,GO_Biological_Process_2021__positive regulation of myeloid leukocyte differentiation (GO:0002763),0.9877595409234535,1.3267321340282434,0.248,1.0,1.0,1/33,1.23%,CD4
prerank,Elsevier_Pathway_Collection__Proteins Involved in Endometrial Cancer,0.9830206453096724,1.3266330338701235,0.21238938053097345,1.0,1.0,3/49,1.71%,CDK6;MSH2;CDH1
prerank,Reactome_2022__HSP90 Chaperone Cycle For Steroid Hormone Receptors (SHR) In Presence Of Ligand R-HSA-3371497,-0.9756003086111402,-1.3263337215208029,0.4732824427480916,1.0,1.0,2/38,2.45%,NR3C1;DNAJA4
prerank,GO_Biological_Process_2021__positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0090100),-0.9851563119521762,-1.3262013798366763,0.09848484848484848,1.0,1.0,5/84,1.50%,SLC2A10;CREBBP;TGFB1I1;INHBB;BMP4
prerank,GO_Biological_Process_2021__receptor signaling pathway via JAK-STAT (GO:0007259),-0.9829518369668037,-1.3260890367861071,0.3474576271186441,1.0,1.0,1/30,1.71%,STAT5A
prerank,GO_Biological_Process_2021__Wnt signaling pathway (GO:0016055),0.9797503397802418,1.3260584581945687,0.23333333333333334,1.0,1.0,2/90,2.02%,LRP5;CPE
prerank,MSigDB_Oncogenic_Signatures__BCAT GDS748 DN,-0.982525239781303,-1.3259411991107042,0.3178294573643411,1.0,1.0,3/41,1.76%,EXOC2;HLX;BASP1
prerank,GO_Biological_Process_2021__regulation of purine nucleotide metabolic process (GO:1900542),0.9775579213763781,1.3258707474984166,0.4251968503937008,1.0,1.0,2/43,2.25%,NUP210;SLC2A6
prerank,Reactome_2022__DNA Damage Recognition In GG-NER R-HSA-5696394,-0.9883746171293003,-1.3258590371698717,0.203125,1.0,1.0,1/36,1.17%,INO80D
prerank,Elsevier_Pathway_Collection__Myeloid Derived Suppressor Cells in Cancer Immune Escape,-0.9773591098743402,-1.3254466094130282,0.3230769230769231,1.0,1.0,3/50,2.27%,STAT5A;IL10RA;CIITA
prerank,GO_Biological_Process_2021__positive regulation of wound healing (GO:0090303),0.979409848450896,1.3253073184153807,0.41739130434782606,1.0,1.0,3/39,2.07%,PTK2;ANXA1;SERPINE1
prerank,Elsevier_Pathway_Collection__Dendritic Cell Dysfunction in Psoriatic Arthritis,-0.9977966847195986,-1.3250809496149873,0.024,1.0,1.0,1/62,0.23%,MAP2K6
prerank,Reactome_2022__RAB Geranylgeranylation R-HSA-8873719,0.9916779281108946,1.3249805595526305,0.04411764705882353,1.0,1.0,3/62,0.84%,RAB40C;RAB20;RAB7A
prerank,GO_Biological_Process_2021__nuclear-transcribed mRNA catabolic process (GO:0000956),0.8341337728788094,1.3249710390269709,0.03225806451612903,1.0,1.0,4/171,0.81%,DIS3L2;UPF2;TENT2;PARN
prerank,GO_Biological_Process_2021__JNK cascade (GO:0007254),0.9910689541841244,1.324855549331049,0.1206896551724138,1.0,1.0,2/41,0.90%,IRAK2;NOD2
prerank,Elsevier_Pathway_Collection__Cardiomyocyte Hypertrophy,-0.9808168055036154,-1.3247867391949923,0.20161290322580644,1.0,1.0,3/61,1.93%,PTK2B;MAP2K6;MMP2
prerank,Reactome_2022__Keratan Sulfate/Keratin Metabolism R-HSA-1638074,0.9937658938969145,1.32477806990103,0.12307692307692308,1.0,1.0,2/31,0.63%,ST3GAL1;SLC35D2
prerank,Reactome_2022__Transport Of Mature mRNA Derived From An Intronless Transcript R-HSA-159231,0.9895266756328996,1.324773194342806,0.13709677419354838,1.0,1.0,1/42,1.05%,NUP210
prerank,MSigDB_Oncogenic_Signatures__CSR LATE UP.V1 UP,0.8552849409349026,1.3247722885532272,0.06451612903225806,1.0,1.0,11/154,2.38%,CDH2;HERC4;HAUS2;IGFBP3;PBK;ANLN;UBE2C;SMS;TIMP3;SHCBP1;RRM2
prerank,GO_Biological_Process_2021__cognition (GO:0050890),-0.9786384063800794,-1.324769984571854,0.390625,1.0,1.0,2/40,2.14%,APP;MGAT3
prerank,GO_Biological_Process_2021__mitotic cytokinesis (GO:0000281),0.9785182701489089,1.3247530610549072,0.3277310924369748,1.0,1.0,4/47,2.16%,CENPA;SEPTIN6;ANLN;KIF23
prerank,WikiPathway_2021_Human__Sphingolipid Metabolism (general overview) WP4725,-0.8126428216587771,-1.3246045760664753,0.42028985507246375,1.0,1.0,3/22,2.08%,SGPP1;SGPL1;SMPD1
prerank,GO_Biological_Process_2021__positive regulation of mitochondrion organization (GO:0010822),0.9813981465428089,1.3244867929013655,0.24806201550387597,1.0,1.0,3/56,1.87%,PLAUR;ADCK1;BOK
prerank,Reactome_2022__Striated Muscle Contraction R-HSA-390522,0.9825288505189467,1.3244731688866525,0.38524590163934425,1.0,1.0,1/29,1.75%,TNNC2
prerank,GO_Biological_Process_2021__regulation of intracellular steroid hormone receptor signaling pathway (GO:0033143),0.9958788380094928,1.3240168125933582,0.045454545454545456,1.0,1.0,1/36,0.41%,PRMT2
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Age-Related Macular Degeneration,0.9801138321052459,1.3237412832098416,0.4380165289256198,1.0,1.0,2/23,1.99%,TIMP3;APOE
prerank,GO_Biological_Process_2021__regulation of cell communication (GO:0010646),0.9830284342916673,1.3237129683675544,0.275,1.0,1.0,2/34,1.70%,ANXA1;GRK3
prerank,GO_Biological_Process_2021__regulation of DNA recombination (GO:0000018),0.9922996005908643,1.3234166834438437,0.1484375,1.0,1.0,1/37,0.77%,MSH2
prerank,Elsevier_Pathway_Collection__Eosinophil Activation and Degranulation in Asthma,-0.9767122280707089,-1.3231551436085165,0.3939393939393939,1.0,1.0,3/43,2.34%,CREBBP;GNA14;VAV1
prerank,WikiPathway_2021_Human__PI3K-AKT-mTOR signaling pathway and therapeutic opportunities WP3844,-0.9843028191479555,-1.323074583007269,0.2764227642276423,1.0,1.0,2/30,1.58%,PIK3CB;GRB10
prerank,Reactome_2022__Synthesis Of Substrates In N-glycan Biosythesis R-HSA-446219,0.983895845780857,1.3230100967078446,0.184,1.0,1.0,2/61,1.61%,ST3GAL1;FUOM
prerank,Reactome_2022__Vpr-mediated Nuclear Import Of PICs R-HSA-180910,0.9895295992308247,1.3229950116083478,0.176,1.0,1.0,1/35,1.05%,NUP210
prerank,GO_Biological_Process_2021__metal ion transport (GO:0030001),0.9832519644374828,1.3228498804643947,0.17272727272727273,1.0,1.0,1/80,1.67%,CYP27B1
prerank,GO_Biological_Process_2021__positive regulation of axonogenesis (GO:0050772),-0.9775545419401722,-1.3227934998865212,0.375,1.0,1.0,1/41,2.25%,SEMA4D
prerank,GO_Biological_Process_2021__termination of RNA polymerase II transcription (GO:0006369),0.9998424215787679,1.322768084377364,0.0,1.0,1.0,1/34,0.02%,ZNF473
prerank,Reactome_2022__TP53 Regulates Transcription Of Cell Cycle Genes R-HSA-6791312,0.9840613926677042,1.3226047130454746,0.2636363636363636,1.0,1.0,4/48,1.61%,ARID3A;RBL1;TFDP2;PCBP4
prerank,GO_Biological_Process_2021__activation of phospholipase C activity (GO:0007202),0.9771092441409719,1.322533496956936,0.47413793103448276,1.0,1.0,2/29,2.29%,LPAR1;CD86
prerank,GO_Biological_Process_2021__response to unfolded protein (GO:0006986),0.9789415961395879,1.3224635980280375,0.35344827586206895,1.0,1.0,3/47,2.11%,ERN1;ERP44;OPTN
prerank,TRRUST_Transcription_Factors_2019__FOXO1 mouse,-0.9846375767146401,-1.3224634080063737,0.24166666666666667,1.0,1.0,1/42,1.54%,CCND2
prerank,GO_Biological_Process_2021__ribosome assembly (GO:0042255),0.9974921402986243,1.3223859952114254,0.025210084033613446,1.0,1.0,1/47,0.25%,EIF2A
prerank,GO_Biological_Process_2021__negative regulation of stress-activated MAPK cascade (GO:0032873),0.9792570350572993,1.322365657274888,0.423728813559322,1.0,1.0,2/37,2.08%,DLG1;SH3RF2
prerank,WikiPathway_2021_Human__The influence of laminopathies on Wnt signaling WP4844,0.9933404489499215,1.3223483147957706,0.09836065573770492,1.0,1.0,1/33,0.67%,CDK6
prerank,KEGG_2021_Human__Nucleotide excision repair,0.9914878500276025,1.3222452898881407,0.056910569105691054,1.0,1.0,1/45,0.85%,POLE4
prerank,GO_Biological_Process_2021__regulation of JUN kinase activity (GO:0043506),0.9781023600224859,1.3215814527807497,0.452991452991453,1.0,1.0,1/32,2.19%,MAPK8IP1
prerank,GO_Biological_Process_2021__negative regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043124),-0.9778641956410725,-1.3212604592554613,0.41353383458646614,1.0,1.0,1/39,2.22%,RHOH
prerank,GO_Biological_Process_2021__epithelial to mesenchymal transition (GO:0001837),0.9765909606049665,1.3211912361630314,0.4083333333333333,1.0,1.0,2/46,2.34%,HGF;TBX3
prerank,GO_Biological_Process_2021__chloride transmembrane transport (GO:1902476),-0.9761654767779223,-1.321125198190154,0.4098360655737705,1.0,1.0,1/43,2.39%,SLC12A8
prerank,GO_Biological_Process_2021__nucleus organization (GO:0006997),-0.9769309431289205,-1.3210824871100495,0.358974358974359,1.0,1.0,1/46,2.31%,SYNE1
prerank,WikiPathway_2021_Human__Genotoxicity pathway WP4286,0.9961428528930314,1.3208848821295005,0.07017543859649122,1.0,1.0,1/52,0.39%,CENPE
prerank,GO_Biological_Process_2021__negative regulation of metabolic process (GO:0009892),-0.9886009435970816,-1.3208029040988671,0.11678832116788321,1.0,1.0,3/53,1.15%,MAP2K6;ADAMTS5;RB1
prerank,WikiPathway_2021_Human__Synaptic Vesicle Pathway WP2267,0.9765168797901496,1.3205510564468692,0.41228070175438597,1.0,1.0,3/45,2.36%,SLC6A4;SLC38A1;STX1A
prerank,KEGG_2021_Human__Pancreatic secretion,-0.981035338909364,-1.3204167079135054,0.14285714285714285,1.0,1.0,4/78,1.91%,RAP1B;RAP1A;ADCY3;PLCB4
prerank,Reactome_2022__Ovarian Tumor Domain Proteases R-HSA-5689896,0.991070403720644,1.3203943433941072,0.11382113821138211,1.0,1.0,2/38,0.90%,TRAF3;NOD2
prerank,GO_Biological_Process_2021__negative regulation of protein ubiquitination (GO:0031397),0.9763982441945637,1.3203786056034201,0.4198473282442748,1.0,1.0,3/49,2.37%,HDAC8;SH3RF2;PRR7
prerank,GO_Biological_Process_2021__tRNA modification (GO:0006400),-0.9788504245780857,-1.3199713350268099,0.28346456692913385,1.0,1.0,4/64,2.13%,TYW1;THADA;MOCS3;TRMT9B
prerank,Reactome_2022__Sema4D Induced Cell Migration And Growth-Cone Collapse R-HSA-416572,-0.9775768842723597,-1.319971010744218,0.5035460992907801,1.0,1.0,1/20,2.25%,SEMA4D
prerank,GO_Biological_Process_2021__regulation of interleukin-17 production (GO:0032660),0.9910338775566246,1.3198976058495815,0.1826086956521739,1.0,1.0,1/29,0.90%,NOD2
prerank,GO_Biological_Process_2021__transcription initiation from RNA polymerase I promoter (GO:0006361),0.9801465090455095,1.3197206648631272,0.40336134453781514,1.0,1.0,2/32,1.99%,TAF1B;CAVIN1
prerank,GO_Biological_Process_2021__ATP-dependent chromatin remodeling (GO:0043044),0.999456528267701,1.319703061596408,0.008264462809917356,1.0,1.0,1/42,0.06%,ARID1B
prerank,GO_Biological_Process_2021__regulation of gene silencing by miRNA (GO:0060964),0.9895130983543197,1.319588071967372,0.07633587786259542,1.0,1.0,1/66,1.05%,NUP210
prerank,GO_Biological_Process_2021__nucleosome assembly (GO:0006334),0.9963402844898641,1.3195211732044512,0.07751937984496124,1.0,1.0,2/46,0.37%,NAA60;HIRA
prerank,WikiPathway_2021_Human__MAPK Cascade WP422,-0.9978031984353763,-1.3192124646666632,0.024390243902439025,1.0,1.0,1/33,0.23%,MAP2K6
prerank,KEGG_2021_Human__Long-term depression,-0.9809294156535078,-1.3192029084707801,0.2440944881889764,1.0,1.0,1/53,1.91%,PLCB4
prerank,WikiPathway_2021_Human__Kit receptor signaling pathway WP304,-0.9767754124172516,-1.3191936348480031,0.352,1.0,1.0,5/59,2.34%,TEC;GRB10;STAT5A;SH2B2;VAV1
prerank,Elsevier_Pathway_Collection__B-Cell Mediated IgE Production in Asthma,0.9795349916255457,1.318985079524897,0.45454545454545453,1.0,1.0,4/28,2.06%,TRAF3;SYK;IL13RA1;PIK3AP1
prerank,GO_Biological_Process_2021__IRE1-mediated unfolded protein response (GO:0036498),0.998917342022404,1.3188515831510579,0.008130081300813009,1.0,1.0,1/52,0.11%,ERN1
prerank,GO_Biological_Process_2021__phosphatidylserine metabolic process (GO:0006658),-0.988186784483012,-1.3187526040163706,0.19548872180451127,1.0,1.0,1/29,1.19%,PLAAT3
prerank,TRRUST_Transcription_Factors_2019__HNF1A mouse,-0.7803502075756856,-1.3186334490567713,0.3968253968253968,1.0,1.0,3/19,1.98%,CYP39A1;RORC;CYP1A2
prerank,Reactome_2022__Sema4D In Semaphorin Signaling R-HSA-400685,-0.9775728889544774,-1.3183160034755708,0.5144927536231884,1.0,1.0,1/24,2.25%,SEMA4D
prerank,GO_Biological_Process_2021__response to alcohol (GO:0097305),-0.9807654485687106,-1.3182100451179741,0.33858267716535434,1.0,1.0,2/27,1.93%,GRIN2B;SLIT3
prerank,GO_Biological_Process_2021__negative regulation of proteolysis involved in cellular protein catabolic process (GO:1903051),-0.9791084492440358,-1.3179392789547413,0.5,1.0,1.0,1/25,2.09%,PML
prerank,KEGG_2021_Human__Fatty acid degradation,0.9777439567026242,1.3176246713028117,0.44166666666666665,1.0,1.0,1/43,2.22%,ACSL5
prerank,MSigDB_Oncogenic_Signatures__KRAS.50 UP.V1 UP,0.9788670029389638,1.3175046538472772,0.4251968503937008,1.0,1.0,4/44,2.12%,ETV5;ITGA2;A2M;RBP4
prerank,Reactome_2022__Transport Of SLBP Dependant Mature mRNA R-HSA-159230,0.9895296132348447,1.317346409710501,0.14166666666666666,1.0,1.0,1/36,1.05%,NUP210
prerank,Reactome_2022__Kinesins R-HSA-983189,0.9759836629268286,1.317224395815118,0.4583333333333333,1.0,1.0,3/40,2.41%,CENPE;KIF23;KIF3B
prerank,GO_Biological_Process_2021__ncRNA export from nucleus (GO:0097064),0.9895282439448536,1.3171397399885034,0.13178294573643412,1.0,1.0,1/38,1.05%,NUP210
prerank,GO_Biological_Process_2021__regulation of mRNA catabolic process (GO:0061013),0.888855299781265,1.3170158563055578,0.12844036697247707,1.0,1.0,6/120,1.61%,YTHDF3;PARN;PSMB9;IGF2BP1;IGF2BP3;PCBP4
prerank,GO_Biological_Process_2021__regulation of transcription elongation from RNA polymerase II promoter (GO:0034243),-0.9930357762609464,-1.3168561608099758,0.1092436974789916,1.0,1.0,1/25,0.70%,NELFA
prerank,GO_Biological_Process_2021__long-term synaptic potentiation (GO:0060291),-0.9893470467046719,-1.316802933470196,0.22388059701492538,1.0,1.0,2/20,1.08%,PTK2B;GRIN2B
prerank,GO_Biological_Process_2021__negative regulation of transferase activity (GO:0051348),0.9773741073676779,1.3165415793229729,0.4672131147540984,1.0,1.0,1/29,2.26%,PIF1
prerank,GO_Biological_Process_2021__histone exchange (GO:0043486),0.9884124223503168,1.3164990203965738,0.12295081967213115,1.0,1.0,1/38,1.16%,CENPA
prerank,GO_Biological_Process_2021__iron ion transport (GO:0006826),0.9760910573497465,1.3163399503191249,0.42857142857142855,1.0,1.0,2/47,2.39%,LMTK2;MELTF
prerank,Reactome_2022__HIV Transcription Initiation R-HSA-167161,0.991029035424295,1.3163390582949444,0.14655172413793102,1.0,1.0,2/45,0.90%,TAF4;GTF2E2
prerank,Reactome_2022__Ion Transport By P-type ATPases R-HSA-936837,-0.9969916136758482,-1.316288969076214,0.029850746268656716,1.0,1.0,1/47,0.31%,ATP11C
prerank,Reactome_2022__Signaling By FGFR2 R-HSA-5654738,0.9762560012088761,1.316185364514147,0.31932773109243695,1.0,1.0,1/65,2.37%,FGF1
prerank,GO_Biological_Process_2021__action potential (GO:0001508),-0.9756336132609204,-1.3161761386165998,0.4666666666666667,1.0,1.0,2/41,2.44%,GNA14;KCNE1
prerank,GO_Biological_Process_2021__regulation of neurogenesis (GO:0050767),0.9857838741597698,1.3160804910033663,0.18382352941176472,1.0,1.0,1/53,1.42%,CX3CL1
prerank,Reactome_2022__Inhibition Of DNA Recombination At Telomere R-HSA-9670095,0.9784801644321203,1.3159737401106049,0.43902439024390244,1.0,1.0,1/38,2.15%,ACD
prerank,Reactome_2022__RHO GTPases Activate Formins R-HSA-5663220,0.8889420928128964,1.3158048211051283,0.1111111111111111,1.0,1.0,6/115,2.03%,CENPE;NDC80;MRTFA;CENPA;ERCC6L;FMNL2
prerank,WikiPathway_2021_Human__Eukaryotic Transcription Initiation WP405,0.9909891990858094,1.315664665010296,0.11304347826086956,1.0,1.0,1/42,0.90%,GTF2E2
prerank,GO_Biological_Process_2021__regulation of neuron migration (GO:2001222),0.9782255816693813,1.3156081977166612,0.4864864864864865,1.0,1.0,2/28,2.18%,CX3CL1;ULK4
prerank,GO_Biological_Process_2021__RNA methylation (GO:0001510),-0.9868980858695287,-1.3155608126023213,0.10606060606060606,1.0,1.0,1/60,1.31%,THADA
prerank,GO_Biological_Process_2021__glycosphingolipid metabolic process (GO:0006687),-0.9792880900754809,-1.3149520397256407,0.3609022556390977,1.0,1.0,3/46,2.08%,STS;GALC;SMPD1
prerank,GO_Biological_Process_2021__regulation of T cell mediated cytotoxicity (GO:0001914),-0.9780667639739152,-1.3146755041777483,0.5038759689922481,1.0,1.0,1/29,2.20%,HLA-B
prerank,TRRUST_Transcription_Factors_2019__BRCA1 human,-0.9821989014742977,-1.3145224961488482,0.23846153846153847,1.0,1.0,1/56,1.78%,CYP1B1
prerank,WikiPathway_2021_Human__Ferroptosis WP4313,0.9777475837620242,1.3143674884158458,0.4067796610169492,1.0,1.0,1/39,2.22%,ACSL5
prerank,Reactome_2022__Viral Messenger RNA Synthesis R-HSA-168325,0.9895235010658823,1.3143111791678816,0.13821138211382114,1.0,1.0,1/47,1.05%,NUP210
prerank,KEGG_2021_Human__Ferroptosis,0.9777466021993615,1.3140724910668908,0.39316239316239315,1.0,1.0,1/40,2.22%,ACSL5
prerank,GO_Biological_Process_2021__receptor signaling pathway via STAT (GO:0097696),-0.982955917159961,-1.3139341732507754,0.38333333333333336,1.0,1.0,1/25,1.71%,STAT5A
prerank,Reactome_2022__Interactions Of Vpr With Host Cellular Proteins R-HSA-176033,0.9895277639761458,1.3139101140109024,0.15873015873015872,1.0,1.0,1/38,1.05%,NUP210
prerank,WikiPathway_2021_Human__Tryptophan metabolism WP465,-0.9784482164955334,-1.3139021363537304,0.4461538461538462,1.0,1.0,5/39,2.17%,CYP1B1;CYP1A2;AADAT;AOC1;MAOB
prerank,Reactome_2022__Signaling By Retinoic Acid R-HSA-5362517,0.9845207327009003,1.3137589637201974,0.183206106870229,1.0,1.0,1/38,1.55%,PDK3
prerank,Elsevier_Pathway_Collection__EGFR -> AP-1/ATF2 Signaling,-0.9767526672078771,-1.3137183036937794,0.4435483870967742,1.0,1.0,4/42,2.34%,PTK2B;MAP2K6;NRG1;VAV1
prerank,Reactome_2022__RHOF GTPase Cycle R-HSA-9035034,0.9149861720430107,1.3136650221803379,0.3893805309734513,1.0,1.0,7/40,1.38%,DEPDC1B;SLC4A7;SENP1;RAB7A;ARHGAP12;ARHGAP39;BAIAP2L2
prerank,Elsevier_Pathway_Collection__mTOR Signaling Hyperfunction,-0.984634171341363,-1.3136046061085538,0.21138211382113822,1.0,1.0,1/46,1.54%,CCND2
prerank,WikiPathway_2021_Human__Endoplasmic reticulum stress response in coronavirus infection WP4861,0.9892207713861417,1.3135298345216908,0.104,1.0,1.0,4/46,1.09%,ERN1;PPP1R9A;PPP1R12A;PPP1R16B
prerank,GO_Biological_Process_2021__cellular response to heat (GO:0034605),0.9763330836825286,1.3133612453374213,0.5163934426229508,1.0,1.0,2/35,2.37%,TRPV1;FGF1
prerank,Elsevier_Pathway_Collection__Subepithelial Fibroblasts in Middle Ear Cholesteatoma,-0.9978003814379235,-1.3132873281084538,0.017543859649122806,1.0,1.0,1/45,0.23%,MAP2K6
prerank,Reactome_2022__Interactions Of Rev With Host Cellular Proteins R-HSA-177243,0.9895286623290962,1.3132101122317164,0.13333333333333333,1.0,1.0,1/37,1.05%,NUP210
prerank,KEGG_2021_Human__Legionellosis,0.9809724583138167,1.312767940360549,0.225,1.0,1.0,2/56,1.91%,CASP7;NAIP
prerank,WikiPathway_2021_Human__Copper homeostasis WP3286,-0.9919508338171742,-1.3125616340710644,0.08695652173913043,1.0,1.0,2/51,0.81%,ADAM10;APP
prerank,WikiPathway_2021_Human__PDGFR-beta pathway WP3972,-0.9829534319875808,-1.312514566540829,0.3162393162393162,1.0,1.0,1/29,1.71%,STAT5A
prerank,GO_Biological_Process_2021__regulation of epithelial cell migration (GO:0010632),0.9805155911704508,1.3120640300799042,0.2727272727272727,1.0,1.0,2/50,1.95%,PTK2;CTSH
prerank,WikiPathway_2021_Human__Novel intracellular components of RIG-I-like receptor (RLR) pathway WP3865,0.980242149258721,1.3120230736999154,0.27692307692307694,1.0,1.0,2/55,1.98%,TRAF3;MAPK13
prerank,GO_Biological_Process_2021__spliceosomal complex assembly (GO:0000245),0.986404803788875,1.3119178696688258,0.211864406779661,1.0,1.0,1/45,1.36%,SF3A2
prerank,KEGG_2021_Human__Other types of O-glycan biosynthesis,-0.9770921772585779,-1.311897786843999,0.3953488372093023,1.0,1.0,2/46,2.30%,GALNT7;GALNT3
prerank,Reactome_2022__RNA Polymerase I Transcription Termination R-HSA-73863,0.9801481630458496,1.311804797550357,0.3865546218487395,1.0,1.0,2/30,1.99%,TAF1B;CAVIN1
prerank,Reactome_2022__Deposition Of New CENPA-containing Nucleosomes At Centromere R-HSA-606279,0.9884095100400568,1.3116057992005012,0.136,1.0,1.0,1/43,1.16%,CENPA
prerank,GO_Biological_Process_2021__regulation of translational initiation (GO:0006446),0.9987603470821339,1.3115506298826651,0.008403361344537815,1.0,1.0,1/61,0.13%,YTHDF3
prerank,WikiPathway_2021_Human__Cholesterol metabolism (includes both Bloch and Kandutsch-Russell pathways) WP4718,0.9850992547512172,1.3114318219459735,0.2230769230769231,1.0,1.0,2/46,1.49%,ELOVL2;SOAT2
prerank,Reactome_2022__Clathrin-mediated Endocytosis R-HSA-8856828,0.8581566625609997,1.3113780227629062,0.07142857142857142,1.0,1.0,7/136,1.70%,IGF2R;ACTR3;FNBP1;CD4;PACSIN3;SLC2A8;GRK3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Systemic Lupus Erythematosus,0.9771969276929164,1.3112371558524984,0.2892561983471074,1.0,1.0,5/61,2.29%,CD4;IL1RN;SIGIRR;PTGS2;CD86
prerank,Elsevier_Pathway_Collection__Airway Epithelial Cell Dysfunction,-0.9792084588239358,-1.3111907752682863,0.3492063492063492,1.0,1.0,3/49,2.09%,MAP2K6;TICAM2;AQP3
prerank,WikiPathway_2021_Human__Translation inhibitors in chronically activated PDGFRA cells WP4566,-0.9937242724352812,-1.3110281271725206,0.04411764705882353,1.0,1.0,4/46,0.65%,MAP2K6;AKT3;PIK3CB;MAP2K5
prerank,Reactome_2022__SUMOylation Of DNA Replication Proteins R-HSA-4615885,0.9895245868285106,1.310671499212721,0.15625,1.0,1.0,1/45,1.05%,NUP210
prerank,GO_Biological_Process_2021__glycolipid metabolic process (GO:0006664),-0.9792839271448442,-1.310374974747683,0.33070866141732286,1.0,1.0,3/51,2.08%,STS;GALC;SMPD1
prerank,GO_Biological_Process_2021__negative regulation of type I interferon production (GO:0032480),-0.9830562349183048,-1.309980009221568,0.31666666666666665,1.0,1.0,1/43,1.70%,HERC5
prerank,GO_Biological_Process_2021__positive regulation of epidermal growth factor receptor signaling pathway (GO:0045742),0.9928784799723769,1.309960643395729,0.112,1.0,1.0,1/32,0.71%,PLAUR
prerank,GO_Biological_Process_2021__regulation of innate immune response (GO:0045088),-0.9764516831770843,-1.3098724668488446,0.31451612903225806,1.0,1.0,1/61,2.36%,IRAK3
prerank,Reactome_2022__Export Of Viral Ribonucleoproteins From Nucleus R-HSA-168274,0.9895291097913456,1.3098088519910014,0.1532258064516129,1.0,1.0,1/36,1.05%,NUP210
prerank,GO_Biological_Process_2021__regulation of generation of precursor metabolites and energy (GO:0043467),0.9775514337188372,1.3097737530231837,0.416,1.0,1.0,2/50,2.25%,NUP210;SLC2A6
prerank,GO_Biological_Process_2021__negative regulation of fat cell differentiation (GO:0045599),0.981368898475527,1.3093717842491888,0.3416666666666667,1.0,1.0,1/35,1.86%,ZFPM1
prerank,WikiPathway_2021_Human__Neovascularisation processes WP4331,0.9831810529349827,1.3091119290257118,0.2920353982300885,1.0,1.0,2/37,1.69%,NOTCH3;SMAD9
prerank,GO_Biological_Process_2021__regulation of interleukin-2 production (GO:0032663),0.9771716984268046,1.3088589319236152,0.376,1.0,1.0,4/46,2.29%,CD4;HOMER3;ANXA1;CD86
prerank,GO_Biological_Process_2021__negative regulation of neurogenesis (GO:0050768),0.9867207883259871,1.3086528462148264,0.2661290322580645,1.0,1.0,1/33,1.33%,THY1
prerank,Elsevier_Pathway_Collection__Dilated Cardiomyopathy,-0.9807743535595692,-1.3082137853423612,0.168,1.0,1.0,2/63,1.93%,MAP2K6;MMP2
prerank,GO_Biological_Process_2021__regulation of tyrosine phosphorylation of STAT protein (GO:0042509),0.9942946272784227,1.308130423387702,0.034482758620689655,1.0,1.0,1/56,0.57%,PTPN2
prerank,GO_Biological_Process_2021__response to growth factor (GO:0070848),-0.9796003401998443,-1.3079277612492393,0.3387096774193548,1.0,1.0,2/40,2.05%,MAP2K5;KLF4
prerank,GO_Biological_Process_2021__cellular response to radiation (GO:0071478),-0.9763271441388679,-1.307886696250457,0.4881889763779528,1.0,1.0,1/36,2.37%,INTS7
prerank,Reactome_2022__Separation Of Sister Chromatids R-HSA-2467813,0.8342160695974687,1.3078042212271086,0.04132231404958678,1.0,1.0,7/165,1.78%,HDAC8;CENPE;NDC80;CENPA;PSMB9;UBE2C;ERCC6L
prerank,Reactome_2022__XBP1(S) Activates Chaperone Genes R-HSA-381038,0.9784743109859232,1.3075808535308016,0.3511450381679389,1.0,1.0,1/46,2.15%,ACD
prerank,"GO_Biological_Process_2021__mRNA splicing, via spliceosome (GO:0000398)",0.7758786752941064,1.3074845297266808,0.058333333333333334,1.0,1.0,4/270,1.36%,PRPF40A;CDC5L;RAVER2;SF3A2
prerank,Reactome_2022__RNA Polymerase I Promoter Escape R-HSA-73772,0.9922182724372034,1.3073650752490669,0.072,1.0,1.0,1/49,0.78%,TAF1B
prerank,Reactome_2022__Deactivation Of Beta-Catenin Transactivating Complex R-HSA-3769402,-0.9905665629025628,-1.3068310495906632,0.13008130081300814,1.0,1.0,1/40,0.95%,TLE4
prerank,Elsevier_Pathway_Collection__Proteins Involved in Cystic Fibrosis,0.9765447750413715,1.306801658914761,0.4,1.0,1.0,4/57,2.36%,PTGS2;HGF;GSTM3;STX1A
prerank,KEGG_2021_Human__Amino sugar and nucleotide sugar metabolism,0.9772851630514244,1.306206506450643,0.41964285714285715,1.0,1.0,4/48,2.28%,UAP1L1;CYB5R2;HK2;HKDC1
prerank,Elsevier_Pathway_Collection__BDKRB1/2 -> Prostaglandin Generation,-0.9799589701832767,-1.3060194695740508,0.44,1.0,1.0,2/26,2.01%,MAP2K6;BDKRB2
prerank,WikiPathway_2021_Human__miRNAs involvement in the immune response in sepsis WP4329,0.9979180268237545,1.3059687540737532,0.0,1.0,1.0,1/36,0.21%,TRAF3
prerank,Elsevier_Pathway_Collection__Proerythroblast -> Erythrocyte Surface Expression Markers,0.9874861675149398,1.3059609001803647,0.13768115942028986,1.0,1.0,2/47,1.26%,ITGA4;SYK
prerank,GO_Biological_Process_2021__aerobic respiration (GO:0009060),-0.9924217827600943,-1.3057000919494792,0.19047619047619047,1.0,1.0,1/21,0.76%,MTFR1
prerank,GO_Biological_Process_2021__organelle fission (GO:0048285),-0.9924201801424437,-1.3054804224824657,0.1015625,1.0,1.0,1/26,0.76%,MTFR1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Presbycusis,0.9800523617373247,1.3053076407597415,0.375,1.0,1.0,1/43,1.99%,APOE
prerank,GO_Biological_Process_2021__DNA recombination (GO:0006310),0.9922989120999858,1.3052393674683653,0.10084033613445378,1.0,1.0,1/38,0.77%,MSH2
prerank,Reactome_2022__NEP/NS2 Interacts With Cellular Export Machinery R-HSA-168333,0.9895295750452324,1.3049909062252911,0.16,1.0,1.0,1/35,1.05%,NUP210
prerank,Reactome_2022__Aspirin ADME R-HSA-9749641,-0.9877986710026662,-1.3048424942564054,0.19148936170212766,1.0,1.0,3/41,1.23%,GLYAT;CYP2C8;ACSM2B
prerank,Reactome_2022__Association Of TriC/CCT With Target Proteins During Biosynthesis R-HSA-390471,0.9849524319343186,1.3047464646079765,0.2558139534883721,1.0,1.0,2/36,1.51%,KIF13A;WRAP53
prerank,Elsevier_Pathway_Collection__Cardiomyocyte Dysfunction,-0.9978010539334257,-1.3045789698677117,0.007462686567164179,1.0,1.0,1/42,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__triglyceride biosynthetic process (GO:0019432),0.8338410670931883,1.304438082499943,0.472,1.0,1.0,5/18,2.35%,GPAT4;PNPLA3;MOGAT2;LPIN3;GK
prerank,KEGG_2021_Human__Glycosphingolipid biosynthesis,0.9806368969910377,1.3038563317095557,0.35658914728682173,1.0,1.0,2/43,1.94%,ST3GAL1;FUT6
prerank,Reactome_2022__Keratinization R-HSA-6805567,0.9864784516165279,1.3034511053782103,0.14166666666666666,1.0,1.0,2/59,1.36%,PKP4;KRT23
prerank,GO_Biological_Process_2021__positive regulation of synaptic transmission (GO:0050806),-0.9889049736831076,-1.3028123529011275,0.11510791366906475,1.0,1.0,4/63,1.13%,PTK2B;APP;GRIN2B;DTNBP1
prerank,GO_Biological_Process_2021__positive regulation of mitotic cell cycle (GO:0045931),-0.9919198247172483,-1.3027767086852953,0.1796875,1.0,1.0,1/27,0.81%,APP
prerank,Reactome_2022__Inwardly Rectifying K+ Channels R-HSA-1296065,0.9766838415784534,1.3025517468381527,0.5403225806451613,1.0,1.0,3/32,2.34%,KCNJ10;GNB5;GNG2
prerank,Reactome_2022__GABA Receptor Activation R-HSA-977443,0.9766665147427189,1.302516711816707,0.35714285714285715,1.0,1.0,3/50,2.34%,KCNJ10;GNB5;GNG2
prerank,Reactome_2022__Nuclear Import Of Rev Protein R-HSA-180746,0.9895302411380537,1.302441158242723,0.13821138211382114,1.0,1.0,1/34,1.05%,NUP210
prerank,GO_Biological_Process_2021__negative regulation of cold-induced thermogenesis (GO:0120163),-0.9886052368644679,-1.3022906471740532,0.16666666666666666,1.0,1.0,3/44,1.15%,MAP2K6;ADAMTS5;RB1
prerank,Reactome_2022__SUMOylation Of SUMOylation Proteins R-HSA-4085377,0.9895296438121417,1.3019344541211055,0.18110236220472442,1.0,1.0,1/35,1.05%,NUP210
prerank,TRRUST_Transcription_Factors_2019__ETS1 human,-0.9776852919572377,-1.3016337096050123,0.2748091603053435,1.0,1.0,2/70,2.24%,BMP4;TNFSF14
prerank,GO_Biological_Process_2021__positive regulation of leukocyte chemotaxis (GO:0002690),0.9794397805831018,1.301506442495166,0.2923076923076923,1.0,1.0,4/50,2.07%,PTK2;MOSPD2;F7;SERPINE1
prerank,Reactome_2022__Effects Of PIP2 Hydrolysis R-HSA-114508,-0.9863810006562598,-1.3013308761830653,0.288135593220339,1.0,1.0,1/25,1.37%,RASGRP2
prerank,Reactome_2022__Glyoxylate Metabolism And Glycine Degradation R-HSA-389661,-0.982027013377319,-1.3011652765950952,0.3865546218487395,1.0,1.0,1/30,1.80%,HAO1
prerank,KEGG_2021_Human__Mineral absorption,-0.9781500288520968,-1.3010482212910803,0.2777777777777778,1.0,1.0,1/58,2.19%,VDR
prerank,GO_Biological_Process_2021__regulation of extrinsic apoptotic signaling pathway in absence of ligand (GO:2001239),-0.9763418163401548,-1.3010196329880406,0.5419847328244275,1.0,1.0,2/27,2.37%,MAP2K5;IFI6
prerank,Reactome_2022__IRE1alpha Activates Chaperones R-HSA-381070,0.9785165655154289,1.3009920314671999,0.3387096774193548,1.0,1.0,2/48,2.15%,ERN1;ACD
prerank,Reactome_2022__Glucagon-type Ligand Receptors R-HSA-420092,0.976645528188651,1.300934784264941,0.5378787878787878,1.0,1.0,2/30,2.34%,GNB5;GNG2
prerank,Reactome_2022__ROS And RNS Production In Phagocytes R-HSA-1222556,0.978448876206929,1.300735065687564,0.525,1.0,1.0,1/31,2.16%,CYBA
prerank,Reactome_2022__Defective Homologous Recombination Repair (HRR) Due To BRCA2 Loss Of Function R-HSA-9701190,0.988488137441268,1.3006523514339483,0.1891891891891892,1.0,1.0,1/41,1.15%,BRIP1
prerank,WikiPathway_2021_Human__miRNA regulation of prostate cancer signaling pathways WP3981,-0.9878791287387966,-1.3004051102493723,0.2288135593220339,1.0,1.0,2/33,1.22%,AKT3;CREBBP
prerank,GO_Biological_Process_2021__regulation of ATP metabolic process (GO:1903578),0.9775456178164219,1.3003883588120242,0.3779527559055118,1.0,1.0,2/56,2.25%,NUP210;SLC2A6
prerank,GO_Biological_Process_2021__negative regulation of proteolysis (GO:0045861),0.9814824713133176,1.299974350195026,0.3389830508474576,1.0,1.0,1/37,1.85%,TIMP3
prerank,Elsevier_Pathway_Collection__IDO1 in Cancer Immune Escape,0.9770308149501622,1.2995689794417449,0.3333333333333333,1.0,1.0,1/61,2.29%,CD86
prerank,Reactome_2022__RHO GTPases Activate PKNs R-HSA-5625740,0.9912185430490277,1.2995211271380083,0.09565217391304348,1.0,1.0,2/52,0.88%,YWHAQ;PPP1R12A
prerank,GO_Biological_Process_2021__positive regulation of T cell differentiation (GO:0045582),-0.9758297653589837,-1.299250463914846,0.5,1.0,1.0,5/41,2.44%,VNN1;SHH;GLI3;RHOH;ZAP70
prerank,Reactome_2022__Amino Acids Regulate mTORC1 R-HSA-9639288,0.9935670433801979,1.2990562454291568,0.08270676691729323,1.0,1.0,2/52,0.65%,FNIP2;FNIP1
prerank,Elsevier_Pathway_Collection__beta-Cell Destruction through Cytokines in Diabetes Mellitus,-0.9977975881198742,-1.2988173350630352,0.02564102564102564,1.0,1.0,1/57,0.23%,MAP2K6
prerank,Elsevier_Pathway_Collection__Adipokines Production by Adipocyte,0.9787869078239171,1.298804891115555,0.3669064748201439,1.0,1.0,2/44,2.12%,SERPINE1;RBP4
prerank,GO_Biological_Process_2021__cell junction assembly (GO:0034329),0.86193752096214,1.2986827493879147,0.10084033613445378,1.0,1.0,8/95,2.29%,CDH2;TJP1;PKP4;GJC1;FBLIM1;CDH1;FN1;FLNA
prerank,GO_Biological_Process_2021__positive regulation of response to stimulus (GO:0048584),-0.9856356999074292,-1.2984434549099415,0.14393939393939395,1.0,1.0,1/44,1.44%,ECHDC3
prerank,Elsevier_Pathway_Collection__VEGFA Dependent Angiogenesis in Cancer,0.9858952820476332,1.2983578344575304,0.15151515151515152,1.0,1.0,1/60,1.41%,MYCN
prerank,GO_Biological_Process_2021__bone development (GO:0060348),0.995685813786445,1.298027750842214,0.046875,1.0,1.0,1/35,0.43%,LRP5
prerank,GO_Biological_Process_2021__cytoplasmic microtubule organization (GO:0031122),0.9825179438500753,1.2980228300816579,0.232,1.0,1.0,4/53,1.76%,CLIP2;DLG1;CAMSAP3;STMN3
prerank,GO_Biological_Process_2021__glycolipid biosynthetic process (GO:0009247),-0.9772541132397806,-1.2977649758442633,0.47244094488188976,1.0,1.0,2/38,2.28%,PIGZ;PGAP4
prerank,GO_Biological_Process_2021__transition metal ion transport (GO:0000041),0.9761028272420693,1.2975536375313272,0.5149253731343284,1.0,1.0,2/34,2.39%,SLC30A10;MELTF
prerank,GO_Biological_Process_2021__mononuclear cell differentiation (GO:1903131),-0.9787295703817157,-1.297378706674874,0.4740740740740741,1.0,1.0,2/24,2.14%,BMP4;PIR
prerank,Elsevier_Pathway_Collection__Macrophage Dysfunction,0.9838375914210634,1.2973549776340934,0.3253968253968254,1.0,1.0,5/37,1.63%,ERN1;IGF2R;NOD2;CD4;LAMP2
prerank,Elsevier_Pathway_Collection__AGTR1 -> ARRB1/ARRB2 Signaling,-0.9766490097249627,-1.2970770281640396,0.5230769230769231,1.0,1.0,1/25,2.34%,VAV1
prerank,WikiPathway_2021_Human__Prostaglandin Synthesis and Regulation WP98,0.9818284053236004,1.2969308671429824,0.26153846153846155,1.0,1.0,2/43,1.82%,ANXA1;PTGS2
prerank,"GO_Biological_Process_2021__regulation of DNA-templated transcription, elongation (GO:0032784)",0.9881516203615461,1.2969252884053075,0.2992125984251969,1.0,1.0,2/26,1.19%,ZNF326;HTATSF1
prerank,KEGG_2021_Human__Glycosaminoglycan biosynthesis,0.9921825175367602,1.296700215678927,0.058823529411764705,1.0,1.0,3/51,0.79%,HS2ST1;ST3GAL1;CHST11
prerank,"Reactome_2022__Base-Excision Repair, AP Site Formation R-HSA-73929",0.9784839714921629,1.2966629945029982,0.44285714285714284,1.0,1.0,1/34,2.15%,ACD
prerank,WikiPathway_2021_Human__ATM Signaling Pathway WP2516,0.9957629634776594,1.295904880024884,0.07964601769911504,1.0,1.0,1/39,0.43%,CREB1
prerank,WikiPathway_2021_Human__Gastric Cancer Network 2 WP2363,0.9792248679970118,1.2950959091668868,0.40625,1.0,1.0,4/31,2.09%,CEBPZ;CD48;UBE2C;COL9A3
prerank,GO_Biological_Process_2021__regulation of cardiac conduction (GO:1903779),-0.9843608854091256,-1.2949945996595873,0.23809523809523808,1.0,1.0,1/49,1.57%,FXYD6
prerank,GO_Biological_Process_2021__negative regulation of DNA binding (GO:0043392),-0.9903796528922236,-1.2944024397867446,0.18699186991869918,1.0,1.0,1/30,0.97%,TNKS
prerank,Reactome_2022__Glucagon Signaling In Metabolic Regulation R-HSA-163359,0.9766041031836761,1.2940283099346426,0.5081967213114754,1.0,1.0,1/30,2.34%,GNG2
prerank,Elsevier_Pathway_Collection__DNA Persistent Repair Inhibits mTOR Signaling,0.9898350466323734,1.29391586545928,0.1440677966101695,1.0,1.0,1/40,1.02%,ATR
prerank,"GO_Biological_Process_2021__RNA splicing, via transesterification reactions with bulged adenosine as nucleophile (GO:0000377)",0.7758914044034384,1.2938862867159466,0.058333333333333334,1.0,1.0,4/247,1.36%,PRPF40A;CDC5L;RAVER2;SF3A2
prerank,GO_Biological_Process_2021__negative regulation of secretion by cell (GO:1903531),0.9801433318859076,1.2938087652510823,0.36363636363636365,1.0,1.0,3/35,1.99%,ANXA1;DRD4;APOE
prerank,GO_Biological_Process_2021__positive regulation of reproductive process (GO:2000243),-0.985109427784536,-1.2934287354034215,0.29411764705882354,1.0,1.0,1/28,1.49%,INHBB
prerank,Elsevier_Pathway_Collection__SIRT1 Signaling in Aging,-0.9791387500647074,-1.293425296938069,0.4015748031496063,1.0,1.0,2/40,2.09%,ADAM10;PML
prerank,MSigDB_Hallmark_2020__E2F Targets,0.7712503339727717,1.2925940138756726,0.03278688524590164,1.0,1.0,9/199,2.38%,MMS22L;CENPE;GINS1;MSH2;POLE4;MELK;MKI67;DEPDC1;RRM2
prerank,GO_Biological_Process_2021__cardiac muscle cell action potential (GO:0086001),-0.9756049849920452,-1.2925254473616163,0.5714285714285714,1.0,1.0,1/28,2.44%,KCNE1
prerank,GO_Biological_Process_2021__sensory perception (GO:0007600),0.9768667376651894,1.2920473228739493,0.4881889763779528,1.0,1.0,1/36,2.31%,MYO7A
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Glomerulonephritis,-0.9798887124177093,-1.2918634279254737,0.3089430894308943,1.0,1.0,1/54,2.01%,BDKRB2
prerank,GO_Biological_Process_2021__regulation of protein targeting to mitochondrion (GO:1903214),-0.9825963593596847,-1.2917690436495801,0.288,1.0,1.0,1/38,1.74%,ABLIM3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Stem Cell Exhaustion in Aging,-0.9791423143568848,-1.2911421931779905,0.4188034188034188,1.0,1.0,2/36,2.09%,RB1;PML
prerank,WikiPathway_2021_Human__Vitamin A and carotenoid metabolism WP716,0.9764456797759538,1.2909334400664985,0.5043478260869565,1.0,1.0,2/38,2.36%,RBP4;SULT1A1
prerank,GO_Biological_Process_2021__regulation of intracellular estrogen receptor signaling pathway (GO:0033146),0.9894163598924279,1.2907336275194252,0.18181818181818182,1.0,1.0,1/31,1.06%,STRN3
prerank,Reactome_2022__Cooperation Of Prefoldin And TriC/CCT In Actin And Tubulin Folding R-HSA-389958,0.9785277473922337,1.2901771587038702,0.460431654676259,1.0,1.0,1/29,2.15%,TUBA1A
prerank,GO_Biological_Process_2021__replication fork processing (GO:0031297),0.9898772577788965,1.289435943557754,0.19130434782608696,1.0,1.0,2/38,1.02%,MMS22L;ATR
prerank,Elsevier_Pathway_Collection__RAS/RAF/MAPK Signaling Activation by Blocking of Tumor Suppressors,-0.9830950533644892,-1.2891596044523936,0.32,1.0,1.0,1/41,1.69%,RASSF5
prerank,Reactome_2022__Homologous DNA Pairing And Strand Exchange R-HSA-5693579,0.9884869655477403,1.2883574547440546,0.1834862385321101,1.0,1.0,1/43,1.15%,BRIP1
prerank,GO_Biological_Process_2021__cellular respiration (GO:0045333),-0.9917612872244137,-1.2878709394493069,0.08870967741935484,1.0,1.0,2/42,0.83%,MTFR1;NDUFS4
prerank,GO_Biological_Process_2021__positive regulation of interferon-beta production (GO:0032728),-0.99276449111138,-1.2878415763641402,0.1,1.0,1.0,2/35,0.73%,OAS1;TOMM70
prerank,GO_Biological_Process_2021__acylglycerol biosynthetic process (GO:0046463),0.8338374311689715,1.287793650401996,0.4608695652173913,1.0,1.0,5/22,2.35%,GPAT4;PNPLA3;MOGAT2;LPIN3;GK
prerank,Reactome_2022__G Alpha (Z) Signaling Events R-HSA-418597,0.9766331308589369,1.2874378836027307,0.4444444444444444,1.0,1.0,2/43,2.34%,GNB5;GNG2
prerank,WikiPathway_2021_Human__Parkinson's disease pathway WP2371,0.9802578356845331,1.2872843396487526,0.41025641025641024,1.0,1.0,2/36,1.98%,CASP7;MAPK13
prerank,Reactome_2022__GPER1 Signaling R-HSA-9634597,0.976637269769457,1.2872829150809066,0.4745762711864407,1.0,1.0,2/39,2.34%,GNB5;GNG2
prerank,Elsevier_Pathway_Collection__Myocardial Remodeling,-0.9807852499824565,-1.28665032945971,0.31932773109243695,1.0,1.0,2/51,1.93%,PTK2B;MMP2
prerank,GO_Biological_Process_2021__regulation of receptor signaling pathway via JAK-STAT (GO:0046425),-0.9802552424378228,-1.285801759101654,0.4322033898305085,1.0,1.0,2/38,1.98%,CYP1B1;IL10RA
prerank,Reactome_2022__Prefoldin Mediated Transfer Of Substrate To CCT/TriC R-HSA-389957,0.9785319674671363,1.2856980450229192,0.48872180451127817,1.0,1.0,1/25,2.15%,TUBA1A
prerank,GO_Biological_Process_2021__establishment of protein localization to plasma membrane (GO:0061951),0.9789907107612774,1.2853702795110111,0.4214876033057851,1.0,1.0,4/35,2.11%,RAB7A;KIF13A;AMN;OPTN
prerank,Reactome_2022__Presynaptic Phase Of Homologous DNA Pairing And Strand Exchange R-HSA-5693616,0.9884888515705036,1.285342172862685,0.1926605504587156,1.0,1.0,1/40,1.15%,BRIP1
prerank,Elsevier_Pathway_Collection__Goblet-Cell Related Mucus Secretion in Asthma,0.9818276628484662,1.2849382036629535,0.31932773109243695,1.0,1.0,2/44,1.82%,IL13RA1;PTGS2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Osteopetrosis,-0.9760984302836619,-1.2843882404587357,0.5079365079365079,1.0,1.0,2/40,2.40%,PTK2B;SPI1
prerank,GO_Biological_Process_2021__signal transduction by p53 class mediator (GO:0072331),0.9813344997425566,1.284311545514437,0.4017094017094017,1.0,1.0,1/31,1.87%,BOK
prerank,GO_Biological_Process_2021__regulation of natural killer cell mediated cytotoxicity (GO:0042269),-0.9795303089565367,-1.2838863374048262,0.453125,1.0,1.0,1/28,2.05%,PIK3R6
prerank,GO_Biological_Process_2021__regulation of microtubule polymerization (GO:0031113),0.9857973992506586,1.2834549185339912,0.2421875,1.0,1.0,2/39,1.43%,TBCD;CAMSAP3
prerank,GO_Biological_Process_2021__chromatin assembly (GO:0031497),0.9976824981188828,1.2833319788785047,0.047244094488188976,1.0,1.0,1/56,0.23%,NAA60
prerank,Reactome_2022__Signaling By FGFR4 R-HSA-5654743,0.9763320693960723,1.2833011357854982,0.552,1.0,1.0,2/36,2.37%,KLB;FGF1
prerank,GO_Biological_Process_2021__establishment of protein localization to extracellular region (GO:0035592),-0.9767102188580491,-1.2831217911651494,0.4744525547445255,1.0,1.0,2/44,2.34%,TANGO6;OLFM2
prerank,Reactome_2022__RET Signaling R-HSA-8853659,-0.9842969408073705,-1.2830347834018583,0.26865671641791045,1.0,1.0,2/38,1.58%,PIK3CB;GRB10
prerank,GO_Biological_Process_2021__response to light stimulus (GO:0009416),0.993141119419588,1.2828821932216161,0.06976744186046512,1.0,1.0,1/50,0.69%,BRSK1
prerank,GO_Biological_Process_2021__regulation of pathway-restricted SMAD protein phosphorylation (GO:0060393),-0.9850562713613175,-1.2828318324158483,0.16666666666666666,1.0,1.0,2/54,1.50%,INHBB;BMP4
prerank,GO_Biological_Process_2021__defense response to symbiont (GO:0140546),-0.8648413827794678,-1.2827373306020426,0.12598425196850394,1.0,1.0,6/115,2.42%,OAS1;IFI44L;SLFN11;OASL;IFI6;RTP4
prerank,GO_Biological_Process_2021__negative regulation of protein modification by small protein conjugation or removal (GO:1903321),0.9763962696754233,1.2823665217337876,0.456,1.0,1.0,3/51,2.37%,HDAC8;SH3RF2;PRR7
prerank,GO_Biological_Process_2021__regulation of cell-cell adhesion (GO:0022407),0.9829852018435152,1.2823035847079483,0.27906976744186046,1.0,1.0,2/42,1.71%,PTK2;CDH1
prerank,MSigDB_Oncogenic_Signatures__KRAS.PROSTATE UP.V1 DN,0.8566469468185794,1.2822879369872398,0.11403508771929824,1.0,1.0,8/116,1.46%,EPHX2;PPP1R9A;ACSS3;IGFBP3;PTPRH;CGREF1;CD48;CADM4
prerank,GO_Biological_Process_2021__vasculogenesis (GO:0001570),-0.9857988592858842,-1.2820312917767223,0.26666666666666666,1.0,1.0,1/32,1.43%,SHH
prerank,Reactome_2022__Base Excision Repair R-HSA-73884,0.9776580399681265,1.281461773575686,0.3492063492063492,1.0,1.0,4/62,2.24%,SLC19A1;POLE4;ACD;LRIG1
prerank,TRRUST_Transcription_Factors_2019__ETS2 human,-0.980840148198242,-1.2806639129898572,0.43448275862068964,1.0,1.0,3/31,1.93%,APP;CD163;MMP2
prerank,KEGG_2021_Human__RIG-I-like receptor signaling pathway,0.980243832792927,1.2805834267270706,0.29457364341085274,1.0,1.0,2/53,1.98%,TRAF3;MAPK13
prerank,GO_Biological_Process_2021__negative regulation of G0 to G1 transition (GO:0070317),0.9762551803271398,1.2805227687830105,0.528,1.0,1.0,2/37,2.38%,TFDP2;RRM2
prerank,Elsevier_Pathway_Collection__Diabetes Induced Periodontitis,-0.997804167348091,-1.2804563600670025,0.044642857142857144,1.0,1.0,1/30,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of neuron death (GO:1901216),-0.9769395429771248,-1.2801231135936586,0.43410852713178294,1.0,1.0,2/46,2.31%,GRIN2B;EFNB2
prerank,Elsevier_Pathway_Collection__Vascular Smooth Muscle Cell/Pericyte Migration and Proliferation,-0.976665611097967,-1.280043678313751,0.44755244755244755,1.0,1.0,2/48,2.34%,CD44;VAV1
prerank,GO_Biological_Process_2021__positive regulation of small GTPase mediated signal transduction (GO:0051057),-0.976644096579672,-1.2799912361100605,0.5528455284552846,1.0,1.0,1/28,2.34%,VAV1
prerank,Reactome_2022__SUMOylation Of Chromatin Organization Proteins R-HSA-4551638,0.9869030864214778,1.2792217013273448,0.14049586776859505,1.0,1.0,2/56,1.31%,NUP210;CBX2
prerank,Reactome_2022__Chemokine Receptors Bind Chemokines R-HSA-380108,0.9857836823938375,1.2789463302989872,0.21008403361344538,1.0,1.0,1/51,1.42%,CX3CL1
prerank,Elsevier_Pathway_Collection__Peripheral Tissue Microangiopathy,0.9773613366330942,1.2787366847147337,0.42857142857142855,1.0,1.0,2/46,2.27%,SERPINE1;FN1
prerank,Elsevier_Pathway_Collection__beta-Cell Granules Exocytois,-0.8308473462153466,-1.2780520792535375,0.45185185185185184,1.0,1.0,3/22,1.54%,STXBP5;RAP1A;RAPGEF3
prerank,GO_Biological_Process_2021__sprouting angiogenesis (GO:0002040),-0.9770515009665196,-1.2771826776989148,0.3548387096774194,1.0,1.0,5/52,2.31%,PTK2B;BMP4;ADGRA2;TEK;EFNB2
prerank,GO_Biological_Process_2021__mitochondrial transport (GO:0006839),-0.9927148835892701,-1.2771132021094285,0.07317073170731707,1.0,1.0,1/55,0.73%,TOMM70
prerank,GO_Biological_Process_2021__defense response to virus (GO:0051607),-0.8648327492881371,-1.2770920254369276,0.12096774193548387,1.0,1.0,6/124,2.42%,OAS1;IFI44L;SLFN11;OASL;IFI6;RTP4
prerank,GO_Biological_Process_2021__negative regulation of protein tyrosine kinase activity (GO:0061099),0.9867679894967029,1.2768744227600757,0.26548672566371684,1.0,1.0,2/24,1.33%,ZGPAT;THY1
prerank,Reactome_2022__Transport Of Ribonucleoproteins Into Host Nucleus R-HSA-168271,0.9895297070330731,1.2768711092557998,0.15447154471544716,1.0,1.0,1/35,1.05%,NUP210
prerank,WikiPathway_2021_Human__Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway WP2203,-0.9830216809685491,-1.2768479236770924,0.24060150375939848,1.0,1.0,3/47,1.71%,TEC;HCK;STAT5A
prerank,GO_Biological_Process_2021__mitotic spindle assembly (GO:0090307),0.9759801757516068,1.276796367785587,0.5083333333333333,1.0,1.0,3/43,2.41%,KIF23;FLNA;KIF3B
prerank,Reactome_2022__Cleavage Of Damaged Pyrimidine R-HSA-110329,0.9784860051746189,1.2758538101616923,0.4666666666666667,1.0,1.0,1/32,2.15%,ACD
prerank,Reactome_2022__B-WICH Complex Positively Regulates rRNA Expression R-HSA-5250924,0.9922187525098869,1.275279926108218,0.12,1.0,1.0,1/48,0.78%,TAF1B
prerank,GO_Biological_Process_2021__glutathione derivative metabolic process (GO:1901685),-0.7874249059984211,-1.2750203332655914,0.4222222222222222,1.0,1.0,2/20,1.27%,GSTA1;GSTA2
prerank,GO_Biological_Process_2021__glutathione derivative biosynthetic process (GO:1901687),-0.7874249059984211,-1.2750203332655914,0.4222222222222222,1.0,1.0,2/20,1.27%,GSTA1;GSTA2
prerank,GO_Biological_Process_2021__stress-activated MAPK cascade (GO:0051403),0.9802766794305274,1.2742625000206833,0.2920353982300885,1.0,1.0,3/62,1.98%,IRAK2;NOD2;MAPK13
prerank,GO_Biological_Process_2021__regulation of activated T cell proliferation (GO:0046006),-0.9775233409216109,-1.2741348284367606,0.4961832061068702,1.0,1.0,1/33,2.25%,CD274
prerank,Elsevier_Pathway_Collection__IGF1R -> MEF/MYOD/MYOG Signaling,-0.9768034068486968,-1.2737524525575419,0.5746268656716418,1.0,1.0,5/29,2.34%,PTK2B;PAK2;MAP2K6;MAP2K5;VAV1
prerank,Reactome_2022__Signaling By Erythropoietin R-HSA-9006335,-0.9767305179534466,-1.2737488342833831,0.5555555555555556,1.0,1.0,3/24,2.34%,PIK3CB;STAT5A;VAV1
prerank,Reactome_2022__Regulation Of Complement Cascade R-HSA-977606,-0.9838702584540443,-1.272997623614805,0.24166666666666667,1.0,1.0,4/45,1.63%,C4BPA;PROS1;C5AR2;C1R
prerank,Elsevier_Pathway_Collection__Neutrophil Recruitment and Priming,-0.9829696950521012,-1.2722642712904466,0.1968503937007874,1.0,1.0,2/64,1.71%,MAP2K6;STAT5A
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect in Migraine Type 1,0.7947637435496359,1.2718935022595095,0.4496124031007752,1.0,1.0,4/19,2.36%,SLC38A3;GLS;SLC38A1;STX1A
prerank,GO_Biological_Process_2021__regulation of heart rate by cardiac conduction (GO:0086091),-0.9755941697006485,-1.270354724220406,0.5655737704918032,1.0,1.0,1/37,2.44%,KCNE1
prerank,Reactome_2022__Interleukin-37 Signaling R-HSA-9008059,0.7321564013862791,1.2687744191047061,0.3923076923076923,1.0,1.0,2/20,1.79%,PTPN2;SIGIRR
prerank,GO_Biological_Process_2021__regulation of cytokine production involved in inflammatory response (GO:1900015),0.988413747501695,1.2681966689010813,0.25,1.0,1.0,3/42,1.17%,PPARA;NOD2;MEFV
prerank,GO_Biological_Process_2021__antimicrobial humoral immune response mediated by antimicrobial peptide (GO:0061844),-0.9762452462201596,-1.2675619735772716,0.456,1.0,1.0,2/47,2.38%,FAM3A;HRG
prerank,GO_Biological_Process_2021__glycosaminoglycan biosynthetic process (GO:0006024),0.885150727096075,1.2675280939980411,0.18110236220472442,1.0,1.0,5/94,1.50%,HS2ST1;ST3GAL1;SLC35D2;CHST11;HAS3
prerank,Reactome_2022__Transcriptional Regulation By E2F6 R-HSA-8953750,0.9762592129128059,1.2665640105390106,0.5775862068965517,1.0,1.0,2/33,2.38%,TFDP2;RRM2
prerank,GO_Biological_Process_2021__intracellular protein transmembrane transport (GO:0065002),-0.9862558789234946,-1.2662036969664365,0.1984126984126984,1.0,1.0,2/44,1.38%,TOMM70;SEC61A2
prerank,WikiPathway_2021_Human__MAPK Signaling Pathway WP382,-0.7723092990848968,-1.266097530325622,0.05,1.0,1.0,12/228,2.39%,PAK2;MAP2K6;RASA2;RAP1B;AKT3;MAP2K5;RAP1A;RASGRP2;NTF3;DUSP4;RASGRP3;MAP4K1
prerank,Reactome_2022__Immunoregulatory Interactions Between A Lymphoid And A non-Lymphoid Cell R-HSA-198933,0.8259897137273847,1.2656674050170529,0.12727272727272726,1.0,1.0,6/112,1.42%,LILRA2;CD300A;CD33;ITGA4;ITGAL;SIGLEC7
prerank,Elsevier_Pathway_Collection__IL17 Signaling in Psoriasis,-0.9761025976697103,-1.2655081263204229,0.515625,1.0,1.0,2/36,2.40%,MAP2K6;SPI1
prerank,Elsevier_Pathway_Collection__ANGPT/TEK Maintains Endothelial Cell Quiescence in Cancer,-0.9810613072857313,-1.2653572699573008,0.362962962962963,1.0,1.0,1/35,1.90%,TEK
prerank,KEGG_2021_Human__Toxoplasmosis,-0.8523856278689037,-1.2647910955451658,0.14615384615384616,1.0,1.0,5/109,2.27%,MAP2K6;AKT3;IL10RA;PIK3R6;CIITA
prerank,WikiPathway_2021_Human__Estrogen metabolism WP697,-0.8375332949839218,-1.2646307464978057,0.5037593984962406,1.0,1.0,4/17,1.98%,GSTA1;STS;CYP1B1;CYP1A2
prerank,GO_Biological_Process_2021__DNA duplex unwinding (GO:0032508),0.9773942987455799,1.263918201590815,0.423728813559322,1.0,1.0,2/51,2.26%,ANXA1;PIF1
prerank,Reactome_2022__MTOR Signaling R-HSA-165159,0.9890289264696787,1.2633963548328013,0.16964285714285715,1.0,1.0,2/41,1.10%,CAB39;PRKAA2
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Pyelonephritis,0.9793282005244742,1.2632859264010923,0.416,1.0,1.0,1/37,2.07%,SERPINE1
prerank,GO_Biological_Process_2021__regulation of G0 to G1 transition (GO:0070316),0.9762520918216594,1.2625944501583795,0.5245901639344263,1.0,1.0,2/40,2.38%,TFDP2;RRM2
prerank,Elsevier_Pathway_Collection__Apoptotic Keratinocytes Clearance Recession in Systemic Lupus Erythematosus,-0.9766263363652048,-1.2624676404798854,0.4460431654676259,1.0,1.0,1/44,2.34%,VAV1
prerank,KEGG_2021_Human__Long-term potentiation,-0.9811280344151628,-1.2613529010259972,0.26277372262773724,1.0,1.0,6/59,1.91%,RAP1B;GRIN2B;RAP1A;CREBBP;RAPGEF3;PLCB4
prerank,TRRUST_Transcription_Factors_2019__NRF1 mouse,-0.7893482495431652,-1.2611673334693259,0.44029850746268656,1.0,1.0,2/18,1.08%,NR3C1;GRIN2B
prerank,Reactome_2022__HCMV Infection R-HSA-9609646,0.8467219712101817,1.2610571173010447,0.128,1.0,1.0,3/107,1.05%,TBL1X;CREB1;NUP210
prerank,GO_Biological_Process_2021__regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043122),0.7733268702363849,1.2602481097210536,0.058333333333333334,1.0,1.0,13/217,2.29%,NEK6;TRAF3;NOD2;LPAR1;CD4;TSPAN6;APOL3;PLEKHG5;CX3CL1;EDA2R;OPTN;UNC5CL;FLNA
prerank,Reactome_2022__Pyruvate Metabolism R-HSA-70268,0.9845280123342678,1.2596414102402844,0.34285714285714286,1.0,1.0,1/30,1.55%,PDK3
prerank,GO_Biological_Process_2021__regulation of protein binding (GO:0043393),-0.8312140860901093,-1.2594447150752714,0.14545454545454545,1.0,1.0,3/115,1.50%,AMFR;APP;BMP4
prerank,Elsevier_Pathway_Collection__Acute Cytotoxic CD8+T-Cell Response against Melanocytes,-0.9757440593892134,-1.258527174108677,0.48,1.0,1.0,3/49,2.44%,PTK2B;STAT5A;ZAP70
prerank,GO_Biological_Process_2021__cellular response to starvation (GO:0009267),0.805978614325693,1.25819201211959,0.10077519379844961,1.0,1.0,7/152,2.17%,CLEC16A;PPARA;FNIP1;BRSK1;PRKAA2;LAMP2;STK26
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect in Familial Hemiplegic Migraine Type 3,0.794764656368109,1.2577141739185835,0.44274809160305345,1.0,1.0,4/18,2.36%,SLC38A3;GLS;SLC38A1;STX1A
prerank,TRRUST_Transcription_Factors_2019__AR human,0.90617154906775,1.257349836325046,0.2719298245614035,1.0,1.0,9/86,2.27%,CDH2;TJP1;CDK6;IGFBP3;ERBB3;CDH1;MID1;PTGS2;FN1
prerank,WikiPathway_2021_Human__PDGF Pathway WP2526,-0.9766323916975626,-1.257266494953317,0.4793388429752066,1.0,1.0,1/39,2.34%,VAV1
prerank,KEGG_2021_Human__Steroid hormone biosynthesis,-0.9798596117797139,-1.2521471350730697,0.3252032520325203,1.0,1.0,5/55,2.03%,STS;CYP3A7;CYP1B1;CYP1A2;HSD17B6
prerank,Elsevier_Pathway_Collection__Extracellular Matrix Turnover,0.7274286298396249,1.252047441508572,0.38461538461538464,1.0,1.0,3/18,2.27%,TIMP3;A2M;FN1
prerank,MSigDB_Hallmark_2020__mTORC1 Signaling,0.7764159748888476,1.2505923959477787,0.11403508771929824,1.0,1.0,10/200,2.38%,PLOD2;ACACA;ACTR3;TCEA1;FDXR;HPRT1;DAPP1;ELOVL6;HK2;RRM2
prerank,Elsevier_Pathway_Collection__AXL Receptor Tyrosine Kinase Signaling,-0.9869837538243234,-1.249987718463915,0.18584070796460178,1.0,1.0,1/46,1.31%,PROS1
prerank,GO_Biological_Process_2021__translesion synthesis (GO:0019985),-0.9827177142861562,-1.249762968236269,0.3135593220338983,1.0,1.0,3/42,1.74%,REV3L;POLK;USP43
prerank,GO_Biological_Process_2021__interferon-gamma-mediated signaling pathway (GO:0060333),-0.872238444811113,-1.2492864675465711,0.288,1.0,1.0,7/66,2.27%,OAS1;HCK;CD44;PML;OASL;HLA-B;CIITA
prerank,GO_Biological_Process_2021__regulation of DNA binding (GO:0051101),0.9928726442440576,1.2489824258281261,0.06923076923076923,1.0,1.0,1/47,0.71%,PLAUR
prerank,Elsevier_Pathway_Collection__Vitamin A (Retinol) Metabolism and Visual Cycle,-0.8375268928683441,-1.2476548659178779,0.4580152671755725,1.0,1.0,4/25,1.98%,CYP3A7;CYP2C8;CYP1B1;CYP1A2
prerank,Elsevier_Pathway_Collection__Norepinephrine Neuronal Release,0.9759810355072542,1.2475991910496582,0.5277777777777778,1.0,1.0,3/43,2.41%,RHOQ;STX1A;KIF3B
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect in Migraine Type 2,0.7947647042983129,1.2426970557892738,0.45864661654135336,1.0,1.0,4/18,2.36%,SLC38A3;GLS;SLC38A1;STX1A
prerank,WikiPathway_2021_Human__Sphingolipid Metabolism (integrated pathway) WP4726,-0.8126420089383787,-1.2393275731765458,0.4732824427480916,1.0,1.0,3/23,2.08%,SGPP1;SGPL1;SMPD1
prerank,GO_Biological_Process_2021__positive regulation of developmental growth (GO:0048639),-0.977593841511516,-1.2373340596726934,0.46153846153846156,1.0,1.0,2/45,2.25%,SYT2;SEMA4D
prerank,GO_Biological_Process_2021__positive regulation of pathway-restricted SMAD protein phosphorylation (GO:0010862),-0.9850632844586164,-1.2364431728618765,0.26666666666666666,1.0,1.0,2/43,1.50%,INHBB;BMP4
prerank,GO_Biological_Process_2021__DNA synthesis involved in DNA repair (GO:0000731),-0.9826781995117931,-1.2359349655508314,0.3277310924369748,1.0,1.0,2/42,1.74%,POLK;USP43
prerank,Reactome_2022__SUMOylation Of RNA Binding Proteins R-HSA-4570464,0.9869089150751612,1.2358805930402725,0.1951219512195122,1.0,1.0,2/46,1.31%,NUP210;CBX2
prerank,WikiPathway_2021_Human__Primary focal segmental glomerulosclerosis (FSGS) WP2572,0.9190834650147114,1.2322969627929865,0.33884297520661155,1.0,1.0,9/71,2.41%,CDH2;ITGA3;CD2AP;LRP5;YWHAQ;PLAUR;PTK2;MKI67;COL4A5
prerank,GO_Biological_Process_2021__positive regulation of cellular component biogenesis (GO:0044089),0.8725759082038848,1.2319145568766017,0.20491803278688525,1.0,1.0,8/88,2.05%,FNIP2;FNIP1;RAB7A;CRB3;SYK;CX3CL1;HAS3;LGALS3
prerank,Reactome_2022__RHOQ GTPase Cycle R-HSA-9013406,0.8782923537475883,1.2316759971304987,0.3333333333333333,1.0,1.0,10/58,1.68%,DEPDC1B;SLC4A7;FNBP1;RAB7A;RHOQ;WWP2;ARHGEF7;CDC42EP1;IQGAP3;DLC1
prerank,GO_Biological_Process_2021__protein localization to membrane (GO:0072657),0.7480044223131835,1.2299313378679644,0.08870967741935484,1.0,1.0,15/187,2.29%,ARL5A;RAB40C;DLG1;DLG3;LIN7A;RAPGEF6;LRRC4;ITGA4;CRB3;THY1;ITGAL;CDH1;CPE;SYNE3;FLNA
prerank,TRRUST_Transcription_Factors_2019__TCF4 mouse,0.8107995849061314,1.2282349978425233,0.4793388429752066,1.0,1.0,4/19,2.27%,PLAUR;CDH1;PTGS2;FN1
prerank,Elsevier_Pathway_Collection__Ions Reabsorption Dysregulation in Nephrolithiasis,0.7333501285369703,1.2273320284826637,0.40441176470588236,1.0,1.0,2/18,1.67%,CREB1;CYP27B1
prerank,TRRUST_Transcription_Factors_2019__TWIST1 mouse,-0.827344844270834,-1.227086750703796,0.4609375,1.0,1.0,4/26,1.90%,ZEB1;SHH;IL12RB2;TEK
prerank,GO_Biological_Process_2021__purine ribonucleoside bisphosphate metabolic process (GO:0034035),-0.7922718479627104,-1.2259106632115866,0.49264705882352944,1.0,1.0,2/15,0.78%,TPST1;SULT1B1
prerank,GO_Biological_Process_2021__positive regulation of metabolic process (GO:0009893),0.8253575671060427,1.2250602152266665,0.15702479338842976,1.0,1.0,4/103,2.09%,ACACA;SYK;ELOVL6;PRLR
prerank,KEGG_2021_Human__Basal cell carcinoma,-0.86174620893702,-1.2216624309467492,0.3023255813953488,1.0,1.0,5/61,2.08%,POLK;SUFU;SHH;BMP4;GLI3
prerank,Reactome_2022__EPH-ephrin Mediated Repulsion Of Cells R-HSA-3928665,-0.9769778802714513,-1.2216357894473133,0.47794117647058826,1.0,1.0,3/47,2.31%,ADAM10;MMP2;EFNB2
prerank,GO_Biological_Process_2021__response to calcium ion (GO:0051592),-0.8098773843762753,-1.220929981034461,0.1597222222222222,1.0,1.0,7/102,2.37%,NEDD4;CARF;RASGRP2;SYT2;SMPD1;AQP3;SYT7
prerank,TRRUST_Transcription_Factors_2019__SNAI1 mouse,0.8107961040701473,1.220714999840205,0.48760330578512395,1.0,1.0,4/23,2.27%,TJP1;CDH1;PTGS2;FN1
prerank,WikiPathway_2021_Human__Signal Transduction of S1P Receptor WP26,-0.8357193115608945,-1.2206269074728389,0.4573643410852713,1.0,1.0,4/25,2.16%,AKT3;MAPK6;MAPK4;S1PR1
prerank,"WikiPathway_2021_Human__GPCRs, Class A Rhodopsin-like WP455",-0.7869466345635638,-1.2201569052659214,0.13432835820895522,1.0,1.0,6/155,2.27%,RABGAP1;GPR39;HRH2;C5AR2;BDKRB2;GPR17
prerank,GO_Biological_Process_2021__positive regulation of I-kappaB kinase/NF-kappaB signaling (GO:0043123),0.7822556009249334,1.2198410823210277,0.14166666666666666,1.0,1.0,11/164,2.29%,NEK6;NOD2;LPAR1;CD4;TSPAN6;APOL3;PLEKHG5;CX3CL1;EDA2R;UNC5CL;FLNA
prerank,GO_Biological_Process_2021__regulation of Rho protein signal transduction (GO:0035023),0.8738144788239558,1.2198246366898289,0.2734375,1.0,1.0,6/70,2.11%,ITGA3;LPAR1;ARHGEF18;DLC1;APOE;GPR35
prerank,Reactome_2022__Common Pathway Of Fibrin Clot Formation R-HSA-140875,-0.73053984314233,-1.2190936062431343,0.42063492063492064,1.0,1.0,2/22,1.96%,PROS1;PROCR
prerank,MSigDB_Oncogenic_Signatures__ALK DN.V1 DN,-0.8378730382565657,-1.2183799991444377,0.16296296296296298,1.0,1.0,9/110,2.45%,PTK2B;OAS1;IFI44L;FXYD6;AQP3;VAV1;IFI6;RTP4;DNAJA4
prerank,GO_Biological_Process_2021__positive regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043280),0.8025796365269976,1.217630361669948,0.16417910447761194,1.0,1.0,7/116,2.37%,TNFRSF10A;SENP1;SYK;DLC1;BOK;UACA;PRR7
prerank,WikiPathway_2021_Human__Methionine De Novo and Salvage Pathway WP3580,0.7816552773098825,1.2168187157206718,0.42857142857142855,1.0,1.0,3/22,1.84%,MTAP;SMS;CHDH
prerank,KEGG_2021_Human__Circadian rhythm,0.7890350548961571,1.2165047849762152,0.4461538461538462,1.0,1.0,2/30,1.10%,CREB1;PRKAA2
prerank,Reactome_2022__Glycosaminoglycan Metabolism R-HSA-1630316,0.8313314813596533,1.2153374935074535,0.21138211382113822,1.0,1.0,6/115,1.50%,HS2ST1;ST3GAL1;SLC35D2;CHST11;PAPSS1;HAS3
prerank,Reactome_2022__Mitotic Metaphase And Anaphase R-HSA-2555396,0.7362175365046668,1.2144799962544528,0.09230769230769231,1.0,1.0,8/224,2.15%,HDAC8;CENPE;NDC80;CENPA;PSMB9;UBE2C;ERCC6L;TUBA1A
prerank,GO_Biological_Process_2021__regulation of cellular senescence (GO:2000772),0.7969456433187924,1.2139723799833877,0.4049586776859504,1.0,1.0,5/31,2.14%,NEK6;RBL1;CDK6;NEK4;SLC30A10
prerank,GO_Biological_Process_2021__toll-like receptor 4 signaling pathway (GO:0034142),-0.7816567610918483,-1.2137968995525497,0.45384615384615384,1.0,1.0,3/20,1.85%,OAS1;SCIMP;TICAM2
prerank,GO_Biological_Process_2021__cell cycle G2/M phase transition (GO:0044839),0.768232015347051,1.2136719253780957,0.11206896551724138,1.0,1.0,9/131,2.15%,HAUS8;CEP164;BRSK1;HAUS2;PPP1R12A;MELK;PKMYT1;OPTN;TUBA1A
prerank,KEGG_2021_Human__Pyruvate metabolism,0.9877567395352816,1.2134860447531028,0.23809523809523808,1.0,1.0,2/46,1.23%,ACACA;PKLR
prerank,Reactome_2022__Mitotic Anaphase R-HSA-68882,0.7362183769797738,1.2127951243124822,0.09090909090909091,1.0,1.0,8/223,2.15%,HDAC8;CENPE;NDC80;CENPA;PSMB9;UBE2C;ERCC6L;TUBA1A
prerank,GO_Biological_Process_2021__regulation of cytokine production (GO:0001817),0.8218819994880654,1.2108064978172588,0.1678832116788321,1.0,1.0,7/136,1.83%,TRAF3;PIK3CD;IGF2BP1;NFAM1;IGF2BP3;ANXA1;HDAC9
prerank,GO_Biological_Process_2021__epiboly involved in wound healing (GO:0090505),0.7771996239182487,1.208801950104277,0.46616541353383456,1.0,1.0,3/16,2.29%,MRTFA;CARMIL2;FLNA
prerank,GO_Biological_Process_2021__positive regulation of chemotaxis (GO:0050921),0.9857170549732026,1.2081359591393148,0.2727272727272727,1.0,1.0,2/44,1.43%,MEGF8;F7
prerank,GO_Biological_Process_2021__G2/M transition of mitotic cell cycle (GO:0000086),0.7682328374106381,1.2080699396055208,0.11965811965811966,1.0,1.0,9/130,2.15%,HAUS8;CEP164;BRSK1;HAUS2;PPP1R12A;MELK;PKMYT1;OPTN;TUBA1A
prerank,GO_Biological_Process_2021__post-Golgi vesicle-mediated transport (GO:0006892),-0.8505110120725524,-1.2076482766114727,0.21052631578947367,1.0,1.0,7/88,1.64%,EXOC2;MON2;EXOC6B;VPS13C;APP;DTNBP1;VPS35L
prerank,Reactome_2022__Protein Folding R-HSA-391251,0.8656391653336628,1.2068697794787597,0.2421875,1.0,1.0,6/87,2.34%,TBCD;KIF13A;WRAP53;GNB5;TUBA1A;GNG2
prerank,WikiPathway_2021_Human__Regulatory circuits of the STAT3 signaling pathway WP4538,-0.8951609447130924,-1.2067822766450735,0.29838709677419356,1.0,1.0,8/77,2.18%,MAPK6;CREBBP;DEPTOR;IL11RA;IL12RB2;MAPK4;IL10RA;IL21R
prerank,WikiPathway_2021_Human__Male infertility WP4673,-0.8135699288967816,-1.2064053596425852,0.1484375,1.0,1.0,7/116,2.00%,CDC42BPA;SOD2;CREBBP;PIWIL4;BHMT;MMP2;EPSTI1
prerank,MSigDB_Oncogenic_Signatures__MTOR UP.V1 UP,0.7945316441470118,1.205552633828037,0.14018691588785046,1.0,1.0,7/145,2.38%,ERN1;CPPED1;UBE2C;RCOR2;LGALS3;ATXN7L1;RRM2
prerank,MSigDB_Oncogenic_Signatures__CSR EARLY UP.V1 DN,-0.7788715868844944,-1.2053942223554759,0.17692307692307693,1.0,1.0,9/134,2.14%,PDE5A;GLG1;ZNF33A;RABGAP1;RAPGEF3;SNPH;ZNF302;NYNRIN;APBB3
prerank,"GO_Biological_Process_2021__DNA damage response, signal transduction by p53 class mediator (GO:0030330)",0.8346763749703272,1.2012915532524275,0.25,1.0,1.0,4/73,2.26%,ARID3A;TFDP2;PCBP4;PRAP1
prerank,GO_Biological_Process_2021__cortical actin cytoskeleton organization (GO:0030866),0.8131443286610549,1.2010093153640002,0.5128205128205128,1.0,1.0,3/20,2.03%,DLG1;RHOQ;FMNL2
prerank,GO_Biological_Process_2021__regulation of signal transduction by p53 class mediator (GO:1901796),0.7672360138143143,1.1979170531255738,0.13821138211382114,1.0,1.0,6/154,1.86%,TAF4;ING5;ATR;PRKAA2;BRIP1;PPP1R13L
prerank,GO_Biological_Process_2021__positive regulation of protein localization to membrane (GO:1905477),0.8129654094705502,1.1972940685182347,0.211864406779661,1.0,1.0,6/100,2.05%,ITGA3;DLG1;YWHAQ;TFDP2;MTCL1;LGALS3
prerank,GO_Biological_Process_2021__regulation of lipopolysaccharide-mediated signaling pathway (GO:0031664),0.8003776986736296,1.1971315008210637,0.5074626865671642,1.0,1.0,3/19,1.79%,LILRA2;CX3CL1;SIGIRR
prerank,Reactome_2022__Diseases Of Glycosylation R-HSA-3781865,-0.7931152286833105,-1.1957599930316998,0.2,1.0,1.0,10/135,2.30%,ADAMTS2;MUC6;ALG6;ALG13;ADAMTS5;ADAMTS9;SDC3;ADAMTSL5;ADAMTSL2;GALNT3
prerank,Elsevier_Pathway_Collection__Cowden Syndrome,0.8180913840919826,1.1954923740510885,0.36923076923076925,1.0,1.0,3/42,1.53%,CREB1;PTK2;BCAR1
prerank,Reactome_2022__Transmission Across Chemical Synapses R-HSA-112315,0.7175322309674546,1.19431751226731,0.12380952380952381,1.0,1.0,14/214,2.36%,CREB1;DLG1;LIN7A;ARHGEF7;PRKAA2;MAOA;KCNJ10;SLC6A4;GNB5;SLC38A1;PPFIA4;GPRIN1;GNG2;STX1A
prerank,Reactome_2022__Ion Channel Transport R-HSA-983712,-0.7868939640043032,-1.1930717205048027,0.14728682170542637,1.0,1.0,4/153,1.32%,ATP11C;WNK3;WWP1;SGK3
prerank,GO_Biological_Process_2021__positive regulation of cell division (GO:0051781),0.8185598107206777,1.1926576571163285,0.4806201550387597,1.0,1.0,5/32,2.37%,PKP4;SVIL;CDC14B;KIF23;FGF1
prerank,GO_Biological_Process_2021__positive regulation of actin cytoskeleton reorganization (GO:2000251),-0.766911336707661,-1.1918968087414155,0.48175182481751827,1.0,1.0,4/18,1.90%,BCAS3;HCK;NTF3;TEK
prerank,Elsevier_Pathway_Collection__OPTN Associated Glaucoma,0.7289252666673949,1.1903041095031925,0.4406779661016949,1.0,1.0,2/21,2.11%,PPP1R12A;OPTN
prerank,WikiPathway_2021_Human__Gastrin signaling pathway WP4659,0.8128425296618281,1.1901100741744663,0.18548387096774194,1.0,1.0,7/109,2.07%,TJP1;CREB1;PTK2;BCAR1;CDH1;PTGS2;SERPINE1
prerank,Reactome_2022__Resolution Of Sister Chromatid Cohesion R-HSA-2500257,0.8005116479443164,1.1899607168728565,0.20967741935483872,1.0,1.0,5/103,1.78%,HDAC8;CENPE;NDC80;CENPA;ERCC6L
prerank,Reactome_2022__Azathioprine ADME R-HSA-9748787,-0.8100670968161912,-1.1893104430740287,0.5,1.0,1.0,3/21,2.34%,GSTA1;GSTA2;VAV1
prerank,Elsevier_Pathway_Collection__Hedgehog Signaling Activation by Blocking of Tumor Suppressors,-0.7651049658903841,-1.1885199075179989,0.46923076923076923,1.0,1.0,4/17,2.08%,SUFU;SHH;CCND2;GLI3
prerank,Elsevier_Pathway_Collection__Hedgehog Signaling Activation in Cancer,-0.7651049658903841,-1.1885199075179989,0.46923076923076923,1.0,1.0,4/17,2.08%,SUFU;SHH;CCND2;GLI3
prerank,Reactome_2022__HS-GAG Biosynthesis R-HSA-2022928,0.7937674172383273,1.1879814611222579,0.46825396825396826,1.0,1.0,2/28,0.63%,HS2ST1;SLC35D2
prerank,GO_Biological_Process_2021__regulation of mitotic cell cycle phase transition (GO:1901990),0.7461958695127107,1.1878569150774534,0.11009174311926606,1.0,1.0,10/183,2.15%,NEK6;HAUS8;CENPE;CEP164;HAUS2;CDC14B;PSMB9;ANLN;UBE2C;TUBA1A
prerank,MSigDB_Oncogenic_Signatures__KRAS.AMP.LUNG UP.V1 UP,-0.7983102587700519,-1.1873501962747621,0.2032520325203252,1.0,1.0,5/106,2.00%,SLC7A9;SDCCAG8;CYP3A7;ATG10;FAM174B
prerank,GO_Biological_Process_2021__negative regulation of B cell activation (GO:0050869),0.8347603539716868,1.1841330677856696,0.5,1.0,1.0,4/22,2.25%,CD300A;TNFRSF21;SAMSN1;MNDA
prerank,TRRUST_Transcription_Factors_2019__SRF human,0.8544994046136288,1.1841237262354705,0.5630252100840336,1.0,1.0,5/25,2.07%,LMO7;CREB1;FHL2;FOSL1;SERPINE1
prerank,GO_Biological_Process_2021__regulation of mRNA stability (GO:0043488),0.7582264166944311,1.1840076891532156,0.152,1.0,1.0,7/142,1.97%,YTHDF3;PARN;PSMB9;IGF2BP1;IGF2BP3;PCBP4;AXIN2
prerank,MSigDB_Oncogenic_Signatures__CSR EARLY UP.V1 UP,0.7597724449135418,1.1829290077690868,0.1732283464566929,1.0,1.0,8/142,1.82%,VGLL4;ST3GAL1;CD33;ACTR3;SHB;PLAUR;BCAR1;PTGS2
prerank,WikiPathway_2021_Human__Sphingolipid pathway WP1422,-0.7899210605518149,-1.1827503635580825,0.46616541353383456,1.0,1.0,2/28,1.02%,PLPP1;SGPL1
prerank,Reactome_2022__HCMV Early Events R-HSA-9609690,0.8467324677677585,1.1826056349737442,0.2421875,1.0,1.0,3/83,1.05%,TBL1X;CREB1;NUP210
prerank,GO_Biological_Process_2021__mitotic G1 DNA damage checkpoint signaling (GO:0031571),0.8599332642669468,1.1821136787813373,0.3217391304347826,1.0,1.0,5/64,2.26%,ARID3A;TFDP2;FBXO31;PCBP4;PRAP1
prerank,Reactome_2022__Synthesis Of PIPs At Plasma Membrane R-HSA-1660499,-0.8546324498172716,-1.1816991724176633,0.3937007874015748,1.0,1.0,4/51,2.05%,SBF2;PIK3CB;PLEKHA5;PIK3R6
prerank,GO_Biological_Process_2021__folic acid-containing compound metabolic process (GO:0006760),0.8331558741380712,1.181375405941681,0.5275590551181102,1.0,1.0,3/20,1.31%,SLC19A1;MTHFS;FTCD
prerank,KEGG_2021_Human__MAPK signaling pathway,-0.708528688155847,-1.1795849976170636,0.136986301369863,1.0,1.0,13/276,2.39%,PAK2;MAP2K6;RASA2;RAP1B;AKT3;MAP2K5;RAP1A;RASGRP2;NTF3;DUSP4;TEK;RASGRP3;MAP4K1
prerank,KEGG_2021_Human__Regulation of actin cytoskeleton,0.7091556319784712,1.1794052484800663,0.10714285714285714,1.0,1.0,17/205,2.37%,ABI2;ITGA3;PIK3CD;ACTR3;PTK2;PPP1R12A;LPAR1;ARHGEF7;ITGA4;ITGAL;BCAR1;ITGA2;IQGAP3;ITGB5;SPATA13;FN1;FGF1
prerank,Elsevier_Pathway_Collection__CHRNA7 -> CREB Signaling,0.6581312376615649,1.1790864002069468,0.37606837606837606,1.0,1.0,2/15,0.86%,CREB1;PTK2
prerank,Reactome_2022__Glutathione Conjugation R-HSA-156590,-0.8445997335232429,-1.1786286447841612,0.484375,1.0,1.0,3/33,1.27%,GSTA1;GGT5;GSTA2
prerank,KEGG_2021_Human__Pyrimidine metabolism,-0.8361575676361547,-1.1779405200807982,0.3387096774193548,1.0,1.0,4/53,2.11%,NT5C1B;DPYS;ENTPD8;ENTPD3
prerank,GO_Biological_Process_2021__gliogenesis (GO:0042063),0.8170701362532675,1.1775063886457497,0.5391304347826087,1.0,1.0,3/15,1.64%,CDH2;CDK6;ANXA1
prerank,GO_Biological_Process_2021__cellular protein metabolic process (GO:0044267),0.6674857887299623,1.1772451016739445,0.12403100775193798,1.0,1.0,16/401,2.39%,PLOD2;CDH2;MANBA;ST3GAL1;PHKA2;WWP2;IGFBP3;CKAP4;IGF2BP3;FDXR;CTSH;APOE;QSOX1;CPE;FN1;MELTF
prerank,GO_Biological_Process_2021__positive regulation of cell cycle process (GO:0090068),0.8452708046697691,1.1771659426243024,0.24786324786324787,1.0,1.0,7/84,2.16%,PKP4;LRP5;NDC80;CEP295;SVIL;CDC14B;KIF23
prerank,GO_Biological_Process_2021__positive regulation of double-strand break repair via nonhomologous end joining (GO:2001034),0.7349663427092569,1.1766132616584497,0.4406779661016949,1.0,1.0,2/16,1.51%,SMCHD1;WRAP53
prerank,KEGG_2021_Human__Pathogenic Escherichia coli infection,0.7433778110056692,1.1763319684420277,0.11428571428571428,1.0,1.0,8/188,2.15%,TJP1;TNFRSF10A;ACTR3;LPAR1;CASP7;NAIP;MAPK13;TUBA1A
prerank,GO_Biological_Process_2021__mRNA processing (GO:0006397),0.6901377387813574,1.176085840877202,0.11475409836065574,1.0,1.0,5/292,1.36%,PRPF40A;ERN1;CDC5L;RAVER2;SF3A2
prerank,KEGG_2021_Human__Shigellosis,0.6983252900689375,1.1754148166529454,0.128,1.0,1.0,11/232,2.28%,PIK3CD;ACTR3;FNBP1;PTK2;SEPTIN6;BCAR1;SEPTIN9;NAIP;MAPK13;HK2;HKDC1
prerank,Elsevier_Pathway_Collection__ROS in Angiotensin Mediated Cardiovascular Remodeling and Hypertrophy,-0.8517833461429303,-1.1744465862532298,0.3828125,1.0,1.0,5/51,2.34%,PTK2B;MAP2K6;MMP2;SMPD1;VAV1
prerank,Reactome_2022__Host Interactions Of HIV Factors R-HSA-162909,0.7570247972343626,1.174272458440264,0.1693548387096774,1.0,1.0,3/128,1.23%,NUP210;PSMB9;CD4
prerank,Reactome_2022__Diseases Associated With N-glycosylation Of Proteins R-HSA-3781860,-0.7937311323257846,-1.1737814165988476,0.5217391304347826,1.0,1.0,2/20,0.64%,ALG6;ALG13
prerank,GO_Biological_Process_2021__regulation of lamellipodium assembly (GO:0010591),0.8145574312848285,1.1736924557877761,0.4351145038167939,1.0,1.0,3/33,1.89%,ABI2;ACTR3;CARMIL2
prerank,MSigDB_Hallmark_2020__Mitotic Spindle,0.7332145820411826,1.173527239535514,0.10743801652892562,1.0,1.0,19/198,2.41%,CLIP2;CD2AP;CENPE;TBCD;DLG1;RAB3GAP1;NDC80;ARHGEF7;RAPGEF6;BCAR1;CDC42EP1;ANLN;MID1;SEPTIN9;SHROOM1;KIF23;PIF1;FLNA;KIF3B
prerank,WikiPathway_2021_Human__Retinoblastoma gene in cancer WP2446,0.8225589335101631,1.1733993693708515,0.25,1.0,1.0,7/86,2.38%,CDC45;PRMT2;CDK6;TFDP2;ANLN;MAPK13;RRM2
prerank,GO_Biological_Process_2021__peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine (GO:0018231),-0.7905386930174351,-1.1732508132640036,0.48872180451127817,1.0,1.0,2/22,0.96%,ZDHHC14;ZDHHC21
prerank,GO_Biological_Process_2021__peptidyl-L-cysteine S-palmitoylation (GO:0018230),-0.7905386930174351,-1.1732508132640036,0.48872180451127817,1.0,1.0,2/22,0.96%,ZDHHC14;ZDHHC21
prerank,TRRUST_Transcription_Factors_2019__SMAD3 human,-0.7944061428780191,-1.1732023412362005,0.4491525423728814,1.0,1.0,4/31,2.39%,CCND2;LTBP4;VDR;COL7A1
prerank,GO_Biological_Process_2021__negative regulation of oxidative stress-induced cell death (GO:1903202),-0.7903443583865969,-1.1731108820268155,0.4785714285714286,1.0,1.0,2/27,0.98%,VNN1;SOD2
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect Caused by Mutations in PRRT2 Gene,0.7947590462674641,1.1716611364412548,0.49612403100775193,1.0,1.0,4/24,2.36%,SLC38A3;GLS;SLC38A1;STX1A
prerank,Reactome_2022__RHOD GTPase Cycle R-HSA-9013405,0.8323316620788372,1.1709582483612444,0.3865546218487395,1.0,1.0,6/51,1.40%,DEPDC1B;SLC4A7;RAB7A;ARHGAP12;ARHGAP39;MOSPD2
prerank,GO_Biological_Process_2021__non-canonical Wnt signaling pathway (GO:0035567),0.7539532433379628,1.170427510567821,0.1941747572815534,1.0,1.0,3/122,2.38%,PSMB9;GNG2;CELSR3
prerank,GO_Biological_Process_2021__digestive tract development (GO:0048565),0.8534304896057818,1.1702009382186507,0.5241935483870968,1.0,1.0,4/34,1.34%,MEGF8;PKDCC;SALL1;CCDC40
prerank,GO_Biological_Process_2021__cell chemotaxis (GO:0060326),0.8523497610113682,1.170062666997879,0.3305785123966942,1.0,1.0,5/63,2.28%,LPAR1;PLEKHG5;CX3CL1;BCAR1;HGF
prerank,GO_Biological_Process_2021__cellular component disassembly (GO:0022411),-0.8380023978656583,-1.168642693053685,0.35877862595419846,1.0,1.0,4/57,1.93%,ADAM10;ADAMTS5;CD44;MMP2
prerank,GO_Biological_Process_2021__carbohydrate derivative catabolic process (GO:1901136),-0.7195289049819685,-1.168388876099295,0.4418604651162791,1.0,1.0,3/18,1.39%,FBXO27;DERA;ADAMTS9
prerank,Elsevier_Pathway_Collection__Proteins Involved in Diabetes Mellitus Type 2,0.8182777297854529,1.1680245095494122,0.2283464566929134,1.0,1.0,8/105,2.19%,PPARA;PRKAA2;IGFBP3;PTGS2;APOE;SERPINE1;RBP4;HK2
prerank,KEGG_2021_Human__PPAR signaling pathway,0.8337552417488977,1.167294567517502,0.328125,1.0,1.0,4/69,2.35%,PPARA;SLC27A2;ACSL5;GK
prerank,Elsevier_Pathway_Collection__Vascular Motility,-0.8466641098683241,-1.1665575396816192,0.25396825396825395,1.0,1.0,4/76,2.01%,PDE5A;RAP1A;HRH2;BDKRB2
prerank,GO_Biological_Process_2021__folic acid metabolic process (GO:0046655),0.7931163802553236,1.1664769291549746,0.49612403100775193,1.0,1.0,2/19,0.70%,SLC19A1;MTHFS
prerank,Reactome_2022__Activation Of HOX Genes During Differentiation R-HSA-5619507,-0.8497454401129134,-1.1660418559618846,0.31451612903225806,1.0,1.0,4/78,1.71%,KDM6A;CREBBP;MEIS1;PBX1
prerank,Reactome_2022__RHOJ GTPase Cycle R-HSA-9013409,0.8076265297885432,1.165867810210214,0.3225806451612903,1.0,1.0,8/54,1.62%,DEPDC1B;SLC4A7;FNBP1;RAB7A;WWP2;ARHGEF7;CDC42EP1;IQGAP3
prerank,GO_Biological_Process_2021__cell-cell junction organization (GO:0045216),0.8430554659382294,1.1655540623545997,0.3089430894308943,1.0,1.0,6/77,2.07%,CDH2;TJP1;PKP4;GJC1;CDH1;CDH15
prerank,GO_Biological_Process_2021__regulation of developmental growth (GO:0048638),-0.816367665604517,-1.165373207644651,0.5038759689922481,1.0,1.0,3/30,1.71%,MBD5;APP;STAT5A
prerank,Reactome_2022__Regulation Of Actin Dynamics For Phagocytic Cup Formation R-HSA-2029482,0.8699132966895082,1.1653060822729455,0.41025641025641024,1.0,1.0,4/57,1.26%,ABI2;ACTR3;PTK2;SYK
prerank,MSigDB_Hallmark_2020__Adipogenesis,0.7194301956234014,1.1647567213244259,0.15748031496062992,1.0,1.0,9/198,2.36%,EPHX2;SLC19A1;AGPAT3;GPAT4;MTARC2;ELOVL6;CAVIN1;APOE;SULT1A1
prerank,GO_Biological_Process_2021__actin filament organization (GO:0007015),0.7230803224442856,1.1647210877390484,0.18333333333333332,1.0,1.0,15/145,2.31%,ABI2;CD2AP;DLG1;PPP1R9A;SVIL;ARHGAP12;BAIAP2L2;PROX1;BCAR1;CARMIL2;SPIRE2;SHROOM1;DPYSL3;FLNA;MYO7A
prerank,GO_Biological_Process_2021__regulation of cell growth (GO:0001558),-0.7097794950390929,-1.1639653311992209,0.1702127659574468,1.0,1.0,11/210,2.38%,ADAM10;DCBLD2;PTPRJ;RB1;SGK3;RASGRP2;SLIT3;IL17RB;LTBP4;PML;HRG
prerank,GO_Biological_Process_2021__regulation of peptide hormone secretion (GO:0090276),-0.8431681768250574,-1.1633852120674146,0.31654676258992803,1.0,1.0,5/64,2.37%,RAP1A;RAPGEF3;PAX8;KCNS3;SYT7
prerank,Reactome_2022__Early SARS-CoV-2 Infection Events R-HSA-9772572,-0.8347099669299016,-1.1633035472198785,0.504,1.0,1.0,4/35,2.26%,UVRAG;RB1;SDC3;TMPRSS2
prerank,GO_Biological_Process_2021__positive regulation of sprouting angiogenesis (GO:1903672),0.7263548428764026,1.1631269788513845,0.44274809160305345,1.0,1.0,2/15,2.37%,TJP1;FGF1
prerank,Reactome_2022__M Phase R-HSA-68886,0.6656333646793609,1.1629238104088142,0.09016393442622951,1.0,1.0,16/360,2.30%,NEK6;HAUS8;HDAC8;CENPE;CEP164;NCAPG;NDC80;HAUS2;NUP210;CENPA;PSMB9;UBE2C;ERCC6L;TUBA1A;KIF23;LPIN3
prerank,Elsevier_Pathway_Collection__Vitamins Insufficiency Causes Homocysteine High Level Synthesis,0.7640902541452816,1.1624457180884071,0.4639175257731959,1.0,1.0,2/15,1.38%,SLC19A1;CBS
prerank,Reactome_2022__Transcriptional Regulation By TP53 R-HSA-3700989,0.6685184934134654,1.1618919405931607,0.12605042016806722,1.0,1.0,16/349,1.86%,TAF4;TNFRSF10A;ARID3A;ING5;RBL1;YWHAQ;TCEA1;MSH2;TFDP2;PRKAA2;BRIP1;PRELID3A;IGFBP3;TNFRSF10D;PCBP4;PPP1R13L
prerank,TRRUST_Transcription_Factors_2019__NFE2L2 mouse,-0.8445935540096224,-1.161726327251366,0.375,1.0,1.0,3/45,1.27%,GSTA1;SOD2;GSTA2
prerank,GO_Biological_Process_2021__regulation of cellular metabolic process (GO:0031323),0.8415900875302078,1.1611627945460226,0.432,1.0,1.0,4/47,1.57%,PPARA;ACACA;PDK3;MPV17
prerank,GO_Biological_Process_2021__cellular response to nutrient levels (GO:0031669),0.847994161506053,1.1610529498112054,0.3464566929133858,1.0,1.0,6/63,2.17%,CLEC16A;PPARA;FNIP1;PRKAA2;LAMP2;STK26
prerank,GO_Biological_Process_2021__peptide catabolic process (GO:0043171),-0.7915759227088333,-1.160404046539879,0.4838709677419355,1.0,1.0,2/25,0.85%,CPQ;GGT5
prerank,GO_Biological_Process_2021__negative regulation of type I interferon-mediated signaling pathway (GO:0060339),0.6610144314218427,1.159971135459689,0.39669421487603307,1.0,1.0,2/16,0.57%,YTHDF3;PTPN2
prerank,Elsevier_Pathway_Collection__Steroids Induced Cataract,-0.8558588725639129,-1.159938894575595,0.4028776978417266,1.0,1.0,4/58,1.93%,MAP2K6;NR3C1;CREBBP;MMP2
prerank,Reactome_2022__Signaling By ROBO Receptors R-HSA-376176,0.7032212887813107,1.1599294580603061,0.17355371900826447,1.0,1.0,5/202,2.41%,UPF2;ARHGEF7;PSMB9;ARHGAP39;COL4A5
prerank,MSigDB_Hallmark_2020__G2-M Checkpoint,0.7187031050095607,1.1593170296296056,0.2033898305084746,1.0,1.0,12/198,2.16%,CDC45;HIRA;CENPE;RBL1;NDC80;CENPA;MKI67;PBK;UBE2C;SLC7A1;SLC38A1;KIF23
prerank,GO_Biological_Process_2021__potassium ion transmembrane transport (GO:0071805),-0.7972635503166858,-1.1580319263077987,0.2,1.0,1.0,9/118,2.44%,KCNT2;KCNN2;KCNAB3;KCNK6;KCNS3;KCNAB2;SLC9A9;SLC12A8;KCNE1
prerank,Elsevier_Pathway_Collection__Cell Cycle Overiew,0.7627727360447658,1.1578215919261916,0.21153846153846154,1.0,1.0,6/105,1.16%,CDC45;CENPE;CDK6;TFDP2;ATR;CENPA
prerank,GO_Biological_Process_2021__cellular macromolecule biosynthetic process (GO:0034645),0.684297442584068,1.1578119821155615,0.1721311475409836,1.0,1.0,9/305,2.31%,CDC45;ING5;TAF1B;ATR;BRIP1;IGF2BP3;APOE;PIF1;HOXD3
prerank,Reactome_2022__Neurotransmitter Receptors And Postsynaptic Signal Transmission R-HSA-112314,0.7203945738638058,1.1573588630997114,0.17699115044247787,1.0,1.0,9/156,2.34%,CREB1;DLG1;LIN7A;ARHGEF7;PRKAA2;KCNJ10;GNB5;GPRIN1;GNG2
prerank,GO_Biological_Process_2021__positive regulation of cell-cell adhesion (GO:0022409),0.860909984673905,1.156637348795347,0.45255474452554745,1.0,1.0,4/47,1.42%,TJP1;PLAUR;THY1;CX3CL1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Glomerulonephritis,0.782676554535304,1.1565523275604856,0.20833333333333334,1.0,1.0,10/114,2.41%,PPARA;CD4;SYK;CX3CL1;PTGS2;SERPINE1;FN1;HGF;CD86;COL4A5
prerank,GO_Biological_Process_2021__protein lipidation (GO:0006497),-0.872091344840469,-1.1559021591494776,0.424,1.0,1.0,5/58,2.28%,ZDHHC14;ZDHHC21;ATG10;PIGZ;PGAP4
prerank,GO_Biological_Process_2021__lipid transport (GO:0006869),-0.7824901738357397,-1.1557817602637825,0.21212121212121213,1.0,1.0,7/107,2.42%,TTPA;ABCD3;NCOA1;ABCA6;SLCO1A2;SLCO3A1;ABCA10
prerank,Reactome_2022__ER To Golgi Anterograde Transport R-HSA-199977,0.7637926560871359,1.1549301262067917,0.23076923076923078,1.0,1.0,2/130,1.40%,COG5;SPTBN2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Male Infertility,0.7245050503363294,1.1548347511707993,0.2066115702479339,1.0,1.0,6/153,1.64%,SYCP3;ETV5;MSH2;DMWD;ELOVL2;ANXA1
prerank,Reactome_2022__EML4 And NUDC In Mitotic Spindle Formation R-HSA-9648025,0.8005180130132313,1.1536632198496313,0.24193548387096775,1.0,1.0,5/94,1.78%,NEK6;CENPE;NDC80;CENPA;ERCC6L
prerank,GO_Biological_Process_2021__negative regulation of multicellular organismal process (GO:0051241),-0.7261844671534409,-1.1536204950816673,0.17164179104477612,1.0,1.0,8/199,2.40%,MAP2K6;ADAMTS5;RB1;SHH;BMP4;PROCR;PARP3;SPI1
prerank,GO_Biological_Process_2021__membrane organization (GO:0061024),0.6960415995529795,1.1536109192622581,0.14912280701754385,1.0,1.0,9/232,2.21%,UBXN2A;IGF2R;ACTR3;FNBP1;CD4;BAIAP2L2;SLC2A8;MYOF;LPCAT2
prerank,Reactome_2022__Chromosome Maintenance R-HSA-73886,0.7775048334335191,1.153198301029164,0.2601626016260163,1.0,1.0,6/106,2.26%,SLC19A1;CENPA;WRAP53;ACD;LRIG1;PIF1
prerank,"GO_Biological_Process_2021__DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest (GO:0006977)",0.8346924792133763,1.1526242340100084,0.37606837606837606,1.0,1.0,4/55,2.26%,ARID3A;TFDP2;PCBP4;PRAP1
prerank,Elsevier_Pathway_Collection__GFs/TNF -> Ion Channels,-0.8571083750234337,-1.1524661711062802,0.5396825396825397,1.0,1.0,4/34,1.81%,MAP2K6;MAP2K5;APP;NTF3
prerank,GO_Biological_Process_2021__regulation of synaptic vesicle exocytosis (GO:2000300),-0.7380418192028042,-1.152460378436305,0.46616541353383456,1.0,1.0,3/17,1.21%,RAP1B;DTNBP1;RAP1A
prerank,Reactome_2022__O-glycosylation Of TSR Domain-Containing Proteins R-HSA-5173214,-0.8610355529102968,-1.1520978009344507,0.5217391304347826,1.0,1.0,5/36,2.15%,ADAMTS2;ADAMTS5;ADAMTS9;ADAMTSL5;ADAMTSL2
prerank,Elsevier_Pathway_Collection__Neutrophil Activation via Adherence on Endothelial Cells,0.8535876998019534,1.151961275942724,0.4049586776859504,1.0,1.0,5/57,2.16%,PTK2;SYK;ITGAL;BCAR1;CYBA
prerank,KEGG_2021_Human__Lysine degradation,0.8456637606648296,1.1511291792750518,0.3769230769230769,1.0,1.0,3/61,1.16%,PLOD2;ASH1L;AASS
prerank,GO_Biological_Process_2021__regulation of peptidyl-tyrosine phosphorylation (GO:0050730),-0.7970724855548077,-1.1510326067182157,0.26515151515151514,1.0,1.0,11/86,2.38%,PTK2B;PAK2;TEC;APP;PTPRJ;CD44;NTF3;THBS4;TNFRSF14;SEMA4D;HRG
prerank,Reactome_2022__Defective B3GALTL Causes PpS R-HSA-5083635,-0.8610363749514232,-1.1507536813272887,0.5258620689655172,1.0,1.0,5/35,2.15%,ADAMTS2;ADAMTS5;ADAMTS9;ADAMTSL5;ADAMTSL2
prerank,TRRUST_Transcription_Factors_2019__EGR1 human,0.8009765685387916,1.1505443518193335,0.2682926829268293,1.0,1.0,5/84,2.27%,LMTK2;PLAUR;BCAR1;PTGS2;FN1
prerank,GO_Biological_Process_2021__leukocyte cell-cell adhesion (GO:0007159),0.8045643524706096,1.1502831884374662,0.4672131147540984,1.0,1.0,3/27,1.37%,ITGA4;SYK;ITGAL
prerank,MSigDB_Hallmark_2020__Epithelial Mesenchymal Transition,0.7189210546620144,1.149978735122251,0.17094017094017094,1.0,1.0,16/198,2.29%,PLOD2;CDH2;PLAUR;SNTB1;IGFBP3;COL12A1;THY1;ITGA2;ITGB5;MSX1;TIMP3;QSOX1;SERPINE1;DPYSL3;FN1;FLNA
prerank,Reactome_2022__MHC Class II Antigen Presentation R-HSA-2132295,0.7855682623820729,1.1492500722413534,0.2558139534883721,1.0,1.0,6/100,2.41%,CENPE;RAB7A;SPTBN2;CTSH;KIF23;KIF3B
prerank,KEGG_2021_Human__Thyroid hormone signaling pathway,-0.7697996397082966,-1.148057618948127,0.23308270676691728,1.0,1.0,8/117,2.46%,AKT3;PIK3CB;NCOA1;TBC1D4;CREBBP;BMP4;PLCB4;SLC16A2
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect Caused by Mutations in SLC1A3 Gene,0.7947581426173566,1.147985912444692,0.5078125,1.0,1.0,4/25,2.36%,SLC38A3;GLS;SLC38A1;STX1A
prerank,Elsevier_Pathway_Collection__Glutamate Overdose and Aura Effect Overiew,0.7947581426173566,1.147985912444692,0.5078125,1.0,1.0,4/25,2.36%,SLC38A3;GLS;SLC38A1;STX1A
prerank,GO_Biological_Process_2021__regulation of nucleic acid-templated transcription (GO:1903506),-0.6546892692870971,-1.1479759007635557,0.13138686131386862,1.0,1.0,22/398,2.44%,ZNF341;ZNF678;ZNF90;ZNF85;NR3C1;ZNF221;ZNF66;ZNF708;ZBTB38;NR2C2;ZNF33A;ERC1;ZNF117;RB1;CREBBP;SUFU;HIC1;PML;APBB3;RHOH;SPI1;ZNF653
prerank,GO_Biological_Process_2021__extracellular matrix disassembly (GO:0022617),-0.8380023774187159,-1.1479699799588583,0.3787878787878788,1.0,1.0,4/57,1.93%,ADAM10;ADAMTS5;CD44;MMP2
prerank,Elsevier_Pathway_Collection__Neutrophil Degranulation via FPR1/IL8,0.8535816573663698,1.1475591709686104,0.37719298245614036,1.0,1.0,5/64,2.16%,PTK2;SYK;ITGAL;BCAR1;CYBA
prerank,GO_Biological_Process_2021__mitochondrial translation (GO:0032543),-0.762074161664937,-1.147531152386202,0.18548387096774194,1.0,1.0,4/104,1.58%,MRPS28;GATB;MRPS9;MRRF
prerank,MSigDB_Oncogenic_Signatures__CAHOY ASTROGLIAL,0.7666869628898481,1.1473863840360827,0.2265625,1.0,1.0,7/87,2.30%,IGFBP3;ANXA1;MYOF;LGALS3;SERPINE1;CLCN4;LPIN3
prerank,GO_Biological_Process_2021__dopamine metabolic process (GO:0042417),0.6978676837392734,1.1464834137675197,0.4297520661157025,1.0,1.0,2/16,1.65%,MAOA;DRD4
prerank,Elsevier_Pathway_Collection__Proteins Involved in Epilepsy,0.6863389845165645,1.145571964394022,0.19090909090909092,1.0,1.0,15/242,2.09%,CREB1;RALGAPA1;IRAK2;PLAUR;KCNJ10;SPTBN2;CX3CL1;SLC6A4;KCNC1;PTGS2;NAIP;APOE;TRPV1;DPYSL2;CNN3
prerank,GO_Biological_Process_2021__positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus (GO:1901522),-0.7879241478350496,-1.1444518761023932,0.5084745762711864,1.0,1.0,2/21,1.22%,CHD6;CARF
prerank,Elsevier_Pathway_Collection__Leukocyte Migration toward the Endothelial Cell in Ulcerative Colitis,0.7819946501287603,1.1441994447731034,0.48739495798319327,1.0,1.0,3/31,1.81%,ITGA4;ITGAL;IL13RA1
prerank,Elsevier_Pathway_Collection__Transcytosis,0.8360937563918578,1.143078626807873,0.48717948717948717,1.0,1.0,4/37,2.12%,IGF2R;RAB7A;LAMP2;CLCN4
prerank,GO_Biological_Process_2021__phosphatidic acid metabolic process (GO:0046473),0.847162792819326,1.1428287733787168,0.4796747967479675,1.0,1.0,6/45,2.26%,LCLAT1;AGPAT3;GPAT4;PLD1;PNPLA3;GPD1L
prerank,Reactome_2022__Metabolism Of Carbohydrates R-HSA-71387,0.6892544270354207,1.1425953182147128,0.17592592592592593,1.0,1.0,14/270,2.12%,RPIA;MANBA;HS2ST1;ST3GAL1;MAP4K5;SLC35D2;PHKA2;CHST11;PAPSS1;NUP210;PKLR;HAS3;FUT6;PHKA1
prerank,Reactome_2022__Sphingolipid De Novo Biosynthesis R-HSA-1660661,-0.8470963041692218,-1.1415823512410732,0.4928571428571429,1.0,1.0,3/43,1.02%,PLPP1;SGPP1;SGPL1
prerank,Elsevier_Pathway_Collection__TGFB Signaling activation by Blocking of Tumor Suppressors,-0.8308546446888113,-1.1409809659389802,0.3262411347517731,1.0,1.0,3/72,1.54%,MAP2K6;CREBBP;CCND2
prerank,GO_Biological_Process_2021__beta-catenin-TCF complex assembly (GO:1904837),-0.787881842679112,-1.1408726085493637,0.46099290780141844,1.0,1.0,2/29,1.22%,TLE4;CREBBP
prerank,WikiPathway_2021_Human__Aryl Hydrocarbon Receptor Pathway WP2873,-0.8692974879646432,-1.1400712202942602,0.46923076923076923,1.0,1.0,5/43,1.98%,POLK;NCOA1;GSTA2;CYP1B1;CYP1A2
prerank,WikiPathway_2021_Human__DNA IR-damage and cellular response via ATR WP4016,0.8122359174661379,1.1396944657358243,0.3140495867768595,1.0,1.0,7/79,1.15%,CDC45;HERC2;CEP164;MSH2;ATR;TDP1;BRIP1
prerank,MSigDB_Oncogenic_Signatures__BCAT.100 UP.V1 DN,0.7336169247578449,1.1392360593219715,0.45614035087719296,1.0,1.0,2/21,1.64%,ZNF749;AMH
prerank,GO_Biological_Process_2021__positive regulation of cilium assembly (GO:0045724),-0.7272351561613167,-1.138573448262648,0.4642857142857143,1.0,1.0,2/19,2.29%,CEP120;CROCC
prerank,GO_Biological_Process_2021__heart trabecula morphogenesis (GO:0061384),-0.7563204128579127,-1.1384595197980976,0.4846153846153846,1.0,1.0,3/19,2.16%,NRG1;TEK;S1PR1
prerank,GO_Biological_Process_2021__phosphatidic acid biosynthetic process (GO:0006654),0.8471636705248762,1.1375476948729968,0.4878048780487805,1.0,1.0,6/44,2.26%,LCLAT1;AGPAT3;GPAT4;PLD1;PNPLA3;GPD1L
prerank,GO_Biological_Process_2021__activation of GTPase activity (GO:0090630),-0.7792518542822321,-1.1361921214102415,0.2826086956521739,1.0,1.0,9/94,2.11%,EVI5;RABGAP1;SIPA1L1;TBC1D12;TBC1D4;BCAS3;ARHGEF26;NTF3;GARNL3
prerank,Elsevier_Pathway_Collection__B-Cell Activation in Systemic Lupus Erythematosus,0.8256612882673473,1.1359608760735187,0.325,1.0,1.0,4/62,2.06%,CREB1;SYK;NFATC2;PIK3AP1
prerank,Reactome_2022__Chaperonin-mediated Protein Folding R-HSA-390466,0.8338596921951477,1.1353442792453654,0.3170731707317073,1.0,1.0,5/81,2.34%,KIF13A;WRAP53;GNB5;TUBA1A;GNG2
prerank,WikiPathway_2021_Human__Pregnane X receptor pathway WP2876,-0.8445997637992867,-1.134502052938783,0.5289256198347108,1.0,1.0,3/33,1.27%,CYP3A7;NCOA1;GSTA2
prerank,TRRUST_Transcription_Factors_2019__GLI2 human,-0.6636283908140304,-1.13390265981979,0.40458015267175573,1.0,1.0,1/16,0.31%,TNFRSF10B
prerank,GO_Biological_Process_2021__glutathione metabolic process (GO:0006749),-0.8445965865917681,-1.1336594611303863,0.5083333333333333,1.0,1.0,3/39,1.27%,GSTA1;GGT5;GSTA2
prerank,WikiPathway_2021_Human__Leptin signaling pathway WP2034,0.8024189371851176,1.1331530096902176,0.28688524590163933,1.0,1.0,5/76,1.59%,ACACA;CREB1;PTK2;PRKAA2;IL1RN
prerank,GO_Biological_Process_2021__mitochondrial respiratory chain complex assembly (GO:0033108),-0.7912070786242266,-1.1330289829348286,0.2764227642276423,1.0,1.0,4/90,0.90%,COX16;NDUFAF2;NDUFS4;SDHAF3
prerank,Reactome_2022__Gene Silencing By RNA R-HSA-211000,0.7895447851967049,1.1304536188103953,0.2661290322580645,1.0,1.0,2/95,1.05%,DROSHA;NUP210
prerank,GO_Biological_Process_2021__negative regulation of lymphocyte proliferation (GO:0050672),0.8343246041108308,1.1304114309908848,0.5109489051094891,1.0,1.0,4/36,2.29%,CD300A;TNFRSF21;MNDA;CD86
prerank,"Reactome_2022__Interleukin-3, Interleukin-5 And GM-CSF Signaling R-HSA-512988",-0.8101252168565906,-1.130197420780178,0.4230769230769231,1.0,1.0,5/42,2.34%,PIK3CB;TEC;HCK;STAT5A;VAV1
prerank,Elsevier_Pathway_Collection__Familial Partial Lipodystrophy Type 4 Progression (Hypothesis),0.7966160946218075,1.130141332750887,0.5454545454545454,1.0,1.0,2/17,0.35%,PPARA;ACACA
prerank,TRRUST_Transcription_Factors_2019__YBX1 human,0.8164075502302993,1.1300299360515746,0.48760330578512395,1.0,1.0,4/28,1.71%,ERBB3;MYCN;SLC6A4;CDH1
prerank,GO_Biological_Process_2021__retinoic acid metabolic process (GO:0042573),-0.7938452576854951,-1.129308910531747,0.5172413793103449,1.0,1.0,2/25,0.63%,CYP3A7;CYP2C8
prerank,MSigDB_Oncogenic_Signatures__STK33 UP,-0.6776470052231212,-1.1289722951465881,0.18604651162790697,1.0,1.0,10/254,2.26%,TGIF1;TFPI;ZNF117;GPR137B;CREB5;RASGRP3;IL10RA;FCAMR;CLEC2B;CD9
prerank,GO_Biological_Process_2021__metanephros development (GO:0001656),-0.815910996984317,-1.128493403907429,0.553030303030303,1.0,1.0,4/23,1.76%,SHH;BMP4;PAX8;BASP1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Primary Ovarian Insufficiency,0.8169667704076652,1.128434476495065,0.3769230769230769,1.0,1.0,3/55,1.64%,IGF2R;BRSK1;AMH
prerank,GO_Biological_Process_2021__transforming growth factor beta receptor signaling pathway (GO:0007179),0.7865056913248077,1.1278209391349554,0.24427480916030533,1.0,1.0,6/87,2.32%,USP15;PTK2;ARHGEF18;SMAD9;ITGB5;ZFYVE9
prerank,GO_Biological_Process_2021__cellular response to ionizing radiation (GO:0071479),0.810850554185226,1.1268064132513693,0.44,1.0,1.0,3/48,2.26%,TLK2;ATR;PRAP1
prerank,WikiPathway_2021_Human__22q11.2 copy number variation syndrome WP4657,0.7710655679979141,1.1265272423580954,0.25547445255474455,1.0,1.0,6/102,2.07%,CDC45;HIRA;DROSHA;CHRD;TXNRD2;CDH15
prerank,Elsevier_Pathway_Collection__EphrinB -> Cytoskeleton Signaling,0.7347329315635522,1.1262188480740478,0.4491525423728814,1.0,1.0,2/20,1.53%,PTK2;BCAR1
prerank,Reactome_2022__Mitotic Prometaphase R-HSA-68877,0.6930788665626866,1.1261789167695246,0.17391304347826086,1.0,1.0,11/183,2.15%,NEK6;HAUS8;HDAC8;CENPE;CEP164;NCAPG;NDC80;HAUS2;CENPA;ERCC6L;TUBA1A
prerank,Elsevier_Pathway_Collection__Proteins Involved in Parkinson's Disease,0.7954697426816004,1.1258795240725892,0.2540983606557377,1.0,1.0,4/88,2.28%,MAOA;PTGS2;APOE;HGF
prerank,Elsevier_Pathway_Collection__Glucocorticoids in Insulin Resistance in Skeletal Muscles,-0.8201359915222259,-1.1255828886056949,0.5338983050847458,1.0,1.0,5/34,1.34%,NR3C1;NCOA1;TBC1D4;CREBBP;DEPTOR
prerank,Reactome_2022__RHO GTPase Cycle R-HSA-9012999,0.6264559440781541,1.1244936253736157,0.13636363636363635,1.0,1.0,32/430,2.31%,ABI2;DEPDC1B;PKP4;RALGAPA1;SLC4A7;SENP1;FNBP1;RBBP6;RAB7A;RHOQ;WWP2;ARHGEF7;ARHGAP12;CKAP4;ARHGAP39;PLEKHG5;BAIAP2L2;MOSPD2;ARHGEF18;CDC42EP1;DOCK11;IQGAP3;ANLN;DLC1;SPATA13;CAVIN1;FMNL2;PLEKHG6;CYBA;SH3RF1;RHPN2;UACA
prerank,GO_Biological_Process_2021__RNA processing (GO:0006396),0.7197530228093909,1.1244422062612478,0.22413793103448276,1.0,1.0,3/171,1.36%,TENT2;DROSHA;SF3A2
prerank,GO_Biological_Process_2021__regulation of sodium ion transmembrane transporter activity (GO:2000649),-0.8306076812593778,-1.1236284395910343,0.5343511450381679,1.0,1.0,3/36,1.57%,WNK3;NEDD4;FXYD6
prerank,WikiPathway_2021_Human__Fragile X Syndrome  WP4549,-0.7559904871846259,-1.1231301271313296,0.22627737226277372,1.0,1.0,5/116,1.34%,PIK3CB;ABCD3;APP;GRIN2B;DEPTOR
prerank,TRRUST_Transcription_Factors_2019__AHR mouse,-0.7803501283689107,-1.123054511866532,0.5327868852459017,1.0,1.0,3/19,1.98%,GSTA1;CYP1B1;CYP1A2
prerank,GO_Biological_Process_2021__positive regulation of protein binding (GO:0032092),-0.8312494188520296,-1.1224675764832563,0.4166666666666667,1.0,1.0,3/57,1.50%,AMFR;APP;BMP4
prerank,GO_Biological_Process_2021__regulation of epithelial cell proliferation (GO:0050678),0.799892306241182,1.1217747856979783,0.25925925925925924,1.0,1.0,4/89,2.37%,CDK6;ZNF304;NOD2;FGF1
prerank,Reactome_2022__Interleukin-2 Family Signaling R-HSA-451927,-0.7783714419783471,-1.12126693692016,0.39568345323741005,1.0,1.0,4/40,2.18%,PTK2B;PIK3CB;STAT5A;IL21R
prerank,TRRUST_Transcription_Factors_2019__NR3C1 mouse,0.7318519760852928,1.1205828752106624,0.4957983193277311,1.0,1.0,2/16,1.82%,CDK6;PTGS2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hashimoto's Thyroiditis,0.6961329043977719,1.1201757646549353,0.44,1.0,1.0,2/22,1.82%,CD4;PTGS2
prerank,GO_Biological_Process_2021__endoplasmic reticulum organization (GO:0007029),-0.7912517968756724,-1.119764130903089,0.3014705882352941,1.0,1.0,2/69,0.88%,APP;ATL2
prerank,KEGG_2021_Human__Sphingolipid metabolism,-0.8682551373707995,-1.119583597999013,0.5185185185185185,1.0,1.0,5/47,2.08%,PLPP1;SGPP1;SGPL1;GALC;SMPD1
prerank,GO_Biological_Process_2021__regulation of RIG-I signaling pathway (GO:0039535),0.6585524867826584,1.119399776202175,0.3958333333333333,1.0,1.0,1/18,0.81%,USP15
prerank,KEGG_2021_Human__Arrhythmogenic right ventricular cardiomyopathy,0.7916833304447112,1.1190063816768652,0.325,1.0,1.0,6/71,1.80%,CDH2;ITGA3;ITGA4;ITGA2;ITGB5;CACNA2D4
prerank,Elsevier_Pathway_Collection__Vitamin K Metabolism,-0.6452891009439288,-1.1186665985057838,0.425531914893617,1.0,1.0,2/16,2.15%,PROS1;PRRG4
prerank,"GO_Biological_Process_2021__retrograde transport, endosome to Golgi (GO:0042147)",-0.7892805293999142,-1.1186235015288715,0.2894736842105263,1.0,1.0,4/87,1.09%,EVI5;RIC1;ERC1;VPS50
prerank,Reactome_2022__Interferon Signaling R-HSA-913531,-0.690603800683247,-1.118473027305075,0.18333333333333332,1.0,1.0,12/181,2.40%,KPNA3;OAS1;NEDD4;HERC5;CD44;TRIM46;PML;OASL;HLA-B;CIITA;IFI6;GBP4
prerank,GO_Biological_Process_2021__positive regulation of phosphoprotein phosphatase activity (GO:0032516),0.7412715687629647,1.1184010034590268,0.5,1.0,1.0,3/17,0.88%,CD300A;CD33;PPP1R12A
prerank,Reactome_2022__Sphingolipid Metabolism R-HSA-428157,-0.8127066997381628,-1.118323902809498,0.30303030303030304,1.0,1.0,6/86,2.08%,STS;PLPP1;SGPP1;SGPL1;GALC;SMPD1
prerank,Reactome_2022__L1CAM Interactions R-HSA-373760,0.7573351928833673,1.1182536164969594,0.25,1.0,1.0,5/96,2.06%,DLG1;CNTNAP1;SPTBN2;ITGA2;DPYSL2
prerank,KEGG_2021_Human__Hypertrophic cardiomyopathy,0.7916761984804064,1.1180937599049618,0.28695652173913044,1.0,1.0,6/81,1.80%,ITGA3;PRKAA2;ITGA4;ITGA2;ITGB5;CACNA2D4
prerank,WikiPathway_2021_Human__Hedgehog Signaling Pathway WP4249,-0.8460757614501441,-1.117901147653059,0.4806201550387597,1.0,1.0,5/41,2.08%,SUFU;SHH;CCND2;BOC;GLI3
prerank,GO_Biological_Process_2021__fatty acid transmembrane transport (GO:1902001),0.655707165161764,1.1175456471622853,0.41935483870967744,1.0,1.0,2/19,1.10%,ACACA;PRKAA2
prerank,KEGG_2021_Human__Necroptosis,-0.7277918544922246,-1.1174795649930025,0.25384615384615383,1.0,1.0,5/130,2.23%,TNFRSF10B;STAT5A;TICAM2;SMPD1;PYGM
prerank,GO_Biological_Process_2021__protein-containing complex subunit organization (GO:0043933),-0.7440218472168357,-1.117450195288106,0.234375,1.0,1.0,8/110,2.09%,PTK2B;SLC7A9;KPNA3;PARD3;CREBBP;MATN1;CARD10;PML
prerank,GO_Biological_Process_2021__protein palmitoylation (GO:0018345),-0.7905354293720698,-1.1173324661662727,0.48760330578512395,1.0,1.0,2/30,0.96%,ZDHHC14;ZDHHC21
prerank,MSigDB_Oncogenic_Signatures__STK33 SKM UP,-0.6793863266635928,-1.117281862982564,0.23529411764705882,1.0,1.0,16/239,2.26%,ZNF678;EVI5;TFPI;ZNF117;GPR137B;ZNF763;TNFAIP2;TGFB1I1;GPR132;CREB5;STOX2;RASGRP3;IL10RA;FCAMR;MFAP3L;CD9
prerank,GO_Biological_Process_2021__Golgi to endosome transport (GO:0006895),-0.6592073300688711,-1.1170213425690583,0.45,1.0,1.0,2/16,0.76%,MON2;VPS13C
prerank,GO_Biological_Process_2021__cellular response to organic cyclic compound (GO:0071407),-0.7258508127639602,-1.1166521364267505,0.22137404580152673,1.0,1.0,10/143,2.44%,NR3C1;RAP1B;TFPI;RAP1A;RAPGEF3;ADCY3;CYP1B1;RORC;AOC1;KCNE1
prerank,GO_Biological_Process_2021__regulation of cytoskeleton organization (GO:0051493),0.7664576005922492,1.1164458711245473,0.24786324786324787,1.0,1.0,9/109,1.76%,TJP1;KATNBL1;PTK2;RHOQ;PRKAA2;CAMSAP3;IQGAP3;DLC1;STMN3
prerank,WikiPathway_2021_Human__Apoptosis WP254,0.790980820673727,1.116184194618123,0.30952380952380953,1.0,1.0,5/83,1.87%,TRAF3;TNFRSF21;CASP7;TNFRSF25;BOK
prerank,MSigDB_Oncogenic_Signatures__HOXA9 DN.V1 DN,0.7121834538595911,1.1148206835591423,0.24603174603174602,1.0,1.0,13/169,2.29%,CDC45;CD300A;FANCL;GINS1;ITGA4;CBS;ITGB5;ZNF395;SLC38A1;ELOVL6;SPON2;COL9A3;RNF144A
prerank,Reactome_2022__Transport To Golgi And Subsequent Modification R-HSA-948021,0.7160094048694704,1.1147686291153025,0.2457627118644068,1.0,1.0,4/159,1.74%,COG5;SPTBN2;MOGAT2;MAN1A1
prerank,Reactome_2022__Cargo Recognition For Clathrin-Mediated Endocytosis R-HSA-8856825,0.7687788523827975,1.1147681973997745,0.28,1.0,1.0,4/99,1.70%,IGF2R;CD4;SLC2A8;GRK3
prerank,GO_Biological_Process_2021__RNA stabilization (GO:0043489),0.8137124675382911,1.1142512488615888,0.5172413793103449,1.0,1.0,3/31,1.97%,TENT2;PARN;AXIN2
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Breast Cancer,0.7329971072959811,1.1142036970227258,0.4482758620689655,1.0,1.0,2/28,1.71%,TNFRSF10A;CDH1
prerank,GO_Biological_Process_2021__regulation of T cell proliferation (GO:0042129),0.8343314497656873,1.1141108906886505,0.3333333333333333,1.0,1.0,5/71,2.29%,TNFRSF21;ANXA1;SLC7A1;LGALS3;CD86
prerank,GO_Biological_Process_2021__regulation of stress-activated MAPK cascade (GO:0032872),0.811543191222975,1.113509457224075,0.43548387096774194,1.0,1.0,4/48,2.19%,NOD2;MID1;ULK4;MAPK8IP1
prerank,MSigDB_Hallmark_2020__Myc Targets V1,0.695849457537316,1.113413692391045,0.2564102564102564,1.0,1.0,3/200,1.84%,CDC45;YWHAQ;HPRT1
prerank,Reactome_2022__RHOV GTPase Cycle R-HSA-9013424,0.7561139978197248,1.1134006573160324,0.4473684210526316,1.0,1.0,4/36,2.18%,DEPDC1B;ARHGEF7;ARHGAP12;SH3RF1
prerank,MSigDB_Hallmark_2020__Oxidative Phosphorylation,-0.6925186075091808,-1.1126815563352104,0.24305555555555555,1.0,1.0,3/200,2.17%,TOMM70;NDUFS4;MAOB
prerank,GO_Biological_Process_2021__regulation of macroautophagy (GO:0016241),0.7577500563149671,1.1123626299495322,0.3064516129032258,1.0,1.0,4/108,2.01%,ERN1;CLEC16A;PRKAA2;QSOX1
prerank,GO_Biological_Process_2021__negative regulation of cell aging (GO:0090344),0.6929850529441521,1.1123387621801126,0.43902439024390244,1.0,1.0,3/16,2.14%,RBL1;CDK6;SLC30A10
prerank,MSigDB_Oncogenic_Signatures__ESC V6.5 UP LATE.V1 UP,0.7186128623449257,1.1120963990625174,0.22950819672131148,1.0,1.0,14/167,2.18%,PLOD2;CDH2;MICU1;RNF130;PKDCC;SOAT2;MOGAT2;ZFPM1;SGCE;CTSH;RBP4;CYBA;ZDHHC9;SH3RF1
prerank,MSigDB_Oncogenic_Signatures__BMI1 DN MEL18 DN.V1 UP,0.7203014548507551,1.1120259112075102,0.22807017543859648,1.0,1.0,10/131,2.36%,ITGA3;SLC19A1;PLAUR;CHST11;ITGA4;TUFT1;FOSL1;SCML2;TIMP3;STX1A
prerank,GO_Biological_Process_2021__positive regulation of cold-induced thermogenesis (GO:0120162),0.7569535937899035,1.1118582502624978,0.288,1.0,1.0,3/89,2.09%,SYK;ELOVL6;PRLR
prerank,Elsevier_Pathway_Collection__Proteins Involved in Breast Cancer Related to WNT Signaling Pathway,0.7803775096759623,1.1112630335640838,0.49074074074074076,1.0,1.0,3/33,1.97%,LRP5;CDH1;AXIN2
prerank,GO_Biological_Process_2021__fat-soluble vitamin metabolic process (GO:0006775),-0.7282323897674333,-1.1106330752024867,0.45454545454545453,1.0,1.0,2/22,2.19%,TTPA;VDR
prerank,GO_Biological_Process_2021__positive regulation of pri-miRNA transcription by RNA polymerase II (GO:1902895),-0.7761455198264444,-1.1105380602936277,0.49572649572649574,1.0,1.0,3/33,2.40%,NR3C1;KLF4;SPI1
prerank,WikiPathway_2021_Human__Arrhythmogenic Right Ventricular Cardiomyopathy WP2118,0.7916854822326191,1.1105235583570152,0.35,1.0,1.0,6/68,1.80%,CDH2;ITGA3;ITGA4;ITGA2;ITGB5;CACNA2D4
prerank,GO_Biological_Process_2021__axonal transport (GO:0098930),-0.788840228482843,-1.1103183909399081,0.5,1.0,1.0,2/36,1.13%,AP3B1;DTNBP1
prerank,GO_Biological_Process_2021__cellular response to reactive oxygen species (GO:0034614),0.780316747784803,1.1102692804933456,0.3709677419354839,1.0,1.0,4/61,1.98%,MPV17;AGAP3;ANXA1;MAPK13
prerank,GO_Biological_Process_2021__positive regulation of B cell activation (GO:0050871),0.7982779849618841,1.1100846506981543,0.4224137931034483,1.0,1.0,3/48,2.00%,NOD2;SYK;NFATC2
prerank,Reactome_2022__E2F Mediated Regulation Of DNA Replication R-HSA-113510,-0.7386167349873877,-1.1098114936932335,0.5040650406504065,1.0,1.0,3/21,1.15%,ORC4;PRIM2;RB1
prerank,GO_Biological_Process_2021__regulation of intracellular signal transduction (GO:1902531),0.6293354169194298,1.1097843666586162,0.1981981981981982,1.0,1.0,23/428,2.37%,TAF4;WWC2;TRAF3;DEPDC1B;ING5;DLG1;NEK8;RHOQ;ATR;ARHGEF7;PPP1R16B;PRKAA2;ARHGAP12;BRIP1;ARHGAP39;PLEKHG5;ARHGEF18;DLC1;PPP1R13L;A2M;OPTN;ULK4;FGF1
prerank,Elsevier_Pathway_Collection__ROS and RNS in Vasoconstriction and Vasodilation Regulation,-0.7767288821429706,-1.1092907487380896,0.5407407407407407,1.0,1.0,3/26,2.34%,PTK2B;SMPD1;VAV1
prerank,Elsevier_Pathway_Collection__Metastatic Colorectal Cancer,0.7774644041829969,1.108961872042721,0.31496062992125984,1.0,1.0,9/109,2.28%,MSH2;PTK2;CASP7;CDH1;FHL2;PTGS2;AXIN2;FN1;HGF
prerank,Reactome_2022__DNA Replication R-HSA-69306,0.7196422171123266,1.1086679350528068,0.2564102564102564,1.0,1.0,7/141,2.24%,CDC45;SLC19A1;GINS1;POLE4;PSMB9;UBE2C;LRIG1
prerank,Elsevier_Pathway_Collection__MHC1 Causes Antigen Presentation Failure in Cancer Immune Escape,0.7658539604025015,1.1085793663821273,0.5151515151515151,1.0,1.0,2/25,1.20%,TPP2;PSMB9
prerank,GO_Biological_Process_2021__positive regulation of receptor signaling pathway via JAK-STAT (GO:0046427),-0.7803071076671274,-1.1084382087541835,0.5343511450381679,1.0,1.0,3/25,1.98%,PTK2B;CYP1B1;IL10RA
prerank,MSigDB_Oncogenic_Signatures__AKT UP.V1 DN,-0.7083845962799332,-1.108195561855811,0.2711864406779661,1.0,1.0,11/169,2.36%,CDC42BPA;ZEB1;TYW1;HIC1;SLCO3A1;C1R;STAT5A;SLIT3;RORC;GNA14;FBXO32
prerank,GO_Biological_Process_2021__glutamate metabolic process (GO:0006536),0.7348084481926118,1.107845212874547,0.48412698412698413,1.0,1.0,2/22,1.53%,MTHFS;GLS
prerank,Elsevier_Pathway_Collection__Nociception Expression Targets Signaling,-0.7476316595871167,-1.107730704029544,0.2727272727272727,1.0,1.0,10/128,2.01%,PTK2B;MAP2K6;CCL23;GRIN2B;RAP1A;CREBBP;HRH2;STAT5A;MMP2;BDKRB2
prerank,GO_Biological_Process_2021__positive regulation of transport (GO:0051050),0.8118946543387511,1.107630664496877,0.33858267716535434,1.0,1.0,5/87,2.16%,TUB;ANXA1;BOK;APOE;CYBA
prerank,GO_Biological_Process_2021__energy reserve metabolic process (GO:0006112),-0.7277745371740659,-1.1074795409017588,0.4881889763779528,1.0,1.0,2/18,2.23%,PHKB;PYGM
prerank,GO_Biological_Process_2021__negative regulation of DNA recombination (GO:0045910),0.8118864605217629,1.107251712872416,0.4444444444444444,1.0,1.0,3/52,2.15%,MSH2;SMCHD1;ACD
prerank,TRRUST_Transcription_Factors_2019__VDR human,0.7926692543632783,1.1068846482445178,0.43846153846153846,1.0,1.0,6/37,1.71%,PLD1;TNFRSF21;IGFBP3;ASAP2;AMH;CDH1
prerank,Reactome_2022__Nicotinamide Salvaging R-HSA-197264,-0.6664352709206437,-1.1064830366598193,0.4016393442622951,1.0,1.0,1/17,0.03%,PARP8
prerank,GO_Biological_Process_2021__negative regulation of response to biotic stimulus (GO:0002832),0.7321501276044897,1.1060531665858557,0.4666666666666667,1.0,1.0,2/29,1.79%,LILRA2;SIGIRR
prerank,Reactome_2022__Synthesis Of DNA R-HSA-69239,0.7196649225699381,1.1056674426246351,0.26356589147286824,1.0,1.0,7/115,2.24%,CDC45;SLC19A1;GINS1;POLE4;PSMB9;UBE2C;LRIG1
prerank,GO_Biological_Process_2021__sensory perception of mechanical stimulus (GO:0050954),0.7950944719002646,1.1056595247447611,0.352,1.0,1.0,3/77,2.31%,TBL1X;TSPEAR;MYO7A
prerank,WikiPathway_2021_Human__Hematopoietic Stem Cell Differentiation WP2849,-0.8330789654491606,-1.1054060095088052,0.4330708661417323,1.0,1.0,6/51,2.43%,STAT5A;RHOH;CIITA;VAV1;SPI1;FOSB
prerank,GO_Biological_Process_2021__cellular response to interferon-gamma (GO:0071346),-0.7429293127484786,-1.1045852705023724,0.23140495867768596,1.0,1.0,9/115,2.40%,OAS1;CCL23;HCK;CD44;PML;OASL;HLA-B;CIITA;GBP4
prerank,Reactome_2022__HIV Life Cycle R-HSA-162587,0.7018032005145083,1.1044900832490345,0.25,1.0,1.0,6/144,2.24%,TAF4;TCEA1;GTF2E2;NUP210;CD4;LRIG1
prerank,KEGG_2021_Human__Retinol metabolism,-0.8369585873646044,-1.104477091914546,0.432,1.0,1.0,4/62,2.03%,CYP3A7;CYP2C8;CYP1A2;HSD17B6
prerank,GO_Biological_Process_2021__glutamate receptor signaling pathway (GO:0007215),-0.8465240160995877,-1.1041473798640873,0.616,1.0,1.0,3/31,1.08%,PTK2B;APP;GRIN2B
prerank,WikiPathway_2021_Human__Prion disease pathway WP3995,0.7914576338669264,1.1039287832984135,0.4830508474576271,1.0,1.0,2/33,0.86%,CREB1;PTK2
prerank,Elsevier_Pathway_Collection__Osteoarthritis,-0.8126339334726155,-1.1037347514547586,0.3467741935483871,1.0,1.0,3/79,2.08%,MAP2K6;ADAMTS5;GLI3
prerank,KEGG_2021_Human__One carbon pool by folate,0.7647416593475277,1.1035578553420053,0.5299145299145299,1.0,1.0,2/19,1.31%,MTHFS;FTCD
prerank,KEGG_2021_Human__Ras signaling pathway,-0.6862026032073186,-1.1031798922007234,0.2246376811594203,1.0,1.0,15/212,2.44%,EXOC2;PAK2;RASA2;RAP1B;AKT3;PIK3CB;GRIN2B;PLAAT3;RAP1A;RASGRP2;RASSF5;NTF3;TEK;RASGRP3;ZAP70
prerank,Reactome_2022__Formation Of beta-catenin:TCF Transactivating Complex R-HSA-201722,-0.7878716274116705,-1.1028784039939807,0.4411764705882353,1.0,1.0,2/49,1.22%,TLE4;CREBBP
prerank,GO_Biological_Process_2021__ncRNA metabolic process (GO:0034660),0.7912652578617259,1.10278854007886,0.5126050420168067,1.0,1.0,2/33,0.88%,PARN;DROSHA
prerank,GO_Biological_Process_2021__positive regulation of interleukin-10 production (GO:0032733),0.7652747344839138,1.102605308634897,0.47692307692307695,1.0,1.0,2/29,1.26%,NOD2;SYK
prerank,GO_Biological_Process_2021__regulation of endopeptidase activity (GO:0052548),0.8252762165988395,1.1024351077183505,0.4180327868852459,1.0,1.0,5/62,2.10%,PSMB9;TIMP3;SERPINA7;SERPINE1;SERPINA5
prerank,WikiPathway_2021_Human__LncRNA involvement in canonical Wnt signaling and colorectal cancer WP4258,0.7803742158859412,1.1018194864133015,0.3252032520325203,1.0,1.0,4/87,1.97%,LRP5;CDK6;FOSL1;AXIN2
prerank,Elsevier_Pathway_Collection__Coagulation Cascade,-0.7143116294319323,-1.1014143276368364,0.47580645161290325,1.0,1.0,2/23,1.31%,TFPI;PROS1
prerank,Elsevier_Pathway_Collection__Hereditary Thrombophilia and Pregnancy Complications,-0.7143116294319323,-1.1014143276368364,0.47580645161290325,1.0,1.0,2/23,1.31%,TFPI;PROS1
prerank,Elsevier_Pathway_Collection__Thrombophilia Hereditary,-0.7143116294319323,-1.1014143276368364,0.47580645161290325,1.0,1.0,2/23,1.31%,TFPI;PROS1
prerank,GO_Biological_Process_2021__sphingolipid metabolic process (GO:0006665),-0.7544680630084262,-1.1013485662703748,0.2962962962962963,1.0,1.0,9/113,2.08%,STS;PLPP1;SGPP1;SGPL1;AGK;HACD2;ARV1;GALC;SMPD1
prerank,GO_Biological_Process_2021__sensory perception of sound (GO:0007605),0.7950927391339905,1.1012061839735552,0.3524590163934426,1.0,1.0,3/79,2.31%,TBL1X;TSPEAR;MYO7A
prerank,Reactome_2022__RND1 GTPase Cycle R-HSA-9696273,0.8332984507734772,1.1010045641034816,0.52,1.0,1.0,3/41,1.29%,DEPDC1B;PKP4;PLEKHG5
prerank,GO_Biological_Process_2021__hexose metabolic process (GO:0019318),-0.7952653755883593,-1.1002354667674918,0.4645669291338583,1.0,1.0,2/38,0.48%,ALDOB;OAS1
prerank,MSigDB_Oncogenic_Signatures__GCNP SHH UP LATE.V1 UP,0.6938420910180257,1.1002301654071782,0.25,1.0,1.0,10/163,2.38%,YTHDF3;ARL5A;EIF2A;ASB3;PHTF2;STRN3;ELOVL2;BOK;CDCA7;RRM2
prerank,GO_Biological_Process_2021__actin polymerization or depolymerization (GO:0008154),0.7804424848419349,1.1000968191607086,0.4049586776859504,1.0,1.0,4/49,1.97%,ABI2;SVIL;SPIRE2;MICAL3
prerank,KEGG_2021_Human__Proteoglycans in cancer,0.6626142840509273,1.100095785581895,0.25862068965517243,1.0,1.0,13/194,2.29%,PIK3CD;PLAUR;PTK2;DROSHA;PPP1R12A;ERBB3;ITGA2;ITGB5;TIMP3;MAPK13;FN1;HGF;FLNA
prerank,WikiPathway_2021_Human__PI3K/AKT/mTOR - VitD3 signaling WP4141,0.7271180793144438,1.0995601041960417,0.48598130841121495,1.0,1.0,2/21,2.29%,PRKAA2;CD86
prerank,GO_Biological_Process_2021__regulation of interleukin-1 beta production (GO:0032651),0.8176472779771489,1.0994839276597792,0.36363636363636365,1.0,1.0,6/76,2.25%,LILRA2;CD33;NOD2;MEFV;CX3CL1;MNDA
prerank,WikiPathway_2021_Human__Focal Adhesion-PI3K-Akt-mTOR-signaling pathway WP3932,0.6515741962134762,1.0985807962208478,0.23076923076923078,1.0,1.0,18/283,2.39%,ITGA3;ACACA;PIK3CD;CREB1;CAB39;PTK2;LPAR1;PRKAA2;ITGA4;ITGAL;ITGA2;ITGB5;PRLR;FN1;HGF;GNG2;FGF1;PIK3C2B
prerank,GO_Biological_Process_2021__regulation of lipid biosynthetic process (GO:0046890),0.8551854893290867,1.0985641718167565,0.6071428571428571,1.0,1.0,4/33,1.99%,PPARA;CREB1;PRKAA2;APOE
prerank,KEGG_2021_Human__Protein processing in endoplasmic reticulum,0.6910455327608905,1.0983123602117535,0.23931623931623933,1.0,1.0,5/165,1.74%,ERN1;UBXN2A;DAD1;CKAP4;MAN1A1
prerank,Elsevier_Pathway_Collection__MacrophageR -> CEBPB -> NF-kB Signaling,-0.6851975777260098,-1.0982552988918157,0.4351145038167939,1.0,1.0,2/15,1.49%,PTK2B;HCK
prerank,"GO_Biological_Process_2021__wound healing, spreading of cells (GO:0044319)",0.7771932538006678,1.098198708792171,0.5390625,1.0,1.0,3/23,2.29%,MRTFA;CARMIL2;FLNA
prerank,TRRUST_Transcription_Factors_2019__RFX1 human,0.6906402106526701,1.0977923095478683,0.4426229508196721,1.0,1.0,2/15,2.37%,ITGAL;FGF1
prerank,GO_Biological_Process_2021__cation transport (GO:0006812),-0.7128341935955909,-1.0975153043168064,0.30708661417322836,1.0,1.0,9/157,2.42%,SLC22A1;CATSPER3;KCNN2;SLC36A4;SLC7A8;KCNAB3;KCNK6;KCNS3;SLC17A4
prerank,Elsevier_Pathway_Collection__WNT Signaling in Breast Cancer,0.7329920695203225,1.0972675404975545,0.4406779661016949,1.0,1.0,2/35,1.71%,LRP5;CDH1
prerank,KEGG_2021_Human__Parkinson disease,0.6626974469529728,1.0967471781214688,0.26229508196721313,1.0,1.0,4/222,2.15%,ERN1;NDUFA10;MAOA;TUBA1A
prerank,KEGG_2021_Human__PI3K-Akt signaling pathway,0.6265470262701288,1.0965501730899683,0.17543859649122806,1.0,1.0,23/313,2.41%,ITGA3;PIK3CD;CREB1;YWHAQ;CDK6;PTK2;LPAR1;PRKAA2;ERBB3;ITGA4;SYK;ITGA2;GNB5;ITGB5;PIK3AP1;PRLR;COL9A3;FN1;HGF;COL9A2;GNG2;FGF1;COL4A5
prerank,GO_Biological_Process_2021__positive regulation of TORC1 signaling (GO:1904263),-0.6540551820081365,-1.0963734149135431,0.45,1.0,1.0,2/16,1.27%,SIK3;GPR137B
prerank,WikiPathway_2021_Human__Ovarian infertility WP34,-0.7560444494109138,-1.0961524823093316,0.5,1.0,1.0,3/27,2.19%,CCND2;SMPD1;VDR
prerank,"GO_Biological_Process_2021__regulation of gene expression, epigenetic (GO:0040029)",0.7920567283965426,1.0959854509217144,0.3064516129032258,1.0,1.0,2/82,0.80%,TAF1B;PHF2
prerank,TRRUST_Transcription_Factors_2019__NFKB1 mouse,0.6947946939015006,1.0958340265975441,0.2824427480916031,1.0,1.0,13/179,2.29%,PPARA;PLAUR;UBE2H;TNFRSF25;AMH;CDH1;PTGS2;MSX1;TIMP3;PPP1R13L;APOE;FN1;CD86
prerank,GO_Biological_Process_2021__regulation of catecholamine secretion (GO:0050433),-0.7946424372699915,-1.095685907857909,0.5692307692307692,1.0,1.0,3/25,2.37%,DTNBP1;SYT2;SYT7
prerank,WikiPathway_2021_Human__Association Between Physico-Chemical Features and Toxicity Associated Pathways WP3680,0.8107205175262153,1.095545255125624,0.40476190476190477,1.0,1.0,3/64,2.27%,ACTR3;PTK2;FN1
prerank,Reactome_2022__G2/M Checkpoints R-HSA-69481,0.7087227036790112,1.0955123589379625,0.2773109243697479,1.0,1.0,6/139,1.56%,CDC45;HERC2;YWHAQ;BRIP1;PSMB9;PKMYT1
prerank,MSigDB_Oncogenic_Signatures__BCAT BILD ET AL DN,0.7751933467610125,1.095457740073653,0.46846846846846846,1.0,1.0,4/44,1.44%,ASH1L;IRAK2;ZSWIM6;ARHGEF18
prerank,GO_Biological_Process_2021__release of cytochrome c from mitochondria (GO:0001836),-0.7263517721321385,-1.0953505628504334,0.49074074074074076,1.0,1.0,2/18,2.37%,SOD2;IFI6
prerank,"Elsevier_Pathway_Collection__Integrins in Cancer Cell Motility, Invasion and Survival",0.766969187876744,1.0951222463885895,0.272,1.0,1.0,6/73,2.27%,PTK2;ITGA4;BCAR1;ITGA2;PTGS2;FN1
prerank,WikiPathway_2021_Human__Hippo-Yap signaling pathway WP4537,0.7315005277480306,1.0947805284140528,0.5080645161290323,1.0,1.0,2/23,1.86%,YWHAQ;TEAD4
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Activation by Blood Coagulation Factors,-0.7800126227446431,-1.0947313097071463,0.39705882352941174,1.0,1.0,4/57,2.01%,TFPI;PROS1;PROCR;BDKRB2
prerank,Elsevier_Pathway_Collection__Thyroid Hormones Common Genomic Effects in Hyperthyroidism,-0.7755713377451268,-1.0946144110514155,0.5081967213114754,1.0,1.0,3/30,2.46%,NCOA1;VDR;SLC16A2
prerank,GO_Biological_Process_2021__positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway (GO:0051482),0.7289607991778134,1.094301715072023,0.4642857142857143,1.0,1.0,2/25,2.11%,LPAR1;GPR35
prerank,Reactome_2022__HIV Infection R-HSA-162906,0.6633504491278628,1.0942577143492602,0.22764227642276422,1.0,1.0,7/222,2.24%,TAF4;TCEA1;GTF2E2;NUP210;PSMB9;CD4;LRIG1
prerank,GO_Biological_Process_2021__regulation of fat cell differentiation (GO:0045598),0.8147551778575941,1.0942481816614738,0.33043478260869563,1.0,1.0,3/77,1.86%,CREB1;LRP5;ZFPM1
prerank,GO_Biological_Process_2021__anterograde trans-synaptic signaling (GO:0098916),-0.6813057330470048,-1.0940371419691977,0.30597014925373134,1.0,1.0,5/184,1.88%,GRIN2B;HRH2;PMP22;OMP;DLG2
prerank,GO_Biological_Process_2021__gene expression (GO:0010467),0.6330731422117588,1.0939246971677072,0.18333333333333332,1.0,1.0,6/349,2.31%,UPF2;TAF1B;DROSHA;NUP210;IGF2BP3;HOXD3
prerank,WikiPathway_2021_Human__Cell cycle WP179,0.716381830500526,1.09376345858053,0.26548672566371684,1.0,1.0,8/119,1.56%,CDC45;RBL1;YWHAQ;CDK6;TFDP2;ATR;CDC14B;PKMYT1
prerank,Reactome_2022__Xenobiotics R-HSA-211981,-0.7303098853438098,-1.0937075565642391,0.49230769230769234,1.0,1.0,2/21,1.98%,CYP2C8;CYP1A2
prerank,KEGG_2021_Human__Systemic lupus erythematosus,-0.7337552624914829,-1.0933267847454808,0.2677165354330709,1.0,1.0,2/101,1.63%,GRIN2B;C1R
prerank,MSigDB_Oncogenic_Signatures__PRC2 SUZ12 UP.V1 DN,-0.7135826934827455,-1.093174617747938,0.29310344827586204,1.0,1.0,11/151,2.01%,DCBLD2;PLEKHA5;GGT5;POU2F1;TRIM58;VILL;SLC15A3;STAT5A;CYP1B1;IPCEF1;GIMAP4
prerank,GO_Biological_Process_2021__diacylglycerol metabolic process (GO:0046339),-0.6969022861632443,-1.092876456657854,0.4689655172413793,1.0,1.0,2/22,1.75%,LIPE;MOGAT1
prerank,WikiPathway_2021_Human__Ras signaling WP4223,-0.7048318731923292,-1.0920675605192371,0.24806201550387597,1.0,1.0,13/171,2.44%,EXOC2;PAK2;RASA2;RAP1B;AKT3;PIK3CB;GRIN2B;RAP1A;RASGRP2;RASSF5;TEK;RASGRP3;ZAP70
prerank,WikiPathway_2021_Human__Oxidative Damage WP3941,0.7984765988364346,1.0917145539640776,0.49242424242424243,1.0,1.0,3/40,1.98%,TRAF3;MAP3K9;MAPK13
prerank,Reactome_2022__NCAM Signaling For Neurite Out-Growth R-HSA-375165,0.8708638028508595,1.0908388154698052,0.5396825396825397,1.0,1.0,6/53,2.41%,CREB1;PTK2;SPTBN2;COL9A3;COL9A2;COL4A5
prerank,Reactome_2022__Citric Acid (TCA) Cycle And Respiratory Electron Transport R-HSA-1428517,-0.719073437130876,-1.0907139387771472,0.272,1.0,1.0,4/161,0.83%,SUCLG2;COX16;NDUFAF2;NDUFS4
prerank,Elsevier_Pathway_Collection__Proteins Involved in Psoriatic Arthritis,0.8225547536995272,1.0902578695868563,0.4453125,1.0,1.0,4/48,2.37%,NOD2;CD4;SIGIRR;FGF1
prerank,Elsevier_Pathway_Collection__Basophil Activation,-0.7767613672435058,-1.0897987078518154,0.3793103448275862,1.0,1.0,5/75,2.34%,MAP2K6;GRAP2;STAT5A;IL17RB;VAV1
prerank,Reactome_2022__FLT3 Signaling R-HSA-9607240,-0.8331454940714075,-1.0897079820348212,0.5555555555555556,1.0,1.0,6/37,1.71%,AKT3;PTPRJ;HCK;GRB10;GRAP2;STAT5A
prerank,Reactome_2022__Fatty acyl-CoA Biosynthesis R-HSA-75105,0.8040397153826222,1.0896546307707977,0.5166666666666667,1.0,1.0,6/35,2.22%,ACSF3;ACACA;SLC27A2;ELOVL2;ELOVL6;ACSL5
prerank,WikiPathway_2021_Human__Overview of nanoparticle effects WP3287,0.7274663531973927,1.0896326415854827,0.5038759689922481,1.0,1.0,4/19,2.27%,PIK3CD;PTK2;PTGS2;FN1
prerank,GO_Biological_Process_2021__regulation of neural precursor cell proliferation (GO:2000177),0.6952499325135287,1.0895682530208852,0.4444444444444444,1.0,1.0,2/20,1.91%,PROX1;SHCBP1
prerank,WikiPathway_2021_Human__Constitutive Androstane Receptor Pathway WP2875,-0.7874187851777134,-1.0895551988683065,0.504,1.0,1.0,2/32,1.27%,NCOA1;GSTA2
prerank,GO_Biological_Process_2021__regulation of Notch signaling pathway (GO:0008593),0.8038806095702764,1.088968596995718,0.3161764705882353,1.0,1.0,5/81,1.44%,NIBAN2;NOD2;WWP2;NOTCH3;TSPEAR
prerank,KEGG_2021_Human__Cushing syndrome,-0.7180226330533692,-1.0888331321632028,0.32167832167832167,1.0,1.0,9/146,1.91%,CREB3L2;RAP1B;RB1;RAP1A;PDE11A;ADCY3;PBX1;CREB5;PLCB4
prerank,Elsevier_Pathway_Collection__AMPK Signaling,0.8054405198585165,1.0886515430843067,0.47794117647058826,1.0,1.0,4/41,1.82%,ACACA;CREB1;CAB39;PTGS2
prerank,GO_Biological_Process_2021__regulation of wound healing (GO:0061041),0.8255975829328059,1.0883869891681395,0.4247787610619469,1.0,1.0,4/46,2.07%,PTK2;CADM4;ANXA1;SERPINE1
prerank,GO_Biological_Process_2021__neutrophil activation involved in immune response (GO:0002283),0.6110233613136641,1.0883449443970123,0.19130434782608696,1.0,1.0,27/469,2.27%,LILRA2;MANBA;CD300A;CD33;IGF2R;CD53;ATAD3B;ERP44;PLAUR;CAB39;RAB7A;PLD1;CPPED1;SLC27A2;PADI2;CKAP4;SYK;NFAM1;ITGAL;MOSPD2;LAMP2;CTSH;QSOX1;LGALS3;CYBA;MNDA;COTL1
prerank,GO_Biological_Process_2021__protein glycosylation (GO:0006486),0.7140662380078158,1.0882441646226153,0.319672131147541,1.0,1.0,6/124,1.94%,PLOD2;TRAK1;POMGNT2;ST3GAL1;DAD1;FUT6
prerank,MSigDB_Hallmark_2020__DNA Repair,0.6958883633217939,1.0880710716014486,0.26717557251908397,1.0,1.0,3/147,1.84%,POLE4;DAD1;HPRT1
prerank,GO_Biological_Process_2021__regulation of organelle assembly (GO:1902115),-0.8113686612479453,-1.0880578871839062,0.3865546218487395,1.0,1.0,5/69,1.49%,EVI5;SDCCAG8;RABGAP1;TBC1D12;HCK
prerank,GO_Biological_Process_2021__cellular response to interleukin-1 (GO:0071347),0.6946526627671097,1.0878982227256668,0.3063063063063063,1.0,1.0,7/148,1.98%,IRAK2;NOD2;PSMB9;CX3CL1;IL1RN;CCL14;MAPK13
prerank,GO_Biological_Process_2021__homophilic cell adhesion via plasma membrane adhesion molecules (GO:0007156),0.7820133638057957,1.0877449824929386,0.3684210526315789,1.0,1.0,3/58,1.81%,CDH2;CDH1;PTPRM
prerank,GO_Biological_Process_2021__regulation of mitotic nuclear division (GO:0007088),0.797060385427933,1.0874758160754747,0.41379310344827586,1.0,1.0,4/51,1.56%,LRP5;TOM1L1;MKI67;PKMYT1
prerank,Reactome_2022__Amyloid Fiber Formation R-HSA-977225,-0.79194637540107,-1.0873700682299405,0.3652173913043478,1.0,1.0,2/66,0.81%,ADAM10;APP
prerank,Reactome_2022__Heparan Sulfate/Heparin (HS-GAG) Metabolism R-HSA-1638091,0.7937608796122095,1.0872155113707365,0.4715447154471545,1.0,1.0,2/51,0.63%,HS2ST1;SLC35D2
prerank,MSigDB_Oncogenic_Signatures__KRAS.LUNG.BREAST UP.V1 UP,0.7158935168694658,1.0870498628714536,0.27350427350427353,1.0,1.0,8/116,2.34%,IGFBP3;ITGA2;KCNC1;PTGS2;A2M;RBP4;GFI1;TBX3
prerank,"GO_Biological_Process_2021__positive regulation of DNA damage response, signal transduction by p53 class mediator (GO:0043517)",0.6483655729566565,1.0870187221241083,0.456,1.0,1.0,2/15,1.84%,ATR;MSX1
prerank,WikiPathway_2021_Human__FOXA2 pathway WP5066,-0.6540915633852018,-1.086586796825305,0.4583333333333333,1.0,1.0,2/20,1.27%,GSTA1;GSTA2
prerank,Elsevier_Pathway_Collection__Ras-GAP Regulation Signaling,-0.8451702993919759,-1.0865254702524447,0.48905109489051096,1.0,1.0,3/46,1.21%,RASA2;APP;RAP1A
prerank,Elsevier_Pathway_Collection__BMPR2 Signaling,-0.7628505293155458,-1.0865173343180086,0.532258064516129,1.0,1.0,2/30,1.50%,CREBBP;BMP4
prerank,GO_Biological_Process_2021__long-chain fatty-acyl-CoA biosynthetic process (GO:0035338),0.7112237053976844,1.0863004744936782,0.49166666666666664,1.0,1.0,4/18,2.22%,ACSF3;ELOVL2;ELOVL6;ACSL5
prerank,GO_Biological_Process_2021__regulation of integrin activation (GO:0033623),-0.6629752101434495,-1.0860332250183538,0.40425531914893614,1.0,1.0,1/15,0.38%,RAP1B
prerank,MSigDB_Oncogenic_Signatures__CORDENONSI YAP CONSERVED SIGNATURE,0.8194268726950025,1.0859137749381615,0.46875,1.0,1.0,7/52,2.29%,ETV5;GLS;DLC1;ITGB5;SHCBP1;SERPINE1;FLNA
prerank,Reactome_2022__Transcriptional Regulation By RUNX2 R-HSA-8878166,-0.6993525755806349,-1.0858519464679965,0.3053435114503817,1.0,1.0,5/112,2.08%,NR3C1;AKT3;WWP1;RB1;GLI3
prerank,Reactome_2022__SARS-CoV-1 Infection R-HSA-9678108,-0.77759372854074,-1.0858472748816834,0.408,1.0,1.0,5/49,2.26%,PARP8;UVRAG;RB1;MOGAT1;TMPRSS2
prerank,GO_Biological_Process_2021__regulation of cellular macromolecule biosynthetic process (GO:2000112),-0.6183825427867466,-1.0853931727190644,0.22137404580152673,1.0,1.0,24/435,2.40%,ZNF341;ZNF678;ZNF90;ZNF85;NR3C1;RABL3;ZNF221;ZNF66;ZNF708;ZBTB38;NR2C2;ZNF33A;USP37;APP;ERC1;ZNF117;RB1;CREBBP;SUFU;HIC1;PML;APBB3;RHOH;SPI1
prerank,MSigDB_Hallmark_2020__Interferon Alpha Response,-0.7347071657276325,-1.08536647028379,0.28888888888888886,1.0,1.0,9/97,2.42%,OAS1;IFI44L;GMPR;PROCR;EPSTI1;HERC6;OASL;GBP4;RTP4
prerank,GO_Biological_Process_2021__organic hydroxy compound transport (GO:0015850),-0.7872994011834732,-1.0851391500157102,0.5175438596491229,1.0,1.0,2/39,1.28%,NCOA1;SLCO1A2
prerank,GO_Biological_Process_2021__regulation of establishment of planar polarity (GO:0090175),0.7539876796852415,1.084954745008634,0.3090909090909091,1.0,1.0,3/86,2.38%,PSMB9;SAPCD2;CELSR3
prerank,GO_Biological_Process_2021__negative regulation of epithelial cell proliferation (GO:0050680),0.7801175377919661,1.084657432852015,0.34959349593495936,1.0,1.0,3/69,1.99%,CDK6;PTPRM;APOE
prerank,WikiPathway_2021_Human__Wnt/beta-catenin signaling pathway in leukemia WP3658,0.7303451520767361,1.0845988388454686,0.4878048780487805,1.0,1.0,2/25,1.97%,LRP5;AXIN2
prerank,Elsevier_Pathway_Collection__T-lymphoid precursor cell -> CD8+ Naive T-cell Surface Expression Markers,-0.8271681021529783,-1.0843316029644479,0.46715328467153283,1.0,1.0,5/56,1.92%,HRH2;CD2;CD44;IL12RB2;CD27
prerank,GO_Biological_Process_2021__regulation of interleukin-10 production (GO:0032653),0.8336813169469984,1.0842026509312883,0.5083333333333333,1.0,1.0,3/45,1.26%,NOD2;TNFRSF21;SYK
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> STAT Signaling,0.6914057272854737,1.0840246393463544,0.5042735042735043,1.0,1.0,2/19,2.29%,CD4;CD86
prerank,Elsevier_Pathway_Collection__Neuroblastoma,-0.7442042967148739,-1.083781943262651,0.3064516129032258,1.0,1.0,9/123,2.08%,MAP2K6;RAP1A;SUFU;SHH;BMP4;CCND2;NTF3;MYCL;GLI3
prerank,Reactome_2022__Antigen Activates B Cell Receptor Leading To Second Messenger Generation R-HSA-983695,0.757271935372078,1.0833035332468048,0.49137931034482757,1.0,1.0,3/31,2.06%,SYK;DAPP1;PIK3AP1
prerank,MSigDB_Oncogenic_Signatures__CTIP DN.V1 UP,-0.776390551661377,-1.082812691331344,0.33858267716535434,1.0,1.0,5/101,2.37%,ADAMTS2;MYOM1;ZNF528;TEK;IFI6
prerank,KEGG_2021_Human__Chemical carcinogenesis,-0.6772522197892326,-1.0826429212929203,0.2535211267605634,1.0,1.0,16/203,2.19%,GSTA1;CREB3L2;CYP3A7;KPNA3;AKT3;PIK3CB;CYP2C8;RB1;GSTA2;ADCY3;STAT5A;CREB5;CYP1B1;CYP1A2;KLF4;VDR
prerank,GO_Biological_Process_2021__aminoglycan biosynthetic process (GO:0006023),0.7937620128443756,1.0823497876912316,0.4634146341463415,1.0,1.0,2/47,0.63%,HS2ST1;SLC35D2
prerank,GO_Biological_Process_2021__cellular response to glucocorticoid stimulus (GO:0071385),-0.663512954681992,-1.0822575442673166,0.4573643410852713,1.0,1.0,1/16,0.32%,NR3C1
prerank,Elsevier_Pathway_Collection__Sonic Hedgehog Signaling in Neuroblastoma,-0.7651033195879174,-1.0816296645856947,0.5565217391304348,1.0,1.0,4/19,2.08%,SUFU;SHH;CCND2;GLI3
prerank,GO_Biological_Process_2021__amide biosynthetic process (GO:0043604),-0.779288560759724,-1.081506603344149,0.45901639344262296,1.0,1.0,3/47,2.08%,AGK;CYP4F22;SMPD1
prerank,GO_Biological_Process_2021__histone deacetylation (GO:0016575),0.7808292272251738,1.0812262732693865,0.40458015267175573,1.0,1.0,5/47,1.93%,TBL1X;MIER2;HDAC8;HDAC9;RCOR2
prerank,GO_Biological_Process_2021__regulation of keratinocyte differentiation (GO:0045616),-0.7782642137351868,-1.0808182206671646,0.5447761194029851,1.0,1.0,3/30,2.19%,SGPP1;AQP3;VDR
prerank,GO_Biological_Process_2021__positive regulation of epidermal cell differentiation (GO:0045606),-0.6925209338097585,-1.0806139471001193,0.47058823529411764,1.0,1.0,2/19,2.19%,BMP4;VDR
prerank,Reactome_2022__Stimuli-sensing Channels R-HSA-2672351,-0.7368897615400792,-1.0805071822362615,0.3464566929133858,1.0,1.0,3/87,1.32%,WNK3;WWP1;SGK3
prerank,Reactome_2022__DNA Strand Elongation R-HSA-69190,0.755464448102416,1.080200174236356,0.4596774193548387,1.0,1.0,4/31,2.24%,CDC45;SLC19A1;GINS1;LRIG1
prerank,GO_Biological_Process_2021__positive regulation of interleukin-8 production (GO:0032757),0.8461012412591852,1.079680428938385,0.4666666666666667,1.0,1.0,4/57,2.07%,LILRA2;NOD2;SYK;SERPINE1
prerank,TRRUST_Transcription_Factors_2019__SPI1 human,-0.8151523002768819,-1.0796614868373358,0.3880597014925373,1.0,1.0,4/61,1.83%,ITGAX;HCK;CD163;DAPK2
prerank,KEGG_2021_Human__Metabolism of xenobiotics by cytochrome P450,-0.7581663937924683,-1.0794910189514741,0.3358208955223881,1.0,1.0,5/69,1.98%,GSTA1;GSTA2;CYP1B1;AKR7A3;CYP1A2
prerank,Reactome_2022__ABC-family Proteins Mediated Transport R-HSA-382556,-0.7451210098413387,-1.0794729257294342,0.2706766917293233,1.0,1.0,3/99,2.42%,ABCD3;ABCA6;ABCA10
prerank,Reactome_2022__Aberrant Regulation Of Mitotic Exit In Cancer Due To RB1 Defects R-HSA-9687136,-0.6552062266371946,-1.0793425235080079,0.47107438016528924,1.0,1.0,1/20,1.15%,RB1
prerank,Elsevier_Pathway_Collection__HTR1 -> Membrane Transport,-0.6644739248331784,-1.0792354160618842,0.44696969696969696,1.0,1.0,1/20,0.23%,MAP2K6
prerank,Elsevier_Pathway_Collection__Proteins Involved in Ulcerative Colitis,0.7349058957877324,1.0790954058417974,0.2777777777777778,1.0,1.0,10/130,2.29%,NOD2;MEFV;ITGA4;IL1RN;CDH1;PTGS2;NR1I2;APOE;HGF;CD86
prerank,GO_Biological_Process_2021__regulation of fibroblast migration (GO:0010762),0.7893852495294924,1.0789139666206398,0.5615384615384615,1.0,1.0,2/21,1.07%,PTK2;ARHGEF7
prerank,GO_Biological_Process_2021__positive regulation of T cell proliferation (GO:0042102),0.7953406459014388,1.0788809806931172,0.37719298245614036,1.0,1.0,4/61,2.29%,SYK;ANXA1;SLC7A1;CD86
prerank,GO_Biological_Process_2021__ventricular cardiac muscle cell action potential (GO:0086005),0.6441354070943595,1.0788391497561902,0.4609375,1.0,1.0,2/16,2.26%,SNTA1;GPD1L
prerank,GO_Biological_Process_2021__positive regulation of Wnt signaling pathway (GO:0030177),0.6760179969730604,1.0778561015375294,0.2764227642276423,1.0,1.0,5/149,1.97%,TBL1X;DEPDC1B;PSMB9;SALL1;AXIN2
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Melanoma,0.7946620237212334,1.0774892517344816,0.4772727272727273,1.0,1.0,6/46,2.37%,CDH2;PLAUR;PTK2;CDH1;HGF;FGF1
prerank,KEGG_2021_Human__Adrenergic signaling in cardiomyocytes,-0.7091130284149396,-1.077379552739371,0.2907801418439716,1.0,1.0,8/136,2.44%,CREB3L2;AKT3;RAPGEF3;ADCY3;CREB5;PLCB4;PIK3R6;KCNE1
prerank,GO_Biological_Process_2021__mammary gland development (GO:0030879),0.7039296933458703,1.0773540586063686,0.5041322314049587,1.0,1.0,3/21,2.34%,GPAT4;PRLR;TBX3
prerank,MSigDB_Hallmark_2020__PI3K/AKT/mTOR  Signaling,0.7313671801700095,1.077343076844019,0.3,1.0,1.0,5/101,1.88%,ACACA;ACTR3;CAB39;PRKAA2;DAPP1
prerank,Elsevier_Pathway_Collection__Airway Smooth Muscle Cell High Rate Proliferation,-0.7828638249158411,-1.0772772641016184,0.48,1.0,1.0,3/54,1.73%,PTK2B;STAT5A;IL11RA
prerank,MSigDB_Oncogenic_Signatures__ATF2 S UP.V1 DN,-0.6942815753591663,-1.077137296729418,0.2923076923076923,1.0,1.0,10/165,2.39%,KLHL3;C4BPA;AADAC;DENND4C;SDC3;CYP1B1;KCNAB2;SLIT3;SLC12A8;COL7A1
prerank,KEGG_2021_Human__Regulation of lipolysis in adipocytes,-0.7345619943299593,-1.0766366006964427,0.39849624060150374,1.0,1.0,5/49,1.56%,AKT3;PIK3CB;PLAAT3;LIPE;ADCY3
prerank,Elsevier_Pathway_Collection__APP and Glutamate Signaling Cause Neuronal Dysfunction in Alzheimer Disease,-0.7280366006199535,-1.0765049241208609,0.484375,1.0,1.0,2/26,2.21%,APP;DAB1
prerank,GO_Biological_Process_2021__negative regulation of autophagy (GO:0010507),0.7772774715427404,1.076010456300877,0.408,1.0,1.0,3/57,2.28%,TLK2;QSOX1;HGF
prerank,Elsevier_Pathway_Collection__Monoblast -> Promonocyte Surface Expression Markers,0.6878103118553277,1.075917264454138,0.4444444444444444,1.0,1.0,2/18,1.23%,CD33;CD4
prerank,Reactome_2022__Processive Synthesis On Lagging Strand R-HSA-69183,-0.6570926191274088,-1.075487769895931,0.4358974358974359,1.0,1.0,1/15,0.96%,PRIM2
prerank,GO_Biological_Process_2021__negative regulation of developmental growth (GO:0048640),0.7841097947631746,1.0750774737180067,0.5128205128205128,1.0,1.0,3/32,1.60%,WWC2;SLC6A4;SEMA3G
prerank,Reactome_2022__DNA Repair R-HSA-73894,0.6228901164345636,1.0747874956294672,0.2288135593220339,1.0,1.0,11/295,2.24%,HERC2;FANCL;SLC19A1;DCLRE1C;TCEA1;MSH2;POLE4;TDP1;BRIP1;ACD;LRIG1
prerank,"Reactome_2022__Respiratory Electron Transport, ATP Synthesis By Chemiosmotic Coupling, Heat Production By Uncoupling Proteins R-HSA-163200",-0.7417780780786867,-1.0746769346156904,0.3252032520325203,1.0,1.0,3/111,0.83%,COX16;NDUFAF2;NDUFS4
prerank,Elsevier_Pathway_Collection__Kidney Cells Cilia Organization,0.7260755436200137,1.0744952778705754,0.5,1.0,1.0,5/26,2.41%,LRP5;CDH1;FOSL1;FN1;KIF3B
prerank,Elsevier_Pathway_Collection__Blau Syndrome,0.7883772768072841,1.0735874390252496,0.5,1.0,1.0,2/38,1.17%,NOD2;MEFV
prerank,GO_Biological_Process_2021__regulation of complement activation (GO:0030449),-0.7838678644605298,-1.0734832123518179,0.43902439024390244,1.0,1.0,4/50,1.63%,C4BPA;PROS1;C5AR2;C1R
prerank,WikiPathway_2021_Human__Photodynamic therapy-induced AP-1 survival signaling. WP3611,-0.8141603359160434,-1.0732706391943474,0.44029850746268656,1.0,1.0,3/49,1.93%,MAP2K6;RB1;MMP2
prerank,MSigDB_Hallmark_2020__Inflammatory Response,0.6771937027115853,1.0729243435190987,0.2962962962962963,1.0,1.0,9/194,2.07%,IRAK2;PLAUR;NOD2;LPAR1;MEFV;CD48;CX3CL1;SLC7A1;SERPINE1
prerank,Reactome_2022__Mitotic G2-G2/M Phases R-HSA-453274,0.6543540370395622,1.0728874809908984,0.29245283018867924,1.0,1.0,8/181,2.15%,HAUS8;CEP164;HAUS2;PPP1R12A;PSMB9;PKMYT1;OPTN;TUBA1A
prerank,Elsevier_Pathway_Collection__beta-Cell Destruction in Diabetes Mellitus Type 1,0.8023543453817171,1.0728588555215408,0.4166666666666667,1.0,1.0,3/54,1.59%,CASP7;ITGAL;IL1RN
prerank,GO_Biological_Process_2021__establishment or maintenance of epithelial cell apical/basal polarity (GO:0045197),0.7235488821282252,1.0727469841744512,0.47115384615384615,1.0,1.0,5/32,1.58%,DLG1;DLG3;LIN7A;CAMSAP3;MTCL1
prerank,Reactome_2022__G1/S-Specific Transcription R-HSA-69205,0.7541207851444699,1.072452061851318,0.5169491525423728,1.0,1.0,4/28,2.38%,CDC45;RBL1;TFDP2;RRM2
prerank,GO_Biological_Process_2021__response to peptide hormone (GO:0043434),0.8170496015368158,1.0723429449498927,0.4824561403508772,1.0,1.0,3/46,1.64%,CREB1;SORT1;ANXA1
prerank,GO_Biological_Process_2021__cellular response to ketone (GO:1901655),-0.7943995741267813,-1.0721595436045361,0.5104895104895105,1.0,1.0,3/38,2.39%,NR3C1;ADCY3;MAP4K1
prerank,GO_Biological_Process_2021__long-chain fatty acid transport (GO:0015909),0.7579649678330573,1.072131563790375,0.5210084033613446,1.0,1.0,4/31,1.99%,ACACA;SLC27A2;PRKAA2;APOE
prerank,TRRUST_Transcription_Factors_2019__STAT3 human,-0.6928103890360431,-1.0718060248911214,0.2727272727272727,1.0,1.0,12/134,2.19%,STS;TNFRSF10B;OAS1;NR2C2;POU2F1;PROS1;FGL1;SHH;CCND2;MMP2;S1PR1;VDR
prerank,GO_Biological_Process_2021__retinoid metabolic process (GO:0001523),-0.7304166135480639,-1.0714537835548354,0.3305785123966942,1.0,1.0,6/83,1.98%,CYP3A7;CYP2C8;CYP4V2;SDC3;CYP1B1;CYP1A2
prerank,Reactome_2022__Regulation Of Signaling By CBL R-HSA-912631,-0.7267365847366261,-1.071268860683058,0.5220588235294118,1.0,1.0,3/18,2.34%,PIK3CB;HCK;VAV1
prerank,GO_Biological_Process_2021__interleukin-1-mediated signaling pathway (GO:0070498),0.748894769291685,1.0712175212129433,0.32231404958677684,1.0,1.0,4/91,1.59%,IRAK2;NOD2;PSMB9;IL1RN
prerank,GO_Biological_Process_2021__neuromuscular junction development (GO:0007528),-0.6555892458784672,-1.070987938521552,0.4806201550387597,1.0,1.0,1/23,1.11%,NEDD4
prerank,Reactome_2022__G2/M Transition R-HSA-69275,0.6543557070292345,1.0708894372980913,0.3090909090909091,1.0,1.0,8/179,2.15%,HAUS8;CEP164;HAUS2;PPP1R12A;PSMB9;PKMYT1;OPTN;TUBA1A
prerank,GO_Biological_Process_2021__protein methylation (GO:0006479),0.795573143637901,1.0706940241809972,0.5294117647058824,1.0,1.0,2/39,0.45%,PRMT2;SETD3
prerank,GO_Biological_Process_2021__glutamine family amino acid metabolic process (GO:0009064),0.7761798942587015,1.0705125635688288,0.5151515151515151,1.0,1.0,3/37,2.39%,MTHFS;GLS;PYCR1
prerank,GO_Biological_Process_2021__ventricular septum development (GO:0003281),0.7814532220528405,1.0703014428818638,0.5038759689922481,1.0,1.0,3/35,1.86%,SALL1;PROX1;ZFPM1
prerank,Reactome_2022__Macroautophagy R-HSA-1632852,-0.7395011616171564,-1.0699307746427478,0.32575757575757575,1.0,1.0,3/111,1.06%,TOMM70;UVRAG;ATG10
prerank,GO_Biological_Process_2021__odontogenesis (GO:0042476),0.7631015125927645,1.0698652205462482,0.5086206896551724,1.0,1.0,6/34,1.97%,BCOR;ZNF22;ANKRD11;TUFT1;MSX1;AXIN2
prerank,GO_Biological_Process_2021__monocarboxylic acid catabolic process (GO:0072329),0.7270741299304325,1.069731751210388,0.48717948717948717,1.0,1.0,2/27,2.30%,CYP4F3;LPIN3
prerank,WikiPathway_2021_Human__Folate Metabolism WP176,0.77946817974048,1.0695625139002898,0.3492063492063492,1.0,1.0,5/64,2.07%,SLC19A1;MTHFS;CBS;F7;SERPINE1
prerank,Reactome_2022__Metabolism Of Amino Acids And Derivatives R-HSA-71291,0.6214399827705998,1.0693300471771012,0.24074074074074073,1.0,1.0,13/350,2.39%,SMOX;AUH;MTAP;PAPSS1;SCLY;AASS;PSMB9;FTCD;PAH;CHDH;SLC38A1;ASRGL1;PYCR1
prerank,GO_Biological_Process_2021__positive regulation of vascular associated smooth muscle cell proliferation (GO:1904707),0.6655891624301928,1.069077235384205,0.4375,1.0,1.0,1/21,0.11%,ERN1
prerank,GO_Biological_Process_2021__ceramide biosynthetic process (GO:0046513),-0.7792960160807361,-1.0690194420030903,0.5317460317460317,1.0,1.0,3/38,2.08%,AGK;CYP4F22;SMPD1
prerank,Elsevier_Pathway_Collection__Find me Signal: Apoptotic Cell Attracts Phagocyte,0.676043582048977,1.0687615179447503,0.48760330578512395,1.0,1.0,3/16,1.64%,CASP7;CX3CL1;ANXA1
prerank,KEGG_2021_Human__Melanogenesis,-0.7457315858346256,-1.0685940598952204,0.3409090909090909,1.0,1.0,4/93,1.91%,CREB3L2;CREBBP;ADCY3;PLCB4
prerank,MSigDB_Oncogenic_Signatures__IL2 UP.V1 DN,-0.6745869695621094,-1.0682520267157203,0.2867647058823529,1.0,1.0,13/156,2.22%,MAP2K6;SDCCAG8;SULT1B1;ZNF571;DEPTOR;TNFAIP2;VILL;SNPH;PBX1;COLQ;TEK;RASGRP3;CLEC2B
prerank,GO_Biological_Process_2021__fatty-acyl-CoA biosynthetic process (GO:0046949),0.7673921999403169,1.068127583870474,0.5652173913043478,1.0,1.0,5/30,2.22%,ACSF3;ACACA;ELOVL2;ELOVL6;ACSL5
prerank,WikiPathway_2021_Human__Hepatitis C and Hepatocellular Carcinoma WP3646,0.8096560610664801,1.0680491962051515,0.49206349206349204,1.0,1.0,4/49,2.38%,CASP7;MYOF;PTGS2;RRM2
prerank,GO_Biological_Process_2021__ureteric bud morphogenesis (GO:0060675),-0.7116623530494326,-1.0675706106203404,0.5227272727272727,1.0,1.0,3/16,1.58%,SHH;BMP4;PAX8
prerank,GO_Biological_Process_2021__positive regulation of biosynthetic process (GO:0009891),0.7785620478679991,1.0675462330157128,0.4921875,1.0,1.0,4/42,2.16%,PPARA;CREB1;APOE;CYBA
prerank,Reactome_2022__Respiratory Electron Transport R-HSA-611105,-0.741785324838452,-1.0674029710061366,0.336,1.0,1.0,3/90,0.83%,COX16;NDUFAF2;NDUFS4
prerank,GO_Biological_Process_2021__regulation of protein localization to plasma membrane (GO:1903076),0.7573508482615315,1.0671971419977233,0.36585365853658536,1.0,1.0,4/77,2.05%,ITGA3;DLG1;RHOQ;LGALS3
prerank,GO_Biological_Process_2021__cellular response to organonitrogen compound (GO:0071417),-0.7357381791621189,-1.0669049086349172,0.31851851851851853,1.0,1.0,6/98,2.44%,CPEB3;RAP1B;RAP1A;RAPGEF3;AOC1;KCNE1
prerank,WikiPathway_2021_Human__Tamoxifen metabolism WP691,-0.7803502697373632,-1.0668548832104152,0.5703703703703704,1.0,1.0,3/19,1.98%,CYP2C8;CYP1B1;CYP1A2
prerank,Elsevier_Pathway_Collection__NTRK -> FOXO/MYCN Signaling,0.5859270199975435,1.0667007129134929,0.3629032258064516,1.0,1.0,1/16,1.41%,MYCN
prerank,GO_Biological_Process_2021__DNA-dependent DNA replication maintenance of fidelity (GO:0045005),0.789876416104993,1.0666576953149192,0.5,1.0,1.0,2/42,1.02%,MMS22L;ATR
prerank,GO_Biological_Process_2021__negative regulation of NIK/NF-kappaB signaling (GO:1901223),0.6912864338885221,1.066233571642494,0.4676258992805755,1.0,1.0,2/23,2.31%,TSPAN6;UACA
prerank,Elsevier_Pathway_Collection__TERT/WNT Activation in Cancer,0.6623582071157699,1.0660179604139834,0.4806201550387597,1.0,1.0,1/23,0.43%,LRP5
prerank,Elsevier_Pathway_Collection__Exocytosis: Vesicle Trafficking,-0.6593218790831474,-1.0655607323333314,0.44274809160305345,1.0,1.0,1/18,0.74%,MYRIP
prerank,GO_Biological_Process_2021__positive regulation of cell migration (GO:0030335),0.6281470628193129,1.065473865948252,0.29906542056074764,1.0,1.0,15/262,2.37%,TJP1;PIK3CD;ELP3;PTK2;ZNF304;ARHGEF7;F7;BCAR1;SEMA3G;CARMIL2;CTSH;SH3RF2;FN1;HGF;FGF1
prerank,Elsevier_Pathway_Collection__HIF1A in Vasculogenic Mimicry of Cancer,0.7795620086995458,1.0654335791016574,0.5225225225225225,1.0,1.0,3/42,2.05%,PTK2;PTGS2;LGALS3
prerank,TRRUST_Transcription_Factors_2019__GATA4 mouse,-0.7346968738932643,-1.06542339442553,0.544,1.0,1.0,2/16,1.54%,BMP4;CCND2
prerank,Reactome_2022__Downregulation Of ERBB2 Signaling R-HSA-8863795,-0.7292651875530146,-1.0653678920807197,0.5259259259259259,1.0,1.0,3/29,2.09%,AKT3;NRG1;PTPN18
prerank,TRRUST_Transcription_Factors_2019__ELK1 human,-0.663628288153632,-1.0649084957476351,0.4496124031007752,1.0,1.0,1/18,0.31%,TNFRSF10B
prerank,GO_Biological_Process_2021__negative regulation of intracellular signal transduction (GO:1902532),0.6496125087187503,1.0644598852349965,0.36666666666666664,1.0,1.0,11/192,2.31%,WWC2;VGLL4;PPARA;CD2AP;FNIP1;PLAUR;PRKAA2;ARHGAP12;TSPAN6;GPD1L;UACA
prerank,GO_Biological_Process_2021__regulation of protein kinase B signaling (GO:0051896),0.6504533687986968,1.064020924465268,0.29411764705882354,1.0,1.0,11/192,2.37%,PPARA;PIK3CD;PTK2;ERBB3;CX3CL1;F7;KLB;PIK3AP1;HGF;CD86;FGF1
prerank,Reactome_2022__Drug ADME R-HSA-9748784,-0.7460961976224261,-1.0639179256265037,0.32857142857142857,1.0,1.0,8/89,2.34%,GSTA1;SLC22A1;GLYAT;CYP2C8;GGT5;ACSM2B;GSTA2;VAV1
prerank,GO_Biological_Process_2021__N-glycan processing (GO:0006491),-0.6666271420649164,-1.0637393476552626,0.44525547445255476,1.0,1.0,1/18,0.01%,GANC
prerank,GO_Biological_Process_2021__regulation of filopodium assembly (GO:0051489),0.727986427444502,1.0636599517685044,0.48333333333333334,1.0,1.0,4/40,2.21%,RHOQ;PPP1R16B;DOCK11;DPYSL3
prerank,GO_Biological_Process_2021__ncRNA processing (GO:0034470),0.6578273009710295,1.063614651725873,0.2923076923076923,1.0,1.0,1/199,0.88%,DROSHA
prerank,Reactome_2022__Synthesis Of PA R-HSA-1483166,0.8010594141872404,1.063583612802276,0.5573770491803278,1.0,1.0,4/34,2.26%,LCLAT1;AGPAT3;GPAT4;GPD1L
prerank,GO_Biological_Process_2021__positive regulation of lymphocyte proliferation (GO:0050671),0.7771522314068022,1.0635300905077354,0.39669421487603307,1.0,1.0,4/68,2.29%,ANXA1;SLC7A1;NFATC2;CD86
prerank,KEGG_2021_Human__GABAergic synapse,0.7624350121690264,1.0634558360403281,0.37404580152671757,1.0,1.0,5/77,2.34%,SLC38A3;GLS;GNB5;SLC38A1;GNG2
prerank,GO_Biological_Process_2021__positive regulation of protein kinase activity (GO:0045860),0.6721517594369728,1.0634183725460404,0.3333333333333333,1.0,1.0,7/149,1.23%,CENPE;TOM1L1;DLG3;CAB39;PTK2;ERBB3;CD4
prerank,WikiPathway_2021_Human__7q11.23 copy number variation syndrome WP4932,0.7265860505624553,1.0632907461084788,0.3157894736842105,1.0,1.0,6/99,2.36%,CLIP2;EIF2A;ACACA;GTF2I;PKLR;STX1A
prerank,Reactome_2022__RAC2 GTPase Cycle R-HSA-9013404,0.738601663949443,1.06325277297396,0.30578512396694213,1.0,1.0,6/87,2.16%,ABI2;DEPDC1B;RAB7A;ARHGAP39;CDC42EP1;CYBA
prerank,WikiPathway_2021_Human__Amino Acid metabolism WP3925,0.7362921797532386,1.0630558101271794,0.3235294117647059,1.0,1.0,7/83,2.39%,AUH;MAOA;FTCD;CBS;GLS;SMS;PYCR1
prerank,GO_Biological_Process_2021__protein targeting to membrane (GO:0006612),-0.7616971198467054,-1.0630447134306709,0.34146341463414637,1.0,1.0,6/84,2.42%,ZDHHC14;ATAD1;ABCD3;ZDHHC21;PARD3;RTP4
prerank,GO_Biological_Process_2021__regulation of humoral immune response (GO:0002920),-0.783865957775118,-1.0630267756504825,0.45081967213114754,1.0,1.0,4/53,1.63%,C4BPA;PROS1;C5AR2;C1R
prerank,GO_Biological_Process_2021__potassium ion transport (GO:0006813),-0.7484989736682968,-1.0627075534737918,0.32116788321167883,1.0,1.0,7/103,2.44%,KCNN2;KCNAB3;KCNK6;KCNS3;KCNAB2;SLC9A9;KCNE1
prerank,WikiPathway_2021_Human__Thyroid hormones production and their peripheral downstream signaling effects WP4746,-0.7449014403535785,-1.0623412739063403,0.319672131147541,1.0,1.0,7/88,2.46%,AKT3;TBC1D4;SHH;ADCY3;PAX8;IYD;SLC16A2
prerank,GO_Biological_Process_2021__cellular response to interleukin-12 (GO:0071349),-0.8004359953754068,-1.062303706524703,0.4956521739130435,1.0,1.0,5/46,1.79%,PAK2;RAP1B;SOD2;GSTA2;IL12RB2
prerank,GO_Biological_Process_2021__cell projection assembly (GO:0030031),0.6572818841201524,1.0621278994168084,0.48091603053435117,1.0,1.0,1/22,0.94%,RHOQ
prerank,Elsevier_Pathway_Collection__Hodgkin and Reed-Sternberg Cells Reprogramming,-0.7261568168108987,-1.0620280356154908,0.5357142857142857,1.0,1.0,3/21,2.40%,STAT5A;IL21R;SPI1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Acute Myeloid Leukemia,-0.765695680315616,-1.0619734704343669,0.49635036496350365,1.0,1.0,5/34,2.40%,RB1;CREBBP;MEIS1;STAT5A;SPI1
prerank,MSigDB_Oncogenic_Signatures__EGFR UP.V1 UP,0.6534093152666249,1.061565705738492,0.3333333333333333,1.0,1.0,15/180,2.35%,FNDC3B;ITGA3;SLC4A7;ETV5;RHOQ;TNFRSF21;CASP7;PSMB9;MAOA;ITGA2;CYP27B1;A2M;HK2;COTL1;GK
prerank,GO_Biological_Process_2021__epidermis development (GO:0008544),-0.794344900108573,-1.0614307921063642,0.45454545454545453,1.0,1.0,3/55,2.39%,STS;GJB5;COL7A1
prerank,WikiPathway_2021_Human__Gastric Cancer Network 1 WP2361,-0.7869216727144267,-1.06115429335497,0.5692307692307692,1.0,1.0,2/26,1.32%,INO80D;LIN9
prerank,Reactome_2022__Interferon Gamma Signaling R-HSA-877300,-0.7262517214339763,-1.0611361431760262,0.36065573770491804,1.0,1.0,8/85,2.40%,OAS1;CD44;TRIM46;PML;OASL;HLA-B;CIITA;GBP4
prerank,WikiPathway_2021_Human__mRNA Processing WP411,0.7197776295690809,1.0610933591419975,0.3983050847457627,1.0,1.0,3/126,1.36%,PRPF40A;PRMT2;SF3A2
prerank,GO_Biological_Process_2021__negative regulation of blood vessel endothelial cell migration (GO:0043537),-0.8096711042418612,-1.0603548868737105,0.5348837209302325,1.0,1.0,4/33,2.38%,MAP2K5;CARD10;KLF4;HRG
prerank,Elsevier_Pathway_Collection__WNT in Epithelial to Mesenchymal Transition in Cancer,0.7553387083141281,1.0603519658109326,0.48333333333333334,1.0,1.0,7/43,2.27%,CDH2;TJP1;LRP5;CRB3;CDH1;SERPINE1;FN1
prerank,GO_Biological_Process_2021__negative regulation of cell-substrate junction organization (GO:0150118),-0.6564000969062707,-1.0601484787356863,0.45185185185185184,1.0,1.0,1/16,1.03%,BCAS3
prerank,GO_Biological_Process_2021__negative regulation of focal adhesion assembly (GO:0051895),-0.6564000969062707,-1.0601484787356863,0.45185185185185184,1.0,1.0,1/16,1.03%,BCAS3
prerank,GO_Biological_Process_2021__determination of left/right symmetry (GO:0007368),0.725993552994491,1.0600964718361219,0.47863247863247865,1.0,1.0,3/31,2.41%,MEGF8;CCDC40;KIF3B
prerank,GO_Biological_Process_2021__positive regulation of peptidyl-tyrosine phosphorylation (GO:0050731),-0.7206604397053308,-1.059872413842973,0.35766423357664234,1.0,1.0,9/119,2.25%,PTK2B;PAK2;TEC;PTPRJ;CD44;NTF3;THBS4;TNFRSF14;SEMA4D
prerank,Reactome_2022__Cellular Senescence R-HSA-2559583,0.6822928780097506,1.059849685033356,0.33884297520661155,1.0,1.0,6/148,2.15%,HIRA;CDK6;TFDP2;CBX2;UBE2C;ACD
prerank,WikiPathway_2021_Human__Corticotropin-releasing hormone signaling pathway WP2355,0.7375957605238724,1.059781946877243,0.34375,1.0,1.0,9/86,1.94%,ERN1;ACACA;CREB1;PTK2;PRKAA2;GNB5;GRK3;FOSL1;FOSL2
prerank,WikiPathway_2021_Human__Nonalcoholic fatty liver disease WP4396,0.680212639527775,1.0595703156850487,0.29310344827586204,1.0,1.0,7/144,1.23%,ERN1;PPARA;PIK3CD;CASP7;NDUFA10;PRKAA2;PKLR
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Permeability Activation,0.818094290262952,1.0595675812461307,0.5641025641025641,1.0,1.0,3/37,1.53%,TJP1;PTK2;BCAR1
prerank,Reactome_2022__Translesion Synthesis By POLK R-HSA-5655862,-0.6625907296843342,-1.0594319169054687,0.4330708661417323,1.0,1.0,2/17,0.42%,REV3L;POLK
prerank,GO_Biological_Process_2021__neutrophil mediated immunity (GO:0002446),0.5914853035770522,1.0592211860643646,0.2782608695652174,1.0,1.0,25/472,2.27%,MANBA;CD300A;CD33;IGF2R;CD53;ATAD3B;ERP44;PLAUR;CAB39;RAB7A;PLD1;CPPED1;SLC27A2;PADI2;CKAP4;NFAM1;ITGAL;MOSPD2;LAMP2;CTSH;QSOX1;LGALS3;CYBA;MNDA;COTL1
prerank,GO_Biological_Process_2021__calcium ion transmembrane transport (GO:0070588),0.7297606485617106,1.058739404716695,0.3620689655172414,1.0,1.0,4/83,2.03%,MICU1;SLC25A23;CACNA2D4;TRPV1
prerank,GO_Biological_Process_2021__peptidyl-threonine modification (GO:0018210),-0.7549317396000399,-1.0584882214471663,0.39655172413793105,1.0,1.0,4/67,2.30%,CDC42BPA;WNK3;TNKS;GALNT3
prerank,GO_Biological_Process_2021__protein stabilization (GO:0050821),0.6809151848733226,1.0583859394392505,0.3488372093023256,1.0,1.0,7/176,2.29%,TBL1X;CREB1;CPN2;A1CF;LAMP2;MSX1;FLNA
prerank,KEGG_2021_Human__Non-alcoholic fatty liver disease,0.6877262353570769,1.0583715908349332,0.31896551724137934,1.0,1.0,8/144,1.98%,ERN1;PPARA;PIK3CD;CASP7;NDUFA10;PRKAA2;PKLR;MAPK13
prerank,GO_Biological_Process_2021__positive regulation of establishment of protein localization to mitochondrion (GO:1903749),0.7909100720280238,1.0581223842813847,0.453125,1.0,1.0,2/56,0.91%,YWHAQ;TFDP2
prerank,MSigDB_Oncogenic_Signatures__BRCA1 DN.V1 DN,0.7356601420456046,1.0580388118541764,0.29838709677419356,1.0,1.0,8/106,2.21%,ZNF124;TRAF3;RAB40C;PPP1R9A;PROX1;GPR35;RBP4;DPYSL3
prerank,TRRUST_Transcription_Factors_2019__EZH2 human,-0.8098973777863424,-1.0573360399753184,0.5166666666666667,1.0,1.0,5/38,2.36%,PAX8;MMP2;VDR;CIITA;FBXO32
prerank,Reactome_2022__Uptake And Actions Of Bacterial Toxins R-HSA-5339562,-0.7957542394476246,-1.05700613676688,0.5597014925373134,1.0,1.0,3/29,2.26%,MAP2K6;SYT2;CD9
prerank,Reactome_2022__Notch-HLH Transcription Pathway R-HSA-350054,0.7465495588196236,1.0567246325125157,0.5225225225225225,1.0,1.0,4/28,1.83%,TBL1X;HDAC8;NOTCH3;HDAC9
prerank,Reactome_2022__Nucleotide Salvage R-HSA-8956321,0.7316549719680705,1.0564632646421983,0.5116279069767442,1.0,1.0,2/22,1.84%,PUDP;HPRT1
prerank,GO_Biological_Process_2021__neutrophil degranulation (GO:0043312),0.5914913860455977,1.0561532060163783,0.3076923076923077,1.0,1.0,25/465,2.27%,MANBA;CD300A;CD33;IGF2R;CD53;ATAD3B;ERP44;PLAUR;CAB39;RAB7A;PLD1;CPPED1;SLC27A2;PADI2;CKAP4;NFAM1;ITGAL;MOSPD2;LAMP2;CTSH;QSOX1;LGALS3;CYBA;MNDA;COTL1
prerank,GO_Biological_Process_2021__superoxide metabolic process (GO:0006801),-0.7324200025795466,-1.0561042392850608,0.48672566371681414,1.0,1.0,2/28,1.77%,SOD2;NOXA1
prerank,"Reactome_2022__Transport Of Vitamins, Nucleosides, And Related Molecules R-HSA-425397",-0.7403055194265473,-1.0560453273683108,0.4583333333333333,1.0,1.0,4/41,2.46%,SLC35A3;SLCO1A2;SLCO3A1;SLC16A2
prerank,MSigDB_Oncogenic_Signatures__LEF1 UP.V1 UP,0.6556424284013619,1.0558602967617476,0.35537190082644626,1.0,1.0,13/177,2.27%,WWC2;ZNF22;FNBP1;CHST11;PRKAA2;MAOA;DENND1C;KRT23;CBS;FOSL1;SERPINE1;COL9A3;FN1
prerank,Elsevier_Pathway_Collection__Macrophage Survival through CCR5 and CXCR4 Mediated Signaling,0.677081171558668,1.055709423429222,0.47368421052631576,1.0,1.0,3/17,1.53%,PTK2;CD4;BCAR1
prerank,Elsevier_Pathway_Collection__Follicular Lymphoma,-0.7710437907780185,-1.0556710509057947,0.36428571428571427,1.0,1.0,9/94,2.24%,PTK2B;CREBBP;CCND2;STAT5A;SCIMP;IL12RB2;IL21R;TNFRSF14;TNFSF14
prerank,Reactome_2022__RAC1 GTPase Cycle R-HSA-9013149,0.6455053135063764,1.0554572935139968,0.33064516129032256,1.0,1.0,14/175,2.16%,ABI2;DEPDC1B;RAB7A;ARHGEF7;ARHGAP12;ARHGAP39;ARHGEF18;CDC42EP1;DOCK11;IQGAP3;DLC1;SPATA13;PLEKHG6;CYBA
prerank,GO_Biological_Process_2021__endocytic recycling (GO:0032456),0.7475253938424162,1.0552564995539402,0.48,1.0,1.0,5/51,1.26%,ANKRD50;LMTK2;ACAP2;RAB7A;DENND1C
prerank,Elsevier_Pathway_Collection__G0/G1 Cell Cycle Phase Transition Activation in Cancer,0.7414913281453426,1.0547065308267176,0.42735042735042733,1.0,1.0,3/49,0.86%,AATF;CDK6;PTK2
prerank,Elsevier_Pathway_Collection__Vitamine D Deficite and Dentin Formation,-0.7964477018296856,-1.0546030300114444,0.5757575757575758,1.0,1.0,3/28,2.19%,PTK2B;RAPGEF3;VDR
prerank,Reactome_2022__TGF-beta Receptor Signaling Activates SMADs R-HSA-2173789,0.7769044000915621,1.0545020253383153,0.5118110236220472,1.0,1.0,3/44,2.32%,USP15;ITGB5;ZFYVE9
prerank,Elsevier_Pathway_Collection__Proteins Involved in Chronic Obstructive Pulmonary Disease,0.676480366403898,1.0542975096336349,0.3247863247863248,1.0,1.0,8/156,2.07%,PIK3CD;PLAUR;NOD2;ERBB3;SLC6A4;PTGS2;LGALS3;SERPINE1
prerank,Elsevier_Pathway_Collection__Microglia and Motor Neuron Interaction Dysregulation,-0.796614744485903,-1.0541869148879695,0.5669291338582677,1.0,1.0,3/26,0.35%,PTK2B;MAP2K6;ADAM10
prerank,Elsevier_Pathway_Collection__High Fat Diet Activates cAMP Related Exocytosis in Synapse and Endocrine Cell,-0.7949081723947479,-1.0541140395597222,0.5939849624060151,1.0,1.0,3/29,2.34%,RAP1A;RAPGEF3;VAV1
prerank,Reactome_2022__Synthesis Of Very Long-Chain Fatty acyl-CoAs R-HSA-75876,0.7112202337032361,1.05406217461002,0.5121951219512195,1.0,1.0,4/22,2.22%,ACSF3;ELOVL2;ELOVL6;ACSL5
prerank,GO_Biological_Process_2021__negative regulation of endopeptidase activity (GO:0010951),0.7790893326982133,1.0530968180519993,0.47540983606557374,1.0,1.0,4/55,2.10%,TIMP3;SERPINA7;SERPINE1;SERPINA5
prerank,GO_Biological_Process_2021__calcium-mediated signaling (GO:0019722),0.7296343183021117,1.0527725333567248,0.3252032520325203,1.0,1.0,4/96,2.04%,PPP1R9A;MCTP2;MCTP1;RCAN3
prerank,GO_Biological_Process_2021__regulation of immune effector process (GO:0002697),-0.7838659033821971,-1.0527517150387853,0.44,1.0,1.0,4/53,1.63%,C4BPA;PROS1;C5AR2;C1R
prerank,MSigDB_Oncogenic_Signatures__TBK1.DF DN,0.631954056093982,1.0526504399618084,0.32727272727272727,1.0,1.0,18/263,2.41%,CLEC16A;CD2AP;PKP4;ACAP2;CDK6;ZNF557;MSH2;MTAP;SMC5;ANKRD11;PSMB9;MAOA;IGF2BP3;ITGA2;IL1RN;ZNF395;AMMECR1;COL4A5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Age-Related Macular Degeneration,-0.6924192312496812,-1.0522794897639007,0.36585365853658536,1.0,1.0,5/138,2.20%,APP;RAP1A;BMP4;MMP2;HLA-B
prerank,WikiPathway_2021_Human__Wnt Signaling Pathway WP363,0.8372762314317859,1.0522662309512352,0.5365853658536586,1.0,1.0,4/50,2.00%,LRP5;CDK6;AXIN2;NFATC2
prerank,GO_Biological_Process_2021__negative regulation of transport (GO:0051051),0.8296725527491162,1.0522115631738433,0.5149253731343284,1.0,1.0,6/49,2.05%,RAB7A;WWP2;ERBB3;PACSIN3;MCTP1;LGALS3
prerank,MSigDB_Oncogenic_Signatures__IL15 UP.V1 DN,-0.6838209599480762,-1.051905762926967,0.34710743801652894,1.0,1.0,7/141,2.22%,ADAMTS2;MAP2K6;ZNF571;DEPTOR;TNFAIP2;TGFB1I1;CLEC2B
prerank,Reactome_2022__RHOH GTPase Cycle R-HSA-9013407,0.7548462575364872,1.0517515303257328,0.5333333333333333,1.0,1.0,4/34,2.31%,RALGAPA1;SLC4A7;RAB7A;UACA
prerank,GO_Biological_Process_2021__granulocyte chemotaxis (GO:0071621),0.779658144593569,1.0516344597547427,0.40310077519379844,1.0,1.0,6/67,2.05%,PIK3CD;SYK;CX3CL1;ANXA1;CCL14;LGALS3
prerank,Reactome_2022__Signaling By B Cell Receptor (BCR) R-HSA-983705,0.7295101819643738,1.0513373918218543,0.3853211009174312,1.0,1.0,5/107,2.06%,PSMB9;SYK;DAPP1;NFATC2;PIK3AP1
prerank,GO_Biological_Process_2021__negative regulation of peptidyl-tyrosine phosphorylation (GO:0050732),0.7830341115315868,1.051305073885436,0.5714285714285714,1.0,1.0,5/31,1.71%,CD300A;PTPN2;THY1;CADM4;SAMSN1
prerank,Elsevier_Pathway_Collection__Metabolic Effects of Oncogenes and Tumor Suppressor in Cancer Cells,0.7657428711859076,1.0510870153628473,0.39855072463768115,1.0,1.0,6/66,2.39%,ACACA;PKLR;GLS;PDK3;HK2;PYCR1
prerank,GO_Biological_Process_2021__positive regulation of focal adhesion assembly (GO:0051894),-0.7035862675110043,-1.0506385072606164,0.5255474452554745,1.0,1.0,3/18,2.38%,PTPRJ;TEK;HRG
prerank,GO_Biological_Process_2021__regulation of axon extension involved in axon guidance (GO:0048841),0.7340766666196195,1.0505380884597302,0.5041322314049587,1.0,1.0,2/24,1.60%,MEGF8;SEMA3G
prerank,GO_Biological_Process_2021__regulation of cellular component movement (GO:0051270),0.7682095458734999,1.050422827708553,0.43846153846153846,1.0,1.0,5/50,1.46%,ZSWIM5;CDK6;ZSWIM6;ERBB3;CADM4
prerank,Elsevier_Pathway_Collection__Positive Acute Phase Proteins Synthesis,0.7773931571695671,1.0504132905089827,0.45864661654135336,1.0,1.0,3/57,2.27%,PPARA;A2M;FN1
prerank,GO_Biological_Process_2021__regulation of calcium ion transport (GO:0051924),0.7742242384546758,1.0501274001363505,0.42276422764227645,1.0,1.0,5/55,1.54%,LILRA2;CD33;CD4;PACSIN3;HOMER3
prerank,TRRUST_Transcription_Factors_2019__GATA3 human,-0.7811453367301043,-1.0501244361201927,0.5294117647058824,1.0,1.0,3/35,1.90%,ZEB1;IL12RB2;TEK
prerank,GO_Biological_Process_2021__cell-cell adhesion via plasma-membrane adhesion molecules (GO:0098742),0.6750074860327928,1.0499961795113735,0.35658914728682173,1.0,1.0,6/156,2.07%,CDH2;LRRC4;ITGAL;CDH1;PTPRM;CDH15
prerank,GO_Biological_Process_2021__regulation of muscle cell differentiation (GO:0051147),0.7793394952990783,1.049635065367904,0.5727272727272728,1.0,1.0,3/32,2.07%,CDH2;HDAC9;CDH15
prerank,GO_Biological_Process_2021__lipid catabolic process (GO:0016042),-0.7698964631274996,-1.04934735404166,0.5378787878787878,1.0,1.0,5/25,1.98%,STS;PLAAT3;LIPE;LIPG;CYP1A2
prerank,GO_Biological_Process_2021__regulation of nitric-oxide synthase activity (GO:0050999),-0.7905336768142184,-1.0492485274144498,0.5546218487394958,1.0,1.0,2/35,0.96%,PIK3CB;ZDHHC21
prerank,GO_Biological_Process_2021__regulation of defense response to virus (GO:0050688),0.6645899002553293,1.0490501161188281,0.47692307692307695,1.0,1.0,1/15,0.21%,TRAF3
prerank,MSigDB_Oncogenic_Signatures__P53 DN.V2 DN,0.7037085353381342,1.0483565175128973,0.3486238532110092,1.0,1.0,9/126,1.75%,LILRA2;EPHX2;AGPAT3;NDC80;SNTB1;CENPA;ITGA4;CYP27B1;TNNC2
prerank,Reactome_2022__Signaling By NOTCH R-HSA-157118,0.6485496490903414,1.0481429003140184,0.3,1.0,1.0,8/191,1.83%,TBL1X;HDAC8;CREB1;TFDP2;WWP2;PSMB9;NOTCH3;HDAC9
prerank,Elsevier_Pathway_Collection__CHRM1 -> IL2 Production,-0.7380370312020661,-1.0479860510081993,0.5185185185185185,1.0,1.0,3/27,1.21%,PTK2B;MAP2K6;RAP1A
prerank,GO_Biological_Process_2021__sphingolipid biosynthetic process (GO:0030148),-0.7536179663462081,-1.047866987712988,0.4307692307692308,1.0,1.0,7/71,2.08%,PLPP1;SGPP1;SGPL1;AGK;HACD2;CYP4F22;SMPD1
prerank,WikiPathway_2021_Human__Type II interferon signaling (IFNG) WP619,-0.776221709331339,-1.0478062383929387,0.4915254237288136,1.0,1.0,5/34,2.40%,OAS1;HLA-B;CIITA;IFI6;SPI1
prerank,GO_Biological_Process_2021__positive regulation of fat cell differentiation (GO:0045600),0.815201101685765,1.0476763084877243,0.5630252100840336,1.0,1.0,3/47,1.82%,CREB1;LRP5;PTGS2
prerank,Elsevier_Pathway_Collection__NMDA Receptors -> Ca2+/CREB Activation/PGE2 Synthesis,-0.6546699354578909,-1.0475066227696521,0.48854961832061067,1.0,1.0,2/17,1.21%,GRIN2B;RAP1A
prerank,WikiPathway_2021_Human__Biomarkers for pyrimidine metabolism disorders WP4584,-0.6595536071284495,-1.047367429969606,0.46774193548387094,1.0,1.0,1/15,0.72%,DPYS
prerank,GO_Biological_Process_2021__macroautophagy (GO:0016236),-0.7168099378830032,-1.047143567468569,0.30708661417322836,1.0,1.0,4/119,1.06%,KLHL3;TOMM70;UVRAG;ATG10
prerank,MSigDB_Hallmark_2020__Complement,0.6568834090988362,1.0471288115291593,0.3125,1.0,1.0,12/198,2.34%,PLAUR;USP15;CASP7;AKAP10;PSMB9;F7;LAMP2;CTSH;LGALS3;SERPINE1;FN1;GNG2
prerank,WikiPathway_2021_Human__PI3K-Akt signaling pathway WP4172,0.6001370428074885,1.0470358677911427,0.25862068965517243,1.0,1.0,21/300,2.41%,ITGA3;PIK3CD;CREB1;CDK6;PTK2;LPAR1;PRKAA2;ITGA4;SYK;ITGA2;GNB5;ITGB5;PIK3AP1;PRLR;COL9A3;FN1;HGF;COL9A2;GNG2;FGF1;COL4A5
prerank,GO_Biological_Process_2021__long-term memory (GO:0007616),-0.6648970439677794,-1.0468631843686962,0.48412698412698413,1.0,1.0,1/17,0.18%,CPEB3
prerank,GO_Biological_Process_2021__neurogenesis (GO:0022008),0.8072864474565701,1.0465260995670502,0.5267175572519084,1.0,1.0,4/43,1.64%,TRAK1;CDK6;LPAR1;ANXA1
prerank,GO_Biological_Process_2021__synaptic vesicle cycle (GO:0099504),0.7264991686055368,1.0462986747353376,0.5625,1.0,1.0,2/25,2.36%,BRSK1;STX1A
prerank,GO_Biological_Process_2021__regulation of potassium ion transport (GO:0043266),-0.7652406053578102,-1.0455785922326595,0.5611510791366906,1.0,1.0,5/27,2.44%,PTK2B;KCNN2;KCNAB3;KCNAB2;KCNE1
prerank,MSigDB_Oncogenic_Signatures__MEK UP.V1 UP,0.6375315579352657,1.0452698456908893,0.3700787401574803,1.0,1.0,15/181,2.42%,LRP5;ETV5;CHST11;TNFRSF21;MAOA;SPTBN2;MAP3K9;PACSIN3;MAN1A1;FOSL1;SGCE;SLC2A6;COTL1;DBNDD1;LGALSL
prerank,Reactome_2022__Factors Involved In Megakaryocyte Development And Platelet Production R-HSA-983231,0.7033024640581256,1.0450565628915456,0.371900826446281,1.0,1.0,6/116,2.41%,CENPE;AKAP10;DOCK11;ZFPM1;KIF23;KIF3B
prerank,WikiPathway_2021_Human__Rett syndrome causing genes WP4312,0.7761153954484644,1.0449000508421316,0.48333333333333334,1.0,1.0,4/47,1.35%,TBL1X;HDAC8;TAF1B;KCNJ10
prerank,Elsevier_Pathway_Collection__HPV E1 and E2 Expression in Early Phase of Cancer,-0.6552082924835071,-1.0444509639098105,0.4855072463768116,1.0,1.0,1/16,1.15%,RB1
prerank,Reactome_2022__Bile Acid And Bile Salt Metabolism R-HSA-194068,-0.73733654522041,-1.0444063943628665,0.48360655737704916,1.0,1.0,3/43,1.28%,CYP39A1;NCOA1;SLCO1A2
prerank,Elsevier_Pathway_Collection__Scavenger Receptor OLR1 in Inflammation Related Endothelial Dysfunction,0.7773984762228737,1.044297633323098,0.432,1.0,1.0,3/51,2.27%,CREB1;SERPINE1;FN1
prerank,GO_Biological_Process_2021__regulation of glycolytic process (GO:0006110),0.7553932377855156,1.0442674997553596,0.3761467889908257,1.0,1.0,4/68,2.25%,PPARA;NUP210;PRKAA2;SLC2A6
prerank,MSigDB_Oncogenic_Signatures__KRAS.KIDNEY UP.V1 UP,-0.6760506220031628,-1.0442539838506923,0.35294117647058826,1.0,1.0,3/124,1.63%,CPEB3;CCND2;PELI2
prerank,Elsevier_Pathway_Collection__Dopamine Synthesis and Release in Migraine,0.5878102761412921,1.043931143405505,0.3944954128440367,1.0,1.0,1/18,1.22%,MAOA
prerank,Elsevier_Pathway_Collection__Dopamine Synthesis and Release,0.5878102761412921,1.043931143405505,0.3944954128440367,1.0,1.0,1/18,1.22%,MAOA
prerank,GO_Biological_Process_2021__regulation of proteolysis involved in cellular protein catabolic process (GO:1903050),-0.6654344992460153,-1.0433164047448387,0.4700854700854701,1.0,1.0,1/25,0.13%,PTK2B
prerank,GO_Biological_Process_2021__glycosaminoglycan metabolic process (GO:0030203),0.7937604178237005,1.0429483695242325,0.5041322314049587,1.0,1.0,2/53,0.63%,HS2ST1;SLC35D2
prerank,Reactome_2022__Diseases Associated With O-glycosylation Of Proteins R-HSA-3906995,-0.784966891792399,-1.0429156211749409,0.45132743362831856,1.0,1.0,7/62,2.30%,ADAMTS2;MUC6;ADAMTS5;ADAMTS9;ADAMTSL5;ADAMTSL2;GALNT3
prerank,Reactome_2022__Syndecan Interactions R-HSA-3000170,0.6487843043376222,1.0428505966612909,0.4537037037037037,1.0,1.0,2/20,1.79%,ITGA2;ITGB5
prerank,GO_Biological_Process_2021__regulation of cell morphogenesis (GO:0022604),-0.7324553912710604,-1.0428465029962788,0.4634146341463415,1.0,1.0,2/32,1.76%,ZNF135;CD44
prerank,Reactome_2022__Signaling By NTRKs R-HSA-166520,-0.7092364723035471,-1.0427477718739766,0.32413793103448274,1.0,1.0,7/128,2.43%,PIK3CB;MAP2K5;GRIN2B;RAP1A;NTF3;DUSP4;FOSB
prerank,GO_Biological_Process_2021__regulation of double-strand break repair via nonhomologous end joining (GO:2001032),0.7349582843463234,1.0425836989530655,0.5132743362831859,1.0,1.0,2/29,1.51%,SMCHD1;WRAP53
prerank,GO_Biological_Process_2021__monosaccharide transmembrane transport (GO:0015749),-0.6568619835339423,-1.0416015856716048,0.4921875,1.0,1.0,2/16,0.99%,SLC23A2;SLC2A10
prerank,Reactome_2022__FOXO-mediated Transcription R-HSA-9614085,-0.7766207220412403,-1.0415790570771433,0.4435483870967742,1.0,1.0,7/61,2.36%,NR3C1;AKT3;GLYAT;ABCA6;CREBBP;KLF4;FBXO32
prerank,KEGG_2021_Human__Chemokine signaling pathway,-0.6488514188286655,-1.041257164838963,0.31007751937984496,1.0,1.0,13/181,2.34%,PTK2B;RAP1B;AKT3;PIK3CB;CCL23;PARD3;RAP1A;RASGRP2;HCK;ADCY3;PLCB4;PIK3R6;VAV1
prerank,Elsevier_Pathway_Collection__Ca2+ Flux Regulation,-0.7446901008964555,-1.0411306685080954,0.3893129770992366,1.0,1.0,4/93,2.01%,PTK2B;GRIN2B;HRH2;BDKRB2
prerank,Elsevier_Pathway_Collection__Scavenger Receptors in Platelet Activation,-0.7040056398877506,-1.0410792053322053,0.5,1.0,1.0,3/22,2.34%,MAP2K6;CD9;VAV1
prerank,TRRUST_Transcription_Factors_2019__CREM human,0.6624744920566772,1.0409123377313743,0.46551724137931033,1.0,1.0,2/22,0.43%,TAF4;CREB1
prerank,GO_Biological_Process_2021__cellular response to calcium ion (GO:0071277),-0.7542786793603576,-1.040865412033717,0.417910447761194,1.0,1.0,5/65,2.37%,CARF;RASGRP2;SYT2;SMPD1;SYT7
prerank,Elsevier_Pathway_Collection__Proteins Involved in Atherosclerosis,0.6515456113049927,1.0408152211067587,0.42276422764227645,1.0,1.0,11/186,2.37%,PLAUR;ITGA4;CD4;CX3CL1;FOSL1;PTGS2;APOE;SERPINE1;FN1;HGF;FGF1
prerank,GO_Biological_Process_2021__protein O-linked mannosylation (GO:0035269),0.6582838464125741,1.040614717121465,0.5,1.0,1.0,2/18,0.85%,POMGNT2;TMTC2
prerank,KEGG_2021_Human__Aldosterone synthesis and secretion,-0.758844129029117,-1.0399319150017579,0.3383458646616541,1.0,1.0,5/90,1.91%,CREB3L2;LIPE;ADCY3;CREB5;PLCB4
prerank,GO_Biological_Process_2021__endocrine system development (GO:0035270),0.6912514460105934,1.0398827806049304,0.5043478260869565,1.0,1.0,2/19,2.31%,SALL1;HOXD3
prerank,KEGG_2021_Human__Acute myeloid leukemia,-0.7539707184240508,-1.0397123255193508,0.3722627737226277,1.0,1.0,5/65,2.40%,AKT3;PIK3CB;STAT5A;PML;SPI1
prerank,WikiPathway_2021_Human__Chemokine signaling pathway WP3929,-0.6621056231790939,-1.0394229004578468,0.32558139534883723,1.0,1.0,11/157,2.34%,PTK2B;RAP1B;AKT3;PIK3CB;PARD3;RAP1A;RASGRP2;HCK;ADCY3;PLCB4;VAV1
prerank,GO_Biological_Process_2021__peptidyl-threonine phosphorylation (GO:0018107),-0.7404472557545981,-1.0393337458997542,0.3949579831932773,1.0,1.0,3/60,0.97%,CDC42BPA;WNK3;TNKS
prerank,Elsevier_Pathway_Collection__Potassium Flux Regulation,-0.764227539706738,-1.0393216397996523,0.4863013698630137,1.0,1.0,2/44,1.36%,RAP1A;HRH2
prerank,WikiPathway_2021_Human__TGF-beta Signaling Pathway WP366,-0.7049463394240414,-1.039141586944699,0.33098591549295775,1.0,1.0,13/131,2.43%,PAK2;MAP2K6;TGIF1;ZFYVE16;ZEB1;APP;WWP1;CREBBP;TGFB1I1;MAPK4;PML;MAP4K1;FOSB
prerank,Elsevier_Pathway_Collection__Proteins Involved in Frontotemporal Dementia,-0.6585897185942085,-1.0388823274276688,0.4666666666666667,1.0,1.0,1/22,0.81%,APP
prerank,GO_Biological_Process_2021__steroid metabolic process (GO:0008202),-0.7403845837298451,-1.0388169289785856,0.36,1.0,1.0,10/95,2.19%,STS;CYP39A1;CYP3A7;CYP2C8;CYP4V2;SHH;ARV1;CYP1B1;CYP1A2;VDR
prerank,GO_Biological_Process_2021__negative regulation of protein modification process (GO:0031400),0.744521984205119,1.038754752937961,0.37719298245614036,1.0,1.0,5/78,1.75%,PPP1R16B;PRKAA2;IGFBP3;CADM4;SNTA1
prerank,GO_Biological_Process_2021__plasma membrane invagination (GO:0099024),0.7806105566308567,1.038547123533357,0.5789473684210527,1.0,1.0,3/30,1.95%,ARHGAP12;HAVCR1;SPIRE2
prerank,GO_Biological_Process_2021__regulation of blood vessel endothelial cell migration (GO:0043535),-0.7762792153151425,-1.0384380193601235,0.43283582089552236,1.0,1.0,3/54,2.38%,AKT3;STAT5A;HRG
prerank,GO_Biological_Process_2021__activation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0006919),0.7314204277563008,1.0383579629414599,0.4222222222222222,1.0,1.0,4/80,1.87%,TNFRSF10A;SENP1;DLC1;BOK
prerank,GO_Biological_Process_2021__amyloid precursor protein metabolic process (GO:0042982),-0.6632053686988749,-1.0381990837660402,0.45864661654135336,1.0,1.0,1/17,0.35%,ADAM10
prerank,WikiPathway_2021_Human__Apoptosis Modulation and Signaling WP1772,0.705284265166032,1.0381558904762103,0.3700787401574803,1.0,1.0,7/87,1.91%,TRAF3;TNFRSF10A;CASP7;TNFRSF25;TNFRSF10D;BOK;NAIP
prerank,KEGG_2021_Human__Neutrophil extracellular trap formation,0.6661222542005575,1.037989604444533,0.3790322580645161,1.0,1.0,8/155,2.16%,HDAC8;PIK3CD;SYK;ITGAL;HDAC9;MAPK13;CLCN4;CYBA
prerank,GO_Biological_Process_2021__regulation of calcium ion import (GO:0090279),-0.6577438790519873,-1.037653180809607,0.5039370078740157,1.0,1.0,1/21,0.90%,WNK3
prerank,GO_Biological_Process_2021__positive regulation of Rho protein signal transduction (GO:0035025),0.7289561920241795,1.03743579982285,0.528,1.0,1.0,2/30,2.11%,LPAR1;GPR35
prerank,WikiPathway_2021_Human__Phosphodiesterases in neuronal function WP4222,-0.7815583191090401,-1.0368304719876893,0.48507462686567165,1.0,1.0,5/50,1.86%,PDE5A;GRIN2B;PDE11A;ADCY3;PDE6D
prerank,GO_Biological_Process_2021__neutrophil migration (GO:1990266),0.7573948437531555,1.0362776371378197,0.42063492063492064,1.0,1.0,5/70,2.05%,PIK3CD;SYK;CX3CL1;CCL14;LGALS3
prerank,MSigDB_Hallmark_2020__Glycolysis,0.6378938726617104,1.036250795257731,0.35398230088495575,1.0,1.0,11/194,2.19%,PLOD2;HS2ST1;PHKA2;CENPA;IGFBP3;DEPDC1;PDK3;IL13RA1;PPFIA4;QSOX1;HK2
prerank,WikiPathway_2021_Human__Small Ligand GPCRs WP247,0.657476756632509,1.036155226560585,0.48760330578512395,1.0,1.0,1/16,0.92%,LPAR1
prerank,Reactome_2022__DNA Double-Strand Break Repair R-HSA-5693532,0.6553070618096549,1.0358654263543257,0.38181818181818183,1.0,1.0,6/141,1.15%,HERC2;SLC19A1;DCLRE1C;POLE4;TDP1;BRIP1
prerank,GO_Biological_Process_2021__neuropeptide signaling pathway (GO:0007218),0.7297917549873985,1.0356646620644103,0.44715447154471544,1.0,1.0,2/43,2.02%,SORT1;CPE
prerank,GO_Biological_Process_2021__serine family amino acid metabolic process (GO:0009069),-0.6447507110748374,-1.0354017225278003,0.4732824427480916,1.0,1.0,2/16,2.20%,GLYAT;CDO1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Multiple Myeloma,0.7898572921598302,1.0352364717576292,0.4594594594594595,1.0,1.0,5/55,2.28%,CDK6;ITGA4;IL1RN;PTGS2;HGF
prerank,MSigDB_Oncogenic_Signatures__P53 DN.V1 UP,0.6374432454353007,1.0351897939159151,0.34513274336283184,1.0,1.0,12/178,2.24%,ZNF165;NDC80;MTAP;PTPRH;ITGA2;ANXA1;MYOF;FHL2;HDAC9;CPE;CNN3;LRIG1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Glioblastoma,0.670935538660155,1.0350908559270982,0.3770491803278688,1.0,1.0,9/161,2.37%,RFX1;CDK6;PLAUR;MYCN;CDH1;PTGS2;HK2;HGF;FGF1
prerank,MSigDB_Hallmark_2020__Hypoxia,0.6253003586912517,1.0344360998686606,0.36923076923076925,1.0,1.0,9/194,2.19%,PLAUR;IGFBP3;PKLR;PDK3;PPFIA4;FOSL2;CAVIN1;SERPINE1;HK2
prerank,Elsevier_Pathway_Collection__Th17-Cell Activation in Crohn's Disease,-0.7450677937439839,-1.0343886780950062,0.5503875968992248,1.0,1.0,5/34,2.44%,STAT5A;IL12RB2;RORC;IL21R;ZAP70
prerank,WikiPathway_2021_Human__Serotonin Receptor 4/6/7 and NR3C Signaling WP734,-0.6546694607968994,-1.034314470829024,0.48936170212765956,1.0,1.0,2/18,1.21%,NR3C1;RAP1A
prerank,Elsevier_Pathway_Collection__Proteins Involved in Neuroblastoma,0.625650403555799,1.0340868426922152,0.3826086956521739,1.0,1.0,12/199,2.28%,CDH2;HDAC8;TNFRSF10A;PTK2;MYCN;CX3CL1;PROX1;TNFRSF10D;MSX1;TIMP3;SERPINE1;HGF
prerank,TRRUST_Transcription_Factors_2019__ATF4 human,0.7135180584583465,1.0337383210751168,0.5116279069767442,1.0,1.0,4/34,1.99%,NDC80;F7;PTGS2;APOE
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hodgkin Lymphoma,0.7318273592507306,1.0336530800059385,0.43478260869565216,1.0,1.0,2/49,1.82%,TRAF3;PTGS2
prerank,Reactome_2022__Transcription-Coupled Nucleotide Excision Repair (TC-NER) R-HSA-6781827,0.7554247568318576,1.0335866388470445,0.37777777777777777,1.0,1.0,4/76,2.24%,SLC19A1;TCEA1;POLE4;LRIG1
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Activation through ITSM-Containing Receptors,0.6943550758495483,1.0334473538899118,0.4396551724137931,1.0,1.0,2/33,2.00%,CD48;NFATC2
prerank,Elsevier_Pathway_Collection__FOXL2 Mutation in Ovarian Dysgenesis,-0.6210602069188529,-1.0333812734448782,0.4642857142857143,1.0,1.0,2/17,1.54%,SOD2;CCND2
prerank,Reactome_2022__Apoptotic Cleavage Of Cellular Proteins R-HSA-111465,0.7561526491798285,1.033239218919704,0.49206349206349204,1.0,1.0,4/36,2.17%,TJP1;PTK2;CASP7;STK26
prerank,WikiPathway_2021_Human__Neural Crest Cell Migration during Development WP4564,-0.7796807625595072,-1.0331860800481405,0.5664335664335665,1.0,1.0,5/39,2.05%,PAK2;AKT3;PIK3CB;MMP2;PIK3R6
prerank,WikiPathway_2021_Human__Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways WP706,0.674598460807073,1.0331166360156447,0.3875968992248062,1.0,1.0,9/142,2.26%,CREB1;YWHAQ;MAOA;SLC6A4;IL1RN;PAH;SNTA1;HDAC9;GPD1L
prerank,KEGG_2021_Human__Renal cell carcinoma,-0.7880179555643642,-1.0329853238287492,0.4090909090909091,1.0,1.0,6/68,1.22%,PAK2;RAP1B;AKT3;PIK3CB;RAP1A;CREBBP
prerank,Elsevier_Pathway_Collection__Graves Ophthalmopathy,0.7641917688888423,1.0325932412813814,0.5,1.0,1.0,4/41,1.37%,PPARA;CREB1;THY1;ITGAL
prerank,GO_Biological_Process_2021__intracellular steroid hormone receptor signaling pathway (GO:0030518),-0.7889920650024759,-1.0324778138975899,0.5230769230769231,1.0,1.0,3/41,1.11%,PLPP1;NR3C1;NEDD4
prerank,WikiPathway_2021_Human__AGE/RAGE pathway WP2324,-0.7585927909217357,-1.0322793537864667,0.43478260869565216,1.0,1.0,3/64,1.93%,INHBB;STAT5A;MMP2
prerank,GO_Biological_Process_2021__ion transport (GO:0006811),-0.6901340392237442,-1.0321194795134854,0.36363636363636365,1.0,1.0,4/103,2.42%,KCNN2;SLC15A3;SLC9A9;SLC17A4
prerank,GO_Biological_Process_2021__mRNA transport (GO:0051028),0.7168151314704843,1.0319331093642337,0.4049586776859504,1.0,1.0,2/103,1.05%,UPF2;NUP210
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> CREBBP Signaling,-0.7030440539841669,-1.0319108545448046,0.5503875968992248,1.0,1.0,3/22,2.44%,CREBBP;GRAP2;ZAP70
prerank,GO_Biological_Process_2021__positive regulation of macromolecule metabolic process (GO:0010604),-0.602597406402215,-1.0316956425657422,0.3383458646616541,1.0,1.0,13/352,2.45%,MYOM1;ATAD1;PIK3CB;MAP2K5;APP;SLC2A10;DTNBP1;ITGAX;BMP4;NTF3;KLF4;VDR;DNAJA4
prerank,KEGG_2021_Human__Epstein-Barr virus infection,-0.639384573168386,-1.0312208713372544,0.392,1.0,1.0,12/183,2.20%,MAP2K6;POLK;AKT3;OAS1;PIK3CB;NEDD4;RB1;CCND2;ENTPD8;CD44;ENTPD3;HLA-B
prerank,Reactome_2022__Activation Of NMDA Receptors And Postsynaptic Events R-HSA-442755,0.7370818028348844,1.0311894024772208,0.39814814814814814,1.0,1.0,6/71,2.17%,CREB1;DLG1;LIN7A;ARHGEF7;PRKAA2;GPRIN1
prerank,GO_Biological_Process_2021__negative regulation of epithelial cell apoptotic process (GO:1904036),0.7293758367644574,1.0311507808030291,0.5,1.0,1.0,2/34,2.07%,PPARA;SERPINE1
prerank,MSigDB_Oncogenic_Signatures__ESC J1 UP LATE.V1 UP,0.6625202787546247,1.0310473221216245,0.3445378151260504,1.0,1.0,16/169,2.31%,LMO7;RNF130;AMN;KLB;SOAT2;CDC42EP1;TUFT1;MOGAT2;FHL2;ZFPM1;SGCE;CTSH;RBP4;ZDHHC9;HKDC1;MYO7A
prerank,KEGG_2021_Human__Axon guidance,-0.650289747675652,-1.0310273137259185,0.38405797101449274,1.0,1.0,12/176,2.31%,PAK2;NEO1;PIK3CB;NTN4;PARD3;SHH;BOC;ABLIM3;PARD6G;SLIT3;SEMA4D;EFNB2
prerank,TRRUST_Transcription_Factors_2019__SOX9 human,-0.6939042312062014,-1.0309949263261773,0.5144927536231884,1.0,1.0,2/20,2.05%,SHH;KLF4
prerank,GO_Biological_Process_2021__RNA export from nucleus (GO:0006405),0.7168155719863519,1.0308512368357934,0.3508771929824561,1.0,1.0,2/102,1.05%,UPF2;NUP210
prerank,Elsevier_Pathway_Collection__CD46/CD55/CD59 Inhibit Complement Mediated Lysis of Cancer Cells,0.6624366454329297,1.0306992644364972,0.47540983606557374,1.0,1.0,1/15,0.43%,CREB1
prerank,GO_Biological_Process_2021__mRNA export from nucleus (GO:0006406),0.7168142416404133,1.0303944099878104,0.3813559322033898,1.0,1.0,2/105,1.05%,UPF2;NUP210
prerank,Reactome_2022__Signaling By ERBB2 R-HSA-1227986,-0.7292485942107905,-1.030393254982208,0.5177304964539007,1.0,1.0,3/49,2.09%,AKT3;NRG1;PTPN18
prerank,GO_Biological_Process_2021__regulation of type I interferon-mediated signaling pathway (GO:0060338),0.661011046161166,1.0303312334816672,0.48333333333333334,1.0,1.0,2/30,0.57%,YTHDF3;PTPN2
prerank,KEGG_2021_Human__Cholesterol metabolism,0.7801329967841273,1.0299993241798346,0.524822695035461,1.0,1.0,3/50,1.99%,SORT1;SOAT2;APOE
prerank,GO_Biological_Process_2021__bicarbonate transport (GO:0015701),0.7284159892088355,1.0299946422641277,0.5307692307692308,1.0,1.0,2/32,2.16%,SLC4A7;CYB5R2
prerank,GO_Biological_Process_2021__protein maturation (GO:0051604),0.713164648666148,1.029700287204041,0.359375,1.0,1.0,4/91,2.02%,NAA60;F7;NAA10;CPE
prerank,WikiPathway_2021_Human__Selenium Micronutrient Network WP15,0.7294515867568708,1.0294896426049365,0.41025641025641024,1.0,1.0,5/84,2.07%,CBS;F7;PTGS2;TXNRD2;SERPINE1
prerank,GO_Biological_Process_2021__long-chain fatty-acyl-CoA metabolic process (GO:0035336),0.7112184740550658,1.0294431815342244,0.5583333333333333,1.0,1.0,4/24,2.22%,ACSF3;ELOVL2;ELOVL6;ACSL5
prerank,WikiPathway_2021_Human__Allograft Rejection WP2328,0.7270628776909756,1.0291081592217974,0.4146341463414634,1.0,1.0,2/80,2.29%,CASP7;CD86
prerank,Elsevier_Pathway_Collection__Immune System Activation in Hyperthyroidism,0.7771385017325518,1.028945947500357,0.5555555555555556,1.0,1.0,3/41,2.29%,CD4;SYK;CD86
prerank,GO_Biological_Process_2021__negative regulation of ERK1 and ERK2 cascade (GO:0070373),0.8148932413394026,1.028762308979757,0.5327102803738317,1.0,1.0,3/47,1.85%,DLG1;PTPN2;TIMP3
prerank,WikiPathway_2021_Human__Interleukin-11 Signaling Pathway WP2332,0.7344490288361074,1.0286332234180344,0.4603174603174603,1.0,1.0,2/43,1.56%,CREB1;ITGA2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Chronic Myeloid Leukemia,-0.7330003940943647,-1.0285397527941202,0.5555555555555556,1.0,1.0,2/23,1.71%,RB1;STAT5A
prerank,GO_Biological_Process_2021__interleukin-12-mediated signaling pathway (GO:0035722),-0.8004374056199991,-1.0284380661874684,0.5272727272727272,1.0,1.0,5/44,1.79%,PAK2;RAP1B;SOD2;GSTA2;IL12RB2
prerank,WikiPathway_2021_Human__Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms WP4534,0.6816005882773314,1.0282012433371506,0.39823008849557523,1.0,1.0,5/45,1.86%,MAP4K5;YWHAQ;CDH1;ITGB5;TEAD4
prerank,TRRUST_Transcription_Factors_2019__IRF1 human,0.7658420444611098,1.0278676010567176,0.44715447154471544,1.0,1.0,2/48,1.20%,CASP7;PSMB9
prerank,Elsevier_Pathway_Collection__Huntingtin Gene Mutation in Striatal Neuron,0.7458442279410045,1.0277951673465406,0.5039370078740157,1.0,1.0,3/33,0.43%,TAF4;PRPF40A;CREB1
prerank,GO_Biological_Process_2021__positive regulation of autophagy (GO:0010508),0.693197244123259,1.0277399630703936,0.3445378151260504,1.0,1.0,3/84,2.11%,PRKAA2;MEFV;OPTN
prerank,Elsevier_Pathway_Collection__IL1B Induced Arthralgia,-0.6644735611914789,-1.02760195737408,0.45588235294117646,1.0,1.0,1/21,0.23%,MAP2K6
prerank,WikiPathway_2021_Human__Tryptophan catabolism leading to NAD+ production WP4210,0.6605909861592185,1.0274196683174028,0.5118110236220472,1.0,1.0,1/16,0.61%,QPRT
prerank,GO_Biological_Process_2021__positive regulation of transcription of Notch receptor target (GO:0007221),-0.649709843197257,-1.0272608332691677,0.472,1.0,1.0,2/17,1.71%,CREBBP;PBX1
prerank,WikiPathway_2021_Human__Aryl Hydrocarbon Receptor Netpath WP2586,-0.7803301693394911,-1.027087701468687,0.5080645161290323,1.0,1.0,3/44,1.98%,RB1;CYP1B1;CYP1A2
prerank,Reactome_2022__ESR-mediated Signaling R-HSA-8939211,-0.6425278525217986,-1.0269064860114094,0.375,1.0,1.0,7/173,2.43%,AKT3;NCOA1;POU2F1;ZDHHC21;CREBBP;MMP2;FOSB
prerank,WikiPathway_2021_Human__Neural Crest Differentiation WP2064,0.7404969483024973,1.0268277605502645,0.3951612903225806,1.0,1.0,7/79,1.97%,CDH2;HDAC8;NOTCH3;CDH1;HDAC9;MSX1;AXIN2
prerank,GO_Biological_Process_2021__regulation of defense response (GO:0031347),0.7414747069332419,1.0267694510910659,0.3973509933774834,1.0,1.0,6/81,2.06%,TRAF3;NOD2;ANXA1;PTGS2;APOE;PIK3AP1
prerank,Reactome_2022__Intrinsic Pathway For Apoptosis R-HSA-109606,0.7548271513516533,1.0267033717399103,0.45535714285714285,1.0,1.0,4/55,2.31%,YWHAQ;TFDP2;CASP7;UACA
prerank,Reactome_2022__HDR Thru Homologous Recombination (HRR) R-HSA-5685942,0.7385573926677202,1.0265350039414056,0.42735042735042733,1.0,1.0,3/66,1.15%,SLC19A1;POLE4;BRIP1
prerank,WikiPathway_2021_Human__PKC-gamma calcium signaling pathway in ataxia WP4760,-0.6435171549351667,-1.0264466459131254,0.46715328467153283,1.0,1.0,2/19,2.32%,PLCB4;GNA14
prerank,GO_Biological_Process_2021__positive regulation of nitric-oxide synthase activity (GO:0051000),-0.6612447428811287,-1.0263666582877682,0.48672566371681414,1.0,1.0,1/16,0.55%,PIK3CB
prerank,KEGG_2021_Human__Neuroactive ligand-receptor interaction,-0.6255738254789316,-1.0252617954019145,0.3515625,1.0,1.0,7/237,2.16%,NR3C1;PARD3;GRIN2B;HRH2;GRIK5;BDKRB2;S1PR1
prerank,KEGG_2021_Human__cAMP signaling pathway,-0.6385076723630815,-1.025206055405522,0.373134328358209,1.0,1.0,13/189,2.34%,CREB3L2;RAP1B;AKT3;PIK3CB;GRIN2B;RAP1A;CREBBP;LIPE;RAPGEF3;ADCY3;CREB5;GLI3;VAV1
prerank,Reactome_2022__Antiviral Mechanism By IFN-stimulated Genes R-HSA-1169410,-0.7058014761086298,-1.0248607823968365,0.3709677419354839,1.0,1.0,5/82,2.16%,KPNA3;OAS1;NEDD4;HERC5;OASL
prerank,WikiPathway_2021_Human__Metapathway biotransformation Phase I and II WP702,-0.6519360731084737,-1.0248507996395053,0.40714285714285714,1.0,1.0,15/165,1.98%,GSTA1;CYP39A1;CYP3A7;GLYAT;CYP2C8;SULT1B1;CYP4V2;CYP20A1;GSTA2;KCNAB3;CYP4F22;CYP1B1;AKR7A3;KCNAB2;CYP1A2
prerank,Reactome_2022__Glycosphingolipid Metabolism R-HSA-1660662,-0.7792918030024549,-1.0247651340823924,0.5658914728682171,1.0,1.0,3/43,2.08%,STS;GALC;SMPD1
prerank,Reactome_2022__DDX58/IFIH1-mediated Induction Of Interferon-Alpha/Beta R-HSA-168928,-0.7609422719626134,-1.0247312951775929,0.4251968503937008,1.0,1.0,4/66,1.70%,TOMM70;APP;CREBBP;HERC5
prerank,GO_Biological_Process_2021__central nervous system development (GO:0007417),-0.6262433758730768,-1.024610821321779,0.4122137404580153,1.0,1.0,12/230,2.22%,NDUFS4;BTD;WWP1;GRIN2B;MEIS1;SHH;ADGRA2;PAX8;PBX1;POU6F1;EML1;DSCAML1
prerank,GO_Biological_Process_2021__positive regulation of lymphocyte differentiation (GO:0045621),-0.642441859430335,-1.0245721838024835,0.53125,1.0,1.0,3/18,2.44%,CD27;RHOH;ZAP70
prerank,GO_Biological_Process_2021__positive regulation of lamellipodium organization (GO:1902745),0.7590421337602741,1.0243946566226523,0.5564516129032258,1.0,1.0,4/31,1.89%,ABI2;ACTR3;ARHGEF7;CARMIL2
prerank,GO_Biological_Process_2021__antigen processing and presentation of exogenous peptide antigen via MHC class I (GO:0042590),0.756271231500585,1.024207378483851,0.423728813559322,1.0,1.0,3/76,2.16%,PSMB9;ITGB5;CYBA
prerank,GO_Biological_Process_2021__cellular response to interferon-beta (GO:0035458),-0.661898470534479,-1.0237401837954707,0.46153846153846156,1.0,1.0,1/16,0.48%,OAS1
prerank,Reactome_2022__E3 Ubiquitin Ligases Ubiquitinate Target Proteins R-HSA-8866654,-0.7280903317707864,-1.0236544824061746,0.424,1.0,1.0,2/52,2.20%,SHPRH;HLA-B
prerank,Reactome_2022__Voltage Gated Potassium Channels R-HSA-1296072,-0.7596562704486048,-1.023370358184405,0.584,1.0,1.0,3/32,1.83%,KCNAB3;KCNS3;KCNAB2
prerank,Elsevier_Pathway_Collection__GUCY2C Signaling in Colorectal Cancer,-0.6662040977060486,-1.0233271936534176,0.4645669291338583,1.0,1.0,1/26,0.05%,PDE5A
prerank,GO_Biological_Process_2021__protein modification by small protein removal (GO:0070646),-0.6037823402813586,-1.0232716265787258,0.3170731707317073,1.0,1.0,6/250,1.18%,USP40;USP37;MBD5;SENP7;INO80D;BRCC3
prerank,GO_Biological_Process_2021__protein localization to lysosome (GO:0061462),-0.6556262600187783,-1.0231817513421906,0.5338983050847458,1.0,1.0,2/28,1.11%,ZFYVE16;NEDD4
prerank,GO_Biological_Process_2021__cellular response to UV (GO:0034644),-0.7066156723520394,-1.0230747968044558,0.44166666666666665,1.0,1.0,5/76,2.08%,POLK;NEDD4;CREBBP;MMP2;SMPD1
prerank,GO_Biological_Process_2021__protein-containing complex assembly (GO:0065003),-0.6127212205745285,-1.023074125078226,0.36153846153846153,1.0,1.0,13/265,2.39%,PTK2B;SLC7A9;ADAM10;KPNA3;DNAJB14;TLE4;PARD3;CREBBP;MATN1;BIN2;CARD10;PML;COL7A1
prerank,Reactome_2022__Neutrophil Degranulation R-HSA-6798695,0.576352044493409,1.0227688702740818,0.3333333333333333,1.0,1.0,25/451,2.27%,MANBA;CD300A;CD33;IGF2R;CD53;ATAD3B;ERP44;PLAUR;CAB39;RAB7A;CPPED1;SLC27A2;PADI2;CKAP4;NFAM1;ITGAL;MOSPD2;LAMP2;DLC1;CTSH;QSOX1;LGALS3;CYBA;MNDA;COTL1
prerank,GO_Biological_Process_2021__regulation of cellular catabolic process (GO:0031329),-0.7317392879451393,-1.0226674352017304,0.39849624060150374,1.0,1.0,2/64,1.83%,GPR137B;DAPK2
prerank,GO_Biological_Process_2021__regulation of amyloid fibril formation (GO:1905906),-0.6585921302383168,-1.0223814665258695,0.4878048780487805,1.0,1.0,1/15,0.81%,APP
prerank,WikiPathway_2021_Human__Ciliopathies WP4803,-0.6622089657578772,-1.0222189383332563,0.4306569343065693,1.0,1.0,11/171,2.33%,WDPCP;SDCCAG8;CEP120;CPLANE1;ATXN10;ANKS6;TTBK2;SUFU;PDE6D;GLI3;BBS5
prerank,Reactome_2022__Oxidative Stress Induced Senescence R-HSA-2559580,0.7202647218913146,1.0220668161347615,0.36607142857142855,1.0,1.0,3/81,1.31%,CDK6;TFDP2;CBX2
prerank,GO_Biological_Process_2021__cellular amino acid catabolic process (GO:0009063),0.7121566499788534,1.0219297036492472,0.3728813559322034,1.0,1.0,5/90,1.53%,AUH;AASS;FTCD;CBS;GLS
prerank,GO_Biological_Process_2021__negative regulation of cell cycle process (GO:0010948),0.745503855095706,1.021531279316522,0.4462809917355372,1.0,1.0,3/61,2.38%,TOM1L1;TFDP2;RRM2
prerank,WikiPathway_2021_Human__Lung fibrosis WP3624,0.7763506147137937,1.0213883973731657,0.4628099173553719,1.0,1.0,3/60,2.37%,PARN;HGF;FGF1
prerank,GO_Biological_Process_2021__cellular response to molecule of bacterial origin (GO:0071219),0.6914066714276624,1.0213792163787472,0.3770491803278688,1.0,1.0,4/103,2.29%,NOD2;SERPINE1;GFI1;CD86
prerank,Reactome_2022__Activated TAK1 Mediates P38 MAPK Activation R-HSA-450302,0.657745160265707,1.0211037106733964,0.4883720930232558,1.0,1.0,2/19,0.90%,IRAK2;NOD2
prerank,GO_Biological_Process_2021__positive regulation of cell death (GO:0010942),-0.7103358344578226,-1.0210160363984166,0.4186046511627907,1.0,1.0,4/64,2.31%,GRIN2B;BMP4;SLFN11;EFNB2
prerank,Reactome_2022__Telomere Maintenance R-HSA-157579,0.7274881713968051,1.0207721234478344,0.4094488188976378,1.0,1.0,5/81,2.26%,SLC19A1;WRAP53;ACD;LRIG1;PIF1
prerank,GO_Biological_Process_2021__cardiac muscle cell action potential involved in contraction (GO:0086002),0.7552731712278675,1.0206921615618,0.5833333333333334,1.0,1.0,3/29,2.26%,GJC1;SNTA1;GPD1L
prerank,"Reactome_2022__Plasma Lipoprotein Assembly, Remodeling, And Clearance R-HSA-174824",0.7578950607512507,1.0202266445846981,0.43846153846153846,1.0,1.0,3/69,1.99%,AMN;SOAT2;APOE
prerank,Elsevier_Pathway_Collection__OPRD/OPRM -> Ion Channels,-0.5846197817259647,-1.020211839810209,0.44166666666666665,1.0,1.0,1/16,1.54%,RAPGEF3
prerank,Reactome_2022__Fatty Acid Metabolism R-HSA-8978868,0.6507602303606731,1.0201534954128584,0.3673469387755102,1.0,1.0,11/167,2.22%,ACSF3;EPHX2;ACACA;SLC27A2;CYP4F3;PRKAA2;PTGR1;ELOVL2;PTGS2;ELOVL6;ACSL5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Systemic Scleroderma,0.755067039092465,1.0199287934570305,0.504,1.0,1.0,3/44,2.28%,CX3CL1;FN1;HGF
prerank,GO_Biological_Process_2021__skeletal muscle organ development (GO:0060538),0.6558566109818506,1.0196490207911508,0.48739495798319327,1.0,1.0,1/27,1.08%,SVIL
prerank,GO_Biological_Process_2021__neuromuscular synaptic transmission (GO:0007274),-0.6583610710716085,-1.0191637413436117,0.49612403100775193,1.0,1.0,1/16,0.84%,ERC1
prerank,Reactome_2022__Polo-like Kinase Mediated Events R-HSA-156711,-0.6535550795278813,-1.0190890097624388,0.5210084033613446,1.0,1.0,1/16,1.32%,LIN9
prerank,Reactome_2022__Death Receptor Signaling R-HSA-73887,0.651946827950369,1.019087570321651,0.40336134453781514,1.0,1.0,6/139,1.49%,AATF;TNFRSF10A;ARHGEF7;PLEKHG5;ARHGEF18;TNFRSF10D
prerank,GO_Biological_Process_2021__glycerophospholipid metabolic process (GO:0006650),-0.720399565715918,-1.0190819425261293,0.45132743362831856,1.0,1.0,5/77,1.89%,ABHD3;PIGX;AGK;PIGZ;HDHD5
prerank,Reactome_2022__CTLA4 Inhibitory Signaling R-HSA-389513,-0.662012467310734,-1.0188309017684858,0.5033557046979866,1.0,1.0,1/21,0.47%,AKT3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Polycystic Kidney Disease,0.6916896809384624,1.018686615361659,0.36036036036036034,1.0,1.0,7/90,2.28%,FNIP2;FNIP1;NEK8;HAVCR1;LGALS3;FN1;HGF
prerank,MSigDB_Oncogenic_Signatures__STK33 NOMO UP,-0.612918129710081,-1.018582274827056,0.352,1.0,1.0,10/261,2.36%,HECTD2;TGIF1;SGPL1;GPR137B;RASGRP3;IL10RA;CLEC2B;SEMA4D;EFNB2;FBXO32
prerank,Elsevier_Pathway_Collection__Thyroid Hormones in Adipose Tissue Metabolism,0.7293802802596223,1.0178013886550314,0.5362318840579711,1.0,1.0,2/29,2.07%,ACACA;SERPINE1
prerank,WikiPathway_2021_Human__Pathways Regulating Hippo Signaling WP4540,0.7571459884974285,1.0177556258390024,0.41818181818181815,1.0,1.0,5/92,2.07%,CDH2;PRKAA2;CDH1;TEAD4;CDH15
prerank,Reactome_2022__Peptide Hormone Metabolism R-HSA-2980736,-0.7443567824401656,-1.0176362371740866,0.40625,1.0,1.0,4/76,2.05%,EXOC2;MYRIP;INHBB;KLF4
prerank,GO_Biological_Process_2021__regulation of protein polymerization (GO:0032271),0.7551522008480281,1.017056054134046,0.525,1.0,1.0,3/35,2.27%,CAMSAP3;FCHSD2;COTL1
prerank,WikiPathway_2021_Human__The Overlap Between Signal Transduction Pathways that Contribute to a Range of LMNA Laminopathies WP4879,-0.7475905407324541,-1.0170019354372593,0.4603174603174603,1.0,1.0,3/53,2.17%,RB1;CREBBP;MAOB
prerank,MSigDB_Oncogenic_Signatures__TGFB UP.V1 UP,0.6295802958835184,1.0168899440327395,0.4496124031007752,1.0,1.0,10/173,2.37%,SMOX;BCOR;PIK3CD;CHST11;TMC7;ARHGAP12;DLC1;PPP1R13L;TBX3;FGF1
prerank,GO_Biological_Process_2021__negative regulation of chemokine production (GO:0032682),-0.6046598790033539,-1.0168497658434341,0.47368421052631576,1.0,1.0,3/17,2.05%,OAS1;MAP2K5;KLF4
prerank,Reactome_2022__NGF-stimulated Transcription R-HSA-9031628,0.7324137963368754,1.0166613506368485,0.509090909090909,1.0,1.0,2/37,1.76%,CREB1;FOSL1
prerank,Elsevier_Pathway_Collection__MIF Role in Cholesteatoma,-0.7324598428014165,-1.0165802365473657,0.5845070422535211,1.0,1.0,2/26,1.76%,RAP1A;CD44
prerank,Elsevier_Pathway_Collection__G0/G1 Phase Transition,0.740956413767706,1.0165729716787475,0.5,1.0,1.0,3/38,0.91%,CDK6;PTK2;TFDP2
prerank,"GO_Biological_Process_2021__protein localization to chromosome, telomeric region (GO:0070198)",0.5785463748702777,1.0162878642054125,0.417910447761194,1.0,1.0,2/15,2.15%,ATR;ACD
prerank,WikiPathway_2021_Human__Energy Metabolism WP1541,0.7390676234462584,1.016163191373099,0.4778761061946903,1.0,1.0,3/45,1.10%,PPARA;CREB1;PRKAA2
prerank,"GO_Biological_Process_2021__antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent (GO:0002479)",0.7562756417703511,1.0160830456951642,0.43089430894308944,1.0,1.0,3/71,2.16%,PSMB9;ITGB5;CYBA
prerank,GO_Biological_Process_2021__protein insertion into membrane (GO:0051205),-0.7258778023310213,-1.0160458394858978,0.5037593984962406,1.0,1.0,2/31,2.42%,APP;RTP4
prerank,GO_Biological_Process_2021__generation of neurons (GO:0048699),0.6354855692420381,1.0160141437139105,0.3779527559055118,1.0,1.0,7/166,2.18%,POMGNT2;ELP3;CDK6;BRSK1;CX3CL1;VAX2;SH3RF1
prerank,GO_Biological_Process_2021__regulation of anoikis (GO:2000209),0.6578213438243194,1.0159835163058866,0.5075757575757576,1.0,1.0,2/21,0.89%,PTK2;ZNF304
prerank,GO_Biological_Process_2021__negative regulation of interleukin-10 production (GO:0032693),0.6571302721137748,1.0158790414183345,0.49166666666666664,1.0,1.0,1/17,0.96%,TNFRSF21
prerank,GO_Biological_Process_2021__protein import into nucleus (GO:0006606),-0.7232627103209933,-1.0157825595482801,0.391304347826087,1.0,1.0,2/72,0.41%,IPO11;KPNA3
prerank,GO_Biological_Process_2021__defense response to Gram-negative bacterium (GO:0050829),0.7789428702830006,1.0156675547823437,0.5294117647058824,1.0,1.0,3/46,2.11%,DROSHA;SERPINE1;OPTN
prerank,Elsevier_Pathway_Collection__Intraflagellar Transport: BBSome Interaction,-0.6910875288287028,-1.0155741745988602,0.49572649572649574,1.0,1.0,2/30,2.33%,SHH;BBS5
prerank,Reactome_2022__Synthesis Of Bile Acids And Bile Salts R-HSA-192105,-0.6589709693946333,-1.0155652605072487,0.48854961832061067,1.0,1.0,2/34,0.78%,CYP39A1;NCOA1
prerank,WikiPathway_2021_Human__miRNA regulation of p53 pathway in prostate cancer WP3982,-0.6636271305961002,-1.0154875830883934,0.48507462686567165,1.0,1.0,1/24,0.31%,TNFRSF10B
prerank,Reactome_2022__G2/M DNA Damage Checkpoint R-HSA-69473,0.7385552005535716,1.0152858374625071,0.4583333333333333,1.0,1.0,3/71,1.15%,HERC2;YWHAQ;BRIP1
prerank,GO_Biological_Process_2021__cellular response to hormone stimulus (GO:0032870),-0.750120511489609,-1.015215673956781,0.42857142857142855,1.0,1.0,6/69,1.93%,NR3C1;NCOA1;TFPI;BCAS3;PAX8;SLIT3
prerank,Reactome_2022__TNF Receptor Superfamily (TNFSF) Members Mediating Non-Canonical NF-kB Pathway R-HSA-5676594,0.6645897174284455,1.0150442879647348,0.4830508474576271,1.0,1.0,1/17,0.21%,TRAF3
prerank,GO_Biological_Process_2021__negative regulation of stress fiber assembly (GO:0051497),0.7114498804500129,1.0147676858719314,0.5080645161290323,1.0,1.0,4/23,2.20%,TJP1;ARHGEF18;DLC1;RHPN2
prerank,GO_Biological_Process_2021__cation transmembrane transport (GO:0098655),-0.7640754272746705,-1.0147254023379657,0.5396825396825397,1.0,1.0,2/41,1.38%,SLC36A4;SLC7A8
prerank,GO_Biological_Process_2021__regulation of sodium ion transmembrane transport (GO:1902305),0.7047729186608787,1.0143178934788348,0.536,1.0,1.0,3/24,2.26%,DLG1;SNTA1;GPD1L
prerank,GO_Biological_Process_2021__positive regulation of filopodium assembly (GO:0051491),0.6446276277838265,1.0139939339544979,0.4953271028037383,1.0,1.0,3/25,2.21%,RHOQ;DOCK11;DPYSL3
prerank,GO_Biological_Process_2021__synaptic vesicle exocytosis (GO:0016079),-0.7764492176068263,-1.0138397220710962,0.5481481481481482,1.0,1.0,3/37,2.37%,SYT2;SNPH;SYT7
prerank,Reactome_2022__Extension Of Telomeres R-HSA-180786,0.7275166506123367,1.0137869690379062,0.4838709677419355,1.0,1.0,5/49,2.26%,SLC19A1;WRAP53;ACD;LRIG1;PIF1
prerank,Elsevier_Pathway_Collection__CCL2 Role in CGRP Expression and Release,0.6432092231344311,1.0134247526216738,0.49166666666666664,1.0,1.0,3/20,2.36%,CREB1;TRPV1;STX1A
prerank,WikiPathway_2021_Human__Sterol regulatory element-binding proteins (SREBP) signaling WP1982,0.7566260554594247,1.0129573665242388,0.4296875,1.0,1.0,4/68,2.12%,ACACA;CREB1;PRKAA2;RBP4
prerank,Elsevier_Pathway_Collection__EGFR Transactivation in Cancer and Non-Cancer Cells,-0.7400878679816204,-1.0127406205766556,0.4696969696969697,1.0,1.0,6/60,2.01%,PTK2B;ADAM10;PIK3CB;CCND2;MMP2;BDKRB2
prerank,GO_Biological_Process_2021__establishment of epithelial cell polarity (GO:0090162),0.6221735494449158,1.0126791799056063,0.4636363636363636,1.0,1.0,2/20,1.43%,SIPA1L3;CAMSAP3
prerank,GO_Biological_Process_2021__mRNA-containing ribonucleoprotein complex export from nucleus (GO:0071427),0.7168173466966495,1.012603735261982,0.4152542372881356,1.0,1.0,2/98,1.05%,UPF2;NUP210
prerank,GO_Biological_Process_2021__telomere organization (GO:0032200),0.7285181749110248,1.0125883836381293,0.49230769230769234,1.0,1.0,2/47,2.15%,ATR;ACD
prerank,Reactome_2022__Estrogen-dependent Nuclear Events Downstream Of ESR-membrane Signaling R-HSA-9634638,0.6581283476255266,1.0125403375135107,0.5238095238095238,1.0,1.0,2/23,0.86%,CREB1;PTK2
prerank,GO_Biological_Process_2021__positive regulation of protein serine/threonine kinase activity (GO:0071902),0.6985752106264925,1.0120108507070857,0.3464566929133858,1.0,1.0,4/100,2.37%,CAB39;NOD2;PROX1;FGF1
prerank,TRRUST_Transcription_Factors_2019__CREB1 human,0.7210518749323199,1.0120007663378723,0.464,1.0,1.0,5/81,1.82%,ACACA;SLC19A1;NDC80;CD4;PTGS2
prerank,Reactome_2022__Late Phase Of HIV Life Cycle R-HSA-162599,0.6562763627271574,1.010880591696351,0.38345864661654133,1.0,1.0,4/131,1.05%,TAF4;TCEA1;GTF2E2;NUP210
prerank,Elsevier_Pathway_Collection__Crohn's Disease,0.7773446286946625,1.010676614067827,0.4925373134328358,1.0,1.0,4/52,1.23%,ERN1;TRAF3;NOD2;CD4
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Activation by Growth Factors,-0.758372828617659,-1.010666465618933,0.5230769230769231,1.0,1.0,4/51,1.96%,MAP2K6;TFPI;PROS1;PROCR
prerank,GO_Biological_Process_2021__positive regulation of dephosphorylation (GO:0035306),0.7332656323227696,1.010666002252605,0.5111111111111111,1.0,1.0,2/29,1.68%,PPP1R16B;DLC1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Erectile Dysfunction,-0.7285250124911403,-1.01044928778623,0.47580645161290325,1.0,1.0,3/40,2.16%,PDE5A;SHH;S1PR1
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Vitiligo,0.6961302725804585,1.0101814557667503,0.48,1.0,1.0,2/26,1.82%,CD4;PTGS2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Rheumatoid Arthritis,0.6961664619302703,1.010030401960838,0.40476190476190477,1.0,1.0,4/83,1.82%,CD4;CX3CL1;IL1RN;PTGS2
prerank,GO_Biological_Process_2021__regulation of protein dephosphorylation (GO:0035304),0.7332586789740714,1.009969614171051,0.5142857142857142,1.0,1.0,2/39,1.68%,PPP1R16B;DLC1
prerank,Reactome_2022__Downstream Signal Transduction R-HSA-186763,-0.7329969701494083,-1.0099096015582514,0.5396825396825397,1.0,1.0,2/28,1.71%,PIK3CB;STAT5A
prerank,MSigDB_Hallmark_2020__IL-6/JAK/STAT3 Signaling,0.6947779797264009,1.0098292886618934,0.4065040650406504,1.0,1.0,5/85,1.96%,PTPN2;TNFRSF21;ITGA4;IL13RA1;A2M
prerank,Reactome_2022__Dual Incision In TC-NER R-HSA-6782135,0.7415629567768777,1.0096966931511013,0.4357142857142857,1.0,1.0,3/64,0.85%,SLC19A1;TCEA1;POLE4
prerank,TRRUST_Transcription_Factors_2019__STAT1 mouse,-0.7273406174526265,-1.0095657436150944,0.5245901639344263,1.0,1.0,2/30,2.27%,APP;CIITA
prerank,WikiPathway_2021_Human__Pyrimidine metabolism and related diseases WP4225,-0.6595528480642283,-1.009457771227292,0.5338983050847458,1.0,1.0,1/17,0.72%,DPYS
prerank,Reactome_2022__tRNA Processing R-HSA-72306,-0.6930647717919485,-1.0094035241889336,0.47107438016528924,1.0,1.0,3/104,2.13%,TYW1;THADA;TRMT9B
prerank,Elsevier_Pathway_Collection__Mitochondrial Dysfunction in Alzheimer's Disease,-0.6965920771671688,-1.0090137678920736,0.5179856115107914,1.0,1.0,3/26,1.78%,APP;SOD2;CYP1B1
prerank,Reactome_2022__Interleukin-10 Signaling R-HSA-6783783,0.7271361773791528,1.008966357902452,0.5080645161290323,1.0,1.0,3/43,2.29%,IL1RN;PTGS2;CD86
prerank,GO_Biological_Process_2021__negative regulation of T cell receptor signaling pathway (GO:0050860),0.6718897595269768,1.008592225742522,0.5126050420168067,1.0,1.0,3/18,2.05%,PTPN2;THY1;LGALS3
prerank,GO_Biological_Process_2021__regulation of interferon-gamma production (GO:0032649),-0.7275646906104516,-1.008197101076266,0.47761194029850745,1.0,1.0,3/80,2.25%,CD2;IL12RB2;CD274
prerank,Elsevier_Pathway_Collection__Proteins Involved in Acne Vulgaris,0.7596505950382049,1.0080941471465548,0.5483870967741935,1.0,1.0,3/40,1.82%,CD4;IL1RN;PTGS2
prerank,Elsevier_Pathway_Collection__Apoptosis of Myocyte,0.6567837824002912,1.007887219719073,0.5079365079365079,1.0,1.0,2/19,1.00%,TNFRSF10A;CASP7
prerank,WikiPathway_2021_Human__Glycerolipids and Glycerophospholipids WP4722,0.7530398050685813,1.0076002308751515,0.5966386554621849,1.0,1.0,3/22,1.63%,GPAT4;PLD1;PNPLA3
prerank,Elsevier_Pathway_Collection__Th0-Cell Aberrant Activation in Systemic Lupus Erythematosus,0.7014001843707324,1.0075922044455299,0.4016393442622951,1.0,1.0,7/76,2.29%,TNFRSF10A;CREB1;CD4;SYK;TNFRSF25;NFATC2;CD86
prerank,GO_Biological_Process_2021__steroid hormone biosynthetic process (GO:0120178),0.733074389574447,1.0074564465002274,0.5522388059701493,1.0,1.0,2/27,1.70%,HSD17B11;FDXR
prerank,Reactome_2022__Gap-filling DNA Repair Synthesis And Ligation In TC-NER R-HSA-6782210,0.7554362485618451,1.0070767578044124,0.4330708661417323,1.0,1.0,4/63,2.24%,SLC19A1;TCEA1;POLE4;LRIG1
prerank,TRRUST_Transcription_Factors_2019__HSF1 human,-0.7297649101025674,-1.0069566356429573,0.5818181818181818,1.0,1.0,2/29,2.03%,POLK;HSD17B6
prerank,GO_Biological_Process_2021__regulation of immune response (GO:0050776),0.6526650411928303,1.0068346655339004,0.38181818181818183,1.0,1.0,7/168,1.42%,TRAF3;CD300A;CD33;ITGA4;SYK;ITGAL;SIGLEC7
prerank,Reactome_2022__RHOC GTPase Cycle R-HSA-9013106,0.719053900988558,1.0067553711899708,0.4375,1.0,1.0,7/73,2.03%,DEPDC1B;ARHGAP39;IQGAP3;ANLN;DLC1;CAVIN1;FMNL2
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Arterial Hypertension,-0.7299550281536875,-1.006661754880366,0.5736434108527132,1.0,1.0,2/32,2.01%,PTK2B;BDKRB2
prerank,GO_Biological_Process_2021__TRIF-dependent toll-like receptor signaling pathway (GO:0035666),0.6645878039863893,1.0065234127190317,0.504,1.0,1.0,1/30,0.21%,TRAF3
prerank,Reactome_2022__Norepinephrine Neurotransmitter Release Cycle R-HSA-181430,0.6129089004672468,1.00636366015314,0.4909090909090909,1.0,1.0,3/17,2.36%,MAOA;PPFIA4;STX1A
prerank,Elsevier_Pathway_Collection__Mucin Hyperproduction in Goblet and Mucous Cells,-0.7315936703763396,-1.0062966696189066,0.46825396825396826,1.0,1.0,2/52,1.85%,MAP2K6;TICAM2
prerank,Reactome_2022__Biological Oxidations R-HSA-211859,-0.6384299662460836,-1.0062469409366224,0.4195804195804196,1.0,1.0,19/202,2.17%,GSTA1;CYP39A1;GLYAT;CYP2C8;TPST1;AADAC;NCOA1;SULT1B1;GGT5;CYP4V2;ACSM2B;GSTA2;CYP4F22;CYP1B1;AKR7A3;CYP1A2;AS3MT;AOC1;MAOB
prerank,Reactome_2022__G Alpha (Q) Signaling Events R-HSA-416476,-0.6269822959178181,-1.0060205391820802,0.4195804195804196,1.0,1.0,9/174,2.32%,CCL23;APP;GPR39;RASGRP2;GPR132;PLCB4;BDKRB2;GPR17;GNA14
prerank,GO_Biological_Process_2021__limb development (GO:0060173),0.7652366635954895,1.005935169739414,0.6071428571428571,1.0,1.0,2/28,1.26%,MEGF8;SALL1
prerank,Reactome_2022__Intrinsic Pathway Of Fibrin Clot Formation R-HSA-140837,-0.6536677049902403,-1.0055963685493474,0.5503875968992248,1.0,1.0,1/21,1.31%,PROS1
prerank,GO_Biological_Process_2021__positive regulation of programmed cell death (GO:0043068),0.5994895418031627,1.0052780671033816,0.4051724137931034,1.0,1.0,12/279,2.37%,TNFRSF10A;PRMT2;ING5;ARHGEF7;MELK;IGFBP3;SYK;PLEKHG5;ARHGEF18;BOK;MNDA;PRR7
prerank,GO_Biological_Process_2021__neutrophil chemotaxis (GO:0030593),0.7573996963063095,1.0050418009934128,0.46825396825396826,1.0,1.0,5/64,2.05%,PIK3CD;SYK;CX3CL1;CCL14;LGALS3
prerank,MSigDB_Oncogenic_Signatures__CRX DN.V1 UP,-0.654893022504066,-1.0047685943720344,0.4461538461538462,1.0,1.0,2/113,1.18%,ARHGAP10;TTC39C
prerank,WikiPathway_2021_Human__Bladder cancer WP2828,-0.7808337793581771,-1.004754335947477,0.5571428571428572,1.0,1.0,3/40,1.93%,RB1;DAPK2;MMP2
prerank,Elsevier_Pathway_Collection__Platelet Activation via GPCR Signaling,-0.7622227174460946,-1.0044917594411118,0.49645390070921985,1.0,1.0,2/49,1.56%,RAP1A;ADCY3
prerank,WikiPathway_2021_Human__Mammalian disorder of sexual development WP4842,0.6979027623178061,1.0044749938095874,0.5338983050847458,1.0,1.0,2/21,1.64%,CBX2;AMH
prerank,"GO_Biological_Process_2021__DNA-templated transcription, initiation (GO:0006352)",0.6399307459010186,1.0044018962830072,0.44166666666666665,1.0,1.0,10/163,1.99%,TAF4;TBL1X;PPARA;TAF1B;GTF2E2;NOTCH3;HDAC9;TEAD4;NR1I2;CAVIN1
prerank,GO_Biological_Process_2021__positive regulation of defense response (GO:0031349),0.711894689214755,1.0041183565016794,0.4152542372881356,1.0,1.0,5/88,2.16%,CX3CL1;MAPK13;SERPINE1;OPTN;CYBA
prerank,TRRUST_Transcription_Factors_2019__EGR1 mouse,-0.7624433427021651,-1.0040585096607049,0.4745762711864407,1.0,1.0,2/66,1.54%,CREBBP;CCND2
prerank,KEGG_2021_Human__GnRH secretion,-0.7588257662304465,-1.003742812239923,0.4418604651162791,1.0,1.0,4/63,1.91%,AKT3;PIK3CB;KCNN2;PLCB4
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer Metastases,0.68811379916222,1.003383491353838,0.41935483870967744,1.0,1.0,9/101,2.27%,CDH2;ITGA3;TJP1;PTK2;NOTCH3;CDH1;LGALS3;SERPINE1;FN1
prerank,GO_Biological_Process_2021__positive regulation of cytokine-mediated signaling pathway (GO:0001961),-0.7316067082988837,-1.003280001793712,0.5289855072463768,1.0,1.0,2/35,1.85%,TRIM44;TICAM2
prerank,Reactome_2022__FCGR3A-mediated Phagocytosis R-HSA-9664422,0.7375617161738751,1.003272261745866,0.4424778761061947,1.0,1.0,4/55,1.26%,ABI2;ACTR3;PTK2;SYK
prerank,Elsevier_Pathway_Collection__TNFR -> NF-kB Signaling,-0.7278036540746123,-1.0032438031710587,0.549618320610687,1.0,1.0,4/29,2.24%,MAP2K6;TNFRSF10B;TNFRSF14;TNFSF14
prerank,WikiPathway_2021_Human__Oncostatin M Signaling Pathway WP2374,0.7294302608470622,1.0032349265253406,0.4264705882352941,1.0,1.0,4/63,2.07%,CREB1;CASP7;TIMP3;SERPINE1
prerank,GO_Biological_Process_2021__monocarboxylic acid metabolic process (GO:0032787),-0.6532565874310641,-1.0031121893224628,0.4148148148148148,1.0,1.0,10/139,1.98%,CYP3A7;AASDH;GLYAT;CYP2C8;VNN1;GGT5;BTD;SGPL1;ECHDC3;CYP1A2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Diabetes Mellitus Type 1,0.6961695077778045,1.003028391175294,0.4344262295081967,1.0,1.0,4/79,1.82%,ITGA4;CD4;CYP27B1;PTGS2
prerank,KEGG_2021_Human__Cell cycle,0.6513389377452188,1.002935005921541,0.42857142857142855,1.0,1.0,8/123,1.56%,CDC45;RBL1;YWHAQ;CDK6;TFDP2;ATR;CDC14B;PKMYT1
prerank,Elsevier_Pathway_Collection__Thyrotropin Releasing Hormone (TRH) Hypothalamic Release in non-Autoimmune Hypothyroidism,0.6624362281329271,1.0026519663602462,0.4782608695652174,1.0,1.0,1/18,0.43%,CREB1
prerank,GO_Biological_Process_2021__negative regulation of actin filament bundle assembly (GO:0032232),0.711447271135406,1.0026027761794367,0.5,1.0,1.0,4/26,2.20%,TJP1;ARHGEF18;DLC1;RHPN2
prerank,GO_Biological_Process_2021__regulation of endothelial cell apoptotic process (GO:2000351),0.693654615422396,1.0024206786962206,0.4715447154471545,1.0,1.0,2/42,2.07%,ITGA4;SERPINE1
prerank,GO_Biological_Process_2021__receptor-mediated endocytosis (GO:0006898),0.6468464605733234,1.0022654203346766,0.43333333333333335,1.0,1.0,6/140,1.99%,IGF2R;SYK;AMN;GRK3;FCHSD2;APOE
prerank,Reactome_2022__Downstream Signaling Events Of B Cell Receptor (BCR) R-HSA-1168372,0.6943193696745743,1.002072208005644,0.4406779661016949,1.0,1.0,2/77,2.00%,PSMB9;NFATC2
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Activation by NO,0.7294170698651237,1.0018594944236754,0.568,1.0,1.0,3/31,2.07%,SLC7A1;PTGS2;SERPINE1
prerank,GO_Biological_Process_2021__negative regulation of translation (GO:0017148),0.70067460868162,1.0015752449745337,0.4473684210526316,1.0,1.0,3/86,1.37%,YTHDF3;IGF2BP1;IGF2BP3
prerank,GO_Biological_Process_2021__positive regulation of protein kinase B signaling (GO:0051897),0.6193980354473366,1.001482385510337,0.408,1.0,1.0,10/149,2.37%,PIK3CD;PTK2;ERBB3;CX3CL1;F7;KLB;PIK3AP1;HGF;CD86;FGF1
prerank,MSigDB_Oncogenic_Signatures__AKT UP MTOR DN.V1 DN,-0.63315804446994,-1.0011041495051585,0.432,1.0,1.0,7/170,2.32%,CDC42BPA;TYW1;HIC1;SLCO3A1;KCNAB3;C1R;GNA14
prerank,GO_Biological_Process_2021__regulation of T cell receptor signaling pathway (GO:0050856),0.7443136061560066,1.0010221212744916,0.5625,1.0,1.0,4/34,2.05%,CD300A;PTPN2;THY1;LGALS3
prerank,GO_Biological_Process_2021__heart morphogenesis (GO:0003007),0.7544869673077994,1.0008856270748159,0.5112781954887218,1.0,1.0,5/48,2.34%,MEGF8;PTK2;DLC1;ZFPM1;TBX3
prerank,GO_Biological_Process_2021__intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator (GO:0042771),0.6589744326145969,1.000528955150194,0.5390625,1.0,1.0,1/21,0.77%,MSH2
prerank,Reactome_2022__Biosynthesis Of Specialized Proresolving Mediators (SPMs) R-HSA-9018678,0.6068892138237769,1.0003972928123894,0.45528455284552843,1.0,1.0,3/18,1.82%,EPHX2;PTGR1;PTGS2
prerank,"Reactome_2022__Platelet Activation, Signaling And Aggregation R-HSA-76002",-0.6142123305609942,-1.0001708459253695,0.4552238805970149,1.0,1.0,14/245,2.38%,RAP1B;A1BG;PIK3CB;APP;RAP1A;NHLRC2;PROS1;RASGRP2;RAPGEF3;PIK3R6;CD9;GNA14;VAV1;HRG
prerank,GO_Biological_Process_2021__purine nucleotide metabolic process (GO:0006163),-0.6623201624474523,-1.0001276613499586,0.4888888888888889,1.0,1.0,1/22,0.44%,NT5C1B
prerank,Reactome_2022__Glucose Metabolism R-HSA-70326,0.721111631322572,0.9999790864142751,0.411214953271028,1.0,1.0,3/83,1.23%,MAP4K5;NUP210;PKLR
prerank,Elsevier_Pathway_Collection__Dexamethasone Induced Diabetes,-0.6580912771287522,-0.9998862875707762,0.525,1.0,1.0,2/19,0.87%,NR3C1;TBC1D4
prerank,Elsevier_Pathway_Collection__Proplatelet Maturation,0.69370258589662,0.9997939362190974,0.35185185185185186,1.0,1.0,4/79,2.07%,MRTFA;PTGS2;ZFPM1;SERPINE1
prerank,GO_Biological_Process_2021__regulation of cell-substrate adhesion (GO:0010810),0.7636907493543111,0.9996555425898302,0.5365853658536586,1.0,1.0,4/42,1.42%,TBCD;PTK2;THY1;CX3CL1
prerank,KEGG_2021_Human__Thyroid cancer,-0.734337393333489,-0.9991363537863017,0.5571428571428572,1.0,1.0,2/37,1.58%,POLK;PAX8
prerank,GO_Biological_Process_2021__positive regulation of apoptotic process (GO:0043065),0.5931861397748117,0.99880741852592,0.44144144144144143,1.0,1.0,12/300,2.37%,TNFRSF10A;PRMT2;ING5;ARHGEF7;MELK;IGFBP3;PLEKHG5;ARHGEF18;DLC1;BOK;MNDA;PRR7
prerank,GO_Biological_Process_2021__DNA conformation change (GO:0071103),-0.6598223635273109,-0.99865569631522,0.5220588235294118,1.0,1.0,1/15,0.69%,TOP1MT
prerank,Reactome_2022__Signaling By Interleukins R-HSA-449147,-0.5702933391428905,-0.998370721394387,0.42758620689655175,1.0,1.0,25/421,2.36%,PTK2B;MAP2K6;RAP1B;ZEB1;PIK3CB;TEC;APP;POU2F1;GSTA2;ITGAX;HCK;PELI2;STAT5A;IL11RA;IL12RB2;DUSP4;MMP2;RORC;IL17RB;IL10RA;PTPN18;S1PR1;IL21R;VAV1;IRAK3
prerank,KEGG_2021_Human__Rap1 signaling pathway,-0.6234578419971121,-0.9983421262514312,0.4370860927152318,1.0,1.0,17/198,2.34%,MAP2K6;RAP1B;AKT3;PIK3CB;SIPA1L1;PARD3;GRIN2B;RAP1A;RASGRP2;RAPGEF3;ADCY3;RASSF5;PARD6G;TEK;PLCB4;RASGRP3;VAV1
prerank,Reactome_2022__Regulation Of PLK1 Activity At G2/M Transition R-HSA-2565942,0.6929646344888764,0.9982315633317272,0.43478260869565216,1.0,1.0,6/87,2.15%,HAUS8;CEP164;HAUS2;PPP1R12A;OPTN;TUBA1A
prerank,GO_Biological_Process_2021__sodium ion transport (GO:0006814),-0.7257914445673666,-0.998021800172049,0.4307692307692308,1.0,1.0,2/80,2.42%,CATSPER3;SLC17A4
prerank,WikiPathway_2021_Human__Complement system WP2806,-0.6981638996586815,-0.9978086748021109,0.456,1.0,1.0,5/95,1.63%,C4BPA;PROS1;ITGAX;C5AR2;C1R
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Enabling of Replicative Immortality,0.6223280141906402,0.9977727647765579,0.5039370078740157,1.0,1.0,2/19,1.41%,ATR;MYCN
prerank,Elsevier_Pathway_Collection__Proteins Involved in Azoospermia,0.721600603280437,0.9977444954614724,0.575,1.0,1.0,3/28,1.18%,SYCP3;DROSHA;IGFBP3
prerank,GO_Biological_Process_2021__negative regulation of peptidase activity (GO:0010466),0.7790909822245569,0.9975799668780803,0.5289256198347108,1.0,1.0,4/53,2.10%,TIMP3;SERPINA7;SERPINE1;SERPINA5
prerank,Elsevier_Pathway_Collection__ANGPT/TEK Stimulates Endothelial Cell Migration in Cancer,0.6580907979625455,0.9974550194479352,0.5109489051094891,1.0,1.0,1/19,0.86%,PTK2
prerank,"Reactome_2022__TICAM1, RIP1-mediated IKK Complex Recruitment R-HSA-168927",-0.5973858025748864,-0.9971384488717655,0.44360902255639095,1.0,1.0,9/19,18.36%,RIPK1;UBE2D3;UBB;UBE2D2;UBA52;BIRC2;TICAM1;TLR3;TRAF6
prerank,GO_Biological_Process_2021__response to molecule of bacterial origin (GO:0002237),-0.7264944509332129,-0.9971177177317746,0.46564885496183206,1.0,1.0,2/70,2.36%,GGT5;IRAK3
prerank,GO_Biological_Process_2021__calcium ion homeostasis (GO:0055074),0.6953961207272374,0.9970096573897225,0.425,1.0,1.0,4/82,1.90%,TMTC2;DRD4;CYP27B1;CCL14
prerank,Elsevier_Pathway_Collection__Proteins Involved in Follicular Lymphoma,0.5874649933907592,0.9970068756357081,0.4406779661016949,1.0,1.0,1/16,1.26%,SYK
prerank,Elsevier_Pathway_Collection__Treg Cells Promote Immunosuppression in Cancer Immune Escape,-0.7757511636263691,-0.9969821211784833,0.5714285714285714,1.0,1.0,3/43,2.44%,PTK2B;STAT5A;ZAP70
prerank,Elsevier_Pathway_Collection__MAVS in Antiviral Innate Immune Response in Myocarditis,0.6645892100547117,0.9969403174338789,0.528,1.0,1.0,1/20,0.21%,TRAF3
prerank,GO_Biological_Process_2021__activation of protein kinase B activity (GO:0032148),-0.6963201841724438,-0.9969177883299312,0.5461538461538461,1.0,1.0,2/29,1.81%,NRG1;NTF3
prerank,GO_Biological_Process_2021__response to hydrogen peroxide (GO:0042542),0.728324019168237,0.9966101649866321,0.5081967213114754,1.0,1.0,3/49,2.17%,ANXA1;MAPK13;STK26
prerank,TRRUST_Transcription_Factors_2019__EP300 mouse,0.7421798041977586,0.9966008541651095,0.484375,1.0,1.0,5/54,2.27%,CREB1;F7;PTGS2;AXIN2;FN1
prerank,Reactome_2022__CDC42 GTPase Cycle R-HSA-9013148,0.6126746524581684,0.9964396749363498,0.4107142857142857,1.0,1.0,11/146,2.03%,DEPDC1B;FNBP1;RAB7A;ARHGEF7;ARHGAP39;CDC42EP1;DOCK11;IQGAP3;DLC1;SPATA13;FMNL2
prerank,GO_Biological_Process_2021__MAPK cascade (GO:0000165),0.5931989766571115,0.9964376040412629,0.44642857142857145,1.0,1.0,13/286,2.37%,DLG1;DLG3;PTK2;KSR1;ERBB3;PSMB9;SPTBN2;KLB;CTSH;MAPK13;ZDHHC9;HGF;FGF1
prerank,GO_Biological_Process_2021__organic cyclic compound biosynthetic process (GO:1901362),0.7261863007767975,0.9963066421994271,0.5583333333333333,1.0,1.0,3/30,2.39%,FDXR;PRLR;PYCR1
prerank,MSigDB_Oncogenic_Signatures__PDGF ERK DN.V1 UP,0.6540162222291331,0.9962908524570514,0.44881889763779526,1.0,1.0,8/123,2.19%,RPIA;CDK6;TAF1B;CDC14B;MAOA;MID1;FCHSD2;OXCT1
prerank,GO_Biological_Process_2021__cellular response to DNA damage stimulus (GO:0006974),0.5798453064539928,0.996227973601738,0.4344262295081967,1.0,1.0,17/343,2.26%,AATF;FNIP2;HERC2;FANCL;BRSK1;TLK2;NEK4;MSH2;RBBP6;SMC5;ATR;TDP1;FBXO31;BOK;NFATC2;MNDA;PRAP1
prerank,WikiPathway_2021_Human__TLR4 Signaling and Tolerance WP3851,0.6645882727047073,0.9961090796022345,0.5255474452554745,1.0,1.0,1/27,0.21%,TRAF3
prerank,KEGG_2021_Human__Rheumatoid arthritis,0.6913458684765341,0.9960037410029722,0.4566929133858268,1.0,1.0,2/83,2.29%,ITGAL;CD86
prerank,MSigDB_Oncogenic_Signatures__CYCLIN D1 UP.V1 UP,0.649496085181483,0.9959126299100083,0.4260869565217391,1.0,1.0,9/165,1.74%,SMOX;SLC19A1;KSR1;DMWD;MKI67;THY1;CGREF1;FDXR;FHL2
prerank,MSigDB_Oncogenic_Signatures__ATF2 UP.V1 UP,-0.6436683325064523,-0.9959075666371021,0.4846153846153846,1.0,1.0,9/152,2.32%,NEO1;SULT1B1;LIPE;KCNAB3;PCDH1;STAT5A;ABLIM3;PLCB4;GNA14
prerank,Reactome_2022__Apoptotic Execution Phase R-HSA-75153,0.7561423382556507,0.9958193114243514,0.5,1.0,1.0,4/48,2.17%,TJP1;PTK2;CASP7;STK26
prerank,Reactome_2022__P75 NTR Receptor-Mediated Signaling R-HSA-193704,0.6856906684819761,0.9955476125047048,0.4351851851851852,1.0,1.0,4/95,1.44%,AATF;ARHGEF7;PLEKHG5;ARHGEF18
prerank,Reactome_2022__CREB1 Phosphorylation Thru NMDA Receptor-Mediated Activation Of RAS Signaling R-HSA-442742,0.6926682059302984,0.9953015628814449,0.5428571428571428,1.0,1.0,3/27,2.17%,CREB1;DLG1;GPRIN1
prerank,MSigDB_Oncogenic_Signatures__RB P130 DN.V1 DN,-0.6782270047057013,-0.9952374144894975,0.40310077519379844,1.0,1.0,4/119,2.19%,EVI5;ATAD1;RB1;VDR
prerank,GO_Biological_Process_2021__negative regulation of transforming growth factor beta receptor signaling pathway (GO:0030512),-0.7433245700237607,-0.9949396785804999,0.4236111111111111,1.0,1.0,4/66,2.15%,SLC2A10;ZNF451;TGFB1I1;ADAMTSL2
prerank,MSigDB_Oncogenic_Signatures__E2F3 UP.V1 DN,-0.6735000354143654,-0.9949244995263942,0.4318181818181818,1.0,1.0,8/118,2.37%,FBXO27;ZNF135;RAP1A;GJB5;NYNRIN;BDKRB2;CIITA;INTS7
prerank,GO_Biological_Process_2021__negative regulation of vascular associated smooth muscle cell proliferation (GO:1904706),-0.6569773390188565,-0.9949043563256432,0.5245901639344263,1.0,1.0,1/16,0.98%,SOD2
prerank,KEGG_2021_Human__Glycerophospholipid metabolism,0.679950998078963,0.9945203333268391,0.4083333333333333,1.0,1.0,8/92,2.30%,LCLAT1;PNPLA6;AGPAT3;GPAT4;PLD1;LPCAT2;GPD1L;LPIN3
prerank,GO_Biological_Process_2021__regulation of erythrocyte differentiation (GO:0045646),0.7314130867607886,0.9944320608364016,0.5254237288135594,1.0,1.0,2/37,1.86%,CDK6;ZFPM1
prerank,MSigDB_Oncogenic_Signatures__YAP1 DN,0.695893215244509,0.9941296355537311,0.5163934426229508,1.0,1.0,4/35,1.85%,RFX1;ITGA2;DOCK11;TIMP3
prerank,GO_Biological_Process_2021__adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway (GO:0007193),0.7044444073084588,0.9940775161539944,0.45161290322580644,1.0,1.0,3/47,2.29%,LPAR1;DRD4;FLNA
prerank,GO_Biological_Process_2021__regulation of cell cycle phase transition (GO:1901987),0.696852471718256,0.993806485608098,0.4126984126984127,1.0,1.0,2/91,1.74%,PSMB9;UBE2C
prerank,Elsevier_Pathway_Collection__Diffuse Large-B-Cell Lymphoma ABC Subtype,0.7652647245454469,0.9937582490061453,0.5371900826446281,1.0,1.0,2/48,1.26%,ATR;SYK
prerank,Elsevier_Pathway_Collection__Proteins Involved in Vitiligo,0.6984301211226137,0.9935633230944237,0.4959349593495935,1.0,1.0,2/38,1.59%,CD4;IL1RN
prerank,GO_Biological_Process_2021__positive regulation of cell motility (GO:2000147),0.6056699835572961,0.9934319903252973,0.45217391304347826,1.0,1.0,14/213,2.37%,TJP1;PIK3CD;ELP3;PTK2;ZNF304;F7;BCAR1;SEMA3G;CARMIL2;CTSH;CAVIN1;SH3RF2;HGF;FGF1
prerank,GO_Biological_Process_2021__retinol metabolic process (GO:0042572),-0.6469773300514763,-0.9932233203820401,0.5603448275862069,1.0,1.0,2/20,1.98%,CYP1B1;CYP1A2
prerank,Reactome_2022__Degradation Of Extracellular Matrix R-HSA-1474228,-0.6853416834857703,-0.9926707934267289,0.4166666666666667,1.0,1.0,6/101,2.32%,ADAM10;ADAMTS5;ADAMTS9;CD44;MMP2;COL26A1
prerank,"Elsevier_Pathway_Collection__Hyperparathyroidism, Secondary Effect",0.6975112459169645,0.9926429169813439,0.5128205128205128,1.0,1.0,3/32,1.69%,CREB1;LRP5;SMAD9
prerank,Elsevier_Pathway_Collection__Proteins Involved in Spontaneous Abortion,0.6914665211769396,0.992478482406545,0.44776119402985076,1.0,1.0,5/80,2.29%,CDH1;PTGS2;SERPINE1;FN1;CD86
prerank,GO_Biological_Process_2021__positive regulation of receptor-mediated endocytosis (GO:0048260),-0.7320256863614483,-0.9924050766113852,0.5078125,1.0,1.0,2/41,1.81%,ATAD1;NTF3
prerank,GO_Biological_Process_2021__regulation of p38MAPK cascade (GO:1900744),0.728219102561345,0.9922535106942899,0.5583333333333333,1.0,1.0,2/37,2.18%,DLG1;ULK4
prerank,GO_Biological_Process_2021__skeletal system development (GO:0001501),0.6594766630504331,0.9920341559147833,0.4117647058823529,1.0,1.0,11/139,2.37%,PAPSS1;ANKRD11;PKDCC;CHRD;TEAD4;SNORC;RBP4;COL9A2;HOXD3;TBX3;DLX6
prerank,Reactome_2022__Gap-filling DNA Repair Synthesis And Ligation In GG-NER R-HSA-5696397,0.6919389541708858,0.9918533594585266,0.5491803278688525,1.0,1.0,3/25,2.24%,SLC19A1;POLE4;LRIG1
prerank,Elsevier_Pathway_Collection__IL1 Receptor Antagonist (IL1RN) Deficiency (DIRA),-0.731603687982487,-0.9918511630872185,0.5284552845528455,1.0,1.0,2/39,1.85%,MAP2K6;TICAM2
prerank,Elsevier_Pathway_Collection__Exocytosis: Vesicle Priming,-0.6556301494348457,-0.9917534846500943,0.5454545454545454,1.0,1.0,1/18,1.11%,STXBP5
prerank,GO_Biological_Process_2021__protein deacetylation (GO:0006476),0.7550288429312655,0.9916965030981055,0.5147058823529411,1.0,1.0,5/45,2.29%,TBL1X;MIER2;HDAC9;RCOR2;FLNA
prerank,Reactome_2022__NOTCH3 Activation And Transmission Of Signal To Nucleus R-HSA-9013507,0.623709105729194,0.9916613385521553,0.5163934426229508,1.0,1.0,2/25,1.27%,WWP2;NOTCH3
prerank,Reactome_2022__Neurotransmitter Release Cycle R-HSA-112310,0.7098912417852759,0.9916112004428822,0.49137931034482757,1.0,1.0,4/45,2.36%,LIN7A;MAOA;PPFIA4;STX1A
prerank,Elsevier_Pathway_Collection__Goblet-Cell Exocytosis in Asthma,0.6486325869303253,0.9913114176912473,0.5327868852459017,1.0,1.0,2/18,1.81%,PTK2;IL13RA1
prerank,TRRUST_Transcription_Factors_2019__CTCF human,0.6905900651484229,0.991271779738425,0.49107142857142855,1.0,1.0,4/28,2.38%,IRAK2;ASAP2;SLC6A4;CELSR3
prerank,GO_Biological_Process_2021__negative regulation of antigen receptor-mediated signaling pathway (GO:0050858),0.7443216319323446,0.9912186157268257,0.6153846153846154,1.0,1.0,4/24,2.05%,CD300A;PTPN2;THY1;LGALS3
prerank,GO_Biological_Process_2021__protein polyubiquitination (GO:0000209),-0.5813590840845788,-0.9911458037196197,0.4444444444444444,1.0,1.0,15/307,2.36%,UBE3D;HECTD2;KLHL3;FBXO27;SHPRH;AMFR;TTC3;WWP1;TNKS;NEDD4;RNF217;PELI2;HERC5;HERC6;FBXO32
prerank,Reactome_2022__Glycolysis R-HSA-70171,0.7211204891809695,0.9908194385320007,0.43103448275862066,1.0,1.0,3/65,1.23%,MAP4K5;NUP210;PKLR
prerank,Reactome_2022__Transcription Of E2F Targets Under Negative Control By P107 (RBL1) And P130 (RBL2) In Complex With HDAC1 R-HSA-1362300,0.6575925973126091,0.9906889825015073,0.5284552845528455,1.0,1.0,2/16,0.91%,RBL1;TFDP2
prerank,MSigDB_Oncogenic_Signatures__NOTCH DN.V1 DN,0.6642741774764103,0.9906877232696267,0.49166666666666664,1.0,1.0,9/147,2.34%,LMTK2;NOTCH3;MYCN;MAN1A1;PPFIA4;MAPK13;FMNL2;SERPINE1;TBX3
prerank,GO_Biological_Process_2021__cell cycle G1/S phase transition (GO:0044843),-0.7187734397680023,-0.9905587414676919,0.47368421052631576,1.0,1.0,3/61,1.47%,USP37;RB1;GPR132
prerank,GO_Biological_Process_2021__regulation of small molecule metabolic process (GO:0062012),0.686072800198705,0.9903759992606315,0.5217391304347826,1.0,1.0,4/27,1.99%,PPARA;EPHX2;PDK3;APOE
prerank,GO_Biological_Process_2021__neurotransmitter transport (GO:0006836),0.6966574943394895,0.990199132590447,0.456,1.0,1.0,7/63,2.36%,BRSK1;LIN7A;GLS;SLC6A4;SLC38A1;PPFIA4;STX1A
prerank,MSigDB_Oncogenic_Signatures__TBK1.DF UP,-0.6087080338065469,-0.9900824796361136,0.424,1.0,1.0,15/261,2.13%,TNFRSF10B;ZFYVE16;MREG;DERA;TPST1;RNGTT;SLC2A10;RB1;PROS1;TNFAIP2;FEZ1;SLCO3A1;LIPG;CD83;EML1
prerank,GO_Biological_Process_2021__regulation of response to biotic stimulus (GO:0002831),0.763620529698128,0.9899726004603845,0.5642857142857143,1.0,1.0,2/29,1.42%,TRAF3;CX3CL1
prerank,GO_Biological_Process_2021__positive regulation of ion transport (GO:0043270),0.7275202275840295,0.9899194639987642,0.5166666666666667,1.0,1.0,4/45,2.26%,LILRA2;DLG1;DRD4;GPD1L
prerank,GO_Biological_Process_2021__aspartate family amino acid catabolic process (GO:0009068),0.6551299638054418,0.9898405869150151,0.5163934426229508,1.0,1.0,1/19,1.16%,AASS
prerank,GO_Biological_Process_2021__eye development (GO:0001654),0.7010853977572052,0.9898237279367154,0.475,1.0,1.0,4/50,2.12%,SIPA1L3;RAB3GAP1;MAB21L2;RBP4
prerank,GO_Biological_Process_2021__embryonic organ development (GO:0048568),0.7288933871663399,0.9897579146378142,0.4878048780487805,1.0,1.0,5/60,2.12%,PKDCC;SALL1;TEAD4;ZFPM1;RBP4
prerank,Elsevier_Pathway_Collection__Apoptosis Block by Death Receptor Signaling in Cancer,0.7499598073523066,0.9897090053219186,0.496,1.0,1.0,4/50,1.49%,TNFRSF10A;TNFRSF21;TNFRSF25;TNFRSF10D
prerank,Elsevier_Pathway_Collection__Dedifferentiation and Metastatic Progression in Melanoma,0.6973155924760372,0.9896826711023795,0.5038759689922481,1.0,1.0,3/37,1.71%,CDH2;PTK2;CDH1
prerank,WikiPathway_2021_Human__Kynurenine Pathway and links to Cellular Senescence WP5044,0.6605891684883666,0.9896656187832142,0.5037593984962406,1.0,1.0,1/22,0.61%,QPRT
prerank,KEGG_2021_Human__Tryptophan metabolism,-0.7476779352146925,-0.9894419361876345,0.5737704918032787,1.0,1.0,5/41,2.17%,CYP1B1;CYP1A2;AADAT;AOC1;MAOB
prerank,WikiPathway_2021_Human__Resistin as a regulator of inflammation WP4481,-0.6953176832640507,-0.9893962020899292,0.5441176470588235,1.0,1.0,3/33,1.91%,AKT3;PIK3CB;PLCB4
prerank,Elsevier_Pathway_Collection__Insulin Synthesis in beta-Cell,0.6941257060316305,0.9891261751757584,0.5528455284552846,1.0,1.0,3/32,2.02%,ERN1;CREB1;CPE
prerank,Elsevier_Pathway_Collection__HTR5 -> TNF Production,-0.654668956431674,-0.988990115437819,0.556390977443609,1.0,1.0,2/19,1.21%,MAP2K6;RAP1A
prerank,GO_Biological_Process_2021__plasma membrane bounded cell projection organization (GO:0120036),-0.6608159297969486,-0.9888817603279833,0.4420289855072464,1.0,1.0,8/122,2.12%,CARMIL1;WDPCP;APP;ATXN10;NEDD4;DTNBP1;RB1;HDGFL3
prerank,TRRUST_Transcription_Factors_2019__STAT3 mouse,-0.7095243832083997,-0.9887164242433737,0.4649122807017544,1.0,1.0,5/67,2.40%,CCND2;MMP2;KLF4;S1PR1;SPI1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Prostate Cancer,-0.636807822227038,-0.9886062084315929,0.4523809523809524,1.0,1.0,10/130,2.26%,PTK2B;NR3C1;PIK3CB;RB1;TGFB1I1;STAT5A;CD44;MMP2;VDR;TMPRSS2
prerank,GO_Biological_Process_2021__positive regulation of morphogenesis of an epithelium (GO:1905332),-0.6510525738964248,-0.9885294678253209,0.5528455284552846,1.0,1.0,3/22,1.58%,ITGAX;BMP4;PAX8
prerank,GO_Biological_Process_2021__negative regulation of axonogenesis (GO:0050771),0.6983593158323682,0.9884735785230548,0.5447154471544715,1.0,1.0,2/28,1.60%,THY1;SEMA3G
prerank,GO_Biological_Process_2021__regulation of ossification (GO:0030278),-0.6927764282139496,-0.9884068681347117,0.5446428571428571,1.0,1.0,2/34,2.16%,BMP4;S1PR1
prerank,GO_Biological_Process_2021__regulation of cardiac muscle cell membrane repolarization (GO:0099623),0.6438240274830633,0.9883858334898648,0.5447154471544715,1.0,1.0,2/20,2.29%,SNTA1;FLNA
prerank,Reactome_2022__Muscle Contraction R-HSA-397014,-0.6422571096013641,-0.9883663121904512,0.47368421052631576,1.0,1.0,4/171,2.44%,PDE5A;ITGA1;KCNK6;KCNE1
prerank,"GO_Biological_Process_2021__Wnt signaling pathway, planar cell polarity pathway (GO:0060071)",0.6904592665483822,0.9882795946762178,0.42592592592592593,1.0,1.0,2/83,2.38%,PSMB9;CELSR3
prerank,KEGG_2021_Human__Staphylococcus aureus infection,0.7363202112800679,0.9881216009135564,0.472,1.0,1.0,2/68,1.37%,KRT23;ITGAL
prerank,Elsevier_Pathway_Collection__Complement Component GPCRs Signaling,-0.5840442438476842,-0.987990262786326,0.43884892086330934,1.0,1.0,2/15,1.61%,MAP2K6;C5AR2
prerank,TRRUST_Transcription_Factors_2019__HDAC2 human,0.697283747310213,0.9874850612727963,0.5476190476190477,1.0,1.0,2/26,1.71%,MYCN;CDH1
prerank,GO_Biological_Process_2021__positive regulation of cytokine production (GO:0001819),0.5913213749607866,0.987288815574977,0.4954128440366973,1.0,1.0,13/312,2.29%,LILRA2;PIK3CD;NOD2;CD4;SYK;NFAM1;ANXA1;PTGS2;ZFPM1;MAPK13;SERPINE1;CYBA;CD86
prerank,MSigDB_Hallmark_2020__Fatty Acid Metabolism,0.6330223978008302,0.9872329761023554,0.4489795918367347,1.0,1.0,6/154,2.22%,AUH;PPARA;HSD17B11;MAOA;SMS;ACSL5
prerank,MSigDB_Oncogenic_Signatures__KRAS.300 UP.V1 DN,-0.6870297364799287,-0.9871756082355323,0.4084507042253521,1.0,1.0,11/112,2.44%,MAP2K6;OAS1;IFI44L;DPYS;PDE11A;VILL;NTF3;APBB3;CIITA;RTP4;KCNE1
prerank,GO_Biological_Process_2021__plasma membrane organization (GO:0007009),-0.7098378293489263,-0.9870806914753446,0.48951048951048953,1.0,1.0,5/61,2.37%,ARV1;BIN2;TLCD2;SMPD1;SYT7
prerank,Elsevier_Pathway_Collection__Proteins Involved in Breast Cancer Related to ESR1 Signaling Pathway,-0.7308548492501629,-0.9869096896132349,0.4921875,1.0,1.0,4/64,1.93%,NCOA1;CREBBP;STAT5A;MMP2
prerank,GO_Biological_Process_2021__cell projection organization (GO:0030030),0.6572784989768881,0.9863620040494189,0.5303030303030303,1.0,1.0,1/30,0.94%,RHOQ
prerank,GO_Biological_Process_2021__signal release from synapse (GO:0099643),0.745756459910099,0.9862140474400406,0.56,1.0,1.0,3/38,2.36%,BRSK1;LIN7A;STX1A
prerank,GO_Biological_Process_2021__neurotransmitter secretion (GO:0007269),0.745756459910099,0.9862140474400406,0.56,1.0,1.0,3/38,2.36%,BRSK1;LIN7A;STX1A
prerank,GO_Biological_Process_2021__regulation of B cell differentiation (GO:0045577),0.5874643584927808,0.9858962789760243,0.44029850746268656,1.0,1.0,1/17,1.26%,SYK
prerank,GO_Biological_Process_2021__regulation of T cell differentiation (GO:0045580),-0.7257595267586712,-0.9857512535148469,0.6050420168067226,1.0,1.0,3/34,2.44%,CD2;RHOH;ZAP70
prerank,Elsevier_Pathway_Collection__HTR7 -> IL6 Production,-0.6546694598601555,-0.9856940446750284,0.5555555555555556,1.0,1.0,2/18,1.21%,NR3C1;RAP1A
prerank,GO_Biological_Process_2021__glial cell differentiation (GO:0010001),0.688190549370962,0.9856805104042052,0.544,1.0,1.0,2/27,1.19%,CDH2;ERBB3
prerank,GO_Biological_Process_2021__regulation of vascular endothelial growth factor signaling pathway (GO:1900746),-0.6429407788439035,-0.9854103963810382,0.5040650406504065,1.0,1.0,2/19,2.38%,PIK3CB;HRG
prerank,WikiPathway_2021_Human__GDNF/RET signaling axis WP4830,-0.6043110348699491,-0.9853453920253396,0.5,1.0,1.0,2/20,2.08%,BMP4;GLI3
prerank,TRRUST_Transcription_Factors_2019__SIRT1 human,-0.7191677132865258,-0.9852603302424121,0.5111111111111111,1.0,1.0,3/45,1.43%,TNFRSF10B;ADAMTS5;HIC1
prerank,KEGG_2021_Human__Cortisol synthesis and secretion,-0.7457947462996722,-0.9852005689909619,0.4852941176470588,1.0,1.0,5/60,1.91%,CREB3L2;ADCY3;PBX1;CREB5;PLCB4
prerank,"KEGG_2021_Human__Valine, leucine and isoleucine degradation",0.6924961314053775,0.9850680778541586,0.4715447154471545,1.0,1.0,3/48,2.19%,ACSF3;AUH;OXCT1
prerank,Reactome_2022__Regulation Of TP53 Activity Thru Acetylation R-HSA-6804758,-0.6934741750312249,-0.9850139366774231,0.5072463768115942,1.0,1.0,3/29,2.09%,MAP2K6;AKT3;PML
prerank,GO_Biological_Process_2021__camera-type eye development (GO:0043010),0.661088746465257,0.9849994357503272,0.5294117647058824,1.0,1.0,1/23,0.56%,RAB3GAP1
prerank,GO_Biological_Process_2021__glycoprotein catabolic process (GO:0006516),-0.6225212379090864,-0.9848701632598471,0.48484848484848486,1.0,1.0,2/17,1.39%,FBXO27;ADAMTS9
prerank,GO_Biological_Process_2021__ceramide metabolic process (GO:0006672),-0.7793624072114417,-0.9847701705166215,0.5714285714285714,1.0,1.0,5/52,2.08%,PLPP1;SGPL1;AGK;CYP4F22;SMPD1
prerank,MSigDB_Oncogenic_Signatures__STK33 DN,-0.588226780643935,-0.9845768939744449,0.5140845070422535,1.0,1.0,14/236,2.39%,GAS2;MREG;NEO1;PIK3CB;KCNN2;VPS13C;TNKS;ARHGEF26;TRIM58;NHLRC2;RRP15;DCHS1;ADCY3;MAP4K1
prerank,GO_Biological_Process_2021__interstrand cross-link repair (GO:0036297),0.7399105138769442,0.9845344426539178,0.49193548387096775,1.0,1.0,3/54,1.02%,FANCL;DCLRE1C;ATR
prerank,KEGG_2021_Human__Bladder cancer,-0.7808330055913943,-0.9843381985770234,0.5986394557823129,1.0,1.0,3/41,1.93%,RB1;DAPK2;MMP2
prerank,GO_Biological_Process_2021__positive regulation of immune response (GO:0050778),0.7284612529529134,0.9843208764265594,0.4918032786885246,1.0,1.0,2/68,2.16%,NOD2;CYBA
prerank,GO_Biological_Process_2021__regulation of dendritic spine development (GO:0060998),-0.6648964025808091,-0.9842169674728668,0.5241935483870968,1.0,1.0,1/21,0.18%,CPEB3
prerank,Elsevier_Pathway_Collection__Neurogenic Transcription Factors Role in Hirschsprung Disease,-0.5850421551011588,-0.9841821767503,0.46774193548387094,1.0,1.0,1/17,1.50%,BMP4
prerank,WikiPathway_2021_Human__Splicing factor NOVA regulated synaptic proteins WP4148,-0.7559190810288945,-0.9840976377340207,0.6,1.0,1.0,5/39,2.21%,NEO1;GRIN2B;MAPK4;PLCB4;DAB1
prerank,KEGG_2021_Human__Transcriptional misregulation in cancer,-0.6127310064106133,-0.9839357834264719,0.4316546762589928,1.0,1.0,12/170,2.40%,KDM6A;POLK;ZEB1;MLLT1;MEIS1;ETV7;CCND2;PAX8;PBX1;PML;TMPRSS2;SPI1
prerank,Elsevier_Pathway_Collection__EGFR/ERBB3 -> MEF/MYOD/NFATC/MYOG Signaling,-0.7845191385003255,-0.9838422629065933,0.5692307692307692,1.0,1.0,6/46,2.34%,PTK2B;PAK2;MAP2K6;MAP2K5;NRG1;VAV1
prerank,GO_Biological_Process_2021__positive regulation of protein phosphorylation (GO:0001934),-0.5897232809899051,-0.9837552302974624,0.49624060150375937,1.0,1.0,21/348,2.25%,PTK2B;PAK2;TEC;APP;WNK3;PTPRJ;RAP1A;NIBAN1;INHBB;BMP4;SLCO3A1;CCND2;RAPGEF3;KNDC1;PELI2;CD44;NTF3;TEK;THBS4;TNFRSF14;SEMA4D
prerank,GO_Biological_Process_2021__peptide biosynthetic process (GO:0043043),-0.6508501703469394,-0.9837090666639743,0.46956521739130436,1.0,1.0,2/157,1.58%,GGT5;MRRF
prerank,GO_Biological_Process_2021__regulation of chemotaxis (GO:0050920),0.6973409850656654,0.9835498627972687,0.544,1.0,1.0,3/32,0.86%,ZSWIM5;PTPN2;ZSWIM6
prerank,Reactome_2022__Molecules Associated With Elastic Fibres R-HSA-2129379,-0.6944361278260721,-0.9832276268339436,0.5547445255474452,1.0,1.0,2/28,1.99%,BMP4;LTBP4
prerank,GO_Biological_Process_2021__nucleotide-excision repair (GO:0006289),0.6551674411743211,0.9830977404297617,0.47794117647058826,1.0,1.0,2/104,1.15%,TCEA1;BRIP1
prerank,GO_Biological_Process_2021__mitotic cell cycle phase transition (GO:0044772),0.5994640182352111,0.9830849756760522,0.4915254237288136,1.0,1.0,11/206,2.15%,HAUS8;CEP164;CDK6;BRSK1;HAUS2;PPP1R12A;MELK;PKMYT1;UBE2C;OPTN;TUBA1A
prerank,Reactome_2022__GPCR Downstream Signaling R-HSA-388396,-0.5634345720194673,-0.9825162711359589,0.49645390070921985,1.0,1.0,15/498,2.34%,AKT3;CCL23;APP;ARHGEF26;GPR39;HRH2;RASGRP2;PDE11A;GPR132;PLCB4;BDKRB2;PIK3R6;GPR17;GNA14;VAV1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Medulloblastoma,0.6773487717129318,0.9825130595567109,0.4608695652173913,1.0,1.0,5/65,2.28%,CDH2;MAOA;MYCN;AMH;HGF
prerank,GO_Biological_Process_2021__cellular response to transforming growth factor beta stimulus (GO:0071560),0.6569598199877171,0.9822397881550431,0.4696969696969697,1.0,1.0,6/112,2.32%,USP15;PTK2;ARHGEF18;SMAD9;ITGB5;ZFYVE9
prerank,Elsevier_Pathway_Collection__CCR5 Signaling in Macrophages,-0.7251170757417926,-0.9821747979286483,0.5503875968992248,1.0,1.0,2/34,0.23%,PTK2B;MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of binding (GO:0051099),-0.6994016309636788,-0.9821514100942419,0.47058823529411764,1.0,1.0,4/89,1.50%,AMFR;HMBOX1;APP;BMP4
prerank,GO_Biological_Process_2021__positive regulation of kinase activity (GO:0033674),0.6503423668974757,0.9821121987081681,0.39344262295081966,1.0,1.0,6/111,1.65%,CENPE;LMTK2;PTK2;ERBB3;CD4;DRD4
prerank,Reactome_2022__NCAM1 Interactions R-HSA-419037,0.7260295964109319,0.9820996261955452,0.5522388059701493,1.0,1.0,3/33,2.41%,COL9A3;COL9A2;COL4A5
prerank,GO_Biological_Process_2021__regulation of inflammatory response (GO:0050727),0.6254335009435301,0.9818709479301023,0.48360655737704916,1.0,1.0,11/190,2.07%,PPARA;PTPN2;NOD2;MEFV;CX3CL1;ANXA1;PTGS2;MAPK13;APOE;PIK3AP1;SERPINE1
prerank,GO_Biological_Process_2021__regulation of insulin secretion (GO:0050796),-0.6688210924053883,-0.981850972883599,0.4485294117647059,1.0,1.0,6/94,2.37%,MYRIP;RAP1A;INHBB;RAPGEF3;KCNS3;SYT7
prerank,GO_Biological_Process_2021__regulation of cyclin-dependent protein kinase activity (GO:1904029),-0.6973813411694735,-0.981715350884716,0.504,1.0,1.0,2/52,1.70%,CCND2;HERC5
prerank,GO_Biological_Process_2021__MyD88-independent toll-like receptor signaling pathway (GO:0002756),0.6645876212187989,0.9815898120111131,0.5163934426229508,1.0,1.0,1/31,0.21%,TRAF3
prerank,WikiPathway_2021_Human__FGFR3 signaling in chondrocyte proliferation and terminal differentiation WP4767,0.6469336889657427,0.9814990333229217,0.528,1.0,1.0,2/27,1.98%,RBL1;MAPK13
prerank,WikiPathway_2021_Human__Signaling of Hepatocyte Growth Factor Receptor WP313,-0.7262991072358534,-0.9814962274883808,0.536,1.0,1.0,5/34,2.39%,PTK2B;ITGA1;RAP1B;RAP1A;MAP4K1
prerank,KEGG_2021_Human__Human papillomavirus infection,0.5673886067054313,0.9813273992303139,0.4649122807017544,1.0,1.0,21/302,2.41%,ITGA3;TRAF3;PIK3CD;CREB1;DLG1;DLG3;RBL1;CDK6;PTK2;ATR;ITGA4;CRB3;NOTCH3;ITGA2;ITGB5;PTGS2;AXIN2;COL9A3;FN1;COL9A2;COL4A5
prerank,TRRUST_Transcription_Factors_2019__HMGA1 human,0.6485182414114168,0.9810524033608313,0.5161290322580645,1.0,1.0,2/16,1.82%,CDH1;PTGS2
prerank,Reactome_2022__Signaling By NOTCH4 R-HSA-9013694,-0.7151293278668889,-0.9808949984667042,0.5109489051094891,1.0,1.0,2/80,1.22%,ADAM10;CREBBP
prerank,GO_Biological_Process_2021__embryonic digit morphogenesis (GO:0042733),-0.6293899710819819,-0.9808458767367734,0.5323741007194245,1.0,1.0,4/18,2.08%,WDPCP;CREBBP;SHH;GLI3
prerank,GO_Biological_Process_2021__regulation of substrate adhesion-dependent cell spreading (GO:1900024),0.7261683003104282,0.980755921725869,0.5275590551181102,1.0,1.0,4/50,2.39%,PTK2;ARHGEF7;FLNA;MELTF
prerank,Reactome_2022__ISG15 Antiviral Mechanism R-HSA-1169408,-0.6974060978961278,-0.980589579986191,0.4435483870967742,1.0,1.0,3/74,1.70%,KPNA3;NEDD4;HERC5
prerank,Reactome_2022__Programmed Cell Death R-HSA-5357801,0.6097679116984026,0.9804952321737072,0.46774193548387094,1.0,1.0,9/199,2.31%,TJP1;TNFRSF10A;YWHAQ;PTK2;TFDP2;CASP7;PSMB9;STK26;UACA
prerank,WikiPathway_2021_Human__IL-4 signaling pathway WP395,0.7271272173147926,0.9803963340331302,0.5294117647058824,1.0,1.0,2/53,2.29%,PIK3CD;FLNA
prerank,GO_Biological_Process_2021__histone modification (GO:0016570),0.677829225015107,0.9803066819828978,0.43478260869565216,1.0,1.0,7/110,1.93%,TBL1X;MIER2;PRMT2;SUPT3H;PADI2;HDAC9;RCOR2
prerank,Elsevier_Pathway_Collection__PTGER2/3 -> Inflammation-Related Expression Targets,0.6624346455686652,0.9802489914200964,0.525,1.0,1.0,1/24,0.43%,CREB1
prerank,GO_Biological_Process_2021__platelet-derived growth factor receptor signaling pathway (GO:0048008),-0.6568998945758726,-0.9802136727321089,0.5454545454545454,1.0,1.0,1/16,0.98%,PTPRJ
prerank,Reactome_2022__Metabolism Of Folate And Pterines R-HSA-196757,0.6612832666908984,0.9802071593998236,0.5223880597014925,1.0,1.0,1/16,0.54%,SLC19A1
prerank,GO_Biological_Process_2021__ethanol metabolic process (GO:0006067),-0.658898957585817,-0.9801140958637451,0.5333333333333333,1.0,1.0,1/18,0.78%,SULT1B1
prerank,Elsevier_Pathway_Collection__Th1-Cell Function in Systemic Lupus Erythematosus,0.7549848647539882,0.9801121369419694,0.5043478260869565,1.0,1.0,5/51,2.29%,CREB1;CD4;SYK;NFATC2;CD86
prerank,GO_Biological_Process_2021__stem cell development (GO:0048864),-0.5848510168159334,-0.9798500531749638,0.45925925925925926,1.0,1.0,2/16,1.53%,SHH;NRG1
prerank,GO_Biological_Process_2021__protein localization to cell periphery (GO:1990778),0.6343933604479055,0.979836544351884,0.4672131147540984,1.0,1.0,7/133,2.29%,RAB40C;DLG1;LIN7A;RAPGEF6;CRB3;CDH1;FLNA
prerank,Reactome_2022__Activation Of Kainate Receptors Upon Glutamate Binding R-HSA-451326,0.7039625069792388,0.9797297637183559,0.5454545454545454,1.0,1.0,3/27,2.34%,DLG1;GNB5;GNG2
prerank,Reactome_2022__RHOA GTPase Cycle R-HSA-8980692,0.6227270995006685,0.9795803398994096,0.4491525423728814,1.0,1.0,11/146,2.20%,DEPDC1B;ARHGEF7;ARHGAP39;PLEKHG5;ARHGEF18;IQGAP3;ANLN;DLC1;CAVIN1;PLEKHG6;RHPN2
prerank,Elsevier_Pathway_Collection__Hair Follicle Keratinocyte Apoptosis,0.6470019872190511,0.9794403863019402,0.5214285714285715,1.0,1.0,2/37,1.97%,PTGS2;AXIN2
prerank,GO_Biological_Process_2021__establishment or maintenance of apical/basal cell polarity (GO:0035088),0.6093494835894938,0.9794307230193277,0.49107142857142855,1.0,1.0,3/19,1.58%,DLG1;DLG3;MTCL1
prerank,WikiPathway_2021_Human__Ciliary landscape WP4352,-0.6065430134796916,-0.9791154979365146,0.4928571428571429,1.0,1.0,9/208,2.33%,EXOC2;EXOC6B;NEK7;RNGTT;TBC1D4;ANKS6;RB1;CREBBP;BBS5
prerank,Reactome_2022__Ephrin Signaling R-HSA-3928664,0.6560148021030731,0.9788653694772584,0.5511811023622047,1.0,1.0,1/18,1.07%,ARHGEF7
prerank,TRRUST_Transcription_Factors_2019__YY1 human,-0.7378937569798522,-0.978781489358148,0.4576271186440678,1.0,1.0,3/84,1.22%,TNFRSF10B;NR3C1;CREBBP
prerank,GO_Biological_Process_2021__organelle assembly (GO:0070925),0.554207355913062,0.9786971638327111,0.4351851851851852,1.0,1.0,18/408,2.41%,NEK6;YTHDF3;EIF2A;HAUS8;UBXN2A;CENPE;CEP164;ACTR3;NUDCD3;HAUS2;RAB7A;CDC14B;CENPA;SEPTIN6;DZIP1L;ANLN;FLNA;KIF3B
prerank,GO_Biological_Process_2021__regulation of translation (GO:0006417),0.6071101548824537,0.9786693957926919,0.4661016949152542,1.0,1.0,5/174,1.37%,YTHDF3;EIF2A;PLD1;IGF2BP1;IGF2BP3
prerank,Elsevier_Pathway_Collection__Club-Cell Role in Asthma,0.7278716929637692,0.9785867442765362,0.5462184873949579,1.0,1.0,3/38,2.22%,IL13RA1;LGALS3;FOXA3
prerank,GO_Biological_Process_2021__intrinsic apoptotic signaling pathway by p53 class mediator (GO:0072332),0.7313759791716185,0.9785078897833166,0.5916666666666667,1.0,1.0,2/35,1.87%,MSH2;BOK
prerank,GO_Biological_Process_2021__protein mannosylation (GO:0035268),0.6582824731540886,0.9784268412676206,0.5546875,1.0,1.0,2/22,0.85%,POMGNT2;TMTC2
prerank,GO_Biological_Process_2021__cardiac muscle tissue morphogenesis (GO:0055008),0.6957075109637192,0.9784082700598109,0.5267175572519084,1.0,1.0,2/25,1.86%,PROX1;ZFPM1
prerank,MSigDB_Oncogenic_Signatures__CTIP DN.V1 DN,0.680921153908501,0.9783989658155247,0.4642857142857143,1.0,1.0,7/102,1.63%,ARL5A;CD53;FOXRED2;CYP4F3;CX3CL1;IL1RN;KCNC1
prerank,WikiPathway_2021_Human__IL17 signaling pathway WP2112,0.664588031465649,0.9783888300707544,0.5384615384615384,0.9998957083357969,1.0,1/27,0.21%,TRAF3
prerank,KEGG_2021_Human__GnRH signaling pathway,-0.6951620319339713,-0.9780949100899249,0.45112781954887216,1.0,1.0,5/87,1.93%,PTK2B;MAP2K6;ADCY3;PLCB4;MMP2
prerank,GO_Biological_Process_2021__regulation of intrinsic apoptotic signaling pathway (GO:2001242),0.7313628085543616,0.9777172960699199,0.4878048780487805,1.0,1.0,2/52,1.87%,PLAUR;BOK
prerank,MSigDB_Oncogenic_Signatures__PDGF UP.V1 UP,0.6311890780793651,0.9775580388079418,0.4017094017094017,1.0,1.0,7/135,1.76%,ZNF394;CDK6;ZNF304;ZNF460;CBX2;ELOVL2;FOSL1
prerank,KEGG_2021_Human__p53 signaling pathway,0.7071486743902876,0.9774690165038191,0.4918032786885246,0.9996101063051117,1.0,6/72,2.38%,TNFRSF10A;CDK6;ATR;IGFBP3;SERPINE1;RRM2
prerank,Elsevier_Pathway_Collection__Macrophage Function in Diabetes Mellitus Type 1,-0.7267272636676063,-0.9773610987266547,0.6076923076923076,1.0,1.0,3/28,2.34%,PTK2B;HCK;VAV1
prerank,GO_Biological_Process_2021__regulation of cellular component organization (GO:0051128),-0.6492821175640129,-0.9770862261644868,0.48412698412698413,1.0,1.0,12/134,2.38%,RAP1B;ZFYVE16;SLC2A10;NEDD4;RAP1A;SGK3;RASGRP2;IL17RB;LTBP4;SEMA4D;IRAK3;HRG
prerank,GO_Biological_Process_2021__regulation of inflammatory response to antigenic stimulus (GO:0002861),-0.6608963152378218,-0.9768657375628347,0.46153846153846156,1.0,1.0,6/111,1.79%,GGT5;GPR39;HRH2;HCK;ADCY3;CD163
prerank,"Elsevier_Pathway_Collection__BSG (CD147) in Cancer Cells Motility, Invasion and Survival",0.7295977851417594,0.9767633822905526,0.5431034482758621,1.0,1.0,4/46,2.05%,ITGA3;PTK2;BCAR1;LGALS3
prerank,Elsevier_Pathway_Collection__Endometrial Cancer,0.6410344798563394,0.9765845679352974,0.4672131147540984,0.9998430959729231,1.0,7/105,1.71%,ARID1B;CREB1;LRP5;CDK6;MSH2;ERBB3;CDH1
prerank,MSigDB_Oncogenic_Signatures__CAMP UP.V1 DN,0.5984557746845928,0.9765405708156043,0.4649122807017544,0.9993612644358165,1.0,11/189,2.40%,TJP1;RALGAPA1;CASP7;ASAP2;GLS;MPZL3;ANXA1;MS4A6A;NFATC2;DPYSL3;FRY
prerank,TRRUST_Transcription_Factors_2019__YY1 mouse,-0.655245352616444,-0.9763443087938737,0.5328467153284672,1.0,1.0,2/20,1.15%,NR3C1;RB1
prerank,Reactome_2022__Asparagine N-linked Glycosylation R-HSA-446203,0.5827552460783428,0.976315449891478,0.5333333333333333,0.9991609919806733,1.0,8/275,1.74%,ST3GAL1;COG5;DAD1;ASGR2;SPTBN2;FUOM;MOGAT2;MAN1A1
prerank,GO_Biological_Process_2021__regulation of signal transduction (GO:0009966),0.6022107389993215,0.9756082500779183,0.5,0.999693714384324,1.0,8/187,1.70%,ITGA3;PTPN2;IRAK2;IGFBP3;ERBB3;CX3CL1;TSPEAR;GRK3
prerank,GO_Biological_Process_2021__regulation of cytokinesis (GO:0032465),0.7119091552033003,0.9755973987565464,0.4583333333333333,0.9991336843791825,1.0,6/72,2.16%,PRPF40A;PKP4;SVIL;KIF13A;CDC14B;KIF23
prerank,Elsevier_Pathway_Collection__Dystrophin Glycoprotein Complex Signaling in Muscular Dystrophies,-0.657011882238515,-0.9754222136816206,0.5327868852459017,1.0,1.0,2/26,0.98%,PTK2B;SOD2
prerank,Elsevier_Pathway_Collection__Tight Junction Assembly (Claudins),0.6239794604514921,0.9751791664228322,0.5196850393700787,0.9992195154482962,1.0,2/23,1.24%,TJP1;CRB3
prerank,GO_Biological_Process_2021__positive regulation of peptidyl-threonine phosphorylation (GO:0010800),-0.6577818118716193,-0.9750163652498688,0.5423728813559322,1.0,1.0,2/24,0.90%,APP;WNK3
prerank,GO_Biological_Process_2021__glucose transmembrane transport (GO:1904659),0.6442867489035257,0.9746983306462099,0.5491803278688525,0.9993791658401845,1.0,3/19,2.25%,SORT1;SLC2A8;SLC2A6
prerank,GO_Biological_Process_2021__protein alkylation (GO:0008213),0.6625509823980955,0.9743834625015869,0.5169491525423728,0.9992507782852401,1.0,1/21,0.41%,PRMT2
prerank,Elsevier_Pathway_Collection__Mucin Production in Goblet Airway Epithelial Cells,-0.731599967792836,-0.9742741924542948,0.5564516129032258,1.0,1.0,2/44,1.85%,MAP2K6;TICAM2
prerank,"WikiPathway_2021_Human__4-hydroxytamoxifen, Dexamethasone, and Retinoic Acids Regulation of p27 Expression WP3879",-0.664474058328383,-0.9741792660564185,0.5275590551181102,1.0,1.0,1/18,0.23%,MAP2K6
prerank,Reactome_2022__Homology Directed Repair R-HSA-5693538,0.6552428061872642,0.9740488929898741,0.49107142857142855,0.9992167368516438,1.0,4/111,1.15%,HERC2;SLC19A1;POLE4;BRIP1
prerank,Reactome_2022__PTEN Regulation R-HSA-6807070,-0.622036803031372,-0.9738132569472899,0.5,1.0,1.0,5/135,2.09%,AKT3;MTA3;TNKS;NEDD4;PML
prerank,GO_Biological_Process_2021__melanosome organization (GO:0032438),-0.6555113268631916,-0.973680054950944,0.5801526717557252,1.0,1.0,2/27,1.13%,AP3B1;DTNBP1
prerank,Reactome_2022__Signaling By Receptor Tyrosine Kinases R-HSA-9006934,-0.5590948696837008,-0.973568334741526,0.5163398692810458,1.0,1.0,27/473,2.43%,FLRT2;PTK2B;ADAM10;RAP1B;AKT3;PIK3CB;TEC;MAP2K5;WWP1;PTPRJ;GRIN2B;NEDD4;RAP1A;NRG1;GRB10;GRAP2;STAT5A;NTF3;DUSP4;COL4A4;SH2B2;PTPN18;THBS4;CD274;GALNT3;VAV1;FOSB
prerank,GO_Biological_Process_2021__lipid modification (GO:0030258),-0.7211914887818804,-0.9734344806114856,0.5634920634920635,1.0,1.0,4/41,0.63%,PLPP1;CYP3A7;SGPP1;CYP2C8
prerank,GO_Biological_Process_2021__regulation of canonical Wnt signaling pathway (GO:0060828),-0.5863893866511982,-0.9731452966737648,0.5378787878787878,1.0,1.0,5/243,2.08%,AMFR;TLE4;TNKS;ADGRA2;GLI3
prerank,Reactome_2022__Chromatin Modifying Enzymes R-HSA-3247509,0.607382243425222,0.9730660163895785,0.48148148148148145,1.0,1.0,10/220,1.20%,ARID1B;TBL1X;HDAC8;SETD3;SUPT3H;ING5;ASH1L;ELP3;PHF2;PADI2
prerank,Reactome_2022__Regulation Of TP53 Activity R-HSA-5633007,0.6243405747930513,0.9728598756381982,0.43103448275862066,0.9999625556730756,1.0,5/154,1.86%,TAF4;ING5;PRKAA2;BRIP1;PPP1R13L
prerank,GO_Biological_Process_2021__cytosolic transport (GO:0016482),-0.6560134088433143,-0.9728375212647422,0.42105263157894735,1.0,1.0,6/115,1.09%,MON2;EVI5;VPS13C;RIC1;ERC1;VPS50
prerank,Elsevier_Pathway_Collection__Alveolar Macrophages Dysfunction in COPD,-0.6951362664376468,-0.9722660996262743,0.5158730158730159,1.0,1.0,4/69,1.93%,MAP2K6;CD44;TICAM2;MMP2
prerank,KEGG_2021_Human__Drug metabolism,-0.6680911602977229,-0.9719330857068904,0.4375,1.0,1.0,6/101,2.17%,GSTA1;CYP2C8;DPYS;GSTA2;CYP1A2;MAOB
prerank,Elsevier_Pathway_Collection__TRPM4/6/7/8 Signaling in Arterial Hypertension (Hypothesis),-0.7329891214023472,-0.9719258196819999,0.5639097744360902,1.0,1.0,2/39,1.71%,PTK2B;STAT5A
prerank,Reactome_2022__Apoptosis R-HSA-109581,0.6097929012015517,0.97187392238126,0.448,1.0,1.0,9/171,2.31%,TJP1;TNFRSF10A;YWHAQ;PTK2;TFDP2;CASP7;PSMB9;STK26;UACA
prerank,GO_Biological_Process_2021__embryonic skeletal system morphogenesis (GO:0048704),0.7269567688941941,0.9717036740470023,0.6218487394957983,1.0,1.0,2/29,2.31%,MEGF8;HOXD3
prerank,MSigDB_Hallmark_2020__Apical Junction,0.613831713349027,0.9714771038969637,0.4953271028037383,1.0,1.0,15/194,2.29%,ITGA3;TJP1;DLG1;PTK2;CRB3;SYK;THY1;CX3CL1;ITGA2;AMH;CDH1;SGCE;MAPK13;CDH15;CD86
prerank,Reactome_2022__O-linked Glycosylation R-HSA-5173105,-0.654663177678762,-0.9710895662731954,0.5089285714285714,1.0,1.0,7/97,2.30%,ADAMTS2;MUC6;ADAMTS5;ADAMTS9;ADAMTSL5;ADAMTSL2;GALNT3
prerank,Elsevier_Pathway_Collection__NOTCH -> TCF3 Signaling,-0.6644736512214705,-0.9709576338128327,0.5454545454545454,1.0,1.0,1/21,0.23%,MAP2K6
prerank,TRRUST_Transcription_Factors_2019__E2F1 human,0.6342974790363087,0.970819006826231,0.4728682170542636,1.0,1.0,8/131,2.38%,CD2AP;DROSHA;CASP7;MEFV;MYCN;SERPINE1;CDCA7;RRM2
prerank,Elsevier_Pathway_Collection__Thyroid Stimulating Hormone (TSH) Secretion in Overt Hypothyroidism,0.6624345202401883,0.970767149295149,0.5193798449612403,1.0,1.0,1/27,0.43%,CREB1
prerank,KEGG_2021_Human__Insulin secretion,-0.6953613715096918,-0.9707289729035369,0.45714285714285713,1.0,1.0,5/78,1.91%,CREB3L2;KCNN2;ADCY3;CREB5;PLCB4
prerank,Reactome_2022__NOTCH3 Intracellular Domain Regulates Transcription R-HSA-9013508,-0.6497057034529929,-0.9706790597630318,0.5625,1.0,1.0,2/23,1.71%,CREBBP;PBX1
prerank,GO_Biological_Process_2021__leukotriene metabolic process (GO:0006691),0.6555899344771157,0.9703989930345064,0.5431034482758621,1.0,1.0,2/23,1.11%,CYP4F3;PTGR1
prerank,GO_Biological_Process_2021__neuron apoptotic process (GO:0051402),0.624557652638938,0.9701945037198675,0.5037037037037037,1.0,1.0,2/20,1.19%,TNFRSF21;ERBB3
prerank,GO_Biological_Process_2021__protein secretion (GO:0009306),-0.7266967493541449,-0.97016553681237,0.5179856115107914,1.0,1.0,2/60,2.34%,TANGO6;OLFM2
prerank,GO_Biological_Process_2021__positive regulation of MAP kinase activity (GO:0043406),0.7263067665978147,0.9700403999747386,0.48951048951048953,1.0,1.0,2/65,2.37%,NOD2;FGF1
prerank,GO_Biological_Process_2021__positive regulation of nucleic acid-templated transcription (GO:1903508),0.5526289491608749,0.9699774222820137,0.514018691588785,0.9995709769581009,1.0,20/484,2.29%,ARID1B;TBL1X;PPARA;PRMT2;CREB1;LRP5;SETD3;SUPT3H;ING5;NEK4;NIBAN2;CD4;SALL1;MYCN;HAS3;CDH1;NR1I2;APOE;NFATC2;CD86
prerank,GO_Biological_Process_2021__innate immune response (GO:0045087),-0.5793558790894473,-0.9697579479530304,0.45528455284552843,1.0,1.0,12/248,2.44%,PTK2B;OAS1;VNN1;APP;TRIM58;HCK;SMPD1;PML;PGLYRP2;CIITA;IFI6;ZAP70
prerank,GO_Biological_Process_2021__regulation of protein-containing complex disassembly (GO:0043244),0.6649742217374832,0.969752586743833,0.512396694214876,0.9993852589864806,1.0,1/17,0.17%,CLEC16A
prerank,KEGG_2021_Human__Sphingolipid signaling pathway,-0.6453210453063054,-0.9695665130571538,0.4666666666666667,1.0,1.0,8/117,2.16%,AKT3;SGPP1;PIK3CB;SGPL1;PLCB4;BDKRB2;SMPD1;S1PR1
prerank,GO_Biological_Process_2021__protein complex oligomerization (GO:0051259),0.6957015162658426,0.9695265350345043,0.5081967213114754,0.9991820584840241,1.0,4/86,1.87%,MICU1;LRRC8C;KCNC1;BOK
prerank,GO_Biological_Process_2021__supramolecular fiber organization (GO:0097435),0.5708079266479027,0.9692220843188342,0.518796992481203,0.9990043457005696,1.0,15/337,2.41%,PLOD2;CLIP2;CD2AP;DLG1;PPP1R9A;ARHGAP12;COL12A1;CAMSAP3;BCAR1;STMN3;COL9A3;SHROOM1;COL9A2;MYO7A;COL4A5
prerank,MSigDB_Hallmark_2020__p53 Pathway,-0.6098962995975779,-0.9690844886371103,0.4580152671755725,1.0,1.0,8/196,2.19%,APP;WWP1;RB1;INHBB;CCND2;PROCR;KLF4;VDR
prerank,GO_Biological_Process_2021__negative regulation of inflammatory response to antigenic stimulus (GO:0002862),-0.6608970132249098,-0.9690340865958718,0.49612403100775193,1.0,1.0,6/110,1.79%,GGT5;GPR39;HRH2;HCK;ADCY3;CD163
prerank,Elsevier_Pathway_Collection__Leukotriene Effect on Vascular Endothelial Cell Response,0.6973174289731245,0.9689741885189523,0.5315315315315315,0.9988116855434674,1.0,3/34,1.71%,TJP1;CREB1;CDH1
prerank,GO_Biological_Process_2021__regulation of glucose metabolic process (GO:0010906),-0.7307233234227627,-0.9688473256152959,0.5714285714285714,1.0,1.0,2/33,1.94%,SDHAF3;RORC
prerank,GO_Biological_Process_2021__negative regulation of cell growth (GO:0030308),-0.6430377839806849,-0.9687985455585669,0.562962962962963,1.0,1.0,7/123,2.38%,DCBLD2;PTPRJ;RB1;TRIM46;SLIT3;PML;HRG
prerank,TRRUST_Transcription_Factors_2019__NR1H3 mouse,-0.5854271330843295,-0.9687662696271823,0.4634146341463415,1.0,1.0,1/16,1.46%,LIPE
prerank,Reactome_2022__Deubiquitination R-HSA-5688426,-0.5737670037544351,-0.9685386427666316,0.49586776859504134,1.0,1.0,6/243,1.18%,TOMM70;USP37;MBD5;TNKS;INO80D;BRCC3
prerank,GO_Biological_Process_2021__negative regulation of ion transport (GO:0043271),-0.655666661383314,-0.9685089810949291,0.5384615384615384,1.0,1.0,3/24,1.11%,PTK2B;WNK3;NEDD4
prerank,KEGG_2021_Human__Estrogen signaling pathway,-0.675415380946102,-0.9684598210775301,0.4460431654676259,1.0,1.0,8/116,1.93%,CREB3L2;AKT3;PIK3CB;NCOA1;ADCY3;CREB5;PLCB4;MMP2
prerank,GO_Biological_Process_2021__regulation of cell cycle process (GO:0010564),0.6645683716312414,0.9682777742679383,0.49107142857142855,0.999169275579679,1.0,5/102,1.56%,PRPF40A;CEP85;KIF13A;MKI67;PKMYT1
prerank,Reactome_2022__RAC3 GTPase Cycle R-HSA-9013423,0.6823022725042031,0.9682623040406625,0.4959349593495935,0.9986237045780406,1.0,6/91,2.16%,ABI2;DEPDC1B;RAB7A;ARHGAP39;CDC42EP1;CYBA
prerank,TRRUST_Transcription_Factors_2019__CDX2 human,0.6167460135070517,0.9681985401252393,0.5254237288135594,0.998156873632719,1.0,3/27,1.97%,IGFBP3;PTGS2;AXIN2
prerank,GO_Biological_Process_2021__endodermal cell differentiation (GO:0035987),0.6917406377006664,0.9681643163270295,0.5495495495495496,0.9976351513810471,1.0,4/32,2.27%,COL12A1;ITGA4;ITGB5;FN1
prerank,KEGG_2021_Human__JAK-STAT signaling pathway,-0.6541655852507492,-0.9681510528144952,0.4883720930232558,1.0,1.0,9/129,2.18%,AKT3;PIK3CB;CREBBP;CCND2;STAT5A;IL11RA;IL12RB2;IL10RA;IL21R
prerank,Reactome_2022__Post NMDA Receptor Activation Events R-HSA-438064,0.6984326730335388,0.9680919121272212,0.46846846846846846,0.9971769496180325,1.0,5/59,2.17%,CREB1;DLG1;ARHGEF7;PRKAA2;GPRIN1
prerank,Reactome_2022__Platelet Homeostasis R-HSA-418346,-0.668062984504498,-0.9680658954021523,0.49264705882352944,1.0,1.0,3/79,2.43%,PDE5A;PDE11A;IRAG1
prerank,KEGG_2021_Human__Prostate cancer,-0.6776691479267613,-0.9676773153271486,0.47058823529411764,1.0,1.0,8/96,2.26%,CREB3L2;ZEB1;AKT3;PIK3CB;RB1;CREBBP;CREB5;TMPRSS2
prerank,Reactome_2022__HDR Thru Homologous Recombination (HRR) Or Single Strand Annealing (SSA) R-HSA-5693567,0.655245086452664,0.9675678674526866,0.5,0.9974715531805569,1.0,4/106,1.15%,HERC2;SLC19A1;POLE4;BRIP1
prerank,Reactome_2022__Carboxyterminal Post-Translational Modifications Of Tubulin R-HSA-8955332,-0.7282583721083759,-0.9672101597468629,0.5488721804511278,1.0,1.0,2/36,2.18%,AGBL3;TTLL11
prerank,GO_Biological_Process_2021__phosphatidylinositol 3-kinase signaling (GO:0014065),0.6685313745194368,0.9669199680516529,0.48760330578512395,0.9979217334356917,1.0,3/32,2.39%,PIK3CD;ERBB3;PIK3C2B
prerank,GO_Biological_Process_2021__histone deubiquitination (GO:0016578),0.658591101182627,0.9668658211141163,0.5546875,0.9974339816290049,1.0,2/19,0.81%,SUPT3H;USP15
prerank,Reactome_2022__Oncogene Induced Senescence R-HSA-2559585,0.6575862264965393,0.9668604553882185,0.5294117647058824,0.9968789562760038,1.0,2/33,0.91%,CDK6;TFDP2
prerank,Reactome_2022__Nuclear Signaling By ERBB4 R-HSA-1251985,-0.6972795491412703,-0.9668555919991906,0.5655172413793104,1.0,1.0,2/32,1.71%,NRG1;STAT5A
prerank,Reactome_2022__Signaling By ERBB4 R-HSA-1236394,-0.7052785418304273,-0.9667072819635171,0.5211267605633803,1.0,1.0,4/55,1.71%,WWP1;NEDD4;NRG1;STAT5A
prerank,Reactome_2022__Fc Epsilon Receptor (FCERI) Signaling R-HSA-2454202,-0.6690602818498368,-0.9666242994659476,0.464,1.0,1.0,6/128,2.34%,PIK3CB;TEC;RASGRP2;SLC7A8;GRAP2;VAV1
prerank,Reactome_2022__Autophagy R-HSA-9612973,-0.6561624266263888,-0.9663631502895612,0.464,1.0,1.0,3/125,1.06%,TOMM70;UVRAG;ATG10
prerank,GO_Biological_Process_2021__cellular response to lectin (GO:1990858),-0.6780076318373188,-0.9662736941518002,0.45161290322580644,1.0,1.0,4/105,2.21%,PAK2;MUC6;CREBBP;CLEC10A
prerank,GO_Biological_Process_2021__stimulatory C-type lectin receptor signaling pathway (GO:0002223),-0.6780076318373188,-0.9662736941518002,0.45161290322580644,1.0,1.0,4/105,2.21%,PAK2;MUC6;CREBBP;CLEC10A
prerank,TRRUST_Transcription_Factors_2019__ATF2 human,0.6440472858362499,0.965760418332872,0.5689655172413793,0.9979588247762484,1.0,2/28,2.27%,PTGS2;FN1
prerank,Elsevier_Pathway_Collection__Androgen Receptor/Akt Signaling,-0.654545905720791,-0.9657512857849725,0.5609756097560976,1.0,1.0,2/35,1.22%,NCOA1;CREBBP
prerank,GO_Biological_Process_2021__regulation of Golgi organization (GO:1903358),-0.5662757602416252,-0.9657070099217622,0.43661971830985913,1.0,1.0,1/17,0.52%,ARMH3
prerank,TRRUST_Transcription_Factors_2019__HDAC4 human,-0.7296169305998487,-0.9655926067514524,0.6015037593984962,1.0,1.0,2/22,2.05%,TGIF1;KLF4
prerank,MSigDB_Oncogenic_Signatures__VEGF A UP.V1 UP,-0.6151136424339272,-0.9649970400685034,0.5384615384615384,1.0,1.0,9/173,1.93%,ALDOB;ABHD3;PTPRJ;SMG6;SHH;KANK3;COLQ;DLG2;MMP2
prerank,GO_Biological_Process_2021__positive regulation of plasma membrane bounded cell projection assembly (GO:0120034),0.66560769218826,0.9649512602678674,0.39285714285714285,0.9987313889769848,1.0,8/79,2.21%,ABI2;ACTR3;RHOQ;CDC42EP1;DOCK11;ANLN;CARMIL2;DPYSL3
prerank,GO_Biological_Process_2021__nucleic acid-templated transcription (GO:0097659),0.726944467648014,0.9649472024666558,0.536,0.9981790763995534,1.0,2/42,2.31%,TAF1B;HOXD3
prerank,GO_Biological_Process_2021__regulation of exocytosis (GO:0017157),-0.7333660735327686,-0.9635718449115143,0.5476190476190477,1.0,1.0,2/50,1.67%,STXBP5;CPLANE2
prerank,WikiPathway_2021_Human__Cardiac Hypertrophic Response WP2795,-0.740947487933433,-0.9632668937877502,0.5182481751824818,1.0,1.0,4/54,2.39%,MAP2K6;MAP2K5;NRG1;MAP4K1
prerank,MSigDB_Oncogenic_Signatures__RB P107 DN.V1 DN,0.6474060778103913,0.9632607450225145,0.48333333333333334,1.0,1.0,3/113,1.93%,DAD1;ANXA1;ELOVL6
prerank,GO_Biological_Process_2021__response to reactive oxygen species (GO:0000302),0.6926820253607225,0.9631051417920796,0.5,1.0,1.0,5/56,2.17%,MPV17;AGAP3;APOE;TXNRD2;STK26
prerank,MSigDB_Oncogenic_Signatures__MTOR UP.N4.V1 UP,0.6012422028097121,0.9630768437545473,0.4566929133858268,0.9996250554567288,1.0,8/179,2.39%,ACACA;GTF2E2;ASPHD1;ELOVL6;SLC43A1;GK;FGF1;PYCR1
prerank,GO_Biological_Process_2021__regulation of transcription involved in G1/S transition of mitotic cell cycle (GO:0000083),0.7263400999266445,0.9630684822932726,0.6050420168067226,0.9990884874976101,1.0,4/31,2.38%,CDC45;TFDP2;GFI1;RRM2
prerank,GO_Biological_Process_2021__positive regulation of GTPase activity (GO:0043547),-0.5867043265098438,-0.9629778072805285,0.5328467153284672,1.0,1.0,16/196,2.25%,EVI5;CCL23;RABGAP1;SIPA1L1;RIC1;TBC1D12;TBC1D4;SNX13;BCAS3;ARHGEF26;RAP1A;RASGRP2;RAPGEF3;NTF3;GARNL3;SEMA4D
prerank,GO_Biological_Process_2021__protein localization to plasma membrane (GO:0072659),0.6343969139971565,0.9627905554509493,0.5084745762711864,0.9990276356802927,1.0,7/129,2.29%,ASB3;RAB40C;DLG1;RAPGEF6;CRB3;CDH1;FLNA
prerank,Elsevier_Pathway_Collection__S/G2 Phase Transition,0.6575888651188775,0.9626562007844002,0.552,0.998659445606638,1.0,2/26,0.91%,CDC45;TFDP2
prerank,GO_Biological_Process_2021__natural killer cell activation (GO:0030101),-0.692669842072702,-0.962646489460064,0.5677966101694916,1.0,1.0,4/25,2.18%,RABL3;CD2;PBX1;IL21R
prerank,GO_Biological_Process_2021__organonitrogen compound catabolic process (GO:1901565),-0.7399462495685154,-0.9624308383092404,0.5178571428571429,1.0,1.0,3/61,1.02%,CPQ;GGACT;SGPL1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Female Infertility,0.73170807028865,0.9624303630127915,0.5522388059701493,0.9984839990091462,1.0,3/54,1.84%,CDH1;PTGS2;MSX1
prerank,GO_Biological_Process_2021__double-strand break repair (GO:0006302),0.6202105469174027,0.9623911948810785,0.5121951219512195,0.9979842077610409,1.0,6/161,1.15%,MMS22L;HERC2;DCLRE1C;SMC5;TDP1;BRIP1
prerank,MSigDB_Hallmark_2020__TNF-alpha Signaling via NF-kB,-0.5975358581229104,-0.9621449790247558,0.5104895104895105,1.0,1.0,9/199,2.43%,TGIF1;SOD2;TNFAIP2;STAT5A;CD44;DUSP4;KLF4;CD83;FOSB
prerank,WikiPathway_2021_Human__Eicosanoid metabolism via lipooxygenases (LOX) WP4721,0.6940512242258644,0.9620308704869038,0.5405405405405406,0.9980288972772191,1.0,3/29,2.03%,PPARA;PTGR1;TRPV1
prerank,GO_Biological_Process_2021__actin cytoskeleton reorganization (GO:0031532),-0.6785454611244188,-0.9619911346514389,0.45528455284552843,1.0,1.0,4/62,2.16%,CDC42BPA;SIPA1L1;DTNBP1;S1PR1
prerank,Reactome_2022__MAPK Targets/ Nuclear Events Mediated By MAP Kinases R-HSA-450282,0.6624335660062071,0.9617097220756768,0.5309734513274337,0.9979762833759044,1.0,1/30,0.43%,CREB1
prerank,Reactome_2022__Meiotic Synapsis R-HSA-1221632,0.7285181326555847,0.9616906651720025,0.5581395348837209,0.9974476976674872,1.0,2/47,2.15%,SYCP3;ACD
prerank,Elsevier_Pathway_Collection__FOXO1 Signaling,-0.6727547965535714,-0.9616878060965812,0.5354330708661418,1.0,1.0,3/43,1.97%,SOD2;CCND2;SH2B2
prerank,Reactome_2022__PI Metabolism R-HSA-1483255,-0.679608873274884,-0.9616722447932987,0.4830508474576271,1.0,1.0,4/81,2.05%,SBF2;PIK3CB;PLEKHA5;PIK3R6
prerank,WikiPathway_2021_Human__IL-2 signaling pathway WP49,-0.7330270418289142,-0.9614890240739837,0.5462184873949579,1.0,1.0,3/41,1.71%,PTK2B;CCND2;STAT5A
prerank,GO_Biological_Process_2021__regulation of cellular localization (GO:0060341),0.6598519829299025,0.961474119892414,0.5,0.9972335542735246,1.0,2/47,0.69%,LRP5;BRSK1
prerank,Elsevier_Pathway_Collection__Il17 Signaling Related Neutrophilia in Asthma,0.6624341958690625,0.9612644273462343,0.5398230088495575,0.9970221377005578,1.0,1/26,0.43%,CREB1
prerank,GO_Biological_Process_2021__muscle tissue morphogenesis (GO:0060415),0.6064297327407798,0.9611692362614138,0.4838709677419355,0.9966143902579659,1.0,2/15,1.86%,PROX1;ZFPM1
prerank,Elsevier_Pathway_Collection__Hippo/YAP1 Signaling,0.6973196213591896,0.9609253820062988,0.53125,0.9964930746817457,1.0,3/31,1.71%,TJP1;DLG1;CDH1
prerank,"Reactome_2022__Cell Death Signaling Via NRAGE, NRIF And NADE R-HSA-204998",0.6857027017140439,0.960890195966641,0.4375,0.9960040523106551,1.0,4/74,1.44%,AATF;ARHGEF7;PLEKHG5;ARHGEF18
prerank,GO_Biological_Process_2021__positive regulation of cellular biosynthetic process (GO:0031328),0.617250275843493,0.9607412932790732,0.5,0.9957217457653639,1.0,5/176,2.28%,YTHDF3;PTPN2;PLD1;PTGS2;HGF
prerank,Elsevier_Pathway_Collection__HRAS Signaling,-0.7305609484110814,-0.9607409628504114,0.5648854961832062,1.0,1.0,2/44,1.95%,RASA2;RASGRP3
prerank,GO_Biological_Process_2021__anterior/posterior pattern specification (GO:0009952),0.7269379234521898,0.9606981386191729,0.5,0.995241137896477,1.0,2/49,2.31%,LRP5;HOXD3
prerank,WikiPathway_2021_Human__Calcium Regulation in the Cardiac Cell WP536,0.623684764041738,0.9606635093625479,0.5275590551181102,0.9947312852536626,1.0,4/139,2.34%,YWHAQ;GJC1;GNB5;GNG2
prerank,MSigDB_Oncogenic_Signatures__NFE2L2.V2,0.5521180179773807,0.9603119577233454,0.6293103448275862,0.9948345369747851,1.0,20/375,2.38%,CDC45;NLN;ZNF326;ZSWIM6;SMC5;CYP4F3;PTGR1;BRIP1;IGFBP3;CKAP4;SYK;CBS;SLC47A1;SEMA3G;SMAD9;HDAC9;NR1I2;AXIN2;ZNF430;RRM2
prerank,"GO_Biological_Process_2021__protein alpha-1,2-demannosylation (GO:0036508)",-0.6633962161956508,-0.9602761449059689,0.536,1.0,1.0,1/24,0.33%,AMFR
prerank,GO_Biological_Process_2021__protein acetylation (GO:0006473),0.6956670175832429,0.9595898130294079,0.5905511811023622,0.9954978288345814,1.0,3/29,1.87%,NAA60;ING5;NAA10
prerank,GO_Biological_Process_2021__positive regulation of alpha-beta T cell activation (GO:0046635),-0.6043117761428898,-0.9594422010691608,0.4930555555555556,1.0,1.0,2/19,2.08%,SHH;GLI3
prerank,WikiPathway_2021_Human__Inflammatory Response Pathway WP453,0.6437782325888919,0.9593566825427163,0.5652173913043478,0.995320621523481,1.0,2/28,2.29%,FN1;CD86
prerank,Elsevier_Pathway_Collection__Sialophorin -> CTNNB/MYC/TP53 Signaling,-0.6644731222710935,-0.9590425899160161,0.5307692307692308,1.0,1.0,1/25,0.23%,MAP2K6
prerank,Elsevier_Pathway_Collection__Toll-like Receptors in Sterile Inflammation,0.7303972464246327,0.9589461052986528,0.5384615384615384,0.9955248867642047,1.0,2/56,1.96%,TRAF3;A2M
prerank,GO_Biological_Process_2021__microtubule bundle formation (GO:0001578),0.6985818573665121,0.9586338576562415,0.5142857142857142,0.9955161232109085,1.0,2/41,1.58%,CCDC40;MTCL1
prerank,GO_Biological_Process_2021__negative regulation of protein localization to membrane (GO:1905476),0.6572813339644944,0.9584908252756369,0.5409836065573771,0.9952402743605442,1.0,1/24,0.94%,RHOQ
prerank,Elsevier_Pathway_Collection__TNFR -> AP-1/ATF/TP53 Signaling,-0.7277949159346687,-0.9584499234651318,0.5873015873015873,1.0,1.0,4/39,2.24%,MAP2K6;TNFRSF10B;TNFRSF14;TNFSF14
prerank,Elsevier_Pathway_Collection__Myeloblast -> Neutrophil Surface Expression Markers,0.6996609286061013,0.9583878246687838,0.5042016806722689,0.9948510288889704,1.0,6/64,2.05%,CD300A;CD33;ITGA4;ITGAL;ITGA2;LGALS3
prerank,Reactome_2022__EPHB-mediated Forward Signaling R-HSA-3928662,0.6926638879753645,0.9583680685113224,0.5433070866141733,0.9943461034343143,1.0,3/32,2.17%,ACTR3;PTK2;GPRIN1
prerank,Elsevier_Pathway_Collection__IGF1R/AKT Signaling in Breast Cancer,0.6624309837241356,0.9580636220381468,0.544,0.9942960334033659,1.0,1/42,0.43%,CREB1
prerank,MSigDB_Hallmark_2020__Reactive Oxygen Species Pathway,-0.731212113609642,-0.9578847530300542,0.53125,1.0,1.0,2/48,1.89%,SOD2;IPCEF1
prerank,GO_Biological_Process_2021__negative regulation of viral process (GO:0048525),-0.705735749757366,-0.9576423880470967,0.47863247863247865,1.0,1.0,3/67,2.16%,OAS1;PML;OASL
prerank,Reactome_2022__G Alpha (12/13) Signaling Events R-HSA-416482,0.6767224039874015,0.9575125157850172,0.45454545454545453,0.994628507047382,1.0,5/76,2.34%,ARHGEF7;PLEKHG5;ARHGEF18;GNB5;GNG2
prerank,Reactome_2022__FCGR3A-mediated IL10 Synthesis R-HSA-9664323,0.6874941077102618,0.9574873820953019,0.5517241379310345,0.9941294677334647,1.0,2/35,1.26%,CREB1;SYK
prerank,GO_Biological_Process_2021__regulation of osteoclast differentiation (GO:0045670),-0.6540081083566992,-0.9573959992141147,0.5777777777777777,1.0,1.0,1/31,1.27%,GPR137B
prerank,GO_Biological_Process_2021__anterior/posterior axis specification (GO:0009948),-0.5858125248938406,-0.9573454767409746,0.4701492537313433,1.0,1.0,1/15,1.43%,SHH
prerank,Elsevier_Pathway_Collection__Polycystins Mutation Effects in Cystic Kidney Disease,-0.7367185525984992,-0.95724759776746,0.5461538461538461,1.0,1.0,3/47,1.34%,PIK3CB;RAP1A;DEPTOR
prerank,Elsevier_Pathway_Collection__Osteoclast Activation in Gout,-0.7251142747964218,-0.9570003596275578,0.5403225806451613,1.0,1.0,2/58,0.23%,PTK2B;MAP2K6
prerank,KEGG_2021_Human__Purine metabolism,-0.6457799675209889,-0.956986848853027,0.5,1.0,1.0,8/122,2.11%,PDE5A;NT5C1B;PDE11A;ADCY3;ENTPD8;GMPR;PDE6D;ENTPD3
prerank,GO_Biological_Process_2021__negative regulation of myeloid leukocyte differentiation (GO:0002762),0.6957466477086959,0.9568464268704067,0.5793650793650794,0.994594775921815,1.0,3/25,1.86%,PTPN2;CDK6;ZFPM1
prerank,GO_Biological_Process_2021__protein dephosphorylation (GO:0006470),0.6385638516722987,0.9567778081003102,0.5483870967741935,0.9941628197700264,1.0,7/134,1.88%,PPM1H;PTPN2;PPP1R12A;CDC14B;PTPRH;PTPRM;DAPP1
prerank,Reactome_2022__Transcription Of E2F Targets Under Negative Control By DREAM Complex R-HSA-1362277,0.6575915515227047,0.9567768765040482,0.5739130434782609,0.9936205352798018,1.0,2/19,0.91%,RBL1;TFDP2
prerank,KEGG_2021_Human__Tuberculosis,0.6108736911275916,0.9567616574299046,0.48360655737704916,0.9930960711317188,1.0,9/156,1.98%,CREB1;IRAK2;RAB7A;NOD2;KSR1;SYK;LAMP2;CYP27B1;MAPK13
prerank,GO_Biological_Process_2021__sterol homeostasis (GO:0055092),0.680194612914027,0.9565739094376959,0.5038167938931297,0.9929238988933372,1.0,5/71,1.99%,EPHX2;LRP5;SOAT2;HDAC9;APOE
prerank,WikiPathway_2021_Human__Nuclear Receptors Meta-Pathway WP2882,-0.5783847074188723,-0.9565098979321618,0.5925925925925926,1.0,1.0,12/301,2.19%,GSTA1;NR3C1;CYP3A7;POLK;NCOA1;SLC2A10;GSTA2;NRG1;CYP1B1;CYP1A2;PRRG4;VDR
prerank,WikiPathway_2021_Human__ID signaling pathway WP53,-0.5843518404442958,-0.9562447618057919,0.45864661654135336,1.0,1.0,2/15,1.58%,RB1;PAX8
prerank,GO_Biological_Process_2021__negative regulation of cellular amide metabolic process (GO:0034249),0.646773760595112,0.9562100558956864,0.5080645161290323,0.9929682383366603,1.0,3/83,1.99%,IGF2BP1;IGF2BP3;APOE
prerank,Elsevier_Pathway_Collection__Immune Sustem Activation in Hashimoto's Thyroiditis,0.6438155082482802,0.9561918570460928,0.5789473684210527,0.992472016706673,1.0,3/30,2.29%,CD4;SYK;CD86
prerank,GO_Biological_Process_2021__establishment of protein localization to mitochondrion (GO:0072655),-0.6593883949756368,-0.9561893902422146,0.5,1.0,1.0,1/48,0.73%,TOMM70
prerank,MSigDB_Oncogenic_Signatures__ESC V6.5 UP EARLY.V1 DN,-0.6325353427097047,-0.9558724259237579,0.5041322314049587,1.0,1.0,12/154,2.09%,APP;PMP22;TGFB1I1;INHBB;BMP4;GJB5;OAF;PBX1;CD44;PCOLCE;KLF4;AQP3
prerank,GO_Biological_Process_2021__positive regulation of signal transduction by p53 class mediator (GO:1901798),0.6483603408818202,0.9555539375139834,0.5954198473282443,0.9930641384466232,1.0,2/22,1.84%,ATR;MSX1
prerank,GO_Biological_Process_2021__negative regulation of neuron projection development (GO:0010977),0.7001940600414636,0.9553045738441184,0.5147058823529411,0.9929267184601142,1.0,5/57,2.22%,LPAR1;THY1;APOE;DPYSL3;GFI1
prerank,WikiPathway_2021_Human__Non-small cell lung cancer WP4255,-0.697409622539712,-0.9548097332170138,0.4485294117647059,1.0,1.0,6/70,1.71%,POLK;AKT3;PIK3CB;RB1;RASSF5;STAT5A
prerank,KEGG_2021_Human__mTOR signaling pathway,0.6271610302254582,0.9547870613659383,0.4642857142857143,0.9931647348719683,1.0,7/147,2.30%,FNIP2;PIK3CD;LRP5;FNIP1;CAB39;PRKAA2;LPIN3
prerank,GO_Biological_Process_2021__mRNA stabilization (GO:0048255),0.6946219322133416,0.9547706765390721,0.5217391304347826,0.9926498767930474,1.0,2/36,1.97%,IGF2BP1;AXIN2
prerank,KEGG_2021_Human__Starch and sucrose metabolism,-0.6444695536637147,-0.9547182093716648,0.5877862595419847,1.0,1.0,3/30,2.23%,GANC;GYG2;PYGM
prerank,GO_Biological_Process_2021__DNA integrity checkpoint signaling (GO:0031570),0.7158814861271993,0.9545888795680068,0.5206611570247934,0.9924712544590699,1.0,4/39,1.15%,CDC45;CDC5L;ATR;BRIP1
prerank,KEGG_2021_Human__Pathways of neurodegeneration,0.5401149328419522,0.9545049433578912,0.5727272727272728,0.9921018171311355,1.0,11/429,2.36%,ERN1;LRP5;CASP7;NDUFA10;SPTBN2;PTGS2;AXIN2;MAPK13;OPTN;TUBA1A;STX1A
prerank,Elsevier_Pathway_Collection__Antigen-Presenting Cell Role in Asthma,0.7018079207952641,0.9544356291231307,0.5461538461538461,0.991676489551091,1.0,3/56,1.26%,TRAF3;CD4;SYK
prerank,GO_Biological_Process_2021__positive regulation of mitotic cell cycle phase transition (GO:1901992),-0.7180437333026496,-0.9544166465917083,0.52,1.0,1.0,3/57,1.54%,NSMCE2;RB1;CCND2
prerank,GO_Biological_Process_2021__ion homeostasis (GO:0050801),-0.6909362506418343,-0.9543882775232011,0.5447154471544715,1.0,1.0,3/28,2.35%,KLHL3;WNK3;SLC4A5
prerank,Reactome_2022__Meiosis R-HSA-1500620,0.7284972653482715,0.9543668289283568,0.5,0.9912809791493157,1.0,2/71,2.15%,SYCP3;ACD
prerank,KEGG_2021_Human__C-type lectin receptor signaling pathway,0.6601739353276641,0.954310802600084,0.47540983606557374,0.9908418919079447,1.0,6/98,2.00%,PIK3CD;KSR1;SYK;PTGS2;MAPK13;NFATC2
prerank,GO_Biological_Process_2021__cell junction organization (GO:0034330),0.6914753178271604,0.954115099998849,0.44,0.9906916170306095,1.0,4/70,2.29%,TJP1;FBLIM1;PPFIA4;FLNA
prerank,GO_Biological_Process_2021__regulation of cell migration (GO:0030334),0.5474349288548023,0.9540320275204648,0.5370370370370371,0.9902972867395544,1.0,29/387,2.37%,YTHDF3;TJP1;SRGAP2B;PIK3CD;ELP3;PTK2;ZNF304;THY1;CX3CL1;CAMSAP3;F7;CHRD;BCAR1;SEMA3G;ANXA1;DLC1;CDH1;MCTP1;SPATA13;CARMIL2;CTSH;SERPINE1;SH3RF2;STK26;ULK4;DPYSL3;HGF;FLNA;FGF1
prerank,GO_Biological_Process_2021__regulation of JNK cascade (GO:0046328),0.6445985529503551,0.9540275140650286,0.5462962962962963,0.9897740192023031,1.0,8/104,2.23%,TRAF3;NOD2;EDA2R;SH3RF2;SH3RF1;ULK4;MAPK8IP1;UNC5CL
prerank,GO_Biological_Process_2021__positive regulation of establishment of protein localization (GO:1904951),0.5849645058175807,0.9537602983006673,0.4666666666666667,0.9896636013820241,1.0,2/19,1.51%,CEP295;WRAP53
prerank,MSigDB_Oncogenic_Signatures__GLI1 UP.V1 DN,-0.6631277292366364,-0.9535565015390371,0.5483870967741935,1.0,1.0,2/24,0.37%,SLC22A1;CYP3A7
prerank,Elsevier_Pathway_Collection__FSH Action in Polycystic Ovary Syndrome,0.5836182065722658,0.9533437496586953,0.5043478260869565,0.9898678327613271,1.0,2/20,1.64%,CREB1;AMH
prerank,GO_Biological_Process_2021__B cell receptor signaling pathway (GO:0050853),0.7049568822652985,0.9533222662875318,0.5447154471544715,0.9893627076494336,1.0,6/34,2.25%,PIK3CD;SYK;NFAM1;BCAR1;NFATC2;MNDA
prerank,Reactome_2022__Transcriptional Regulation Of White Adipocyte Differentiation R-HSA-381340,-0.6719928219086173,-0.9529201257460422,0.43119266055045874,1.0,1.0,5/82,2.05%,CDK19;NCOA1;CREBBP;LIN9;KLF4
prerank,Elsevier_Pathway_Collection__Interstitial Fibroblasts in Pyelonephritis,-0.7307950520926996,-0.9524551324321276,0.5588235294117647,1.0,1.0,2/40,1.93%,MAP2K6;MMP2
prerank,GO_Biological_Process_2021__organonitrogen compound biosynthetic process (GO:1901566),-0.6098567551250185,-0.9522624792825259,0.5036496350364964,1.0,1.0,10/152,2.20%,GSTA1;PLPP1;SGPP1;ABHD3;SGPL1;TYW1;GSTA2;HACD2;MOCS3;CDO1
prerank,GO_Biological_Process_2021__cellular response to organic substance (GO:0071310),-0.6459781809222909,-0.9519360127252301,0.518796992481203,1.0,1.0,6/115,2.09%,MAP2K5;NCOA1;CYP1B1;SLIT3;KLF4;PTPN18
prerank,Reactome_2022__Phase II - Conjugation Of Compounds R-HSA-156580,-0.6897419926857363,-0.9516203667159838,0.5369127516778524,1.0,1.0,9/99,2.17%,GSTA1;GLYAT;TPST1;SULT1B1;GGT5;ACSM2B;GSTA2;CYP1A2;AS3MT
prerank,Elsevier_Pathway_Collection__CD38/CD3 -> JUN/FOS/NF-kB Signaling in T-cell Proliferation,-0.642392691652238,-0.9516098210248537,0.6131386861313869,1.0,1.0,2/29,2.44%,PTK2B;ZAP70
prerank,MSigDB_Oncogenic_Signatures__RELA DN.V1 DN,0.6437090817201163,0.9515654701532018,0.5267857142857143,0.991654163500409,1.0,6/106,2.31%,CD53;PKLR;FTCD;HDAC9;TXNRD2;HOXD3
prerank,WikiPathway_2021_Human__Joubert Syndrome WP4656,-0.6644550049199783,-0.9513785287382641,0.5037037037037037,1.0,1.0,7/75,2.33%,CEP120;CPLANE1;ANKS6;SUFU;SHH;PDE6D;BBS5
prerank,GO_Biological_Process_2021__cellular protein catabolic process (GO:0044257),0.6948373234410947,0.9512781876182833,0.46564885496183206,0.9916062569368163,1.0,3/57,1.95%,RSPRY1;RAB7A;CTSH
prerank,MSigDB_Hallmark_2020__Interferon Gamma Response,-0.5928912631857823,-0.9512771125485424,0.5522388059701493,1.0,1.0,15/199,2.42%,IFI44L;APOL6;SOD2;TNFAIP2;C1R;IL10RA;EPSTI1;PML;HERC6;OASL;HLA-B;CD274;CIITA;GBP4;RTP4
prerank,TRRUST_Transcription_Factors_2019__KLF4 human,-0.7282568343227184,-0.9511544108275722,0.532258064516129,1.0,1.0,3/38,2.19%,MMP2;BDKRB2;VDR
prerank,WikiPathway_2021_Human__Vitamin D-sensitive calcium signaling in depression WP4698,-0.7282198026150846,-0.951017649367627,0.6102941176470589,1.0,1.0,2/36,2.19%,GRIN2B;VDR
prerank,Reactome_2022__SMAD2/SMAD3:SMAD4 Heterotrimer Regulates Transcription R-HSA-2173796,0.693700013355891,0.9507557987446438,0.544,0.9919087444333023,1.0,3/35,2.07%,RBL1;TFDP2;SERPINE1
prerank,GO_Biological_Process_2021__mitotic G2 DNA damage checkpoint signaling (GO:0007095),0.65535512557962,0.9506902328177207,0.5348837209302325,0.9914789883512711,1.0,2/32,1.14%,BRSK1;CDC14B
prerank,Elsevier_Pathway_Collection__Neutrophil and Macrophage Function in Systemic Lupus Erythematosus,0.6770746281957178,0.9505833924707415,0.5859375,0.9911444788303292,1.0,3/28,1.53%,PTK2;SYK;BCAR1
prerank,KEGG_2021_Human__cGMP-PKG signaling pathway,-0.6169435039617858,-0.9504283496305872,0.5140845070422535,1.0,1.0,9/154,2.43%,PDE5A;CREB3L2;AKT3;ADCY3;CREB5;PLCB4;BDKRB2;PIK3R6;IRAG1
prerank,Elsevier_Pathway_Collection__Persisted DNA Repair Triggers Genomic Instability,0.6565478390398851,0.9503400119631412,0.5798319327731093,0.9910119368246144,1.0,2/32,1.02%,DCLRE1C;ATR
prerank,MSigDB_Oncogenic_Signatures__PTEN DN.V1 DN,0.6131815236969205,0.9502843211810549,0.5,0.9905857894411055,1.0,10/142,2.34%,ETV5;LIN7A;PSMB9;KCNJ10;KRT23;PROX1;PAH;FOSL1;SGCE;TBX3
prerank,GO_Biological_Process_2021__mitotic spindle organization (GO:0007052),0.6076513642905899,0.9502834660945501,0.5241935483870968,0.9900509159046903,1.0,8/154,2.41%,NEK6;CENPE;NDC80;CENPA;ERCC6L;KIF23;FLNA;KIF3B
prerank,MSigDB_Hallmark_2020__Coagulation,-0.6206874218776572,-0.9502582322236931,0.5652173913043478,1.0,1.0,11/137,2.41%,CPQ;CTSO;PROS1;RAPGEF3;C1R;ITIH1;MMP2;SH2B2;CD9;HRG;PRSS23
prerank,GO_Biological_Process_2021__insulin receptor signaling pathway (GO:0008286),0.6990280728299195,0.9501879540763853,0.5225225225225225,0.9896984987257074,1.0,3/68,1.53%,PTPN2;RHOQ;BCAR1
prerank,KEGG_2021_Human__Gastric acid secretion,-0.7082808478571319,-0.9496972704878036,0.5227272727272727,1.0,1.0,3/64,1.91%,HRH2;ADCY3;PLCB4
prerank,GO_Biological_Process_2021__positive regulation of proteasomal protein catabolic process (GO:1901800),-0.6550228177187826,-0.9494928972146491,0.5,1.0,1.0,2/83,1.17%,RNF217;RNF180
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Rheumatoid Arthritis,-0.6640124504639642,-0.9492600458672823,0.5819672131147541,1.0,1.0,1/20,0.27%,ITGA1
prerank,MSigDB_Oncogenic_Signatures__MYC UP.V1 UP,0.619399921388715,0.948864546849664,0.5470085470085471,0.9913072722416222,1.0,9/147,2.37%,SLC19A1;FOXRED2;AGPAT3;SLC27A2;CGREF1;LRRC61;PRAP1;GPD1L;PRR7
prerank,GO_Biological_Process_2021__cilium movement (GO:0003341),0.7001244749687353,0.9486404264245568,0.5517241379310345,0.9911507753386124,1.0,3/37,1.43%,DNAAF5;CCDC40;CAMSAP3
prerank,GO_Biological_Process_2021__positive regulation of ATP metabolic process (GO:1903580),0.6557027006991908,0.9485945627207368,0.5726495726495726,0.9906990686998199,1.0,2/29,1.10%,PPARA;PRKAA2
prerank,GO_Biological_Process_2021__cell-cell junction assembly (GO:0007043),0.6964662948375282,0.9485851830030196,0.5,0.9901800932996908,1.0,6/61,1.34%,CDH2;TJP1;PKP4;TBCD;GJC1;CNTNAP1
prerank,GO_Biological_Process_2021__positive regulation of cell differentiation (GO:0045597),0.5697594239035593,0.9483601932548879,0.5420560747663551,0.9900220372172089,1.0,12/228,2.31%,CDH2;CREB1;LRP5;IGFBP3;PKDCC;RIN2;ZC4H2;PPP1R13L;AXIN2;CDH15;HGF;HOXD3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Endometriosis,0.5800245427555226,0.9482328160698583,0.5045045045045045,0.9896635213327022,1.0,15/238,2.38%,PTK2;TNFRSF21;IGFBP3;IL1RN;ANXA1;AMH;CDH1;PTGS2;TIMP3;LGALS3;DPYSL2;SERPINE1;HGF;FGF1;RRM2
prerank,MSigDB_Oncogenic_Signatures__PKCA DN.V1 UP,-0.5892335892702989,-0.9481839443268981,0.4796747967479675,1.0,1.0,7/144,1.56%,SLC23A2;CREB3L2;CYP2C8;GSTA2;SGK3;SLC7A8;ADCY3
prerank,GO_Biological_Process_2021__negative regulation of catabolic process (GO:0009895),0.7271352470564909,0.9481374394787234,0.5523809523809524,0.9892933113117541,1.0,2/44,2.29%,PPARA;FLNA
prerank,GO_Biological_Process_2021__endomembrane system organization (GO:0010256),-0.6020438705417459,-0.9479084843246625,0.5084745762711864,1.0,1.0,7/191,2.31%,ATL2;BCAS3;ZNF501;TICAM2;FAM174B;TLCD2;SYNE1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Melanoma,0.5691007746515799,0.9476800161603235,0.5396825396825397,0.989457132225438,1.0,17/228,2.39%,CDH2;CREB1;CDK6;PLAUR;PTK2;IGFBP3;ERBB3;SYK;IGF2BP3;CDH1;PTGS2;TIMP3;LGALS3;FN1;HGF;TBX3;MELTF
prerank,GO_Biological_Process_2021__N-terminal protein amino acid acetylation (GO:0006474),0.5813531657771749,0.9476101567931536,0.48333333333333334,0.9890657107024273,1.0,2/15,1.87%,NAA60;NAA10
prerank,WikiPathway_2021_Human__Trans-sulfuration and one-carbon metabolism WP2525,-0.7078059463326727,-0.9474862010898882,0.6048387096774194,1.0,1.0,3/31,1.96%,AHCYL2;BHMT;MTHFD2L
prerank,GO_Biological_Process_2021__regulation of cellular response to stress (GO:0080135),0.6562823209599098,0.9474626757275803,0.464,0.988780839017251,1.0,4/117,1.05%,NEK6;NEK4;ATR;NUP210
prerank,GO_Biological_Process_2021__MyD88-dependent toll-like receptor signaling pathway (GO:0002755),0.6602798912137426,0.9473862754182312,0.5737704918032787,0.9883685036048971,1.0,1/28,0.64%,IRAK2
prerank,GO_Biological_Process_2021__ubiquitin-dependent ERAD pathway (GO:0030433),-0.659075057828358,-0.9473224886754831,0.5251798561151079,1.0,1.0,3/71,0.77%,FBXO27;AMFR;DNAJB14
prerank,GO_Biological_Process_2021__Rho protein signal transduction (GO:0007266),0.6984969610965931,0.9472695595318238,0.512,0.9880313033395858,1.0,2/53,1.58%,PLEKHG5;CDC42EP1
prerank,Elsevier_Pathway_Collection__Thyroid Hormones Common non-Genomic Effects in Hyperthyroidism,0.6580842795670105,0.9471861714244902,0.5298507462686567,0.987622219712662,1.0,1/36,0.86%,PTK2
prerank,KEGG_2021_Human__Cell adhesion molecules,0.6052279337085708,0.9471381687886672,0.5454545454545454,0.9871750644014818,1.0,10/141,2.29%,CDH2;LRRC4;ITGA4;CD4;CNTNAP1;ITGAL;CDH1;PTPRM;CDH15;CD86
prerank,GO_Biological_Process_2021__negative regulation of cell migration (GO:0030336),0.6293371412527317,0.9470043205870211,0.4485981308411215,0.9868462613071178,1.0,11/137,2.21%,SRGAP2B;IGFBP3;THY1;CX3CL1;CHRD;DLC1;CDH1;MCTP1;SERPINE1;STK26;DPYSL3
prerank,GO_Biological_Process_2021__positive regulation of organelle organization (GO:0010638),0.698011971026095,0.9467327706004992,0.5803571428571429,0.9867390050914632,1.0,3/31,1.64%,RAB3GAP1;KATNBL1;ANXA1
prerank,GO_Biological_Process_2021__membrane lipid biosynthetic process (GO:0046467),-0.6827125082113645,-0.946630204784037,0.5151515151515151,1.0,1.0,4/57,1.31%,PLPP1;SGPP1;SGPL1;HACD2
prerank,GO_Biological_Process_2021__regulation of transforming growth factor beta receptor signaling pathway (GO:0017015),-0.682376695628645,-0.9465759497990665,0.5100671140939598,1.0,1.0,6/94,2.15%,SLC2A10;ZNF451;CREBBP;TGFB1I1;LTBP4;ADAMTSL2
prerank,GO_Biological_Process_2021__cellular response to metal ion (GO:0071248),-0.6431948076342778,-0.946439627043,0.5238095238095238,1.0,1.0,7/120,2.37%,CARF;RASGRP2;SYT2;DLG2;SMPD1;AOC1;SYT7
prerank,Reactome_2022__Cellular Hexose Transport R-HSA-189200,0.6442858086648697,0.9464018624655838,0.5669291338582677,0.9867015508226645,1.0,3/20,2.25%,MFSD4B;SLC2A8;SLC2A6
prerank,GO_Biological_Process_2021__positive regulation of cell population proliferation (GO:0008284),0.5366676397799983,0.9462551198916757,0.592,0.9864287676643729,1.0,20/437,2.37%,TJP1;LRP5;CDK6;PTK2;ZNF304;NOD2;ERBB3;CX3CL1;PROX1;CHRD;FOSL1;IL13RA1;CCL14;CTSH;SAPCD2;PRLR;FN1;CD86;TBX3;FGF1
prerank,WikiPathway_2021_Human__Endoderm differentiation WP2853,-0.6240416241519788,-0.9462247464313339,0.5206611570247934,1.0,1.0,7/130,2.32%,PARP8;NR3C1;SP4;APP;PBX1;DUSP4;ZFHX4
prerank,WikiPathway_2021_Human__16p11.2 distal deletion syndrome WP4950,-0.6637030823865894,-0.9462168959542321,0.5522388059701493,1.0,1.0,1/29,0.30%,SDCCAG8
prerank,MSigDB_Hallmark_2020__Cholesterol Homeostasis,0.6670755228830939,0.9461963441149334,0.49206349206349204,0.9859738424430243,1.0,4/74,2.05%,PLAUR;CBS;PDK3;LGALS3
prerank,GO_Biological_Process_2021__endothelial cell proliferation (GO:0001935),0.610001263304341,0.94591856275817,0.5275590551181102,0.9859488524833581,1.0,2/18,0.55%,ERN1;DLG1
prerank,Elsevier_Pathway_Collection__Tertiary Hypothyroidism,0.662435090394907,0.9456915737252403,0.5555555555555556,0.9852662501164096,1.0,1/24,0.43%,CREB1
prerank,Elsevier_Pathway_Collection__Central Hypothyroidism,0.662435090394907,0.9456915737252403,0.5555555555555556,0.9852662501164096,1.0,1/24,0.43%,CREB1
prerank,Elsevier_Pathway_Collection__Familial Mediterranean Fever,0.6550113500502811,0.9456699063064355,0.5702479338842975,0.984776984725436,1.0,1/25,1.17%,MEFV
prerank,WikiPathway_2021_Human__Oxidation by Cytochrome P450 WP43,-0.7027370629936908,-0.945656987073462,0.4925373134328358,1.0,1.0,8/56,1.98%,CYP39A1;CYP3A7;CYP2C8;CYP4V2;CYP20A1;CYP4F22;CYP1B1;CYP1A2
prerank,MSigDB_Oncogenic_Signatures__JAK2 DN.V1 DN,-0.6237473201785801,-0.9455846853109291,0.5583333333333333,1.0,1.0,6/114,2.35%,NSMCE2;ZNF221;HIBADH;ZNF44;TLE4;SLC4A5
prerank,Reactome_2022__Metal Ion SLC Transporters R-HSA-425410,-0.6655115198832537,-0.9454633474082149,0.5514705882352942,1.0,1.0,1/25,0.12%,SLC41A2
prerank,GO_Biological_Process_2021__prostanoid metabolic process (GO:0006692),0.5841965905028603,0.9454454248098169,0.452991452991453,0.9846114369267003,1.0,2/17,1.59%,PTGR1;CYP2S1
prerank,GO_Biological_Process_2021__Rac protein signal transduction (GO:0016601),0.66539684549362,0.9453725011251023,0.562962962962963,0.9842235376691618,1.0,1/19,0.13%,ABI2
prerank,GO_Biological_Process_2021__negative regulation of osteoblast differentiation (GO:0045668),0.6730735785398967,0.9451736335230765,0.5691056910569106,0.9840799841060003,1.0,3/30,1.45%,LRP5;CDK6;CHRD
prerank,TRRUST_Transcription_Factors_2019__FOXA2 mouse,-0.6572403464105872,-0.9451678726778636,0.559322033898305,1.0,1.0,1/30,0.95%,TLE4
prerank,WikiPathway_2021_Human__DNA Repair Pathways Full Network WP4946,0.6553169208233355,0.9451569074737411,0.5161290322580645,0.9835804395671671,1.0,6/119,1.15%,FANCL;DCLRE1C;MSH2;POLE4;ATR;BRIP1
prerank,GO_Biological_Process_2021__phosphatidylinositol biosynthetic process (GO:0006661),-0.6243172585132348,-0.9450800223946123,0.484375,1.0,1.0,4/123,2.28%,PIK3CB;PIGZ;PIK3R6;PGAP4
prerank,GO_Biological_Process_2021__synaptic vesicle recycling (GO:0036465),-0.6907001676461743,-0.9450665855276007,0.5547945205479452,1.0,1.0,2/33,2.37%,SYT2;SYT7
prerank,MSigDB_Hallmark_2020__Pancreas Beta Cells,-0.6448929558065353,-0.9446659508291576,0.5984848484848485,1.0,1.0,2/29,2.19%,AKT3;VDR
prerank,GO_Biological_Process_2021__acylglycerol catabolic process (GO:0046464),-0.6981677317081966,-0.9443150990552123,0.5725806451612904,1.0,1.0,2/27,1.62%,LIPE;LIPG
prerank,MSigDB_Oncogenic_Signatures__TBK1.DN.48HRS UP,0.7095795889176879,0.9442123944303131,0.52,0.9845004656845873,1.0,4/49,2.39%,PTK2;IGFBP3;APOE;PIK3C2B
prerank,Elsevier_Pathway_Collection__Proteins Involved in High-Grade Serous Ovarian Carcinoma,0.6873293623724007,0.9440886598650597,0.49624060150375937,0.9841468774365132,1.0,2/56,1.27%,MSH2;NOTCH3
prerank,WikiPathway_2021_Human__Hippo-Merlin Signaling Dysregulation WP4541,0.6588687892148763,0.9437544419492526,0.5188679245283019,0.9841802644642303,1.0,12/112,2.07%,CDH2;ITGA3;VGLL4;PTK2;PPP1R12A;ITGA4;ITGAL;ITGA2;CDH1;ITGB5;TEAD4;CDH15
prerank,MSigDB_Oncogenic_Signatures__CSR LATE UP.V1 DN,-0.610887944462766,-0.9436603376838585,0.5609756097560976,1.0,1.0,11/147,2.41%,PDE5A;NTN4;SOD2;ABCA6;MAMDC2;OAF;DUSP4;NYNRIN;EPSTI1;GLI3;KLHL29
prerank,KEGG_2021_Human__Pentose phosphate pathway,-0.6615118148796701,-0.943573390585113,0.5572519083969466,1.0,1.0,2/27,0.53%,ALDOB;DERA
prerank,Elsevier_Pathway_Collection__HPV Infection and Cancer,0.6973033488931912,0.943420193628522,0.4915254237288136,0.9842374675625655,1.0,3/55,1.71%,CREB1;CASP7;CDH1
prerank,Elsevier_Pathway_Collection__Suppression of Caspase Activity in Cancer,-0.7392983914460081,-0.9433557254510099,0.592,1.0,1.0,3/45,1.08%,GAS2;APP;BIRC6
prerank,Reactome_2022__NRAGE Signals Death Thru JNK R-HSA-193648,0.6857123890880246,0.9428271988419971,0.5284552845528455,0.9846521928679575,1.0,4/57,1.44%,AATF;ARHGEF7;PLEKHG5;ARHGEF18
prerank,WikiPathway_2021_Human__Vitamin D Receptor Pathway WP2877,0.6166479818250808,0.9426955909022696,0.5234375,0.9843731353750365,1.0,10/156,2.00%,TRAK1;CLEC16A;LRP5;IGFBP3;CBS;ASAP2;CYP2S1;CYP27B1;TIMP3;NFATC2
prerank,Elsevier_Pathway_Collection__Thymic Follicular Hyperplasia,0.693744353236384,0.9425424693861286,0.5982905982905983,0.9841253313221874,1.0,2/27,2.06%,SYK;PIK3AP1
prerank,GO_Biological_Process_2021__cellular transition metal ion homeostasis (GO:0046916),-0.6585640428163673,-0.9424478507511352,0.5454545454545454,1.0,1.0,1/92,0.81%,APP
prerank,MSigDB_Oncogenic_Signatures__BMI1 DN MEL18 DN.V1 DN,-0.6235075294873136,-0.9422360980869317,0.5535714285714286,1.0,1.0,7/123,2.37%,PDE5A;EVI5;GAS2;GPR137B;AQP3;MAOB;IFI6
prerank,Elsevier_Pathway_Collection__Proteins Involved in Alzheimer's Disease,-0.6293820595589399,-0.9422261486592839,0.5303030303030303,1.0,1.0,4/122,1.08%,ADAM10;APP;SOD2;GRIN2B
prerank,Reactome_2022__Nuclear Envelope (NE) Reassembly R-HSA-2995410,-0.666508703394803,-0.9422106503885956,0.4396551724137931,1.0,1.0,1/71,0.02%,VRK2
prerank,Elsevier_Pathway_Collection__VEGFR -> NFATC Signaling,-0.6644737015053737,-0.9421787591368841,0.5517241379310345,1.0,1.0,1/21,0.23%,MAP2K6
prerank,KEGG_2021_Human__Arginine and proline metabolism,0.7095410556143411,0.9421655068469018,0.5573770491803278,0.9842776462452835,1.0,4/49,2.39%,SMOX;MAOA;SMS;PYCR1
prerank,GO_Biological_Process_2021__regulation of cellular response to transforming growth factor beta stimulus (GO:1903844),0.6650502270997166,0.9420782713042096,0.5648148148148148,0.983923107394809,1.0,1/21,0.17%,ITGA3
prerank,GO_Biological_Process_2021__cellular response to tumor necrosis factor (GO:0071356),0.5796424882370679,0.9418320701698312,0.5,0.9838090792394724,1.0,7/185,2.05%,TRAF3;TNFRSF21;PSMB9;TNFRSF25;CX3CL1;CCL14;EDA2R
prerank,GO_Biological_Process_2021__extracellular structure organization (GO:0043062),-0.5702060808710359,-0.9416647219403875,0.5413533834586466,1.0,1.0,14/200,2.39%,ADAMTS2;ITGA1;APP;ADAMTS5;ADAMTS9;ITGAX;CD44;COLQ;MATN1;MMP2;COL4A4;ADAMTSL5;ADAMTSL2;COL7A1
prerank,GO_Biological_Process_2021__regulation of extrinsic apoptotic signaling pathway (GO:2001236),-0.7034154297705039,-0.9415822813990176,0.515625,1.0,1.0,6/62,2.09%,PAK2;TNFRSF10B;BIRC6;DEPTOR;BMP4;PML
prerank,Elsevier_Pathway_Collection__IgE Induces Airway Smooth Muscle Cell Proliferation,-0.7251162257361287,-0.941402492988251,0.6068376068376068,1.0,1.0,2/41,0.23%,PTK2B;MAP2K6
prerank,GO_Biological_Process_2021__maintenance of gastrointestinal epithelium (GO:0030277),0.5788145906741787,0.9413116012560996,0.4793388429752066,0.9841442965638283,1.0,2/16,2.12%,NOD2;RBP4
prerank,GO_Biological_Process_2021__small GTPase mediated signal transduction (GO:0007264),0.6416277113973179,0.9409777551618475,0.49206349206349204,0.984111024286336,1.0,6/104,1.48%,ZNF304;PLD1;KSR1;RAPGEF6;ARHGEF18;RIN2
prerank,GO_Biological_Process_2021__synapse organization (GO:0050808),0.6361393262623509,0.9407717949249147,0.5702479338842975,0.9840564228585874,1.0,7/121,1.92%,CDH2;LRRC4;ARHGAP39;CX3CL1;ZC4H2;CDH1;PPFIA4
prerank,GO_Biological_Process_2021__regulation of phosphoprotein phosphatase activity (GO:0043666),0.6578934575983622,0.940663948255297,0.5703703703703704,0.9837408976931177,1.0,2/34,0.88%,CD300A;PPP1R12A
prerank,GO_Biological_Process_2021__external encapsulating structure organization (GO:0045229),-0.5702051486169244,-0.9403133745426293,0.5303030303030303,1.0,1.0,14/201,2.39%,ADAMTS2;ITGA1;APP;ADAMTS5;ADAMTS9;ITGAX;CD44;COLQ;MATN1;MMP2;COL4A4;ADAMTSL5;ADAMTSL2;COL7A1
prerank,KEGG_2021_Human__Tight junction,0.5941203838806387,0.9402657357557946,0.5436893203883495,0.9839141945978271,1.0,9/159,2.15%,TJP1;DLG1;DLG3;ACTR3;PRKAA2;RAPGEF6;CRB3;ARHGEF18;TUBA1A
prerank,Elsevier_Pathway_Collection__EGFR -> AP-1/CREB/ELK/SRF/MYC Signaling,-0.7182028826328177,-0.9402417722544258,0.5950413223140496,1.0,1.0,3/49,1.53%,PTK2B;MAP2K6;NRG1
prerank,Elsevier_Pathway_Collection__Monocytes Function in Gout,0.6961239019802044,0.9400832679911723,0.5652173913043478,0.9836820292200376,1.0,2/34,1.82%,SYK;PTGS2
prerank,Elsevier_Pathway_Collection__Hematopoietic Cell Lineage: B-cell (mouse),0.7112797155223454,0.9400170113108803,0.6,0.9832724481582765,1.0,4/42,2.22%,FNIP1;CD48;ITGA2;GFI1
prerank,Elsevier_Pathway_Collection__ROS in Triggering Vascular Inflammation,-0.6433509818639206,-0.9398500128962746,0.5984848484848485,1.0,1.0,2/32,2.34%,SMPD1;VAV1
prerank,GO_Biological_Process_2021__axonemal dynein complex assembly (GO:0070286),0.6230568445973432,0.939678989271579,0.5338983050847458,0.9833178698274122,1.0,2/22,1.34%,DNAAF5;CCDC40
prerank,GO_Biological_Process_2021__gluconeogenesis (GO:0006094),-0.6645872715426484,-0.9396222124676581,0.5426356589147286,1.0,1.0,1/36,0.22%,ALDOB
prerank,Elsevier_Pathway_Collection__Proliferative Diabetic Retinopathy,0.6917156232050543,0.9396004806876662,0.5462962962962963,0.982944406563527,1.0,4/60,2.27%,PTK2;PTGS2;SERPINE1;FN1
prerank,GO_Biological_Process_2021__modification-dependent protein catabolic process (GO:0019941),-0.572375093160113,-0.9395318432570144,0.5344827586206896,1.0,1.0,7/197,1.12%,KLHL3;AMFR;TTC3;RNF13;BIRC6;NEDD4;RNF217
prerank,"Reactome_2022__Gamma Carboxylation, Hypusine Formation And Arylsulfatase Activation R-HSA-163841",-0.692950639575016,-0.9395300015090864,0.553030303030303,1.0,1.0,3/41,1.31%,STS;TPST1;PROS1
prerank,Reactome_2022__G Alpha (S) Signaling Events R-HSA-418555,-0.6113705925935805,-0.9391675428323477,0.49230769230769234,1.0,1.0,3/121,1.37%,GPR39;HRH2;PDE11A
prerank,WikiPathway_2021_Human__Cancer immunotherapy by PD-1 blockade WP4585,-0.642398030411578,-0.9390798300575677,0.572463768115942,1.0,1.0,2/23,2.44%,CD274;ZAP70
prerank,Reactome_2022__Downregulation Of SMAD2/3:SMAD4 Transcriptional Activity R-HSA-2173795,-0.663933738071498,-0.9389932973955214,0.5401459854014599,1.0,1.0,1/30,0.28%,TGIF1
prerank,GO_Biological_Process_2021__protein deubiquitination (GO:0016579),-0.5597915726229131,-0.9389238441727071,0.6198347107438017,1.0,1.0,5/241,1.18%,USP40;USP37;MBD5;INO80D;BRCC3
prerank,Reactome_2022__Insulin Processing R-HSA-264876,-0.6593585311431956,-0.9387883853722092,0.5916666666666667,1.0,1.0,2/25,0.74%,EXOC2;MYRIP
prerank,GO_Biological_Process_2021__glycerophospholipid biosynthetic process (GO:0046474),0.5886103616296362,0.9385523176489307,0.5419847328244275,0.9841866763926163,1.0,10/172,2.39%,LCLAT1;PIK3CD;AGPAT3;GPAT4;PLD1;PNPLA3;LPCAT2;GPD1L;LPIN3;PIK3C2B
prerank,Elsevier_Pathway_Collection__Epithelial Cell in the Innate Immune Response in Ulcerative Colitis,-0.6644735413268242,-0.9382679591279737,0.5726495726495726,1.0,1.0,1/22,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__positive regulation of chemokine production (GO:0032722),-0.7192262579463167,-0.9382274150166847,0.5833333333333334,1.0,1.0,2/46,0.81%,OAS1;APP
prerank,WikiPathway_2021_Human__Fluoropyrimidine Activity WP1601,-0.659547633859027,-0.9381075880895979,0.5666666666666667,1.0,1.0,1/33,0.72%,DPYS
prerank,GO_Biological_Process_2021__regulation of receptor-mediated endocytosis (GO:0048259),-0.6612391416362363,-0.9380796047947115,0.5531914893617021,1.0,1.0,1/37,0.55%,PIK3CB
prerank,MSigDB_Oncogenic_Signatures__HOXA9 DN.V1 UP,0.5918305208707056,0.9380315543299572,0.6126126126126126,0.9845152040690939,1.0,16/169,2.40%,ZNF394;FNDC3B;FNDC3A;SLC35D2;USP15;NOD2;PHTF2;RNF130;MS4A6A;FDXR;MYOF;IL13RA1;MS4A4A;MNDA;CD86;FRY
prerank,TRRUST_Transcription_Factors_2019__POU5F1 human,-0.6085025228182958,-0.93796807653096,0.5367647058823529,1.0,1.0,2/20,1.66%,BMP4;HLX
prerank,Reactome_2022__CD28 Dependent PI3K/Akt Signaling R-HSA-389357,-0.6620123208985761,-0.9376347946452713,0.5815602836879432,1.0,1.0,1/22,0.47%,AKT3
prerank,GO_Biological_Process_2021__cholesterol homeostasis (GO:0042632),0.6801953971890918,0.9375687510536646,0.5230769230769231,0.9848268482381464,1.0,5/70,1.99%,EPHX2;LRP5;SOAT2;HDAC9;APOE
prerank,GO_Biological_Process_2021__protein-DNA complex assembly (GO:0065004),0.6243893309146853,0.9375642723781107,0.5126050420168067,0.9843140581183258,1.0,2/129,1.20%,NAA60;PSMB9
prerank,Reactome_2022__Post-translational Modification: Synthesis Of GPI-anchored Proteins R-HSA-163125,-0.652059732067376,-0.9373329685227754,0.5434782608695652,1.0,1.0,5/77,1.48%,VNN1;PIGX;CNTN3;RTN4RL1;PIGZ
prerank,KEGG_2021_Human__Chronic myeloid leukemia,-0.6753890249576537,-0.937321247211465,0.4791666666666667,1.0,1.0,5/76,1.71%,POLK;AKT3;PIK3CB;RB1;STAT5A
prerank,GO_Biological_Process_2021__cellular protein-containing complex assembly (GO:0034622),0.5940022330703058,0.9371229648997766,0.5333333333333333,0.9845098358100796,1.0,8/161,2.16%,CENPE;TBCD;CENPA;CCDC40;ANKS4B;ANLN;PRLR;CYBA
prerank,GO_Biological_Process_2021__branching involved in ureteric bud morphogenesis (GO:0001658),-0.5997750500602944,-0.9371078613738826,0.5075757575757576,1.0,1.0,3/15,1.58%,SHH;BMP4;PAX8
prerank,Elsevier_Pathway_Collection__ESR1 Signaling in Breast Cancer,-0.697306142792879,-0.9370761032500176,0.5158730158730159,1.0,1.0,3/51,1.71%,NCOA1;CREBBP;STAT5A
prerank,GO_Biological_Process_2021__protein homotetramerization (GO:0051289),0.6940735785870927,0.9370397174841377,0.5757575757575758,0.9841487173961422,1.0,4/49,2.03%,ACACA;GLS;HPRT1;TRPV1
prerank,WikiPathway_2021_Human__Intracellular trafficking proteins involved in CMT neuropathy WP4856,-0.6224388848865215,-0.9370118512428054,0.5725190839694656,1.0,1.0,2/27,1.40%,SBF2;PMP22
prerank,GO_Biological_Process_2021__Fc receptor signaling pathway (GO:0038093),-0.6433969808332817,-0.9369734698924558,0.5039370078740157,1.0,1.0,5/110,2.34%,PAK2;PIK3CB;TEC;GRAP2;VAV1
prerank,GO_Biological_Process_2021__chromatin remodeling (GO:0006338),-0.6552082083985419,-0.9366115637013651,0.4852941176470588,1.0,1.0,2/100,1.15%,KDM6A;RB1
prerank,TRRUST_Transcription_Factors_2019__NR3C1 human,0.6732226082561282,0.9364435901869748,0.5645161290322581,0.9846202180276687,1.0,3/35,1.92%,CDK6;MAOA;NR1I2
prerank,GO_Biological_Process_2021__protein localization to cell-cell junction (GO:0150105),0.6220226297995807,0.9360265654367176,0.5491803278688525,0.9847542611909251,1.0,2/15,1.44%,TJP1;ARHGEF18
prerank,GO_Biological_Process_2021__negative regulation of macromolecule metabolic process (GO:0010605),-0.5804021912462124,-0.935856908378291,0.6439393939393939,1.0,1.0,9/187,2.40%,ADAM10;ZNF148;APP;SLC2A10;RB1;BMP4;KLF4;VDR;SPI1
prerank,KEGG_2021_Human__Hepatitis B,-0.6114674787785408,-0.9355395906585314,0.5039370078740157,1.0,1.0,10/146,1.85%,PTK2B;MAP2K6;CREB3L2;AKT3;PIK3CB;RB1;CREBBP;STAT5A;CREB5;TICAM2
prerank,MSigDB_Oncogenic_Signatures__KRAS.600.LUNG.BREAST UP.V1 DN,-0.578939499296416,-0.935425061688785,0.5483870967741935,1.0,1.0,15/226,2.42%,MAP2K6;MYOM1;IFI44L;GLYAT;DPYS;PTPRJ;TRIM58;PBX1;IL12RB2;NTF3;NYNRIN;CIITA;PARP3;EPB41L4A;RTP4
prerank,GO_Biological_Process_2021__mRNA destabilization (GO:0061157),0.6644722808470618,0.9353934546760013,0.5537190082644629,0.9852767635034593,1.0,2/37,0.23%,YTHDF3;DIS3L2
prerank,"GO_Biological_Process_2021__retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum (GO:0006890)",0.6426116320168365,0.9352577664519742,0.5739130434782609,0.9849466009158143,1.0,3/82,2.41%,CENPE;KIF23;KIF3B
prerank,Elsevier_Pathway_Collection__Antiviral Signaling through Pattern Recognition Receptors,0.6645888233715743,0.9351972139585588,0.5757575757575758,0.984550908915654,1.0,1/23,0.21%,TRAF3
prerank,MSigDB_Oncogenic_Signatures__NRL DN.V1 UP,-0.6245202468264549,-0.9350683589982492,0.5038759689922481,1.0,1.0,6/119,1.85%,ARHGAP10;TTC39C;TNFAIP2;GRIK5;GALNT7;PCOLCE
prerank,WikiPathway_2021_Human__Genes related to primary cilium development (based on CRISPR) WP4536,-0.6435633005196892,-0.9349851513801027,0.6102941176470589,1.0,1.0,6/97,2.33%,WDPCP;CEP120;CPLANE1;TTBK2;CPLANE2;BBS5
prerank,Elsevier_Pathway_Collection__Dopamine Receptors Signaling,-0.6546611796766929,-0.9347839956946299,0.6115107913669064,1.0,1.0,2/35,1.21%,MAP2K6;RAP1A
prerank,Reactome_2022__MECP2 Regulates Neuronal Receptors And Channels R-HSA-9022699,0.5783540895557729,0.93458446145726,0.4921875,0.9851244293327186,1.0,2/15,2.17%,CREB1;GPRIN1
prerank,GO_Biological_Process_2021__nucleotide-binding oligomerization domain containing signaling pathway (GO:0070423),0.6577421781543009,0.9345677897615634,0.6016260162601627,0.984639749780991,1.0,2/27,0.90%,IRAK2;NOD2
prerank,Elsevier_Pathway_Collection__CC Chemokine Receptor Signaling,-0.6525447220442361,-0.9345528863567188,0.5590551181102362,1.0,1.0,8/85,2.34%,PTK2B;CCL23;PARD3;RAP1A;RASGRP2;STAT5A;GNA14;VAV1
prerank,TRRUST_Transcription_Factors_2019__PAX6 mouse,0.6871878444592383,0.9345151657145198,0.5661764705882353,0.984195509845559,1.0,2/32,1.29%,CDK6;MAB21L2
prerank,Reactome_2022__GPVI-mediated Activation Cascade R-HSA-114604,-0.7039963080597663,-0.9345088756513965,0.5944055944055944,1.0,1.0,3/32,2.34%,PIK3CB;PIK3R6;VAV1
prerank,GO_Biological_Process_2021__regulation of cation transmembrane transport (GO:1904062),-0.6900527301960097,-0.9343520861783778,0.6285714285714286,1.0,1.0,5/27,2.44%,KCNN2;WNK3;KCNAB3;KCNAB2;KCNE1
prerank,KEGG_2021_Human__Ovarian steroidogenesis,-0.6965399366018142,-0.9341584117251226,0.5655737704918032,1.0,1.0,2/44,1.78%,ADCY3;CYP1B1
prerank,Elsevier_Pathway_Collection__OPRK -> Pain Perception,0.5846191610647552,0.93414332469071,0.4918032786885246,0.9842588516779583,1.0,2/18,1.54%,CREB1;SLC6A4
prerank,Reactome_2022__Signaling By NTRK1 (TRKA) R-HSA-187037,-0.6425084426757719,-0.9340188251190176,0.5466666666666666,1.0,1.0,5/111,2.43%,PIK3CB;MAP2K5;RAP1A;DUSP4;FOSB
prerank,KEGG_2021_Human__Notch signaling pathway,-0.7151412907170298,-0.9338386315952611,0.5511811023622047,1.0,1.0,2/56,1.22%,TLE4;CREBBP
prerank,Elsevier_Pathway_Collection__CagA Phosphorylation Dependent Signaling,0.6990458320407359,0.9338166425518442,0.592,0.9842446915196033,1.0,3/39,1.53%,CREB1;PTK2;BCAR1
prerank,TRRUST_Transcription_Factors_2019__PPARA mouse,0.7294078321455149,0.9337841086242916,0.6222222222222222,0.9837825908206995,1.0,3/42,2.07%,PTGS2;NR1I2;SERPINE1
prerank,Elsevier_Pathway_Collection__PAPA Syndrome,0.6550108490549794,0.9336938155773327,0.5853658536585366,0.9834217682027175,1.0,1/26,1.17%,MEFV
prerank,GO_Biological_Process_2021__Fc-epsilon receptor signaling pathway (GO:0038095),-0.6433978712602966,-0.9334716709071724,0.49193548387096775,1.0,1.0,5/109,2.34%,PAK2;PIK3CB;TEC;GRAP2;VAV1
prerank,Reactome_2022__SARS-CoV-2-host Interactions R-HSA-9705683,0.5877344479526432,0.9333278561374273,0.5847457627118644,0.9835439531018857,1.0,7/178,1.24%,TRAF3;TJP1;IRAK2;YWHAQ;NOD2;NUP210;CRB3
prerank,GO_Biological_Process_2021__linoleic acid metabolic process (GO:0043651),-0.5712357006030278,-0.933209700041396,0.5210084033613446,1.0,1.0,1/20,0.03%,GSTA1
prerank,GO_Biological_Process_2021__fatty acid derivative biosynthetic process (GO:1901570),0.6596240763754364,0.9331900872067254,0.5625,0.9832234389309203,1.0,2/37,0.71%,ACACA;ACSS3
prerank,Reactome_2022__Protein Localization R-HSA-9609507,-0.6012239234231419,-0.9331000913689826,0.5984848484848485,1.0,1.0,7/159,1.80%,CHCHD3;ATAD1;ABCD3;GLYAT;TOMM70;APP;HAO1
prerank,WikiPathway_2021_Human__Target Of Rapamycin (TOR) Signaling WP1471,0.6556598439587727,0.9329688977479573,0.5950413223140496,0.9831443228925961,1.0,1/36,1.10%,PRKAA2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Retinitis Pigmentosa,0.658787688082941,0.9329444461834708,0.5350877192982456,0.9826956938218397,1.0,5/101,2.31%,CASP7;SORT1;CBS;TUB;MYO7A
prerank,KEGG_2021_Human__Viral myocarditis,0.6913718541317798,0.932460012464619,0.5533980582524272,0.9829699718359578,1.0,2/55,2.29%,ITGAL;CD86
prerank,KEGG_2021_Human__Influenza A,-0.5965169144792742,-0.9323333374268257,0.5692307692307692,1.0,1.0,8/148,2.27%,TNFRSF10B;AKT3;OAS1;PIK3CB;CREBBP;PML;TMPRSS2;CIITA
prerank,GO_Biological_Process_2021__response to organonitrogen compound (GO:0010243),0.6463888286865278,0.9323103947314166,0.6,0.9826924848568436,1.0,2/34,2.03%,DRD4;TRPV1
prerank,KEGG_2021_Human__Choline metabolism in cancer,-0.6613435171738938,-0.9321917327279486,0.5369127516778524,1.0,1.0,4/95,0.55%,SLC22A1;PLPP1;AKT3;PIK3CB
prerank,Reactome_2022__DAP12 Interactions R-HSA-2172127,-0.705414651486541,-0.932115237443588,0.5905511811023622,1.0,1.0,3/38,2.20%,PIK3CB;GRAP2;HLA-B
prerank,Reactome_2022__Reproduction R-HSA-1474165,-0.6436872370056419,-0.9320495791357238,0.5703125,1.0,1.0,4/87,2.31%,CATSPER3;ADAM20;CD9;SYNE1
prerank,GO_Biological_Process_2021__mitochondrial respiratory chain complex I assembly (GO:0032981),-0.6584239319671039,-0.9315853241272715,0.5645161290322581,1.0,1.0,2/58,0.83%,NDUFAF2;NDUFS4
prerank,GO_Biological_Process_2021__NADH dehydrogenase complex assembly (GO:0010257),-0.6584239319671039,-0.9315853241272715,0.5645161290322581,1.0,1.0,2/58,0.83%,NDUFAF2;NDUFS4
prerank,Reactome_2022__Leishmania Infection R-HSA-9658195,0.5685950568115721,0.9314355824103145,0.5818181818181818,0.9836578063665407,1.0,9/208,2.34%,ABI2;CREB1;ACTR3;PTK2;MEFV;SYK;GNB5;CYBA;GNG2
prerank,Reactome_2022__Paracetamol ADME R-HSA-9753281,0.6128629853955423,0.9312554517729954,0.5446428571428571,0.9834642869943808,1.0,3/25,2.36%,SLC38A3;SLC38A1;SULT1A1
prerank,Elsevier_Pathway_Collection__TAM Receptor Signaling Activation in Cancer,0.6439707222477739,0.9311680032470977,0.5371900826446281,0.9830959831754373,1.0,4/72,2.28%,CDH2;CREB1;CDH1;HGF
prerank,"Elsevier_Pathway_Collection__Hypothyroidism, Secondary (Central)",0.5791958475636483,0.931018173804325,0.5163934426229508,0.9828353302971776,1.0,2/20,2.09%,CREB1;PRLR
prerank,TRRUST_Transcription_Factors_2019__GATA4 human,-0.6210602146719468,-0.9309897590962108,0.5275590551181102,1.0,1.0,2/17,1.54%,SGPL1;CCND2
prerank,GO_Biological_Process_2021__regulation of actin cytoskeleton reorganization (GO:2000249),-0.701260885482442,-0.9309444399517662,0.6333333333333333,1.0,1.0,6/36,1.90%,PTK2B;BCAS3;HCK;RAPGEF3;NTF3;TEK
prerank,Reactome_2022__Signaling By TGF-beta Receptor Complex R-HSA-170834,0.654438803569361,0.9302760454610162,0.5416666666666666,0.9836400861227678,1.0,7/89,2.32%,RBL1;USP15;TFDP2;ARHGEF18;ITGB5;SERPINE1;ZFYVE9
prerank,Reactome_2022__RUNX1 Regulates Transcription Of Genes Involved In Differentiation Of HSCs R-HSA-8939236,-0.6427238810897653,-0.930105797835458,0.5681818181818182,1.0,1.0,2/85,2.40%,LDB2;SPI1
prerank,KEGG_2021_Human__Endocytosis,0.5539185981645756,0.929989651493143,0.6111111111111112,0.9836379970547817,1.0,10/246,2.32%,IGF2R;ACAP2;ACTR3;RAB7A;PLD1;ASAP2;AGAP3;GRK3;IQSEC1;ZFYVE9
prerank,GO_Biological_Process_2021__neuron migration (GO:0001764),0.6925722308141432,0.929296406069996,0.528,0.9843623407393622,1.0,3/49,2.18%,POMGNT2;ELP3;SH3RF1
prerank,"Elsevier_Pathway_Collection__EDN, NRG, NRTN, and GDNF/RET Signaling in Hirschsprung Disease",0.6881858931430243,0.9292820083172277,0.6086956521739131,0.983875843541206,1.0,2/37,1.19%,CREB1;ERBB3
prerank,WikiPathway_2021_Human__AMP-activated protein kinase (AMPK) signaling WP1403,0.6847508096650704,0.929150317954477,0.5203252032520326,0.9835549883602371,1.0,4/63,1.10%,ACACA;PIK3CD;CAB39;PRKAA2
prerank,GO_Biological_Process_2021__negative regulation of microtubule depolymerization (GO:0007026),-0.645515447279002,-0.929033220688793,0.578125,1.0,1.0,2/21,2.12%,TTBK2;HDGFL3
prerank,Reactome_2022__Axon Guidance R-HSA-422475,0.517847418356681,0.9290082576576177,0.6728971962616822,0.9833158292937078,1.0,18/498,2.41%,CREB1;UPF2;DLG1;ACTR3;PTK2;ARHGEF7;PSMB9;ARHGAP39;CNTNAP1;SPTBN2;ITGA2;MAPK13;DPYSL2;COL9A3;GPRIN1;DPYSL3;COL9A2;COL4A5
prerank,GO_Biological_Process_2021__oxoacid metabolic process (GO:0043436),-0.6963970566407631,-0.9289918444930891,0.60431654676259,1.0,1.0,3/30,1.80%,TPST1;SULT1B1;HAO1
prerank,WikiPathway_2021_Human__T-Cell antigen Receptor (TCR) pathway during Staphylococcus aureus infection WP3863,0.6723949848821955,0.9286184778635317,0.45454545454545453,0.9835392915896505,1.0,3/60,2.00%,DLG1;CD4;NFATC2
prerank,WikiPathway_2021_Human__Glycerophospholipid Biosynthetic Pathway WP2533,0.6908959819751931,0.9284636852486572,0.5867768595041323,0.9832864541067096,1.0,3/30,2.35%,PIK3CD;GPAT4;GK
prerank,GO_Biological_Process_2021__B cell differentiation (GO:0030183),0.6961966150292339,0.9284235939805873,0.5419847328244275,0.9828551540935501,1.0,6/42,1.83%,PTPN2;FNIP1;MSH2;ITGA4;NFAM1;HDAC9
prerank,GO_Biological_Process_2021__regulation of G2/M transition of mitotic cell cycle (GO:0010389),0.5857349970267394,0.9283843129347815,0.5084745762711864,0.9824034204066869,1.0,5/145,2.15%,HAUS8;CEP164;HAUS2;PSMB9;TUBA1A
prerank,GO_Biological_Process_2021__regulation of protein tyrosine kinase activity (GO:0061097),0.7010858732036598,0.9281546880290813,0.6206896551724138,0.9822814071702843,1.0,3/38,1.33%,DLG3;ERBB3;THY1
prerank,Elsevier_Pathway_Collection__Adipokines and Cytokines in Insulin Resistance in Skeletal Muscles,0.6632774270766756,0.9280103611701886,0.5396825396825397,0.9820274225028365,1.0,2/51,0.35%,PPARA;ACACA
prerank,GO_Biological_Process_2021__extrinsic apoptotic signaling pathway (GO:0097191),0.6656379793942091,0.9276506195417451,0.5074626865671642,0.9821489405349522,1.0,4/71,1.87%,TNFRSF10A;SORT1;ERBB3;BOK
prerank,WikiPathway_2021_Human__DNA damage response (only ATM dependent) WP710,-0.636892340484932,-0.9274078896888994,0.6111111111111112,1.0,1.0,4/109,1.54%,AKT3;PIK3CB;SOD2;CCND2
prerank,Reactome_2022__SUMOylation Of DNA Damage Response And Repair Proteins R-HSA-3108214,0.7012593417889474,0.9272879488694841,0.5606060606060606,0.9822749635717852,1.0,4/75,1.31%,HERC2;SMC5;NUP210;CBX2
prerank,GO_Biological_Process_2021__negative regulation of cell cycle (GO:0045786),-0.6755429790054966,-0.9271601814264989,0.5037593984962406,1.0,1.0,3/75,1.69%,RB1;BMP4;GMNC
prerank,MSigDB_Oncogenic_Signatures__DCA UP.V1 UP,-0.6215700004364365,-0.9266784455681253,0.6015625,1.0,1.0,7/139,2.15%,KLHL3;ZNF117;CREB5;COLQ;CD27;GARNL3;PRRG4
prerank,Elsevier_Pathway_Collection__Proteins Involved in Inflammatory Bowel Diseases,0.6917180767948911,0.926632351027381,0.5725190839694656,0.9829978471813801,1.0,7/58,2.28%,PPARA;NOD2;ITGA4;CD4;PTGS2;NR1I2;HGF
prerank,Elsevier_Pathway_Collection__Proteins Involved in Multiple Sclerosis,0.6961143903603417,0.9265859824937309,0.5416666666666666,0.9825913767915438,1.0,2/47,1.82%,ITGA4;PTGS2
prerank,MSigDB_Hallmark_2020__Estrogen Response Early,-0.580313683933026,-0.9265087326151804,0.6131386861313869,1.0,1.0,10/199,2.41%,AMFR;MREG;PLAAT3;DEPTOR;INHBB;CD44;IL17RB;KLF4;AQP3;PRSS23
prerank,GO_Biological_Process_2021__glucose 6-phosphate metabolic process (GO:0051156),0.6439399098175909,0.9262828431290175,0.592,0.982622204800148,1.0,3/20,2.28%,RPIA;HK2;HKDC1
prerank,GO_Biological_Process_2021__lymphocyte chemotaxis (GO:0048247),0.6734135308812401,0.9262726161131879,0.5537190082644629,0.9821424143998444,1.0,3/37,1.90%,PIK3CD;CX3CL1;CCL14
prerank,Reactome_2022__RNA Polymerase II Transcribes snRNA Genes R-HSA-6807505,-0.690663499368836,-0.92614050582336,0.5396825396825397,1.0,1.0,3/73,2.37%,POU2F1;RPAP2;INTS7
prerank,Reactome_2022__Opioid Signaling R-HSA-111885,0.6433065408909572,0.9261341312912347,0.5565217391304348,0.9819309796488521,1.0,3/81,2.34%,CREB1;GNB5;GNG2
prerank,Reactome_2022__MAP Kinase Activation R-HSA-450294,0.6577683202278894,0.925974281418306,0.509090909090909,0.9816943743756678,1.0,3/62,0.90%,CREB1;IRAK2;NOD2
prerank,"WikiPathway_2021_Human__GPCRs, Other WP117",-0.6616766449262296,-0.9259676275111947,0.5373134328358209,1.0,1.0,5/63,2.27%,ALG6;GPR132;C5AR2;S1PR1;GPR17
prerank,MSigDB_Oncogenic_Signatures__ESC V6.5 UP LATE.V1 DN,-0.5894999179624821,-0.9257779431672175,0.5735294117647058,1.0,1.0,8/155,2.05%,RBM43;TLE4;BIRC6;RASGRP2;INHBB;GJB5;PCOLCE;KLF4
prerank,GO_Biological_Process_2021__phospholipid biosynthetic process (GO:0008654),-0.6735296425389727,-0.9257050471454705,0.5714285714285714,1.0,1.0,3/36,1.89%,AGK;AGPAT4;HDHD5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Dilated Cardiomyopathy,0.5834112422744033,0.9255345081784674,0.5615384615384615,0.9819332105723008,1.0,7/151,2.28%,CDH2;CREB1;PTK2;CDH1;TIMP3;TXNRD2;HGF
prerank,WikiPathway_2021_Human__Integrated breast cancer pathway WP1984,0.58948634519247,0.9253302637584456,0.5462184873949579,0.9818098216203132,1.0,9/151,1.94%,CREB1;RALGAPA1;MSH2;USP15;ATR;ANXA1;CDH1;FOSL1;FOSL2
prerank,Elsevier_Pathway_Collection__Ovulation Block,0.5836116559321869,0.9252352168677116,0.5454545454545454,0.9814653346002974,1.0,2/30,1.64%,CREB1;AMH
prerank,Elsevier_Pathway_Collection__Thyroid Dysfunction,-0.6987796414580879,-0.9250439685809501,0.6287878787878788,1.0,1.0,3/34,1.56%,RAP1A;RAPGEF3;ADCY3
prerank,GO_Biological_Process_2021__regulation of potassium ion transmembrane transporter activity (GO:1901016),0.6571666881997793,0.924949822856592,0.6134453781512605,0.9814782032266621,1.0,3/24,0.96%,DLG1;CAB39;WWP2
prerank,GO_Biological_Process_2021__regulation of Wnt signaling pathway (GO:0030111),0.6124987714225072,0.9248138804375852,0.5537190082644629,0.9812217174088048,1.0,4/105,1.26%,ITGA3;VGLL4;DEPDC1B;SALL1
prerank,Elsevier_Pathway_Collection__Plasmin Effects in Inflammation,0.644130847951875,0.9246269575779289,0.5772357723577236,0.981055228698436,1.0,5/65,2.27%,PLAUR;BCAR1;A2M;SERPINE1;FN1
prerank,GO_Biological_Process_2021__hexose biosynthetic process (GO:0019319),-0.6645868322227526,-0.9245238200502207,0.5793650793650794,1.0,1.0,1/39,0.22%,ALDOB
prerank,KEGG_2021_Human__Viral carcinogenesis,0.5677189201785001,0.9244978464487871,0.5826771653543307,0.9808015215762154,1.0,11/184,1.83%,TRAF3;HDAC8;PIK3CD;CREB1;DLG1;RBL1;YWHAQ;CDK6;GTF2E2;SYK;HDAC9
prerank,Reactome_2022__G-protein Activation R-HSA-202040,0.6433241674891266,0.9244539301370293,0.6,0.9803940725265649,1.0,2/20,2.34%,GNB5;GNG2
prerank,Reactome_2022__Complex I Biogenesis R-HSA-6799198,-0.6584263912618575,-0.9241057339289217,0.5952380952380952,1.0,1.0,2/51,0.83%,NDUFAF2;NDUFS4
prerank,GO_Biological_Process_2021__regulation of TORC1 signaling (GO:1903432),-0.6540459611689188,-0.9240742882564057,0.6036036036036037,1.0,1.0,2/34,1.27%,SIK3;GPR137B
prerank,GO_Biological_Process_2021__positive regulation of positive chemotaxis (GO:0050927),0.585695773469755,0.9238974516781711,0.5089285714285714,0.9808094929490392,1.0,1/17,1.43%,F7
prerank,GO_Biological_Process_2021__ERAD pathway (GO:0036503),-0.6590707292331593,-0.9238434713281276,0.5230769230769231,1.0,1.0,3/85,0.77%,FBXO27;AMFR;DNAJB14
prerank,KEGG_2021_Human__Propanoate metabolism,0.6596249673760297,0.923675595342436,0.5555555555555556,0.9806894787821047,1.0,2/34,0.71%,ACACA;ACSS3
prerank,GO_Biological_Process_2021__response to interferon-beta (GO:0035456),-0.6618964780765134,-0.9233468355383038,0.5775862068965517,1.0,1.0,1/24,0.48%,OAS1
prerank,KEGG_2021_Human__Adipocytokine signaling pathway,0.6920969731245571,0.9233304127988826,0.5491803278688525,0.980817448037138,1.0,3/64,2.22%,PPARA;PRKAA2;ACSL5
prerank,KEGG_2021_Human__Yersinia infection,0.6072668278487218,0.9233022671156396,0.5603448275862069,0.9803534769058072,1.0,11/133,2.27%,PIK3CD;ACTR3;PTK2;ARHGEF7;MEFV;ITGA4;CD4;BCAR1;MAPK13;NFATC2;FN1
prerank,Elsevier_Pathway_Collection__HTR1 -> IL6 Production,-0.6546656294756042,-0.9229906651614393,0.6397058823529411,1.0,1.0,2/26,1.21%,MAP2K6;RAP1A
prerank,TRRUST_Transcription_Factors_2019__SP3 mouse,0.7045388673697311,0.9229509196900709,0.5703125,0.9804058290357061,1.0,3/70,2.28%,ACACA;PTGS2;HGF
prerank,GO_Biological_Process_2021__female gonad development (GO:0008585),-0.5851192744449539,-0.9228341727237662,0.5245901639344263,1.0,1.0,1/17,1.49%,INHBB
prerank,GO_Biological_Process_2021__negative regulation of macroautophagy (GO:0016242),0.6466265858274743,0.9227934945802693,0.626984126984127,0.9801946056470388,1.0,2/26,2.01%,CLEC16A;QSOX1
prerank,GO_Biological_Process_2021__positive regulation of protein-containing complex assembly (GO:0031334),0.6334271912707842,0.9227048540875208,0.5454545454545454,0.9798507585022028,1.0,5/116,2.05%,FNIP2;FNIP1;ATR;SYK;LGALS3
prerank,GO_Biological_Process_2021__respiratory tube development (GO:0030323),0.6764584520960076,0.9226623475267524,0.5945945945945946,0.9794179843655181,1.0,5/28,2.37%,ITGA3;CCDC40;PROX1;RBP4;FGF1
prerank,TRRUST_Transcription_Factors_2019__MTA1 human,-0.6564357032574771,-0.9226263892827821,0.5984251968503937,1.0,1.0,2/24,1.03%,MTA3;BCAS3
prerank,Reactome_2022__Cellular Response To Chemical Stress R-HSA-9711123,-0.5827837912909539,-0.9225424758562653,0.6044776119402985,1.0,1.0,7/176,1.32%,GSTA1;COX16;AKT3;GLYAT;NCOA1;CREBBP;LIN9
prerank,Reactome_2022__Transcriptional Regulation Of Granulopoiesis R-HSA-9616222,0.6921873011072238,0.9224086576607107,0.5348837209302325,0.9793608823603565,1.0,3/49,2.22%,CREB1;TFDP2;GFI1
prerank,WikiPathway_2021_Human__Insulin Signaling WP481,-0.6014170702345605,-0.922115534760902,0.5905511811023622,1.0,1.0,11/158,2.39%,MAP2K6;PIK3CB;MAP2K5;MAPK6;TBC1D4;SGK3;LIPE;GRB10;MAPK4;SH2B2;MAP4K1
prerank,Elsevier_Pathway_Collection__Centriole Duplication and Separation,0.662048353328137,0.9218026984060842,0.5607476635514018,0.9798526781823745,1.0,1/33,0.46%,CEP164
prerank,Reactome_2022__Formation Of Fibrin Clot (Clotting Cascade) R-HSA-140877,-0.6472340040001108,-0.921679164135499,0.6220472440944882,1.0,1.0,3/37,1.96%,TFPI;PROS1;PROCR
prerank,Elsevier_Pathway_Collection__Donohue Syndrome Progression (Hypothesis),-0.6471199116076333,-0.9216434867629193,0.5853658536585366,1.0,1.0,3/35,1.97%,TBC1D4;STAT5A;SH2B2
prerank,GO_Biological_Process_2021__cartilage development (GO:0051216),-0.674791157242373,-0.9216345209201441,0.5590551181102362,1.0,1.0,3/48,1.76%,CREB3L2;BMP4;CD44
prerank,Elsevier_Pathway_Collection__ER Stress (Unfolded Protein Response),0.656778973312263,0.9215094208156238,0.5789473684210527,0.9798868399181048,1.0,2/31,1.00%,ERN1;CASP7
prerank,GO_Biological_Process_2021__sterol metabolic process (GO:0016125),-0.6665277713988654,-0.9214726050753043,0.5714285714285714,1.0,1.0,4/66,1.78%,CYP39A1;CYP4V2;ARV1;CYP1B1
prerank,GO_Biological_Process_2021__mitochondrion organization (GO:0007005),-0.5925721647642912,-0.9214514234298614,0.59375,1.0,1.0,6/172,0.76%,CHCHD3;AKT3;VPS13D;TOMM70;VPS13C;MTFR1
prerank,GO_Biological_Process_2021__regulation of neuronal synaptic plasticity (GO:0048168),0.6468182597106621,0.9214414794683201,0.5982905982905983,0.9794914796181715,1.0,3/27,1.99%,RAB3GAP1;MCTP1;APOE
prerank,Elsevier_Pathway_Collection__Prolactin Production,0.6881801129977017,0.9212855341925712,0.5327868852459017,0.9792632053719118,1.0,2/49,1.19%,CREB1;ERBB3
prerank,KEGG_2021_Human__Vascular smooth muscle contraction,-0.6120794967607804,-0.9211030041366306,0.5538461538461539,1.0,1.0,3/120,2.43%,ADCY3;PLCB4;IRAG1
prerank,GO_Biological_Process_2021__regulation of microtubule depolymerization (GO:0031114),-0.6455120508500773,-0.9210604335119598,0.6106870229007634,1.0,1.0,2/25,2.12%,TTBK2;HDGFL3
prerank,GO_Biological_Process_2021__positive regulation of developmental process (GO:0051094),-0.5954657967050437,-0.9210046401845833,0.6071428571428571,1.0,1.0,6/159,1.76%,CPEB3;NR2C2;SHH;BMP4;RAPGEF3;BASP1
prerank,GO_Biological_Process_2021__phosphatidylethanolamine metabolic process (GO:0046337),-0.654855265418737,-0.9207636237236793,0.6,1.0,1.0,1/30,1.19%,PLAAT3
prerank,WikiPathway_2021_Human__TGF-beta receptor signaling in skeletal dysplasias WP4816,-0.662836283333828,-0.9207248823591648,0.4881889763779528,1.0,1.0,4/58,2.15%,TGIF1;CREBBP;BMP4;ADAMTSL2
prerank,GO_Biological_Process_2021__negative regulation of peptidyl-threonine phosphorylation (GO:0010801),-0.5615468281963832,-0.9206460232041512,0.4881889763779528,1.0,1.0,1/16,1.00%,PARD3
prerank,Elsevier_Pathway_Collection__T-Cell Independent B-Cell Activation,0.6265735254467594,0.9205674301280083,0.5813953488372093,0.9801146371822889,1.0,4/54,2.06%,TRAF3;SYK;NFATC2;PIK3AP1
prerank,GO_Biological_Process_2021__apoptotic process (GO:0006915),0.5615559522191589,0.9205580707649312,0.6216216216216216,0.9796262411737902,1.0,9/217,2.19%,TNFRSF10A;TNFRSF21;CASP7;MELK;ERBB3;TNFRSF25;DLC1;BOK;HK2
prerank,GO_Biological_Process_2021__regulation of cell adhesion mediated by integrin (GO:0033628),0.6717236929047128,0.9205149222168832,0.5811965811965812,0.9791998972555943,1.0,3/33,2.07%,PTK2;SYK;SERPINE1
prerank,MSigDB_Oncogenic_Signatures__E2F1 UP.V1 DN,0.5847777315946654,0.920334708134356,0.5929203539823009,0.9790451527673809,1.0,6/179,2.24%,LCLAT1;UBE2H;ERBB3;ANXA1;PTGS2;LRIG1
prerank,GO_Biological_Process_2021__brain development (GO:0007420),-0.6169118606368855,-0.9202303302476972,0.5808823529411765,1.0,1.0,8/133,2.22%,NDUFS4;GRIN2B;SPEF2;MEIS1;PBX1;POU6F1;EML1;DSCAML1
prerank,Reactome_2022__Dectin-2 Family R-HSA-5621480,-0.6446685161149202,-0.920099080515897,0.5934959349593496,1.0,1.0,2/22,2.21%,MUC6;CLEC10A
prerank,GO_Biological_Process_2021__response to estrogen (GO:0043627),0.6434673862439041,0.9200696204950889,0.5798319327731093,0.9790636596716336,1.0,3/32,2.33%,TRIM24;CYP27B1;GSTM3
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Endometriosis,0.6485002495143107,0.9198191786426814,0.5648854961832062,0.9790275140852843,1.0,2/40,1.82%,CDH1;PTGS2
prerank,KEGG_2021_Human__Bacterial invasion of epithelial cells,0.6699178916265062,0.9197368192253458,0.5130434782608696,0.9787206499688508,1.0,9/75,2.27%,CD2AP;PIK3CD;ACTR3;PTK2;SEPTIN6;BCAR1;CDH1;SEPTIN9;FN1
prerank,KEGG_2021_Human__Type II diabetes mellitus,0.7106252711906366,0.9197362284584156,0.5905511811023622,0.9782276200979708,1.0,4/42,2.28%,PIK3CD;PKLR;HK2;HKDC1
prerank,MSigDB_Oncogenic_Signatures__STK33 NOMO DN,-0.5584360562105435,-0.9196956546402625,0.65625,1.0,1.0,11/235,2.39%,BIVM;NEO1;VPS13C;TNKS;NEDD4;TRIM58;NHLRC2;RRP15;ADCY3;MTHFD2L;MAP4K1
prerank,"GO_Biological_Process_2021__nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway (GO:0035872)",0.6577433090130081,0.9196551972858897,0.6220472440944882,0.9778782849370913,1.0,2/24,0.90%,IRAK2;NOD2
prerank,GO_Biological_Process_2021__transcription initiation from RNA polymerase II promoter (GO:0006367),0.590789633268475,0.9195668887754708,0.5725806451612904,0.9775679236372795,1.0,8/136,1.92%,TAF4;TBL1X;PPARA;GTF2E2;NOTCH3;HDAC9;TEAD4;NR1I2
prerank,GO_Biological_Process_2021__mitotic nuclear division (GO:0140014),0.6902771171291184,0.9195616711953996,0.5433070866141733,0.977087576910156,1.0,4/74,2.41%,NDC80;UBE2C;FLNA;KIF3B
prerank,GO_Biological_Process_2021__cytoskeleton organization (GO:0007010),0.6046967931266636,0.9194613453585151,0.556390977443609,0.9768006235304081,1.0,11/117,2.06%,PRPF40A;ABI2;SIPA1L3;THY1;CNTNAP1;PACSIN3;MICAL3;APOE;FMNL2;DPYSL2;SYNE3
prerank,Elsevier_Pathway_Collection__NTRK -> AP-1/CREB/ELK/SRF/MYC/SMAD3/TP53 Signaling,-0.6963441728025381,-0.9191937525939167,0.575,1.0,1.0,3/50,1.81%,PTK2B;MAP2K6;NTF3
prerank,Elsevier_Pathway_Collection__Smooth Muscle Cell Dysfunction in Pulmonary Hypertension,0.6513215670612925,0.9190104791397201,0.52,0.9771014656126727,1.0,4/86,1.54%,MRTFA;MAOA;NOTCH3;SLC6A4
prerank,Reactome_2022__Class A/1 (Rhodopsin-like Receptors) R-HSA-373076,-0.5552438790859046,-0.9188630851394551,0.6319444444444444,1.0,1.0,9/240,2.27%,CCL23;APP;GPR39;HRH2;GPR132;C5AR2;BDKRB2;S1PR1;GPR17
prerank,GO_Biological_Process_2021__positive regulation of protein localization to plasma membrane (GO:1903078),0.6938410735539295,0.9188114384691162,0.5423728813559322,0.9769803016633417,1.0,3/51,2.05%,ITGA3;DLG1;LGALS3
prerank,GO_Biological_Process_2021__regulation of autophagy (GO:0010506),0.5562334985285001,0.9187678231545157,0.627906976744186,0.9765714684951149,1.0,7/224,2.28%,ERN1;TLK2;PRKAA2;MEFV;BOK;OPTN;HGF
prerank,Reactome_2022__Nucleotide Excision Repair R-HSA-5696398,0.6139847775506698,0.9185987041487836,0.5413533834586466,0.9763759510661398,1.0,4/106,2.24%,SLC19A1;TCEA1;POLE4;LRIG1
prerank,GO_Biological_Process_2021__neuron projection morphogenesis (GO:0048812),-0.5986351836790961,-0.9185320300937544,0.541095890410959,1.0,1.0,6/133,2.22%,APP;PARD3;DTNBP1;NTF3;SLITRK3;DSCAML1
prerank,Reactome_2022__Transcriptional Regulation By MECP2 R-HSA-8986944,0.7284004306480917,0.9184386510429485,0.6166666666666667,0.9761896857960052,1.0,4/51,2.17%,TBL1X;CREB1;SLC6A4;GPRIN1
prerank,GO_Biological_Process_2021__negative regulation of axon extension (GO:0030517),-0.6442752552936725,-0.9184294913539516,0.6,1.0,1.0,2/31,2.25%,TRIM46;SEMA4D
prerank,GO_Biological_Process_2021__sensory organ development (GO:0007423),0.6588373324077668,0.9183624273413225,0.5462184873949579,0.9758293839685045,1.0,5/46,2.31%,SIPA1L3;SMCHD1;MAB21L2;RBP4;MYO7A
prerank,WikiPathway_2021_Human__RANKL/RANK signaling pathway WP2018,0.6669204307788299,0.9182438467565351,0.5245901639344263,0.9755553822707644,1.0,4/55,1.74%,TRAF3;PTK2;SYK;FHL2
prerank,Reactome_2022__Thromboxane Signaling Thru TP Receptor R-HSA-428930,0.6433222314854183,0.9181864057909149,0.6111111111111112,0.9751844601120917,1.0,2/22,2.34%,GNB5;GNG2
prerank,GO_Biological_Process_2021__negative regulation of protein depolymerization (GO:1901880),-0.6455128398131004,-0.918180180910902,0.6015037593984962,1.0,1.0,2/24,2.12%,TTBK2;HDGFL3
prerank,MSigDB_Oncogenic_Signatures__KRAS.600 UP.V1 UP,-0.5547139787719655,-0.9181706391161317,0.65625,1.0,1.0,11/233,2.45%,EXOC6B;ZEB1;DCBLD2;TFPI;ZNF528;KCNAB3;PELI2;DUSP4;FAM174B;MAP4K1;DNAJA4
prerank,WikiPathway_2021_Human__Autophagy WP4923,-0.6533556756325059,-0.9181212745458766,0.6268656716417911,1.0,1.0,2/30,1.34%,UVRAG;DEPTOR
prerank,GO_Biological_Process_2021__protein localization to nucleus (GO:0034504),-0.6219844133714227,-0.9177646987807051,0.55,1.0,1.0,3/103,2.09%,IPO11;BMP4;PML
prerank,GO_Biological_Process_2021__response to lipid (GO:0033993),0.6455620455680481,0.9176478462171247,0.5964912280701754,0.9756362736921591,1.0,6/105,2.12%,PPARA;STRN3;ANXA1;CYP27B1;CTSH;RBP4
prerank,GO_Biological_Process_2021__substrate adhesion-dependent cell spreading (GO:0034446),-0.6478027638832803,-0.9175553912702155,0.6,1.0,1.0,3/48,1.90%,PEAK1;NTN4;TEK
prerank,Elsevier_Pathway_Collection__Growth Factor Signaling in Pancreatic Neoplasms,0.6201250656447304,0.9174894059830161,0.5703703703703704,0.9754124603701926,1.0,3/69,2.28%,CREB1;ERBB3;HGF
prerank,GO_Biological_Process_2021__negative regulation of insulin receptor signaling pathway (GO:0046627),0.6609726888753542,0.9174829939283589,0.5811965811965812,0.9749293204480228,1.0,1/27,0.57%,PTPN2
prerank,Reactome_2022__Regulation Of Expression Of SLITs And ROBOs R-HSA-9010553,0.5759085794523695,0.9174777801050348,0.5806451612903226,0.9744511772778932,1.0,3/162,2.41%,UPF2;PSMB9;COL4A5
prerank,MSigDB_Oncogenic_Signatures__P53 DN.V2 UP,-0.5982376378877079,-0.9172811598939462,0.582089552238806,1.0,1.0,9/123,2.11%,PTK2B;C4BPA;CYP2C8;DPYS;PCDH1;HAO1;POU6F1;RORC;CD83
prerank,TRRUST_Transcription_Factors_2019__ATM human,-0.6636272977801969,-0.9170762897944934,0.6062992125984252,1.0,1.0,1/22,0.31%,TNFRSF10B
prerank,Reactome_2022__Activation Of BH3-only Proteins R-HSA-114452,0.6575872820524257,0.917064755194934,0.5826771653543307,0.9746747268802409,1.0,2/30,0.91%,YWHAQ;TFDP2
prerank,Elsevier_Pathway_Collection__Ovarian Cancer,0.5833929448296332,0.9169631651094992,0.544,0.974359448247638,1.0,6/128,2.28%,ARID1B;CREB1;LRP5;ERBB3;NOTCH3;HGF
prerank,GO_Biological_Process_2021__regulation of toll-like receptor 4 signaling pathway (GO:0034143),0.6662807048041179,0.9165330850386252,0.5915492957746479,0.9746548979168255,1.0,1/23,0.04%,LILRA2
prerank,GO_Biological_Process_2021__negative regulation of blood coagulation (GO:0030195),0.6636989617065878,0.9162762690663413,0.5859375,0.9746438726790505,1.0,5/39,2.07%,PLAUR;F7;A2M;APOE;SERPINE1
prerank,Elsevier_Pathway_Collection__Ras-GRF Regulation Signaling,-0.6767900557399721,-0.9161991672492724,0.5590551181102362,1.0,1.0,5/44,2.34%,RAP1A;RASGRP2;RAPGEF3;RASGRP3;VAV1
prerank,GO_Biological_Process_2021__positive regulation of interleukin-6 production (GO:0032755),0.6928629643699883,0.9160680014849601,0.5954198473282443,0.9745090981520547,1.0,5/70,2.16%,LILRA2;NOD2;SYK;MAPK13;CYBA
prerank,Reactome_2022__Interleukin-12 Family Signaling R-HSA-447115,-0.696456980647345,-0.9159084949068271,0.6,1.0,1.0,3/54,1.79%,RAP1B;GSTA2;IL12RB2
prerank,KEGG_2021_Human__HIF-1 signaling pathway,-0.6240297546754822,-0.9157523072468297,0.5572519083969466,1.0,1.0,5/104,1.90%,ALDOB;AKT3;PIK3CB;CREBBP;TEK
prerank,GO_Biological_Process_2021__positive regulation of protein localization to cell periphery (GO:1904377),0.693841036512028,0.9154197666668429,0.5677966101694916,0.9751841207164756,1.0,3/51,2.05%,ITGA3;DLG1;LGALS3
prerank,MSigDB_Oncogenic_Signatures__RB DN.V1 DN,-0.6139427905613917,-0.915296477606457,0.5658914728682171,1.0,1.0,5/110,2.26%,CREB3L2;RB1;BASP1;CD44;CD9
prerank,Reactome_2022__Synthesis Of PC R-HSA-1483191,-0.6597799171616818,-0.9152683607580698,0.6198347107438017,1.0,1.0,1/27,0.70%,ABHD3
prerank,KEGG_2021_Human__Inflammatory mediator regulation of TRP channels,-0.6322005329911289,-0.9151304285892651,0.625,1.0,1.0,5/89,2.01%,MAP2K6;PIK3CB;ADCY3;PLCB4;BDKRB2
prerank,"Elsevier_Pathway_Collection__Overt Hypothyroidism, Primary",-0.6987815274847379,-0.9151255345876791,0.648854961832061,1.0,1.0,3/31,1.56%,RAP1A;RAPGEF3;ADCY3
prerank,Reactome_2022__RORA Activates Gene Expression R-HSA-1368082,-0.5869647932247184,-0.9151169759273441,0.5238095238095238,1.0,1.0,3/18,1.32%,NCOA1;CREBBP;LIN9
prerank,GO_Biological_Process_2021__regulation of type I interferon production (GO:0032479),-0.6475034908215308,-0.9149822885896176,0.5772357723577236,1.0,1.0,3/87,1.93%,CREBBP;HERC5;LRRFIP1
prerank,GO_Biological_Process_2021__primary alcohol metabolic process (GO:0034308),-0.6469691171892465,-0.9149176571091107,0.6476190476190476,1.0,1.0,2/30,1.98%,CYP1B1;CYP1A2
prerank,GO_Biological_Process_2021__positive regulation of T cell activation (GO:0050870),0.6614008412229747,0.9145898519049925,0.49606299212598426,0.9763799891940477,1.0,5/70,2.29%,NOD2;THY1;ANXA1;SLC7A1;CD86
prerank,GO_Biological_Process_2021__mRNA 3'-end processing (GO:0031124),0.6599588223597619,0.9145270184482102,0.5130434782608696,0.9760198675150854,1.0,2/78,0.68%,ZNF473;TENT2
prerank,GO_Biological_Process_2021__positive regulation of phosphorylation (GO:0042327),0.5527699038850415,0.9145152203547401,0.6545454545454545,0.9755478212923243,1.0,11/238,2.37%,LMTK2;FNIP1;PLAUR;PTK2;PRKAA2;ERBB3;CD4;DRD4;AXIN2;HGF;FGF1
prerank,GO_Biological_Process_2021__ubiquinone biosynthetic process (GO:0006744),0.5830829896499385,0.9143756883119399,0.49635036496350365,0.9753478393706392,1.0,2/15,1.70%,COQ8A;FDXR
prerank,KEGG_2021_Human__Neurotrophin signaling pathway,-0.6266886643756576,-0.9140611832948418,0.5671641791044776,1.0,1.0,8/114,2.36%,RAP1B;AKT3;PIK3CB;MAP2K5;RAP1A;NTF3;SH2B2;IRAK3
prerank,GO_Biological_Process_2021__regulation of small GTPase mediated signal transduction (GO:0051056),0.603285916503934,0.914045228611546,0.5315315315315315,0.975486817686324,1.0,10/140,1.96%,CD2AP;DEPDC1B;RHOQ;ARHGEF7;ARHGAP12;ARHGAP39;PLEKHG5;ARHGEF18;DLC1;A2M
prerank,GO_Biological_Process_2021__positive regulation of interleukin-1 production (GO:0032732),0.6918318801636578,0.914024127445278,0.5564516129032258,0.9750493790310013,1.0,3/59,2.25%,LILRA2;NOD2;MNDA
prerank,GO_Biological_Process_2021__peptidyl-tyrosine dephosphorylation (GO:0035335),-0.6459277769070452,-0.9139093869955276,0.6412213740458015,1.0,1.0,3/34,2.09%,PTPRJ;DUSP4;PTPN18
prerank,TRRUST_Transcription_Factors_2019__NR2F2 mouse,0.5695058216627324,0.9131896361068521,0.49612403100775193,0.976156570090439,1.0,1/15,0.20%,PPARA
prerank,Reactome_2022__Negative Regulation Of MAPK Pathway R-HSA-5675221,0.6559657342909075,0.9131043957531528,0.6052631578947368,0.975835718489267,1.0,1/40,1.07%,KSR1
prerank,GO_Biological_Process_2021__chemical homeostasis (GO:0048878),-0.663233247503951,-0.9130729727745891,0.5130434782608696,1.0,1.0,7/63,2.45%,KLHL3;WNK3;TLCD4;THADA;TLCD2;SLC4A5;TM6SF2
prerank,KEGG_2021_Human__Spinocerebellar ataxia,-0.6232631289063505,-0.9130381490302056,0.5531914893617021,1.0,1.0,6/131,2.21%,AKT3;PIK3CB;ATXN10;GRIN2B;PLCB4;DAB1
prerank,Reactome_2022__NOD1/2 Signaling Pathway R-HSA-168638,0.6945873918446366,0.9129780796591439,0.6147540983606558,0.9756316133798347,1.0,3/32,1.98%,IRAK2;NOD2;MAPK13
prerank,GO_Biological_Process_2021__positive regulation of RNA metabolic process (GO:0051254),0.6859504286298276,0.9126623749539493,0.5932203389830508,0.9758059100900277,1.0,2/43,1.41%,ERN1;MYCN
prerank,WikiPathway_2021_Human__Toll-like Receptor Signaling related to MyD88 WP3858,0.664587838417668,0.9125612148133894,0.5847457627118644,0.9755326838458062,1.0,1/30,0.21%,TRAF3
prerank,GO_Biological_Process_2021__protein modification by small protein conjugation (GO:0032446),-0.5200780817830566,-0.91238592039604,0.6859504132231405,1.0,1.0,14/383,2.36%,KLHL3;SHPRH;AMFR;NSMCE2;TRIM44;WWP1;ZNF451;ATG10;BIRC6;NEDD4;TRIM58;HERC5;MOCS3;FBXO32
prerank,KEGG_2021_Human__Malaria,0.6915334663808348,0.9122204042696404,0.5905511811023622,0.9757202701514089,1.0,2/47,2.28%,ITGAL;HGF
prerank,GO_Biological_Process_2021__cellular response to lipid (GO:0071396),-0.5660073684476014,-0.9120949838667748,0.6689655172413793,1.0,1.0,8/198,2.39%,PTK2B;NR3C1;TFPI;ADCY3;TICAM2;RORC;CD274;MAP4K1
prerank,GO_Biological_Process_2021__macromolecule catabolic process (GO:0009057),-0.6556266786912365,-0.9120727540007935,0.6403508771929824,1.0,1.0,2/27,1.11%,UVRAG;NEDD4
prerank,Elsevier_Pathway_Collection__G1/S Phase Transition,0.6575862821634686,0.9120296966487803,0.6017699115044248,0.9755680224493885,1.0,2/33,0.91%,CDK6;TFDP2
prerank,Reactome_2022__Transcriptional Regulation By RUNX3 R-HSA-8878159,0.6285852082390363,0.9119519862949006,0.5041322314049587,0.9752260860600198,1.0,4/94,1.86%,PSMB9;ITGA4;ITGAL;TEAD4
prerank,Elsevier_Pathway_Collection__CXC Chemokine Receptor Signaling,-0.6319741424440122,-0.9117841506044075,0.5801526717557252,1.0,1.0,6/74,2.34%,PTK2B;PARD3;RAP1A;RASGRP2;STAT5A;VAV1
prerank,GO_Biological_Process_2021__phosphate-containing compound metabolic process (GO:0006796),-0.5759553874282962,-0.911740645920858,0.6402877697841727,1.0,1.0,9/197,2.42%,PAK2;ALDOB;PLPP1;PIK3CB;AGK;PLAAT3;DUSP4;PLCB4;SLC17A4
prerank,GO_Biological_Process_2021__regulation of cysteine-type endopeptidase activity (GO:2000116),0.6244408042338492,0.9114193590630651,0.584,0.975683653725373,1.0,2/23,1.20%,MEFV;PSMB9
prerank,Reactome_2022__SARS-CoV-2 Infection R-HSA-9694516,0.5402151271683344,0.9113341811096362,0.6949152542372882,0.9753486930643225,1.0,12/264,2.17%,TRAF3;TJP1;ST3GAL1;IRAK2;YWHAQ;NOD2;DAD1;NUP210;CRB3;MOGAT2;HAVCR1;ZDHHC9
prerank,WikiPathway_2021_Human__Vitamin B12 metabolism WP1533,0.6937288300944072,0.9111999829020861,0.5241935483870968,0.9751166488679772,1.0,4/47,2.07%,CBS;F7;APOE;SERPINE1
prerank,GO_Biological_Process_2021__negative regulation of protein polymerization (GO:0032272),0.6619723540569616,0.9111412145212855,0.5806451612903226,0.9747243482631367,1.0,1/27,0.47%,TBCD
prerank,GO_Biological_Process_2021__positive regulation of cell migration involved in sprouting angiogenesis (GO:0090050),0.5818129143995421,0.9109496733166416,0.5371900826446281,0.9746287441088856,1.0,3/17,1.83%,ANXA1;PTGS2;HDAC9
prerank,Reactome_2022__Netrin-1 Signaling R-HSA-373752,-0.6779806049451592,-0.9107879602471222,0.5590551181102362,1.0,1.0,5/47,2.22%,NEO1;NTN4;ABLIM3;SLIT3;DSCAML1
prerank,GO_Biological_Process_2021__regulation of transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0090092),0.6650493912127188,0.9105872907478133,0.575,0.9748071276141176,1.0,1/28,0.17%,ITGA3
prerank,Reactome_2022__Cell Junction Organization R-HSA-446728,0.661430417107067,0.9104954400134316,0.5833333333333334,0.9745223953244568,1.0,5/80,2.29%,CDH2;CRB3;FBLIM1;CDH15;FLNA
prerank,Elsevier_Pathway_Collection__Drugs Targets in Autistic Disoreder (Hypothesis),0.5846197154591725,0.9104232256509627,0.5343511450381679,0.974166758807598,1.0,2/17,1.54%,CREB1;SLC6A4
prerank,Reactome_2022__SUMOylation R-HSA-2990846,0.5703322735144082,0.9103821176523529,0.6287878787878788,0.9737936865025916,1.0,9/171,1.92%,RWDD3;PPARA;HERC2;SENP1;SMC5;MRTFA;NUP210;CBX2;NR1I2
prerank,Reactome_2022__Cell Surface Interactions At Vascular Wall R-HSA-202733,-0.6235290817718384,-0.9098593497409903,0.6062992125984252,1.0,1.0,13/122,2.10%,SLC7A9;TNFRSF10B;GLG1;PIK3CB;PROS1;SLC7A8;ITGAX;CD2;SDC3;CD44;TEK;PROCR;FCAMR
prerank,GO_Biological_Process_2021__myelination (GO:0042552),-0.6514614629884009,-0.9096515524714079,0.6412213740458015,1.0,1.0,4/46,1.54%,SBF2;PARD3;PMP22;MARVELD1
prerank,GO_Biological_Process_2021__regulation of cholesterol metabolic process (GO:0090181),0.6467845342305999,0.9096117090360077,0.6120689655172413,0.9747610702242588,1.0,2/21,1.99%,EPHX2;APOE
prerank,GO_Biological_Process_2021__positive regulation of dendritic spine development (GO:0060999),-0.6648966474629081,-0.9095851772745303,0.6186440677966102,1.0,1.0,1/21,0.18%,CPEB3
prerank,WikiPathway_2021_Human__EGF/EGFR signaling pathway WP437,-0.5846845984976342,-0.9094672877291299,0.5905511811023622,1.0,1.0,10/161,2.43%,PTK2B;MAP2K5;NEDD4;RAP1A;GRB10;STAT5A;MAPK4;VAV1;MAP4K1;FOSB
prerank,GO_Biological_Process_2021__extracellular matrix organization (GO:0030198),-0.5383406377869083,-0.9092336991907715,0.6666666666666666,1.0,1.0,18/275,2.39%,FLRT2;ADAMTS2;ITGA1;ADAM10;APP;ADAMTS5;ADAMTS9;ITGAX;CD44;CYP1B1;COLQ;MATN1;MMP2;COL4A4;ADAMTSL5;ADAMTSL2;COL26A1;COL7A1
prerank,GO_Biological_Process_2021__cellular response to light stimulus (GO:0071482),-0.6793172959692759,-0.9091976367502511,0.5581395348837209,1.0,1.0,4/60,2.08%,POLK;NEDD4;CREBBP;SMPD1
prerank,GO_Biological_Process_2021__regulation of fibroblast proliferation (GO:0048145),0.6916902708747037,0.9091812663200789,0.5528455284552846,0.9750544533647247,1.0,3/45,2.27%,CD300A;CDK6;FN1
prerank,GO_Biological_Process_2021__positive regulation of DNA recombination (GO:0045911),-0.6572795743770458,-0.9091796634543141,0.6014492753623188,1.0,1.0,1/28,0.95%,ARID2
prerank,Reactome_2022__Cellular Response To Heat Stress R-HSA-3371556,0.656212051607842,0.9090703375048786,0.5163934426229508,0.9747836232916438,1.0,2/97,1.05%,TNFRSF21;NUP210
prerank,GO_Biological_Process_2021__response to axon injury (GO:0048678),-0.5856185533480072,-0.9089838891412318,0.5163934426229508,1.0,1.0,1/18,1.44%,RTN4RL1
prerank,GO_Biological_Process_2021__positive regulation of gene expression (GO:0010628),0.5065469727454681,0.9088091150239007,0.7647058823529411,0.9748059784900025,1.0,14/444,2.37%,ERN1;YTHDF3;EPHX2;PIK3CD;TAF1B;PHF2;PLD1;NFAM1;MYCN;AMH;CTSH;FN1;HOXD3;FGF1
prerank,Elsevier_Pathway_Collection__T-Cells Differentiation Block in Psoriasis,-0.6473866632467911,-0.908613167633249,0.5966386554621849,1.0,1.0,2/37,1.94%,IL12RB2;RORC
prerank,GO_Biological_Process_2021__regulation of Rac protein signal transduction (GO:0035020),0.5380227594022461,0.9085596136309289,0.472,0.9748016958740885,1.0,2/16,1.76%,CADM4;STMN3
prerank,KEGG_2021_Human__Vasopressin-regulated water reabsorption,-0.712589732211162,-0.9085487957416901,0.6541353383458647,1.0,1.0,4/40,2.09%,CREB3L2;ADCY3;CREB5;AQP3
prerank,GO_Biological_Process_2021__prostaglandin metabolic process (GO:0006693),0.6485477024203743,0.9084920691292405,0.5916666666666667,0.9744648847918365,1.0,3/29,1.82%,PTGR1;CYP2S1;PTGS2
prerank,Reactome_2022__Diseases Of Metabolism R-HSA-5668914,-0.563113885445683,-0.908469025915739,0.6810344827586207,1.0,1.0,14/228,2.30%,ADAMTS2;ALDOB;MUC6;ALG6;ALG13;ADAMTS5;ADAMTS9;CYP4F22;SDC3;CYP1B1;GYG2;ADAMTSL5;ADAMTSL2;GALNT3
prerank,MSigDB_Oncogenic_Signatures__KRAS.DF.V1 DN,0.5916414168563646,0.908293809328151,0.5950413223140496,0.974403164013235,1.0,12/164,2.41%,TAF4;ERN1;COG5;IGFBP3;SF3A2;TUFT1;MOGAT2;PTGS2;HDAC9;LRRC61;TCFL5;COL4A5
prerank,TRRUST_Transcription_Factors_2019__USF2 human,0.6661182311905429,0.9080839914263669,0.5511811023622047,0.9742662042931934,1.0,4/46,1.82%,IGF2R;SLC19A1;PKLR;PTGS2
prerank,Elsevier_Pathway_Collection__Serotonin Receptors Signaling,-0.6546602916306176,-0.9079683097653212,0.6642335766423357,1.0,1.0,2/37,1.21%,MAP2K6;RAP1A
prerank,GO_Biological_Process_2021__regulation of neutrophil chemotaxis (GO:0090022),-0.6456274744039507,-0.9077355770197462,0.628099173553719,1.0,1.0,3/25,2.12%,C5AR2;DAPK2;THBS4
prerank,Reactome_2022__Transcriptional Activity Of SMAD2/SMAD3:SMAD4 Heterotrimer R-HSA-2173793,0.6936885639784182,0.9076139870154881,0.6086956521739131,0.974611946146264,1.0,3/49,2.07%,RBL1;TFDP2;SERPINE1
prerank,KEGG_2021_Human__Fat digestion and absorption,-0.6643949632818462,-0.9074708875149361,0.5517241379310345,1.0,1.0,1/35,0.23%,PLPP1
prerank,GO_Biological_Process_2021__glucose homeostasis (GO:0042593),0.6440067464847922,0.9074670077101541,0.5954198473282443,0.9744042179051918,1.0,6/75,2.28%,PTPN2;PRKAA2;RBP4;HK2;FOXA3;HKDC1
prerank,Reactome_2022__Laminin Interactions R-HSA-3000157,0.5844627518600318,0.9074458191440279,0.5476190476190477,0.973962282574958,1.0,2/22,1.56%,ITGA3;ITGA2
prerank,GO_Biological_Process_2021__positive regulation of heterotypic cell-cell adhesion (GO:0034116),0.5867351148565104,0.9072577796725907,0.5116279069767442,0.9738213885067107,1.0,1/15,1.33%,THY1
prerank,WikiPathway_2021_Human__Mitochondrial complex I assembly model OXPHOS system WP4324,-0.6584267773643925,-0.907100821320407,0.5895522388059702,1.0,1.0,2/50,0.83%,NDUFAF2;NDUFS4
prerank,GO_Biological_Process_2021__negative regulation of protein phosphorylation (GO:0001933),-0.581947125139821,-0.9070921978451041,0.6,1.0,1.0,9/146,2.25%,PAK2;PARD3;DTNBP1;RB1;DEPTOR;NIBAN1;NTF3;PRR5L;SEMA4D
prerank,GO_Biological_Process_2021__positive regulation of DNA binding (GO:0043388),0.6587786907515196,0.9069748905847872,0.5808823529411765,0.9738374900977291,1.0,2/33,0.80%,PLAUR;NIBAN2
prerank,Elsevier_Pathway_Collection__Ras Signaling,-0.6567771902450277,-0.9069457168492137,0.6209677419354839,1.0,1.0,1/33,1.00%,PARD3
prerank,GO_Biological_Process_2021__regulation of cytosolic calcium ion concentration (GO:0051480),0.5788705377684206,0.9068116947349639,0.6324786324786325,0.9736658814491743,1.0,2/132,2.11%,LPAR1;GPR35
prerank,Reactome_2022__Negative Regulators Of DDX58/IFIH1 Signaling R-HSA-936440,0.664587383511921,0.906710620385953,0.5984848484848485,0.9733840871237028,1.0,1/34,0.21%,TRAF3
prerank,GO_Biological_Process_2021__defense response to bacterium (GO:0042742),0.6086261108866939,0.9066915788195063,0.5511811023622047,0.9729613853763421,1.0,6/123,2.11%,DROSHA;NOD2;SYK;NAIP;SERPINE1;OPTN
prerank,Elsevier_Pathway_Collection__SPP1 Induced Survival of Myelin Specific T-Cells in Multiple Sclerosis,0.6242840533946086,0.9066470085030187,0.5967741935483871,0.9725721722355293,1.0,2/29,1.21%,CREB1;ITGA4
prerank,WikiPathway_2021_Human__Fas ligand pathway and stress induction of heat shock proteins WP314,-0.6552354869636526,-0.9066442089743358,0.6030534351145038,1.0,1.0,2/41,1.15%,PAK2;RB1
prerank,Elsevier_Pathway_Collection__Thyroid Stimulating Hormone (TSH) Resistance in Congenital Hypothyroidism,-0.6987815153952815,-0.9064474106592926,0.6592592592592592,1.0,1.0,3/31,1.56%,RAP1A;RAPGEF3;ADCY3
prerank,GO_Biological_Process_2021__cellular component assembly (GO:0022607),0.5607903066541211,0.906432823241909,0.6484375,0.9725161203590077,1.0,15/251,2.29%,YTHDF3;CD2AP;RHOQ;LIN7A;ESPN;CCDC40;BAIAP2L2;ANKS4B;HAS3;FBLIM1;QSOX1;SHROOM1;ACD;DPYSL3;FLNA
prerank,MSigDB_Oncogenic_Signatures__VEGF A UP.V1 DN,0.5691787018450662,0.9063971984911984,0.5916666666666667,0.9721098850076159,1.0,14/185,2.38%,PRPF40A;ZNF124;CDC45;CEBPZ;HIRA;CENPE;SLC4A7;NDC80;AASS;CENPA;ITGA2;PHKA1;KIF23;RRM2
prerank,Reactome_2022__TNFR2 Non-Canonical NF-kB Pathway R-HSA-5668541,0.6462625219361249,0.9063080021692862,0.5798319327731093,0.9718185349949905,1.0,4/97,2.05%,TRAF3;PSMB9;TNFRSF25;EDA2R
prerank,GO_Biological_Process_2021__protein destabilization (GO:0031648),-0.6545074427617166,-0.9060866723805077,0.6206896551724138,1.0,1.0,1/33,1.22%,CREBBP
prerank,GO_Biological_Process_2021__snRNA transcription by RNA polymerase II (GO:0042795),-0.6906662984724837,-0.9060792698023702,0.576,1.0,1.0,3/70,2.37%,POU2F1;RPAP2;INTS7
prerank,Elsevier_Pathway_Collection__Hemapoietic Stem Cell -> Lymphoid Multipotent Progenitor Surface Expression Markers,-0.7049081124615929,-0.9060642042729903,0.5857142857142857,1.0,1.0,4/45,2.25%,CD2;CD44;CD27;CD274
prerank,Elsevier_Pathway_Collection__KRAS Signaling,-0.6974315088942693,-0.9059366468802014,0.6083333333333333,1.0,1.0,2/35,1.69%,RASGRP2;RASSF5
prerank,GO_Biological_Process_2021__muscle organ development (GO:0007517),0.6479130505664867,0.9059276128758496,0.5982142857142857,0.9720930245285417,1.0,2/53,1.88%,TEAD4;SGCE
prerank,GO_Biological_Process_2021__snRNA transcription (GO:0009301),-0.690665368828362,-0.9058283248451333,0.584,1.0,1.0,3/71,2.37%,POU2F1;RPAP2;INTS7
prerank,GO_Biological_Process_2021__cellular divalent inorganic cation homeostasis (GO:0072503),0.5786301394627338,0.9057034622617932,0.6271186440677966,0.9720571126330302,1.0,3/97,2.14%,DRD4;CCL14;SLC30A10
prerank,GO_Biological_Process_2021__anaphase-promoting complex-dependent catabolic process (GO:0031145),0.6492803486498814,0.9056912614818741,0.56,0.9716123247851371,1.0,3/82,1.74%,PSMB9;FBXO31;UBE2C
prerank,Elsevier_Pathway_Collection__Macrophage M2-Related Phagocytosis,0.6937410015264015,0.9055953454584588,0.5905511811023622,0.9713173932126355,1.0,2/31,2.06%,SYK;PIK3AP1
prerank,GO_Biological_Process_2021__epithelial cell differentiation (GO:0030855),-0.6364143392360958,-0.9052581939228155,0.5579710144927537,1.0,1.0,5/94,1.76%,GSTA1;SULT1B1;GSTA2;BMP4;BASP1
prerank,MSigDB_Oncogenic_Signatures__ERB2 UP.V1 DN,0.5890584975767267,0.9051835204158203,0.6119402985074627,0.9716794429553988,1.0,14/177,2.24%,CEBPZ;HS2ST1;HIRA;CENPE;RALGAPA1;NCAPG;MSH2;ATR;DEPDC1;DLC1;FHL2;COL9A3;ZNF430;LRIG1
prerank,GO_Biological_Process_2021__Golgi organization (GO:0007030),-0.6199223383118128,-0.9050892701908086,0.6333333333333333,1.0,1.0,6/124,2.31%,ATL2;BCAS3;ZNF501;TICAM2;FAM174B;SYNE1
prerank,GO_Biological_Process_2021__cytoplasmic pattern recognition receptor signaling pathway (GO:0002753),0.6577422451404359,0.9050568979253283,0.6417910447761194,0.9714725757450732,1.0,2/27,0.90%,IRAK2;NOD2
prerank,GO_Biological_Process_2021__regulation of cell cycle (GO:0051726),-0.5416781131744163,-0.9047565837818431,0.6546762589928058,1.0,1.0,8/281,2.09%,MAP2K6;ADAM10;NEK7;RB1;LIN9;BMP4;GMNC;PML
prerank,Reactome_2022__Extracellular Matrix Organization R-HSA-1474244,-0.5427672227985049,-0.9047502089643625,0.7007874015748031,1.0,1.0,17/277,2.39%,ADAMTS2;ITGA1;ADAM10;NTN4;ADAMTS5;ADAMTS9;ITGAX;BMP4;SDC3;CD44;PCOLCE;MATN1;MMP2;COL4A4;LTBP4;COL26A1;COL7A1
prerank,Elsevier_Pathway_Collection__DNA Repair and Chromatin Remodeling Block in Pancreatic Neoplasms,0.6552008856101937,0.9046524777546746,0.6333333333333333,0.9717442358825986,1.0,2/33,1.15%,MSH2;BRIP1
prerank,Elsevier_Pathway_Collection__HIF1A as Master Regulator of Angiogenesis in Cancer,0.7293678091882763,0.9046472891465518,0.6272727272727273,0.9712787552894103,1.0,2/44,2.07%,PLAUR;SERPINE1
prerank,GO_Biological_Process_2021__phosphatidylcholine acyl-chain remodeling (GO:0036151),-0.6548571862083796,-0.9045173246523319,0.6434108527131783,1.0,1.0,1/26,1.19%,PLAAT3
prerank,MSigDB_Oncogenic_Signatures__RAF UP.V1 UP,0.5766668914703569,0.9044811190465702,0.6062992125984252,0.9711447226731954,1.0,14/181,2.37%,LRP5;ETV5;NDC80;TNFRSF21;HSD17B11;PSMB9;MAN1A1;FCHSD2;SGCE;OPTN;SLC2A6;COTL1;RNF144A;FGF1
prerank,Reactome_2022__Acyl Chain Remodelling Of PC R-HSA-1482788,-0.6548587161016287,-0.9044684079806229,0.6507936507936508,1.0,1.0,1/23,1.19%,PLAAT3
prerank,Elsevier_Pathway_Collection__CD19 -> JUN/ELK Signaling,0.5874618719412884,0.9043201731452674,0.5118110236220472,0.9709450924518767,1.0,1/22,1.26%,SYK
prerank,MSigDB_Oncogenic_Signatures__PTEN DN.V2 DN,0.6100180342568042,0.9042979299861051,0.6017699115044248,0.970517909720326,1.0,6/118,2.34%,ZNF124;MEGF8;BCOR;KRT23;MID1;TBX3
prerank,GO_Biological_Process_2021__dephosphorylation (GO:0016311),0.5897774815279659,0.9042792947839629,0.6220472440944882,0.9700780102887281,1.0,8/146,2.02%,PPM1H;EPHX2;PPP1R12A;CDC14B;PTPRH;PTPRM;DAPP1;PLPPR1
prerank,KEGG_2021_Human__Huntington disease,-0.5458429754410014,-0.9040417231637827,0.7121212121212122,1.0,1.0,9/274,2.04%,DNAH14;CREB3L2;NDUFS4;SOD2;GRIN2B;CREBBP;CREB5;PLCB4;DNAH10
prerank,GO_Biological_Process_2021__blood vessel morphogenesis (GO:0048514),0.6524187012083181,0.9040091762078755,0.559322033898305,0.9701460956791269,1.0,4/55,1.44%,CDH2;LRP5;SYK;PROX1
prerank,Elsevier_Pathway_Collection__HPV E5 Regulates EDNRA and EGFR Signaling Pathway in Keratinocytes,0.6182678960148308,0.9039772240500303,0.5564516129032258,0.9697264854148742,1.0,4/51,1.82%,CREB1;PTK2;CASP7;PTGS2
prerank,GO_Biological_Process_2021__DNA damage checkpoint signaling (GO:0000077),0.6552400322684498,0.9038814443033197,0.6220472440944882,0.969447162712668,1.0,3/32,1.15%,CDC5L;ATR;BRIP1
prerank,GO_Biological_Process_2021__negative regulation of cytoskeleton organization (GO:0051494),0.6645492811762711,0.9038342856154494,0.584,0.9690501457418499,1.0,1/29,0.22%,TJP1
prerank,Reactome_2022__G0 And Early G1 R-HSA-1538133,0.6575888396215182,0.9038119449217468,0.6302521008403361,0.9686251292119994,1.0,2/26,0.91%,RBL1;TFDP2
prerank,Reactome_2022__SARS-CoV-2 Activates/Modulates Innate And Adaptive Immune Responses R-HSA-9705671,0.6050053846264205,0.9038049812608713,0.5785123966942148,0.9681656066264422,1.0,4/105,1.05%,TRAF3;IRAK2;NOD2;NUP210
prerank,GO_Biological_Process_2021__protein K48-linked ubiquitination (GO:0070936),-0.6607353759268072,-0.9037858784980135,0.5416666666666666,1.0,1.0,3/57,0.61%,KLHL3;AMFR;TTC3
prerank,Reactome_2022__Activation Of BAD And Translocation To Mitochondria R-HSA-111447,-0.49534755684366405,-0.9037211925890803,0.410958904109589,1.0,1.0,1/15,0.47%,AKT3
prerank,Reactome_2022__Response To Elevated Platelet Cytosolic Ca2+ R-HSA-76005,-0.6013290263517745,-0.9036493445287928,0.5789473684210527,1.0,1.0,6/127,2.38%,A1BG;APP;NHLRC2;PROS1;CD9;HRG
prerank,GO_Biological_Process_2021__regulation of cell-substrate junction assembly (GO:0090109),0.6221729671844525,0.9036105388932892,0.5675675675675675,0.9680969956621762,1.0,2/21,1.43%,PTK2;CAMSAP3
prerank,Elsevier_Pathway_Collection__Th2-Cell Function in Systemic Lupus Erythematosus,0.6437973954476763,0.903136707386853,0.6198347107438017,0.968464513879825,1.0,3/50,2.29%,CD4;SYK;CD86
prerank,GO_Biological_Process_2021__regulation of glucose import (GO:0046324),0.65727660365601,0.9031103222061304,0.640625,0.9680340680690103,1.0,1/34,0.94%,RHOQ
prerank,KEGG_2021_Human__Platelet activation,-0.6138783610614479,-0.903091925708729,0.6014492753623188,1.0,1.0,8/121,2.05%,RAP1B;AKT3;PIK3CB;RAP1A;RASGRP2;ADCY3;PLCB4;PIK3R6
prerank,GO_Biological_Process_2021__microtubule polymerization or depolymerization (GO:0031109),-0.6426260404250973,-0.9030162721226378,0.624,1.0,1.0,2/26,2.41%,HDGFL3;TPPP2
prerank,GO_Biological_Process_2021__positive regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032436),-0.6550256205779711,-0.9029654342487291,0.5739130434782609,1.0,1.0,2/77,1.17%,RNF217;RNF180
prerank,Reactome_2022__BBSome-mediated Cargo-Targeting To Cilium R-HSA-5620922,0.665973121937725,0.9026797970353796,0.6260162601626016,0.9684099732917963,1.0,1/23,0.07%,SMOX
prerank,GO_Biological_Process_2021__negative regulation of biosynthetic process (GO:0009890),0.5786601865530743,0.9024318874171808,0.5378151260504201,0.9684284626577585,1.0,2/17,2.14%,PPARA;SLC30A10
prerank,GO_Biological_Process_2021__positive regulation of phospholipase C activity (GO:0010863),0.7271002777258647,0.9023676372954078,0.6837606837606838,0.9680944075943986,1.0,2/40,2.29%,LPAR1;CD86
prerank,TRRUST_Transcription_Factors_2019__PITX2 mouse,0.568698072420541,0.9022978273102497,0.5307692307692308,0.9677759011689362,1.0,1/17,0.28%,DEPDC1B
prerank,Reactome_2022__Cytochrome P450 - Arranged By Substrate Type R-HSA-211897,-0.6679755268746856,-0.9021197864803938,0.549618320610687,1.0,1.0,7/57,1.98%,CYP39A1;CYP2C8;NCOA1;CYP4V2;CYP4F22;CYP1B1;CYP1A2
prerank,GO_Biological_Process_2021__semaphorin-plexin signaling pathway (GO:0071526),0.643810016628831,0.9019077385201939,0.5873015873015873,0.9679968509796271,1.0,2/35,2.29%,SEMA3G;FLNA
prerank,GO_Biological_Process_2021__regulation of ERK1 and ERK2 cascade (GO:0070372),0.5411960668270064,0.901873936164425,0.6909090909090909,0.9675830907169435,1.0,11/222,2.27%,DLG1;PTPN2;NOD2;CD4;SYK;CX3CL1;TIMP3;CCL14;APOE;SLC30A10;FN1
prerank,Elsevier_Pathway_Collection__Dendritic Cell Dysfunction in Crohn's disease,0.6577366380737886,0.90186899520655,0.6453900709219859,0.9671262927637453,1.0,2/42,0.90%,TRAF3;NOD2
prerank,WikiPathway_2021_Human__ATM Signaling Network in Development and Disease  WP3878,0.6565428949762718,0.9017137874323085,0.6333333333333333,0.9669326070009894,1.0,2/44,1.02%,DCLRE1C;ATR
prerank,Reactome_2022__Platelet Degranulation R-HSA-114608,-0.6013327083505206,-0.9016686592765105,0.562962962962963,1.0,1.0,6/123,2.38%,A1BG;APP;NHLRC2;PROS1;CD9;HRG
prerank,TRRUST_Transcription_Factors_2019__SMAD4 human,-0.6428183901650361,-0.9016378196303494,0.6495726495726496,1.0,1.0,2/26,2.39%,FBXO32;COL7A1
prerank,KEGG_2021_Human__Longevity regulating pathway,-0.6193927353373692,-0.9015130634942091,0.6230769230769231,1.0,1.0,6/97,1.72%,CREB3L2;AKT3;PIK3CB;SOD2;ADCY3;CREB5
prerank,GO_Biological_Process_2021__positive regulation of interleukin-1 beta production (GO:0032731),0.6918363076053602,0.9014155496418297,0.5655737704918032,0.9670407084240441,1.0,3/54,2.25%,LILRA2;NOD2;MNDA
prerank,Elsevier_Pathway_Collection__Peutz-Jeghers Syndrome,0.6589650792863521,0.9013538463107402,0.5294117647058824,0.9666759206208326,1.0,2/52,0.78%,CREB1;CAB39
prerank,TRRUST_Transcription_Factors_2019__CTNNB1 mouse,0.6642120094487891,0.9012447421932358,0.5447154471544715,0.9664307078087718,1.0,5/45,2.34%,MYCN;CDH1;PTGS2;AXIN2;TBX3
prerank,MSigDB_Oncogenic_Signatures__STK33 SKM DN,0.533975935033236,0.9010256869230288,0.6068376068376068,0.9663265634912983,1.0,14/226,2.33%,LILRA2;PPM1H;EPHX2;SNTB1;FAM117B;CYP4F3;MCTP2;PADI2;KRT23;FBLIM1;UAP1L1;TEAD4;ELOVL6;SLC43A1
prerank,GO_Biological_Process_2021__regulation of long-term synaptic potentiation (GO:1900271),-0.6585873247385848,-0.9007828034790344,0.6062992125984252,1.0,1.0,1/28,0.81%,APP
prerank,Elsevier_Pathway_Collection__Insulin Resistance in Hepatocytes,0.6647396631585706,0.9006776157546408,0.5275590551181102,0.9665365319109732,1.0,1/47,0.20%,PPARA
prerank,TRRUST_Transcription_Factors_2019__HIF1A mouse,0.5794275005354425,0.9005663532385341,0.5348837209302325,0.9662614367653896,1.0,3/19,2.07%,TUFT1;PTGS2;SERPINE1
prerank,GO_Biological_Process_2021__positive regulation of JNK cascade (GO:0046330),0.6207780091776464,0.900234498354688,0.575,0.9663998382911103,1.0,7/72,2.23%,TRAF3;NOD2;EDA2R;SH3RF2;SH3RF1;MAPK8IP1;UNC5CL
prerank,GO_Biological_Process_2021__mitochondrial gene expression (GO:0140053),-0.6575827110227681,-0.900178805520579,0.6416666666666667,1.0,1.0,2/42,0.92%,MRPS28;GATB
prerank,Reactome_2022__Downstream Signaling Of Activated FGFR1 R-HSA-5654687,-0.6661653682876935,-0.9001351888526538,0.6290322580645161,1.0,1.0,1/25,0.06%,FLRT2
prerank,Reactome_2022__Ub-specific Processing Proteases R-HSA-5689880,-0.561835674553004,-0.8998133367004029,0.6120689655172413,1.0,1.0,3/167,0.97%,TOMM70;USP37;TNKS
prerank,GO_Biological_Process_2021__lung development (GO:0030324),0.6764547280046646,0.8997897424158949,0.6083333333333333,0.9667543542094913,1.0,5/32,2.37%,ITGA3;CCDC40;PROX1;RBP4;FGF1
prerank,MSigDB_Oncogenic_Signatures__KRAS.600.LUNG.BREAST UP.V1 UP,0.5453695764015004,0.8997665308864855,0.6752136752136753,0.966326089309376,1.0,13/226,2.36%,PLAUR;IGFBP3;ITGA2;KCNC1;PTGS2;HDAC9;A2M;COL9A3;RBP4;GFI1;FAM120C;TBX3;STX1A
prerank,WikiPathway_2021_Human__TYROBP causal network in microglia WP3945,-0.6619822744983233,-0.8996635698091705,0.5691056910569106,1.0,1.0,6/61,2.01%,CREB3L2;ITGAX;HLX;STAT5A;IL10RA;BIN2
prerank,Reactome_2022__Interleukin-12 Signaling R-HSA-9020591,-0.6964640111882628,-0.8995012056344222,0.6454545454545455,1.0,1.0,3/44,1.79%,RAP1B;GSTA2;IL12RB2
prerank,GO_Biological_Process_2021__negative regulation of cytokine production (GO:0001818),0.5737536797476844,0.8991908030824693,0.7196969696969697,0.9668876978853068,1.0,11/176,2.27%,PPARA;CD33;TNFRSF21;MEFV;CX3CL1;HOMER3;ANXA1;SIGIRR;HDAC9;ZFPM1;FN1
prerank,MSigDB_Oncogenic_Signatures__BMI1 DN.V1 UP,0.5808760548950221,0.8990706232104249,0.609375,0.9666584414889127,1.0,10/134,2.36%,ITGA3;LRP5;SLC19A1;CHST11;ITGA4;SEMA3G;TIMP3;LRIG1;SLC2A6;STX1A
prerank,Reactome_2022__KEAP1-NFE2L2 Pathway R-HSA-9755511,-0.6194674769053624,-0.8990140346359354,0.6044776119402985,1.0,1.0,3/96,1.22%,GSTA1;AKT3;CREBBP
prerank,GO_Biological_Process_2021__post-translational protein modification (GO:0043687),0.5185535547332314,0.8989983991696371,0.7368421052631579,0.9663128559651665,1.0,11/330,2.39%,CDH2;LMO7;ASB3;IGFBP3;PSMB9;CKAP4;FBXO31;APOE;QSOX1;FN1;MELTF
prerank,MSigDB_Oncogenic_Signatures__ATF2 UP.V1 DN,-0.5851052749705613,-0.8988689953030871,0.6640625,1.0,1.0,10/166,2.39%,REV3L;AADAC;SOD2;DENND4C;PELI2;BHMT;SDC3;CYP1B1;SLIT3;SLC12A8
prerank,KEGG_2021_Human__Non-small cell lung cancer,-0.6497900515079436,-0.898685867507112,0.5373134328358209,1.0,1.0,6/71,1.71%,POLK;AKT3;PIK3CB;RB1;RASSF5;STAT5A
prerank,Elsevier_Pathway_Collection__Exocytosis: Vesicle Tethering,-0.6593562457063475,-0.8985680149498687,0.6209677419354839,1.0,1.0,2/32,0.74%,EXOC2;MYRIP
prerank,Elsevier_Pathway_Collection__anti-Inflammatory Function of Macrophage M2 Lineage,-0.6469455716434193,-0.898536029172657,0.6492537313432836,1.0,1.0,3/61,1.98%,NR3C1;CD163;IL10RA
prerank,Elsevier_Pathway_Collection__Growth Factor Signaling in Neuroblastoma,-0.6486889385166977,-0.8983228599751667,0.592,1.0,1.0,2/46,1.81%,MAP2K6;NTF3
prerank,GO_Biological_Process_2021__L-amino acid transport (GO:0015807),-0.6738463865129607,-0.8982652566899035,0.6299212598425197,1.0,1.0,3/24,1.38%,SLC7A9;SLC36A4;SLC7A8
prerank,GO_Biological_Process_2021__regulation of cell migration involved in sprouting angiogenesis (GO:0090049),-0.6463537453117697,-0.8981941410171184,0.6376811594202898,1.0,1.0,4/31,2.05%,AKT3;MAP2K5;CARD10;KLF4
prerank,Elsevier_Pathway_Collection__Hypoxia Inhibits mTOR Signaling,0.658934649775144,0.8981360186626273,0.6428571428571429,0.9673396356555355,1.0,1/25,0.78%,CAB39
prerank,TRRUST_Transcription_Factors_2019__MYOD1 mouse,-0.6923876168696452,-0.8980690560771273,0.6277372262773723,1.0,1.0,3/40,2.20%,RB1;CREBBP;CDO1
prerank,KEGG_2021_Human__Progesterone-mediated oocyte maturation,-0.6366724561951751,-0.8979753558216992,0.6746031746031746,1.0,1.0,4/90,1.56%,CPEB3;AKT3;PIK3CB;ADCY3
prerank,GO_Biological_Process_2021__protein homooligomerization (GO:0051260),0.6161396781012509,0.8978915125329655,0.6044776119402985,0.9673304299273936,1.0,5/113,2.03%,MICU1;ACACA;GLS;HPRT1;TRPV1
prerank,GO_Biological_Process_2021__regulation of NMDA receptor activity (GO:2000310),-0.6177458473154436,-0.8977847079708166,0.5942028985507246,1.0,1.0,4/28,1.88%,PTK2B;APP;GRIN2B;DLG2
prerank,GO_Biological_Process_2021__regulation of insulin receptor signaling pathway (GO:0046626),0.6609683081212728,0.8977675408784799,0.5967741935483871,0.9670755384193562,1.0,1/43,0.57%,PTPN2
prerank,Reactome_2022__Retrograde Transport At Trans-Golgi-Network R-HSA-6811440,0.6630467275320981,0.8976896170958024,0.5476190476190477,0.9667648825441835,1.0,2/48,0.37%,COG5;IGF2R
prerank,GO_Biological_Process_2021__cellular defense response (GO:0006968),-0.6601992061724083,-0.89754700283203,0.6422764227642277,1.0,1.0,2/44,0.66%,PTK2B;ZNF148
prerank,Reactome_2022__Anti-inflammatory Response Favoring Leishmania Infection R-HSA-9662851,-0.5748651367116004,-0.8975325248893119,0.6503496503496503,1.0,1.0,5/131,1.79%,GGT5;GPR39;HRH2;HCK;CD163
prerank,Reactome_2022__Tight Junction Interactions R-HSA-420029,-0.6485493047153718,-0.897501883206068,0.6538461538461539,1.0,1.0,2/27,1.82%,PARD3;PARD6G
prerank,MSigDB_Oncogenic_Signatures__BCAT GDS748 UP,0.6439966793814363,0.8973305747805168,0.6343283582089553,0.9669562084430301,1.0,2/41,2.27%,ASRGL1;COTL1
prerank,Reactome_2022__Potential Therapeutics For SARS R-HSA-9679191,-0.6433741820231853,-0.8972723058705353,0.6229508196721312,1.0,1.0,4/92,2.34%,NR3C1;MTA3;S1PR1;VAV1
prerank,WikiPathway_2021_Human__MET in type 1 papillary renal cell carcinoma WP4205,-0.6547669225888505,-0.8972574619986549,0.6307692307692307,1.0,1.0,5/57,1.21%,PAK2;RAP1B;AKT3;PIK3CB;RAP1A
prerank,KEGG_2021_Human__Phagosome,0.587250242802173,0.8968871188609133,0.627906976744186,0.9673109121467436,1.0,6/143,2.16%,RAB7A;ITGA2;LAMP2;ITGB5;TUBA1A;CYBA
prerank,Elsevier_Pathway_Collection__Genes with Mutations in Cancer-Associated Evading of Growth Suppressors,0.6470722442484294,0.8968518421782069,0.6190476190476191,0.9668930352751125,1.0,4/47,1.97%,TRAF3;CDH1;TEAD4;AXIN2
prerank,GO_Biological_Process_2021__negative regulation of cell junction assembly (GO:1901889),-0.6563962860529389,-0.8967970524520498,0.6194029850746269,1.0,1.0,1/25,1.03%,BCAS3
prerank,GO_Biological_Process_2021__negative regulation of cellular response to insulin stimulus (GO:1900077),0.6609723928841518,0.8967816290240661,0.6173913043478261,0.9665508103807988,1.0,1/28,0.57%,PTPN2
prerank,MSigDB_Hallmark_2020__TGF-beta Signaling,0.6460651478922079,0.8966149645610595,0.6065573770491803,0.9664431572639972,1.0,3/54,2.07%,TJP1;CDH1;SERPINE1
prerank,TRRUST_Transcription_Factors_2019__TRP53 mouse,-0.56465391603556,-0.8964996635084566,0.6371681415929203,1.0,1.0,8/145,2.09%,TNFRSF10B;NR3C1;POLK;SOD2;DUSP4;MMP2;KLF4;PML
prerank,Reactome_2022__Processing Of DNA Double-Strand Break Ends R-HSA-5693607,0.6551821477670468,0.8964423048503165,0.6101694915254238,0.9663184230312077,1.0,2/73,1.15%,HERC2;BRIP1
prerank,MSigDB_Oncogenic_Signatures__JAK2 DN.V1 UP,-0.5923285766695205,-0.8964210251961983,0.6538461538461539,1.0,1.0,6/130,2.32%,ZEB1;IMPG2;SHH;NEK11;CYP1B1;ZFHX4
prerank,Reactome_2022__NR1H3 And NR1H2 Regulate Gene Expression Linked To Cholesterol Transport And Efflux R-HSA-9029569,0.5801060041430852,0.8963848804645059,0.5826086956521739,0.9659576404020336,1.0,2/36,1.99%,TBL1X;APOE
prerank,MSigDB_Oncogenic_Signatures__IL21 UP.V1 UP,-0.5684336051831157,-0.8963463840320542,0.6666666666666666,1.0,1.0,6/153,2.43%,ABCA6;SLCO1A2;VDR;PYGM;SLC12A8;FOSB
prerank,Reactome_2022__Neuronal System R-HSA-112316,0.5133439190058884,0.8962986166546766,0.7619047619047619,0.9656594349903608,1.0,16/337,2.36%,CREB1;DLG1;LIN7A;ARHGEF7;PRKAA2;MAOA;KCNJ10;HOMER3;SLC6A4;KCNC1;GNB5;SLC38A1;PPFIA4;GPRIN1;GNG2;STX1A
prerank,WikiPathway_2021_Human__16p11.2 proximal deletion syndrome WP4949,0.6494821263352243,0.8960342606585475,0.6307692307692307,0.9656510796028751,1.0,5/70,1.73%,HIRA;QPRT;IGFBP3;SEZ6L2;ASPHD1
prerank,GO_Biological_Process_2021__nervous system development (GO:0007399),-0.511523734749138,-0.8958656251883587,0.7867647058823529,1.0,1.0,18/393,2.22%,WDPCP;NR2C2;MBD5;BTD;ATXN10;WWP1;LDB2;PMP22;SHH;FEZ1;DCHS1;ADGRA2;NRG1;PAX8;PCDH1;NTF3;SMPD1;DSCAML1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Myocardial Ischemia,0.5425769666286462,0.8958330553921379,0.6796875,0.965520529596833,1.0,12/236,2.37%,PPARA;EPHX2;PTK2;ANXA1;PTGS2;APOE;TRPV1;SERPINE1;CYBA;HGF;STX1A;FGF1
prerank,GO_Biological_Process_2021__central nervous system neuron differentiation (GO:0021953),0.6086503855559108,0.8957597240218447,0.5867768595041323,0.9652058161861905,1.0,2/29,1.64%,PROX1;ZC4H2
prerank,GO_Biological_Process_2021__phosphorylation (GO:0016310),-0.520699587742147,-0.8957578835773398,0.765625,1.0,1.0,26/390,2.44%,VRK2;PTK2B;PAK2;CDK19;PEAK1;SIK3;CDC42BPA;ADAM10;TESK2;AKT3;PIK3CB;TEC;MAPK6;NEK7;APP;WNK3;AGK;BIRC6;SGK3;LIPE;HCK;NEK11;DAPK2;IRAK3;MAP4K1;ZAP70
prerank,GO_Biological_Process_2021__B cell activation (GO:0042113),0.6647713373770434,0.8956723387346037,0.5963302752293578,0.9648699841748432,1.0,7/66,2.29%,PIK3CD;PTPN2;MSH2;ITGA4;NFAM1;HDAC9;CD86
prerank,GO_Biological_Process_2021__regulation of plasma membrane bounded cell projection organization (GO:0120035),0.643549761127323,0.8956197391364611,0.6384615384615384,0.9645002187010198,1.0,3/26,2.32%,BRSK1;ULK4;FRMD7
prerank,Reactome_2022__Ras Activation Upon Ca2+ Influx Thru NMDA Receptor R-HSA-442982,0.578350739325326,0.8955028625483549,0.5344827586206896,0.9642484955662427,1.0,2/19,2.17%,DLG1;GPRIN1
prerank,KEGG_2021_Human__Phenylalanine metabolism,-0.523808731020618,-0.8948359858790886,0.44696969696969696,1.0,1.0,2/15,2.17%,GLYAT;MAOB
prerank,GO_Biological_Process_2021__heart development (GO:0007507),0.5862828122216001,0.8946753589648283,0.6307692307692307,0.965248211810625,1.0,10/146,2.27%,MEGF8;BCOR;PTK2;ERBB3;SALL1;DLC1;HDAC9;ZFPM1;RBP4;FN1
prerank,GO_Biological_Process_2021__positive regulation of mitotic nuclear division (GO:0045840),-0.6552404941848247,-0.8946500416397581,0.6173913043478261,1.0,1.0,2/30,1.15%,NSMCE2;RB1
prerank,WikiPathway_2021_Human__Fatty Acid Biosynthesis WP357,0.6444763399546096,0.8946104397440624,0.6134453781512605,0.9649108609159813,1.0,2/22,2.22%,ACACA;ACSL5
prerank,GO_Biological_Process_2021__regulation of response to cytokine stimulus (GO:0060759),-0.5796179773247703,-0.8943793999396746,0.562962962962963,1.0,1.0,2/21,2.05%,MAP2K5;KLF4
prerank,Elsevier_Pathway_Collection__Th17-Cell Differentiation in Asthma,-0.6424800434578131,-0.8942730819944991,0.6287878787878788,1.0,1.0,5/59,2.44%,GRAP2;IL12RB2;RORC;IL21R;ZAP70
prerank,Elsevier_Pathway_Collection__Acute Myeloid Leukemia,-0.6603887126164829,-0.8942515578867828,0.546875,1.0,1.0,5/81,2.40%,CREBBP;MEIS1;STAT5A;PML;SPI1
prerank,GO_Biological_Process_2021__negative regulation of protein serine/threonine kinase activity (GO:0071901),-0.6318190359263597,-0.8942118175588396,0.632,1.0,1.0,6/75,2.36%,PIK3CB;PTPRJ;RB1;BMP4;SMPD1;IRAK3
prerank,GO_Biological_Process_2021__acute inflammatory response (GO:0002526),-0.6599346700775203,-0.8941870057523897,0.5985401459854015,1.0,1.0,1/25,0.68%,VNN1
prerank,Elsevier_Pathway_Collection__Oncogene Induced Cellular Senescence,0.6565421055085006,0.8940276399300612,0.5968992248062015,0.9654434958138032,1.0,2/46,1.02%,CDK6;ATR
prerank,Reactome_2022__PD-1 Signaling R-HSA-389948,0.5877716517481727,0.8939393723384575,0.5307692307692308,0.9651747168874608,1.0,1/18,1.23%,CD4
prerank,GO_Biological_Process_2021__positive regulation of response to external stimulus (GO:0032103),0.5785674679942426,0.8936362235567611,0.6065573770491803,0.9652861768340071,1.0,6/128,2.16%,USP15;CX3CL1;MAPK13;SERPINE1;OPTN;CYBA
prerank,WikiPathway_2021_Human__Striated Muscle Contraction Pathway WP383,-0.6620479109576548,-0.8933181721922321,0.6484375,1.0,1.0,1/33,0.47%,MYOM1
prerank,Elsevier_Pathway_Collection__T-Cell Cytotoxic Mediated Cell Death,0.6334309255540078,0.8932841102228789,0.6065573770491803,0.965403932106022,1.0,3/47,1.37%,TNFRSF10A;CASP7;ITGAL
prerank,Elsevier_Pathway_Collection__Eosinophil Survival by Cytokine Signaling,-0.649636191416513,-0.8930106848163184,0.6260162601626016,1.0,1.0,2/68,1.71%,CREBBP;STAT5A
prerank,KEGG_2021_Human__Base excision repair,0.6581623032208859,0.893009347299406,0.6356589147286822,0.9654426652424825,1.0,1/33,0.85%,POLE4
prerank,Elsevier_Pathway_Collection__Lipoxin A4/FPR2-Related Neutrophil Depression,0.6577379617304735,0.8929964027678535,0.6031746031746031,0.9650102557719309,1.0,1/36,0.90%,PLD1
prerank,GO_Biological_Process_2021__BMP signaling pathway (GO:0030509),0.6651012411556785,0.8929714253113307,0.5317460317460317,0.9646038246419488,1.0,5/62,1.69%,MEGF8;USP15;CHRD;AMH;SMAD9
prerank,KEGG_2021_Human__MicroRNAs in cancer,0.5656149094774741,0.8929461521021506,0.6190476190476191,0.964197778754744,1.0,10/159,2.16%,PIK3CD;CDK6;ERBB3;NOTCH3;IGF2BP1;GLS;SLC7A1;PTGS2;TIMP3;KIF23
prerank,GO_Biological_Process_2021__transcription elongation from RNA polymerase II promoter (GO:0006368),-0.6541071839777378,-0.8928737648681775,0.6102941176470589,1.0,1.0,2/65,1.26%,NELFA;MLLT1
prerank,GO_Biological_Process_2021__mitotic metaphase plate congression (GO:0007080),0.6588881441617037,0.8927581833593496,0.6183206106870229,0.9640816168593596,1.0,2/51,0.78%,CENPE;NDC80
prerank,"GO_Biological_Process_2021__DNA-templated transcription, elongation (GO:0006354)",-0.654106155979696,-0.8926333191394009,0.6323529411764706,1.0,1.0,2/67,1.26%,NELFA;MLLT1
prerank,GO_Biological_Process_2021__negative regulation of DNA-binding transcription factor activity (GO:0043433),0.5814930680809777,0.892631918595101,0.6071428571428571,0.963825139181083,1.0,9/135,2.29%,RWDD3;TRAF3;PRMT2;IRAK2;WWP2;PROX1;SIGIRR;GFI1;FLNA
prerank,Elsevier_Pathway_Collection__Proteins Involved in Myocarditis,0.5529645594162304,0.8921885929063782,0.68,0.9641920146086199,1.0,8/182,2.29%,PPARA;CD4;IL1RN;SMAD9;PTGS2;SERPINE1;HGF;CD86
prerank,MSigDB_Oncogenic_Signatures__KRAS.LUNG UP.V1 UP,0.6017655645501566,0.8921849804052928,0.5923076923076923,0.9637380418605125,1.0,8/114,2.34%,ZNF749;ASGR2;CD48;SLC6A4;ITGA2;RBP4;LRIG1;TBX3
prerank,WikiPathway_2021_Human__RAC1/PAK1/p38/MMP2 Pathway WP3303,0.7047353124548491,0.8921281793415711,0.5754716981132075,0.9633907306731598,1.0,5/67,2.27%,MSH2;PTK2;CASP7;MAPK13;FN1
prerank,GO_Biological_Process_2021__negative regulation of mitotic cell cycle phase transition (GO:1901991),0.6214957227101716,0.892006686076357,0.5798319327731093,0.9631732898799868,1.0,5/89,1.20%,PRMT2;DLG1;RBL1;CDK6;PSMB9
prerank,WikiPathway_2021_Human__Neurodegeneration with brain iron accumulation (NBIA) subtypes pathway WP4577,-0.6533486049568025,-0.8918611324731386,0.6666666666666666,1.0,1.0,2/43,1.34%,ATG10;DEPTOR
prerank,GO_Biological_Process_2021__protein-containing complex disassembly (GO:0032984),-0.6579618330926748,-0.8917923521381954,0.625,1.0,1.0,1/54,0.88%,UVRAG
prerank,GO_Biological_Process_2021__cardiac epithelial to mesenchymal transition (GO:0060317),-0.5850407827724543,-0.8917743879615577,0.5537190082644629,1.0,1.0,1/19,1.50%,BMP4
prerank,WikiPathway_2021_Human__RAS and bradykinin pathways in COVID-19 WP4969,-0.6448960579976886,-0.8914779826239182,0.6410256410256411,1.0,1.0,2/25,2.19%,BDKRB2;VDR
prerank,Elsevier_Pathway_Collection__Primary Mediastinal B-cell Lymphoma (PMBL) Subtype,-0.6440086664842406,-0.8912541383811633,0.6349206349206349,1.0,1.0,2/28,2.27%,CD274;CIITA
prerank,WikiPathway_2021_Human__Glioblastoma signaling pathways WP2261,-0.6237017839970695,-0.8911249379413556,0.5748031496062992,1.0,1.0,6/81,1.54%,MAP2K6;AKT3;PIK3CB;MAP2K5;RB1;CCND2
prerank,GO_Biological_Process_2021__positive regulation of signal transduction (GO:0009967),0.5479264541746265,0.8910014679967428,0.6909090909090909,0.9646329387034784,1.0,11/239,2.37%,RWDD3;ERN1;DEPDC1B;ING5;TTC23;NOD2;SALL1;F7;CYP27B1;FLNA;FGF1
prerank,GO_Biological_Process_2021__positive regulation of cellular catabolic process (GO:0031331),0.5901366361433732,0.8909701767155619,0.6198347107438017,0.964217804585625,1.0,7/135,2.11%,VGLL4;PPARA;PRKAA2;MEFV;PACSIN3;APOE;OPTN
prerank,GO_Biological_Process_2021__ribonucleoside bisphosphate metabolic process (GO:0033875),-0.6544324122463776,-0.8909469569353256,0.6220472440944882,1.0,1.0,2/31,1.23%,GLYAT;ACSM2B
prerank,GO_Biological_Process_2021__purine nucleoside bisphosphate metabolic process (GO:0034032),-0.6544324122463776,-0.8909469569353256,0.6220472440944882,1.0,1.0,2/31,1.23%,GLYAT;ACSM2B
prerank,TRRUST_Transcription_Factors_2019__SOX2 mouse,-0.6043128122065513,-0.8907917670600541,0.5789473684210527,1.0,1.0,2/18,2.08%,SHH;GLI3
prerank,Reactome_2022__Signaling By ALK R-HSA-201556,-0.6442420506733593,-0.8906819230208285,0.632,1.0,1.0,2/26,2.25%,PIK3CB;CD274
prerank,GO_Biological_Process_2021__cholesterol transport (GO:0030301),0.6467594732518158,0.8905979297929776,0.5877862595419847,0.9644477352632754,1.0,2/51,1.99%,SOAT2;APOE
prerank,GO_Biological_Process_2021__exogenous drug catabolic process (GO:0042738),-0.5803102017342683,-0.8905141624291155,0.5447154471544715,1.0,1.0,2/21,1.98%,CYP2C8;CYP1A2
prerank,KEGG_2021_Human__Type I diabetes mellitus,0.6437695198756421,0.890478449638092,0.6299212598425197,0.9642280865141932,1.0,2/37,2.29%,CPE;CD86
prerank,Reactome_2022__Retinoid Metabolism And Transport R-HSA-975634,0.6454588253905875,0.8902363052776902,0.6119402985074627,0.9641929661394946,1.0,2/41,2.12%,APOE;RBP4
prerank,Elsevier_Pathway_Collection__Golgi to Endosome Transport,0.6630082833628417,0.8901247155486639,0.6115702479338843,0.9639948208389146,1.0,1/41,0.37%,IGF2R
prerank,GO_Biological_Process_2021__neural crest cell differentiation (GO:0014033),0.5703899629110066,0.8898904612345908,0.5126050420168067,0.9639958262924281,1.0,1/17,0.11%,CDH2
prerank,KEGG_2021_Human__Chagas disease,-0.6132591132512284,-0.8890054899025118,0.5859375,1.0,1.0,5/98,2.32%,AKT3;PIK3CB;PLCB4;BDKRB2;GNA14
prerank,WikiPathway_2021_Human__IL-18 signaling pathway WP4754,0.5355518582369568,0.8889536618068736,0.6857142857142857,0.9651160057912702,1.0,8/257,2.27%,SLC4A7;GPAT4;SNTB1;PLD1;PTGS2;TIMP3;PPP1R13L;FN1
prerank,KEGG_2021_Human__Cholinergic synapse,-0.6160711981036469,-0.8888538912292353,0.635036496350365,1.0,1.0,7/103,2.05%,CREB3L2;AKT3;PIK3CB;ADCY3;CREB5;PLCB4;PIK3R6
prerank,GO_Biological_Process_2021__import into cell (GO:0098657),0.6313356688752391,0.8888514385296095,0.6259541984732825,0.9648394639105398,1.0,5/39,1.88%,SLC19A1;SLC47A1;LRRC8C;SLC7A1;SLC38A1
prerank,GO_Biological_Process_2021__autophagosome maturation (GO:0097352),-0.6579695710830537,-0.8886824399105892,0.6470588235294118,1.0,1.0,1/34,0.88%,UVRAG
prerank,GO_Biological_Process_2021__negative regulation of intrinsic apoptotic signaling pathway (GO:2001243),-0.6569968827879505,-0.8885882147480694,0.6296296296296297,1.0,1.0,2/63,0.98%,VNN1;SOD2
prerank,GO_Biological_Process_2021__negative regulation of toll-like receptor signaling pathway (GO:0034122),0.6637032511188691,0.8884053270399332,0.6178861788617886,0.9651782550452228,1.0,2/34,0.30%,LILRA2;CD300A
prerank,GO_Biological_Process_2021__DNA repair (GO:0006281),0.527074788253991,0.888306630733703,0.7627118644067796,0.9648702540473592,1.0,7/290,1.15%,HERC2;FANCL;DCLRE1C;MSH2;ATR;TDP1;BRIP1
prerank,MSigDB_Oncogenic_Signatures__CYCLIN D1 KE .V1 DN,-0.5892385512044879,-0.8881360154068602,0.6515151515151515,1.0,1.0,7/162,2.38%,GRIN2B;NEDD4;INHBB;MAPK4;CD27;EML1;HRG
prerank,GO_Biological_Process_2021__protein ubiquitination (GO:0016567),-0.5012440876854614,-0.8880692846334994,0.8571428571428571,1.0,1.0,18/495,2.36%,UBE3D;HECTD2;KLHL3;FBXO27;SHPRH;AMFR;TRIM44;RNF13;WWP1;TNKS;BIRC6;NEDD4;RNF217;TRIM58;PELI2;HERC5;HERC6;FBXO32
prerank,Elsevier_Pathway_Collection__Hepatic Stellate Cells in non-Alcoholic Fatty Liver Disease,0.6440242229867861,0.8879268780823361,0.656934306569343,0.9651432506562828,1.0,2/53,2.27%,CDH1;FN1
prerank,Reactome_2022__Telomere C-strand (Lagging Strand) Synthesis R-HSA-174417,0.6443128388399619,0.8878556531841606,0.64,0.9648186700461622,1.0,3/33,2.24%,SLC19A1;ACD;LRIG1
prerank,Elsevier_Pathway_Collection__CNR1/2 -> IL1B/2/4/6/10 Production,-0.6546602006817378,-0.8877483490807083,0.6666666666666666,1.0,1.0,2/37,1.21%,MAP2K6;RAP1A
prerank,GO_Biological_Process_2021__ubiquinone metabolic process (GO:0006743),0.5830830281433674,0.8877083776108619,0.5227272727272727,0.9646273042450318,1.0,2/15,1.70%,COQ8A;FDXR
prerank,WikiPathway_2021_Human__ESC Pluripotency Pathways WP3931,-0.6178420893787088,-0.8876167114778742,0.6106870229007634,1.0,1.0,6/108,1.87%,MAP2K6;AKT3;MAP2K5;MAPK6;BMP4;MAPK4
prerank,GO_Biological_Process_2021__positive regulation of peptide hormone secretion (GO:0090277),-0.6593151819895372,-0.8875769525227944,0.6076923076923076,1.0,1.0,1/36,0.74%,MYRIP
prerank,GO_Biological_Process_2021__visual system development (GO:0150063),0.6216950951030988,0.887519615401993,0.6147540983606558,0.964507813612997,1.0,3/34,2.12%,SIPA1L3;MAB21L2;RBP4
prerank,Elsevier_Pathway_Collection__Proteins Involved in Autistic Disorder and Aggression,0.6439791753096382,0.8874745039357163,0.6206896551724138,0.9641249720628171,1.0,3/19,2.28%,PLAUR;SLC6A4;HGF
prerank,WikiPathway_2021_Human__Cardiac Progenitor Differentiation WP2406,-0.6515037917353796,-0.8874615300972702,0.6870229007633588,1.0,1.0,2/38,1.53%,BMP4;NRG1
prerank,GO_Biological_Process_2021__positive regulation of epithelial cell proliferation (GO:0050679),0.5940626450122461,0.8872528060216839,0.6578947368421053,0.964064817022215,1.0,6/117,2.37%,PIK3CD;ZNF304;NOD2;PPP1R16B;PROX1;FGF1
prerank,KEGG_2021_Human__Herpes simplex virus 1 infection,0.49652796703383234,0.8868073202279807,0.8951612903225806,0.9644027010893303,1.0,53/461,1.26%,ZNF473;ZSCAN32;ZNF563;ZNF124;ZNF530;ZNF175;ZNF189;ZNF780B;ZNF211;ZNF250;ZNF778;TRAF3;ZNF256;ZNF805;ZNF234;ZNF417;ZNF2;ZNF587;PIK3CD;ZNF564;ZNF101;ZNF251;ZNF283;ZNF419;ZNF878;ZNF37A;ZNF669;ZNF200;ZNF548;ZNF557;ZNF845;ZNF317;ZNF426;ZNF304;ZNF561;ZNF772;ZNF599;ZNF436;ZFP30;ZNF432;ZNF684;ZNF791;ZNF460;ZNF275;ZNF577;ZNF749;ZNF79;ZNF383;ZNF816;ZNF184;ZNF286A;ZNF853;SYK
prerank,Elsevier_Pathway_Collection__Apoptosis Block in Synovial Fibroblast,-0.6636645283322429,-0.8867176313297207,0.591304347826087,1.0,1.0,2/35,0.31%,MAP2K6;TNFRSF10B
prerank,GO_Biological_Process_2021__cell-matrix adhesion (GO:0007160),0.6076788163288596,0.8866373371603791,0.640625,0.9642351304517469,1.0,11/97,2.31%,ITGA3;ARHGEF7;ITGA4;THY1;ITGAL;ITGA2;DLC1;ITGB5;SGCE;FN1;HOXD3
prerank,Reactome_2022__ECM Proteoglycans R-HSA-3000178,0.6437955715944578,0.8865663942100518,0.5735294117647058,0.9638910011212966,1.0,5/52,2.30%,ITGA2;ITGB5;SERPINE1;COL9A3;COL9A2
prerank,KEGG_2021_Human__Calcium signaling pathway,-0.548300011677253,-0.8865651140012412,0.6642335766423357,1.0,1.0,7/211,2.32%,PTK2B;PHKB;HRH2;ADCY3;PLCB4;BDKRB2;GNA14
prerank,GO_Biological_Process_2021__negative regulation of cell motility (GO:2000146),0.6031595369518317,0.886502690668261,0.5855855855855856,0.9635366799953902,1.0,10/109,2.21%,SRGAP2B;THY1;CX3CL1;CHRD;DLC1;CDH1;MCTP1;SERPINE1;STK26;DPYSL3
prerank,Reactome_2022__ADP Signaling Thru P2Y Purinoceptor 1 R-HSA-418592,0.6433213315711213,0.8864435033944598,0.6370967741935484,0.9631721813749571,1.0,2/23,2.34%,GNB5;GNG2
prerank,GO_Biological_Process_2021__RNA metabolic process (GO:0016070),0.5912716324839795,0.8863949055829852,0.6101694915254238,0.9627975195341831,1.0,3/127,0.88%,TENT2;PARN;DROSHA
prerank,Reactome_2022__TP53 Regulates Transcription Of DNA Repair Genes R-HSA-6796648,0.6590010380773637,0.8862280556447111,0.6403508771929824,0.9626751868227928,1.0,2/60,0.77%,TCEA1;MSH2
prerank,KEGG_2021_Human__Lipid and atherosclerosis,-0.5602577978015244,-0.8861869541590643,0.6301369863013698,1.0,1.0,12/196,2.34%,MAP2K6;TNFRSF10B;RAP1B;AKT3;PIK3CB;CYP2C8;POU2F1;SOD2;RAP1A;TICAM2;PLCB4;VAV1
prerank,GO_Biological_Process_2021__regulation of cation channel activity (GO:2001257),-0.6423853886883645,-0.8861455407521152,0.6617647058823529,1.0,1.0,5/78,2.44%,PTK2B;APP;GRIN2B;DLG2;KCNE1
prerank,Elsevier_Pathway_Collection__EZH2 Methyltransferase Role in Cancer,-0.6552022640709095,-0.8861232851805266,0.6370967741935484,1.0,1.0,1/28,1.15%,RB1
prerank,GO_Biological_Process_2021__cilium organization (GO:0044782),-0.5383467632084552,-0.8859788627014449,0.746268656716418,1.0,1.0,10/218,2.33%,EXOC2;WDPCP;CPLANE1;TTBK2;TTC39C;RTTN;CPLANE2;ABLIM3;PDE6D;BBS5
prerank,Elsevier_Pathway_Collection__Atopic Dermatitis,0.6242096343710011,0.8859185351196119,0.6218487394957983,0.962748160884243,1.0,4/71,2.29%,PKP4;CD4;CDH1;CD86
prerank,GO_Biological_Process_2021__regulation of actin filament-based process (GO:0032970),0.6499428651290339,0.8857500988320367,0.5873015873015873,0.9626112803896139,1.0,3/71,1.68%,RHOQ;IQGAP3;DLC1
prerank,Reactome_2022__Assembly And Cell Surface Presentation Of NMDA Receptors R-HSA-9609736,0.6926697600232354,0.885439478807329,0.6699029126213593,0.9627408320694868,1.0,3/25,2.17%,DLG1;LIN7A;GPRIN1
prerank,KEGG_2021_Human__Hedgehog signaling pathway,-0.6636111906564854,-0.8853648854072803,0.6076923076923076,1.0,1.0,5/52,2.08%,SUFU;SHH;CCND2;BOC;GLI3
prerank,TRRUST_Transcription_Factors_2019__MYB human,-0.6447356626101162,-0.8851772138655976,0.6451612903225806,1.0,1.0,2/33,2.20%,NR3C1;CDO1
prerank,GO_Biological_Process_2021__skeletal system morphogenesis (GO:0048705),0.6770263902544253,0.8849804240615468,0.6186440677966102,0.9631112922308379,1.0,4/38,2.31%,MEGF8;LRP5;ANKRD11;HOXD3
prerank,GO_Biological_Process_2021__phagosome maturation (GO:0090382),0.658316717482681,0.8849339848391113,0.5925925925925926,0.9627670358034573,1.0,2/34,0.84%,RAB20;RAB7A
prerank,KEGG_2021_Human__Renin secretion,0.6624272095158078,0.8848473894826674,0.5675675675675675,0.9624775430134087,1.0,1/59,0.43%,CREB1
prerank,Elsevier_Pathway_Collection__Myoblast -> Neutrophil Surface Expression Markers,0.6575000388678144,0.8848372641207822,0.5803571428571429,0.9620501833059503,1.0,2/57,0.92%,ITGA3;LPAR1
prerank,Elsevier_Pathway_Collection__Th17-Cell Differentiation,-0.6424819388623433,-0.8846644728873322,0.6466165413533834,1.0,1.0,5/57,2.44%,GRAP2;IL12RB2;RORC;IL21R;ZAP70
prerank,TRRUST_Transcription_Factors_2019__RB1 human,0.5829952784712275,0.884603539147839,0.559322033898305,0.9619997822759654,1.0,2/31,1.71%,RBL1;CDH1
prerank,GO_Biological_Process_2021__endothelial cell development (GO:0001885),-0.6317507460142794,-0.8845907631347912,0.6176470588235294,1.0,1.0,3/25,1.54%,RAP1B;RAP1A;RAPGEF3
prerank,Reactome_2022__Glucagon-like Peptide-1 (GLP1) Regulates Insulin Secretion R-HSA-381676,-0.6757978595010877,-0.8845774700200031,0.6390977443609023,1.0,1.0,3/39,1.66%,RAP1A;RAPGEF3;KCNS3
prerank,Elsevier_Pathway_Collection__beta-Cell Function Inhibition by Ciclosporine and Tacrolimus (Rodent Model),0.5671975892239538,0.8844821654262537,0.5691056910569106,0.9617716905376092,1.0,1/22,0.43%,CREB1
prerank,GO_Biological_Process_2021__mitotic G2/M transition checkpoint (GO:0044818),0.6553501301647138,0.8844565142895702,0.648,0.9613682460895964,1.0,2/43,1.14%,BRSK1;CDC14B
prerank,GO_Biological_Process_2021__inorganic anion transmembrane transport (GO:0098661),0.6652003079374287,0.8843680261905776,0.608,0.9611030564747567,1.0,1/58,0.15%,SLC20A2
prerank,KEGG_2021_Human__Glutamatergic synapse,0.5897192344348607,0.8842369077130325,0.5275590551181102,0.9608777875180577,1.0,8/101,2.34%,PLD1;SLC38A3;GLS;HOMER3;GNB5;GRK3;SLC38A1;GNG2
prerank,Elsevier_Pathway_Collection__Th1-Cell Activation in Crohn's Disease,-0.6424264247009224,-0.8840613473462422,0.6376811594202898,1.0,1.0,3/34,2.44%,STAT5A;IL12RB2;ZAP70
prerank,GO_Biological_Process_2021__gland development (GO:0048732),0.6434001260745521,0.8839435537620247,0.5867768595041323,0.9609553639765295,1.0,6/64,2.34%,PHF2;SALL1;PROX1;ANXA1;HOXD3;TBX3
prerank,GO_Biological_Process_2021__TOR signaling (GO:0031929),0.6602034638027782,0.8837266687567895,0.6115702479338843,0.9608346815963913,1.0,1/26,0.65%,FNIP1
prerank,MSigDB_Hallmark_2020__heme Metabolism,0.5469278267589861,0.8829170587270753,0.696,0.9617421191902601,1.0,8/193,2.14%,SMOX;TCEA1;USP15;TFDP2;FTCD;LAMP2;OPTN;SLC30A10
prerank,GO_Biological_Process_2021__striated muscle cell differentiation (GO:0051146),0.5613535592250909,0.8828751257216063,0.5121951219512195,0.9613606536333118,1.0,1/18,1.01%,SORT1
prerank,GO_Biological_Process_2021__axon development (GO:0061564),-0.6301305715914906,-0.8826158754992413,0.6640625,1.0,1.0,5/75,2.22%,APP;PARD3;RTN4RL1;SLITRK3;DSCAML1
prerank,GO_Biological_Process_2021__activation of NF-kappaB-inducing kinase activity (GO:0007250),-0.5798526632711382,-0.8825422406092215,0.556390977443609,1.0,1.0,2/16,2.02%,TNFRSF10B;CARD10
prerank,GO_Biological_Process_2021__negative regulation of Wnt signaling pathway (GO:0030178),-0.5562200271141082,-0.88233806038385,0.7054263565891473,1.0,1.0,5/181,2.08%,AMFR;TLE4;HIC1;GRB10;GLI3
prerank,GO_Biological_Process_2021__histone H3 acetylation (GO:0043966),0.6617784318955515,0.8822305751820146,0.6068376068376068,0.9619836805353943,1.0,3/41,0.50%,NAA60;SUPT3H;ING5
prerank,KEGG_2021_Human__FoxO signaling pathway,-0.60451031400211,-0.882218951728803,0.6541353383458647,1.0,1.0,8/123,2.36%,AKT3;PIK3CB;SOD2;CREBBP;SGK3;CCND2;S1PR1;FBXO32
prerank,GO_Biological_Process_2021__negative regulation of protein kinase B signaling (GO:0051898),-0.6569300291520315,-0.8821868389817852,0.6412213740458015,1.0,1.0,2/38,0.98%,PIK3CB;PTPRJ
prerank,GO_Biological_Process_2021__negative regulation of transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0090101),-0.6186286183190006,-0.8821060015850417,0.6159420289855072,1.0,1.0,5/101,2.15%,SLC2A10;ZNF451;TGFB1I1;RBPMS2;ADAMTSL2
prerank,Elsevier_Pathway_Collection__Androgens Promote Scalp Dermal Papilla Regression,0.6470089430034102,0.8819228498449305,0.6341463414634146,0.9621167871619197,1.0,2/29,1.97%,ATR;AXIN2
prerank,Reactome_2022__Myogenesis R-HSA-525793,-0.6077689126920087,-0.8818788302894632,0.6044776119402985,1.0,1.0,3/25,1.74%,MAP2K6;NEO1;BOC
prerank,WikiPathway_2021_Human__Nuclear receptors WP170,-0.6449645742383306,-0.8814868951952667,0.624,1.0,1.0,4/36,2.19%,NR3C1;NR2C2;RORC;VDR
prerank,Reactome_2022__Formation Of RNA Pol II Elongation Complex R-HSA-112382,-0.6541123237839078,-0.8814278860745798,0.5746268656716418,1.0,1.0,2/55,1.26%,NELFA;MLLT1
prerank,KEGG_2021_Human__Protein digestion and absorption,-0.630095235538623,-0.8813748422837012,0.6451612903225806,1.0,1.0,6/88,2.39%,SLC7A9;SLC36A4;SLC7A8;COL4A4;COL26A1;COL7A1
prerank,GO_Biological_Process_2021__regulation of anatomical structure morphogenesis (GO:0022603),-0.6093025688583055,-0.8812115048624377,0.6190476190476191,1.0,1.0,7/122,2.25%,PAK2;SIPA1L1;NEDD4;ZNF135;ADGRA2;KNDC1;SEMA4D
prerank,Elsevier_Pathway_Collection__Cell Cycle Dysregulation in Melanoma,-0.6552366254512404,-0.8811801278852675,0.6461538461538462,1.0,1.0,2/39,1.15%,AKT3;RB1
prerank,WikiPathway_2021_Human__Pathogenesis of SARS-CoV-2 Mediated by nsp9-nsp10 Complex WP4884,-0.547163162045502,-0.8810211347014734,0.5267175572519084,1.0,1.0,2/20,2.44%,CD2;ZAP70
prerank,GO_Biological_Process_2021__positive regulation of potassium ion transport (GO:0043268),0.6237772910399555,0.8810007595757771,0.6186440677966102,0.9632904432751254,1.0,4/38,2.34%,DLG1;KCNJ10;FLNA;GNG2
prerank,GO_Biological_Process_2021__negative regulation of viral genome replication (GO:0045071),-0.6451055074210746,-0.8809570815369823,0.6456692913385826,1.0,1.0,2/50,2.16%,OAS1;OASL
prerank,GO_Biological_Process_2021__protein import (GO:0017038),-0.6257560773075598,-0.8809328131874299,0.6590909090909091,1.0,1.0,3/86,0.60%,IPO11;ATAD1;ABCD3
prerank,WikiPathway_2021_Human__Epithelial to mesenchymal transition in colorectal cancer WP4239,0.5694866237651147,0.880762602024558,0.6638655462184874,0.9632647126403768,1.0,12/154,2.41%,CDH2;TJP1;PIK3CD;LRP5;CRB3;NOTCH3;PROX1;CDH1;MAPK13;FMNL2;FN1;COL4A5
prerank,Elsevier_Pathway_Collection__EDNRA/B -> Vascular Motility,-0.6546591394645271,-0.8805912440092005,0.6470588235294118,1.0,1.0,2/39,1.21%,MAP2K6;RAP1A
prerank,Elsevier_Pathway_Collection__LH and FSH Signaling Impairment in Primary Ovarian Insufficiency,0.5671985278272063,0.8804643049674337,0.5166666666666667,0.9628973972390988,1.0,1/18,0.43%,CREB1
prerank,Elsevier_Pathway_Collection__LH and FSH Signaling and Steroidogenesis,0.5671985278272063,0.8804643049674337,0.5166666666666667,0.9628973972390988,1.0,1/18,0.43%,CREB1
prerank,KEGG_2021_Human__Glutathione metabolism,-0.6541144117850877,-0.880374652480074,0.646551724137931,1.0,1.0,3/52,1.27%,GSTA1;GGT5;GSTA2
prerank,GO_Biological_Process_2021__regulation of mitotic spindle organization (GO:0060236),0.6603163766595993,0.8802045796731323,0.6356589147286822,0.9628781164949052,1.0,1/35,0.64%,CCSAP
prerank,GO_Biological_Process_2021__regulation of RNA metabolic process (GO:0051252),0.6507203611331507,0.8801037694074161,0.5867768595041323,0.9626262814758358,1.0,4/61,1.61%,ZNF326;IGF2BP1;IGF2BP3;PCBP4
prerank,KEGG_2021_Human__Amyotrophic lateral sclerosis,-0.5181051924539881,-0.8800594334275151,0.7183098591549296,1.0,1.0,6/330,2.04%,DNAH14;MAP2K6;NDUFS4;GRIN2B;NRG1;DNAH10
prerank,Elsevier_Pathway_Collection__Genes with Mutations in Cancer-Associated Resisting to Cell Death,0.6567789471926244,0.8800357255853343,0.6722689075630253,0.9623165629311125,1.0,2/31,1.00%,TNFRSF10A;CASP7
prerank,Elsevier_Pathway_Collection__FGFR -> AP-1/CREB/CREBBP/ELK/SRF/MYC Signaling,-0.6545777803047486,-0.8799364826186222,0.6717557251908397,1.0,1.0,3/49,1.22%,PTK2B;MAP2K6;CREBBP
prerank,KEGG_2021_Human__ECM-receptor interaction,0.6313491828425466,0.8797592791233937,0.6446280991735537,0.9623058755280915,1.0,8/83,2.41%,ITGA3;ITGA4;ITGA2;ITGB5;COL9A3;FN1;COL9A2;COL4A5
prerank,Reactome_2022__Phosphorylation Of CD3 And TCR Zeta Chains R-HSA-202427,-0.5616616363588443,-0.8795991499527596,0.5230769230769231,1.0,1.0,1/17,0.98%,PTPRJ
prerank,Elsevier_Pathway_Collection__Proteins Involved in Diabetic Nephropathy,0.5552332447720985,0.879521634909041,0.7154471544715447,0.9622516510911513,1.0,10/164,2.28%,PPARA;CREB1;PTK2;PTGS2;TIMP3;APOE;SERPINE1;CYBA;FN1;HGF
prerank,GO_Biological_Process_2021__cellular response to nerve growth factor stimulus (GO:1990090),-0.582040639911927,-0.8793258060119664,0.5492957746478874,1.0,1.0,2/21,1.81%,RAP1A;NTF3
prerank,GO_Biological_Process_2021__negative regulation of cell population proliferation (GO:0008285),0.5074129180539375,0.8791738580089256,0.8449612403100775,0.962361220396168,1.0,19/353,2.34%,THAP12;VGLL4;DIS3L2;CD300A;CD33;ING5;PTPN2;DLG3;CDK6;NIBAN2;IGFBP3;CGREF1;PROX1;CYP27B1;DLC1;P3H3;AXIN2;RBP4;TBX3
prerank,Reactome_2022__Toll Like Receptor 3 (TLR3) Cascade R-HSA-168164,0.6065110440088064,0.8791523557945896,0.6120689655172413,0.961963109991384,1.0,4/102,0.90%,TRAF3;CREB1;IRAK2;NOD2
prerank,GO_Biological_Process_2021__negative regulation of cell adhesion (GO:0007162),0.6223578144033617,0.8790861376680011,0.6695652173913044,0.9616337027430236,1.0,6/72,2.07%,TBCD;PTK2;ERBB3;CX3CL1;CDH1;SERPINE1
prerank,Reactome_2022__p75NTR Signals Via NF-kB R-HSA-193639,-0.5335511787284174,-0.8790109129349233,0.4957983193277311,1.0,1.0,7/16,18.36%,NFKB1;RELA;UBB;MYD88;UBA52;SQSTM1;TRAF6
prerank,Elsevier_Pathway_Collection__Proteins Involved in Pancreatic Cancer,0.6225682232298092,0.8786933606283549,0.6311475409836066,0.961859316380879,1.0,7/87,2.28%,CDH2;PTK2;ERBB3;NOTCH3;CDH1;FN1;HGF
prerank,GO_Biological_Process_2021__positive regulation of insulin secretion (GO:0032024),-0.6593154252824139,-0.8786748125832362,0.6120689655172413,1.0,1.0,1/36,0.74%,MYRIP
prerank,Elsevier_Pathway_Collection__Arterial Hypertension,-0.680601510791675,-0.8786746469931142,0.6153846153846154,1.0,1.0,4/43,1.96%,NCOA1;CREBBP;PROS1;PROCR
prerank,WikiPathway_2021_Human__Senescence and Autophagy in Cancer WP615,-0.5911816690270086,-0.8786638238942392,0.6518518518518519,1.0,1.0,4/101,1.76%,UVRAG;ATG10;RB1;CD44
prerank,MSigDB_Oncogenic_Signatures__ERB2 UP.V1 UP,0.5489751676231956,0.8785629224222137,0.7058823529411765,0.9616316357616609,1.0,9/173,1.49%,LRP5;ETV5;CHST11;TNFRSF21;HSD17B11;MAOA;NOTCH3;SPTBN2;PACSIN3
prerank,GO_Biological_Process_2021__negative regulation of cell cycle G1/S phase transition (GO:1902807),0.660125584729474,0.8785548161948495,0.6228070175438597,0.9612015069604175,1.0,4/34,0.67%,PRMT2;DLG1;RBL1;CDK6
prerank,WikiPathway_2021_Human__Neural Crest Cell Migration in Cancer WP4565,-0.6463452562618385,-0.8785466820122414,0.6643356643356644,1.0,1.0,5/42,2.05%,PAK2;AKT3;PIK3CB;MMP2;PIK3R6
prerank,GO_Biological_Process_2021__protein targeting to lysosome (GO:0006622),-0.5603918994046624,-0.8785262789681163,0.5454545454545454,1.0,1.0,2/20,1.11%,ZFYVE16;NEDD4
prerank,GO_Biological_Process_2021__RNA modification (GO:0009451),0.6586152626092546,0.8783355376346891,0.6260162601626016,0.9610611517438113,1.0,1/57,0.81%,PARN
prerank,Elsevier_Pathway_Collection__Plasmin Role in Glomerulonephritis,-0.664469615619347,-0.8782754953020505,0.6050420168067226,1.0,1.0,1/49,0.23%,MAP2K6
prerank,WikiPathway_2021_Human__ErbB signaling pathway WP673,-0.5902157860308361,-0.8778501927816067,0.60431654676259,1.0,1.0,5/89,1.71%,PAK2;AKT3;PIK3CB;NRG1;STAT5A
prerank,GO_Biological_Process_2021__glycogen catabolic process (GO:0005980),0.47885405993766555,0.8778028250843005,0.4262295081967213,0.9614766888789389,1.0,2/15,2.12%,PHKA2;PHKA1
prerank,GO_Biological_Process_2021__ubiquitin-dependent protein catabolic process (GO:0006511),-0.5025383117666669,-0.8775781342693995,0.8347826086956521,1.0,1.0,12/345,2.09%,UBE3D;KLHL3;AMFR;TTC3;RNF13;ATE1;WWP1;BIRC6;NEDD4;RNF217;TGFB1I1;PML
prerank,GO_Biological_Process_2021__regulation of reactive oxygen species metabolic process (GO:2000377),0.6510703892639846,0.8775262563006462,0.6328125,0.9614891524981112,1.0,3/55,1.57%,AATF;PDK3;MPV17
prerank,MSigDB_Oncogenic_Signatures__MYC UP.V1 DN,-0.6002750019845406,-0.8774775501685167,0.6888888888888889,1.0,1.0,8/135,1.90%,PTK2B;FBXO27;ABHD3;RAP1A;TNFAIP2;GJB5;ZNF334;NYNRIN
prerank,KEGG_2021_Human__Glioma,-0.6552995586578422,-0.8773543033856729,0.6541353383458647,1.0,1.0,4/71,1.15%,POLK;AKT3;PIK3CB;RB1
prerank,GO_Biological_Process_2021__inorganic cation transmembrane transport (GO:0098662),-0.5423140272953445,-0.8772431549754853,0.7401574803149606,1.0,1.0,7/235,2.44%,KCNN2;KCNAB3;KCNK6;KCNS3;KCNAB2;SLC9A9;KCNE1
prerank,Reactome_2022__Toll-like Receptor Cascades R-HSA-168898,0.5446760550393323,0.8771436682476118,0.6608695652173913,0.961772006545474,1.0,5/159,1.79%,TRAF3;CREB1;IRAK2;NOD2;SIGIRR
prerank,Reactome_2022__TAK1-dependent IKK And NF-kappa-B Activation R-HSA-445989,0.6577359389233235,0.8771222109229939,0.632,0.9613716853772711,1.0,2/44,0.90%,IRAK2;NOD2
prerank,GO_Biological_Process_2021__activation of protein kinase activity (GO:0032147),-0.5910833248133026,-0.8770661805649419,0.7050359712230215,1.0,1.0,7/110,2.02%,PTK2B;PAK2;TNFRSF10B;NRG1;ADCY3;NTF3;CARD10
prerank,GO_Biological_Process_2021__negative regulation of canonical Wnt signaling pathway (GO:0090090),-0.5674726539298401,-0.8770592859604048,0.6198347107438017,1.0,1.0,3/158,2.08%,AMFR;TLE4;GLI3
prerank,GO_Biological_Process_2021__adherens junction organization (GO:0034332),0.675058900749157,0.8769822401527552,0.6209677419354839,0.9611573334161522,1.0,5/45,2.07%,CDH2;TJP1;TBCD;CDH1;CDH15
prerank,MSigDB_Oncogenic_Signatures__SNF5 DN.V1 UP,0.554137788566213,0.8768295822907554,0.75,0.9609844040266488,1.0,11/149,1.99%,LRP5;CD53;RBL1;FNBP1;USP15;PSMB9;KCNJ10;CD48;UBE2C;MSX1;APOE
prerank,Reactome_2022__DNA Replication Pre-Initiation R-HSA-69002,0.6016775610087798,0.8767936378624737,0.6239316239316239,0.9606262016425923,1.0,4/116,1.74%,CDC45;POLE4;PSMB9;UBE2C
prerank,GO_Biological_Process_2021__negative regulation of apoptotic process (GO:0043066),0.49182579840055696,0.876753428529435,0.853448275862069,0.9602518523308954,1.0,25/456,2.34%,AATF;TJP1;FNIP1;PLAUR;MSH2;NIBAN2;PTK2;ZNF304;PRKAA2;ERBB3;CX3CL1;TNFRSF10D;ANXA1;FHL2;NAIP;CTSH;APOE;SH3RF2;PRLR;SLC30A10;SH3RF1;PRAP1;HGF;FLNA;TBX3
prerank,Reactome_2022__Pyruvate Metabolism And Citric Acid (TCA) Cycle R-HSA-71406,-0.6653930103936881,-0.8767472473110535,0.6153846153846154,1.0,1.0,1/53,0.13%,SUCLG2
prerank,GO_Biological_Process_2021__negative regulation of myeloid cell differentiation (GO:0045638),-0.6225955067965522,-0.8766899370842802,0.6050420168067226,1.0,1.0,2/22,1.39%,PTK2B;MEIS1
prerank,WikiPathway_2021_Human__Dopaminergic Neurogenesis WP2855,-0.5858072692287369,-0.8766435150306323,0.578125,1.0,1.0,1/23,1.43%,SHH
prerank,GO_Biological_Process_2021__positive regulation of ERK1 and ERK2 cascade (GO:0070374),-0.5601571498468498,-0.8765991006492906,0.7007299270072993,1.0,1.0,7/159,1.90%,PTK2B;CCL23;APP;RAP1A;SCIMP;CD44;TEK
prerank,Reactome_2022__MyD88-independent TLR4 Cascade R-HSA-166166,0.6065099681923113,0.8765907565132165,0.6324786324786325,0.9601310369574266,1.0,4/105,0.90%,TRAF3;CREB1;IRAK2;NOD2
prerank,GO_Biological_Process_2021__negative regulation of G1/S transition of mitotic cell cycle (GO:2000134),0.6601250626943661,0.8763988348434991,0.625,0.9600453100718774,1.0,4/36,0.67%,PRMT2;DLG1;RBL1;CDK6
prerank,MSigDB_Oncogenic_Signatures__CYCLIN D1 KE .V1 UP,0.5557338676635123,0.8763447404939321,0.6875,0.9597149287541465,1.0,8/175,1.94%,CDK6;PTPRH;DMWD;SLC38A3;THY1;CGREF1;FHL2;FOSL2
prerank,GO_Biological_Process_2021__fatty acid beta-oxidation (GO:0006635),0.656270242760443,0.8763195053200348,0.6521739130434783,0.959317013645933,1.0,2/51,1.05%,AUH;SLC27A2
prerank,GO_Biological_Process_2021__steroid biosynthetic process (GO:0006694),0.6458678323432181,0.876119973315548,0.6299212598425197,0.9592112295829119,1.0,3/60,2.09%,SLC27A2;FDXR;PRLR
prerank,Reactome_2022__GPCR Ligand Binding R-HSA-500792,-0.5119407545147504,-0.8760721054948714,0.795774647887324,1.0,1.0,11/338,2.27%,CCL23;APP;GPR39;HRH2;SHH;GPR132;C5AR2;BDKRB2;S1PR1;ADGRE5;GPR17
prerank,Elsevier_Pathway_Collection__TGF-beta Signaling,-0.6545322655278621,-0.8760028382704597,0.6691729323308271,1.0,1.0,2/62,1.22%,MAP2K6;CREBBP
prerank,GO_Biological_Process_2021__protein targeting (GO:0006605),-0.5759098374572297,-0.8758941863670059,0.7063492063492064,1.0,1.0,5/121,2.42%,ZDHHC14;TOMM70;ZDHHC21;PARD3;RTP4
prerank,GO_Biological_Process_2021__positive regulation of production of molecular mediator of immune response (GO:0002702),0.6438117175211062,0.8757285488442977,0.65625,0.9593807459462457,1.0,3/34,2.29%,NOD2;RBP4;CD86
prerank,Reactome_2022__Pre-NOTCH Expression And Processing R-HSA-1912422,0.623686955825344,0.8754640358894944,0.6201550387596899,0.9594043571403076,1.0,2/68,1.27%,TFDP2;NOTCH3
prerank,WikiPathway_2021_Human__Hepatitis B infection WP4666,-0.5818055654694769,-0.8754514783991326,0.6484375,1.0,1.0,9/137,1.85%,PTK2B;MAP2K6;CREB3L2;AKT3;PIK3CB;CREBBP;STAT5A;CREB5;TICAM2
prerank,GO_Biological_Process_2021__positive regulation of NIK/NF-kappaB signaling (GO:1901224),-0.6444512936393407,-0.875415793694404,0.6762589928057554,1.0,1.0,4/51,2.24%,TRIM44;APP;CD27;TNFSF14
prerank,Reactome_2022__Smooth Muscle Contraction R-HSA-445355,-0.6640489745547536,-0.8753762426125485,0.6031746031746031,1.0,1.0,2/38,0.27%,PDE5A;ITGA1
prerank,GO_Biological_Process_2021__regulation of vesicle-mediated transport (GO:0060627),-0.6014776496203689,-0.8753706734829214,0.6444444444444445,1.0,1.0,5/91,2.37%,ZFYVE16;STXBP5;HCK;CPLANE2;SYT7
prerank,GO_Biological_Process_2021__signal transduction in response to DNA damage (GO:0042770),0.6552308203295725,0.8752684261293903,0.6470588235294118,0.9593130412893708,1.0,3/52,1.15%,CDC5L;ATR;BRIP1
prerank,WikiPathway_2021_Human__Monoamine GPCRs WP58,-0.5864235317446768,-0.8752467384163268,0.556390977443609,1.0,1.0,1/22,1.36%,HRH2
prerank,KEGG_2021_Human__Signaling pathways regulating pluripotency of stem cells,-0.5925909466159748,-0.8752074126888323,0.6771653543307087,1.0,1.0,6/128,2.05%,AKT3;PIK3CB;MEIS1;INHBB;BMP4;KLF4
prerank,GO_Biological_Process_2021__positive regulation of endothelial cell migration (GO:0010595),-0.6201520006806178,-0.8749065928283362,0.6311475409836066,1.0,1.0,7/86,1.90%,PTK2B;AKT3;PIK3CB;BCAS3;BMP4;STAT5A;TEK
prerank,GO_Biological_Process_2021__RNA phosphodiester bond hydrolysis (GO:0090501),0.5634270937760765,0.8748459251333123,0.5581395348837209,0.9595253489655815,1.0,2/28,0.81%,ERN1;PARN
prerank,GO_Biological_Process_2021__negative regulation of growth (GO:0045926),-0.5763326692986747,-0.8747599135153492,0.7230769230769231,1.0,1.0,6/123,2.38%,DCBLD2;PTPRJ;RB1;SLIT3;PML;HRG
prerank,Elsevier_Pathway_Collection__NOTCH Receptors Signaling,0.6237072864601212,0.8746531307588307,0.6390977443609023,0.9593992110402864,1.0,2/29,1.27%,SLC35D2;NOTCH3
prerank,GO_Biological_Process_2021__monocyte chemotaxis (GO:0002548),0.6719136827349036,0.8746323410517826,0.6046511627906976,0.9589883664964604,1.0,4/36,2.05%,CX3CL1;ANXA1;CCL14;LGALS3
prerank,"GO_Biological_Process_2021__transcription, DNA-templated (GO:0006351)",0.5347022516683301,0.8745510099556812,0.743801652892562,0.9587028331745109,1.0,7/210,2.35%,TAF4;TRIM24;TCEA1;TAF1B;GTF2E2;HOXD3;TCFL5
prerank,Elsevier_Pathway_Collection__Prolactinoma Overiew,0.5993280913643699,0.8742387196817099,0.5934959349593496,0.9587594440256877,1.0,3/54,1.19%,CREB1;CDK6;ERBB3
prerank,Reactome_2022__Chondroitin Sulfate/Dermatan Sulfate Metabolism R-HSA-1793185,0.6587719902784789,0.8742151684565547,0.6335877862595419,0.9583576371872742,1.0,1/49,0.79%,CHST11
prerank,WikiPathway_2021_Human__One-carbon metabolism and related pathways WP3940,-0.6447995513030843,-0.8742077688412476,0.652542372881356,1.0,1.0,4/49,2.20%,DMGDH;SOD2;BHMT;CDO1
prerank,Reactome_2022__Gene And Protein Expression By JAK-STAT Signaling After Interleukin-12 Stimulation R-HSA-8950505,-0.654084008878023,-0.8741179959709708,0.6696428571428571,1.0,1.0,2/35,1.27%,RAP1B;GSTA2
prerank,WikiPathway_2021_Human__Type I collagen synthesis in the context of Osteogenesis imperfecta WP4786,0.6623955374346513,0.87406672384968,0.616,0.9581566400322726,1.0,2/31,0.43%,PLOD2;LRP5
prerank,Reactome_2022__Signal Amplification R-HSA-392518,0.6433146734294566,0.8740066088613404,0.6299212598425197,0.9578270275962797,1.0,2/30,2.34%,GNB5;GNG2
prerank,GO_Biological_Process_2021__endoderm formation (GO:0001706),0.6024523839426885,0.8739506808273364,0.625,0.9574772800869679,1.0,4/35,2.27%,COL12A1;ITGA4;ITGB5;FN1
prerank,KEGG_2021_Human__Alzheimer disease,0.49710954788473927,0.873712188932659,0.89,0.957413808491482,1.0,9/333,2.15%,ERN1;PIK3CD;LRP5;CASP7;NDUFA10;PTGS2;AXIN2;APOE;TUBA1A
prerank,Reactome_2022__Diseases Of Signal Transduction By Growth Factor Receptors And Second Messengers R-HSA-5663202,0.48570624071223495,0.8735539578771451,0.9145299145299145,0.9572462714996227,1.0,18/409,2.37%,TRAK1;TBL1X;LMO7;HDAC8;CREB1;LRP5;TRIM24;PAPSS1;KSR1;ERBB3;PSMB9;KLB;HDAC9;PIK3AP1;FN1;CD86;ZFYVE9;FGF1
prerank,Reactome_2022__G Alpha (I) Signaling Events R-HSA-418594,0.5195038840939753,0.8734511275047286,0.7327586206896551,0.9569870550999675,1.0,7/245,2.34%,CREB1;LPAR1;CX3CL1;ANXA1;DRD4;GNB5;GNG2
prerank,GO_Biological_Process_2021__positive regulation of inflammatory response (GO:0050729),0.6157401394173583,0.8731695767674543,0.6666666666666666,0.9569320515663127,1.0,3/81,2.07%,CX3CL1;MAPK13;SERPINE1
prerank,GO_Biological_Process_2021__determination of heart left/right asymmetry (GO:0061371),0.6194977272374231,0.872823674225057,0.6451612903225806,0.9570911771813041,1.0,3/39,2.34%,MEGF8;CCDC40;TBX3
prerank,KEGG_2021_Human__Dilated cardiomyopathy,0.6321112933036143,0.8727228464568758,0.6095238095238096,0.9568221941684824,1.0,5/85,1.80%,ITGA3;ITGA4;ITGA2;ITGB5;CACNA2D4
prerank,Reactome_2022__Vasopressin Regulates Renal Water Homeostasis Via Aquaporins R-HSA-432040,0.6433068867742451,0.8726897351933699,0.6396396396396397,0.9564414199430479,1.0,2/38,2.34%,GNB5;GNG2
prerank,GO_Biological_Process_2021__positive regulation of viral process (GO:0048524),0.6583077936797728,0.8725461340519707,0.6124031007751938,0.9562727429355061,1.0,2/60,0.84%,PPARA;RAB7A
prerank,Elsevier_Pathway_Collection__CD8+ T-Cell Activation,-0.642442620656176,-0.8724236275563313,0.6412213740458015,1.0,1.0,4/58,2.44%,PTK2B;STAT5A;IL12RB2;ZAP70
prerank,Elsevier_Pathway_Collection__Doxorubicin Induced Cardiotoxicity,-0.5792710922618086,-0.8722361952842614,0.5666666666666667,1.0,1.0,2/22,2.08%,SOD2;SMPD1
prerank,GO_Biological_Process_2021__regulation of extrinsic apoptotic signaling pathway via death domain receptors (GO:1902041),0.6460757843144027,0.8715064774656069,0.6754385964912281,0.9575593554694767,1.0,3/41,2.07%,TNFRSF10A;LGALS3;SERPINE1
prerank,MSigDB_Oncogenic_Signatures__RB P130 DN.V1 UP,0.5857608239475531,0.8713627790887093,0.628099173553719,0.9573292980478059,1.0,7/114,2.16%,CASP7;CRB3;UBE2C;SNTA1;STMN3;SPATA13;CYBA
prerank,Reactome_2022__TGF-beta Receptor Signaling In EMT (Epithelial To Mesenchymal Transition) R-HSA-2173791,-0.561546864413504,-0.8712865828808565,0.5344827586206896,1.0,1.0,1/16,1.00%,PARD3
prerank,KEGG_2021_Human__Lysosome,0.5806158868157539,0.8709842631761111,0.6311475409836066,0.9575244115595433,1.0,6/126,1.95%,MANBA;IGF2R;SORT1;ARSG;LAMP2;CTSH
prerank,TRRUST_Transcription_Factors_2019__EP300 human,-0.6489534414592131,-0.8709684905528646,0.6693548387096774,1.0,1.0,3/54,1.78%,ZEB1;CREBBP;CYP1B1
prerank,GO_Biological_Process_2021__regulation of cellular response to heat (GO:1900034),0.6562199228430268,0.8709568320152893,0.5806451612903226,0.9571360512433335,1.0,2/79,1.05%,ATR;NUP210
prerank,Reactome_2022__Aquaporin-mediated Transport R-HSA-445717,0.6433003316470707,0.8709498272460975,0.6422018348623854,0.956715538449218,1.0,2/45,2.34%,GNB5;GNG2
prerank,Reactome_2022__Regulation Of Gene Expression In Beta Cells R-HSA-210745,0.5334089349399933,0.8707965233599579,0.47058823529411764,0.9565147059702707,1.0,2/16,2.22%,PKLR;FOXA3
prerank,Reactome_2022__Negative Regulation Of NMDA Receptor-Mediated Neuronal Transmission R-HSA-9617324,0.5783489196386782,0.8705582719699348,0.5677966101694916,0.9565048411630926,1.0,2/21,2.17%,DLG1;GPRIN1
prerank,Elsevier_Pathway_Collection__Cetuximab Resistance in Colorectal Cancer,0.6440164766076539,0.8704671201350171,0.6153846153846154,0.9562170499855064,1.0,5/64,2.28%,PLAUR;IGFBP3;ERBB3;PTGS2;HGF
prerank,GO_Biological_Process_2021__negative regulation of smoothened signaling pathway (GO:0045879),0.6125383308219013,0.8702971708491899,0.5925925925925926,0.95605929833382,1.0,2/22,0.29%,MEGF8;HERC4
prerank,GO_Biological_Process_2021__cellular lipid catabolic process (GO:0044242),-0.6489340705189026,-0.8702018978456723,0.6893939393939394,1.0,1.0,2/26,1.78%,LIPG;CYP1B1
prerank,GO_Biological_Process_2021__embryonic heart tube morphogenesis (GO:0003143),0.6194967826239299,0.8700933177138728,0.6446280991735537,0.9559665496171014,1.0,3/40,2.34%,MEGF8;CCDC40;TBX3
prerank,GO_Biological_Process_2021__regulation of TOR signaling (GO:0032006),0.6556852774546229,0.8700921593719916,0.6697247706422018,0.9555355457624498,1.0,2/68,1.10%,FNIP1;PRKAA2
prerank,GO_Biological_Process_2021__positive regulation of viral life cycle (GO:1903902),0.587769021945865,0.8700269861751952,0.5693430656934306,0.9551920082833903,1.0,1/23,1.23%,CD4
prerank,MSigDB_Hallmark_2020__UV Response Dn,-0.577241367636314,-0.8699571020769686,0.6666666666666666,1.0,1.0,11/144,2.31%,CDC42BPA;RASA2;NR3C1;AKT3;MAP2K5;SIPA1L1;NEK7;TFPI;PMP22;PLCB4;SYNE1
prerank,WikiPathway_2021_Human__Pyrimidine metabolism WP4022,-0.60395331886933,-0.8699498601715923,0.6178861788617886,1.0,1.0,3/81,2.11%,DPYS;PRIM2;ENTPD3
prerank,GO_Biological_Process_2021__regulation of double-strand break repair (GO:2000779),0.647230760653694,0.8699252015890904,0.6842105263157895,0.9549074808057488,1.0,2/40,1.95%,WRAP53;SPIRE2
prerank,KEGG_2021_Human__Fluid shear stress and atherosclerosis,-0.5979821131577321,-0.8697166190064147,0.6785714285714286,1.0,1.0,8/130,1.93%,GSTA1;MAP2K6;AKT3;PIK3CB;MAP2K5;GSTA2;BMP4;MMP2
prerank,GO_Biological_Process_2021__unsaturated fatty acid metabolic process (GO:0033559),0.6325427985671668,0.869677122143148,0.6846846846846847,0.9549206264240659,1.0,3/52,1.46%,CYP4F3;PTGR1;ELOVL2
prerank,"GO_Biological_Process_2021__chemical synaptic transmission, postsynaptic (GO:0099565)",0.5835795519655357,0.8692935465252126,0.5714285714285714,0.955071278890377,1.0,2/20,1.65%,RAB3GAP1;DRD4
prerank,GO_Biological_Process_2021__triglyceride metabolic process (GO:0006641),0.6130759637288202,0.8692265022980097,0.6111111111111112,0.9547548469188382,1.0,6/45,2.35%,GPAT4;PNPLA3;MOGAT2;APOE;LPIN3;GK
prerank,KEGG_2021_Human__Serotonergic synapse,-0.6117736020890615,-0.8691396684489117,0.6356589147286822,1.0,1.0,6/96,2.17%,CYP2C8;KCNN2;APP;RAPGEF3;PLCB4;MAOB
prerank,GO_Biological_Process_2021__neuron maturation (GO:0042551),-0.5633539229001873,-0.868812175843713,0.5223880597014925,1.0,1.0,1/16,0.81%,APP
prerank,"Reactome_2022__Unblocking Of NMDA Receptors, Glutamate Binding And Activation R-HSA-438066",0.5783506806275083,0.8687787036360911,0.5575221238938053,0.9551095104511033,1.0,2/19,2.17%,DLG1;GPRIN1
prerank,WikiPathway_2021_Human__IL-1 signaling pathway WP195,-0.6432170743131065,-0.8686214607266093,0.6612903225806451,1.0,1.0,3/53,2.36%,MAP2K6;PELI2;IRAK3
prerank,GO_Biological_Process_2021__cardiac conduction system development (GO:0003161),-0.5850385458590763,-0.8686033001596082,0.5726495726495726,1.0,1.0,1/23,1.50%,BMP4
prerank,GO_Biological_Process_2021__negative regulation of nucleic acid-templated transcription (GO:1903507),-0.5044978981093223,-0.868591464689628,0.8382352941176471,1.0,1.0,21/437,2.44%,ZHX3;NR3C1;ZEB1;ZBTB38;ZNF148;HMBOX1;MTA3;POU2F1;WWP1;RB1;LBH;BMP4;NRG1;BASP1;KLF4;GLI3;PML;VDR;CIITA;SPI1;ZNF653
prerank,GO_Biological_Process_2021__positive regulation of cell-substrate adhesion (GO:0010811),0.6294045554687729,0.8685461028948661,0.6546762589928058,0.9551023455690973,1.0,5/68,2.29%,CDK6;ARHGEF7;CX3CL1;FN1;FLNA
prerank,Elsevier_Pathway_Collection__Enamel Formation Disruption,-0.585113754679262,-0.8683504864854351,0.5882352941176471,1.0,1.0,3/27,1.50%,SUFU;SHH;BMP4
prerank,GO_Biological_Process_2021__epithelium development (GO:0060429),-0.6140372862030132,-0.8682507097537109,0.626984126984127,1.0,1.0,5/113,1.58%,GSTA1;SULT1B1;GSTA2;SHH;PAX8
prerank,GO_Biological_Process_2021__membrane protein proteolysis (GO:0033619),-0.6632014489969688,-0.8681585760896472,0.6349206349206349,1.0,1.0,1/38,0.35%,ADAM10
prerank,GO_Biological_Process_2021__regulation of axon extension (GO:0030516),0.6467712425359953,0.8680909752447742,0.6148148148148148,0.9554161603466839,1.0,2/37,1.99%,SEMA3G;APOE
prerank,MSigDB_Oncogenic_Signatures__KRAS.LUNG.BREAST UP.V1 DN,-0.5914576102467319,-0.8680759303305534,0.6528925619834711,1.0,1.0,9/112,2.42%,MAP2K6;IFI44L;GLYAT;PBX1;NTF3;NYNRIN;PARP3;EPB41L4A;RTP4
prerank,WikiPathway_2021_Human__Thyroid stimulating hormone (TSH) signaling pathway WP2032,-0.6618949803262524,-0.8680632924010568,0.6170212765957447,1.0,1.0,6/65,1.58%,MAP2K6;RAP1B;RB1;RAP1A;ADCY3;PAX8
prerank,Reactome_2022__TCF Dependent Signaling In Response To WNT R-HSA-201681,-0.559277221906344,-0.8679677060004176,0.7404580152671756,1.0,1.0,3/179,1.22%,TLE4;TNKS;CREBBP
prerank,Reactome_2022__Nuclear Pore Complex (NPC) Disassembly R-HSA-3301854,0.6562381698032176,0.8679099367266668,0.6451612903225806,0.9553019211714758,1.0,2/36,1.05%,NEK6;NUP210
prerank,MSigDB_Oncogenic_Signatures__AKT UP MTOR DN.V1 UP,-0.5604066190024354,-0.8677560652208031,0.6888888888888889,1.0,1.0,8/159,2.31%,TGIF1;ADAM10;PTPRJ;SGPL1;MLLT1;HCK;VILL;EFNB2
prerank,Reactome_2022__Metabolic Disorders Of Biological Oxidation Enzymes R-HSA-5579029,0.6194751044102652,0.8676488003613668,0.6546762589928058,0.9552543418288443,1.0,3/30,1.70%,MAOA;CYP27B1;FDXR
prerank,KEGG_2021_Human__Relaxin signaling pathway,-0.570557388404937,-0.867501762454054,0.656934306569343,1.0,1.0,8/120,1.94%,CREB3L2;AKT3;PIK3CB;ADCY3;CREB5;PLCB4;MMP2;COL4A4
prerank,GO_Biological_Process_2021__protein localization to cell junction (GO:1902414),0.622019118316181,0.867491194539054,0.6461538461538462,0.9550959261370138,1.0,2/21,1.44%,TJP1;ARHGEF18
prerank,Elsevier_Pathway_Collection__Hypothalamic-Pituitary-Adrenal Axis in Acute Phase Response,-0.631750016017216,-0.8674609251693034,0.6386554621848739,1.0,1.0,3/26,1.54%,NR3C1;RAP1A;RAPGEF3
prerank,GO_Biological_Process_2021__regulation of angiogenesis (GO:0045765),0.5425370576349023,0.867418459822295,0.7272727272727273,0.9547905517897368,1.0,10/195,2.37%,PIK3CD;GTF2I;NIBAN2;ZNF304;PPP1R16B;PTPRM;CTSH;SERPINE1;HK2;FGF1
prerank,Elsevier_Pathway_Collection__T-Cell Cytotoxic Response in Ulcerative Colitis,-0.642377168816124,-0.8673785686231851,0.6935483870967742,1.0,1.0,2/45,2.44%,PTK2B;ZAP70
prerank,GO_Biological_Process_2021__sister chromatid segregation (GO:0000819),-0.6552387380248499,-0.8673263490680039,0.6416666666666667,1.0,1.0,2/34,1.15%,NSL1;RB1
prerank,KEGG_2021_Human__TNF signaling pathway,0.5804346174754386,0.8668449054411609,0.6341463414634146,0.9552709795677807,1.0,8/111,1.98%,TRAF3;PIK3CD;CREB1;NOD2;CASP7;CX3CL1;PTGS2;MAPK13
prerank,GO_Biological_Process_2021__calcium ion transmembrane import into cytosol (GO:0097553),-0.6559665608498785,-0.8666954236295529,0.6834532374100719,1.0,1.0,1/38,1.08%,GRIN2B
prerank,GO_Biological_Process_2021__regulated exocytosis (GO:0045055),-0.5577578553175107,-0.8664628433360089,0.75,1.0,1.0,8/175,2.38%,A1BG;APP;NHLRC2;PROS1;SYT2;CD9;SYT7;HRG
prerank,Reactome_2022__Dual Incision In GG-NER R-HSA-5696400,0.6581988308595943,0.8663570399948008,0.648,0.9556422601184522,1.0,2/41,0.85%,SLC19A1;POLE4
prerank,WikiPathway_2021_Human__MECP2 and Associated Rett Syndrome WP3584,0.6429756545462602,0.8662743886840156,0.6446280991735537,0.9553209524026935,1.0,3/64,2.37%,CREB1;GPRIN1;DLX6
prerank,Reactome_2022__SARS-CoV Infections R-HSA-9679506,0.49506514440667015,0.8662327839807569,0.859504132231405,0.954951657047182,1.0,14/345,2.17%,TRAF3;TJP1;ST3GAL1;IRAK2;YWHAQ;NOD2;DAD1;NUP210;ITGA4;CRB3;SYK;MOGAT2;HAVCR1;ZDHHC9
prerank,MSigDB_Oncogenic_Signatures__PRC1 BMI UP.V1 UP,0.565657843989091,0.8662130650625627,0.7142857142857143,0.9545545441700467,1.0,11/151,1.96%,EPHX2;SLC25A23;QPRT;MTHFS;SPTBN2;PACSIN3;SOAT2;KCNC1;PNPLA3;STMN3;SERPINA7
prerank,Elsevier_Pathway_Collection__CD16/CD14 Proinflammatory Monocyte Activation,0.6358998433592844,0.8661445020990882,0.635593220338983,0.9542442023597647,1.0,4/66,1.42%,TRAF3;CD4;SYK;CX3CL1
prerank,WikiPathway_2021_Human__Proteasome Degradation WP183,-0.6447513070385399,-0.8661043085062017,0.6691176470588235,1.0,1.0,2/59,2.20%,NEDD4;HLA-B
prerank,MSigDB_Hallmark_2020__Bile Acid Metabolism,-0.5940446503831736,-0.8660646547515741,0.7111111111111111,1.0,1.0,10/112,2.03%,SLC23A2;CYP39A1;ABCD3;SULT1B1;NEDD4;ABCA6;SLCO1A2;LIPE;HAO1;HSD17B6
prerank,KEGG_2021_Human__Insulin signaling pathway,0.5815773647971088,0.8659799043515557,0.6166666666666667,0.9540606907084233,1.0,9/127,2.28%,ACACA;PIK3CD;PHKA2;RHOQ;PRKAA2;PKLR;PHKA1;HK2;HKDC1
prerank,GO_Biological_Process_2021__positive regulation of catalytic activity (GO:0043085),0.6577381570367271,0.865853535116544,0.6190476190476191,0.9538351776701258,1.0,2/38,0.90%,MSH2;NOD2
prerank,WikiPathway_2021_Human__White fat cell differentiation WP4149,-0.6463151132831297,-0.8656763794619066,0.6564885496183206,1.0,1.0,3/31,2.05%,NR3C1;STAT5A;KLF4
prerank,GO_Biological_Process_2021__immune response-activating cell surface receptor signaling pathway (GO:0002429),0.5847320650228778,0.8655451254574901,0.5785123966942148,0.9538687663135014,1.0,2/22,1.53%,LILRA2;BCAR1
prerank,Elsevier_Pathway_Collection__Th17-Cell and Th1 Immune Responsein Psoriatic Arthritis,-0.6424800123108173,-0.865513325836683,0.6666666666666666,1.0,1.0,5/59,2.44%,GRAP2;IL12RB2;RORC;IL21R;ZAP70
prerank,Elsevier_Pathway_Collection__Lipoxins and Resolvins in Inflammation Resolution,0.6068480066663908,0.865032269164847,0.59375,0.9543236023210784,1.0,2/21,1.82%,CX3CL1;PTGS2
prerank,WikiPathway_2021_Human__TGF-beta Receptor Signaling WP560,-0.6321566553167155,-0.8649552120085418,0.7022900763358778,1.0,1.0,3/54,1.50%,TGIF1;CREBBP;BMP4
prerank,GO_Biological_Process_2021__axonogenesis (GO:0007409),-0.5397083947646667,-0.8648737170232966,0.75,1.0,1.0,13/225,2.31%,PIK3CB;APP;NTN4;PARD3;SHH;FEZ1;GRB10;SLIT3;SLITRK3;DAB1;DSCAML1;SEMA4D;EFNB2
prerank,KEGG_2021_Human__Histidine metabolism,0.5869626380355087,0.8647750140138528,0.5702479338842975,0.9542546784778198,1.0,2/22,1.31%,MAOA;FTCD
prerank,Reactome_2022__Late SARS-CoV-2 Infection Events R-HSA-9772573,0.6451005341942194,0.8647721121548769,0.6557377049180327,0.9538370691209785,1.0,4/57,2.17%,ST3GAL1;DAD1;MOGAT2;ZDHHC9
prerank,GO_Biological_Process_2021__negative regulation of programmed cell death (GO:0043069),0.500817473622211,0.8647683747320506,0.8363636363636363,0.953415825331901,1.0,20/363,2.34%,AATF;TJP1;PLAUR;NIBAN2;RAB7A;PTK2;PRKAA2;CX3CL1;TNFRSF10D;ANXA1;FHL2;NAIP;CTSH;SH3RF2;PRLR;SH3RF1;PRAP1;HGF;FLNA;TBX3
prerank,MSigDB_Oncogenic_Signatures__JNK DN.V1 DN,0.5558111355016586,0.8647376671392467,0.7522123893805309,0.9530510271714588,1.0,7/154,2.01%,CDC45;SHB;THY1;SMAD9;UBE2C;PAQR4;QSOX1
prerank,Elsevier_Pathway_Collection__VEGFR -> AP-1/CREB/MYC Signaling,-0.6645101891204475,-0.8647367875250276,0.5813953488372093,1.0,1.0,2/43,0.23%,PTK2B;MAP2K6
prerank,"KEGG_2021_Human__Growth hormone synthesis, secretion and action",-0.5853746563862411,-0.8647035721146825,0.6222222222222222,1.0,1.0,9/109,1.91%,MAP2K6;CREB3L2;AKT3;PIK3CB;CREBBP;ADCY3;STAT5A;CREB5;PLCB4
prerank,GO_Biological_Process_2021__neuron projection development (GO:0031175),-0.5642914191842624,-0.8644445693702473,0.7132352941176471,1.0,1.0,7/163,2.12%,APP;ATXN10;NEDD4;DTNBP1;RB1;NTF3;HDGFL3
prerank,GO_Biological_Process_2021__axon guidance (GO:0007411),-0.5371608881670035,-0.864351489747408,0.7384615384615385,1.0,1.0,11/191,2.31%,PIK3CB;NTN4;SHH;FEZ1;GRB10;SLIT3;DAB1;RHOH;DSCAML1;SEMA4D;EFNB2
prerank,WikiPathway_2021_Human__Netrin-UNC5B signaling pathway WP4747,-0.658581428761976,-0.8642812024410375,0.65,1.0,1.0,3/49,0.82%,PTK2B;NEO1;NTN4
prerank,Elsevier_Pathway_Collection__Amyloid beta and APP Intracellular Transport in Alzheimer Disease,0.5801187492986237,0.8642267835189914,0.5811965811965812,0.9533490884799377,1.0,2/20,1.99%,RAB7A;APOE
prerank,GO_Biological_Process_2021__cellular response to oxidative stress (GO:0034599),0.5762574034219399,0.8642226180555312,0.6617647058823529,0.9529266238925068,1.0,7/121,2.39%,ETV5;PRKAA2;MPV17;AGAP3;TXNRD2;CYBA;PYCR1
prerank,Elsevier_Pathway_Collection__Exocytosis: Vesicle Docking,0.5765048752857787,0.8641938909293162,0.5726495726495726,0.9525425321605564,1.0,2/19,2.36%,RHOQ;STX1A
prerank,Elsevier_Pathway_Collection__FLT3/KIT/MLL Signaling in Leukemia,-0.6225916832296366,-0.8640691953118781,0.6492537313432836,1.0,1.0,2/29,1.39%,CREBBP;MEIS1
prerank,GO_Biological_Process_2021__membrane assembly (GO:0071709),0.6630479786908915,0.8640672344625352,0.6614173228346457,0.9523246944622328,1.0,1/36,0.37%,UBXN2A
prerank,MSigDB_Oncogenic_Signatures__IL15 UP.V1 UP,-0.5338241070836147,-0.8640637760691756,0.7054263565891473,1.0,1.0,6/162,2.19%,SLCO1A2;INHBB;KANK3;DUSP4;HABP2;VDR
prerank,GO_Biological_Process_2021__phospholipid metabolic process (GO:0006644),-0.6315235535270795,-0.8639079737528527,0.7063492063492064,1.0,1.0,5/68,2.08%,PLPP1;PLAAT3;AGPAT4;LIPG;SMPD1
prerank,GO_Biological_Process_2021__response to tumor necrosis factor (GO:0034612),-0.5879791792448685,-0.86387486414025,0.6691729323308271,1.0,1.0,4/102,2.08%,ADAM10;CCL23;GGT5;SMPD1
prerank,MSigDB_Oncogenic_Signatures__TGFB UP.V1 DN,0.5532528820985514,0.8636753682484194,0.7704918032786885,0.9524706964461745,1.0,5/164,1.83%,FNDC3B;ANKMY1;ZNF184;TUFT1;ZNF395
prerank,Reactome_2022__HDACs Deacetylate Histones R-HSA-3214815,0.6635473937446438,0.8636111188989392,0.6239316239316239,0.9521412429722739,1.0,2/48,0.32%,TBL1X;HDAC8
prerank,GO_Biological_Process_2021__protein K63-linked ubiquitination (GO:0070534),0.6571205175020776,0.8635376570035174,0.6612903225806451,0.95182206361321,1.0,2/43,0.96%,TRAF3;WWP2
prerank,GO_Biological_Process_2021__organelle organization (GO:0006996),0.49497553735076655,0.8634733185911273,0.8620689655172413,0.9515171354683949,1.0,21/406,2.11%,PRPF40A;YTHDF3;ABI2;UBXN2A;SIPA1L3;RAB3GAP1;ATAD3B;RAB7A;SORT1;ADCK1;ARHGEF7;THY1;CNTNAP1;PACSIN3;PNPLA3;MICAL3;APOE;FMNL2;DPYSL2;SYNE3;OPTN
prerank,Reactome_2022__Synthesis Of Leukotrienes (LT) And Eoxins (EX) R-HSA-2142691,0.5603533054685461,0.8634152853274368,0.559322033898305,0.9511705933550841,1.0,2/20,1.11%,CYP4F3;PTGR1
prerank,GO_Biological_Process_2021__cellular response to peptide (GO:1901653),0.6242716761851972,0.8632639657841346,0.6302521008403361,0.950971886797393,1.0,2/54,1.21%,NOD2;ITGA4
prerank,KEGG_2021_Human__Homologous recombination,0.6551974716191995,0.8631208885567739,0.6854838709677419,0.9508012548138282,1.0,2/40,1.15%,SYCP3;BRIP1
prerank,Elsevier_Pathway_Collection__MERTK Signaling,0.6045990810062416,0.8630414171920299,0.6475409836065574,0.9505032953732278,1.0,4/45,2.05%,PTK2;TUB;BCAR1;LGALS3
prerank,Elsevier_Pathway_Collection__CD8+ T-Cell Response in Celiac Disease,0.6271833227193122,0.8630406104082406,0.5963302752293578,0.9500821596641568,1.0,4/62,2.00%,SYK;ITGAL;CD48;NFATC2
prerank,WikiPathway_2021_Human__Pre-implantation embryo WP3527,-0.6425753733150784,-0.8628708379274863,0.6722689075630253,1.0,1.0,5/40,2.43%,MTA3;PBX1;KLF4;AQP3;FOSB
prerank,GO_Biological_Process_2021__chemical synaptic transmission (GO:0007268),-0.5268391870084129,-0.8625501401833745,0.7651515151515151,1.0,1.0,8/238,1.88%,ERC1;GRIN2B;HRH2;PMP22;GRIK5;SNPH;OMP;DLG2
prerank,WikiPathway_2021_Human__DNA Replication WP466,-0.65712086704549,-0.8624292776566345,0.6589147286821705,1.0,1.0,2/42,0.96%,ORC4;PRIM2
prerank,GO_Biological_Process_2021__inflammatory response (GO:0006954),0.5271574761271198,0.862347111466691,0.7966101694915254,0.9507101748427667,1.0,13/211,2.16%,PIK3CD;MEFV;APOL3;NFAM1;ITGAL;CX3CL1;LY75;IL1RN;ANXA1;HDAC9;CCL14;NAIP;CYBA
prerank,GO_Biological_Process_2021__establishment of protein localization to membrane (GO:0090150),-0.6122853703922996,-0.8623402237321981,0.627906976744186,1.0,1.0,4/67,2.42%,ZDHHC14;ZDHHC21;PARD3;RTP4
prerank,Reactome_2022__Signaling By Nuclear Receptors R-HSA-9006931,-0.5212521202785818,-0.862328400098247,0.8461538461538461,1.0,1.0,7/241,2.43%,AKT3;NCOA1;POU2F1;ZDHHC21;CREBBP;MMP2;FOSB
prerank,GO_Biological_Process_2021__cellular macromolecule catabolic process (GO:0044265),-0.622503780056333,-0.8622927304118245,0.6564885496183206,1.0,1.0,2/48,1.39%,FBXO27;ADAMTS9
prerank,Elsevier_Pathway_Collection__Gluten Impact on Neuronal System (Hypothesis),-0.642414653718294,-0.8619688808237652,0.6614173228346457,1.0,1.0,3/46,2.44%,GRAP2;IL10RA;ZAP70
prerank,GO_Biological_Process_2021__glucan catabolic process (GO:0009251),0.47885405682208193,0.8619009447431757,0.4576271186440678,0.9509875330715244,1.0,2/15,2.12%,PHKA2;PHKA1
prerank,Reactome_2022__VEGFR2 Mediated Vascular Permeability R-HSA-5218920,-0.5766907567072943,-0.8618272842274977,0.5970149253731343,1.0,1.0,2/26,2.34%,AKT3;VAV1
prerank,GO_Biological_Process_2021__positive regulation of cysteine-type endopeptidase activity (GO:2001056),0.6693145969529743,0.8616943548855239,0.6153846153846154,0.9508709565709744,1.0,3/59,2.31%,MEFV;SYK;UACA
prerank,Reactome_2022__Integration Of Energy Metabolism R-HSA-163685,0.583729174537214,0.8616801707927869,0.6814159292035398,0.9504762401489749,1.0,6/99,2.36%,ACACA;PRKAA2;PKLR;GNB5;GNG2;STX1A
prerank,GO_Biological_Process_2021__negative regulation of epidermal growth factor receptor signaling pathway (GO:0042059),0.6561203204884771,0.8616578923215461,0.6446280991735537,0.9500937921546959,1.0,4/43,1.07%,PTPN2;ZGPAT;RAB7A;ARHGEF7
prerank,WikiPathway_2021_Human__G13 Signaling Pathway WP524,0.6447325595865389,0.8616393357885911,0.6554621848739496,0.949699767998388,1.0,3/37,2.20%,PIK3CD;SH3RF1;RHPN2
prerank,GO_Biological_Process_2021__Notch signaling pathway (GO:0007219),-0.6497202677645604,-0.8616093750695608,0.65625,1.0,1.0,3/59,1.71%,ADAM10;CREBBP;PBX1
prerank,GO_Biological_Process_2021__response to endoplasmic reticulum stress (GO:0034976),-0.5861115874225173,-0.8615881842434743,0.7037037037037037,1.0,1.0,5/110,2.12%,TNFRSF10B;CREB3L2;ATG10;NIBAN1;THBS4
prerank,Elsevier_Pathway_Collection__Preconditioning Ischemia,0.6448113319070419,0.8613460311339457,0.6615384615384615,0.9497288578865768,1.0,3/35,2.19%,ACACA;PTGS2;HK2
prerank,Reactome_2022__Binding And Uptake Of Ligands By Scavenger Receptors R-HSA-2173782,0.6467687977089058,0.8613420676364928,0.6666666666666666,0.9493194712497836,1.0,2/40,1.99%,DLC1;APOE
prerank,MSigDB_Oncogenic_Signatures__RB DN.V1 UP,0.5644872036634822,0.8613276201924748,0.7350427350427351,0.9489203612673696,1.0,4/126,2.38%,ZFP30;SLC2A8;MAPK13;RRM2
prerank,KEGG_2021_Human__VEGF signaling pathway,0.6165315896239377,0.8612240717847395,0.6198347107438017,0.9486583745106082,1.0,5/56,2.00%,PIK3CD;PTK2;PTGS2;MAPK13;NFATC2
prerank,Reactome_2022__Signaling By FGFR1 R-HSA-5654736,-0.6661639585980093,-0.861106424631237,0.628099173553719,1.0,1.0,1/44,0.06%,FLRT2
prerank,MSigDB_Oncogenic_Signatures__BRCA1 DN.V1 UP,-0.6167458376141268,-0.8609824097859042,0.5968992248062015,1.0,1.0,5/93,2.34%,SP4;LDB2;SLCO1A2;RHOH;VAV1
prerank,TRRUST_Transcription_Factors_2019__TP53 human,-0.550627397708946,-0.8609551292642126,0.7542372881355932,1.0,1.0,6/159,2.09%,TNFRSF10B;RB1;MMP2;BDKRB2;AQP3;PML
prerank,GO_Biological_Process_2021__intrinsic apoptotic signaling pathway in response to DNA damage (GO:0008630),0.6480708841295673,0.8609378796897169,0.6693548387096774,0.9486482459383627,1.0,3/50,1.87%,FNIP2;MSH2;BOK
prerank,Elsevier_Pathway_Collection__WNT Canonical Signaling Activation in Cancer,0.5803448034222307,0.8609183977798197,0.5862068965517241,0.948267783457601,1.0,2/26,1.97%,LRP5;AXIN2
prerank,Reactome_2022__Transcriptional Regulation By AP-2 (TFAP2) Family Of Transcription Factors R-HSA-8864260,-0.6545090999968862,-0.8608742409447548,0.6611570247933884,1.0,1.0,1/30,1.22%,CREBBP
prerank,WikiPathway_2021_Human__Focal Adhesion WP306,-0.540309262722488,-0.8607776643083876,0.7185185185185186,1.0,1.0,12/191,2.34%,PAK2;ITGA1;RAP1B;TESK2;AKT3;PIK3CB;RAP1A;HCK;CCND2;COL4A4;THBS4;VAV1
prerank,Reactome_2022__Phase I - Functionalization Of Compounds R-HSA-211945,-0.5908398194192209,-0.8607035001307128,0.6384615384615384,1.0,1.0,10/96,2.17%,CYP39A1;CYP2C8;AADAC;NCOA1;CYP4V2;CYP4F22;CYP1B1;CYP1A2;AOC1;MAOB
prerank,GO_Biological_Process_2021__negative regulation of ubiquitin-dependent protein catabolic process (GO:2000059),0.659238175592219,0.8606717520326624,0.6299212598425197,0.9482123057534911,1.0,1/36,0.75%,TLK2
prerank,GO_Biological_Process_2021__positive regulation of cellular component organization (GO:0051130),0.6046625456287558,0.8606563624447893,0.6916666666666667,0.947802689811037,1.0,7/111,2.05%,FNIP2;FNIP1;CRB3;SYK;HAS3;APOE;LGALS3
prerank,Elsevier_Pathway_Collection__Lymphocyte Mediated Myocardial Injury in Myocarditis,-0.64247145337109,-0.8606227161437313,0.6771653543307087,1.0,1.0,5/68,2.44%,GRAP2;IL12RB2;RORC;IL21R;ZAP70
prerank,GO_Biological_Process_2021__cellular response to oxygen-containing compound (GO:1901701),-0.5228758263372393,-0.8604674479898143,0.8467741935483871,1.0,1.0,10/297,2.44%,PTK2B;CPEB3;RAP1B;RAP1A;RAPGEF3;TICAM2;RORC;AOC1;CD274;KCNE1
prerank,GO_Biological_Process_2021__anterograde axonal transport (GO:0008089),-0.6063368963683327,-0.8604509815694115,0.6124031007751938,1.0,1.0,3/37,1.88%,AP3B1;DTNBP1;DLG2
prerank,WikiPathway_2021_Human__VEGFA-VEGFR2 Signaling Pathway WP3888,0.49059399897784,0.8603126341989026,0.9159663865546218,0.9479234923374923,1.0,21/424,2.27%,ERN1;EIF2A;ACACA;CREB1;SHB;PLAUR;PTK2;PRKAA2;IGFBP3;TNFRSF25;BCAR1;PBK;ANXA1;FHL2;SLC7A1;ITGB5;PTGS2;HDAC9;TEAD4;NFATC2;FN1
prerank,Elsevier_Pathway_Collection__Dexamethasone Induced Neurotoxicity,-0.49684690685393645,-0.8602761662862085,0.4462809917355372,1.0,1.0,1/16,0.32%,NR3C1
prerank,WikiPathway_2021_Human__Breast cancer pathway WP4262,0.5661722909397524,0.860264819918118,0.7247706422018348,0.9475756495686898,1.0,7/145,2.37%,PIK3CD;LRP5;CDK6;ATR;NOTCH3;AXIN2;FGF1
prerank,GO_Biological_Process_2021__negative regulation of immune response (GO:0050777),-0.5512290485939951,-0.8601634043891719,0.7313432835820896,1.0,1.0,8/152,2.40%,GGT5;GPR39;HRH2;HCK;ADCY3;CD163;IRAK3;SPI1
prerank,GO_Biological_Process_2021__antigen receptor-mediated signaling pathway (GO:0050851),0.5463424746827856,0.8601070604705884,0.717741935483871,0.9474217693972122,1.0,10/177,2.25%,PIK3CD;TNFRSF21;PSMB9;CD4;SYK;THY1;NFAM1;BCAR1;NFATC2;MNDA
prerank,KEGG_2021_Human__Butanoate metabolism,-0.6543952569649085,-0.8600900730166793,0.7209302325581395,1.0,1.0,1/27,1.23%,ACSM2B
prerank,WikiPathway_2021_Human__Small cell lung cancer WP4658,0.5849002830384576,0.8599749433604401,0.624,0.9471712387334067,1.0,9/95,2.41%,ITGA3;TRAF3;PIK3CD;CDK6;PTK2;ITGA2;PTGS2;FN1;COL4A5
prerank,MSigDB_Oncogenic_Signatures__EGFR UP.V1 DN,0.5383649551119514,0.8599291482671578,0.7024793388429752,0.9468281336764367,1.0,14/164,2.37%,HIRA;FANCL;GTF2I;TRIM24;SLC27A2;BRIP1;ELOVL2;DEPDC1;DLC1;CTSH;CPE;COL9A3;CYBA;PRR7
prerank,GO_Biological_Process_2021__regulation of double-strand break repair via homologous recombination (GO:0010569),0.5849489062941017,0.8598485447382443,0.5772357723577236,0.9465465080171492,1.0,2/45,1.51%,SMCHD1;WRAP53
prerank,GO_Biological_Process_2021__positive regulation of stress fiber assembly (GO:0051496),-0.6210056872939702,-0.8597610866942266,0.6785714285714286,1.0,1.0,2/43,1.54%,CARMIL1;RAPGEF3
prerank,KEGG_2021_Human__ErbB signaling pathway,-0.5902197266574238,-0.859708531540733,0.6330935251798561,1.0,1.0,5/83,1.71%,PAK2;AKT3;PIK3CB;NRG1;STAT5A
prerank,Elsevier_Pathway_Collection__Neutrophil Activation via FCGR3B,0.6213740161128846,0.8595406027471899,0.6518518518518519,0.9465827212051084,1.0,3/50,2.16%,PLD1;SYK;CYBA
prerank,GO_Biological_Process_2021__regulation of GTPase activity (GO:0043087),-0.5245958019324231,-0.8589272416795302,0.8333333333333334,1.0,1.0,13/181,2.34%,EVI5;CCL23;RABGAP1;SIPA1L1;RIC1;SNX13;BCAS3;RAP1A;GPR137B;RASGRP2;RAPGEF3;SEMA4D;VAV1
prerank,Reactome_2022__Polymerase Switching On C-strand Of Telomere R-HSA-174411,0.5785378542386094,0.8586981751581376,0.5737704918032787,0.9474194343352703,1.0,2/25,2.15%,SLC19A1;ACD
prerank,TRRUST_Transcription_Factors_2019__SP3 human,0.587185996554294,0.8586462356375911,0.6228070175438597,0.9470630261418337,1.0,8/105,2.28%,CDH2;CD2AP;PLAUR;IGFBP3;CBS;MYCN;ITGA2;HGF
prerank,GO_Biological_Process_2021__negative regulation of TOR signaling (GO:0032007),0.6556987832264358,0.8586206373226479,0.6929824561403509,0.9466773800876942,1.0,2/38,1.10%,FNIP1;PRKAA2
prerank,Reactome_2022__Regulation Of RUNX2 Expression And Activity R-HSA-8939902,-0.6059441804917484,-0.8584390385103815,0.6097560975609756,1.0,1.0,2/69,0.95%,NR3C1;WWP1
prerank,GO_Biological_Process_2021__microtubule cytoskeleton organization involved in mitosis (GO:1902850),0.5642574702053527,0.8581865287303386,0.7286821705426356,0.9469281109847535,1.0,6/125,2.41%,NEK6;CENPE;NDC80;CENPA;ERCC6L;KIF3B
prerank,GO_Biological_Process_2021__long-chain fatty acid metabolic process (GO:0001676),0.6351332640899437,0.8580493215378088,0.6347826086956522,0.9466983574365073,1.0,8/81,2.22%,EPHX2;SLC27A2;CYP4F3;ELOVL2;PNPLA3;PTGS2;ELOVL6;ACSL5
prerank,Reactome_2022__Cyclin D Associated Events In G1 R-HSA-69231,0.6225322866905096,0.8580148244637078,0.6410256410256411,0.9463310845140921,1.0,3/47,0.91%,RBL1;CDK6;TFDP2
prerank,Reactome_2022__Signaling To ERKs R-HSA-187687,-0.6546234498111416,-0.8579618764397628,0.6744186046511628,1.0,1.0,1/32,1.21%,RAP1A
prerank,Reactome_2022__Cargo Trafficking To Periciliary Membrane R-HSA-5620920,-0.6434900692325694,-0.8579308323365761,0.6759259259259259,1.0,1.0,3/49,2.33%,EXOC2;PDE6D;BBS5
prerank,Elsevier_Pathway_Collection__Dendritic Cell Function in Ulcerative Colitis,0.6576961657202618,0.8577735501814179,0.6434108527131783,0.9462787851424177,1.0,1/44,0.90%,NOD2
prerank,KEGG_2021_Human__Phospholipase D signaling pathway,-0.5839233500868991,-0.8576535137609503,0.6879432624113475,1.0,1.0,9/139,2.05%,PTK2B;PLPP1;AKT3;PIK3CB;AGPAT4;RAPGEF3;ADCY3;PLCB4;PIK3R6
prerank,Elsevier_Pathway_Collection__HPV E6 and E7 Induced Disruption of TNFR/NF-kB Signaling in Keratinocytes,0.6645847435425439,0.8573273068325522,0.6186440677966102,0.946476177366418,1.0,1/53,0.21%,TRAF3
prerank,Reactome_2022__GRB2:SOS Provides Linkage To MAPK Signaling For Integrins R-HSA-354194,-0.5594329607734172,-0.8572656910067389,0.5478260869565217,1.0,1.0,2/15,1.21%,RAP1B;RAP1A
prerank,GO_Biological_Process_2021__response to amyloid-beta (GO:1904645),-0.6474610323976622,-0.8572433750277212,0.7218045112781954,1.0,1.0,2/41,1.93%,APP;MMP2
prerank,GO_Biological_Process_2021__microglial cell activation (GO:0001774),-0.5633521811481987,-0.8572054660178029,0.584,1.0,1.0,1/21,0.81%,APP
prerank,GO_Biological_Process_2021__peptidyl-serine phosphorylation (GO:0018105),0.5471468572013016,0.85717648591435,0.768595041322314,0.9462764961069613,1.0,10/153,1.98%,NEK6;ERN1;LMTK2;BRSK1;TLK2;CAB39;ATR;PDK3;STK32A;MAPK13
prerank,KEGG_2021_Human__Hippo signaling pathway,0.5618591134515956,0.8571737638671599,0.7363636363636363,0.945870769710254,1.0,9/159,2.37%,DLG1;DLG3;YWHAQ;AMH;CDH1;TEAD4;AXIN2;SERPINE1;FGF1
prerank,GO_Biological_Process_2021__cellular response to cytokine stimulus (GO:0071345),-0.4937166389852099,-0.8570474892011357,0.8705035971223022,1.0,1.0,22/434,2.40%,ZEB1;OAS1;PIK3CB;TEC;CCL23;POU2F1;PTPRJ;ITGAX;HCK;GRB10;GRAP2;STAT5A;IL11RA;IL12RB2;MMP2;RORC;IL10RA;PTPN18;S1PR1;VAV1;IRAK3;GBP4
prerank,Elsevier_Pathway_Collection__Nuclear Lamina Cleavage,-0.5770038316798133,-0.8570124850800783,0.6,1.0,1.0,2/20,2.31%,RB1;SYNE1
prerank,WikiPathway_2021_Human__T-cell receptor (TCR) signaling pathway WP69,-0.5845225823238,-0.8569860784376149,0.639344262295082,1.0,1.0,6/86,2.44%,PTK2B;GRAP2;CD83;VAV1;MAP4K1;ZAP70
prerank,Elsevier_Pathway_Collection__TP53 Signaling in Hepatocellular Carcinoma,-0.6210595602161546,-0.8569720000937585,0.627906976744186,1.0,1.0,2/18,1.54%,RB1;CCND2
prerank,Reactome_2022__Sensory Perception R-HSA-9709957,-0.5314753820053671,-0.8569002205623082,0.7872340425531915,1.0,1.0,5/194,2.03%,KCNN2;CYP4V2;LDB2;SDC3;HSD17B6
prerank,GO_Biological_Process_2021__drug catabolic process (GO:0042737),-0.5803093951932399,-0.8566708564075757,0.576271186440678,1.0,1.0,2/22,1.98%,CYP2C8;CYP1A2
prerank,GO_Biological_Process_2021__positive regulation of DNA repair (GO:0045739),0.6472661062742735,0.8565192715630288,0.6854838709677419,0.946421446494568,1.0,3/45,1.95%,SMCHD1;WRAP53;SPIRE2
prerank,GO_Biological_Process_2021__glycolytic process (GO:0006096),0.613631345915133,0.856443869045843,0.6333333333333333,0.9461023515420723,1.0,3/26,2.28%,PKLR;HK2;HKDC1
prerank,GO_Biological_Process_2021__proteasome-mediated ubiquitin-dependent protein catabolic process (GO:0043161),0.49885824768460885,0.8564018199927144,0.8487394957983193,0.9457756894527217,1.0,10/315,1.74%,TBL1X;UBXN2A;FOXRED2;WWP2;UBR3;PSMB9;FBXO31;AGAP3;MAN1A1;UBE2C
prerank,Elsevier_Pathway_Collection__Proteins Involved in HIV Type 1 Infection,0.62447186972627,0.856355852013823,0.6695652173913044,0.9454316672840467,1.0,4/79,2.27%,PLAUR;CD4;APOE;FN1
prerank,Elsevier_Pathway_Collection__Melanoma,0.5598441203825733,0.8563456398085583,0.6991150442477876,0.9450330731752311,1.0,9/140,2.37%,CDH2;CREB1;CDK6;PLAUR;PTK2;CDH1;HGF;TBX3;FGF1
prerank,MSigDB_Oncogenic_Signatures__MTOR UP.V1 DN,0.5418572488962434,0.8563040234747609,0.7786885245901639,0.9446916335199497,1.0,9/168,2.36%,UBXN2A;QPRT;UBR3;MYCN;CHRD;KCNC1;TNNC2;CPE;STX1A
prerank,Reactome_2022__Signaling By WNT R-HSA-195721,0.4965437127535008,0.8561869794159931,0.9215686274509803,0.944432727692089,1.0,5/272,2.34%,LRP5;PSMB9;GNB5;AXIN2;GNG2
prerank,MSigDB_Oncogenic_Signatures__PRC2 SUZ12 UP.V1 UP,0.5330570839693087,0.8560310842446914,0.7669172932330827,0.9442425477747268,1.0,9/148,2.04%,HS2ST1;ST3GAL1;EPHX2;RAVER2;SOAT2;IL1RN;PNPLA3;NAA10;LRRC61
prerank,GO_Biological_Process_2021__negative regulation of response to external stimulus (GO:0032102),0.5741077942208132,0.8558862803964707,0.6779661016949152,0.944050577145447,1.0,7/105,2.07%,LILRA2;PPARA;PTPN2;MEFV;SIGIRR;APOE;SERPINE1
prerank,MSigDB_Oncogenic_Signatures__KRAS.300 UP.V1 UP,-0.5910240695682261,-0.8558306409072111,0.6470588235294118,1.0,1.0,5/121,2.45%,DCBLD2;TFPI;ZNF528;MAP4K1;DNAJA4
prerank,GO_Biological_Process_2021__positive regulation of fibroblast proliferation (GO:0048146),0.5773820765465556,0.8558203988412931,0.624,0.9437297138634253,1.0,2/27,2.27%,CDK6;FN1
prerank,Elsevier_Pathway_Collection__Mucinous Ovarian Carcinoma,-0.6330533692550917,-0.855816606686262,0.71900826446281,1.0,1.0,4/60,1.71%,NCOA1;CREBBP;NRG1;STAT5A
prerank,WikiPathway_2021_Human__Differentiation of white and brown adipocyte WP2895,-0.5850386239362562,-0.8557168327538649,0.591304347826087,1.0,1.0,1/23,1.50%,BMP4
prerank,GO_Biological_Process_2021__cellular response to hydrogen peroxide (GO:0070301),0.6469263099853544,0.8557066640114078,0.6821705426356589,0.9434931775088912,1.0,2/35,1.98%,ANXA1;MAPK13
prerank,GO_Biological_Process_2021__regulation of cell cycle G2/M phase transition (GO:1902749),0.6149686998736988,0.8556626222926905,0.6134453781512605,0.9431474368354653,1.0,4/83,2.15%,HAUS8;CEP164;HAUS2;TUBA1A
prerank,Reactome_2022__Canonical Retinoid Cycle In Rods (Twilight Vision) R-HSA-2453902,-0.5797734704262835,-0.8555103384152173,0.584070796460177,1.0,1.0,2/19,2.03%,CYP4V2;HSD17B6
prerank,Elsevier_Pathway_Collection__EPCAM in Cancer Cell Motility and Proliferation,0.6493514457087173,0.8553001231121943,0.6576576576576577,0.9432648342030716,1.0,3/35,1.74%,LRP5;CDH1;FHL2
prerank,GO_Biological_Process_2021__negative regulation of signal transduction (GO:0009968),0.5118345334803445,0.8551893085587788,0.813953488372093,0.9430229518943211,1.0,13/252,1.79%,LILRA2;VGLL4;MEGF8;HERC4;PTPN2;NIBAN2;WWP2;IGFBP3;ERBB3;NOTCH3;CX3CL1;CADM4;SIGIRR
prerank,Elsevier_Pathway_Collection__CHRNA7 -> NOS1 Production,0.49146400174892935,0.8551770398780709,0.4358974358974359,0.9426310368591909,1.0,2/17,0.86%,CREB1;PTK2
prerank,GO_Biological_Process_2021__negative regulation of cellular response to growth factor stimulus (GO:0090288),0.6148174606887716,0.8550969159162539,0.6153846153846154,0.9423389302922379,1.0,4/71,1.69%,NIBAN2;CHRD;CADM4;SMAD9
prerank,Elsevier_Pathway_Collection__EGFR Signaling,0.6581179392113701,0.8550786761312932,0.6693548387096774,0.9419632481649398,1.0,2/52,0.86%,CREB1;PTK2
prerank,WikiPathway_2021_Human__Cysteine and methionine catabolism WP4504,-0.5495135513779839,-0.8549444048484435,0.5072463768115942,1.0,1.0,2/15,2.20%,BHMT;CDO1
prerank,GO_Biological_Process_2021__estrogen metabolic process (GO:0008210),-0.6470471144926696,-0.8549241315002133,0.6742424242424242,1.0,1.0,4/30,1.98%,CYP3A7;CYP2C8;CYP1B1;CYP1A2
prerank,GO_Biological_Process_2021__mitotic sister chromatid segregation (GO:0000070),0.5785130934117257,0.8549074633456151,0.7154471544715447,0.9418080911901495,1.0,5/101,2.16%,DIS3L2;CENPE;NCAPG;NDC80;KIF23
prerank,MSigDB_Oncogenic_Signatures__RELA DN.V1 UP,0.5760566048504658,0.8548924743041876,0.6949152542372882,0.9414154344539942,1.0,8/131,1.88%,LMO7;ZNF165;ZNF286A;SAMSN1;FOSL1;SLC7A1;PTGS2;DAPP1
prerank,MSigDB_Oncogenic_Signatures__E2F3 UP.V1 UP,-0.5505054395341664,-0.8548842733509581,0.7398373983739838,1.0,1.0,7/167,2.11%,CDK19;ZDHHC14;RTN4RL1;INHBB;KCNS3;IL17RB;CD83
prerank,Reactome_2022__ER-Phagosome Pathway R-HSA-1236974,-0.6030599569774541,-0.8548392521664688,0.5984251968503937,1.0,1.0,2/87,2.20%,SEC61A2;HLA-B
prerank,Reactome_2022__Signaling By TGFB Family Members R-HSA-9006936,0.5723100304994426,0.8547911072347455,0.6885245901639344,0.9411418836299629,1.0,9/117,2.32%,RBL1;USP15;TFDP2;ARHGEF18;AMH;SMAD9;ITGB5;SERPINE1;ZFYVE9
prerank,KEGG_2021_Human__Pathways in cancer,-0.49016954588429373,-0.854777801437194,0.9457364341085271,1.0,1.0,27/493,2.40%,GSTA1;POLK;AKT3;PIK3CB;NCOA1;RB1;CREBBP;GSTA2;RASGRP2;SUFU;SHH;BMP4;CCND2;ADCY3;PAX8;RASSF5;STAT5A;IL12RB2;DAPK2;PLCB4;MMP2;COL4A4;RASGRP3;BDKRB2;GLI3;PML;SPI1
prerank,Elsevier_Pathway_Collection__Endometrioid Endometrial Cancer,0.5820273220740819,0.8546451511614642,0.648854961832061,0.9409347383301356,1.0,5/91,1.19%,ARID1B;CREB1;LRP5;MSH2;ERBB3
prerank,GO_Biological_Process_2021__cortical cytoskeleton organization (GO:0030865),0.6940799377510596,0.8543021977624722,0.6964285714285714,0.9410215115074548,1.0,3/41,2.03%,DLG1;RHOQ;FMNL2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hepatocellular Carcinoma,0.5588346623768565,0.8542203513842122,0.7795275590551181,0.9407212639391044,1.0,7/120,2.03%,PPARA;CREB1;PTK2;ERBB3;FBXO31;CPE;FMNL2
prerank,TRRUST_Transcription_Factors_2019__RELA human,0.5107252152894404,0.8542189812619024,0.8173913043478261,0.9403163211887458,1.0,15/281,2.29%,PPARA;TNFRSF10A;CDK6;PLAUR;PSMB9;PROX1;IL1RN;AMH;CYP27B1;CDH1;PTGS2;SERPINE1;OPTN;FN1;CD86
prerank,GO_Biological_Process_2021__regulation of chemokine production (GO:0032642),-0.6585833078217397,-0.8540244571332742,0.640625,1.0,1.0,1/39,0.81%,APP
prerank,Reactome_2022__DAP12 Signaling R-HSA-2424491,-0.6500107926019852,-0.8539714917509931,0.6825396825396826,1.0,1.0,2/27,1.68%,PIK3CB;GRAP2
prerank,GO_Biological_Process_2021__mesenchymal cell development (GO:0014031),0.5703898942429436,0.8539262969039765,0.5564516129032258,0.9402808547273621,1.0,1/18,0.11%,CDH2
prerank,Reactome_2022__Signaling By VEGF R-HSA-194138,0.5897410389209176,0.8538975890759937,0.6513761467889908,0.9399133489570389,1.0,7/100,2.16%,ABI2;SHB;PTK2;ARHGEF7;BCAR1;MAPK13;CYBA
prerank,GO_Biological_Process_2021__double-strand break repair via homologous recombination (GO:0000724),0.5902802397550323,0.8537423747337024,0.6532258064516129,0.9397033890378822,1.0,3/95,0.98%,MMS22L;CDC45;SMC5
prerank,GO_Biological_Process_2021__DNA replication (GO:0006260),0.5774672880492896,0.853725535786137,0.7008547008547008,0.939311226683276,1.0,5/106,2.26%,CDC45;ING5;ATR;BRIP1;PIF1
prerank,KEGG_2021_Human__Cocaine addiction,-0.6425715507808765,-0.8535074496663513,0.7307692307692307,1.0,1.0,5/44,2.43%,CREB3L2;GRIN2B;CREB5;MAOB;FOSB
prerank,WikiPathway_2021_Human__Ectoderm Differentiation WP2858,-0.5623875861623966,-0.8534763533566575,0.6821705426356589,1.0,1.0,8/130,2.32%,ARHGAP10;BCAS3;LDB2;SHH;BMP4;BOC;GLI3;ZFHX4
prerank,GO_Biological_Process_2021__adenylate cyclase-modulating G protein-coupled receptor signaling pathway (GO:0007188),-0.5768187790267226,-0.8533882952972128,0.6821705426356589,1.0,1.0,4/139,2.32%,ADCY3;S1PR1;ADGRE5;GNA14
prerank,GO_Biological_Process_2021__regulation of ion transport (GO:0043269),-0.6264571896302134,-0.8533238990455629,0.6692307692307692,1.0,1.0,4/71,2.37%,NEDD4;DTNBP1;SYT2;SYT7
prerank,Reactome_2022__Recruitment Of NuMA To Mitotic Centrosomes R-HSA-380320,0.6149711838504623,0.8532361573706572,0.6782608695652174,0.9395749251883531,1.0,4/80,2.15%,HAUS8;CEP164;HAUS2;TUBA1A
prerank,GO_Biological_Process_2021__negative regulation of kinase activity (GO:0033673),-0.6267502610232072,-0.8532101580975566,0.6412213740458015,1.0,1.0,4/61,1.34%,PAK2;DTNBP1;RB1;DEPTOR
prerank,Elsevier_Pathway_Collection__FibronectinR -> NF-kB Signaling,0.5488582973228717,0.852916902897378,0.5407407407407407,0.9395669951721147,1.0,3/17,2.27%,PTK2;BCAR1;FN1
prerank,Reactome_2022__SUMOylation Of Ubiquitinylation Proteins R-HSA-3232142,0.6561973039921609,0.8526806276169765,0.6456692913385826,0.9394699358350369,1.0,1/39,1.05%,NUP210
prerank,Reactome_2022__Hedgehog Off State R-HSA-5610787,0.5713760093240366,0.8526282477338702,0.7631578947368421,0.9391308467479269,1.0,2/95,1.20%,SMOX;PSMB9
prerank,Elsevier_Pathway_Collection__Negative Acute Phase Proteins Synthesis,0.6647395560249432,0.852571763052497,0.648854961832061,0.938797858071633,1.0,1/46,0.20%,PPARA
prerank,Elsevier_Pathway_Collection__DREAM Complex and FOXM1/MYBL2 Promote Cell Cycle Progression in Cancer,0.6600499067882186,0.8524768155715305,0.680672268907563,0.9384980552714037,1.0,2/28,0.67%,RBL1;CDK6
prerank,Reactome_2022__SLC-mediated Transmembrane Transport R-HSA-425407,-0.5169879405481793,-0.8523275927157633,0.7906976744186046,1.0,1.0,14/227,2.46%,SLC41A2;SLC22A1;SLC7A9;SLC35A3;SLC2A10;AHCYL2;SLC36A4;SLCO1A2;SLC7A8;SLCO3A1;SLC15A3;SLC9A9;SLC4A5;SLC16A2
prerank,MSigDB_Hallmark_2020__Allograft Rejection,0.5255465971513208,0.8523183326188275,0.6545454545454545,0.938283624451562,1.0,7/192,2.29%,CD4;THY1;ITGAL;LY75;HDAC9;FLNA;CD86
prerank,Elsevier_Pathway_Collection__MC1R in anti-Inflammatory Signaling,-0.6288110233550234,-0.8520772750288088,0.664,1.0,1.0,5/43,2.36%,MAP2K6;RAP1A;RAPGEF3;TICAM2;IRAK3
prerank,WikiPathway_2021_Human__Fibrin Complement Receptor 3 Signaling Pathway WP4136,0.6238552377694674,0.8519972702775755,0.6693548387096774,0.938284004840347,1.0,2/40,1.26%,IRAK2;SYK
prerank,Reactome_2022__Inactivation Of CSF3 (G-CSF) Signaling R-HSA-9705462,-0.6079990996171751,-0.8519745951530456,0.6691729323308271,1.0,1.0,2/25,1.71%,HCK;STAT5A
prerank,MSigDB_Oncogenic_Signatures__GLI1 UP.V1 UP,0.5683511293501373,0.851949920820142,0.5887096774193549,0.9379480877969102,1.0,1/23,0.31%,LMO7
prerank,GO_Biological_Process_2021__negative regulation of cytokine-mediated signaling pathway (GO:0001960),0.6344255228269349,0.8519410389109563,0.6637168141592921,0.9375564341695942,1.0,5/50,1.79%,YTHDF3;PTPN2;PADI2;IL1RN;SIGIRR
prerank,Elsevier_Pathway_Collection__Hodgkin Lymphoma,0.5819815561809103,0.8519104914502729,0.6694214876033058,0.9371921522907932,1.0,4/105,1.81%,TRAF3;SYK;ITGAL;IL13RA1
prerank,KEGG_2021_Human__Amoebiasis,0.5914354019490887,0.8518691440538292,0.6637931034482759,0.9368436253796202,1.0,5/94,2.41%,PIK3CD;RAB7A;PTK2;FN1;COL4A5
prerank,GO_Biological_Process_2021__positive regulation of cell-substrate junction organization (GO:0150117),-0.5916936752407552,-0.8516603347402819,0.5984848484848485,1.0,1.0,3/23,2.38%,PTPRJ;TEK;HRG
prerank,MSigDB_Oncogenic_Signatures__PRC2 EZH2 UP.V1 UP,0.557763168321101,0.8515924523811553,0.7391304347826086,0.9368465526650295,1.0,10/166,2.25%,CDC45;EPHX2;LIN7A;MEFV;LRRC20;DEPDC1;SOAT2;FOSL2;LRRC61;SLC2A6
prerank,Reactome_2022__Integrin Cell Surface Interactions R-HSA-216083,0.6223956357841902,0.8514834292280683,0.6451612903225806,0.9366180461016109,1.0,8/64,2.30%,ITGA3;ITGA4;ITGAL;ITGA2;ITGB5;COL9A3;FN1;COL9A2
prerank,GO_Biological_Process_2021__plasma membrane bounded cell projection morphogenesis (GO:0120039),-0.6486869117896223,-0.8514309563748923,0.6715328467153284,1.0,1.0,2/49,1.81%,DTNBP1;NTF3
prerank,Reactome_2022__Peroxisomal Protein Import R-HSA-9033241,0.6094003970313128,0.8513909622956065,0.6574074074074074,0.9363357581182209,1.0,3/61,1.57%,EPHX2;SLC27A2;MPV17
prerank,GO_Biological_Process_2021__epidermal growth factor receptor signaling pathway (GO:0007173),0.6453405761955333,0.8512918428188344,0.6692913385826772,0.9360305889490017,1.0,3/46,2.14%,PTK2;BCAR1;SLC30A10
prerank,GO_Biological_Process_2021__regulation of vascular endothelial cell proliferation (GO:1905562),-0.5667752580298212,-0.8512740963922161,0.5462184873949579,1.0,1.0,1/18,0.47%,AKT3
prerank,KEGG_2021_Human__TGF-beta signaling pathway,-0.6137633023359975,-0.8512260550045125,0.6830985915492958,1.0,1.0,6/92,1.50%,TGIF1;ZFYVE16;NEO1;CREBBP;INHBB;BMP4
prerank,Reactome_2022__Glycerophospholipid Biosynthesis R-HSA-1483206,0.5486144202882327,0.851191790057466,0.7217391304347827,0.9357603514515865,1.0,7/119,2.30%,LCLAT1;AGPAT3;GPAT4;PNPLA3;LPCAT2;GPD1L;LPIN3
prerank,GO_Biological_Process_2021__positive regulation of granulocyte chemotaxis (GO:0071624),-0.5503549696422422,-0.85117612076239,0.5692307692307692,1.0,1.0,2/20,2.12%,DAPK2;THBS4
prerank,GO_Biological_Process_2021__regulation of ion transmembrane transporter activity (GO:0032412),-0.6315131809065277,-0.8511257097471094,0.7,1.0,1.0,3/36,1.57%,WNK3;NEDD4;FXYD6
prerank,Elsevier_Pathway_Collection__HRH2/4 -> IL6/10 Production,-0.5976118813065535,-0.851039040650439,0.5957446808510638,1.0,1.0,3/23,1.36%,RAP1A;CREBBP;HRH2
prerank,Elsevier_Pathway_Collection__Basophil Activation in Asthma,-0.6017369296476512,-0.8508578365441892,0.6581196581196581,1.0,1.0,4/60,2.34%,MAP2K6;GRAP2;STAT5A;VAV1
prerank,GO_Biological_Process_2021__regulation of phosphatidylinositol 3-kinase signaling (GO:0014066),0.5773946849219248,0.8506947371338485,0.6818181818181818,0.9360101736177071,1.0,7/101,2.28%,PIK3CD;PTK2;PPP1R16B;ERBB3;PIK3AP1;FN1;HGF
prerank,MSigDB_Hallmark_2020__KRAS Signaling Dn,-0.5535642759832331,-0.8505823828676197,0.7372262773722628,1.0,1.0,7/162,1.81%,CPEB3;CYP39A1;IFI44L;PTPRJ;VPS50;TENT5C;NTF3
prerank,Elsevier_Pathway_Collection__Dentin Formation Disruption,0.6462773415206968,0.8504866797453364,0.6788990825688074,0.9358922090427825,1.0,3/30,2.05%,SMAD9;MSX1;EDA2R
prerank,Reactome_2022__Peptide Ligand-Binding Receptors R-HSA-375276,-0.5513741503808354,-0.8504271292296832,0.7734375,1.0,1.0,4/143,2.01%,CCL23;APP;C5AR2;BDKRB2
prerank,KEGG_2021_Human__Oxytocin signaling pathway,0.5401013229079676,0.8502153917502809,0.7171717171717171,0.9358705275092316,1.0,5/142,2.00%,PPP1R12A;PRKAA2;CACNA2D4;PTGS2;NFATC2
prerank,GO_Biological_Process_2021__xenobiotic transport (GO:0042908),0.5364432299658717,0.8501870391772658,0.5564516129032258,0.9354989116979953,1.0,2/20,1.92%,SLC47A1;NR1I2
prerank,Elsevier_Pathway_Collection__T-Cell Central Tolerance,-0.6423823503466938,-0.8501794114009356,0.706766917293233,1.0,1.0,2/39,2.44%,CD274;ZAP70
prerank,GO_Biological_Process_2021__positive regulation of neutrophil chemotaxis (GO:0090023),-0.5503558102496828,-0.8501541571741817,0.5634920634920635,1.0,1.0,2/19,2.12%,DAPK2;THBS4
prerank,GO_Biological_Process_2021__positive regulation of multicellular organismal process (GO:0051240),0.48907771375088144,0.8501219602853469,0.9649122807017544,0.935171819671683,1.0,10/307,2.09%,PIK3CD;NIBAN2;SYK;NFAM1;CYP27B1;ELOVL6;AXIN2;APOE;SERPINE1;PRLR
prerank,GO_Biological_Process_2021__positive regulation of neutrophil migration (GO:1902624),-0.5503533093042593,-0.8500929830507842,0.5793650793650794,1.0,1.0,2/22,2.12%,DAPK2;THBS4
prerank,KEGG_2021_Human__Osteoclast differentiation,0.5531949182879509,0.8500160712767628,0.7007874015748031,0.9349295389702496,1.0,10/123,2.16%,LILRA2;PIK3CD;CREB1;SYK;FHL2;FOSL1;FOSL2;MAPK13;NFATC2;CYBA
prerank,GO_Biological_Process_2021__muscle contraction (GO:0006936),0.5822070955932068,0.8499310645865311,0.7610619469026548,0.9346432972362834,1.0,6/114,1.79%,SNTB1;GJC1;MYOF;TNNC2;SNTA1;ITGB5
prerank,Reactome_2022__VEGFA-VEGFR2 Pathway R-HSA-4420097,0.5897485209231479,0.8498866281973741,0.6722689075630253,0.934297794547622,1.0,7/91,2.16%,ABI2;SHB;PTK2;ARHGEF7;BCAR1;MAPK13;CYBA
prerank,MSigDB_Hallmark_2020__Angiogenesis,0.6106850143447876,0.8496447372195103,0.6238532110091743,0.9342365563857137,1.0,4/36,2.10%,PTK2;TNFRSF21;MSX1;SERPINA5
prerank,MSigDB_Oncogenic_Signatures__CYCLIN D1 UP.V1 DN,0.5330332740762163,0.8496403856414453,0.813953488372093,0.9338454927681524,1.0,5/166,1.54%,ITGA3;PPARA;ATR;ASGR2;SLC6A4
prerank,GO_Biological_Process_2021__negative regulation of DNA replication (GO:0008156),0.4898496378543454,0.849480138215441,0.46846846846846846,0.933661806982978,1.0,1/15,1.02%,ATR
prerank,WikiPathway_2021_Human__Selective expression of chemokine receptors during T-cell polarization WP4494,0.5877667679656035,0.8493778160531695,0.6071428571428571,0.9334207901181747,1.0,1/27,1.23%,CD4
prerank,Elsevier_Pathway_Collection__Lipogenesis/Lipolysis Activation in Cancer Cells and Cancer-Associated Adipocytes,0.6068433709387999,0.8492174990104107,0.6423357664233577,0.9332546809315552,1.0,2/32,0.86%,ACACA;PTK2
prerank,Reactome_2022__Interleukin-1 Family Signaling R-HSA-446652,0.5579849123289009,0.8490815259240068,0.7079646017699115,0.9330236160417543,1.0,6/141,1.79%,PTPN2;IRAK2;NOD2;PSMB9;IL1RN;SIGIRR
prerank,Elsevier_Pathway_Collection__Proteins Involved in Glioma,0.5045961828461845,0.848965313861212,0.8617886178861789,0.9327965755897729,1.0,15/256,2.28%,RFX1;PLAUR;PTK2;LRRC4;NOTCH3;MYCN;CYP27B1;FHL2;UBE2C;PTPRM;PTGS2;LGALS3;ACSL5;FN1;HGF
prerank,KEGG_2021_Human__mRNA surveillance pathway,-0.6228263576113133,-0.8489328804419963,0.696969696969697,1.0,1.0,2/92,1.36%,RNGTT;SMG6
prerank,GO_Biological_Process_2021__negative regulation of protein binding (GO:0032091),-0.6041322572596701,-0.8489327497739881,0.6694214876033058,1.0,1.0,2/71,1.13%,CCL23;TTBK2
prerank,"GO_Biological_Process_2021__regulation of synaptic transmission, glutamatergic (GO:0051966)",-0.6620095591297324,-0.8488341671762485,0.6744186046511628,1.0,1.0,2/37,0.48%,PTK2B;ATAD1
prerank,GO_Biological_Process_2021__negative regulation of calcium ion transmembrane transporter activity (GO:1901020),0.5790019670651341,0.84870596027924,0.5819672131147541,0.9327227680410282,1.0,3/22,2.11%,DRD4;GNB5;GPR35
prerank,GO_Biological_Process_2021__mitotic DNA damage checkpoint signaling (GO:0044773),0.6332325447487791,0.8486713417443075,0.7096774193548387,0.932367932715232,1.0,3/58,1.39%,BRSK1;CDC14B;FBXO31
prerank,GO_Biological_Process_2021__protein O-linked glycosylation (GO:0006493),0.6167073439696666,0.8485347121391217,0.6890756302521008,0.9321777768577941,1.0,5/96,0.85%,PLOD2;TRAK1;POMGNT2;ST3GAL1;TMTC2
prerank,Elsevier_Pathway_Collection__VEGFA in Neovascular Glaucoma,0.5818352116806882,0.8484098892084945,0.6033057851239669,0.9319094499468722,1.0,2/39,1.82%,PTK2;PTGS2
prerank,GO_Biological_Process_2021__proteolysis (GO:0006508),-0.4942752490416835,-0.8483876545758299,0.9178082191780822,1.0,1.0,10/255,2.26%,ADAM10;CPQ;GGT5;CTSO;ADAMTS9;SUFU;ADAM33;MMP2;HABP2;TMPRSS2
prerank,Elsevier_Pathway_Collection__CD8+ Naive T-cell -> CD4+ Naive T-cell Surface Expression Markers,0.586339839119493,0.8479800075939292,0.6371681415929203,0.9321264258118785,1.0,2/35,1.37%,CD4;ITGAL
prerank,Elsevier_Pathway_Collection__Potassium Cycling in the Inner Ear (Noise-Induced),0.5865400131354865,0.8477879030693188,0.5929203539823009,0.9319824292480328,1.0,1/20,1.35%,KCNJ10
prerank,Reactome_2022__Centrosome Maturation R-HSA-380287,0.6149703614417885,0.8476732239270767,0.6842105263157895,0.9317297920735109,1.0,4/81,2.15%,HAUS8;CEP164;HAUS2;TUBA1A
prerank,MSigDB_Oncogenic_Signatures__KRAS.LUNG UP.V1 DN,-0.5846175899780753,-0.8476147120796189,0.7037037037037037,1.0,1.0,5/108,2.42%,MAP2K6;GLYAT;NYNRIN;IL10RA;RTP4
prerank,GO_Biological_Process_2021__regulation of trans-synaptic signaling (GO:0099177),-0.6070322878304543,-0.8473684664736277,0.6692307692307692,1.0,1.0,2/32,1.81%,GRIK5;NTF3
prerank,Elsevier_Pathway_Collection__Skin Aging,-0.647262867719808,-0.8473579842409394,0.7226890756302521,1.0,1.0,3/49,1.95%,MAP2K6;MMP2;RASGRP3
prerank,Reactome_2022__Caspase Activation Via Extrinsic Apoptotic Signaling Pathway R-HSA-5357769,-0.5817684838852065,-0.8473271192052949,0.6147540983606558,1.0,1.0,2/25,1.83%,TNFRSF10B;DAPK2
prerank,GO_Biological_Process_2021__endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888),-0.5215396351605324,-0.8473027808932609,0.8428571428571429,1.0,1.0,4/181,2.39%,ATL2;PROS1;TICAM2;COL7A1
prerank,Elsevier_Pathway_Collection__TP53 Signaling in Pancreatic Neoplasms,-0.6210577225506694,-0.8472367743560207,0.6564885496183206,1.0,1.0,2/21,1.54%,RB1;CCND2
prerank,GO_Biological_Process_2021__regulation of kinase activity (GO:0043549),0.5990339622192845,0.847228746145366,0.680327868852459,0.9319065143744124,1.0,5/92,1.65%,LMTK2;RBL1;ERBB3;CD4;DRD4
prerank,MSigDB_Oncogenic_Signatures__SNF5 DN.V1 DN,0.5408639673919413,0.8472041430449649,0.7622950819672131,0.9315378271606515,1.0,7/141,2.18%,ITGA3;TNFRSF21;LY75;FBLIM1;MAPK13;RBP4;SH3RF1
prerank,Elsevier_Pathway_Collection__VEGF Independent Angiogenesis in Cancer,0.6430253557416802,0.847149897792651,0.6694214876033058,0.9312437747024958,1.0,3/52,2.37%,PTK2;HGF;FGF1
prerank,TRRUST_Transcription_Factors_2019__SP1 human,-0.48452265370299696,-0.8471112179219854,0.9705882352941176,1.0,1.0,23/441,2.39%,TNFRSF10B;ADAM10;CYP3A7;MUC6;APP;SOD2;SGPL1;GPR39;ITGAX;CCND2;CD44;CYP1B1;CD163;MMP2;LTBP4;SMPD1;CD83;MAOB;VDR;TNFSF14;ADGRE5;PGLYRP2;COL7A1
prerank,Elsevier_Pathway_Collection__Telogen Maintenance in Androgenic Alopecia,0.5671976604237285,0.8468456050686499,0.5702479338842975,0.9312814216398698,1.0,1/22,0.43%,CREB1
prerank,GO_Biological_Process_2021__regulation of transmembrane transport (GO:0034762),0.622937131188813,0.8467721717482071,0.6762589928057554,0.9309763025545009,1.0,2/30,1.35%,WWP2;KCNJ10
prerank,KEGG_2021_Human__Antigen processing and presentation,0.6241507482716415,0.8466652910659218,0.6890756302521008,0.930709507374414,1.0,2/65,1.23%,CREB1;CD4
prerank,GO_Biological_Process_2021__negative regulation of MAP kinase activity (GO:0043407),-0.6288101721080579,-0.8465217408774842,0.6590909090909091,1.0,1.0,5/44,2.36%,PIK3CB;PTPRJ;BMP4;SMPD1;IRAK3
prerank,Reactome_2022__Nuclear Receptor Transcription Pathway R-HSA-383280,-0.644951790596869,-0.8465152331199596,0.7045454545454546,1.0,1.0,4/51,2.19%,NR3C1;NR2C2;RORC;VDR
prerank,MSigDB_Oncogenic_Signatures__MEL18 DN.V1 UP,0.5511388289476604,0.846405229123604,0.7479674796747967,0.9306274773196571,1.0,9/134,2.36%,ITGA3;SLC19A1;PLAUR;CHST11;ITGA4;FOSL1;LRIG1;SLC2A6;STX1A
prerank,MSigDB_Oncogenic_Signatures__ESC J1 UP LATE.V1 DN,0.5415135547693469,0.8463754357221916,0.7596899224806202,0.9302716774994625,1.0,10/167,1.88%,ZFP62;WWP2;SLC27A2;SALL1;SLC47A1;AMH;DLC1;ERCC6L;NAA10;DAPP1
prerank,GO_Biological_Process_2021__DNA-dependent DNA replication (GO:0006261),0.543661619787701,0.8463169268474252,0.7272727272727273,0.9299637001104821,1.0,4/127,1.20%,CDC45;GINS1;POLE4;PSMB9
prerank,GO_Biological_Process_2021__cellular response to lipopolysaccharide (GO:0071222),0.5653517473558659,0.8461968066416968,0.6859504132231405,0.9297357853893229,1.0,4/109,2.29%,NOD2;SERPINE1;GFI1;CD86
prerank,MSigDB_Oncogenic_Signatures__KRAS.600 UP.V1 DN,-0.5101789106391018,-0.8461758333771818,0.8263888888888888,1.0,1.0,14/222,2.44%,MAP2K6;OAS1;IFI44L;DPYS;PDE11A;ADAMTS9;VILL;NTF3;NYNRIN;APBB3;PRRG4;CIITA;RTP4;KCNE1
prerank,KEGG_2021_Human__Human T-cell leukemia virus 1 infection,-0.5246781967584222,-0.8461001096162567,0.8156028368794326,1.0,1.0,11/211,2.40%,CREB3L2;AKT3;PIK3CB;RB1;CREBBP;CCND2;ADCY3;STAT5A;CREB5;HLA-B;SPI1
prerank,Elsevier_Pathway_Collection__Insulin Signaling,-0.5995259606437316,-0.8460174544596406,0.6829268292682927,1.0,1.0,4/53,1.97%,TBC1D4;CREBBP;LIPE;SH2B2
prerank,MSigDB_Hallmark_2020__UV Response Up,0.5416740129953175,0.8457433331336496,0.7384615384615385,0.9299202005406533,1.0,5/156,2.36%,CDC5L;MAOA;GLS;MSX1;SULT1A1
prerank,Elsevier_Pathway_Collection__IL1B Expression Targets -> Nociception,0.6182330814207846,0.8455980270682031,0.6953125,0.929762739329457,1.0,3/45,1.82%,CX3CL1;IL1RN;PTGS2
prerank,Elsevier_Pathway_Collection__Tubular Cell Dysfunction in Progressive Diabetic Nephropathy,-0.647456784188558,-0.8455606518551811,0.6854838709677419,1.0,1.0,2/46,1.93%,STAT5A;MMP2
prerank,GO_Biological_Process_2021__skeletal muscle contraction (GO:0003009),0.48254285388329954,0.8454217109727274,0.5,0.9295750487773241,1.0,1/17,1.75%,TNNC2
prerank,GO_Biological_Process_2021__mesoderm development (GO:0007498),-0.5851567150185922,-0.8453023122710335,0.6028368794326241,1.0,1.0,1/18,1.49%,HCK
prerank,GO_Biological_Process_2021__regulation of cell development (GO:0060284),0.6067602628149731,0.8451175121404573,0.6466165413533834,0.929567716927831,1.0,2/36,1.83%,CX3CL1;HDAC9
prerank,GO_Biological_Process_2021__response to peptide (GO:1901652),0.5836851708351241,0.844844059031987,0.6614173228346457,0.9294978218019958,1.0,2/35,1.64%,NOD2;ANXA1
prerank,Reactome_2022__G-protein Beta:Gamma Signaling R-HSA-397795,-0.5795722426974765,-0.844640322108049,0.6370370370370371,1.0,1.0,2/30,2.05%,AKT3;PIK3R6
prerank,GO_Biological_Process_2021__negative regulation of inflammatory response (GO:0050728),-0.5374956976410106,-0.8444759088325099,0.7333333333333333,1.0,1.0,10/178,2.05%,GGT5;GPR39;RB1;HRH2;HCK;ADCY3;CD163;FNDC4;TEK;KLF4
prerank,GO_Biological_Process_2021__acylglycerol metabolic process (GO:0006639),0.5766056075795397,0.8444399714378021,0.6470588235294118,0.9296667864627952,1.0,3/35,2.35%,PNPLA3;APOE;GK
prerank,GO_Biological_Process_2021__negative regulation of tumor necrosis factor production (GO:0032720),0.6222000361805622,0.8444250136306787,0.6528925619834711,0.9292937971983085,1.0,2/41,1.42%,CD33;CX3CL1
prerank,GO_Biological_Process_2021__sulfur compound biosynthetic process (GO:0044272),0.5768492042131159,0.8443520276655092,0.696,0.9289949745405719,1.0,6/107,2.33%,ST3GAL1;SLC35D2;CHST11;PAPSS1;CBS;GSTM3
prerank,MSigDB_Oncogenic_Signatures__BMI1 DN.V1 DN,-0.5722359940583245,-0.8440772372283738,0.6916666666666667,1.0,1.0,8/119,2.37%,PDE5A;SUCLG2;GAS2;IFI44L;SOD2;BRCC3;MAOB;IFI6
prerank,MSigDB_Oncogenic_Signatures__RAPA EARLY UP.V1 UP,-0.5399247166004844,-0.8439869520532031,0.7903225806451613,1.0,1.0,6/149,1.91%,PDE5A;NCOA1;HERC3;TNFAIP2;BASP1;MATN1
prerank,Reactome_2022__Nonhomologous End-Joining (NHEJ) R-HSA-5693571,0.5893374014058689,0.8439489406733135,0.6349206349206349,0.9291336519020954,1.0,3/45,1.08%,HERC2;DCLRE1C;TDP1
prerank,MSigDB_Oncogenic_Signatures__TBK1.DN.48HRS DN,0.643142205523261,0.8439253942560208,0.6857142857142857,0.9287878469971429,1.0,2/49,2.36%,IL13RA1;STX1A
prerank,TRRUST_Transcription_Factors_2019__GATA1 human,-0.6427552756065762,-0.8437217810500887,0.6967213114754098,1.0,1.0,2/51,2.40%,LTBP4;SPI1
prerank,GO_Biological_Process_2021__protein phosphorylation (GO:0006468),-0.4836367581319783,-0.8435922524615196,0.967479674796748,1.0,1.0,30/484,2.44%,VRK2;PTK2B;PAK2;CDK19;PEAK1;MAP2K6;SIK3;CDC42BPA;ADAM10;TESK2;AKT3;TEC;MAPK6;NEK7;APP;ERC1;WNK3;TNKS;BIRC6;TTBK2;SGK3;LIPE;HCK;BMP4;NEK11;DAPK2;TEK;IRAK3;MAP4K1;ZAP70
prerank,WikiPathway_2021_Human__Thermogenesis WP4321,0.5778926124914117,0.8435562465592701,0.7288135593220338,0.9288848871618653,1.0,6/105,2.22%,ARID1B;CREB1;PRKAA2;KLB;MAPK13;ACSL5
prerank,WikiPathway_2021_Human__Prolactin Signaling Pathway WP2037,-0.6121623233868149,-0.8434976462964368,0.6870229007633588,1.0,1.0,5/75,2.44%,PIK3CB;TEC;STAT5A;VAV1;ZAP70
prerank,GO_Biological_Process_2021__modulation of chemical synaptic transmission (GO:0050804),0.5739012502171199,0.8434668537446018,0.7622950819672131,0.9285980821529833,1.0,4/94,1.71%,CDH2;MCTP2;LRRC4;MCTP1
prerank,MSigDB_Oncogenic_Signatures__SRC UP.V1 UP,-0.5454823943428363,-0.8434424456257467,0.7394366197183099,1.0,1.0,5/130,1.99%,AADAC;ETV7;FNDC4;COL4A4;ABTB1
prerank,Elsevier_Pathway_Collection__Dendritic Cell Activation in Systemic Lupus Erythematosis,0.6645853241313119,0.8434396014087614,0.6363636363636364,0.9282302627329526,1.0,1/50,0.21%,TRAF3
prerank,GO_Biological_Process_2021__plasma membrane bounded cell projection assembly (GO:0120031),-0.5003080591481974,-0.8434264475225693,0.8985507246376812,1.0,1.0,14/270,2.33%,EXOC2;CARMIL1;WDPCP;RAP1B;CPLANE1;TTBK2;TTC39C;RAP1A;PMP22;CPLANE2;ABLIM3;PDE6D;S1PR1;BBS5
prerank,Elsevier_Pathway_Collection__Genes with Mutations in Cancer-Associated Sustaining of Proliferative Signaling,0.5550249151112931,0.8434134438632809,0.7727272727272727,0.9278854189918457,1.0,6/112,1.27%,TRAF3;CDK6;ATR;ERBB3;SYK;NOTCH3
prerank,Reactome_2022__Cell-Cell Communication R-HSA-1500931,0.577268398153446,0.84324595350749,0.6859504132231405,0.9276975754909117,1.0,7/113,2.29%,CDH2;CD2AP;PTK2;CRB3;FBLIM1;CDH15;FLNA
prerank,Elsevier_Pathway_Collection__Proteins Involved in Breast Cancer Related to IGF1R/Akt Signaling Pathway,0.6245798886041614,0.8429591031018908,0.6614173228346457,0.9277137165338168,1.0,2/54,1.18%,PTK2;IGFBP3
prerank,GO_Biological_Process_2021__DNA metabolic process (GO:0006259),0.5040278392068921,0.8429133038298312,0.8715596330275229,0.927394048361078,1.0,9/271,2.15%,CDC45;FANCL;MSH2;POLE4;ATR;TDP1;CBS;AXIN2;ACD
prerank,GO_Biological_Process_2021__regulation of heterotypic cell-cell adhesion (GO:0034114),-0.5950388174049637,-0.8429083663786958,0.6396396396396397,1.0,1.0,3/24,2.05%,MAP2K5;CD44;KLF4
prerank,MSigDB_Oncogenic_Signatures__SRC UP.V1 DN,0.5415304041120624,0.8426559990087106,0.8018018018018018,0.927317903887682,1.0,8/145,2.39%,FANCL;IRAK2;GINS1;CPPED1;ZNF436;CDCA7;SLC2A6;PIK3C2B
prerank,Elsevier_Pathway_Collection__Lysophosphatidic Acid/LPARs Signaling,-0.6210101122721429,-0.8425990754161455,0.696551724137931,1.0,1.0,2/36,1.54%,RAP1A;RAPGEF3
prerank,GO_Biological_Process_2021__regulation of organelle organization (GO:0033043),0.6121694364544813,0.8425586756920739,0.6585365853658537,0.927042022848551,1.0,5/79,1.76%,CLEC16A;TJP1;PTK2;CAMSAP3;STMN3
prerank,KEGG_2021_Human__AGE-RAGE signaling pathway in diabetic complications,-0.5521807198850575,-0.8425507466824721,0.7401574803149606,1.0,1.0,6/99,1.94%,AKT3;PIK3CB;STAT5A;PLCB4;MMP2;COL4A4
prerank,Reactome_2022__Transcriptional Regulation By RUNX1 R-HSA-8878171,0.537780931273279,0.8425451031667313,0.8306451612903226,0.9266665148204258,1.0,8/187,2.05%,ARID1B;TJP1;CDK6;PSMB9;CBX2;ZFPM1;NFATC2;LGALS3
prerank,Elsevier_Pathway_Collection__GLP1R -> ARRB1 Signaling,0.4957704812136746,0.8422046215615587,0.46956521739130436,0.9267037707969713,1.0,1/15,0.43%,CREB1
prerank,GO_Biological_Process_2021__regulation of protein secretion (GO:0050708),-0.5765341085445682,-0.8420928572195728,0.725925925925926,1.0,1.0,7/114,2.37%,MYOM1;STXBP5;RAP1A;RAPGEF3;KCNS3;APBB3;SYT7
prerank,GO_Biological_Process_2021__positive regulation of monooxygenase activity (GO:0032770),-0.5782292300647499,-0.8420199631508645,0.6363636363636364,1.0,1.0,2/26,2.19%,PIK3CB;VDR
prerank,GO_Biological_Process_2021__circulatory system development (GO:0072359),0.5981866797199107,0.8418736243242839,0.717948717948718,0.9267315828533227,1.0,7/116,2.27%,BCOR;ERBB3;SALL1;HDAC9;ZFPM1;RBP4;FN1
prerank,GO_Biological_Process_2021__cellular response to BMP stimulus (GO:0071773),0.6148214419493562,0.841846251745345,0.6541353383458647,0.926373612341977,1.0,4/65,1.69%,MEGF8;USP15;AMH;SMAD9
prerank,Elsevier_Pathway_Collection__Potassium Cycling in the Inner Ear (Congenital Deafness),0.5865382905792386,0.8418200500094529,0.6097560975609756,0.9260159415129346,1.0,1/23,1.35%,KCNJ10
prerank,Elsevier_Pathway_Collection__Epithelial to Mesenchymal Transition in Cancer: Overview,0.5956083760143954,0.8417853139211536,0.6776859504132231,0.925662330345766,1.0,9/85,2.37%,CDH2;TJP1;PTK2;CRB3;NOTCH3;CDH1;SERPINE1;FN1;FGF1
prerank,Reactome_2022__Regulation Of Insulin Secretion R-HSA-422356,-0.6239388831712186,-0.8416267316913632,0.6423357664233577,1.0,1.0,4/72,2.32%,RAP1A;RAPGEF3;KCNS3;GNA14
prerank,GO_Biological_Process_2021__epithelial tube morphogenesis (GO:0060562),-0.5850713601307017,-0.8415668392507378,0.6356589147286822,1.0,1.0,2/33,1.50%,SHH;BMP4
prerank,Elsevier_Pathway_Collection__T-Cell Dependent B-Cell Activation,0.6265695541824828,0.8415515382931085,0.7007874015748031,0.9256040794314636,1.0,4/59,2.06%,CREB1;SYK;NFATC2;PIK3AP1
prerank,GO_Biological_Process_2021__positive regulation of interferon-gamma production (GO:0032729),-0.6487988658263204,-0.8415257960188447,0.7384615384615385,1.0,1.0,2/53,1.79%,CD2;IL12RB2
prerank,GO_Biological_Process_2021__regulation of leukocyte chemotaxis (GO:0002688),-0.570197565044401,-0.8414987129078584,0.5752212389380531,1.0,1.0,1/18,0.13%,PTK2B
prerank,Elsevier_Pathway_Collection__B-Cell Activation in Crohn's Disease,0.6135152276745031,0.8413658462735659,0.6611570247933884,0.9254463111137323,1.0,3/27,2.29%,CD4;NFATC2;CD86
prerank,Reactome_2022__Cyclin A:Cdk2-associated Events At S Phase Entry R-HSA-69656,-0.6185101731246546,-0.8413465183804978,0.647887323943662,1.0,1.0,3/83,1.32%,AKT3;RB1;LIN9
prerank,GO_Biological_Process_2021__heterotypic cell-cell adhesion (GO:0034113),-0.6092266522292306,-0.8411583194976895,0.6612903225806451,1.0,1.0,2/30,1.59%,ITGAX;CD2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Thrombophilia,-0.6429986774452658,-0.8411288968082616,0.6974789915966386,1.0,1.0,4/40,2.38%,C4BPA;TFPI;PROS1;HRG
prerank,WikiPathway_2021_Human__Pancreatic adenocarcinoma pathway WP4263,-0.6136640841085316,-0.8409521858972644,0.6716417910447762,1.0,1.0,5/88,1.15%,PAK2;POLK;AKT3;PIK3CB;RB1
prerank,GO_Biological_Process_2021__positive chemotaxis (GO:0050918),0.5350998166233583,0.8408178839711826,0.5241935483870968,0.9257524963851377,1.0,2/17,2.05%,CX3CL1;LGALS3
prerank,MSigDB_Oncogenic_Signatures__MEL18 DN.V1 DN,-0.5553944985342232,-0.8406160411085085,0.7478260869565218,1.0,1.0,7/125,2.37%,PDE5A;GAS2;OAS1;GPR137B;AQP3;MAOB;IFI6
prerank,GO_Biological_Process_2021__organic cation transport (GO:0015695),-0.5700819063596421,-0.8405987439555248,0.6183206106870229,1.0,1.0,1/20,0.14%,SLC22A1
prerank,GO_Biological_Process_2021__actin filament capping (GO:0051693),0.5606228369548358,0.8405801150578728,0.5819672131147541,0.9252796258318301,1.0,1/19,1.08%,SVIL
prerank,GO_Biological_Process_2021__barbed-end actin filament capping (GO:0051016),0.5606228369548358,0.8405801150578728,0.5819672131147541,0.9252796258318301,1.0,1/19,1.08%,SVIL
prerank,GO_Biological_Process_2021__positive regulation of protein polymerization (GO:0032273),-0.6259996685616995,-0.8405025497403186,0.728,1.0,1.0,4/66,2.41%,PTK2B;CARMIL1;HCK;TPPP2
prerank,WikiPathway_2021_Human__Oxysterols derived from cholesterol WP4545,0.6059106832854357,0.8404154129253234,0.6666666666666666,0.9251053770887571,1.0,3/41,1.92%,EPHX2;SLC27A2;NR1I2
prerank,GO_Biological_Process_2021__positive regulation of response to DNA damage stimulus (GO:2001022),0.613326308380281,0.8400118326316884,0.7107438016528925,0.9252668427354106,1.0,4/55,1.84%,ATR;SMCHD1;WRAP53;MSX1
prerank,Elsevier_Pathway_Collection__Cortisol Signaling in Arterial Hypertension,-0.5593166663978646,-0.8399463860104304,0.5573770491803278,1.0,1.0,2/17,1.22%,NCOA1;CREBBP
prerank,GO_Biological_Process_2021__regulation of neurotransmitter secretion (GO:0046928),0.5829581117992136,0.839862349747216,0.6111111111111112,0.9250777534083938,1.0,2/29,1.71%,MCTP2;MCTP1
prerank,GO_Biological_Process_2021__positive regulation of angiogenesis (GO:0045766),0.5646923663497223,0.8397829189325273,0.712,0.9247914192597573,1.0,7/114,2.37%,TJP1;PIK3CD;ZNF304;CTSH;SERPINE1;HK2;FGF1
prerank,Reactome_2022__Toll Like Receptor 4 (TLR4) Cascade R-HSA-166016,0.5446906907145832,0.8397737945210157,0.7678571428571429,0.9244135788769158,1.0,5/138,1.79%,TRAF3;CREB1;IRAK2;NOD2;SIGIRR
prerank,GO_Biological_Process_2021__negative chemotaxis (GO:0050919),-0.6442750411899433,-0.8396914189497308,0.7301587301587301,1.0,1.0,2/31,2.25%,SLIT3;SEMA4D
prerank,MSigDB_Oncogenic_Signatures__ESC J1 UP EARLY.V1 UP,-0.5675280221301391,-0.8394080131625302,0.7086614173228346,1.0,1.0,7/139,2.09%,TXNDC16;C4BPA;RB1;KANK3;COLQ;FMNL3;AQP3
prerank,GO_Biological_Process_2021__positive regulation of smoothened signaling pathway (GO:0045880),0.5625829963141203,0.8392019751614462,0.5882352941176471,0.9247921650768322,1.0,1/21,0.89%,TTC23
prerank,Reactome_2022__Class B/2 (Secretin Family Receptors) R-HSA-373080,0.5920231790104757,0.8391866156933554,0.6666666666666666,0.9244239929123496,1.0,3/83,2.34%,SMOX;GNB5;GNG2
prerank,Reactome_2022__Intracellular Signaling By Second Messengers R-HSA-9006925,-0.49591389906340755,-0.8389961514061659,0.8857142857142857,1.0,1.0,8/291,2.34%,AKT3;PIK3CB;MTA3;TNKS;NEDD4;NRG1;PML;VAV1
prerank,Elsevier_Pathway_Collection__GABA(B)R -> Postsynaptic Inhibition,0.5797300506482113,0.8388378095807321,0.6198347107438017,0.9245161487218109,1.0,2/25,2.03%,CREB1;TRPV1
prerank,TRRUST_Transcription_Factors_2019__JUN human,0.5632391301741896,0.8387968805178997,0.7603305785123967,0.9241969976112151,1.0,9/136,2.39%,PPARA;TNFRSF10A;SLC19A1;PLAUR;SYK;FOSL1;PTGS2;LGALS3;MELTF
prerank,GO_Biological_Process_2021__cellular protein localization (GO:0034613),-0.5023229085298146,-0.8387078399718405,0.9126984126984127,1.0,1.0,12/308,2.42%,EVI5;RABL3;AP3B1;RABGAP1;RIC1;TBC1D12;TBC1D4;SNX13;CPLANE2;TICAM2;CROCC;RTP4
prerank,GO_Biological_Process_2021__negative regulation of cell-cell adhesion (GO:0022408),0.6497331558870247,0.8386140195492587,0.6910569105691057,0.9240630885746778,1.0,4/40,1.71%,PPARA;PTK2;IL1RN;CDH1
prerank,Reactome_2022__Metabolism Of Water-Soluble Vitamins And Cofactors R-HSA-196849,0.5681054356285695,0.8385596426630508,0.7153284671532847,0.9237574647866664,1.0,5/114,1.82%,ACACA;SLC19A1;QPRT;AMN;PTGS2
prerank,GO_Biological_Process_2021__chromatin organization (GO:0006325),-0.5642856716409531,-0.8385075526182018,0.7803030303030303,1.0,1.0,3/135,2.40%,KDM6A;RB1;SPI1
prerank,Reactome_2022__Non-integrin membrane-ECM Interactions R-HSA-3000171,-0.5827958721022025,-0.8385019843402469,0.6714285714285714,1.0,1.0,2/41,1.73%,NTN4;SDC3
prerank,Reactome_2022__Generation Of Second Messenger Molecules R-HSA-202433,0.6241686884955845,0.8384891386474855,0.6581196581196581,0.9234670301338676,1.0,2/29,1.23%,ARHGEF7;CD4
prerank,GO_Biological_Process_2021__regulation of peptidyl-threonine phosphorylation (GO:0010799),-0.6217661919440381,-0.838463217889229,0.6694915254237288,1.0,1.0,3/37,1.00%,APP;WNK3;PARD3
prerank,TRRUST_Transcription_Factors_2019__MYC mouse,0.6453804697393248,0.8384046527187542,0.7130434782608696,0.9231880334461705,1.0,3/44,2.14%,CDH1;TIMP3;CDCA7
prerank,GO_Biological_Process_2021__regulation of protein kinase activity (GO:0045859),-0.5701753795752532,-0.8382002437538263,0.6950354609929078,1.0,1.0,7/108,1.34%,PTK2B;PAK2;UVRAG;DTNBP1;RB1;RAP1A;DEPTOR
prerank,GO_Biological_Process_2021__regulation of interferon-beta production (GO:0032648),-0.6594282969065932,-0.8380921864517114,0.6967213114754098,1.0,1.0,2/48,0.73%,OAS1;TOMM70
prerank,MSigDB_Oncogenic_Signatures__CRX NRL DN.V1 DN,0.5595803580041289,0.8379619065366625,0.753968253968254,0.9233737402228831,1.0,7/104,2.12%,GTF2I;LRRC4;ELOVL2;TNNC2;SGCE;QSOX1;RBP4
prerank,MSigDB_Hallmark_2020__Apical Surface,-0.6137323040415604,-0.8379524669626307,0.7073170731707317,1.0,1.0,6/43,2.29%,ADAM10;DCBLD2;APP;AKAP7;RTN4RL1;CROCC
prerank,WikiPathway_2021_Human__Regulation of Microtubule Cytoskeleton WP2038,-0.6626616025640159,-0.8379388003273823,0.6747967479674797,1.0,1.0,1/45,0.41%,TESK2
prerank,Reactome_2022__Cyclin E Associated Events During G1/S Transition R-HSA-69202,-0.6185112213597868,-0.8379232828786903,0.6571428571428571,1.0,1.0,3/81,1.32%,AKT3;RB1;LIN9
prerank,Reactome_2022__Class I MHC Mediated Antigen Processing And Presentation R-HSA-983169,-0.4824578045485614,-0.8378648368148675,0.9767441860465116,1.0,1.0,13/367,2.36%,UBE3D;HECTD2;KLHL3;FBXO27;WWP1;NEDD4;RNF217;HERC3;SEC61A2;HERC5;HERC6;HLA-B;FBXO32
prerank,GO_Biological_Process_2021__cellular response to osmotic stress (GO:0071470),-0.5793478437441375,-0.8377680339187807,0.5950413223140496,1.0,1.0,2/22,2.07%,WNK3;RCSD1
prerank,Reactome_2022__Cholesterol Biosynthesis R-HSA-191273,-0.5857291109449008,-0.8376600493210142,0.6132075471698113,1.0,1.0,1/25,1.43%,ARV1
prerank,KEGG_2021_Human__Complement and coagulation cascades,-0.5977543464524091,-0.8376594447177249,0.6967213114754098,1.0,1.0,7/85,2.01%,C4BPA;TFPI;PROS1;ITGAX;C1R;PROCR;BDKRB2
prerank,GO_Biological_Process_2021__positive regulation of endocytosis (GO:0045807),0.6460314739313566,0.8375782482421407,0.711864406779661,0.9235014910693209,1.0,2/47,2.07%,APOE;SERPINE1
prerank,Elsevier_Pathway_Collection__Celiac Disease,0.6134959305687744,0.8375722392321918,0.6446280991735537,0.9231240457703829,1.0,3/48,2.29%,CD4;FN1;CD86
prerank,GO_Biological_Process_2021__transmembrane receptor protein tyrosine kinase signaling pathway (GO:0007169),0.48122715891487144,0.8375283798325163,0.979381443298969,0.922787900074686,1.0,18/382,2.37%,LMTK2;PTPN2;ACTR3;SHB;PTK2;RHOQ;SORT1;ARHGEF7;ERBB3;CD4;SYK;KLB;BCAR1;SHCBP1;PRLR;CYBA;HGF;FGF1
prerank,WikiPathway_2021_Human__p38 MAPK Signaling Pathway WP400,0.6222809407442609,0.837431210866337,0.640625,0.9224892781227072,1.0,2/34,1.41%,CREB1;MAP3K9
prerank,GO_Biological_Process_2021__peptidyl-lysine modification (GO:0018205),0.5765817472924989,0.8373892839969769,0.75,0.9221611198170184,1.0,6/104,2.36%,PLOD2;SENP1;NUP210;P3H3;HDAC9;STX1A
prerank,GO_Biological_Process_2021__protein transport (GO:0015031),-0.4953449821502195,-0.8372908613908184,0.928,1.0,1.0,12/348,2.34%,EVI5;RABL3;AP3B1;RABGAP1;RIC1;TBC1D12;TBC1D4;SNX13;TANGO6;TICAM2;IL10RA;OLFM2
prerank,Elsevier_Pathway_Collection__Aryl Hydrocarbon Receptor Genomic and non-Genomic Signaling,-0.647118073534145,-0.8371442447414245,0.7299270072992701,1.0,1.0,6/38,1.98%,NCOA1;RB1;STAT5A;CYP1B1;RASGRP3;CYP1A2
prerank,Elsevier_Pathway_Collection__Local Estrogen Production in Endometriosis,0.5818454776487887,0.8370646707591236,0.6386554621848739,0.9222239832876068,1.0,2/25,1.82%,CREB1;PTGS2
prerank,MSigDB_Oncogenic_Signatures__PIGF UP.V1 UP,-0.5336147064750416,-0.8369496376423159,0.8294573643410853,1.0,1.0,11/182,2.22%,REV3L;RNF13;MAPK6;NEK7;ZNF117;AHCYL2;ZNF451;ZNF674;RAP1A;RASGRP3;CLEC2B
prerank,Reactome_2022__Lagging Strand Synthesis R-HSA-69186,0.5776191827211751,0.8369349508753743,0.5950413223140496,0.9220245425912043,1.0,2/20,2.24%,SLC19A1;LRIG1
prerank,GO_Biological_Process_2021__regulation of autophagosome assembly (GO:2000785),-0.6217037986919015,-0.8368709002870072,0.7022900763358778,1.0,1.0,2/34,1.48%,TBC1D12;FEZ1
prerank,GO_Biological_Process_2021__cellular calcium ion homeostasis (GO:0006874),0.5524730341483486,0.8366711642350286,0.7321428571428571,0.9220018885174089,1.0,3/119,1.90%,MICU1;DRD4;CCL14
prerank,GO_Biological_Process_2021__G1/S transition of mitotic cell cycle (GO:0000082),0.5689245529717523,0.836619236242229,0.7542372881355932,0.92170606753583,1.0,5/82,2.38%,CDC45;CDK6;TFDP2;GFI1;RRM2
prerank,GO_Biological_Process_2021__anion transport (GO:0006820),0.6287009366991798,0.8365876575868593,0.711864406779661,0.9213659078354928,1.0,4/41,1.85%,SLC19A1;SLC13A5;LRRC8C;SLC13A3
prerank,Reactome_2022__Basigin Interactions R-HSA-210991,-0.6226705881234064,-0.8365731267312911,0.696,1.0,1.0,2/25,1.38%,SLC7A9;SLC7A8
prerank,Elsevier_Pathway_Collection__Potassium Cycling in the Inner Ear (Age-Related),0.5865394328989065,0.8364192105430747,0.6086956521739131,0.9211838631986883,1.0,1/21,1.35%,KCNJ10
prerank,GO_Biological_Process_2021__positive regulation of protein localization to nucleus (GO:1900182),0.643779706063113,0.8363794749684571,0.6422764227642277,0.9208479124095272,1.0,2/67,2.29%,CDH1;FLNA
prerank,KEGG_2021_Human__Small cell lung cancer,0.5849030464035815,0.8363528025779213,0.6782608695652174,0.920501107017112,1.0,9/92,2.41%,ITGA3;TRAF3;PIK3CD;CDK6;PTK2;ITGA2;PTGS2;FN1;COL4A5
prerank,MSigDB_Hallmark_2020__Unfolded Protein Response,0.5633994086193861,0.8362873861028864,0.7235772357723578,0.9202380435729983,1.0,2/113,0.81%,ERN1;PARN
prerank,WikiPathway_2021_Human__MicroRNAs in cardiomyocyte hypertrophy WP1544,-0.6110881422495739,-0.8362041521793334,0.6639344262295082,1.0,1.0,5/82,1.87%,MAP2K6;PIK3CB;MAP2K5;NRG1;MAPK4
prerank,GO_Biological_Process_2021__negative regulation of chemotaxis (GO:0050922),0.5840719358681916,0.8359585139160673,0.6259541984732825,0.9203051745993739,1.0,2/32,1.60%,PTPN2;SEMA3G
prerank,Reactome_2022__FCERI Mediated Ca+2 Mobilization R-HSA-2871809,-0.592111230300112,-0.8359155482479506,0.6412213740458015,1.0,1.0,3/29,2.34%,TEC;GRAP2;VAV1
prerank,GO_Biological_Process_2021__negative regulation of response to wounding (GO:1903035),-0.5856169569837212,-0.8356865637608676,0.6324786324786325,1.0,1.0,1/20,1.44%,RTN4RL1
prerank,Reactome_2022__Gap Junction Trafficking And Regulation R-HSA-157858,0.5693125433277787,0.8355438298911906,0.6209677419354839,0.9204463719112536,1.0,1/23,0.22%,TJP1
prerank,GO_Biological_Process_2021__cilium assembly (GO:0060271),0.4896039074727778,0.8355068176531452,0.9649122807017544,0.9201151220682809,1.0,12/302,2.41%,HAUS8;CEP164;ACTR3;NUDCD3;HAUS2;CDC14B;SEPTIN6;CCDC40;DZIP1L;TUBA1A;FLNA;KIF3B
prerank,GO_Biological_Process_2021__regulation of platelet aggregation (GO:0090330),0.5874647013051774,0.8353468498001393,0.6068376068376068,0.9199433754223192,1.0,1/17,1.26%,SYK
prerank,MSigDB_Oncogenic_Signatures__LEF1 UP.V1 DN,-0.5243512060398117,-0.8350596343590172,0.7769230769230769,1.0,1.0,11/168,2.31%,OAS1;MYRIP;PROS1;VILL;CYP1B1;GALC;IL17RB;BDKRB2;HERC6;ENTPD3;EFNB2
prerank,GO_Biological_Process_2021__regulation of primary metabolic process (GO:0080090),0.5559482341942803,0.8350384896519687,0.7678571428571429,0.9199475916588702,1.0,6/127,1.99%,TBL1X;PPARA;ACACA;PSMB9;ELOVL6;APOE
prerank,Reactome_2022__Synaptic Adhesion-Like Molecules R-HSA-8849932,0.5783497830487782,0.8350218508968007,0.6166666666666667,0.9195855064527486,1.0,2/20,2.17%,DLG1;GPRIN1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Colorectal Neoplasms,0.6022869564270756,0.8349190316151032,0.6942148760330579,0.9193531652499654,1.0,4/91,2.28%,MSH2;CDH1;PTGS2;HGF
prerank,KEGG_2021_Human__Th1 and Th2 cell differentiation,0.6051073025723808,0.8349159186118158,0.6581196581196581,0.918978683178789,1.0,4/84,2.00%,CD4;NOTCH3;MAPK13;NFATC2
prerank,GO_Biological_Process_2021__positive regulation of canonical Wnt signaling pathway (GO:0090263),0.5428060912446661,0.8345792550197781,0.7758620689655172,0.9190350249623699,1.0,3/126,1.97%,TBL1X;PSMB9;AXIN2
prerank,Elsevier_Pathway_Collection__Bone Loss in Osteoporosis,0.6082183946201853,0.8345116828465494,0.6666666666666666,0.9187570227967214,1.0,3/43,1.69%,CREB1;LRP5;SMAD9
prerank,Reactome_2022__Pre-NOTCH Transcription And Translation R-HSA-1912408,0.6236952699376256,0.8345109890730243,0.6746031746031746,0.9183814010228155,1.0,2/52,1.27%,TFDP2;NOTCH3
prerank,Elsevier_Pathway_Collection__Hepatocellular Carcinoma,0.5439753522896428,0.8344749754663513,0.7364341085271318,0.9180411509616972,1.0,5/111,2.28%,CREB1;LRP5;CDK6;ERBB3;HGF
prerank,Reactome_2022__Cytosolic Sulfonation Of Small Molecules R-HSA-156584,-0.5636990393163704,-0.834401752046583,0.6099290780141844,1.0,1.0,2/20,0.78%,TPST1;SULT1B1
prerank,Reactome_2022__Signal Transduction By L1 R-HSA-445144,0.5426606910714662,0.8343701719029716,0.5508474576271186,0.9178044819786915,1.0,13/20,24.76%,FGFR1;CSNK2B;ITGB3;MAPK1;CSNK2A2;ITGAV;NCAM1;NRP1;L1CAM;ITGA9;EGFR;PKN1;ITGA2B
prerank,KEGG_2021_Human__Hepatitis C,0.5490260025459197,0.8342508173853087,0.7456140350877193,0.9176067294771282,1.0,5/139,0.67%,PPARA;TRAF3;PIK3CD;YWHAQ;CDK6
prerank,GO_Biological_Process_2021__negative regulation of BMP signaling pathway (GO:0030514),0.6081769476467732,0.8341327572848122,0.6717557251908397,0.9174036097194833,1.0,2/46,1.69%,CHRD;SMAD9
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Activation by Cytokines,-0.6169243547975103,-0.834095925149133,0.6752136752136753,1.0,1.0,5/66,2.32%,MAP2K6;TFPI;PROS1;PROCR;GNA14
prerank,MSigDB_Oncogenic_Signatures__GCNP SHH UP EARLY.V1 UP,0.5192615310559736,0.8340952533353924,0.7837837837837838,0.9170680033819271,1.0,11/152,2.20%,ARL5A;RBBP6;PHTF2;MLLT10;STRN3;ELOVL2;ANLN;MAN1A1;TNNC2;FOSL1;RHPN2
prerank,GO_Biological_Process_2021__regulation of postsynaptic membrane potential (GO:0060078),0.5835755685329109,0.8339950298297032,0.6296296296296297,0.9168008131680367,1.0,2/26,1.65%,RAB3GAP1;DRD4
prerank,Elsevier_Pathway_Collection__Eosinophil Activation,-0.6131202524608665,-0.8338517456373308,0.6693548387096774,1.0,1.0,5/81,2.34%,PARD3;CREBBP;AOC1;GNA14;VAV1
prerank,Reactome_2022__RHOU GTPase Cycle R-HSA-9013420,0.5894167493542012,0.8333791044831137,0.6451612903225806,0.9170805877382902,1.0,3/39,1.07%,DEPDC1B;WWP2;ARHGEF7
prerank,GO_Biological_Process_2021__positive regulation of protein dephosphorylation (GO:0035307),0.6083020479662415,0.8331298235624036,0.7054263565891473,0.9169957851910503,1.0,3/33,1.68%,CD300A;PPP1R16B;DLC1
prerank,Reactome_2022__Interleukin-4 And Interleukin-13 Signaling R-HSA-6785807,-0.5857348890321513,-0.8330941526109811,0.7482517482517482,1.0,1.0,6/99,2.16%,ZEB1;POU2F1;ITGAX;MMP2;RORC;S1PR1
prerank,GO_Biological_Process_2021__3'-phosphoadenosine 5'-phosphosulfate metabolic process (GO:0050427),-0.5636987455953776,-0.8329368011890799,0.6,1.0,1.0,2/21,0.78%,TPST1;SULT1B1
prerank,Elsevier_Pathway_Collection__Pancreatic Ductal Carcinoma,0.543970892193896,0.8328923593342269,0.7272727272727273,0.9168963369639964,1.0,5/116,2.28%,CREB1;LRP5;CDK6;ERBB3;HGF
prerank,GO_Biological_Process_2021__embryonic digestive tract development (GO:0048566),0.5329186952009066,0.8328265018546395,0.5447154471544715,0.9166149452060773,1.0,2/19,1.26%,PKDCC;SALL1
prerank,GO_Biological_Process_2021__regulation of cellular protein localization (GO:1903827),-0.6178861138103515,-0.8325050281870556,0.6511627906976745,1.0,1.0,3/46,1.86%,SHH;KCNAB2;TRIM46
prerank,Elsevier_Pathway_Collection__Proteins Involved in B-Cell Chronic Lymphocytic Leukemia,-0.6258211564220444,-0.8321397729607438,0.6865671641791045,1.0,1.0,5/51,2.44%,ADAM10;CCND2;LAIR1;TNFSF14;ZAP70
prerank,Elsevier_Pathway_Collection__Proteins Involved in Breast Cancer Related to ERBB2/VEGFR/Akt Signaling Pathway,0.5930004696076006,0.8321225109159337,0.6363636363636364,0.917131425056032,1.0,4/72,1.82%,PTK2;ERBB3;CDH1;PTGS2
prerank,Elsevier_Pathway_Collection__Apoptosis Evasion in Cancer: Overview,0.5712643343662969,0.8319243184568471,0.7421875,0.9169879521773742,1.0,7/103,1.87%,AATF;TNFRSF10A;TNFRSF21;CASP7;TNFRSF25;TNFRSF10D;BOK
prerank,GO_Biological_Process_2021__regulation of interleukin-6 production (GO:0032675),0.5785895157164443,0.8318904819829479,0.7101449275362319,0.9166572856675509,1.0,6/102,2.16%,LILRA2;NOD2;SYK;CX3CL1;MAPK13;CYBA
prerank,KEGG_2021_Human__Ubiquitin mediated proteolysis,0.5541610109479428,0.8318299002476394,0.7166666666666667,0.9163911364011382,1.0,7/137,1.74%,HERC4;HERC2;FANCL;WWP2;UBE2H;MID1;UBE2C
prerank,GO_Biological_Process_2021__phosphatidylinositol acyl-chain remodeling (GO:0036149),0.49999963962300287,0.8317758198642522,0.48739495798319327,0.9161068556718562,1.0,1/15,0.00%,LCLAT1
prerank,MSigDB_Hallmark_2020__Hedgehog Signaling,0.622387010491945,0.8315721996596732,0.6829268292682927,0.9160080544109691,1.0,3/35,2.06%,CDK6;THY1;DPYSL2
prerank,Reactome_2022__Fcgamma Receptor (FCGR) Dependent Phagocytosis R-HSA-2029480,0.6125486739862054,0.8315566803247638,0.6857142857142857,0.9156471598052405,1.0,4/82,1.26%,ABI2;ACTR3;PTK2;SYK
prerank,Reactome_2022__Sensory Processing Of Sound R-HSA-9659379,0.6128623905742315,0.8315253181396057,0.7053571428571429,0.9153030532970654,1.0,3/67,2.36%,ESPN;MYO7A;STX1A
prerank,GO_Biological_Process_2021__aorta morphogenesis (GO:0035909),-0.4861196856579835,-0.8315112147426281,0.5,1.0,1.0,1/16,1.39%,ADAMTS9
prerank,KEGG_2021_Human__Primary immunodeficiency,0.6241667914712372,0.831336846654318,0.6859504132231405,0.9151643989802215,1.0,2/33,1.23%,DCLRE1C;CD4
prerank,MSigDB_Oncogenic_Signatures__ESC V6.5 UP EARLY.V1 UP,0.5246978422809001,0.8311903082287997,0.8188976377952756,0.9149526119430164,1.0,7/147,2.38%,ZNF286A;PSMB9;KCNC1;DLC1;SH3RF1;LRIG1;CELSR3
prerank,MSigDB_Oncogenic_Signatures__KRAS.BREAST UP.V1 UP,0.5572995863129797,0.8310704882237804,0.776,0.9147446582354628,1.0,8/109,2.36%,IGFBP3;MYCN;A2M;SPON2;COL9A3;CYB5R2;GFI1;STX1A
prerank,Elsevier_Pathway_Collection__DRD1/5 Expression Targets,0.49577008267208755,0.8309168687224808,0.4690265486725664,0.9145496814347438,1.0,1/17,0.43%,CREB1
prerank,"GO_Biological_Process_2021__nuclear-transcribed mRNA catabolic process, nonsense-mediated decay (GO:0000184)",0.5664071007752535,0.8306822381387585,0.776,0.9144426508932355,1.0,1/113,0.50%,UPF2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Huntington Disease,0.5958338736991398,0.8305285168722202,0.728,0.9142662372381808,1.0,3/94,0.43%,TAF4;CDH2;CREB1
prerank,GO_Biological_Process_2021__positive regulation of stress-activated MAPK cascade (GO:0032874),0.5661734282459367,0.8304161285842258,0.784,0.9140186976978153,1.0,8/97,2.23%,TRAF3;NOD2;MID1;EDA2R;SH3RF2;SH3RF1;MAPK8IP1;UNC5CL
prerank,Reactome_2022__AURKA Activation By TPX2 R-HSA-8854518,0.6149779046360194,0.8303923909568467,0.7033898305084746,0.9136909856266535,1.0,4/72,2.15%,HAUS8;CEP164;HAUS2;TUBA1A
prerank,GO_Biological_Process_2021__positive regulation of telomerase activity (GO:0051973),-0.6160485155646894,-0.8303123910009556,0.6690140845070423,1.0,1.0,4/34,2.05%,HMBOX1;NEK7;TNKS;KLF4
prerank,GO_Biological_Process_2021__regulation of interleukin-8 production (GO:0032677),0.6346698592756556,0.8301779155490608,0.7768595041322314,0.9135917817078246,1.0,6/76,2.07%,LILRA2;CD33;NOD2;SYK;ANXA1;SERPINE1
prerank,Reactome_2022__Signaling By Hedgehog R-HSA-5358351,-0.5675325496287422,-0.8301698228630612,0.7819548872180451,1.0,1.0,4/132,2.08%,SUFU;SHH;BOC;GLI3
prerank,MSigDB_Hallmark_2020__KRAS Signaling Up,-0.5247704017690312,-0.82986729698338,0.8267716535433071,1.0,1.0,11/195,2.39%,EVI5;SDCCAG8;DCBLD2;TFPI;ATG10;ADGRA2;CCND2;IL10RA;KLF4;GALNT3;MAP4K1
prerank,GO_Biological_Process_2021__regulation of cellular component biogenesis (GO:0044087),-0.6012959663493055,-0.8298500592961657,0.689922480620155,1.0,1.0,3/37,2.38%,RAP1B;RAP1A;HRG
prerank,GO_Biological_Process_2021__regulation of telomerase activity (GO:0051972),-0.609343587349978,-0.8296931372229699,0.6518518518518519,1.0,1.0,5/46,2.05%,HMBOX1;NEK7;TNKS;SMG6;KLF4
prerank,Reactome_2022__G Beta:Gamma Signaling Thru PI3Kgamma R-HSA-392451,-0.5795779815387894,-0.8295126826609988,0.6201550387596899,1.0,1.0,2/23,2.05%,AKT3;PIK3R6
prerank,Reactome_2022__Thrombin Signaling Thru Proteinase Activated Receptors (PARs) R-HSA-456926,0.6433145883968816,0.8294568122576906,0.7053571428571429,0.91418258132247,1.0,2/30,2.34%,GNB5;GNG2
prerank,MSigDB_Oncogenic_Signatures__P53 DN.V1 DN,0.5205873767771603,0.829435219810896,0.8188976377952756,0.9138387818077837,1.0,8/176,1.81%,RHOQ;ITGA4;ITGAL;ELOVL2;GLS;FDXR;CDH1;PTPRM
prerank,WikiPathway_2021_Human__Genes controlling nephrogenesis WP4823,0.6129597407498868,0.8294201699422096,0.6825396825396826,0.9134897902166766,1.0,2/36,0.25%,ITGA3;CD2AP
prerank,WikiPathway_2021_Human__IL-3 signaling pathway WP286,0.627171525983624,0.8293732252406815,0.6870229007633588,0.9131720723010469,1.0,4/48,2.29%,PIK3CD;YWHAQ;SYK;CD86
prerank,KEGG_2021_Human__Thyroid hormone synthesis,-0.6060062773860039,-0.8292337078498069,0.7153284671532847,1.0,1.0,6/68,1.92%,CREB3L2;ADCY3;PAX8;CREB5;PLCB4;IYD
prerank,GO_Biological_Process_2021__neuron development (GO:0048666),-0.5503779655802233,-0.8291927360211917,0.7307692307692307,1.0,1.0,7/134,2.12%,APP;ATXN10;NEDD4;DTNBP1;RB1;PBX1;HDGFL3
prerank,WikiPathway_2021_Human__Melatonin metabolism and effects WP3298,0.6128554711579918,0.8290635113502663,0.6470588235294118,0.9131498137137425,1.0,3/33,2.36%,MAOA;APOE;SULT1A1
prerank,TRRUST_Transcription_Factors_2019__NR4A1 human,-0.48077592563244453,-0.8288809722577459,0.4796747967479675,1.0,1.0,1/15,1.93%,MMP2
prerank,WikiPathway_2021_Human__Androgen receptor signaling pathway WP138,-0.6135645826110712,-0.8285349132633602,0.7555555555555555,1.0,1.0,7/87,1.46%,PLPP1;TGIF1;NR2C2;NCOA1;RB1;CREBBP;TGFB1I1
prerank,GO_Biological_Process_2021__regulation of cAMP-mediated signaling (GO:0043949),-0.5863450136915722,-0.8284538729416798,0.6384615384615384,1.0,1.0,1/25,1.37%,PDE11A
prerank,GO_Biological_Process_2021__peptidyl-serine modification (GO:0018209),0.5138044606864639,0.8284255635608243,0.8403361344537815,0.9135428737491589,1.0,10/165,1.98%,NEK6;LMTK2;BRSK1;TLK2;CAB39;ATR;PDK3;STK32A;NAA10;MAPK13
prerank,KEGG_2021_Human__Measles,-0.5692578522432074,-0.8280772860148854,0.7478991596638656,1.0,1.0,5/122,1.71%,AKT3;OAS1;PIK3CB;CCND2;STAT5A
prerank,GO_Biological_Process_2021__negative regulation of extrinsic apoptotic signaling pathway via death domain receptors (GO:1902042),0.5793771820661493,0.8280432655702249,0.6396396396396397,0.9136005962074646,1.0,2/33,2.07%,TNFRSF10A;SERPINE1
prerank,Reactome_2022__Interleukin-17 Signaling R-HSA-448424,0.5911004314492203,0.8276994878218281,0.6576576576576577,0.9136418917435726,1.0,3/66,0.90%,CREB1;IRAK2;NOD2
prerank,GO_Biological_Process_2021__regulation of pri-miRNA transcription by RNA polymerase II (GO:1902893),-0.6232330708119624,-0.8276852214273498,0.7241379310344828,1.0,1.0,4/44,2.40%,NR3C1;BMP4;KLF4;SPI1
prerank,MSigDB_Hallmark_2020__Estrogen Response Late,0.5054870003533443,0.8275645724961318,0.856,0.9134302737244736,1.0,9/194,2.10%,SLC27A2;SLC2A8;CDH1;MYOF;HPRT1;MAPK13;CPE;PRLR;SERPINA5
prerank,Reactome_2022__Cooperation Of PDCL (PhLP1) And TRiC/CCT In G-protein Beta Folding R-HSA-6814122,0.6433108298032615,0.8275320215741688,0.7322834645669292,0.9131006215507363,1.0,2/34,2.34%,GNB5;GNG2
prerank,Elsevier_Pathway_Collection__POMC Secretion in adenohypophysis,0.4957697700547233,0.8275245131944223,0.496,0.9127476045622409,1.0,1/18,0.43%,CREB1
prerank,GO_Biological_Process_2021__positive regulation of MAPK cascade (GO:0043410),-0.49695019062145723,-0.8273047385978549,0.8872180451127819,1.0,1.0,10/249,2.05%,PTK2B;CCL23;APP;PTPRJ;RAP1A;PELI2;SCIMP;CD44;TEK;PIK3R6
prerank,Elsevier_Pathway_Collection__Ependymoma,-0.6436507187149988,-0.8272042779680274,0.7419354838709677,1.0,1.0,3/42,2.31%,SHH;NRG1;EFNB2
prerank,GO_Biological_Process_2021__SCF-dependent proteasomal ubiquitin-dependent protein catabolic process (GO:0031146),0.5861183897160629,0.8271443328864718,0.7008547008547008,0.9128436904593681,1.0,2/87,1.39%,PSMB9;FBXO31
prerank,Elsevier_Pathway_Collection__Telomer Attrition Triggers Genomic Instability,0.5801040377044296,0.8271187301133224,0.680672268907563,0.9125219404845906,1.0,3/39,2.00%,ATR;MYCN;NFATC2
prerank,WikiPathway_2021_Human__Hypothesized Pathways in Pathogenesis of Cardiovascular Disease WP3668,0.6135562351769515,0.8271052934454749,0.6842105263157895,0.9121677695999018,1.0,3/24,2.29%,FBN3;SERPINE1;FLNA
prerank,Reactome_2022__Phospholipid Metabolism R-HSA-1483257,-0.5069435533203198,-0.8269693597685838,0.8846153846153846,1.0,1.0,8/199,2.05%,SBF2;PIK3CB;ABHD3;PLEKHA5;AGK;PLAAT3;AGPAT4;PIK3R6
prerank,Reactome_2022__RUNX1 Interacts With Co-Factors Whose Precise Effect On RUNX1 Targets Is Not Known R-HSA-8939243,0.6232813333263012,0.8269090256065321,0.7131782945736435,0.9120280397914442,1.0,2/34,1.31%,ARID1B;CBX2
prerank,GO_Biological_Process_2021__ERBB2 signaling pathway (GO:0038128),-0.6042248498995182,-0.8268863274402259,0.6850393700787402,1.0,1.0,2/31,2.09%,NRG1;PTPN18
prerank,GO_Biological_Process_2021__regulation of heart contraction (GO:0008016),0.566876095072417,0.8268554598059642,0.704,0.9117451057342694,1.0,1/85,0.46%,ASB3
prerank,Elsevier_Pathway_Collection__CD4+ T-Cell Death in HIV,0.5877664889477813,0.8268306865865187,0.6416666666666667,0.9114061843848043,1.0,1/28,1.23%,CD4
prerank,Elsevier_Pathway_Collection__Estrogens/ESR1 non-Genomic Signaling,-0.5829953617430179,-0.8267611661920925,0.6590909090909091,1.0,1.0,2/31,1.71%,PTK2B;STAT5A
prerank,MSigDB_Oncogenic_Signatures__E2F1 UP.V1 UP,0.5296706236768818,0.8264859749892642,0.7899159663865546,0.911460887275584,1.0,9/169,2.16%,TRAF3;PKP4;FNBP1;CASP7;ARHGAP39;SLC7A1;ZFPM1;BOK;CYBA
prerank,GO_Biological_Process_2021__lipid biosynthetic process (GO:0008610),0.5826468435981332,0.826466533607224,0.6587301587301587,0.9111187299627874,1.0,8/75,2.22%,ACSF3;ACACA;AGPAT3;GPAT4;PRKAA2;FDXR;PRLR;ACSL5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Cystic Kidney Disease,0.5818417499300909,0.8264330605124119,0.6260162601626016,0.9108148839929715,1.0,2/30,1.82%,NEK8;PTGS2
prerank,Elsevier_Pathway_Collection__PTPN22 Role in Rheumatoid Arthritis,0.5877627545115383,0.8260696140378554,0.6347826086956522,0.9108407912310357,1.0,1/35,1.23%,CD4
prerank,Elsevier_Pathway_Collection__G2/M Phase Transition,0.5844968412936964,0.8257698081613964,0.5862068965517241,0.9108178141789482,1.0,2/29,1.56%,CENPA;PKMYT1
prerank,WikiPathway_2021_Human__Regulation of Actin Cytoskeleton WP51,0.536357161918037,0.8255566478303326,0.7570093457943925,0.9106971681245118,1.0,9/139,2.39%,ABI2;PIK3CD;PTK2;PPP1R12A;ARHGEF7;BCAR1;FN1;FGF1;PIK3C2B
prerank,GO_Biological_Process_2021__translation (GO:0006412),-0.5105082532478328,-0.8253097567662957,0.8740157480314961,1.0,1.0,3/210,1.58%,MRPS28;GATB;MRRF
prerank,Elsevier_Pathway_Collection__Mast-Cell Activation without Degranulation,-0.58298579425698,-0.8250907042774966,0.6666666666666666,1.0,1.0,2/45,1.71%,MAP2K6;STAT5A
prerank,Reactome_2022__Nonsense Mediated Decay (NMD) Enhanced By Exon Junction Complex (EJC) R-HSA-975957,0.5664076487514924,0.8250066173098647,0.788135593220339,0.9109834866342028,1.0,1/110,0.50%,UPF2
prerank,GO_Biological_Process_2021__sensory perception of light stimulus (GO:0050953),-0.5859302630435621,-0.8248543352123904,0.7165354330708661,1.0,1.0,1/75,1.41%,IMPG2
prerank,GO_Biological_Process_2021__cAMP-mediated signaling (GO:0019933),0.560736203338646,0.8246803034032001,0.616,0.9110418206704914,1.0,1/23,1.07%,KSR1
prerank,GO_Biological_Process_2021__positive regulation of protein metabolic process (GO:0051247),-0.5586494817749679,-0.8245746854036607,0.7619047619047619,1.0,1.0,6/110,2.05%,C4BPA;MAP2K5;APP;WWP1;NEDD4;KLF4
prerank,"Reactome_2022__Nucleotide-binding Domain, Leucine Rich Repeat Containing NLR Signaling Pathways R-HSA-168643",0.6166886373898784,0.8244943648670771,0.680327868852459,0.9108959342381425,1.0,4/52,1.98%,IRAK2;NOD2;MEFV;MAPK13
prerank,TRRUST_Transcription_Factors_2019__SMARCA4 mouse,0.4829674515253868,0.8244900204691953,0.4962962962962963,0.9105334307477816,1.0,1/15,1.71%,CDH1
prerank,GO_Biological_Process_2021__skin development (GO:0043588),0.5836653608702564,0.8244862461559744,0.6666666666666666,0.9101694131480879,1.0,2/65,1.64%,ITGA3;ANXA1
prerank,Reactome_2022__Negative Regulation Of MET Activity R-HSA-6807004,0.577618270121962,0.8244796318052424,0.6062992125984252,0.9098147112756026,1.0,2/21,2.24%,PTPN2;LRIG1
prerank,KEGG_2021_Human__Focal adhesion,0.5048792423894628,0.8241399571093123,0.8672566371681416,0.9098842210870165,1.0,14/193,2.41%,ITGA3;PIK3CD;PTK2;PPP1R12A;ITGA4;BCAR1;ITGA2;ITGB5;COL9A3;FN1;HGF;FLNA;COL9A2;COL4A5
prerank,GO_Biological_Process_2021__negative regulation of extrinsic apoptotic signaling pathway (GO:2001237),-0.6060430835215965,-0.8240598602047086,0.6716417910447762,1.0,1.0,5/77,2.37%,TNFRSF10B;MAP2K5;BIRC6;BMP4;IFI6
prerank,GO_Biological_Process_2021__regulation of cellular protein catabolic process (GO:1903362),0.49826923734678596,0.824001264076108,0.49137931034482757,0.9096795856189999,1.0,1/17,0.18%,VGLL4
prerank,WikiPathway_2021_Human__Integrin-mediated Cell Adhesion WP185,-0.5881977355199351,-0.8237953046578413,0.712,1.0,1.0,10/98,1.87%,PAK2;MAP2K6;ITGA1;RAP1B;AKT3;MAP2K5;MAPK6;RAP1A;ITGAX;MAPK4
prerank,GO_Biological_Process_2021__alpha-amino acid catabolic process (GO:1901606),0.5862647359848061,0.823659143081902,0.6639344262295082,0.90970042644849,1.0,1/30,1.38%,CBS
prerank,MSigDB_Oncogenic_Signatures__MEK UP.V1 DN,-0.5149495775593236,-0.8233099494131003,0.8455284552845529,1.0,1.0,9/165,2.37%,FASTKD1;OAS1;IFI44L;ALG13;TFPI;GALC;HERC6;OASL;IFI6
prerank,GO_Biological_Process_2021__presynaptic endocytosis (GO:0140238),-0.585074297407125,-0.8232636546139699,0.6470588235294118,1.0,1.0,1/27,1.50%,SYT2
prerank,Reactome_2022__trans-Golgi Network Vesicle Budding R-HSA-199992,-0.5888638612944702,-0.8232554889466493,0.6923076923076923,1.0,1.0,3/71,1.13%,AP3B1;APP;DTNBP1
prerank,GO_Biological_Process_2021__O-glycan processing (GO:0016266),-0.6437928732926724,-0.8231703251696715,0.7244094488188977,1.0,1.0,3/55,2.30%,MUC6;GALNT7;GALNT3
prerank,GO_Biological_Process_2021__pyruvate metabolic process (GO:0006090),0.6136087978224953,0.8230472466067227,0.6764705882352942,0.9101158391374145,1.0,3/51,2.28%,PKLR;HK2;HKDC1
prerank,Reactome_2022__NR1H2 And NR1H3-mediated Signaling R-HSA-9024446,0.5800989451709582,0.8229776889510889,0.6752136752136753,0.9098357127009543,1.0,2/45,1.99%,TBL1X;APOE
prerank,Reactome_2022__Translocation Of SLC2A4 (GLUT4) To Plasma Membrane R-HSA-1445148,0.6123774714996616,0.8229466475152056,0.6744186046511628,0.9095198041133216,1.0,4/51,2.41%,YWHAQ;RHOQ;PRKAA2;KIF3B
prerank,KEGG_2021_Human__Thermogenesis,-0.50473176017557,-0.8229202192792218,0.8642857142857143,1.0,1.0,7/211,1.72%,CREB3L2;COX16;NDUFAF2;NDUFS4;LIPE;ADCY3;CREB5
prerank,GO_Biological_Process_2021__transmembrane receptor protein serine/threonine kinase signaling pathway (GO:0007178),0.5520235003566534,0.8227284013094609,0.8015873015873016,0.9094524946776127,1.0,8/128,2.32%,MEGF8;USP15;PTK2;ARHGEF18;AMH;SMAD9;ITGB5;ZFYVE9
prerank,Reactome_2022__PIP3 Activates AKT Signaling R-HSA-1257604,-0.49594666029105494,-0.8227230490841894,0.9402985074626866,1.0,1.0,8/255,2.34%,AKT3;PIK3CB;MTA3;TNKS;NEDD4;NRG1;PML;VAV1
prerank,GO_Biological_Process_2021__regulation of protein-containing complex assembly (GO:0043254),0.5658324452117143,0.8226920497116049,0.7565217391304347,0.9091297968725097,1.0,6/109,2.05%,FNIP2;FNIP1;SYK;FBLIM1;APOE;LGALS3
prerank,Elsevier_Pathway_Collection__Glioma Invasion Signaling,-0.5924551559134582,-0.8226267744072205,0.6976744186046512,1.0,1.0,6/75,2.31%,MAP2K6;ADAM10;CD44;TEK;MMP2;EFNB2
prerank,GO_Biological_Process_2021__regulation of phosphorylation (GO:0042325),0.552493057435935,0.8226108368288122,0.7410714285714286,0.9088702932548655,1.0,7/121,2.27%,FNIP2;FNIP1;PTK2;NUP210;CADM4;SLC2A6;FN1
prerank,Elsevier_Pathway_Collection__Th1-Cells Activation and Proliferation in Atherosclerosis,-0.591150875249322,-0.8225880214671074,0.6592592592592592,1.0,1.0,4/68,2.44%,GRAP2;STAT5A;IL12RB2;ZAP70
prerank,Reactome_2022__Antigen Processing: Ubiquitination And Proteasome Degradation R-HSA-983168,0.4783891964941755,0.8223924074977866,0.9918032786885246,0.9087817549942949,1.0,11/296,2.18%,TPP2;HERC4;LMO7;HERC2;RBBP6;RNF130;UBE2H;PSMB9;FBXO31;UBE2C;SH3RF1
prerank,GO_Biological_Process_2021__regulation of myeloid cell differentiation (GO:0045637),-0.5951995997768317,-0.8223328592325988,0.7424242424242424,0.9998654252499345,1.0,4/68,2.40%,PTK2B;CREBBP;MEIS1;SPI1
prerank,GO_Biological_Process_2021__nitrogen compound transport (GO:0071705),0.5222784909508461,0.8220364721255901,0.8461538461538461,0.9088783508652118,1.0,7/135,2.33%,RAB7A;AMN;SLC38A3;SLC6A4;SLC7A1;SLC38A1;SLC43A1
prerank,MSigDB_Oncogenic_Signatures__ESC J1 UP EARLY.V1 DN,0.5223697915231755,0.8216781620529948,0.8686131386861314,0.9089281731771354,1.0,8/154,2.07%,PACRGL;IGFBP3;ANXA1;AMH;DRD4;DAPP1;VAX2;SERPINE1
prerank,GO_Biological_Process_2021__regulation of protein catabolic process (GO:0042176),-0.5598826481171387,-0.8215735964372978,0.7241379310344828,1.0,1.0,4/97,2.36%,C4BPA;WWP1;NEDD4;IRAK3
prerank,GO_Biological_Process_2021__response to glucagon (GO:0033762),0.5671979534576345,0.8214879727425866,0.6140350877192983,0.9087822684488619,1.0,1/20,0.43%,CREB1
prerank,Reactome_2022__Branched-chain Amino Acid Catabolism R-HSA-70895,0.4981535268576586,0.8214792688328844,0.5227272727272727,0.908430103705336,1.0,1/21,0.19%,AUH
prerank,MSigDB_Oncogenic_Signatures__RB P107 DN.V1 UP,0.5345453653978536,0.8212117958341187,0.8034188034188035,0.9083831767255569,1.0,8/128,2.38%,CDH2;CDC45;HAUS8;FANCL;SPIRE2;PAQR4;TCFL5;RRM2
prerank,GO_Biological_Process_2021__positive regulation of intracellular protein transport (GO:0090316),0.537159636964252,0.8211939700445794,0.7297297297297297,0.9080547631981682,1.0,5/148,2.29%,YWHAQ;TFDP2;MTCL1;CDH1;FLNA
prerank,KEGG_2021_Human__Fc epsilon RI signaling pathway,-0.5854301704689202,-0.8210637929142213,0.7054263565891473,1.0,1.0,4/63,2.34%,MAP2K6;AKT3;PIK3CB;VAV1
prerank,GO_Biological_Process_2021__regulation of DNA metabolic process (GO:0051052),0.6090610433856262,0.8209694451002241,0.6448598130841121,0.9079954763534895,1.0,4/45,2.26%,HDAC8;TOM1L1;MPV17;PIF1
prerank,GO_Biological_Process_2021__positive regulation of interleukin-12 production (GO:0032735),0.5874566209788833,0.8209162545715044,0.6206896551724138,0.9076997302022599,1.0,1/31,1.26%,SYK
prerank,TRRUST_Transcription_Factors_2019__NFKB1 human,0.4840577117072999,0.8208745458515774,0.9482758620689655,0.9073809367675997,1.0,15/282,2.29%,TNFRSF10A;PLAUR;NOD2;PSMB9;PROX1;IL1RN;AMH;CYP27B1;CDH1;PTGS2;A2M;SERPINE1;OPTN;FN1;CD86
prerank,Reactome_2022__Disorders Of Transmembrane Transporters R-HSA-5619115,0.505328388976658,0.8206994995778654,0.8559322033898306,0.9072145719071301,1.0,4/168,1.20%,SLC20A2;MAP4K5;NUP210;PSMB9
prerank,GO_Biological_Process_2021__negative regulation of cell differentiation (GO:0045596),-0.5142572069465033,-0.8205874661295259,0.8120300751879699,1.0,1.0,7/182,2.25%,PTK2B;RB1;MEIS1;SUFU;SHH;BMP4;SEMA4D
prerank,GO_Biological_Process_2021__positive regulation of substrate adhesion-dependent cell spreading (GO:1900026),0.5771440386388434,0.820552796350825,0.6834532374100719,0.9070572874350599,1.0,2/35,2.29%,ARHGEF7;FLNA
prerank,MSigDB_Oncogenic_Signatures__PRC2 EDD UP.V1 UP,0.5212344793744664,0.8205155861992602,0.8688524590163934,0.9067319750205555,1.0,10/174,2.25%,CDC45;LIN7A;LRRC20;TNFRSF10D;PACSIN3;SLC35C2;PNPLA3;FOSL2;KIF23;SLC2A6
prerank,Elsevier_Pathway_Collection__CD4+T-Cell Response in Celiac Disease,-0.5911336449273809,-0.8202965465947102,0.6774193548387096,1.0,1.0,4/86,2.44%,GRAP2;STAT5A;IL12RB2;ZAP70
prerank,Elsevier_Pathway_Collection__Hereditary Breast and Ovarian Cancer Syndrome,0.5885735398178054,0.8202707152066782,0.6637931034482759,0.9066662034997149,1.0,3/32,1.15%,CREB1;MSH2;BRIP1
prerank,GO_Biological_Process_2021__macrophage activation (GO:0042116),0.5858402759390553,0.8201695675258938,0.6538461538461539,0.9064342523479327,1.0,2/34,1.42%,SYK;CX3CL1
prerank,WikiPathway_2021_Human__Endochondral Ossification with Skeletal Dysplasias WP4808,0.6065509883262197,0.8200154663602939,0.6974789915966386,0.9059012484257759,1.0,3/60,1.85%,CAB39;CHST11;TIMP3
prerank,WikiPathway_2021_Human__Endochondral Ossification WP474,0.6065509883262197,0.8200154663602939,0.6974789915966386,0.9059012484257759,1.0,3/60,1.85%,CAB39;CHST11;TIMP3
prerank,MSigDB_Oncogenic_Signatures__WNT UP.V1 DN,-0.5278415821595693,-0.8199045839113351,0.7903225806451613,1.0,1.0,6/147,2.40%,NEO1;OAS1;CD44;CDO1;EFNB2;GBP4
prerank,WikiPathway_2021_Human__p53 transcriptional gene network WP4963,0.6264883082119295,0.8197506631732934,0.6721311475409836,0.90586626174385,1.0,4/64,2.07%,MSH2;CX3CL1;TNFRSF10D;SERPINE1
prerank,WikiPathway_2021_Human__IL-5 signaling pathway WP127,0.5874527855578313,0.8196742487700175,0.6511627906976745,0.9055832433236696,1.0,1/39,1.26%,SYK
prerank,KEGG_2021_Human__Coronavirus disease,0.5002032866516916,0.8196212530069212,0.8863636363636364,0.9053325596747556,1.0,4/210,1.98%,TRAF3;PIK3CD;SYK;MAPK13
prerank,Elsevier_Pathway_Collection__Proteins Involved in Arterial Hypertension,-0.49193549708969253,-0.8193356280409543,0.9398496240601504,1.0,1.0,11/223,2.35%,PDE5A;PTK2B;NR3C1;SOD2;NEDD4;SHH;BMP4;CYP1B1;BDKRB2;VDR;SLC4A5
prerank,GO_Biological_Process_2021__protein localization to Golgi apparatus (GO:0034067),-0.5639662907332444,-0.8191875082470658,0.6299212598425197,1.0,1.0,2/26,0.76%,VPS13D;VPS13C
prerank,GO_Biological_Process_2021__regulation of hematopoietic progenitor cell differentiation (GO:1901532),0.588013235364265,0.8189441319559992,0.6875,0.9057917824389663,1.0,1/72,1.20%,PSMB9
prerank,GO_Biological_Process_2021__respiratory system development (GO:0060541),0.5764934181241407,0.818917251252255,0.6293103448275862,0.9054699158562097,1.0,6/32,2.37%,ITGA3;SMCHD1;CCDC40;PROX1;RBP4;FGF1
prerank,WikiPathway_2021_Human__G Protein Signaling Pathways WP35,-0.5768278192473352,-0.8188615995192162,0.7769230769230769,1.0,1.0,3/87,2.32%,AKAP7;ADCY3;GNA14
prerank,WikiPathway_2021_Human__Triacylglyceride synthesis WP325,-0.5826941747233381,-0.8188147146406847,0.6544117647058824,0.9997672954848171,1.0,4/22,1.75%,PLPP1;AGPAT4;LIPE;MOGAT1
prerank,WikiPathway_2021_Human__Disruption of postsynaptic signaling by CNV WP4875,0.601530574199552,0.8187124922188291,0.6885245901639344,0.9053710258285342,1.0,3/33,2.36%,TJP1;DLG1;STX1A
prerank,GO_Biological_Process_2021__regulation of ubiquitin-dependent protein catabolic process (GO:2000058),-0.5791398223991769,-0.8186381348599412,0.6949152542372882,0.9994792113097881,1.0,2/41,2.09%,PTK2B;PML
prerank,KEGG_2021_Human__Retrograde endocannabinoid signaling,0.548107422002099,0.8185830854269215,0.8203125,0.9051635692722603,1.0,5/124,2.34%,NDUFA10;GNB5;PTGS2;MAPK13;GNG2
prerank,GO_Biological_Process_2021__positive regulation of vasculature development (GO:1904018),0.5478597193852592,0.8183880189018509,0.7131147540983607,0.9049936646337448,1.0,6/100,2.37%,PIK3CD;ZNF304;CTSH;SERPINE1;HK2;FGF1
prerank,GO_Biological_Process_2021__positive regulation of transferase activity (GO:0051347),0.5341884152324206,0.8183599602182917,0.768595041322314,0.9046761833319213,1.0,7/143,2.15%,LMTK2;PARN;ERBB3;CD4;WRAP53;DRD4;ACD
prerank,GO_Biological_Process_2021__response to glucocorticoid (GO:0051384),-0.5807685190510719,-0.818265838160127,0.6159420289855072,0.9994693457539062,1.0,2/25,1.93%,NR3C1;SLIT3
prerank,GO_Biological_Process_2021__alpha-amino acid metabolic process (GO:1901605),0.6125353725720657,0.8181176809882849,0.7272727272727273,0.9045848799206652,1.0,3/46,2.39%,CBS;GLS;PYCR1
prerank,GO_Biological_Process_2021__telomere maintenance (GO:0000723),0.603552827096143,0.818041906095807,0.688,0.9043033765569171,1.0,3/53,2.15%,SMC5;ATR;ACD
prerank,Elsevier_Pathway_Collection__CCR1 Expression Targets,-0.5808063185848146,-0.817988708361713,0.6434782608695652,0.9992706068725691,1.0,2/26,1.93%,CCL23;MMP2
prerank,GO_Biological_Process_2021__intracellular protein transport (GO:0006886),-0.4817174652591782,-0.8179265676224996,0.9784172661870504,0.9988388720460369,1.0,10/316,1.85%,IPO11;EVI5;RABL3;AP3B1;RABGAP1;RIC1;TBC1D12;TBC1D4;SNX13;TICAM2
prerank,MSigDB_Oncogenic_Signatures__PRC2 EDD UP.V1 DN,-0.5274024505689466,-0.8177967340498264,0.7938931297709924,0.9984834342159412,1.0,9/154,2.39%,ZHX3;EVI5;REV3L;CTSO;CCND2;MTHFD2L;GALNT3;IFI6;SLC12A8
prerank,Elsevier_Pathway_Collection__T-Cell Cytotoxic Response against Melanocytes in Vitiligo,-0.5911336393736877,-0.817313968298404,0.6825396825396826,0.9986035334807197,1.0,4/86,2.44%,GRAP2;STAT5A;IL12RB2;ZAP70
prerank,GO_Biological_Process_2021__negative regulation of leukocyte cell-cell adhesion (GO:1903038),0.49807710877684824,0.8172908459321281,0.5298507462686567,0.9049410848975176,1.0,1/18,0.20%,PPARA
prerank,WikiPathway_2021_Human__Canonical and non-canonical Notch signaling WP3845,-0.5679660104825105,-0.8169825435483845,0.6666666666666666,0.9985202356480473,1.0,1/26,0.35%,ADAM10
prerank,Reactome_2022__S Phase R-HSA-69242,0.5071442030950765,0.8168887937758106,0.8461538461538461,0.905100319307209,1.0,8/157,2.24%,CDC45;SLC19A1;GINS1;POLE4;TFDP2;PSMB9;UBE2C;LRIG1
prerank,Reactome_2022__TBC/RABGAPs R-HSA-8854214,0.5789072374391719,0.8167924142129014,0.7068965517241379,0.904893543740032,1.0,2/43,2.11%,RAB7A;OPTN
prerank,GO_Biological_Process_2021__histone methylation (GO:0016571),0.49588407931985584,0.8167322557198659,0.52,0.9046123633117387,1.0,1/24,0.41%,PRMT2
prerank,Reactome_2022__RNA Polymerase II Pre-transcription Events R-HSA-674695,0.5910583744833584,0.816505909335689,0.6972477064220184,0.9045603456006829,1.0,3/76,0.90%,TAF4;TCEA1;GTF2E2
prerank,Elsevier_Pathway_Collection__FibronectinR -> AP-1/ELK/SRF/SREBF Signaling,-0.6131126085741126,-0.8164786284852404,0.7235772357723578,0.9986715880905164,1.0,4/47,2.34%,PTK2B;MAP2K6;RAP1A;VAV1
prerank,GO_Biological_Process_2021__cellular polysaccharide catabolic process (GO:0044247),0.4788532251262856,0.8162068758181589,0.5,0.904627229159975,1.0,2/16,2.12%,PHKA2;PHKA1
prerank,Reactome_2022__Antigen processing-Cross Presentation R-HSA-1236975,0.5618058187848909,0.8160999997244904,0.752,0.9044298333552154,1.0,3/102,2.16%,PSMB9;ITGB5;CYBA
prerank,GO_Biological_Process_2021__negative regulation of NF-kappaB transcription factor activity (GO:0032088),0.57795615465484,0.8159190911407364,0.7350427350427351,0.9042822270158164,1.0,5/76,2.22%,RWDD3;TRAF3;PRMT2;IRAK2;GFI1
prerank,WikiPathway_2021_Human__Nephrotic syndrome WP4758,0.6427272293766708,0.8158098367627957,0.7348484848484849,0.9040762632568784,1.0,4/42,2.41%,ITGA3;CD2AP;ANLN;COL4A5
prerank,GO_Biological_Process_2021__positive regulation of striated muscle cell differentiation (GO:0051155),0.5690268902695998,0.8157693950918857,0.5923076923076923,0.9037500178345739,1.0,2/22,1.44%,NIBAN2;PROX1
prerank,GO_Biological_Process_2021__transcription by RNA polymerase II (GO:0006366),0.47670815797571287,0.8156095030162087,0.9913793103448276,0.9036117065149103,1.0,13/307,2.35%,ZNF473;TAF4;TBL1X;PPARA;GTF2I;TRIM24;TCEA1;GTF2E2;NOTCH3;HDAC9;TEAD4;NR1I2;TCFL5
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Histone Deacetylation,0.49684712734087083,0.8155399144453416,0.5,0.903369083553321,1.0,1/15,0.32%,HDAC8
prerank,Elsevier_Pathway_Collection__PTGIR -> IL6 Production,0.49577017222977154,0.81546541180354,0.48854961832061067,0.9030983453335283,1.0,1/17,0.43%,CREB1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Mucinous Ovarian Carcinoma,-0.5847956909116595,-0.8154047903549876,0.6636363636363637,0.9996534761387584,1.0,1/42,1.53%,NRG1
prerank,Elsevier_Pathway_Collection__Macrophage M1 Lineage,-0.597019049158787,-0.8153447341982639,0.675,0.999198910607489,1.0,3/51,1.85%,MAP2K6;STAT5A;TICAM2
prerank,GO_Biological_Process_2021__nuclear transport (GO:0051169),-0.5010778205934453,-0.8152488282407856,0.48905109489051096,0.9988130504141254,1.0,9/15,28.59%,XPO1;RGS14;BANF1;RSRC1;HMGA1;NPM1;ANP32A;NUP205;NXT1
prerank,WikiPathway_2021_Human__Interferon type I signaling pathways WP585,-0.6121820572465371,-0.8151703879622761,0.6695652173913044,0.9984183779520243,1.0,5/54,2.44%,MAP2K6;RAP1A;STAT5A;VAV1;ZAP70
prerank,GO_Biological_Process_2021__lymphocyte differentiation (GO:0030098),0.6035564299936512,0.815120954430433,0.7213114754098361,0.9032770058757887,1.0,7/63,1.83%,PIK3CD;PTPN2;MSH2;ITGA4;CD4;NFAM1;HDAC9
prerank,Reactome_2022__Regulation Of PTEN Stability And Activity R-HSA-8948751,-0.6205610678542398,-0.8150845695712334,0.7301587301587301,0.9980204334188131,1.0,3/65,1.11%,AKT3;TNKS;NEDD4
prerank,GO_Biological_Process_2021__wound healing (GO:0042060),-0.5875720601338152,-0.8150757399934705,0.6962962962962963,0.9975069106050246,1.0,4/67,2.37%,DCBLD2;NRG1;SMPD1;SYT7
prerank,GO_Biological_Process_2021__embryonic organ morphogenesis (GO:0048562),0.5923687280887678,0.8149410141376955,0.6904761904761905,0.9031408660283311,1.0,3/42,2.31%,MEGF8;RBP4;HOXD3
prerank,GO_Biological_Process_2021__negative regulation of gene expression (GO:0010629),0.4802019275911231,0.8147742362106618,0.9915254237288136,0.902980094457773,1.0,10/314,1.99%,ERN1;DIS3L2;RBL1;WWP2;PRKAA2;IGF2BP1;IGF2BP3;MYCN;HDAC9;APOE
prerank,KEGG_2021_Human__Epithelial cell signaling in Helicobacter pylori infection,0.580235312401212,0.8145292630129116,0.725,0.9029536927973959,1.0,2/67,1.98%,TJP1;MAPK13
prerank,GO_Biological_Process_2021__protein acylation (GO:0043543),-0.5879169737093779,-0.8145004678073988,0.6640625,0.9977760123501271,1.0,3/37,1.22%,ZDHHC14;ZDHHC21;CREBBP
prerank,KEGG_2021_Human__Diabetic cardiomyopathy,-0.507161195592416,-0.8144850853549909,0.8897058823529411,0.9972705094471292,1.0,6/181,1.93%,AKT3;PIK3CB;NDUFS4;TBC1D4;PLCB4;MMP2
prerank,MSigDB_Oncogenic_Signatures__CAHOY NEURONAL,-0.5855831473708113,-0.8144295935364464,0.7461538461538462,0.9968372267355111,1.0,1/76,1.44%,RTN4RL1
prerank,GO_Biological_Process_2021__macrophage differentiation (GO:0030225),0.487773531407616,0.8143123724839272,0.5126050420168067,0.9028602165001389,1.0,1/15,1.23%,CD4
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Sustaining of Proliferative Signaling,0.5037562700070674,0.8141996351686245,0.8796296296296297,0.9026591501875187,1.0,9/170,2.37%,CDK6;PLAUR;PTK2;ATR;ERBB3;SYK;NOTCH3;HGF;FGF1
prerank,Reactome_2022__Loss Of Nlp From Mitotic Centrosomes R-HSA-380259,0.6149804091339361,0.8140878957027655,0.7241379310344828,0.9024511846335109,1.0,4/69,2.15%,HAUS8;CEP164;HAUS2;TUBA1A
prerank,KEGG_2021_Human__Glycolysis / Gluconeogenesis,0.6135998475234212,0.8140725290704013,0.7481481481481481,0.9021146403110879,1.0,3/61,2.28%,PKLR;HK2;HKDC1
prerank,GO_Biological_Process_2021__regulation of G1/S transition of mitotic cell cycle (GO:2000045),0.6044685710263981,0.8137832225161614,0.7213114754098361,0.9021291766028404,1.0,5/70,1.64%,PRMT2;DLG1;RBL1;CDK6;ANXA1
prerank,Elsevier_Pathway_Collection__Eat me Signal: Apoptotic Cell Induces Phagocytosis,0.5847277372404052,0.8136376829482783,0.6640625,0.9019674809010311,1.0,2/29,1.53%,PTK2;BCAR1
prerank,GO_Biological_Process_2021__response to estradiol (GO:0032355),0.5836871724228243,0.8135443597522984,0.6666666666666666,0.9017460204550679,1.0,2/32,1.64%,STRN3;ANXA1
prerank,WikiPathway_2021_Human__Chromosomal and microsatellite instability in colorectal cancer  WP4216,-0.5954137849857206,-0.8135292281899255,0.7299270072992701,0.9975178195336565,1.0,3/72,0.47%,EXOC2;POLK;AKT3
prerank,Reactome_2022__Translation Of Structural Proteins R-HSA-9683701,-0.5826119429972695,-0.8132305979211617,0.6612903225806451,0.9973952069252622,1.0,2/29,1.75%,PARP8;MOGAT1
prerank,GO_Biological_Process_2021__positive regulation of cell adhesion (GO:0045785),0.5855072126499,0.8132180728586671,0.6974789915966386,0.9018064655492657,1.0,2/77,1.45%,SYK;CHRD
prerank,Reactome_2022__Regulation Of Beta-Cell Development R-HSA-186712,-0.6032652604140766,-0.8131870068122076,0.6818181818181818,0.996920320934771,1.0,2/32,1.22%,AKT3;CREBBP
prerank,Elsevier_Pathway_Collection__Proteins Involved in Prolactinoma,-0.5850357652254541,-0.8131639830202646,0.6451612903225806,0.9964385909764071,1.0,1/27,1.50%,BMP4
prerank,GO_Biological_Process_2021__intracellular lipid transport (GO:0032365),-0.5647570067604436,-0.8129331282264084,0.5967741935483871,0.9962250547915474,1.0,3/21,1.43%,SGPP1;ABCD3;ARV1
prerank,GO_Biological_Process_2021__peptide metabolic process (GO:0006518),-0.6150499674843913,-0.8124847467235237,0.728,0.9964039085859488,1.0,4/78,2.14%,GSTA1;CPQ;GSTA2;MGAT3
prerank,Elsevier_Pathway_Collection__TERT Activation in Cancer,-0.5950356299075593,-0.812458608485323,0.6610169491525424,0.9959177022831268,1.0,3/28,2.05%,RB1;PAX8;KLF4
prerank,GO_Biological_Process_2021__positive regulation of protein transport (GO:0051222),-0.578733100377035,-0.8123344247043767,0.7209302325581395,0.9955839453307245,1.0,4/68,2.14%,MYOM1;BCAS3;PRR5L;APBB3
prerank,MSigDB_Oncogenic_Signatures__RPS14 DN.V1 UP,-0.5216125673268862,-0.8123136894010767,0.859375,0.995098668683432,1.0,11/178,2.26%,VNN1;CDCP1;GPR137B;TNFAIP2;ITGAX;HCK;CYP1B1;NYNRIN;RASGRP3;CLEC2B;CD9
prerank,Elsevier_Pathway_Collection__FPR1 -> Cytoskeleton Signaling,0.5874621069811958,0.8122327349086127,0.6363636363636364,0.9027363700692946,1.0,1/22,1.26%,SYK
prerank,GO_Biological_Process_2021__branched-chain amino acid metabolic process (GO:0009081),0.4981536471507724,0.8121472646237641,0.515625,0.9021299762889153,1.0,1/20,0.19%,AUH
prerank,GO_Biological_Process_2021__branched-chain amino acid catabolic process (GO:0009083),0.4981536471507724,0.8121472646237641,0.515625,0.9021299762889153,1.0,1/20,0.19%,AUH
prerank,GO_Biological_Process_2021__phospholipid dephosphorylation (GO:0046839),-0.5661177696299244,-0.8121335627761297,0.7165354330708661,0.9948571204272487,1.0,2/37,0.54%,PLPP1;SGPP1
prerank,Elsevier_Pathway_Collection__ERK5/MAPK7 Signaling,0.607454178912134,0.8121227380620544,0.6796875,0.9018069174667639,1.0,3/35,1.76%,CREB1;PTK2;FOSL1
prerank,KEGG_2021_Human__Prolactin signaling pathway,-0.6020963834988932,-0.8121016555982986,0.7045454545454546,0.9943873457605769,1.0,4/67,1.71%,AKT3;PIK3CB;CCND2;STAT5A
prerank,KEGG_2021_Human__Hepatocellular carcinoma,-0.5260115843027108,-0.812071072209679,0.875,0.9939162307877341,1.0,7/160,1.27%,GSTA1;POLK;AKT3;PIK3CB;ARID2;RB1;GSTA2
prerank,GO_Biological_Process_2021__postreplication repair (GO:0006301),-0.5826779502005881,-0.8119217027058446,0.6818181818181818,0.9936135882996474,1.0,2/45,1.74%,POLK;USP43
prerank,WikiPathway_2021_Human__Phosphoinositides metabolism WP4971,-0.6060202966938303,-0.8118240760291314,0.6916666666666667,0.9932090602317233,1.0,3/49,1.91%,SBF2;PIK3CB;PLCB4
prerank,Reactome_2022__Translesion Synthesis By REV1 R-HSA-110312,-0.4966547068704111,-0.8118186336653069,0.47692307692307695,0.9927082767279066,1.0,1/16,0.34%,REV3L
prerank,Elsevier_Pathway_Collection__T-Cell Maturation (Hypothesis),0.6241523124879231,0.8116228054459422,0.7053571428571429,0.9020341718151527,1.0,2/62,1.23%,CDK6;CD4
prerank,Reactome_2022__Glycogen Metabolism R-HSA-8982491,-0.5492368033045562,-0.8116000637053999,0.6343283582089553,0.9924832975290323,1.0,3/24,2.23%,PHKB;GYG2;PYGM
prerank,Elsevier_Pathway_Collection__PHOX2B Effects in Neuroblastoma,0.6066907444862799,0.8108011910255919,0.6837606837606838,0.9026898819954966,1.0,2/26,1.84%,NOTCH3;MSX1
prerank,KEGG_2021_Human__Hematopoietic cell lineage,0.555966666522699,0.8106278850938308,0.7766990291262136,0.9025970201878698,1.0,5/89,1.56%,ITGA3;CD33;ITGA4;CD4;ITGA2
prerank,"WikiPathway_2021_Human__Metabolic pathway of LDL, HDL and TG, including diseases WP4522",-0.4838511418710446,-0.8106068369110296,0.4793388429752066,0.9933226857886395,1.0,1/16,1.62%,LIPG
prerank,Elsevier_Pathway_Collection__V(D)J Recombination Activation,0.5874552878355614,0.8102903108811293,0.6825396825396826,0.9026797631593892,1.0,1/34,1.26%,SYK
prerank,MSigDB_Oncogenic_Signatures__PKCA DN.V1 DN,0.5245930001490345,0.8102698406530943,0.825,0.9023676482099048,1.0,6/135,2.39%,PRPF40A;RWDD3;CKAP4;TXNRD2;HK2;PYCR1
prerank,Elsevier_Pathway_Collection__Mesangial Cell Dysfunction in Diabetic Nephropathy,-0.6058277601492358,-0.8102430511689925,0.6717557251908397,0.9932724576905089,1.0,3/49,1.93%,PTK2B;MAP2K6;MMP2
prerank,Elsevier_Pathway_Collection__Norepinephrine Release Regulation,0.5764909734427908,0.8101850714678103,0.6886792452830188,0.9021259349912161,1.0,2/34,2.36%,CREB1;STX1A
prerank,GO_Biological_Process_2021__positive regulation of nucleocytoplasmic transport (GO:0046824),-0.6210038905400231,-0.8101160458690193,0.7007874015748031,0.9929110154964751,1.0,2/46,1.54%,NEDD4;RAPGEF3
prerank,Elsevier_Pathway_Collection__Mast-Cell Activation via IgE Signaling,-0.5649514510812234,-0.8100786962001837,0.8173076923076923,0.9924553409640124,1.0,4/83,2.34%,MAP2K6;GRAP2;STAT5A;VAV1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Cataract,-0.5758305273874252,-0.8099778108304839,0.8016528925619835,0.9920928741929501,1.0,4/82,2.43%,NR3C1;APP;COL4A4;FOSB
prerank,GO_Biological_Process_2021__axoneme assembly (GO:0035082),-0.565811486924871,-0.8099491408691595,0.6495726495726496,0.9916180986838351,1.0,1/27,0.57%,TTC12
prerank,KEGG_2021_Human__Cytokine-cytokine receptor interaction,0.48760329150052517,0.8099250315725709,0.9459459459459459,0.9021070753875903,1.0,12/239,2.09%,TNFRSF10A;TNFRSF21;CD4;TNFRSF25;CX3CL1;TNFRSF10D;IL1RN;AMH;IL13RA1;CCL14;EDA2R;PRLR
prerank,GO_Biological_Process_2021__regulation of response to external stimulus (GO:0032101),0.5657440175228062,0.8099055572190215,0.7910447761194029,0.9017815283131996,1.0,6/123,2.06%,TRAF3;NOD2;CX3CL1;ANXA1;PTGS2;PIK3AP1
prerank,Reactome_2022__Rab Regulation Of Trafficking R-HSA-9007101,-0.5583413853300031,-0.8098618725880599,0.8016528925619835,0.9912364546160539,1.0,5/120,1.33%,SBF2;AKT3;RABGAP1;RIC1;DENND4C
prerank,GO_Biological_Process_2021__positive regulation of G1/S transition of mitotic cell cycle (GO:1900087),-0.5846515231655167,-0.8094455416410912,0.6692307692307692,0.9913090994961086,1.0,1/26,1.54%,CCND2
prerank,GO_Biological_Process_2021__positive regulation of neuron differentiation (GO:0045666),0.6133557077662337,0.8094209589379161,0.712,0.9020291065819339,1.0,3/33,2.31%,PROX1;ZC4H2;HOXD3
prerank,GO_Biological_Process_2021__positive regulation of catabolic process (GO:0009896),-0.5889821095941452,-0.8089709516742182,0.6929133858267716,0.9913816696386323,1.0,3/65,1.11%,C4BPA;WWP1;NEDD4
prerank,TRRUST_Transcription_Factors_2019__NR1I2 human,0.5824217373946521,0.8088106507407711,0.6260162601626016,0.9024831355936307,1.0,2/26,1.76%,NOD2;FOSL1
prerank,GO_Biological_Process_2021__cardiac ventricle morphogenesis (GO:0003208),0.604796872525524,0.8087674625032528,0.717741935483871,0.9021945837308983,1.0,2/37,2.02%,PROX1;CPE
prerank,GO_Biological_Process_2021__regulation of plasma membrane bounded cell projection assembly (GO:0120032),-0.5932582537331924,-0.8083795911104752,0.6859504132231405,0.9916518603671044,1.0,3/64,0.69%,EVI5;SDCCAG8;RABGAP1
prerank,TRRUST_Transcription_Factors_2019__PAX5 human,0.5382122257587529,0.808272432538665,0.5648854961832062,0.9025012069620608,1.0,2/20,1.74%,MYCN;FHL2
prerank,Reactome_2022__Activation Of SMO R-HSA-5635838,-0.5382905335586886,-0.8080355960016378,0.5572519083969466,0.9916426044428717,1.0,2/18,1.74%,SHH;BOC
prerank,Elsevier_Pathway_Collection__Glycolysis,0.5336771858873907,0.8078231097304981,0.5664335664335665,0.9027201328394042,1.0,2/17,2.19%,PKLR;HK2
prerank,Reactome_2022__MAPK Family Signaling Cascades R-HSA-5683057,-0.48729027251812507,-0.8078198684947949,0.9852941176470589,0.9914340540406444,1.0,13/299,1.95%,RASA2;RAP1B;PIK3CB;MAPK6;GRIN2B;RAP1A;NRG1;PDE6D;MAPK4;DUSP4;TEK;MMP2;RASGRP3
prerank,GO_Biological_Process_2021__nucleobase-containing compound biosynthetic process (GO:0034654),-0.48227149901549304,-0.807704941317991,0.512,0.9910754110383921,1.0,1/20,1.78%,GMPR
prerank,Elsevier_Pathway_Collection__Platelet Activation via Adhesion Molecules,-0.5974609711524359,-0.8075483920820035,0.728,0.9907895358699038,1.0,5/65,2.34%,PTK2B;MAP2K6;PTPRJ;RAP1A;VAV1
prerank,GO_Biological_Process_2021__regulation of macromolecule metabolic process (GO:0060255),0.5057371292680448,0.8073064674760676,0.8650793650793651,0.9030910071730955,1.0,10/169,1.99%,MEGF8;CDK6;SORT1;MEFV;IGF2BP1;IGF2BP3;PROX1;PCBP4;CDH1;APOE
prerank,Reactome_2022__Insertion Of Tail-Anchored Proteins Into Endoplasmic Reticulum Membrane R-HSA-9609523,0.5765021512073845,0.8069957114832027,0.6422764227642277,0.9031592214940698,1.0,2/22,2.36%,GET3;STX1A
prerank,GO_Biological_Process_2021__phosphatidylinositol phosphate biosynthetic process (GO:0046854),0.5761765365221311,0.8069374441868687,0.6896551724137931,0.9028919333073612,1.0,2/41,2.39%,PIK3CD;PIK3C2B
prerank,GO_Biological_Process_2021__tRNA aminoacylation (GO:0043039),0.5841063992375125,0.8067529109093197,0.7111111111111111,0.9027523439972179,1.0,2/38,1.59%,QRSL1;SARS2
prerank,GO_Biological_Process_2021__positive regulation of protein catabolic process (GO:0045732),0.5516135574563447,0.8064532484504923,0.7938931297709924,0.9028188646099959,1.0,5/84,1.99%,VGLL4;RAB7A;WWP2;PACSIN3;APOE
prerank,KEGG_2021_Human__Dopaminergic synapse,-0.5238757518655401,-0.8059314619652472,0.8115942028985508,0.9924758368808406,1.0,6/119,2.17%,CREB3L2;AKT3;GRIN2B;CREB5;PLCB4;MAOB
prerank,TRRUST_Transcription_Factors_2019__XBP1 human,0.49892303161228546,0.8058719682359625,0.5128205128205128,0.9032884509933301,1.0,1/18,0.11%,ERN1
prerank,Reactome_2022__Signaling By CSF3 (G-CSF) R-HSA-9674555,-0.6079956638939655,-0.8056155911938404,0.732824427480916,0.9924028974526901,1.0,2/30,1.71%,HCK;STAT5A
prerank,Elsevier_Pathway_Collection__Toll-like Receptor Independent Sterile Inflammation,0.5874383115197905,0.8055679725690736,0.6875,0.9033512230042287,1.0,1/65,1.26%,SYK
prerank,GO_Biological_Process_2021__regulation of myelination (GO:0031641),-0.5244995422102406,-0.8054604547163697,0.5901639344262295,0.9921258176437517,1.0,2/25,1.41%,PARD3;ITGAX
prerank,Reactome_2022__Transcriptional Regulation Of Pluripotent Stem Cells R-HSA-452723,-0.5510431452109682,-0.8054176400540759,0.6496350364963503,0.9916647802022038,1.0,2/25,2.05%,PBX1;KLF4
prerank,"WikiPathway_2021_Human__Relationship between inflammation, COX-2 and EGFR WP4483",-0.5660435307712056,-0.8053654041180718,0.65625,0.9912349058334473,1.0,2/25,0.55%,AKT3;PIK3CB
prerank,GO_Biological_Process_2021__negative regulation of response to stimulus (GO:0048585),0.5788164026797338,0.8052786778131011,0.7213114754098361,0.9033912776420375,1.0,7/61,2.14%,RBL1;CDK6;IGFBP3;ERBB3;THY1;MCTP1;SLC30A10
prerank,MSigDB_Oncogenic_Signatures__DCA UP.V1 DN,0.5163286543280391,0.8052397742052712,0.8055555555555556,0.9030896601965129,1.0,5/148,1.71%,CMC1;ZNF286A;SLC38A3;CX3CL1;MCTP1
prerank,GO_Biological_Process_2021__regulation of release of sequestered calcium ion into cytosol (GO:0051279),0.585831659498681,0.8051707794645689,0.7203389830508474,0.902849260321264,1.0,2/49,1.42%,THY1;CX3CL1
prerank,KEGG_2021_Human__Tyrosine metabolism,0.5878029288714788,0.80510624060979,0.6617647058823529,0.9025829210751237,1.0,1/32,1.22%,MAOA
prerank,Elsevier_Pathway_Collection__Proteins Involved in Congenital Deafness,0.5865382921124093,0.8050367501905407,0.6713286713286714,0.9023098240521732,1.0,1/23,1.35%,KCNJ10
prerank,GO_Biological_Process_2021__protein autoubiquitination (GO:0051865),-0.5937972657608335,-0.8050270045423673,0.7218045112781954,0.9912132747143304,1.0,3/65,0.63%,UBE3D;AMFR;RNF13
prerank,GO_Biological_Process_2021__cellular amide metabolic process (GO:0043603),-0.5508963146138117,-0.804798962430559,0.8432835820895522,0.9910004928405791,1.0,9/114,2.08%,PLPP1;GLYAT;VNN1;BTD;SGPL1;PLAAT3;ACSM2B;MTHFD2L;SMPD1
prerank,Elsevier_Pathway_Collection__Cathepsins Role in Periodontitis,-0.4807756950183699,-0.8047165485935143,0.48226950354609927,0.9906292999680252,1.0,1/15,1.93%,MMP2
prerank,MSigDB_Hallmark_2020__Spermatogenesis,0.5481645513799988,0.804679384417779,0.8114754098360656,0.9024494053193519,1.0,3/103,2.33%,MLLT10;GFI1;GSTM3
prerank,Elsevier_Pathway_Collection__Mast-Cell Activation in Asthma,-0.5649605563776293,-0.804588010847087,0.8425925925925926,0.9903017264616338,1.0,4/73,2.34%,MAP2K6;GRAP2;STAT5A;VAV1
prerank,GO_Biological_Process_2021__arachidonic acid metabolic process (GO:0019369),0.5819022136941263,0.8043408536246102,0.7363636363636363,0.9025471258954062,1.0,4/54,1.82%,EPHX2;CYP4F3;CYP2S1;PTGS2
prerank,WikiPathway_2021_Human__Type I interferon induction and signaling during SARS-CoV-2 infection WP4868,-0.5774957993255818,-0.8042138813745648,0.6548672566371682,0.9902752135978505,1.0,2/29,2.26%,OAS1;TMPRSS2
prerank,GO_Biological_Process_2021__synaptic vesicle endocytosis (GO:0048488),-0.5850680079798412,-0.8040918911694647,0.6717557251908397,0.9899391558213739,1.0,1/37,1.50%,SYT2
prerank,GO_Biological_Process_2021__negative regulation of T cell proliferation (GO:0042130),0.5771075048412149,0.8040614929177368,0.6714285714285714,0.9026256416272801,1.0,2/33,2.29%,TNFRSF21;CD86
prerank,KEGG_2021_Human__T cell receptor signaling pathway,-0.5704482772420241,-0.8040577226875353,0.7835820895522388,0.9894757175229699,1.0,7/99,2.44%,PAK2;AKT3;PIK3CB;TEC;GRAP2;VAV1;ZAP70
prerank,GO_Biological_Process_2021__acyl-CoA metabolic process (GO:0006637),-0.5878016309536375,-0.8039269224846182,0.6527777777777778,0.9891547938219407,1.0,3/37,1.23%,SUCLG2;GLYAT;ACSM2B
prerank,GO_Biological_Process_2021__epithelial cilium movement involved in extracellular fluid movement (GO:0003351),-0.560700399759616,-0.8036128315484427,0.6326530612244898,0.9890893833585619,1.0,1/17,1.08%,SPEF2
prerank,GO_Biological_Process_2021__regulation of BMP signaling pathway (GO:0030510),0.5832024229842206,0.8035114097212176,0.7258064516129032,0.9030274290183395,1.0,3/67,1.69%,ITGA3;CHRD;SMAD9
prerank,Elsevier_Pathway_Collection__Proteins Involved in Pulmonary Hypertension,-0.5005755638273596,-0.803452715659179,0.92,0.9888264606550724,1.0,8/157,2.24%,PDE5A;TFPI;SOD2;BMP4;TEK;MMP2;HLA-B;TNFSF14
prerank,Reactome_2022__Intra-Golgi Traffic R-HSA-6811438,0.5826804679240102,0.8032702583686537,0.6788321167883211,0.9030292406359729,1.0,2/41,1.74%,COG5;MAN1A1
prerank,TRRUST_Transcription_Factors_2019__STAT1 human,0.5962318743453018,0.8032453146633431,0.680327868852459,0.902704494409032,1.0,5/77,2.29%,PPARA;PSMB9;GLS;PTGS2;CD86
prerank,Elsevier_Pathway_Collection__Proteins Involved in Diabetic Neuropathy,-0.5572242140610274,-0.8029927402776064,0.7769230769230769,0.9890090293621765,1.0,4/61,2.19%,PDE5A;SHH;NTF3;VDR
prerank,MSigDB_Oncogenic_Signatures__CRX NRL DN.V1 UP,-0.5201948013610397,-0.8028263374166615,0.8872180451127819,0.98875538672082,1.0,7/122,2.29%,ARHGAP10;TTC39C;FXYD6;MOGAT1;PCOLCE;PTPN18;CROCC
prerank,TRRUST_Transcription_Factors_2019__ETV4 human,0.5273031650966703,0.8027908430724232,0.5757575757575758,0.9029165254817205,1.0,2/21,1.82%,PLAUR;PTGS2
prerank,Elsevier_Pathway_Collection__B-Cells Function in Systemic Scleroderma,0.5985923238371863,0.8027785017726925,0.6984126984126984,0.902588602336042,1.0,5/65,2.06%,CREB1;SYK;IL13RA1;NFATC2;PIK3AP1
prerank,GO_Biological_Process_2021__neutral amino acid transport (GO:0015804),-0.5974575841636498,-0.8027042620915277,0.6811594202898551,0.9883908091995349,1.0,3/24,1.38%,SLC7A9;SLC36A4;SLC7A8
prerank,GO_Biological_Process_2021__T cell migration (GO:0072678),0.4961163053580869,0.8026764544121759,0.5126050420168067,0.9024326964614756,1.0,1/17,0.39%,PIK3CD
prerank,WikiPathway_2021_Human__Brain-derived neurotrophic factor (BDNF) signaling pathway WP2380,0.506910419369067,0.8026224182487509,0.9019607843137255,0.9021607114396223,1.0,8/143,2.06%,CDH2;CREB1;DLG1;SORT1;KSR1;PRKAA2;IGF2BP1;DPYSL2
prerank,GO_Biological_Process_2021__regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043281),0.5770991440339268,0.8026064906428144,0.7586206896551724,0.9018299921262196,1.0,6/86,2.31%,FNIP1;SYK;NAIP;SH3RF1;HGF;UACA
prerank,Reactome_2022__Amine Ligand-Binding Receptors R-HSA-375280,-0.586421870630952,-0.8025922793756155,0.6428571428571429,0.9880570750341408,1.0,1/25,1.36%,HRH2
prerank,Elsevier_Pathway_Collection__NGFR -> AP-1/CEBPB/CREB/ELK/SRF/TP53 Signaling,-0.5820320011745267,-0.8024609126233031,0.725,0.9877075553651306,1.0,2/33,1.81%,MAP2K6;NTF3
prerank,Elsevier_Pathway_Collection__ESR1/ERBB Positive Luminal Breast Cancer,0.5239525037733332,0.8023848294178972,0.8067226890756303,0.9018149308184648,1.0,4/92,1.19%,CREB1;MSH2;BRIP1;ERBB3
prerank,KEGG_2021_Human__Human cytomegalovirus infection,-0.5086171079406407,-0.801955620858258,0.8582089552238806,0.9878705309634549,1.0,11/201,2.20%,PTK2B;MAP2K6;CREB3L2;AKT3;PIK3CB;RB1;ADCY3;CREB5;PLCB4;IL10RA;HLA-B
prerank,Reactome_2022__Metabolism Of Steroids R-HSA-8957322,0.5264446237978434,0.8016925724271592,0.84,0.9023628834981282,1.0,10/143,1.93%,TBL1X;PPARA;ACACA;SLC27A2;HSD17B11;SOAT2;PKMYT1;CYP27B1;FDXR;ELOVL6
prerank,Reactome_2022__Downstream TCR Signaling R-HSA-202424,0.5877752162072318,0.8016673744802643,0.7606837606837606,0.9020584433225026,1.0,2/89,1.23%,PSMB9;CD4
prerank,GO_Biological_Process_2021__extrinsic apoptotic signaling pathway via death domain receptors (GO:0008625),0.5613875511534547,0.8016105418887102,0.6821705426356589,0.901788857300402,1.0,2/30,1.01%,TNFRSF10A;SORT1
prerank,Reactome_2022__C-type Lectin Receptors (CLRs) R-HSA-5621481,0.5255265087454156,0.8014587065157065,0.8064516129032258,0.9016596343148644,1.0,4/130,2.00%,ARHGEF7;PSMB9;SYK;NFATC2
prerank,GO_Biological_Process_2021__negative regulation of biomineral tissue development (GO:0070168),-0.4987688299230567,-0.8014302035549776,0.5504587155963303,0.9880852451638872,1.0,1/21,0.13%,PTK2B
prerank,Elsevier_Pathway_Collection__Breast Cancer,0.5291573300736224,0.8013504722470771,0.7982456140350878,0.9014595952463633,1.0,5/108,1.15%,TNFRSF10A;CREB1;LRP5;MSH2;BRIP1
prerank,Reactome_2022__Neddylation R-HSA-8951664,0.4860813434927804,0.8012314908115955,0.9626865671641791,0.9012527941839019,1.0,3/227,1.39%,LMO7;PSMB9;FBXO31
prerank,GO_Biological_Process_2021__regulation of blood coagulation (GO:0030193),-0.5762667977189098,-0.8011284176733606,0.6335877862595419,0.9880314089023993,1.0,2/27,2.38%,TFPI;HRG
prerank,GO_Biological_Process_2021__regulation of cell-matrix adhesion (GO:0001952),0.5721093537440252,0.8011193344180063,0.7043478260869566,0.9010686203247309,1.0,5/62,1.43%,CDK6;PTK2;THY1;CX3CL1;CAMSAP3
prerank,GO_Biological_Process_2021__regulation of cellular amino acid metabolic process (GO:0006521),0.5880238949799513,0.8009830421142421,0.6902654867256637,0.9009329623635983,1.0,1/51,1.20%,PSMB9
prerank,Reactome_2022__Semaphorin Interactions R-HSA-373755,0.5493566960190738,0.8008815266671055,0.68,0.9007266021297573,1.0,3/63,2.21%,ARHGEF7;DPYSL2;DPYSL3
prerank,Reactome_2022__FGFR1 Mutant Receptor Activation R-HSA-1839124,0.5763444794191424,0.8008804265170347,0.6953125,0.9003840207421622,1.0,2/26,2.37%,TRIM24;FGF1
prerank,Reactome_2022__Metabolism Of Vitamins And Cofactors R-HSA-196854,-0.4911619469613182,-0.80066662747197,0.9495798319327731,0.9881903965932567,1.0,7/176,2.06%,PARP8;PDSS2;TTPA;VNN1;SDC3;MTHFD2L;MOCS3
prerank,GO_Biological_Process_2021__positive regulation of stress-activated protein kinase signaling cascade (GO:0070304),-0.48296653014536983,-0.8004044926616483,0.5039370078740157,0.9881097555257115,1.0,2/17,1.71%,RNF13;SCIMP
prerank,Elsevier_Pathway_Collection__TGFBR -> CREB/ELK-SRF Signaling,-0.4978078354227453,-0.8000415311891488,0.52,0.9880684918020831,1.0,1/18,0.23%,MAP2K6
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Activation through ITAM-Containing Receptors,-0.591124751404765,-0.8000072445907468,0.7357142857142858,0.9876148739895826,1.0,3/55,2.44%,PTK2B;HLA-B;ZAP70
prerank,WikiPathway_2021_Human__3q29 copy number variation syndrome WP4906,-0.6127230971598076,-0.7993260994510388,0.7384615384615385,0.9880592483633714,1.0,5/58,1.71%,PAK2;ADAM10;PIGX;PIGZ;STAT5A
prerank,GO_Biological_Process_2021__regulation of proteolysis (GO:0030162),0.6083004135398604,0.7991815276689033,0.703125,0.9022885150289078,1.0,2/48,0.71%,TRAF3;PLAUR
prerank,Elsevier_Pathway_Collection__Proteins Involved in Osteoarthritis,0.5633887781604212,0.799064263204279,0.7540983606557377,0.9020973970806815,1.0,7/80,2.30%,PLAUR;IGFBP3;IL1RN;PTGS2;TIMP3;FN1;COL9A2
prerank,Reactome_2022__Termination Of Translesion DNA Synthesis R-HSA-5656169,0.5629641577382881,0.7989379388054957,0.6846153846153846,0.9019529829367015,1.0,2/32,0.85%,SLC19A1;POLE4
prerank,GO_Biological_Process_2021__negative regulation of endothelial cell migration (GO:0010596),-0.6120050708610546,-0.7989307979668825,0.706766917293233,0.9881143795073042,1.0,3/37,2.45%,ADAMTS9;HRG;DNAJA4
prerank,WikiPathway_2021_Human__TNF-alpha signaling pathway WP231,0.5340388480628117,0.798674684235728,0.7426470588235294,0.9020000076939478,1.0,3/90,2.16%,CASP7;KSR1;CYBA
prerank,KEGG_2021_Human__Mannose type O-glycan biosynthesis,-0.4989610686899348,-0.7985280196908583,0.5655737704918032,0.9881623247065736,1.0,1/22,0.11%,CRPPA
prerank,GO_Biological_Process_2021__innate immune response activating cell surface receptor signaling pathway (GO:0002220),-0.5613388697526402,-0.7983900564051151,0.8110236220472441,0.9878538901076583,1.0,4/108,2.21%,PAK2;MUC6;CREBBP;CLEC10A
prerank,TRRUST_Transcription_Factors_2019__PPARA human,-0.5829912656836402,-0.7979861323362164,0.7033898305084746,0.9879054799107144,1.0,2/37,1.71%,SOD2;STAT5A
prerank,GO_Biological_Process_2021__regulation of steroid metabolic process (GO:0019218),0.5255718136051897,0.7979464819068288,0.5806451612903226,0.9025501169920696,1.0,2/22,1.99%,EPHX2;APOE
prerank,GO_Biological_Process_2021__regulation of platelet activation (GO:0010543),-0.5217270630899951,-0.7976577188967134,0.5511811023622047,0.9878929427312237,1.0,2/21,2.38%,TEC;HRG
prerank,Elsevier_Pathway_Collection__JNK/MAPK Signaling,-0.576181309336985,-0.7975341404224197,0.6779661016949152,0.9875957843648211,1.0,2/36,2.39%,PAK2;MAP4K1
prerank,Elsevier_Pathway_Collection__Myocardial Infarction,0.5804995072152693,0.7975110074788385,0.7310924369747899,0.9027915029811514,1.0,2/74,1.95%,ERN1;CTSH
prerank,GO_Biological_Process_2021__cellular response to growth factor stimulus (GO:0071363),-0.5225243100792953,-0.7975080899074103,0.8705035971223022,0.9871353435922333,1.0,6/154,2.05%,NR3C1;MAP2K5;RAP1A;BMP4;CD44;KLF4
prerank,Reactome_2022__Role Of Phospholipids In Phagocytosis R-HSA-2029485,-0.5660046774254817,-0.7974596485992375,0.6666666666666666,0.9867109101206764,1.0,1/24,0.55%,PIK3CB
prerank,Elsevier_Pathway_Collection__Podocyte Dysfunction in Diabetic Nephropathy,-0.5806430318487631,-0.7972891050331263,0.734375,0.9864165720907587,1.0,2/38,1.94%,MAP2K6;COL4A4
prerank,Reactome_2022__Caspase Activation Via Death Receptors In Presence Of Ligand R-HSA-140534,-0.49696230022649845,-0.7972328693676018,0.4915254237288136,0.986001804467815,1.0,1/15,0.31%,TNFRSF10B
prerank,"Elsevier_Pathway_Collection__Glioblastoma, Primary",0.577247920680669,0.7970210303895703,0.736,0.903154944376682,1.0,2/48,2.28%,CDK6;HGF
prerank,GO_Biological_Process_2021__negative regulation of mitotic cell cycle (GO:0045930),0.5666152400676284,0.7968678362610808,0.6972477064220184,0.9030224489991494,1.0,1/46,0.48%,TOM1L1
prerank,KEGG_2021_Human__Kaposi sarcoma-associated herpesvirus infection,0.4935361941246803,0.7967892149754398,0.918918918918919,0.9028057565926602,1.0,11/171,2.34%,TRAF3;PIK3CD;CREB1;CDK6;SYK;GNB5;PTGS2;MAPK13;NFATC2;CD86;GNG2
prerank,GO_Biological_Process_2021__response to lipopolysaccharide (GO:0032496),0.522577042699174,0.7963577002526491,0.8157894736842105,0.9029950836698184,1.0,5/146,2.29%,NOD2;CYP27B1;SERPINE1;GFI1;CD86
prerank,Elsevier_Pathway_Collection__P2RY11/13/14 -> IL8/10 Production,0.49576958306246516,0.7963399023522189,0.528,0.9026823001171863,1.0,1/20,0.43%,CREB1
prerank,GO_Biological_Process_2021__regulation of leukocyte migration (GO:0002685),0.48365869174911497,0.7963018882831818,0.5259259259259259,0.902381784611543,1.0,1/16,1.64%,ANXA1
prerank,GO_Biological_Process_2021__negative regulation of angiogenesis (GO:0016525),-0.562615145670737,-0.7960685525064765,0.7734375,0.9872395016976537,1.0,7/83,2.38%,PIK3CB;ADAMTS9;TEK;KLF4;PML;THBS4;HRG
prerank,Reactome_2022__Nicotinate Metabolism R-HSA-196807,0.5818426396845159,0.795929590639392,0.6793893129770993,0.9025298307208532,1.0,2/29,1.82%,QPRT;PTGS2
prerank,Elsevier_Pathway_Collection__Muscular Dystrophies,-0.5807886813021348,-0.7958648850578208,0.717948717948718,0.9870251536361951,1.0,2/49,1.93%,SOD2;MMP2
prerank,GO_Biological_Process_2021__erythrocyte differentiation (GO:0030218),0.5814067832897801,0.7955191172262931,0.7037037037037037,0.9027412960265148,1.0,2/46,1.86%,PTPN2;ZFPM1
prerank,MSigDB_Oncogenic_Signatures__NRL DN.V1 DN,0.5279331389313514,0.7952886501577242,0.7936507936507936,0.9026882688961374,1.0,6/112,2.06%,GTF2I;CASP7;ELOVL2;TUFT1;QSOX1;PIK3AP1
prerank,GO_Biological_Process_2021__phospholipid transport (GO:0015914),0.5800883864204587,0.7951703596403142,0.7431192660550459,0.9025357670799568,1.0,2/58,1.99%,PRELID3A;APOE
prerank,Reactome_2022__Diseases Of Carbohydrate Metabolism R-HSA-5663084,-0.5817264478340199,-0.7949809706225107,0.6875,0.9877629629372959,1.0,2/30,1.84%,ALDOB;GYG2
prerank,Elsevier_Pathway_Collection__Clozapine Induced Granulocytopenia,-0.6053334181024776,-0.794954919445781,0.7536231884057971,0.9872845670772069,1.0,3/41,1.98%,MAP2K6;RAP1A;CYP1A2
prerank,KEGG_2021_Human__Oocyte meiosis,0.5135699485972867,0.7948659106175402,0.8362068965517241,0.9025943419401734,1.0,3/116,1.98%,YWHAQ;PKMYT1;MAPK13
prerank,Elsevier_Pathway_Collection__CDC73 Mutations Cause Hyperparathyroidism,0.4933480657885777,0.7946771998875838,0.5486725663716814,0.9025465749817942,1.0,1/16,0.67%,CDK6
prerank,MSigDB_Oncogenic_Signatures__IL2 UP.V1 UP,0.5165301114164891,0.7946123483807546,0.8863636363636364,0.9022880451116638,1.0,8/160,2.42%,TNFRSF21;KIF13A;FOSL1;FOSL2;HK2;RNF144A;PRR7;LGALSL
prerank,KEGG_2021_Human__AMPK signaling pathway,0.5296563989348267,0.7945565440098026,0.7851239669421488,0.9020245728795089,1.0,5/114,1.10%,ACACA;PIK3CD;CREB1;CAB39;PRKAA2
prerank,Elsevier_Pathway_Collection__FcIgER -> ELK-SRF Signaling,-0.547156390132193,-0.7945419936348486,0.648,0.9873751181289064,1.0,2/27,2.44%,VAV1;ZAP70
prerank,Elsevier_Pathway_Collection__NOTCH Signaling Deregulation in Cancer,-0.5671194612428714,-0.7942749111371957,0.6564885496183206,0.9872301636034567,1.0,1/28,0.44%,ZEB1
prerank,KEGG_2021_Human__PD-L1 expression and PD-1 checkpoint pathway in cancer,-0.5965157935716656,-0.7942426877790952,0.7380952380952381,0.9867845993566151,1.0,6/87,2.44%,MAP2K6;AKT3;PIK3CB;TICAM2;CD274;ZAP70
prerank,Reactome_2022__Mitotic G1 Phase And G1/S Transition R-HSA-453279,0.4971850882400554,0.7941705499992799,0.9285714285714286,0.9021500411368482,1.0,7/145,2.38%,CDC45;RBL1;CDK6;POLE4;TFDP2;PSMB9;RRM2
prerank,Elsevier_Pathway_Collection__VEGF Signaling,0.5532890477497673,0.794069442857526,0.7948717948717948,0.9019313305051881,1.0,3/58,1.82%,PTK2;BCAR1;PTGS2
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Prostate Cancer,-0.4968452889827233,-0.7940511639905993,0.6115702479338843,0.9865746604940585,1.0,1/27,0.32%,NR3C1
prerank,Elsevier_Pathway_Collection__ERBB/VEGFR/Akt Signaling in Breast Cancer,0.5715113706869146,0.7939649735266474,0.7226890756302521,0.9017162088573375,1.0,2/54,1.19%,CREB1;ERBB3
prerank,Reactome_2022__Signaling By FGFR R-HSA-190236,-0.5770656010300101,-0.793879453728584,0.7348484848484849,0.9863419561157577,1.0,2/79,2.30%,FLRT2;GALNT3
prerank,GO_Biological_Process_2021__protein tetramerization (GO:0051262),0.5798126674756978,0.793635527730442,0.7109375,0.9018467828758414,1.0,5/67,2.03%,ACACA;GLS;KCNC1;HPRT1;TRPV1
prerank,Reactome_2022__SUMO E3 Ligases SUMOylate Target Proteins R-HSA-3108232,0.5018069398264158,0.793634787453929,0.8962962962962963,0.9015053242922167,1.0,7/165,1.92%,PPARA;HERC2;SMC5;MRTFA;NUP210;CBX2;NR1I2
prerank,GO_Biological_Process_2021__regulation of actin cytoskeleton organization (GO:0032956),-0.5552347087284141,-0.7935676279831861,0.8015267175572519,0.9862967327324798,1.0,4/88,2.38%,PTK2B;RAPGEF3;RHOH;HRG
prerank,Reactome_2022__Regulation Of PTEN Gene Transcription R-HSA-8943724,-0.5624528369122207,-0.7933207531513065,0.7796610169491526,0.9861261966003099,1.0,1/59,0.90%,MTA3
prerank,GO_Biological_Process_2021__organic substance transport (GO:0071702),-0.5315316737337176,-0.7932005313992896,0.8394160583941606,0.9858005354975852,1.0,6/133,2.42%,SLC22A1;ABCD3;ABCA6;SLCO1A2;HRG;ABCA10
prerank,GO_Biological_Process_2021__glucose metabolic process (GO:0006006),-0.5666916025676119,-0.793081125649762,0.7295081967213115,0.9854663808545883,1.0,2/54,0.48%,ALDOB;OAS1
prerank,GO_Biological_Process_2021__regulation of neurotransmitter receptor activity (GO:0099601),-0.6177312234971858,-0.7929919588215978,0.7720588235294118,0.9851061158173059,1.0,4/48,1.88%,PTK2B;APP;GRIN2B;DLG2
prerank,KEGG_2021_Human__Prion disease,-0.48289138861611175,-0.7929002090157226,1.0,0.9847514969197463,1.0,5/246,1.72%,CREB3L2;PIK3CB;NDUFS4;GRIN2B;CREB5
prerank,GO_Biological_Process_2021__cellular response to topologically incorrect protein (GO:0035967),0.5789165685549225,0.7927332940108212,0.6915887850467289,0.9022990692042941,1.0,2/32,2.11%,ERN1;OPTN
prerank,Reactome_2022__Insulin Receptor Signaling Cascade R-HSA-74751,-0.5842943268696921,-0.7925377171268556,0.6715328467153284,0.9848023077597322,1.0,2/45,1.58%,PIK3CB;GRB10
prerank,Elsevier_Pathway_Collection__Proteins Involved in Osteoporosis,0.5608268420774423,0.7925051694158104,0.7603305785123967,0.902253286580695,1.0,4/86,1.82%,LRP5;IGFBP3;IL1RN;PTGS2
prerank,KEGG_2021_Human__Alcoholism,0.5250861582527651,0.7924865402933492,0.8017241379310345,0.901934266232903,1.0,6/145,2.34%,HDAC8;CREB1;MAOA;GNB5;HDAC9;GNG2
prerank,Reactome_2022__Transcription Of HIV Genome R-HSA-167172,0.5910619775562616,0.7924151748949249,0.7610619469026548,0.9016786585635932,1.0,3/66,0.90%,TAF4;TCEA1;GTF2E2
prerank,MSigDB_Hallmark_2020__Pperoxisome,0.5334526453099614,0.7923494779320207,0.811965811965812,0.9014300716750576,1.0,6/100,2.22%,EPHX2;MSH2;SLC27A2;HSD17B11;NR1I2;ACSL5
prerank,MSigDB_Hallmark_2020__Protein Secretion,-0.5643194394926029,-0.7919633103486526,0.8095238095238095,0.9850783888036728,1.0,4/95,1.91%,MON2;ADAM10;AP3B1;GALC
prerank,Reactome_2022__GLI3 Is Processed To GLI3R By Proteasome R-HSA-5610785,-0.6042811010340301,-0.7919532124259012,0.7322834645669292,0.9846029128616015,1.0,2/56,2.08%,SUFU;GLI3
prerank,GO_Biological_Process_2021__positive regulation of embryonic development (GO:0040019),-0.4936559484898892,-0.7918127933680733,0.5462184873949579,0.9843178359480884,1.0,1/15,0.64%,NR2C2
prerank,TRRUST_Transcription_Factors_2019__TWIST2 human,0.5564086729607621,0.7917486915688775,0.6403508771929824,0.9018743127927609,1.0,4/25,2.27%,CDH2;ERBB3;CDH1;FN1
prerank,KEGG_2021_Human__N-Glycan biosynthesis,-0.6036716250231289,-0.7913823823272278,0.6991869918699187,0.9844443421947827,1.0,3/49,2.14%,ALG6;ALG13;MGAT3
prerank,GO_Biological_Process_2021__proteasomal protein catabolic process (GO:0010498),-0.49341304131111907,-0.7912982881290519,0.9302325581395349,0.984064760288636,1.0,5/200,2.09%,UBE3D;ATE1;WWP1;NEDD4;PML
prerank,TRRUST_Transcription_Factors_2019__PTTG1 human,0.49413841740778736,0.7912367645221788,0.4953271028037383,0.9021579128316883,1.0,8/15,19.39%,KDR;CDK1;PTTG1IP;RHOA;DOCK1;FGF2;MYC;S100A4
prerank,Reactome_2022__Organelle Biogenesis And Maintenance R-HSA-1852241,-0.47689593879949954,-0.7911920603387009,1.0,0.9837312106662692,1.0,10/271,2.33%,CHCHD3;EXOC2;SDCCAG8;CEP63;NCOA1;TTBK2;CREBBP;LIN9;PDE6D;BBS5
prerank,GO_Biological_Process_2021__positive regulation of cell development (GO:0010720),0.5635035406582863,0.7910269950730641,0.6693548387096774,0.9020679654126622,1.0,1/28,0.80%,NIBAN2
prerank,GO_Biological_Process_2021__intrinsic apoptotic signaling pathway (GO:0097193),-0.5416096911053844,-0.7909150101115076,0.8368794326241135,0.983655987481763,1.0,5/100,2.37%,TNFRSF10B;HIC1;CYP1B1;PML;IFI6
prerank,GO_Biological_Process_2021__regulation of cholesterol efflux (GO:0010874),-0.5858024481301657,-0.7908380793643676,0.7155172413793104,0.9832615761253337,1.0,1/32,1.43%,SHH
prerank,Reactome_2022__TP53 Regulates Transcription Of Cell Death Genes R-HSA-5633008,0.6043055351269548,0.7908029485622879,0.7301587301587301,0.902015575690738,1.0,4/44,1.49%,TNFRSF10A;PRELID3A;IGFBP3;TNFRSF10D
prerank,KEGG_2021_Human__Aminoacyl-tRNA biosynthesis,0.5841025599315522,0.7907612973204424,0.7194244604316546,0.9017196364573334,1.0,2/44,1.59%,QRSL1;SARS2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hearing Loss,0.4988946803411745,0.7906966181031576,0.8962264150943396,0.9014715992252729,1.0,10/177,2.41%,SALL1;ESPN;KCNJ10;KCNC1;PTGS2;APOE;TRPV1;COL9A3;MYO7A;COL4A5
prerank,Elsevier_Pathway_Collection__Male Sex Determination,0.5391697360710095,0.7905734508000316,0.6339285714285714,0.9012952393905924,1.0,2/26,1.64%,CBX2;AMH
prerank,MSigDB_Hallmark_2020__Wnt-beta Catenin Signaling,-0.5846414635543473,-0.7903794764696833,0.664179104477612,0.9834075794966004,1.0,1/42,1.54%,CCND2
prerank,GO_Biological_Process_2021__regulation of protein serine/threonine kinase activity (GO:0071900),0.5512337180494032,0.7896080767315304,0.8173913043478261,0.902179039027019,1.0,5/105,1.56%,LRP5;CAB39;KSR1;THY1;PKMYT1
prerank,Elsevier_Pathway_Collection__CD157/ITGB2 Signaling in Myeloid Cell,0.5274604213078947,0.7895664547193043,0.6209677419354839,0.9018902893447264,1.0,4/26,2.27%,PTK2;SYK;BCAR1;FN1
prerank,KEGG_2021_Human__Glycerolipid metabolism,0.5481715323661527,0.789508253187501,0.7272727272727273,0.9016255609454094,1.0,7/54,2.35%,LCLAT1;AGPAT3;GPAT4;PNPLA3;MOGAT2;LPIN3;GK
prerank,MSigDB_Oncogenic_Signatures__PIGF UP.V1 DN,0.5171921283645605,0.7892873427919477,0.8702290076335878,0.9015819750275965,1.0,7/165,2.14%,SNX29;UBE2H;PTPRH;PKLR;THY1;PPFIA4;SLC30A10
prerank,WikiPathway_2021_Human__NOTCH1 regulation of endothelial cell calcification WP3413,-0.4973467134463043,-0.7891726454947767,0.518796992481203,0.9846557284511912,1.0,1/16,0.27%,ITGA1
prerank,Elsevier_Pathway_Collection__Estrogen Effects on Pregnancy Gingivitis,-0.6058390692516424,-0.7891119851233944,0.732824427480916,0.9842421408321248,1.0,3/34,1.93%,NCOA1;CREBBP;MMP2
prerank,GO_Biological_Process_2021__nitric oxide biosynthetic process (GO:0006809),0.4843896768696814,0.789075695594611,0.5081967213114754,0.9014840568482775,1.0,1/15,1.56%,MTARC2
prerank,GO_Biological_Process_2021__regulation of osteoblast differentiation (GO:0045667),0.5635428252452294,0.789067310026275,0.7894736842105263,0.9011467564678434,1.0,5/80,2.28%,LRP5;CDK6;PTK2;CHRD;HGF
prerank,GO_Biological_Process_2021__embryonic limb morphogenesis (GO:0030326),-0.5702861943091688,-0.789047245169569,0.6879432624113475,0.9838482215313158,1.0,4/34,2.08%,WDPCP;CREBBP;SHH;GLI3
prerank,MSigDB_Oncogenic_Signatures__PRC2 EZH2 UP.V1 DN,-0.49882343227119647,-0.7889821540584794,0.9416666666666667,0.9834546930234641,1.0,9/172,2.22%,PIK3CB;CDCP1;DCBLD2;FXYD6;ABLIM3;MTHFD2L;KLF4;PIR;CLEC2B
prerank,GO_Biological_Process_2021__mesonephric tubule development (GO:0072164),0.48742750400783236,0.7888594854505747,0.5206611570247934,0.9010745411338468,1.0,1/15,1.26%,SALL1
prerank,GO_Biological_Process_2021__lymphocyte migration (GO:0072676),-0.5911447462283649,-0.7887901249550449,0.664,0.9832556908408824,1.0,3/34,2.44%,CCL23;S1PR1;ZAP70
prerank,GO_Biological_Process_2021__apoptotic mitochondrial changes (GO:0008637),-0.5763379877743477,-0.7886183373161668,0.7117117117117117,0.9829782210565237,1.0,2/33,2.37%,SOD2;IFI6
prerank,Elsevier_Pathway_Collection__ActivinR/BMPR -> SMAD1/5/9 Signaling,-0.5850761772277474,-0.788608217229275,0.6666666666666666,0.9825053350849255,1.0,2/25,1.50%,INHBB;BMP4
prerank,Elsevier_Pathway_Collection__Cortisol in Resolving Inflammation,-0.5650111384751846,-0.7885090328535628,0.7387387387387387,0.9821446854138949,1.0,4/45,1.85%,NR3C1;NCOA1;CREBBP;TICAM2
prerank,WikiPathway_2021_Human__Spinal Cord Injury WP2431,0.5351024125251397,0.7882364163815078,0.819672131147541,0.9015114768435302,1.0,4/110,2.05%,CHST11;ANXA1;PTGS2;LGALS3
prerank,Reactome_2022__Potassium Channels R-HSA-1296071,-0.572827895404148,-0.7880797317951123,0.746031746031746,0.982236480355334,1.0,5/85,1.83%,KCNN2;KCNAB3;KCNK6;KCNS3;KCNAB2
prerank,GO_Biological_Process_2021__protein sumoylation (GO:0016925),-0.5613774308967959,-0.7880454511036803,0.7870370370370371,0.9818065344093628,1.0,2/55,1.01%,NSMCE2;ZNF451
prerank,TRRUST_Transcription_Factors_2019__SP1 mouse,-0.4808785651319273,-0.7877803478405366,0.967479674796748,0.9816647383312352,1.0,8/241,1.93%,TEC;SP4;APP;SOD2;LIPE;BMP4;CCND2;MMP2
prerank,Elsevier_Pathway_Collection__Glycolysis Activation in Cancer (Warburg Effect),-0.5824503045000924,-0.7877526598892813,0.734375,0.9812267850884092,1.0,2/40,1.76%,ALDOB;CD44
prerank,KEGG_2021_Human__Fatty acid elongation,0.5363227032191418,0.7876960586592386,0.6206896551724138,0.9018700506708133,1.0,2/27,1.93%,ELOVL2;ELOVL6
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Activation,0.5590705366721306,0.7875163029111412,0.7456140350877193,0.9017433815059784,1.0,4/64,2.00%,SYK;ITGAL;CD48;NFATC2
prerank,GO_Biological_Process_2021__dermatan sulfate proteoglycan biosynthetic process (GO:0050651),-0.45473994501415743,-0.7874987153027064,0.49612403100775193,0.9810662526425912,1.0,5/15,8.58%,CSPG5;BGN;CSGALNACT2;B3GAT3;BCAN
prerank,TRRUST_Transcription_Factors_2019__HIF1A human,0.5508065341971804,0.7874735106797721,0.8207547169811321,0.9014608616539355,1.0,3/80,2.07%,PPARA;CDH1;SERPINE1
prerank,GO_Biological_Process_2021__positive regulation of macromolecule biosynthetic process (GO:0010557),0.5372572930741715,0.7874204872885948,0.808,0.9012107490103364,1.0,4/125,2.28%,YTHDF3;PLD1;NOD2;HGF
prerank,GO_Biological_Process_2021__phosphatidylcholine biosynthetic process (GO:0006656),0.5770697135477998,0.7873848390784653,0.6666666666666666,0.9009184801652815,1.0,2/32,2.30%,GPAT4;LPIN3
prerank,Reactome_2022__Collagen Chain Trimerization R-HSA-8948216,0.5760596000264053,0.7871626721168369,0.7307692307692307,0.9008499276172156,1.0,4/43,2.41%,COL12A1;COL9A3;COL9A2;COL4A5
prerank,Reactome_2022__ERBB2 Regulates Cell Motility R-HSA-6785631,0.48815801737349657,0.7871146718665677,0.5333333333333333,0.9005817100379322,1.0,1/15,1.19%,ERBB3
prerank,GO_Biological_Process_2021__positive regulation of cell cycle G1/S phase transition (GO:1902808),-0.5846468056857271,-0.7870688409025356,0.7086614173228346,0.9811740241797927,1.0,1/33,1.54%,CCND2
prerank,MSigDB_Oncogenic_Signatures__ATF2 S UP.V1 UP,0.4902746405485401,0.7870210928102397,0.9152542372881356,0.9003458400912724,1.0,7/162,2.34%,PPM1H;ANKRD11;PSMB9;SLC13A3;KIF23;MYO7A;DBNDD1
prerank,GO_Biological_Process_2021__positive regulation of cell projection organization (GO:0031346),-0.5594259612128353,-0.786868839474279,0.7913043478260869,0.9809614657888833,1.0,3/111,1.21%,PTK2B;CARMIL1;RAP1A
prerank,GO_Biological_Process_2021__regulation of protein phosphorylation (GO:0001932),-0.49119019682345605,-0.7866875886789769,0.9545454545454546,0.9807491170216333,1.0,13/254,2.38%,APP;NDUFS4;NIBAN1;BMP4;SLCO3A1;CCND2;KNDC1;PELI2;TEK;PRR5L;PML;SEMA4D;HRG
prerank,WikiPathway_2021_Human__Synaptic signaling pathways associated with autism spectrum disorder WP4539,-0.5893736983599764,-0.7866580794197425,0.7412587412587412,0.9803022624994692,1.0,3/50,1.08%,AKT3;PIK3CB;GRIN2B
prerank,TRRUST_Transcription_Factors_2019__KLF6 human,0.48296655087820345,0.7865692859652865,0.5338983050847458,0.9006361233810071,1.0,1/16,1.71%,CDH1
prerank,Reactome_2022__Regulation Of RUNX1 Expression And Activity R-HSA-8934593,-0.5347152879029161,-0.78640266496634,0.5934959349593496,0.9801790741306802,1.0,2/17,2.09%,CCND2;PML
prerank,GO_Biological_Process_2021__protein localization to chromosome (GO:0034502),0.5619409955427409,0.7860961645735828,0.6616541353383458,0.9008754701320364,1.0,4/34,2.15%,MSH2;ATR;CENPA;ACD
prerank,Reactome_2022__RIP-mediated NFkB Activation Via ZBP1 R-HSA-1810476,-0.4906415589580183,-0.786064020118273,0.5396825396825397,0.980200171267746,1.0,8/17,16.49%,RIPK1;NFKB1;RELA;DHX9;MYD88;TICAM1;NKIRAS2;TLR3
prerank,KEGG_2021_Human__Human immunodeficiency virus 1 infection,0.4878479683754002,0.7858627344076987,0.9385964912280702,0.9008408620273604,1.0,8/189,2.34%,PIK3CD;PTK2;ATR;CD4;GNB5;MAPK13;NFATC2;GNG2
prerank,Elsevier_Pathway_Collection__CDH1 Down regulation Promotes Cancer Cell Migration and Metastases,0.5829862996217995,0.7857192876581026,0.7007874015748031,0.9007066093116767,1.0,2/44,1.71%,LRP5;CDH1
prerank,GO_Biological_Process_2021__bile acid biosynthetic process (GO:0006699),-0.4978837835186094,-0.7856887881853929,0.5905511811023622,0.9801865263746566,1.0,1/27,0.22%,CYP39A1
prerank,GO_Biological_Process_2021__canonical glycolysis (GO:0061621),0.5336728032928504,0.7854619165219877,0.625,0.9003219300950744,1.0,2/22,2.19%,PKLR;HK2
prerank,GO_Biological_Process_2021__glucose catabolic process to pyruvate (GO:0061718),0.5336728032928504,0.7854619165219877,0.625,0.9003219300950744,1.0,2/22,2.19%,PKLR;HK2
prerank,GO_Biological_Process_2021__spindle assembly (GO:0051225),0.5474550094477165,0.78546055580029,0.8333333333333334,0.8999838445036005,1.0,5/79,2.41%,NEK6;HAUS8;HAUS2;FLNA;KIF3B
prerank,"Elsevier_Pathway_Collection__Proteins Involved in Adhesion, Migration and Invasion of Endometriotic Cell",0.4829658918253088,0.7854302241132048,0.5426356589147286,0.8996898694316622,1.0,1/17,1.71%,CDH1
prerank,GO_Biological_Process_2021__regulation of protein metabolic process (GO:0051246),-0.5797147349684069,-0.7852109996809243,0.7050359712230215,0.9803325341625265,1.0,5/45,2.05%,MAP2K5;APP;SHH;LTBP4;KLF4
prerank,GO_Biological_Process_2021__phosphatidylinositol-mediated signaling (GO:0048015),0.5761901616747938,0.7851914123808403,0.7747747747747747,0.8996389224895484,1.0,3/68,2.39%,PIK3CD;ERBB3;PIK3C2B
prerank,Reactome_2022__Signaling By FGFR1 In Disease R-HSA-5655302,0.5763388447222975,0.7851218515101963,0.7265625,0.8993806934789258,1.0,2/32,2.37%,TRIM24;FGF1
prerank,Reactome_2022__MET Promotes Cell Motility R-HSA-8875878,0.5400534732686265,0.7850904327063384,0.6870229007633588,0.8990805356457579,1.0,3/28,1.56%,ITGA3;PTK2;ITGA2
prerank,KEGG_2021_Human__Peroxisome,0.5232897028583977,0.7850520298588209,0.7706422018348624,0.8987991297585703,1.0,4/82,2.22%,EPHX2;SLC27A2;MPV17;ACSL5
prerank,Reactome_2022__Signaling By Insulin Receptor R-HSA-74752,-0.5842809817218372,-0.7850182454367184,0.7111111111111111,0.9800881682339094,1.0,2/66,1.58%,PIK3CB;GRB10
prerank,WikiPathway_2021_Human__Mesodermal commitment pathway WP2857,-0.5175209972626998,-0.7848705804162598,0.8706896551724138,0.9798076388852953,1.0,7/133,2.32%,PARP8;KDM6A;MEIS1;BMP4;PBX1;KLF4;ZFHX4
prerank,GO_Biological_Process_2021__visual perception (GO:0007601),0.548305100013426,0.784724787362594,0.7815126050420168,0.8989287419825153,1.0,2/74,2.31%,CACNA2D4;MYO7A
prerank,Reactome_2022__Translesion Synthesis By POLI R-HSA-5656121,-0.4966545212071618,-0.7847069920834133,0.5227272727272727,0.9795793646816707,1.0,1/17,0.34%,REV3L
prerank,GO_Biological_Process_2021__negative regulation of neuron apoptotic process (GO:0043524),0.5941597482069485,0.7846228406593834,0.7131147540983607,0.8987132409585216,1.0,6/64,2.14%,MSH2;ERBB3;CX3CL1;NAIP;APOE;SLC30A10
prerank,GO_Biological_Process_2021__regulation of MAPK cascade (GO:0043408),0.5024641154225791,0.7843275933702888,0.905511811023622,0.8987553047581431,1.0,7/154,2.27%,LPAR1;KSR1;CD4;SYK;CX3CL1;ULK4;FN1
prerank,Elsevier_Pathway_Collection__Neurofibrillary Tangle Formation,-0.49696219264299735,-0.7842591660046032,0.5307692307692308,0.979735774636375,1.0,1/16,0.31%,TNFRSF10B
prerank,GO_Biological_Process_2021__cellular response to hypoxia (GO:0071456),-0.5245618388332431,-0.7841475381078631,0.796875,0.9794004406773791,1.0,2/127,2.09%,CREBBP;AQP3
prerank,GO_Biological_Process_2021__microvillus assembly (GO:0030033),0.5077660092469625,0.7838066423545534,0.514018691588785,0.8991101418148228,1.0,3/15,2.17%,RAPGEF6;ESPN;STK26
prerank,WikiPathway_2021_Human__One-carbon metabolism WP241,0.5816498457138143,0.7837028352311026,0.7241379310344828,0.8989149881924601,1.0,3/30,1.84%,MTHFS;FTCD;CHDH
prerank,GO_Biological_Process_2021__limb morphogenesis (GO:0035108),0.5220757829889459,0.783596235468659,0.5775862068965517,0.8987115780935434,1.0,2/18,2.34%,MEGF8;TBX3
prerank,GO_Biological_Process_2021__response to interferon-gamma (GO:0034341),0.5600645679802556,0.7835182131938344,0.7674418604651163,0.8984730430200055,1.0,4/74,1.90%,MEFV;CX3CL1;CYP27B1;CCL14
prerank,WikiPathway_2021_Human__Glucocorticoid Receptor Pathway WP2880,-0.5785789868462016,-0.7832179002538843,0.7560975609756098,0.9802367155463846,1.0,2/67,2.15%,NR3C1;PRRG4
prerank,KEGG_2021_Human__Biosynthesis of unsaturated fatty acids,0.5363227105053657,0.7830686323494533,0.6511627906976745,0.8986964750523697,1.0,2/27,1.93%,ELOVL2;ELOVL6
prerank,GO_Biological_Process_2021__diterpenoid metabolic process (GO:0016101),-0.5827847125805116,-0.7830075775624681,0.7258064516129032,0.9800899536006057,1.0,2/57,1.73%,CYP4V2;SDC3
prerank,GO_Biological_Process_2021__defense response to Gram-positive bacterium (GO:0050830),-0.5760919562255998,-0.7828635447780177,0.7457627118644068,0.9798240753226066,1.0,3/49,2.40%,TNFRSF14;PGLYRP2;GBP4
prerank,Elsevier_Pathway_Collection__Melanocyte Role in Skin Aging,0.4957702194600346,0.7827756928379592,0.543859649122807,0.8987183075788455,1.0,1/16,0.43%,CREB1
prerank,GO_Biological_Process_2021__integrin-mediated signaling pathway (GO:0007229),0.572166285231895,0.782312015767956,0.7833333333333333,0.8989532270074556,1.0,8/75,2.27%,PTK2;ZNF304;SYK;THY1;BCAR1;ITGA2;ITGB5;FN1
prerank,GO_Biological_Process_2021__protein localization to centrosome (GO:0071539),-0.49742335913245517,-0.7822464379444859,0.5546218487394958,0.9801993827647939,1.0,1/18,0.27%,CCDC14
prerank,GO_Biological_Process_2021__response to organic cyclic compound (GO:0014070),0.5798237988847134,0.7822272255299001,0.75,0.8987216672948061,1.0,5/53,2.03%,STRN3;ANXA1;DRD4;CYP27B1;TRPV1
prerank,MSigDB_Hallmark_2020__Myogenesis,0.5055344833109874,0.7822190206566472,0.8859649122807017,0.8983997371953976,1.0,8/183,2.09%,SVIL;IGFBP3;ERBB3;TNNC2;ITGB5;TEAD4;PPFIA4;CNN3
prerank,GO_Biological_Process_2021__import into nucleus (GO:0051170),-0.5700379853588484,-0.7821739789519262,0.7751937984496124,0.9798232013894819,1.0,1/74,0.15%,IPO11
prerank,GO_Biological_Process_2021__mitotic recombination (GO:0006312),-0.49611650625241493,-0.782062980635903,0.5217391304347826,0.9795060677154673,1.0,1/15,0.40%,NSMCE2
prerank,Elsevier_Pathway_Collection__Eat me Signal: Apoptotic Cell Initiates Phagocytosis,0.5831148147070043,0.7820284091788299,0.6936936936936937,0.898302644703202,1.0,2/25,1.69%,CASP7;HAVCR1
prerank,MSigDB_Oncogenic_Signatures__CAHOY ASTROCYTIC,-0.5446319315182189,-0.7818620564624114,0.7851851851851852,0.9792858457178099,1.0,5/93,1.44%,RASA2;TTPA;VNN1;APP;AGPAT4
prerank,"Elsevier_Pathway_Collection__Glioblastoma, Secondary",0.5772461639321818,0.7818370981280596,0.7404580152671756,0.8981972472368952,1.0,2/50,2.28%,CDK6;HGF
prerank,GO_Biological_Process_2021__renal system development (GO:0072001),0.594205055637525,0.7817555127707572,0.6774193548387096,0.8979696642178131,1.0,3/55,2.12%,SALL1;PROX1;RBP4
prerank,GO_Biological_Process_2021__regulation of programmed cell death (GO:0043067),0.5046948831546171,0.7816801894574601,0.9193548387096774,0.8977322054220461,1.0,7/169,2.17%,TNFRSF10A;TRIM24;IGFBP3;TNFRSF25;TNFRSF10D;BCAR1;STK26
prerank,Elsevier_Pathway_Collection__BDKRB1/2 -> Ion Channels,-0.47992930007390894,-0.7812130218592724,0.5166666666666667,0.9797296498471122,1.0,1/16,2.01%,BDKRB2
prerank,GO_Biological_Process_2021__regulation of neuron differentiation (GO:0045664),-0.5820084010447779,-0.7809204395446079,0.732824427480916,0.9797128881165617,1.0,2/66,1.81%,ZEB1;NTF3
prerank,GO_Biological_Process_2021__potassium ion import across plasma membrane (GO:1990573),0.5865288388978531,0.7804231121835278,0.7083333333333334,0.8989810833172525,1.0,1/39,1.35%,KCNJ10
prerank,GO_Biological_Process_2021__positive regulation of DNA-binding transcription factor activity (GO:0051091),0.4795260570553318,0.7804044776393854,0.952,0.8986647947070114,1.0,5/234,2.05%,IRAK2;NOD2;NFAM1;CX3CL1;EDA2R
prerank,GO_Biological_Process_2021__cardiac muscle tissue development (GO:0048738),-0.5848704735824525,-0.7803419229802075,0.7647058823529411,0.9800509778102147,1.0,3/48,1.53%,ADAMTS9;BMP4;NRG1
prerank,Reactome_2022__Formation Of Senescence-Associated Heterochromatin Foci (SAHF) R-HSA-2559584,0.49630870650161174,0.7802924105511153,0.5401459854014599,0.8984724959871165,1.0,1/15,0.37%,HIRA
prerank,Elsevier_Pathway_Collection__Mantle Cell Lymphoma,0.5464009210334471,0.7801945155617961,0.8235294117647058,0.8982502491070503,1.0,5/103,1.26%,TRAF3;LRP5;CDK6;ATR;SYK
prerank,GO_Biological_Process_2021__positive regulation of epithelial to mesenchymal transition (GO:0010718),-0.5854507684206711,-0.7801485375707229,0.7661290322580645,0.9798137031880552,1.0,1/40,1.46%,TGFB1I1
prerank,KEGG_2021_Human__Gastric cancer,-0.5287564721537501,-0.78010273710184,0.8582089552238806,0.9793976947961593,1.0,5/138,1.43%,POLK;AKT3;PIK3CB;RB1;SHH
prerank,WikiPathway_2021_Human__Nanoparticle-mediated activation of receptor signaling WP2643,0.5774585724273432,0.7798995849600785,0.675,0.8982988879694829,1.0,4/28,2.27%,PIK3CD;PTK2;MAPK13;FN1
prerank,GO_Biological_Process_2021__positive regulation of calcium ion transport (GO:0051928),0.5795288324042107,0.7798837196925257,0.712,0.8979833232810964,1.0,2/36,2.05%,LILRA2;LGALS3
prerank,Reactome_2022__Termination Of O-glycan Biosynthesis R-HSA-977068,0.4968077044633397,0.7798757315991678,0.5967741935483871,0.8976579738950944,1.0,1/20,0.32%,ST3GAL1
prerank,GO_Biological_Process_2021__negative regulation of ossification (GO:0030279),-0.4987686618056498,-0.7796907505480712,0.5648148148148148,0.979436166990316,1.0,1/22,0.13%,PTK2B
prerank,GO_Biological_Process_2021__regulation of stress fiber assembly (GO:0051492),0.5550357317741439,0.7796158827108788,0.8108108108108109,0.8976166389843787,1.0,5/73,2.20%,TJP1;LPAR1;ARHGEF18;DLC1;RHPN2
prerank,"Elsevier_Pathway_Collection__Hyaluronic Acid, CD44 and HMMR in Cancer Cell Invasion and Survival",-0.5824432892786122,-0.779486062862791,0.75,0.9792975300026782,1.0,2/50,1.76%,ADAM10;CD44
prerank,GO_Biological_Process_2021__regulation of protein import into nucleus (GO:0042306),-0.5850695882086714,-0.7792912280583224,0.71875,0.9790851409499277,1.0,2/36,1.50%,SUFU;BMP4
prerank,GO_Biological_Process_2021__water-soluble vitamin metabolic process (GO:0006767),-0.5405410309426673,-0.7791530246531924,0.8151260504201681,0.9787853678027534,1.0,4/72,1.96%,SLC23A2;VNN1;BTD;MTHFD2L
prerank,Reactome_2022__Cellular Response To Hypoxia R-HSA-1234174,-0.5592505349037533,-0.7789550424618296,0.8257575757575758,0.9785717180491541,1.0,1/71,1.22%,CREBBP
prerank,GO_Biological_Process_2021__maintenance of protein localization in organelle (GO:0072595),-0.4791190530329657,-0.7788674555744179,0.5294117647058824,0.9782330228769527,1.0,1/19,2.09%,PML
prerank,GO_Biological_Process_2021__excitatory postsynaptic potential (GO:0060079),0.49442482022535356,0.7787559287457871,0.5254237288135594,0.898374609345667,1.0,1/15,0.56%,RAB3GAP1
prerank,GO_Biological_Process_2021__positive regulation of lipid kinase activity (GO:0090218),0.5625035974348847,0.7786690279673079,0.6944444444444444,0.8981528937825727,1.0,2/29,0.90%,PTK2;NOD2
prerank,Reactome_2022__Nephrin Family Interactions R-HSA-373753,0.49753824884587783,0.778561476226992,0.5948275862068966,0.8979880341322299,1.0,1/21,0.25%,CD2AP
prerank,Elsevier_Pathway_Collection__TGFB Family in Epithelial to Mesenchymal Transition in Cancer,0.5525674819242751,0.7780709981821637,0.7767857142857143,0.8982599918031478,1.0,8/80,2.27%,CDH2;TJP1;MRTFA;CRB3;SMAD9;CDH1;SERPINE1;FN1
prerank,GO_Biological_Process_2021__negative regulation of innate immune response (GO:0045824),0.5638240448732118,0.7780363968356043,0.7314814814814815,0.8979802498720082,1.0,4/37,1.96%,YTHDF3;PTPN2;USP15;A2M
prerank,MSigDB_Oncogenic_Signatures__GCNP SHH UP LATE.V1 DN,0.5039173031621577,0.7779852619052393,0.8807339449541285,0.8977173707040125,1.0,9/163,2.36%,ARID3A;SLC19A1;RBBP6;TTC23;NDUFA10;CX3CL1;TNNC2;PPFIA4;STX1A
prerank,GO_Biological_Process_2021__positive regulation of leukocyte cell-cell adhesion (GO:1903039),0.5867258054047056,0.7779515655205153,0.6890756302521008,0.8974230528110246,1.0,1/31,1.33%,THY1
prerank,Reactome_2022__RHOG GTPase Cycle R-HSA-9013408,0.5494953055828784,0.7778473198587819,0.7478991596638656,0.8972005180719314,1.0,4/73,1.58%,DEPDC1B;RAB7A;ARHGAP39;CDC42EP1
prerank,GO_Biological_Process_2021__negative regulation of phosphorylation (GO:0042326),0.5410606704230494,0.7778041360297787,0.7391304347826086,0.8969249100510754,1.0,3/83,1.46%,PPARA;IGFBP3;CADM4
prerank,GO_Biological_Process_2021__regulation of actin filament polymerization (GO:0030833),-0.5745716274285002,-0.7774352648692525,0.762589928057554,0.9796919390838396,1.0,4/71,1.65%,PTK2B;CARMIL1;HCK;KANK3
prerank,GO_Biological_Process_2021__hemopoiesis (GO:0030097),-0.5525336166345689,-0.7773485866414114,0.8306451612903226,0.97934102982294,1.0,3/90,1.90%,MEIS1;BMP4;TEK
prerank,Elsevier_Pathway_Collection__Mesangial Cell Dysfunction in Glomerulonephritis,-0.6058337643201288,-0.7773340839850553,0.7293233082706767,0.9788859502390533,1.0,3/41,1.93%,PTK2B;MAP2K6;MMP2
prerank,GO_Biological_Process_2021__epoxygenase P450 pathway (GO:0019373),-0.5517797626288392,-0.7770633641235847,0.6384615384615384,0.9787720932710043,1.0,3/18,1.98%,CYP2C8;CYP1B1;CYP1A2
prerank,GO_Biological_Process_2021__regulation of axonogenesis (GO:0050770),0.5657416477121536,0.7769722090149147,0.7674418604651163,0.8976756224998366,1.0,3/50,1.33%,CDH2;BRSK1;THY1
prerank,Elsevier_Pathway_Collection__Cell Cycle Dysregulation in Mantle Cell Lymphoma,-0.5402860857210878,-0.7769215040780836,0.6546762589928058,0.97850258796908,1.0,3/25,1.54%,RB1;HIC1;CCND2
prerank,GO_Biological_Process_2021__positive regulation of peptidyl-serine phosphorylation (GO:0033138),-0.5610300405084028,-0.776828219669224,0.788135593220339,0.9781597794406531,1.0,4/71,1.81%,APP;RAPGEF3;CD44;NTF3
prerank,Elsevier_Pathway_Collection__NOTCH Signaling in Hepatocellular Carcinoma,0.49576879709268373,0.7765873673965793,0.5775862068965517,0.8978405941185519,1.0,1/24,0.43%,CREB1
prerank,MSigDB_Oncogenic_Signatures__PRC1 BMI UP.V1 DN,-0.4943574652047547,-0.7761838207816186,0.9338842975206612,0.9785525929449812,1.0,5/154,2.30%,SDCCAG8;ZNF117;CCND2;PELI2;GALNT3
prerank,Elsevier_Pathway_Collection__NPY1R -> CRH/POMC Production,0.4957693720437344,0.7761371652217354,0.5581395348837209,0.8980237239965025,1.0,1/21,0.43%,CREB1
prerank,GO_Biological_Process_2021__pyrimidine-containing compound catabolic process (GO:0072529),-0.4928870983786441,-0.7760806136170141,0.5419847328244275,0.9782203472534637,1.0,1/15,0.72%,DPYS
prerank,KEGG_2021_Human__Wnt signaling pathway,-0.49795204630823603,-0.7759674282020905,0.9517241379310345,0.9779003815886937,1.0,5/154,1.94%,TLE4;CREBBP;CCND2;PLCB4;PRICKLE2
prerank,Reactome_2022__Hedgehog On State R-HSA-5632684,-0.5675724578904627,-0.7759491946266243,0.7661290322580645,0.9774372962555437,1.0,4/83,2.08%,SUFU;SHH;BOC;GLI3
prerank,GO_Biological_Process_2021__regulation of chromosome organization (GO:0033044),-0.5249632993718051,-0.7758522956423589,0.5763888888888888,0.9771060723510432,1.0,2/21,1.36%,RB1;SMG6
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> NFATC Signaling,0.5356326876433702,0.7758181929170106,0.6218487394957983,0.8980821262799964,1.0,2/24,2.00%,CD4;NFATC2
prerank,MSigDB_Hallmark_2020__IL-2/STAT5 Signaling,0.4857465462919531,0.7753830348352547,0.9758064516129032,0.8982899407790604,1.0,10/197,2.29%,LCLAT1;IGF2R;PHTF2;TNFRSF21;CKAP4;CD48;LRRC8C;HK2;LRIG1;CD86
prerank,GO_Biological_Process_2021__positive regulation of cell cycle (GO:0045787),-0.568000796093555,-0.7752329259033898,0.8267716535433071,0.9774865047507859,1.0,2/65,1.54%,APP;CCND2
prerank,Reactome_2022__Mitotic Prophase R-HSA-68875,-0.534035278551273,-0.7751730589741889,0.8360655737704918,0.9770822615015112,1.0,3/101,1.15%,VRK2;NEK7;RB1
prerank,GO_Biological_Process_2021__regulation of vascular endothelial growth factor receptor signaling pathway (GO:0030947),0.5239623050775858,0.7751315783315822,0.6218487394957983,0.8982336614393779,1.0,2/23,1.46%,NIBAN2;CADM4
prerank,GO_Biological_Process_2021__regulation of epithelial to mesenchymal transition (GO:0010717),-0.585430341783466,-0.7751110845438481,0.7796610169491526,0.9766750004384195,1.0,1/73,1.46%,TGFB1I1
prerank,MSigDB_Oncogenic_Signatures__KRAS.50 UP.V1 DN,0.5248803438624833,0.7750461522767834,0.6722689075630253,0.8980297380538647,1.0,2/32,1.36%,EPHX2;CGREF1
prerank,GO_Biological_Process_2021__sulfur amino acid metabolic process (GO:0000096),0.5372864649514308,0.77489561322922,0.6554621848739496,0.897875728511124,1.0,2/24,1.83%,CBS;SMS
prerank,GO_Biological_Process_2021__positive regulation of cell morphogenesis involved in differentiation (GO:0010770),0.5771312927908027,0.7747919553814234,0.7605633802816901,0.8976787203581342,1.0,2/49,2.29%,ARHGEF7;FLNA
prerank,KEGG_2021_Human__Olfactory transduction,-0.584407554185568,-0.7746817428463302,0.7465753424657534,0.9767808472303192,1.0,1/46,1.56%,ADCY3
prerank,TRRUST_Transcription_Factors_2019__HDAC1 human,0.5588527261248176,0.7745506806647137,0.8015267175572519,0.8976559005684257,1.0,5/70,1.82%,TJP1;TNFRSF10A;IGFBP3;CDH1;PTGS2
prerank,MSigDB_Oncogenic_Signatures__JNK DN.V1 UP,-0.4899273471067199,-0.7744534432701073,0.9705882352941176,0.9766533427051637,1.0,8/160,2.46%,MYOM1;TEK;IL10RA;CD83;S1PR1;TNFSF14;SYNE1;SLC16A2
prerank,Reactome_2022__Extra-nuclear Estrogen Signaling R-HSA-9009391,0.5221451860913789,0.774426878487324,0.7913043478260869,0.8974756881733079,1.0,4/69,2.34%,CREB1;PTK2;GNB5;GNG2
prerank,Elsevier_Pathway_Collection__Inhibition of THBS1 Activates Angiogenesis in Cancer,-0.5767561692324457,-0.7743911790025272,0.7407407407407407,0.9762741055643035,1.0,4/39,2.34%,TNFRSF10B;PTPRJ;MMP2;VAV1
prerank,GO_Biological_Process_2021__nitric oxide metabolic process (GO:0046209),0.48438897184028723,0.7739894319038838,0.525,0.8976782210141644,1.0,1/16,1.56%,MTARC2
prerank,Elsevier_Pathway_Collection__Osteoclast Activation in Multiple Myeloma,0.5823934198074672,0.7739788655412762,0.7310924369747899,0.8973573969646603,1.0,2/66,1.76%,TRAF3;FOSL1
prerank,GO_Biological_Process_2021__platelet degranulation (GO:0002576),-0.5318875979796167,-0.7739681503733727,0.8373983739837398,0.9763953007069501,1.0,6/124,2.38%,A1BG;APP;NHLRC2;PROS1;CD9;HRG
prerank,TRRUST_Transcription_Factors_2019__CEBPB mouse,0.5772962137564166,0.7739504985466974,0.7384615384615385,0.8970450848023197,1.0,3/37,2.28%,PTGS2;SERPINE1;HGF
prerank,TRRUST_Transcription_Factors_2019__NR5A1 mouse,0.4835804927885566,0.7739262847328348,0.5639097744360902,0.8967462386286406,1.0,1/18,1.64%,AMH
prerank,Elsevier_Pathway_Collection__Multiple Myeloma,-0.5302055879130979,-0.7738753289111768,0.8914728682170543,0.9760352544105865,1.0,5/120,1.54%,PTK2B;RB1;DEPTOR;HCK;CCND2
prerank,Reactome_2022__O-linked Glycosylation Of Mucins R-HSA-913709,-0.5770911410014972,-0.7738259443368938,0.7542372881355932,0.9756279754731784,1.0,2/51,2.30%,MUC6;GALNT3
prerank,Elsevier_Pathway_Collection__mTOR Signaling Activation by Fatty Acids and Glucose,0.5800963056864904,0.7737002964823815,0.6946564885496184,0.8967155429739773,1.0,2/48,1.99%,PLD1;APOE
prerank,GO_Biological_Process_2021__protein autophosphorylation (GO:0046777),-0.5086403393369224,-0.7735979824132485,0.8677685950413223,0.975453776359184,1.0,10/154,2.39%,VRK2;PTK2B;PAK2;PEAK1;TEC;WNK3;HCK;DAPK2;TEK;MAP4K1
prerank,MSigDB_Oncogenic_Signatures__LTE2 UP.V1 DN,0.4789129230273968,0.7733890646263661,0.9918032786885246,0.896803906333011,1.0,10/179,2.13%,SP110;GTF2I;SVIL;ARHGAP12;PSMB9;ELOVL2;DLC1;FHL2;COL9A3;AMMECR1
prerank,GO_Biological_Process_2021__negative regulation of cellular component organization (GO:0051129),-0.5545918202014029,-0.7733818951807675,0.8484848484848485,0.9752576756817042,1.0,4/75,2.45%,CARMIL1;RAPGEF3;IRAK3;DNAJA4
prerank,KEGG_2021_Human__Salmonella infection,-0.47796906659706534,-0.7733815121796774,1.0,0.9747885762706018,1.0,8/242,2.22%,EXOC2;MAP2K6;TNFRSF10B;KPNA3;AKT3;PIK3CB;ARHGEF26;RHOH
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Activation through Integrins and non-ITAM-Containing Receptors,0.5657954938573895,0.773364854744206,0.7398373983739838,0.8964955625375335,1.0,7/44,2.27%,CD2AP;ITGA4;SYK;ITGAL;CD48;NFATC2;FN1
prerank,Elsevier_Pathway_Collection__CagA Phosphorylation Independent Signaling,0.5830680572246787,0.7732707391476485,0.712,0.8962849174806886,1.0,4/38,1.71%,TJP1;PTK2;BCAR1;CDH1
prerank,Elsevier_Pathway_Collection__Tumor Infiltrating Macrophages in Cancer Progression and Immune Escape,-0.5489965215911751,-0.7730863925767535,0.7350427350427351,0.974713399977976,1.0,2/34,2.25%,MMP2;CD274
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Evading of Growth Suppressors,0.5686334870454995,0.7730772558770206,0.8135593220338984,0.8961817722115185,1.0,4/57,1.97%,TRAF3;CDH1;TEAD4;AXIN2
prerank,Reactome_2022__MAPK1/MAPK3 Signaling R-HSA-5684996,-0.4807085748927417,-0.7728540643963128,1.0,0.974539975189763,1.0,10/261,1.95%,RASA2;RAP1B;PIK3CB;GRIN2B;RAP1A;NRG1;PDE6D;DUSP4;TEK;RASGRP3
prerank,GO_Biological_Process_2021__regulation of cell adhesion (GO:0030155),0.5150075933255943,0.7727256475365762,0.87,0.8962834086485119,1.0,5/128,1.45%,PKP4;PTK2;PPP1R12A;ERBB3;CHRD
prerank,Elsevier_Pathway_Collection__Proteins Involved in Obesity,0.532995989615444,0.7727003471052798,0.8455882352941176,0.8959806596926218,1.0,8/93,2.28%,PPARA;CREB1;IL1RN;PTGS2;APOE;SERPINE1;RBP4;HGF
prerank,Reactome_2022__Metabolism Of Fat-Soluble Vitamins R-HSA-6806667,-0.5827931142659863,-0.7726152600772612,0.7079646017699115,0.9744141593856889,1.0,2/45,1.73%,TTPA;SDC3
prerank,GO_Biological_Process_2021__negative regulation of protein catabolic process (GO:0042177),-0.5765266290039833,-0.772558574046433,0.7391304347826086,0.9740344307391294,1.0,2/37,2.36%,RIC1;IRAK3
prerank,GO_Biological_Process_2021__myeloid leukocyte differentiation (GO:0002573),-0.5386509299416498,-0.772483504718146,0.8088235294117647,0.9736601447504121,1.0,4/69,2.40%,BMP4;PML;PIR;SPI1
prerank,GO_Biological_Process_2021__regulation of neuron apoptotic process (GO:0043523),0.5439340327577632,0.7722884058919043,0.823076923076923,0.896158178873633,1.0,5/88,2.14%,MSH2;ERBB3;NAIP;APOE;SLC30A10
prerank,TRRUST_Transcription_Factors_2019__SOX2 human,0.486772833279062,0.7722021300258101,0.5555555555555556,0.8959348518380974,1.0,1/17,1.33%,MKI67
prerank,Reactome_2022__Signaling By FGFR In Disease R-HSA-1226099,0.5763173289821323,0.7720765102346363,0.746031746031746,0.8957578447428227,1.0,2/55,2.37%,TRIM24;FGF1
prerank,Reactome_2022__Biosynthesis Of DHA-derived SPMs R-HSA-9018677,0.48185218999700785,0.7720534377728606,0.5454545454545454,0.8954573804165032,1.0,2/16,1.82%,EPHX2;PTGS2
prerank,GO_Biological_Process_2021__negative regulation of platelet activation (GO:0010544),0.4800832818684632,0.7720251109379954,0.5590551181102362,0.8951538419253865,1.0,1/16,1.99%,APOE
prerank,Elsevier_Pathway_Collection__Receptors and Adaptor Proteins Activated in Cancer,-0.5143737751962851,-0.7716372255826339,0.9044117647058824,0.9743605953186499,1.0,9/119,2.44%,PROS1;NRG1;GRB10;STAT5A;IL11RA;NTF3;EFNB2;VAV1;ZAP70
prerank,MSigDB_Oncogenic_Signatures__NOTCH DN.V1 UP,0.49385662836385513,0.7714952388148152,0.9672131147540983,0.8954581285506379,1.0,6/149,2.14%,KSR1;MEFV;SPTBN2;PNPLA3;PPP1R13L;SLC30A10
prerank,MSigDB_Hallmark_2020__Xenobiotic Metabolism,-0.48547233652293287,-0.771189387705542,0.9663865546218487,0.9744312769196055,1.0,9/197,2.38%,SLC22A1;TTPA;TPST1;VNN1;PROS1;ITIH1;CYP1A2;CDO1;HRG
prerank,Elsevier_Pathway_Collection__Peripheral Tolerance to Autoantigens Recession in Diabetes Mellitus Type 1,-0.547145766888096,-0.7711664929090007,0.7388059701492538,0.9740015585176799,1.0,2/38,2.44%,STAT5A;ZAP70
prerank,GO_Biological_Process_2021__regulation of macrophage chemotaxis (GO:0010758),-0.4987688493919926,-0.771062990820128,0.6015625,0.9736736218541674,1.0,1/20,0.13%,PTK2B
prerank,WikiPathway_2021_Human__SARS-CoV-2 mitochondrial interactions WP5038,-0.5774948513302998,-0.7709174986405933,0.6902654867256637,0.9734084808123293,1.0,2/30,2.26%,TOMM70;TMPRSS2
prerank,GO_Biological_Process_2021__positive regulation of secretion by cell (GO:1903532),-0.5620657788667731,-0.7708726112137428,0.7910447761194029,0.9729883080343573,1.0,4/69,2.14%,MYOM1;STXBP5;DTNBP1;APBB3
prerank,Reactome_2022__ADORA2B Mediated Anti-Inflammatory Cytokine Production R-HSA-9660821,0.5099574679077699,0.7707092987616049,0.8925619834710744,0.8960189708329984,1.0,3/99,2.34%,CREB1;GNB5;GNG2
prerank,GO_Biological_Process_2021__positive regulation of phosphatase activity (GO:0010922),-0.49734622531717837,-0.7706682572689633,0.5508474576271186,0.9727524286688723,1.0,1/20,0.27%,ITGA1
prerank,MSigDB_Oncogenic_Signatures__KRAS.DF.V1 UP,-0.4805351108986713,-0.7706577831826505,0.9699248120300752,0.9723026182942458,1.0,5/182,1.96%,AKT3;IFI44L;SLC2A10;HERC5;PROCR
prerank,Reactome_2022__Signaling By NOTCH3 R-HSA-9012852,-0.571297202284481,-0.7706504191808079,0.7272727272727273,0.9718566086754002,1.0,3/47,1.71%,ADAM10;CREBBP;PBX1
prerank,GO_Biological_Process_2021__positive regulation of response to biotic stimulus (GO:0002833),0.5784864912690989,0.770420365820257,0.8,0.896015025456153,1.0,2/40,2.16%,USP15;CYBA
prerank,GO_Biological_Process_2021__ameboidal-type cell migration (GO:0001667),-0.5685783978282268,-0.7703307559429833,0.7686567164179104,0.9718490369563865,1.0,4/51,2.25%,SGPL1;AMOTL1;SHH;SEMA4D
prerank,KEGG_2021_Human__NOD-like receptor signaling pathway,0.5079571787944757,0.7702843109850941,0.9043478260869565,0.8958104159604697,1.0,6/155,2.16%,TRAF3;NOD2;MEFV;NAIP;MAPK13;CYBA
prerank,Elsevier_Pathway_Collection__STAT3 Inhibits Maturation of Dendritic Cells and Facilitates Cancer Progression,-0.4802369555146787,-0.7701458604136636,0.56,0.9716040486196555,1.0,1/16,1.98%,IL10RA
prerank,Elsevier_Pathway_Collection__Proteins Involved in Noise-Induced Hearing Loss,-0.5756397376466673,-0.7698078824547122,0.75,0.9715831401921938,1.0,2/39,2.44%,NR3C1;KCNE1
prerank,Elsevier_Pathway_Collection__Androgen Receptor Genomic Signaling,-0.5239652764672444,-0.769784877875448,0.625,0.9711568291916735,1.0,2/18,1.46%,PDE5A;TGFB1I1
prerank,TRRUST_Transcription_Factors_2019__TWIST1 human,0.5564007162361043,0.769681125573124,0.7027027027027027,0.8962208906250966,1.0,4/34,2.27%,CDH2;ERBB3;CDH1;FN1
prerank,Elsevier_Pathway_Collection__Th17-Cell Function in Systemic Lupus Erythematosus,-0.5472168161258189,-0.7695636625808667,0.7230769230769231,0.9709780976300741,1.0,4/45,2.44%,IL12RB2;RORC;IL21R;ZAP70
prerank,Reactome_2022__Butyrate Response Factor 1 Binds And Destabilizes mRNA R-HSA-450385,0.46865716117875367,0.769540060004863,0.5175438596491229,0.8960607329332875,1.0,11/17,31.05%,EXOSC4;ZFP36L1;EXOSC9;XRN1;MAPKAPK2;YWHAB;DCP2;AKT1;EXOSC2;DCP1A;EXOSC7
prerank,TRRUST_Transcription_Factors_2019__MYC human,0.5314569978583867,0.769157060340148,0.853448275862069,0.8961717885718375,1.0,7/97,2.14%,ST3GAL1;CD33;CDK6;IGF2BP1;UBE2C;AXIN2;CDCA7
prerank,Elsevier_Pathway_Collection__non-Hereditary Genetic Rearrangements in Neuroblastoma,0.5859193454045155,0.7691539201340001,0.717741935483871,0.8958442404034999,1.0,1/29,1.41%,MYCN
prerank,TRRUST_Transcription_Factors_2019__ETS1 mouse,-0.5683924581758404,-0.7687932663962094,0.762962962962963,0.9715054086097514,1.0,2/54,1.50%,ZEB1;BMP4
prerank,Reactome_2022__Nuclear Events (Kinase And Transcription Factor Activation) R-HSA-198725,0.5823986560977799,0.7687029285845097,0.7941176470588235,0.8960143990326279,1.0,2/59,1.76%,CREB1;FOSL1
prerank,GO_Biological_Process_2021__vitamin transport (GO:0051180),0.5565965621917225,0.768560296075072,0.7293233082706767,0.8958250090071372,1.0,4/30,2.25%,SLC19A1;AMN;SLC2A8;SLC2A6
prerank,Reactome_2022__Antimicrobial Peptides R-HSA-6803157,0.5877585350167291,0.7684032960554854,0.704,0.8956784130790949,1.0,1/42,1.23%,CD4
prerank,GO_Biological_Process_2021__carboxylic acid transport (GO:0046942),-0.6006270820157472,-0.7681481968793877,0.7666666666666667,0.9718911101664942,1.0,5/53,2.46%,SLC23A2;SLC36A4;SLC7A8;SLC17A4;SLC16A2
prerank,Reactome_2022__RAF/MAP Kinase Cascade R-HSA-5673001,-0.4807130909681932,-0.7680997000747314,1.0,0.9714940080395474,1.0,10/255,1.95%,RASA2;RAP1B;PIK3CB;GRIN2B;RAP1A;NRG1;PDE6D;DUSP4;TEK;RASGRP3
prerank,GO_Biological_Process_2021__positive regulation of organelle assembly (GO:1902117),-0.5772110890658042,-0.7679343041416509,0.7461538461538462,0.9712701434487129,1.0,2/46,2.29%,CEP120;CROCC
prerank,Reactome_2022__MAPK6/MAPK4 Signaling R-HSA-5687128,0.5424471939040756,0.7677633801343693,0.7586206896551724,0.8961010073353673,1.0,3/85,1.32%,ARHGEF7;PSMB9;IGF2BP1
prerank,Reactome_2022__APC/C-mediated Degradation Of Cell Cycle Proteins R-HSA-174143,0.5381291101725172,0.7677585442968183,0.8,0.8957757218985832,1.0,2/84,1.74%,PSMB9;UBE2C
prerank,GO_Biological_Process_2021__regulation of ventricular cardiac muscle cell membrane repolarization (GO:0060307),0.48250535922837773,0.7677434670618053,0.52,0.8954637842268441,1.0,1/16,1.75%,SNTA1
prerank,KEGG_2021_Human__Fanconi anemia pathway,0.5885651319116578,0.7676750419169299,0.7543859649122807,0.8951963058162473,1.0,3/50,1.15%,FANCL;ATR;BRIP1
prerank,MSigDB_Oncogenic_Signatures__PDGF UP.V1 DN,0.5315957364007409,0.7676431376317365,0.8863636363636364,0.8949060957020357,1.0,5/105,2.41%,LY75;MSX1;TIMP3;GK;COL4A5
prerank,GO_Biological_Process_2021__positive regulation of supramolecular fiber organization (GO:1902905),-0.5440949496848013,-0.7676218288568407,0.8625954198473282,0.9711471388494067,1.0,5/88,1.49%,PTK2B;CARMIL1;APP;RB1;HCK
prerank,GO_Biological_Process_2021__positive regulation of transcription regulatory region DNA binding (GO:2000679),0.49207814181429443,0.7675942840436951,0.575,0.8946275561874593,1.0,1/19,0.80%,NIBAN2
prerank,Elsevier_Pathway_Collection__Mitochondria Enlargement and Apoptosis in Alzheimer's Disease,0.49719291950552313,0.7675285829108234,0.5454545454545454,0.894396675888913,1.0,1/15,0.28%,MICU1
prerank,WikiPathway_2021_Human__Mammary gland development pathway - Pregnancy and lactation (Stage 3 of 4) WP2817,0.5347423437937863,0.7675112462309711,0.6451612903225806,0.8940907155050146,1.0,2/31,2.09%,ERBB3;PRLR
prerank,GO_Biological_Process_2021__cholesterol metabolic process (GO:0008203),0.5515045336693742,0.7674021460229277,0.8405797101449275,0.8938700100070285,1.0,2/73,1.99%,SOAT2;APOE
prerank,Reactome_2022__Diseases Of Mitotic Cell Cycle R-HSA-9675126,0.5708799465216849,0.7674017055978862,0.7479674796747967,0.8935464827662511,1.0,3/38,1.74%,CDK6;TFDP2;UBE2C
prerank,WikiPathway_2021_Human__Wnt signaling WP428,0.5133840518599497,0.7673622991262419,0.8738738738738738,0.8932607738643871,1.0,3/107,2.00%,LRP5;FOSL1;NFATC2
prerank,Reactome_2022__Constitutive Signaling By NOTCH1 HD+PEST Domain Mutants R-HSA-2894862,0.5373401461533932,0.7672321837085903,0.7410714285714286,0.8930700128629894,1.0,3/57,1.83%,TBL1X;HDAC8;HDAC9
prerank,MSigDB_Oncogenic_Signatures__ATM DN.V1 DN,0.5006230112414887,0.7671561173362548,0.8699186991869918,0.892861429058464,1.0,4/119,2.12%,LILRA2;ST3GAL1;TXNRD2;CLCN4
prerank,KEGG_2021_Human__Pertussis,-0.5530479473910512,-0.7667309200889576,0.8320610687022901,0.9718759915355653,1.0,3/72,1.85%,C4BPA;C1R;TICAM2
prerank,TRRUST_Transcription_Factors_2019__TFAP2A human,-0.5654681973788569,-0.7660829636681646,0.7913043478260869,0.9722455181680041,1.0,6/66,2.30%,NR3C1;DCBLD2;APP;SOD2;MMP2;GALNT3
prerank,GO_Biological_Process_2021__carboxylic acid transmembrane transport (GO:1905039),-0.5633011013714616,-0.7659522665232412,0.7238805970149254,0.9719245683332629,1.0,4/37,1.38%,SLC23A2;SLC7A9;SLC36A4;SLC7A8
prerank,GO_Biological_Process_2021__regulation of transcription from RNA polymerase II promoter in response to stress (GO:0043618),-0.5592435165620471,-0.7657881378290378,0.8560606060606061,0.9716424312903208,1.0,1/85,1.22%,CREBBP
prerank,Elsevier_Pathway_Collection__Medulloblastoma,-0.5536486979050564,-0.7657217327257771,0.8214285714285714,0.9712501127283004,1.0,8/96,1.81%,RB1;SUFU;SHH;HIC1;BMP4;NRG1;CCND2;NTF3
prerank,MSigDB_Oncogenic_Signatures__KRAS.BREAST UP.V1 DN,0.5161189235425109,0.7657077745481233,0.8536585365853658,0.8941595772350976,1.0,5/115,1.73%,MEGF8;EPHX2;APOL3;SPTBN2;ASPHD1
prerank,GO_Biological_Process_2021__regulation of protein modification process (GO:0031399),0.5775164985364533,0.7656987678088463,0.7777777777777778,0.8938430589156767,1.0,6/50,2.27%,FNIP2;FNIP1;PTK2;PPP1R16B;CADM4;FN1
prerank,GO_Biological_Process_2021__regulation of cell death (GO:0010941),-0.534029809868559,-0.7655265521365031,0.8650793650793651,0.9710187434170757,1.0,2/99,2.16%,BMP4;SLFN11
prerank,Elsevier_Pathway_Collection__Proteins Involved in Periodontitis,0.5773568899584707,0.765399305895131,0.7593984962406015,0.8938546174324615,1.0,5/56,2.28%,NOD2;IL1RN;PTGS2;SERPINE1;HGF
prerank,WikiPathway_2021_Human__Regulation of toll-like receptor signaling pathway WP1449,0.5156816994435343,0.7651270608247019,0.868421052631579,0.8938547541448911,1.0,7/124,2.29%,TRAF3;PIK3CD;IRAK2;SYK;SIGIRR;MAPK13;CD86
prerank,GO_Biological_Process_2021__endothelial cell migration (GO:0043542),-0.6072582128158549,-0.7650798404328614,0.7846153846153846,0.9711620959929748,1.0,2/39,1.78%,ADGRA2;CYP1B1
prerank,Elsevier_Pathway_Collection__mTOR Signaling Activation by Amino Acids,0.5649603108357019,0.7650695008320354,0.7463768115942029,0.8936120361548131,1.0,1/45,0.65%,FNIP1
prerank,GO_Biological_Process_2021__positive regulation of protein modification process (GO:0031401),0.48377551132421137,0.7648635770158584,0.9622641509433962,0.8935226489103184,1.0,11/205,2.37%,RAB3GAP1;FNIP1;PLAUR;CEP295;PTK2;PPP1R16B;CD4;DLC1;AXIN2;HGF;FGF1
prerank,GO_Biological_Process_2021__regulation of leukocyte activation (GO:0002694),0.4965394818855776,0.7647442764908688,0.55,0.8933486332746565,1.0,1/15,0.35%,CD33
prerank,KEGG_2021_Human__Amphetamine addiction,-0.5845856371464023,-0.7647274150797475,0.7642857142857142,0.9711047814105807,1.0,5/60,2.43%,CREB3L2;GRIN2B;CREB5;MAOB;FOSB
prerank,Elsevier_Pathway_Collection__Circadian Clock in Sleep Regulation,0.45887246763089745,0.7646134469551124,0.5111111111111111,0.8931975374878393,1.0,9/18,22.03%,CRY1;CLOCK;PER1;ARNTL;BHLHE40;CRY2;BHLHE41;NR1D1;RORA
prerank,GO_Biological_Process_2021__glycolytic process through glucose-6-phosphate (GO:0061620),0.533671942211667,0.764605648199026,0.6511627906976745,0.8928805425450476,1.0,2/23,2.19%,PKLR;HK2
prerank,Elsevier_Pathway_Collection__Hematopoietic Cell Lineage: B-cell,0.5779132061059253,0.7645258814561532,0.7421875,0.892645124447073,1.0,3/36,2.22%,CDH2;THY1;GFI1
prerank,GO_Biological_Process_2021__purine ribonucleotide biosynthetic process (GO:0009152),0.5615726104072807,0.7645225045860805,0.7767857142857143,0.8923269325364263,1.0,1/46,0.99%,PAPSS1
prerank,GO_Biological_Process_2021__cellular response to fibroblast growth factor stimulus (GO:0044344),-0.5485278919684334,-0.7645218051270462,0.823076923076923,0.9708821610775763,1.0,3/85,2.30%,FLRT2;CD44;GALNT3
prerank,GO_Biological_Process_2021__tumor necrosis factor-mediated signaling pathway (GO:0033209),0.5250380390402305,0.7645085539954279,0.8461538461538461,0.8920187254790649,1.0,4/113,2.05%,TRAF3;PSMB9;TNFRSF25;EDA2R
prerank,Elsevier_Pathway_Collection__Natural Killer Cell in Diabetes Mellitus Type 1,-0.5911688647273672,-0.7643861717641763,0.753968253968254,0.97058128435783,1.0,4/49,2.44%,STAT5A;CD274;VAV1;ZAP70
prerank,GO_Biological_Process_2021__regulation of Ras protein signal transduction (GO:0046578),-0.5322322251468646,-0.7643077814899931,0.8294573643410853,0.9702172808133619,1.0,3/84,2.34%,RABL3;DENND4C;VAV1
prerank,Reactome_2022__Biosynthesis Of N-glycan Precursor (Dolichol LLO) And Transfer To Protein R-HSA-446193,-0.5651457506438942,-0.7640442479758881,0.813953488372093,0.9700604453044935,1.0,2/75,0.64%,ALG6;ALG13
prerank,GO_Biological_Process_2021__hippo signaling (GO:0035329),-0.5233834463815366,-0.7639276653560998,0.6747967479674797,0.9697287077224986,1.0,2/26,1.52%,AMOTL1;DCHS1
prerank,WikiPathway_2021_Human__NAD+ biosynthetic pathways WP3645,0.49392317859803625,0.7639168485767311,0.5950413223140496,0.8923803158753858,1.0,1/22,0.61%,QPRT
prerank,GO_Biological_Process_2021__reverse cholesterol transport (GO:0043691),-0.4838503921706061,-0.7638973186204435,0.5416666666666666,0.9693089665533575,1.0,1/17,1.62%,LIPG
prerank,Elsevier_Pathway_Collection__Atopic Dermatitis Onset,0.5326474317941289,0.7638769586328604,0.7333333333333333,0.8917807715571092,1.0,2/50,2.29%,CD4;CD86
prerank,Elsevier_Pathway_Collection__T-Cell Receptor Signaling,0.5326474317941289,0.7638769586328604,0.7333333333333333,0.8917807715571092,1.0,2/50,2.29%,CD4;CD86
prerank,GO_Biological_Process_2021__focal adhesion assembly (GO:0048041),0.5127223645569546,0.7638362962052646,0.5923076923076923,0.891497558490304,1.0,3/20,1.68%,ARHGEF7;THY1;DLC1
prerank,GO_Biological_Process_2021__modified amino acid transport (GO:0072337),-0.4978465636034511,-0.7637859406148717,0.5846153846153846,0.968991221605128,1.0,1/17,0.22%,SLC7A9
prerank,GO_Biological_Process_2021__triglyceride catabolic process (GO:0019433),-0.4838509140434716,-0.7637545472152366,0.5565217391304348,0.9685755542111429,1.0,1/16,1.62%,LIPG
prerank,Elsevier_Pathway_Collection__WNT Canonical Signaling,0.49569147521183177,0.7637544716209843,0.6356589147286822,0.8912567436463201,1.0,1/26,0.43%,LRP5
prerank,WikiPathway_2021_Human__Alzheimer's disease WP2059,-0.5643692459348512,-0.7637217306410167,0.7985611510791367,0.9681602789562089,1.0,4/80,1.91%,ADAM10;APP;GRIN2B;PLCB4
prerank,Reactome_2022__Unfolded Protein Response (UPR) R-HSA-381119,0.5340785439275072,0.7635384088353403,0.875,0.8911783274090828,1.0,3/89,2.15%,ERN1;PARN;ACD
prerank,GO_Biological_Process_2021__vascular transport (GO:0010232),-0.5273248355969813,-0.7634396219872509,0.7925925925925926,0.9680231523115372,1.0,5/81,2.46%,SLC22A1;SLC2A10;SLC7A8;SLCO3A1;SLC16A2
prerank,Reactome_2022__Signaling By Hippo R-HSA-2028269,0.49788444655418657,0.7634328718629506,0.5590551181102362,0.8909702348180651,1.0,1/20,0.22%,TJP1
prerank,Reactome_2022__Aberrant Regulation Of Mitotic G1/S Transition In Cancer Due To RB1 Defects R-HSA-9659787,0.5242590175828152,0.7634108807041742,0.5726495726495726,0.8906731331376293,1.0,2/17,0.91%,CDK6;TFDP2
prerank,Elsevier_Pathway_Collection__Mast-Cells Activation in Atopic Dermatitis,-0.5221215521966548,-0.7633347141146316,0.8067226890756303,0.9676966376699685,1.0,2/52,2.34%,MAP2K6;VAV1
prerank,Reactome_2022__TP53 Regulates Transcription Of Genes Involved In Cytochrome C Release R-HSA-6803204,0.4882709712377467,0.7632820455723871,0.6206896551724138,0.8904961621681563,1.0,1/20,1.18%,PRELID3A
prerank,KEGG_2021_Human__Vibrio cholerae infection,-0.5844477210908923,-0.7632712834884322,0.7906976744186046,0.9673205811597151,1.0,2/46,1.56%,SEC61A2;ADCY3
prerank,GO_Biological_Process_2021__negative regulation of lymphocyte activation (GO:0051250),-0.48677068222244524,-0.7631636419520362,0.6101694915254238,0.9669797569491657,1.0,1/21,1.33%,FGL1
prerank,GO_Biological_Process_2021__regulation of cell differentiation (GO:0045595),-0.49691644954402947,-0.7631097310786281,0.8872180451127819,0.9665794904556136,1.0,6/144,2.05%,CREBBP;SHH;NTF3;RORC;LTBP4;KLF4
prerank,Reactome_2022__PI3K/AKT Signaling In Cancer R-HSA-2219528,0.5121473351081789,0.7630522968771224,0.9,0.8904035540132683,1.0,6/98,2.37%,CREB1;ERBB3;KLB;PIK3AP1;CD86;FGF1
prerank,Elsevier_Pathway_Collection__EphrinB -> MAPK/JUN/FOS Signaling,-0.5476513036969671,-0.7629800264003064,0.7022900763358778,0.9662758401449822,1.0,3/33,2.39%,RAP1A;EFNB2;MAP4K1
prerank,GO_Biological_Process_2021__positive regulation of hydrolase activity (GO:0051345),0.4807977643354552,0.7629616845498018,0.9916666666666667,0.8901798473295156,1.0,11/142,1.95%,PKP4;RAB3GAP1;ARHGEF7;RAPGEF6;THY1;CX3CL1;MTCL1;DOCK11;GNB5;CCL14;CTSH
prerank,GO_Biological_Process_2021__cellular response to alcohol (GO:0097306),-0.5317291656800116,-0.7629020256957616,0.7394366197183099,0.9659310122541304,1.0,2/44,2.39%,ADCY3;MAP4K1
prerank,GO_Biological_Process_2021__regulation of phagocytosis (GO:0050764),0.5618457681696727,0.762835000847337,0.7322834645669292,0.8900048640487409,1.0,3/55,2.16%,SYK;TUB;CYBA
prerank,Elsevier_Pathway_Collection__Humoral Immunity in Vitiligo,0.5584511195779781,0.762822361844416,0.796875,0.8896940815088098,1.0,4/68,2.06%,CREB1;SYK;NFATC2;PIK3AP1
prerank,GO_Biological_Process_2021__cellular senescence (GO:0090398),-0.5475812201250612,-0.7626964766778453,0.6942148760330579,0.9656826576375658,1.0,3/26,2.40%,NSMCE2;PML;SPI1
prerank,Reactome_2022__CD209 (DC-SIGN) Signaling R-HSA-5621575,0.48934848828784805,0.7625964513201224,0.5772357723577236,0.8896261590594396,1.0,1/18,1.07%,ARHGEF7
prerank,Reactome_2022__RNA Polymerase I Transcription R-HSA-73864,0.5801183876855458,0.7625127167908592,0.8360655737704918,0.8894030541107315,1.0,2/69,1.99%,TAF1B;CAVIN1
prerank,GO_Biological_Process_2021__regulation of transcription from RNA polymerase II promoter in response to hypoxia (GO:0061418),-0.5592495346548896,-0.7623487085304672,0.8666666666666667,0.965651598869422,1.0,1/73,1.22%,CREBBP
prerank,MSigDB_Oncogenic_Signatures__WNT UP.V1 UP,-0.49422458681378667,-0.7617792016906456,0.9112903225806451,0.9659021212332235,1.0,6/154,1.94%,STS;MYOM1;RASGRP2;TGFB1I1;INHBB;COL4A4
prerank,GO_Biological_Process_2021__long-chain fatty acid biosynthetic process (GO:0042759),0.5522327838707686,0.7617697861161801,0.6935483870967742,0.8899592202098338,1.0,3/29,1.93%,EPHX2;PTGS2;ELOVL6
prerank,Reactome_2022__Aberrant Regulation Of Mitotic Cell Cycle Due To RB1 Defects R-HSA-9687139,0.5708813144960299,0.7615526690638686,0.7560975609756098,0.8898799648776434,1.0,3/36,1.74%,CDK6;TFDP2;UBE2C
prerank,GO_Biological_Process_2021__carboxylic acid metabolic process (GO:0019752),-0.5637463024207625,-0.7615176920369005,0.762962962962963,0.9657600761005035,1.0,5/38,1.98%,SLC23A2;GLYAT;CYP4F22;HAO1;CYP1A2
prerank,GO_Biological_Process_2021__transport across blood-brain barrier (GO:0150104),-0.5273229457959016,-0.7614363047609785,0.7894736842105263,0.965398097842601,1.0,5/83,2.46%,SLC22A1;SLC2A10;SLC7A8;SLCO3A1;SLC16A2
prerank,WikiPathway_2021_Human__NRF2 pathway WP2884,-0.5020992881508616,-0.7613628655401995,0.9202898550724637,0.9650248819816348,1.0,4/135,1.53%,GSTA1;SLC2A10;GSTA2;NRG1
prerank,GO_Biological_Process_2021__regulation of epidermal growth factor receptor signaling pathway (GO:0042058),0.534860496329266,0.7613049944420575,0.7380952380952381,0.8898201495210045,1.0,3/65,1.07%,PTPN2;PLAUR;ARHGEF7
prerank,MSigDB_Oncogenic_Signatures__MTOR UP.N4.V1 DN,0.4825291791131175,0.7611429130280052,0.9532710280373832,0.889690946363785,1.0,6/152,1.76%,ZNF394;ZNF124;BCOR;HSD17B11;BRIP1;STMN3
prerank,MSigDB_Hallmark_2020__Apoptosis,0.4876263069623389,0.7610097122482123,0.9210526315789473,0.8895053428931547,1.0,9/158,2.28%,IGF2R;PTK2;CASP7;ERBB3;ANXA1;FDXR;TIMP3;LGALS3;HGF
prerank,GO_Biological_Process_2021__purine ribonucleotide metabolic process (GO:0009150),-0.5592521264122032,-0.7609991500325215,0.8321678321678322,0.9650074288901064,1.0,4/72,1.23%,GLYAT;TPST1;SULT1B1;ACSM2B
prerank,MSigDB_Oncogenic_Signatures__ALK DN.V1 UP,-0.5025718721862281,-0.7609822849509079,0.9071428571428571,0.9645868286566454,1.0,5/122,2.39%,VSTM4;BDKRB2;ENTPD3;ARHGAP4;SLC12A8
prerank,Elsevier_Pathway_Collection__Low-Grade Serous Ovarian Carcinoma,-0.5482649805725751,-0.7609799268189276,0.864,0.9641401976702191,1.0,4/69,1.71%,NCOA1;CREBBP;NRG1;STAT5A
prerank,GO_Biological_Process_2021__cell morphogenesis involved in neuron differentiation (GO:0048667),-0.5493880137756965,-0.7608607443570846,0.8345323741007195,0.9638309980116476,1.0,5/72,2.22%,APP;PARD3;RB1;SLITRK3;DSCAML1
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Precursor -> Natural Killer Cell Surface Expression Markers,0.5552442673356229,0.7608453451791958,0.8053097345132744,0.889361823968234,1.0,5/73,1.63%,CD300A;CD33;SYK;CD48;LAMP2
prerank,TRRUST_Transcription_Factors_2019__CTNNB1 human,-0.4824639350012977,-0.7608073065891051,0.5658914728682171,0.9634412380408057,1.0,2/21,1.76%,RB1;CD44
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hypothyroidism,-0.5755881440116326,-0.7607582671108614,0.8034188034188035,0.9630600885995065,1.0,4/53,2.46%,SHH;PAX8;IYD;SLC16A2
prerank,Reactome_2022__Influenza Infection R-HSA-168255,-0.4959364468827554,-0.7607091444356862,0.9402985074626866,0.9626694046795073,1.0,1/155,0.41%,KPNA3
prerank,Elsevier_Pathway_Collection__Dexamethasone Induced Osteoporosis,-0.4968463903793039,-0.7605870690414378,0.5853658536585366,0.9623762987699203,1.0,1/19,0.32%,NR3C1
prerank,MSigDB_Oncogenic_Signatures__CAMP UP.V1 UP,-0.4842120826825583,-0.7605051797282366,0.9765625,0.9620142963284553,1.0,3/179,1.58%,NT5DC1;WWP1;MRRF
prerank,Reactome_2022__Assembly Of Pre-Replicative Complex R-HSA-68867,0.5381185442519574,0.7605047242279823,0.8220338983050848,0.8894006692483668,1.0,2/99,1.74%,PSMB9;UBE2C
prerank,GO_Biological_Process_2021__protein insertion into ER membrane (GO:0045048),0.5764890324954001,0.7601431628039012,0.7796610169491526,0.8894830201572793,1.0,2/36,2.36%,GET3;STX1A
prerank,GO_Biological_Process_2021__regulation of endocytosis (GO:0030100),0.5510153957394576,0.7598952571470298,0.7956204379562044,0.889433146546523,1.0,4/60,2.05%,PACSIN3;MCTP1;APOE;LGALS3
prerank,GO_Biological_Process_2021__regulation of smooth muscle contraction (GO:0006940),0.495539464244162,0.7598903773477869,0.5614035087719298,0.8891271285667213,1.0,1/17,0.45%,SETD3
prerank,Reactome_2022__Negative Regulation Of PI3K/AKT Network R-HSA-199418,-0.5183630582197155,-0.7598586656581473,0.8428571428571429,0.9623505955939897,1.0,4/105,2.34%,AKT3;PIK3CB;NRG1;VAV1
prerank,TRRUST_Transcription_Factors_2019__E2F1 mouse,-0.5599559842713291,-0.7598478419965419,0.792,0.9619116102804198,1.0,1/46,1.15%,RB1
prerank,Reactome_2022__Regulation Of RAS By GAPs R-HSA-5658442,-0.5685373480112799,-0.7596725240326792,0.7769230769230769,0.9616374949088691,1.0,1/63,0.30%,RASA2
prerank,GO_Biological_Process_2021__regulation of mitotic cell cycle (GO:0007346),-0.4830572773952708,-0.7596297124863723,0.9770992366412213,0.9612354154869175,1.0,4/171,1.70%,NEK7;APP;RB1;NEK11
prerank,KEGG_2021_Human__B cell receptor signaling pathway,0.5657799952239478,0.7595438412939806,0.8083333333333333,0.8892030464962486,1.0,6/78,2.06%,LILRA2;PIK3CD;SYK;DAPP1;NFATC2;PIK3AP1
prerank,WikiPathway_2021_Human__Overview of leukocyte-intrinsic Hippo pathway functions WP4542,0.5815307657168414,0.7594127154143284,0.7603305785123967,0.8890180833424088,1.0,3/35,1.86%,YWHAQ;ITGAL;TEAD4
prerank,Elsevier_Pathway_Collection__High-Grade Serous Ovarian Carcinoma,-0.5482569643044224,-0.759220076386065,0.8115942028985508,0.9613003437198587,1.0,4/81,1.71%,NCOA1;CREBBP;NRG1;STAT5A
prerank,GO_Biological_Process_2021__glycogen metabolic process (GO:0005977),-0.5492341590841879,-0.7587252011198703,0.6825396825396826,0.9614144807796322,1.0,3/27,2.23%,PHKB;GYG2;PYGM
prerank,Reactome_2022__SLC Transporter Disorders R-HSA-5619102,-0.5202978233577299,-0.7587210285888639,0.8686131386861314,0.9609720278065614,1.0,4/93,1.83%,SLC7A9;SLC35A3;SLC2A10;SLC9A9
prerank,Elsevier_Pathway_Collection__Proteins Involved in Glaucoma,-0.5559405485118529,-0.758621463302598,0.8303571428571429,0.9606071031552569,1.0,4/75,2.31%,APP;BMP4;CYP1B1;EFNB2
prerank,Reactome_2022__TNFs Bind Their Physiological Receptors R-HSA-5669034,-0.5232206504247909,-0.7585777386036715,0.6491228070175439,0.960219557547003,1.0,3/28,2.24%,CD27;TNFRSF14;TNFSF14
prerank,GO_Biological_Process_2021__androgen metabolic process (GO:0008209),-0.5353282484953956,-0.7584854522494505,0.6638655462184874,0.9598717142735158,1.0,2/20,2.03%,SHH;HSD17B6
prerank,GO_Biological_Process_2021__male gonad development (GO:0008584),0.5791449791320634,0.7583392905504184,0.7363636363636363,0.8897860557155827,1.0,2/35,2.09%,MSH2;COL9A3
prerank,Elsevier_Pathway_Collection__Tight Junction Assembly (JAMs),0.4978841950815699,0.7582810450413724,0.5833333333333334,0.8895253985183912,1.0,1/23,0.22%,TJP1
prerank,KEGG_2021_Human__Apelin signaling pathway,0.49395757179334976,0.7582109063594721,0.9017857142857143,0.8892777944046908,1.0,6/126,2.34%,PRKAA2;NOTCH3;GNB5;CDH1;SERPINE1;GNG2
prerank,GO_Biological_Process_2021__positive regulation of phosphatidylinositol 3-kinase signaling (GO:0014068),0.5257678595981582,0.7580873905413256,0.8275862068965517,0.8890769918424813,1.0,6/73,2.28%,PIK3CD;PTK2;ERBB3;PIK3AP1;FN1;HGF
prerank,Reactome_2022__G1/S Transition R-HSA-69206,0.4885246899771231,0.7580725046941876,0.9727272727272728,0.8887670458960248,1.0,6/127,2.38%,CDC45;RBL1;POLE4;TFDP2;PSMB9;RRM2
prerank,Reactome_2022__Interleukin-1 Signaling R-HSA-9020702,0.504178056087563,0.7578924651447118,0.864406779661017,0.888648505484063,1.0,4/110,1.59%,IRAK2;NOD2;PSMB9;IL1RN
prerank,Elsevier_Pathway_Collection__Proteins Involved in Amyotrophic Lateral Sclerosis,0.4881094041720921,0.7578706653432485,0.975,0.8883437522658342,1.0,9/172,2.37%,SORT1;ARHGEF7;PTGS2;TIMP3;APOE;LGALS3;OPTN;HGF;FGF1
prerank,Reactome_2022__Attenuation Phase R-HSA-3371568,0.4904611901724818,0.7578224199855531,0.5948275862068966,0.8880873799907051,1.0,1/24,0.96%,TNFRSF21
prerank,KEGG_2021_Human__Viral protein interaction with cytokine and cytokine receptor,-0.5377897093544042,-0.7578183157123142,0.8582677165354331,0.9601271604236052,1.0,5/90,2.24%,TNFRSF10B;CCL23;IL10RA;TNFRSF14;TNFSF14
prerank,Reactome_2022__Transport Of Inorganic Cations/Anions And Amino Acids/Oligopeptides R-HSA-425393,-0.5293788358094036,-0.7578052386323936,0.8712121212121212,0.9597010717542352,1.0,7/92,2.35%,SLC7A9;AHCYL2;SLC36A4;SLC7A8;SLC15A3;SLC9A9;SLC4A5
prerank,Reactome_2022__Signaling By Cytosolic FGFR1 Fusion Mutants R-HSA-1839117,0.4928094326574558,0.7577351139821265,0.5634920634920635,0.8878841514202833,1.0,1/17,0.72%,TRIM24
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Pulmonary Hypertension,-0.5481213383536427,-0.7575290108503482,0.8181818181818182,0.9595634860798283,1.0,3/66,2.34%,PDE5A;TEK;VAV1
prerank,GO_Biological_Process_2021__regulation of apoptotic signaling pathway (GO:2001233),-0.5700339271251514,-0.7573816030743918,0.7426470588235294,0.959275496212817,1.0,3/37,1.83%,RB1;DEPTOR;DAPK2
prerank,KEGG_2021_Human__Pancreatic cancer,-0.5600594314956772,-0.7572164513726071,0.8059701492537313,0.9590024924861323,1.0,4/76,1.15%,POLK;AKT3;PIK3CB;RB1
prerank,Elsevier_Pathway_Collection__TNFR -> CREB/ELK-SRF Signaling,-0.57779431565828,-0.7571206375245827,0.7734375,0.9586480068224466,1.0,4/40,2.24%,MAP2K6;TNFRSF10B;TNFRSF14;TNFSF14
prerank,GO_Biological_Process_2021__positive regulation of macroautophagy (GO:0016239),0.5344969142938427,0.7570779623758799,0.7559055118110236,0.8882971165304673,1.0,3/49,2.11%,RAB3GAP1;PRKAA2;OPTN
prerank,Elsevier_Pathway_Collection__Invadopodia Formation in Cancer Cells,-0.5481131736052065,-0.7570242932845478,0.8387096774193549,0.9583199926085652,1.0,3/75,2.34%,PTK2B;MMP2;VAV1
prerank,TRRUST_Transcription_Factors_2019__NR0B2 mouse,-0.48327354717495863,-0.756905768834973,0.5726495726495726,0.958000448038748,1.0,1/17,1.68%,BHMT
prerank,GO_Biological_Process_2021__positive regulation of cartilage development (GO:0061036),0.48750338820222816,0.75688661602003,0.5669291338582677,0.8882046148883789,1.0,1/17,1.25%,PKDCC
prerank,MSigDB_Oncogenic_Signatures__LTE2 UP.V1 UP,-0.4867893233438329,-0.7568291706984961,0.9465648854961832,0.9576436533238536,1.0,9/171,2.32%,CREB3L2;SGPP1;SLC2A10;PROS1;CYP1B1;DUSP4;PLCB4;AQP3;GNA14
prerank,Reactome_2022__Cell-cell Junction Organization R-HSA-421270,0.5793214831016666,0.756659413519912,0.7787610619469026,0.8881073698028206,1.0,3/55,2.07%,CDH2;CRB3;CDH15
prerank,MSigDB_Oncogenic_Signatures__RAF UP.V1 DN,0.4777157840444701,0.7566361524109171,1.0,0.8878130771429551,1.0,8/176,2.24%,PKP4;GTF2I;ELOVL2;PDK3;DLC1;CPE;COL9A3;LRIG1
prerank,GO_Biological_Process_2021__positive regulation of extracellular matrix organization (GO:1903055),-0.48854117399460917,-0.7564928877733962,0.5671641791044776,0.9576069968963029,1.0,1/18,1.15%,RB1
prerank,Reactome_2022__Global Genome Nucleotide Excision Repair (GG-NER) R-HSA-5696399,0.5331599255652403,0.7560398293679492,0.8780487804878049,0.8881341643859616,1.0,3/81,2.24%,SLC19A1;POLE4;LRIG1
prerank,GO_Biological_Process_2021__histone acetylation (GO:0016573),0.5405607933600189,0.7560010295750713,0.8272727272727273,0.8878560862812765,1.0,3/70,0.50%,NAA60;SUPT3H;ING5
prerank,GO_Biological_Process_2021__I-kappaB kinase/NF-kappaB signaling (GO:0007249),-0.5815889160319941,-0.7558895642269293,0.7720588235294118,0.9577987032010041,1.0,2/60,1.85%,ERC1;TICAM2
prerank,GO_Biological_Process_2021__negative regulation of protein kinase activity (GO:0006469),-0.5384599460717584,-0.7558735549608111,0.8333333333333334,0.9573789198481849,1.0,4/89,1.34%,PAK2;DTNBP1;RB1;DEPTOR
prerank,KEGG_2021_Human__Endometrial cancer,-0.5946463349385169,-0.7558089072000426,0.7637795275590551,0.9569953713862698,1.0,3/58,0.55%,POLK;AKT3;PIK3CB
prerank,Reactome_2022__Regulation Of Apoptosis R-HSA-169911,-0.5707722472515032,-0.7557154055825617,0.7407407407407407,0.9566659229036133,1.0,1/50,0.07%,ARHGAP10
prerank,Reactome_2022__RAB GEFs Exchange GTP For GDP On RABs R-HSA-8876198,-0.5386141587033395,-0.7556493805481239,0.824,0.9563188714726021,1.0,4/89,1.33%,SBF2;AKT3;RIC1;DENND4C
prerank,GO_Biological_Process_2021__high-density lipoprotein particle remodeling (GO:0034375),-0.48385041177930205,-0.7553563791387004,0.5847457627118644,0.9562113325617557,1.0,1/17,1.62%,LIPG
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer Immune Escape,0.5326512384705423,0.7551652750601652,0.7164179104477612,0.8883834408757489,1.0,2/46,2.29%,PSMB9;CD86
prerank,WikiPathway_2021_Human__Proximal tubule transport WP4917,0.5440967928450358,0.7551427115204563,0.828125,0.8880894691202874,1.0,3/50,1.85%,SLC20A2;SLC47A1;SLC13A3
prerank,KEGG_2021_Human__Autophagy,-0.50565711623424,-0.7550851507428185,0.8968253968253969,0.9561071456282823,1.0,6/132,1.83%,AKT3;PIK3CB;UVRAG;ATG10;DEPTOR;DAPK2
prerank,GO_Biological_Process_2021__regulation of establishment of protein localization (GO:0070201),-0.4951170220636495,-0.7549595026133266,0.5645161290322581,0.9558047242923953,1.0,1/15,0.50%,CEP120
prerank,Reactome_2022__FCERI Mediated MAPK Activation R-HSA-2871796,-0.5481163059493046,-0.7548820474343962,0.7377049180327869,0.9554310854984107,1.0,2/29,2.34%,GRAP2;VAV1
prerank,Elsevier_Pathway_Collection__Bradykinin Effects in Inflammation,-0.5799512950256478,-0.7547178210124419,0.7661290322580645,0.9551471196822527,1.0,2/37,2.01%,MAP2K6;BDKRB2
prerank,GO_Biological_Process_2021__T cell receptor signaling pathway (GO:0050852),-0.48858773334483624,-0.7545504574499114,0.9491525423728814,0.9548845196179508,1.0,6/150,2.44%,PAK2;PIK3CB;TEC;PTPRJ;GRAP2;ZAP70
prerank,Elsevier_Pathway_Collection__Proteins Involved in Dental Caries,-0.5262623564029807,-0.7544262980671971,0.652542372881356,0.9545523864057542,1.0,2/24,1.93%,CCL23;MMP2
prerank,TRRUST_Transcription_Factors_2019__WT1 human,0.571292470535162,0.7543632956208437,0.7637795275590551,0.8885267806039775,1.0,4/54,1.71%,MYCN;CX3CL1;AMH;CDH1
prerank,GO_Biological_Process_2021__regulation of hydrolase activity (GO:0051336),0.5673910559824609,0.7542296838022011,0.7936507936507936,0.8883401104450114,1.0,6/70,2.10%,RAB3GAP1;PTK2;ARHGAP12;RAPGEF6;STMN3;SERPINA5
prerank,"Reactome_2022__PI5P, PP2A And IER3 Regulate PI3K/AKT Signaling R-HSA-6811558",0.5263940319760021,0.7541046972763642,0.8421052631578947,0.8881663617877165,1.0,5/98,2.37%,ERBB3;KLB;PIK3AP1;CD86;FGF1
prerank,KEGG_2021_Human__Breast cancer,-0.50146313367033,-0.7539422200279245,0.9428571428571428,0.9546487460356884,1.0,5/137,1.15%,POLK;AKT3;PIK3CB;NCOA1;RB1
prerank,GO_Biological_Process_2021__positive regulation of double-strand break repair (GO:2000781),0.552033755314986,0.7538299566882666,0.7131147540983607,0.8880902157723221,1.0,3/38,1.95%,SMCHD1;WRAP53;SPIRE2
prerank,GO_Biological_Process_2021__regulation of cytokine-mediated signaling pathway (GO:0001959),0.5474151985126801,0.7537889145828259,0.8225806451612904,0.887819235071045,1.0,4/72,1.79%,PTPN2;IRAK2;SYK;SIGIRR
prerank,GO_Biological_Process_2021__lamellipodium organization (GO:0097581),-0.5499632239323484,-0.7537092738521077,0.734375,0.9544629323499211,1.0,3/29,2.16%,CARMIL1;ABLIM3;S1PR1
prerank,Reactome_2022__Anchoring Of Basal Body To Plasma Membrane R-HSA-5620912,0.5170552217905636,0.7534708664706727,0.8888888888888888,0.8878294981440253,1.0,4/97,2.15%,HAUS8;CEP164;HAUS2;TUBA1A
prerank,MSigDB_Oncogenic_Signatures__AKT UP.V1 UP,-0.49913847459969113,-0.7533787308440703,0.9626865671641791,0.9544134056616618,1.0,5/144,1.53%,ADAM10;PTPRJ;SGPL1;HCK;VILL
prerank,GO_Biological_Process_2021__positive regulation of Ras protein signal transduction (GO:0046579),-0.5481269151966465,-0.7533116586776822,0.8307692307692308,0.9540480852847517,1.0,3/60,2.34%,PIK3CB;GPR17;VAV1
prerank,WikiPathway_2021_Human__Transcription factor regulation in adipogenesis WP3599,-0.49684605712383684,-0.7532935079030973,0.5818181818181818,0.9536296750421247,1.0,1/21,0.32%,NR3C1
prerank,GO_Biological_Process_2021__proteolysis involved in cellular protein catabolic process (GO:0051603),-0.562180116643867,-0.753291764803442,0.7982456140350878,0.9531922302370595,1.0,2/71,0.93%,ATE1;CTSO
prerank,Elsevier_Pathway_Collection__HGFR -> AP-1/CREB/MYC Signaling,-0.5692729961547252,-0.7530962646327893,0.7583333333333333,0.9529541341698506,1.0,2/38,0.23%,PTK2B;MAP2K6
prerank,KEGG_2021_Human__Cellular senescence,-0.4974725444112481,-0.7529554049614083,0.9357142857142857,0.9526580544602647,1.0,8/149,2.20%,MAP2K6;AKT3;PIK3CB;RB1;LIN9;CCND2;RASSF5;HLA-B
prerank,MSigDB_Oncogenic_Signatures__SIRNA EIF4GI DN,-0.5462117004734147,-0.7528607403219187,0.88,0.9523056867709114,1.0,7/83,2.16%,MBD5;NEK7;NEDD4;PMP22;PDE6D;DUSP4;S1PR1
prerank,GO_Biological_Process_2021__negative regulation of neuron death (GO:1901215),0.5439331749208529,0.7527624452522758,0.8360655737704918,0.8882324472741682,1.0,5/89,2.14%,MSH2;ERBB3;NAIP;APOE;SLC30A10
prerank,WikiPathway_2021_Human__Fatty acid beta-oxidation WP143,0.5479977981089923,0.7526021666805137,0.7203389830508474,0.8880590453521209,1.0,2/32,2.35%,ACSL5;GK
prerank,KEGG_2021_Human__Leukocyte transendothelial migration,-0.5168890952538335,-0.7525640387893197,0.8846153846153846,0.95218785132292,1.0,9/106,2.34%,PTK2B;RAP1B;PIK3CB;RAP1A;RAPGEF3;RASSF5;MMP2;RHOH;VAV1
prerank,Reactome_2022__DNA Damage Bypass R-HSA-73893,-0.5382704662702382,-0.7525587256182331,0.7950819672131147,0.9517585254057013,1.0,3/48,1.74%,REV3L;POLK;USP43
prerank,Reactome_2022__UCH Proteinases R-HSA-5689603,-0.5217281823943143,-0.7524490255062192,0.8601398601398601,0.9514199628748672,1.0,2/85,1.17%,MBD5;INO80D
prerank,GO_Biological_Process_2021__positive regulation of mRNA catabolic process (GO:0061014),-0.579792293645303,-0.7523467020001412,0.7874015748031497,0.9510768708897174,1.0,2/43,2.03%,CPEB3;PRR5L
prerank,Elsevier_Pathway_Collection__beta-Cell Mass Regulation,0.5106273852656166,0.7523176293623663,0.7076923076923077,0.8880420942872348,1.0,3/40,2.28%,CREB1;PRLR;HGF
prerank,MSigDB_Oncogenic_Signatures__PDGF ERK DN.V1 DN,-0.5032136055688183,-0.7518807903991869,0.9124087591240876,0.9510887953145214,1.0,3/138,2.31%,TGIF1;GRIN2B;EFNB2
prerank,Reactome_2022__Constitutive Signaling By Aberrant PI3K In Cancer R-HSA-2219530,0.5264189855724125,0.7518496297556038,0.8264462809917356,0.8881734544492328,1.0,5/71,2.37%,ERBB3;KLB;PIK3AP1;CD86;FGF1
prerank,Reactome_2022__Protein Ubiquitination R-HSA-8852135,0.5486166737565845,0.7516661840606025,0.8110236220472441,0.8880417032726453,1.0,3/72,2.29%,UBE2H;UBE2C;RNF144A
prerank,GO_Biological_Process_2021__establishment of endothelial barrier (GO:0061028),0.51019860285422,0.7516222011313934,0.6484375,0.8877666319692683,1.0,3/29,1.16%,TJP1;PPP1R16B;RAPGEF6
prerank,Reactome_2022__Degradation Of Beta-Catenin By Destruction Complex R-HSA-195253,0.5358563667105463,0.7515143427316585,0.8378378378378378,0.88756980872438,1.0,2/82,1.97%,PSMB9;AXIN2
prerank,Elsevier_Pathway_Collection__Apoptosis and Immediate Early Gene Activation in Epileptiform Disorders,-0.5593019646949671,-0.7514570527919764,0.768,0.9511152127845973,1.0,2/47,1.22%,RAP1A;CREBBP
prerank,"Elsevier_Pathway_Collection__Hyperparathyroidism, Neonatal Severe",-0.49876930916011747,-0.751349890196489,0.5681818181818182,0.9507872272610896,1.0,1/16,0.13%,PTK2B
prerank,Reactome_2022__EPH-Ephrin Signaling R-HSA-2682334,0.5168322174851858,0.7512470562360544,0.8672566371681416,0.8875005133516707,1.0,4/87,2.17%,ACTR3;PTK2;ARHGEF7;GPRIN1
prerank,WikiPathway_2021_Human__Glycogen Synthesis and Degradation WP500,0.5328496201485176,0.7512113924924178,0.7317073170731707,0.8872227424923642,1.0,4/40,2.28%,PHKA2;PHKA1;HK2;HKDC1
prerank,WikiPathway_2021_Human__Factors and pathways affecting insulin-like growth factor (IGF1)-Akt signaling WP3850,-0.5764496082515982,-0.7511930666895594,0.7711864406779662,0.9505223341668371,1.0,2/37,2.36%,DEPTOR;FBXO32
prerank,MSigDB_Oncogenic_Signatures__KRAS.PROSTATE UP.V1 UP,0.5050883520473273,0.7510546500101705,0.8880597014925373,0.8870358682948809,1.0,6/109,2.28%,MEGF8;RAB40C;ETV5;CX3CL1;ITGA2;HKDC1
prerank,Elsevier_Pathway_Collection__Prostate Cancer,0.5024229707892416,0.7509758271397768,0.896,0.8867934531662631,1.0,8/113,2.28%,PTK2;CASP7;IGFBP3;GLS;PTGS2;PRLR;FN1;HGF
prerank,Reactome_2022__Costimulation By CD28 Family R-HSA-388841,-0.5482006491691177,-0.7509748784066782,0.8571428571428571,0.9503365405858786,1.0,5/64,2.34%,AKT3;GRAP2;TNFRSF14;CD274;VAV1
prerank,GO_Biological_Process_2021__regulation of telomere maintenance (GO:0032204),0.5228761050640011,0.7504852766958162,0.6363636363636364,0.8869328338114085,1.0,2/26,2.26%,HDAC8;PIF1
prerank,GO_Biological_Process_2021__regulation of cellular carbohydrate metabolic process (GO:0010675),0.4845437726246012,0.7501474102472416,0.5555555555555556,0.8869274678536889,1.0,1/15,1.55%,PDK3
prerank,GO_Biological_Process_2021__positive regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045737),0.48565771649501804,0.7499069261121997,0.5658914728682171,0.8868664915186942,1.0,1/17,1.44%,PROX1
prerank,GO_Biological_Process_2021__adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189),0.5099611790222944,0.7498210253819946,0.8728813559322034,0.8866324210923884,1.0,3/95,2.34%,LPAR1;ADGRG2;GNG2
prerank,MSigDB_Hallmark_2020__Androgen Response,-0.515972623970035,-0.749750191687665,0.875,0.9511546887515622,1.0,4/100,2.26%,PTK2B;PLPP1;HERC3;TMPRSS2
prerank,GO_Biological_Process_2021__protein processing (GO:0016485),-0.5108051380559879,-0.7495032891321559,0.9274193548387096,0.9509559133055978,1.0,3/100,2.26%,ADAM10;C1R;TMPRSS2
prerank,GO_Biological_Process_2021__ciliary basal body-plasma membrane docking (GO:0097711),0.5170568846893764,0.7493849814255112,0.907563025210084,0.8867033839388637,1.0,4/95,2.15%,HAUS8;CEP164;HAUS2;TUBA1A
prerank,Reactome_2022__Cilium Assembly R-HSA-5617833,-0.47682053432057137,-0.74929150635699,1.0,0.9507155332384902,1.0,6/182,2.33%,EXOC2;SDCCAG8;CEP63;TTBK2;PDE6D;BBS5
prerank,Reactome_2022__RHO GTPases Activate NADPH Oxidases R-HSA-5668599,-0.48238575957854457,-0.7492260401751009,0.635593220338983,0.9503548912036601,1.0,1/22,1.77%,NOXA1
prerank,MSigDB_Oncogenic_Signatures__PTEN DN.V2 UP,0.5050392245656633,0.7489846500978912,0.9166666666666666,0.8868409629382628,1.0,8/121,2.29%,ANKMY1;APOL3;TNFRSF10D;MPV17;PTGS2;SERPINA5;ULK4;CD86
prerank,Reactome_2022__Growth Hormone Receptor Signaling R-HSA-982772,-0.48296371310096414,-0.7488750929652692,0.576,0.9502771772802896,1.0,1/20,1.71%,STAT5A
prerank,Reactome_2022__NLRP3 Inflammasome R-HSA-844456,-0.49192542228276154,-0.7484370382822951,0.5793650793650794,0.9502878063314865,1.0,1/16,0.81%,APP
prerank,GO_Biological_Process_2021__response to insulin (GO:0032868),0.5540671576328996,0.7483922550327005,0.8095238095238095,0.8870673017710518,1.0,5/79,2.30%,RHOQ;SORT1;PKLR;HDAC9;LPIN3
prerank,MSigDB_Oncogenic_Signatures__GCNP SHH UP EARLY.V1 DN,-0.48840450157066884,-0.7482827859994726,0.9637681159420289,0.9499968322896818,1.0,7/145,2.34%,STS;C4BPA;BTD;LIN9;ZNF518B;GNA14;VAV1
prerank,GO_Biological_Process_2021__regulation of telomere maintenance via telomerase (GO:0032210),-0.5421186755955115,-0.7479713799602133,0.8059701492537313,0.9498841102883946,1.0,4/51,1.36%,HMBOX1;NEK7;TNKS;SMG6
prerank,GO_Biological_Process_2021__regulation of DNA replication (GO:0006275),-0.5785925118617143,-0.7478763540981821,0.7954545454545454,0.9495455011841755,1.0,4/52,2.16%,ZBTB38;USP37;GMNC;SLFN11
prerank,Reactome_2022__Degradation Of AXIN R-HSA-4641257,0.5358799897058039,0.7477384364144911,0.775,0.8873601000379933,1.0,2/52,1.97%,PSMB9;AXIN2
prerank,Reactome_2022__Signaling By EGFR R-HSA-177929,0.5775941040777084,0.7477089295135626,0.788135593220339,0.8870723575897655,1.0,2/48,2.24%,ARHGEF7;LRIG1
prerank,Reactome_2022__RAS Processing R-HSA-9648002,-0.48142789308385187,-0.7476463921607666,0.5470085470085471,0.9493417705469915,1.0,1/17,1.86%,PDE6D
prerank,GO_Biological_Process_2021__negative regulation of interleukin-6 production (GO:0032715),-0.5479633615054156,-0.747507942786159,0.7380952380952381,0.9490357411835582,1.0,2/28,2.36%,C5AR2;IRAK3
prerank,TRRUST_Transcription_Factors_2019__NFYA human,0.48627167425022044,0.7473892882856239,0.5819672131147541,0.8871002436712674,1.0,1/19,1.38%,CBS
prerank,GO_Biological_Process_2021__lamellipodium assembly (GO:0030032),-0.5499657958077689,-0.7470508905561721,0.732824427480916,0.9490789161842967,1.0,3/26,2.16%,CARMIL1;ABLIM3;S1PR1
prerank,GO_Biological_Process_2021__cellular response to mechanical stimulus (GO:0071260),-0.5777096079652397,-0.7468862290415511,0.7837837837837838,0.9488020809990901,1.0,2/48,2.24%,TNFRSF10B;TNFSF14
prerank,Reactome_2022__Heme Signaling R-HSA-9707616,0.5600357975678582,0.7465977073070553,0.7669172932330827,0.8875559234789805,1.0,4/43,1.15%,TBL1X;PPARA;CREB1;BRIP1
prerank,GO_Biological_Process_2021__regulation of neuron projection development (GO:0010975),0.48580763488261935,0.7463828256419213,0.96875,0.8874410652538377,1.0,10/158,2.32%,CDH2;ABI2;BRSK1;LPAR1;CX3CL1;APOE;ULK4;DPYSL3;GFI1;FRMD7
prerank,GO_Biological_Process_2021__negative regulation of T cell activation (GO:0050868),0.5485677523960439,0.746004155196109,0.7518796992481203,0.8874608750522325,1.0,3/41,2.29%,TNFRSF21;LGALS3;CD86
prerank,KEGG_2021_Human__Various types of N-glycan biosynthesis,0.5826824586306805,0.7459834406609303,0.7295081967213115,0.8871656897761344,1.0,2/38,1.74%,DAD1;MAN1A1
prerank,GO_Biological_Process_2021__positive regulation of cell junction assembly (GO:1901890),-0.5477096358925049,-0.7458819887944581,0.7941176470588235,0.9493394539146721,1.0,3/53,2.38%,PTPRJ;TEK;HRG
prerank,WikiPathway_2021_Human__Ebola Virus Pathway on Host WP4217,0.48750081248833066,0.7457357519817701,0.9545454545454546,0.8870732419594134,1.0,8/125,2.29%,ITGA3;CD300A;PIK3CD;RAB7A;ITGA4;ITGA2;HAVCR1;FLNA
prerank,GO_Biological_Process_2021__regulation of cytokine production involved in immune response (GO:0002718),0.4910384605108458,0.7454943555397769,0.6102941176470589,0.8870014213943866,1.0,1/23,0.90%,NOD2
prerank,GO_Biological_Process_2021__negative regulation of defense response (GO:0031348),0.5186127490647925,0.7454810020580662,0.8454545454545455,0.8867003847843852,1.0,4/78,1.99%,PPARA;PTPN2;MEFV;APOE
prerank,GO_Biological_Process_2021__positive regulation of NF-kappaB transcription factor activity (GO:0051092),0.47955415963755627,0.7454284386175192,0.9917355371900827,0.8864453971372431,1.0,4/150,2.05%,IRAK2;NOD2;CX3CL1;EDA2R
prerank,KEGG_2021_Human__Ether lipid metabolism,-0.5596499068912277,-0.7453744114595469,0.8320610687022901,0.94942079434154,1.0,2/44,1.19%,PLPP1;PLAAT3
prerank,GO_Biological_Process_2021__negative regulation of cellular catabolic process (GO:0031330),0.54870012289926,0.7453464144819819,0.8145161290322581,0.8862048091389353,1.0,3/65,2.28%,TLK2;TIMP3;HGF
prerank,GO_Biological_Process_2021__ureteric bud development (GO:0001657),0.4874264528715124,0.7453303814178477,0.603448275862069,0.885907528933962,1.0,1/17,1.26%,SALL1
prerank,GO_Biological_Process_2021__peptidyl-glutamic acid modification (GO:0018200),0.4813087272469924,0.7452805442086122,0.5967741935483871,0.8856325626123162,1.0,1/22,1.87%,NAA10
prerank,GO_Biological_Process_2021__Fc receptor mediated stimulatory signaling pathway (GO:0002431),0.5375144867768846,0.7452584070482057,0.7652173913043478,0.8853388489887115,1.0,3/73,1.26%,ACTR3;PTK2;SYK
prerank,Reactome_2022__Nuclear Events Stimulated By ALK Signaling In Cancer R-HSA-9725371,-0.48296524966679377,-0.7452314503883766,0.5748031496062992,0.949123410596663,1.0,1/18,1.71%,STAT5A
prerank,"GO_Biological_Process_2021__protein localization to chromosome, centromeric region (GO:0071459)",-0.4885415053143275,-0.7449859428964649,0.5867768595041323,0.948933292295128,1.0,1/17,1.15%,RB1
prerank,Elsevier_Pathway_Collection__TRPM8 Effects in Prostate Cancer (Hypothesis),-0.4987694066545362,-0.744777203012023,0.5572519083969466,0.9487289799264677,1.0,1/15,0.13%,PTK2B
prerank,GO_Biological_Process_2021__development of primary male sexual characteristics (GO:0046546),0.579144973394609,0.7447463185104938,0.7798165137614679,0.8854697746143465,1.0,2/35,2.09%,MSH2;COL9A3
prerank,GO_Biological_Process_2021__protein localization to organelle (GO:0033365),0.5028274815430153,0.7447182512322259,0.9217391304347826,0.8851810561085289,1.0,5/138,2.36%,TUB;LAMP2;MSX1;OPTN;STX1A
prerank,"GO_Biological_Process_2021__synaptic transmission, cholinergic (GO:0007271)",-0.48215774910950115,-0.7446001388473608,0.5877862595419847,0.9484386946383296,1.0,1/18,1.79%,COLQ
prerank,GO_Biological_Process_2021__phospholipid catabolic process (GO:0009395),0.49446152280729416,0.7442231479977559,0.5982905982905983,0.8852993315379355,1.0,1/22,0.56%,PNPLA6
prerank,TRRUST_Transcription_Factors_2019__NR5A1 human,0.48358260071363857,0.7441927249459671,0.5714285714285714,0.8850077230390867,1.0,1/15,1.64%,AMH
prerank,"GO_Biological_Process_2021__phagocytosis, engulfment (GO:0006911)",0.5831071806371454,0.7440349802902217,0.7338709677419355,0.8848392162147037,1.0,2/36,1.69%,ARHGAP12;HAVCR1
prerank,WikiPathway_2021_Human__FGF23 signaling in hypophosphatemic rickets and related disorders WP4790,0.48331140361203967,0.7439571494410698,0.591304347826087,0.8845841996225675,1.0,1/18,1.67%,CYP27B1
prerank,GO_Biological_Process_2021__Ras protein signal transduction (GO:0007265),-0.48790047280690085,-0.7436547804884701,0.9829059829059829,0.9488727075148813,1.0,9/138,2.22%,RAP1B;RB1;RAP1A;RASGRP2;RAPGEF3;GRAP2;RASGRP3;ARHGAP4;RHOH
prerank,GO_Biological_Process_2021__extracellular matrix assembly (GO:0085029),-0.4918457510548768,-0.7434518607019686,0.6048387096774194,0.9486033425566747,1.0,1/24,0.82%,NTN4
prerank,TRRUST_Transcription_Factors_2019__RB1 mouse,0.48238933396010325,0.7433357662332496,0.5916666666666667,0.884869415492208,1.0,1/17,1.76%,FOSL1
prerank,Reactome_2022__PI3K Events In ERBB2 Signaling R-HSA-1963642,0.48815748983702656,0.7433326078856716,0.5853658536585366,0.8845610526934751,1.0,1/16,1.19%,ERBB3
prerank,KEGG_2021_Human__Toll-like receptor signaling pathway,-0.5201092769831701,-0.7432954296113653,0.8396946564885496,0.9483230674657067,1.0,4/87,1.85%,MAP2K6;AKT3;PIK3CB;TICAM2
prerank,WikiPathway_2021_Human__Tumor suppressor activity of SMARCB1 WP4204,0.5648117296414888,0.7432454779370539,0.717948717948718,0.8843504565202384,1.0,2/29,0.67%,ARID1B;CDK6
prerank,GO_Biological_Process_2021__cellular response to peptide hormone stimulus (GO:0071375),-0.5030125142012789,-0.7431895953653243,0.9112903225806451,0.947990488578816,1.0,4/98,1.56%,TBC1D4;DENND4C;INHBB;ADCY3
prerank,WikiPathway_2021_Human__Renin-angiotensin-aldosterone system (RAAS) WP4756,-0.5829129397310077,-0.7431849652873169,0.7730496453900709,0.9475690626914609,1.0,2/39,1.72%,CREB3L2;CREB5
prerank,Reactome_2022__Translesion Synthesis By Y Family DNA Polymerases Bypasses Lesions On DNA Template R-HSA-110313,-0.538276592057771,-0.7431070009154498,0.76,0.9472212119764453,1.0,3/39,1.74%,REV3L;POLK;USP43
prerank,GO_Biological_Process_2021__purinergic nucleotide receptor signaling pathway (GO:0035590),-0.4919236730775207,-0.742994580073731,0.6518518518518519,0.9468816273138103,1.0,1/21,0.81%,APP
prerank,Reactome_2022__Integrin Signaling R-HSA-354192,-0.5447293970133279,-0.7428229474860141,0.7105263157894737,0.9465932210860227,1.0,4/27,1.54%,RAP1B;RAP1A;RASGRP2;RAPGEF3
prerank,Reactome_2022__TCR Signaling R-HSA-202403,-0.5211807036247929,-0.7427845389622287,0.8914728682170543,0.9461954305584619,1.0,4/111,2.44%,PIK3CB;PTPRJ;GRAP2;ZAP70
prerank,GO_Biological_Process_2021__peptidyl-tyrosine modification (GO:0018212),-0.5516130297392374,-0.7426732036651531,0.828125,0.9458662964220341,1.0,6/56,2.44%,PTK2B;TEC;TPST1;HCK;TEK;ZAP70
prerank,GO_Biological_Process_2021__pre-replicative complex assembly (GO:0036388),-0.5634920157423222,-0.7425704104436838,0.8359375,0.945519994770855,1.0,1/62,0.80%,ORC4
prerank,MSigDB_Oncogenic_Signatures__PTEN DN.V1 UP,0.4892575087317392,0.7425055525771429,0.936,0.8847345441005624,1.0,7/136,2.37%,ACSS3;ZNF22;MEFV;MAN1A1;SLC30A10;CYB5R2;FGF1
prerank,"GO_Biological_Process_2021__regulation of DNA damage response, signal transduction by p53 class mediator (GO:0043516)",0.5271447988668844,0.7424920534227862,0.6521739130434783,0.8844312690677909,1.0,2/27,1.84%,ATR;MSX1
prerank,GO_Biological_Process_2021__regulation of phosphatidylinositol 3-kinase activity (GO:0043551),0.5625017101923278,0.74245631701709,0.75,0.8841612128798518,1.0,2/34,0.90%,PTK2;NOD2
prerank,GO_Biological_Process_2021__regulation of tumor necrosis factor production (GO:0032680),0.5048963953622003,0.7423910348487789,0.8956521739130435,0.8839227694942119,1.0,6/113,2.16%,LILRA2;CD33;NOD2;SYK;CX3CL1;CYBA
prerank,Elsevier_Pathway_Collection__Eosinophil Survival in Asthma,0.5375004582922509,0.7421063472579849,0.7407407407407407,0.8838666880098407,1.0,2/47,1.81%,SYK;IL13RA1
prerank,Elsevier_Pathway_Collection__Metabolic Reprogramming in Cancer: Overview,0.547625196368429,0.7420952519606125,0.8059701492537313,0.8835688503745368,1.0,4/61,2.39%,GLS;PDK3;HK2;PYCR1
prerank,KEGG_2021_Human__Colorectal cancer,-0.5400948241751322,-0.7418579820481994,0.8538461538461538,0.9457579841883741,1.0,3/86,0.55%,POLK;AKT3;PIK3CB
prerank,GO_Biological_Process_2021__regulation of peptidyl-serine phosphorylation (GO:0033135),-0.5058783268669012,-0.7418344935502341,0.8925619834710744,0.9453438366072868,1.0,4/91,1.81%,APP;RAPGEF3;CD44;NTF3
prerank,WikiPathway_2021_Human__Wnt signaling pathway and pluripotency WP399,-0.5118618783754747,-0.7417170121734691,0.8863636363636364,0.9450236042835544,1.0,3/97,1.76%,CREBBP;CCND2;CD44
prerank,GO_Biological_Process_2021__positive regulation of cytosolic calcium ion concentration (GO:0007204),0.47887109773634295,0.7416731718795282,0.9907407407407407,0.8836871518693125,1.0,2/133,2.11%,LPAR1;GPR35
prerank,GO_Biological_Process_2021__response to retinoic acid (GO:0032526),0.5502476714637456,0.7416586394722154,0.8440366972477065,0.8833974299242883,1.0,3/57,2.12%,CREB1;CTSH;RBP4
prerank,WikiPathway_2021_Human__Notch Signaling WP268,-0.5592646757192878,-0.7416318255042046,0.7950819672131147,0.9446577015773855,1.0,1/43,1.22%,CREBBP
prerank,Reactome_2022__Collagen Formation R-HSA-1474290,0.5316506721418801,0.7415799113911273,0.8740740740740741,0.8831439847057632,1.0,6/88,2.41%,PLOD2;COL12A1;P3H3;COL9A3;COL9A2;COL4A5
prerank,GO_Biological_Process_2021__regulation of cellular pH (GO:0030641),0.49403724656621084,0.741561325338273,0.6428571428571429,0.882842111194156,1.0,1/27,0.60%,SLC4A7
prerank,Elsevier_Pathway_Collection__STAT3 and NFkB Activate Inflammation-Induced Tumorigenesis,0.5655454967895358,0.7414592419448854,0.8134328358208955,0.8826266531440323,1.0,4/65,2.28%,MSH2;CDH1;PTGS2;HGF
prerank,Reactome_2022__Metabolism Of Nucleotides R-HSA-15869,-0.534538659948626,-0.741131336286784,0.8571428571428571,0.944699228465636,1.0,4/92,2.11%,DPYS;ENTPD8;GMPR;ENTPD3
prerank,KEGG_2021_Human__Circadian entrainment,-0.5104043405495193,-0.7410698341516475,0.8705035971223022,0.9443179664128466,1.0,3/86,1.91%,GRIN2B;ADCY3;PLCB4
prerank,Reactome_2022__APC/C:Cdh1 Mediated Degradation Of Cdc20 And APC/C:Cdh1 Targets In Late Mitosis/Early G1 R-HSA-174178,0.5381382806883386,0.7410172626065842,0.8278688524590164,0.8827685791389498,1.0,2/71,1.74%,PSMB9;UBE2C
prerank,WikiPathway_2021_Human__Host-pathogen interaction of human coronaviruses - MAPK signaling WP4877,0.5358154498618998,0.7406973038228577,0.7058823529411765,0.8827569118564992,1.0,2/36,1.98%,MAP3K9;MAPK13
prerank,Reactome_2022__Orc1 Removal From Chromatin R-HSA-68949,-0.5634908937995813,-0.7406414641782445,0.8120300751879699,0.9443042164335047,1.0,1/65,0.80%,ORC4
prerank,GO_Biological_Process_2021__chemokine-mediated signaling pathway (GO:0070098),-0.5267102150907989,-0.7399113823406333,0.7950819672131147,0.9445056198419494,1.0,2/52,0.67%,PTK2B;CCL23
prerank,TRRUST_Transcription_Factors_2019__CREBBP mouse,-0.5212532046775408,-0.7397285636562074,0.7377049180327869,0.9442498728757738,1.0,2/34,2.43%,CREBBP;FOSB
prerank,WikiPathway_2021_Human__Osteoblast differentiation WP4787,0.5040870893005375,0.7397120649656466,0.944954128440367,0.8833339645656589,1.0,7/107,2.39%,PIK3CD;LRP5;NOTCH3;SMAD9;MAPK13;FGF1;PIK3C2B
prerank,Reactome_2022__Constitutive Signaling By AKT1 E17K In Cancer R-HSA-5674400,0.49576841394473725,0.7396760416179055,0.6666666666666666,0.8830575934537237,1.0,1/26,0.43%,CREB1
prerank,GO_Biological_Process_2021__neuron differentiation (GO:0030182),-0.4830025174061937,-0.7396157919452817,0.9621212121212122,0.9439026859553106,1.0,3/136,1.71%,SHH;SNPH;PBX1
prerank,Reactome_2022__DNA Damage/Telomere Stress Induced Senescence R-HSA-2559586,0.5785181170248371,0.7396017573034825,0.768,0.8828189659855433,1.0,2/48,2.15%,HIRA;ACD
prerank,Reactome_2022__Signaling By Non-Receptor Tyrosine Kinases R-HSA-9006927,-0.5681631275730747,-0.7395899641236261,0.8,0.9434973576078387,1.0,2/51,1.53%,NR3C1;NRG1
prerank,WikiPathway_2021_Human__Angiopoietin Like Protein 8 Regulatory Pathway WP3915,-0.4872596241201969,-0.7395411742215642,0.9541984732824428,0.9431208157002035,1.0,7/130,2.46%,MAP2K6;PIK3CB;MAP2K5;MAPK6;MAPK4;MAP4K1;SLC16A2
prerank,GO_Biological_Process_2021__Fc-gamma receptor signaling pathway (GO:0038094),0.5375154807550595,0.7395288270076531,0.7543859649122807,0.8825632996655448,1.0,3/71,1.26%,ACTR3;PTK2;SYK
prerank,Reactome_2022__Switching Of Origins To A Post-Replicative State R-HSA-69052,0.5381277510311913,0.7394472365014538,0.8803418803418803,0.8823109383500208,1.0,2/86,1.74%,PSMB9;UBE2C
prerank,GO_Biological_Process_2021__NIK/NF-kappaB signaling (GO:0038061),0.5265154818450498,0.7393876047511697,0.8558558558558559,0.8820790715906919,1.0,2/72,1.20%,TNFRSF10A;PSMB9
prerank,GO_Biological_Process_2021__fatty acid biosynthetic process (GO:0006633),-0.5386061275245893,-0.739376514073687,0.8161764705882353,0.9428550973819724,1.0,7/69,1.98%,ABCD3;CYP2C8;ABHD3;ACSM2B;HACD2;LIPG;CYP1A2
prerank,Reactome_2022__Signaling By ERBB2 TMD/JMD Mutants R-HSA-9665686,0.4881551072096689,0.7393592687771481,0.5916666666666667,0.8817958050069157,1.0,1/21,1.19%,ERBB3
prerank,KEGG_2021_Human__Central carbon metabolism in cancer,0.5328247961207913,0.7393551241609546,0.8372093023255814,0.8814971162062702,1.0,4/68,2.28%,PIK3CD;GLS;HK2;HKDC1
prerank,GO_Biological_Process_2021__bile acid metabolic process (GO:0008206),-0.49788324567017583,-0.739245394803952,0.674074074074074,0.9425422864967178,1.0,1/32,0.22%,CYP39A1
prerank,WikiPathway_2021_Human__Toll-like Receptor Signaling Pathway WP75,-0.5201085918144787,-0.7392150026572121,0.8484848484848485,0.9421382910561965,1.0,4/88,1.85%,MAP2K6;AKT3;PIK3CB;TICAM2
prerank,KEGG_2021_Human__Inflammatory bowel disease,-0.5783197920732209,-0.7391117415256825,0.8,0.9418181986809268,1.0,3/55,2.18%,IL12RB2;RORC;IL21R
prerank,GO_Biological_Process_2021__positive regulation of phosphatidylinositol 3-kinase activity (GO:0043552),0.5625042680136454,0.7389737979362884,0.7272727272727273,0.8814984181626502,1.0,2/27,0.90%,PTK2;NOD2
prerank,GO_Biological_Process_2021__positive regulation of blood coagulation (GO:0030194),0.4793516003499619,0.7389734899649949,0.6178861788617886,0.8811922360097629,1.0,1/17,2.07%,SERPINE1
prerank,Elsevier_Pathway_Collection__PPARGC1A Repression in Huntington Disease,0.49807701281415295,0.7389314509327436,0.5736434108527132,0.8809315147917699,1.0,1/18,0.20%,PPARA
prerank,GO_Biological_Process_2021__regulation of establishment of endothelial barrier (GO:1903140),0.4911946652464612,0.7389033937063779,0.5859375,0.8806538173732306,1.0,1/17,0.88%,PPP1R12A
prerank,GO_Biological_Process_2021__Fc-gamma receptor signaling pathway involved in phagocytosis (GO:0038096),0.5375159741432064,0.738901387180424,0.7565217391304347,0.8803498062031184,1.0,3/70,1.26%,ACTR3;PTK2;SYK
prerank,GO_Biological_Process_2021__negative regulation of supramolecular fiber organization (GO:1902904),0.5095293421366811,0.7388263105484402,0.8615384615384616,0.8801130284364296,1.0,3/71,1.99%,TBCD;CAMSAP3;APOE
prerank,GO_Biological_Process_2021__negative regulation of protein secretion (GO:0050709),0.5515358068442454,0.7387098206154106,0.7166666666666667,0.8799169260540659,1.0,2/34,1.99%,DRD4;APOE
prerank,Reactome_2022__MyD88:MAL(TIRAP) Cascade Initiated On Plasma Membrane R-HSA-166058,0.48217086399551756,0.7386389758269853,0.9834710743801653,0.8796804624765219,1.0,4/111,1.79%,CREB1;IRAK2;NOD2;SIGIRR
prerank,"Reactome_2022__Transport Of Bile Salts And Organic Acids, Metal Ions And Amine Compounds R-HSA-425366",0.5342417062898822,0.7386218604262994,0.8666666666666667,0.8793927803606983,1.0,4/78,2.14%,SLC13A5;SLC47A1;SLC13A3;SLC30A10
prerank,Reactome_2022__NOTCH1 Intracellular Domain Regulates Transcription R-HSA-2122947,0.5373473628530667,0.7385657425692641,0.782608695652174,0.8791348711029703,1.0,3/47,1.83%,TBL1X;HDAC8;HDAC9
prerank,GO_Biological_Process_2021__positive regulation of immune system process (GO:0002684),0.48369514609541386,0.7384914335364792,0.6141732283464567,0.878892700096494,1.0,2/20,1.64%,PIK3CD;ANXA1
prerank,GO_Biological_Process_2021__regulation of potassium ion transmembrane transport (GO:1901379),0.5356076606487989,0.7383988876515344,0.7837837837837838,0.8786491413146295,1.0,6/51,2.34%,DLG1;CAB39;WWP2;KCNJ10;FLNA;GNG2
prerank,GO_Biological_Process_2021__ventricular cardiac muscle tissue development (GO:0003229),-0.4861178655216774,-0.7383496683884893,0.5752212389380531,0.9420529896189057,1.0,1/19,1.39%,ADAMTS9
prerank,GO_Biological_Process_2021__cell-substrate junction assembly (GO:0007044),0.5564015413624225,0.7382246668185595,0.7615384615384615,0.878505263890759,1.0,4/33,2.27%,ARHGEF7;THY1;DLC1;FN1
prerank,Elsevier_Pathway_Collection__Synovial Fibroblast Proliferation in Rheumatoid Arthritis,0.5488236004940469,0.7382162002073387,0.7795275590551181,0.878206051027196,1.0,3/56,2.27%,PTK2;BCAR1;FN1
prerank,GO_Biological_Process_2021__regulation of endothelial cell proliferation (GO:0001936),0.5158954898913515,0.7376666852400157,0.847457627118644,0.8784135878910133,1.0,5/89,1.99%,PIK3CD;PPP1R16B;PROX1;PTPRM;APOE
prerank,GO_Biological_Process_2021__positive regulation of cellular amide metabolic process (GO:0034250),0.524428121297548,0.7376567355656882,0.8467741935483871,0.8781223799452783,1.0,2/81,0.90%,YTHDF3;PLD1
prerank,"Elsevier_Pathway_Collection__Lymphoma, GCB Subtype",0.48984669597564046,0.7372071807944803,0.6583333333333333,0.8782366379876564,1.0,1/22,1.02%,ATR
prerank,Elsevier_Pathway_Collection__Megakaryocyte -> Platelet Precursor Cell Surface Expression Markers,-0.5499144465217503,-0.7371351036180112,0.7692307692307693,0.9426702612675024,1.0,2/40,2.16%,LAIR1;S1PR1
prerank,Elsevier_Pathway_Collection__Ethanol Induced Hepatotoxicity,-0.4903101522234393,-0.7369827570532559,0.584,0.9423834172628105,1.0,1/17,0.98%,SOD2
prerank,"KEGG_2021_Human__Parathyroid hormone synthesis, secretion and action",0.5018941279498534,0.7368214043442383,0.8504672897196262,0.8782545805644372,1.0,4/98,1.67%,CREB1;LRP5;PLD1;CYP27B1
prerank,GO_Biological_Process_2021__cellular response to insulin stimulus (GO:0032869),0.508395496641025,0.7366582060470596,0.9180327868852459,0.8780894141466972,1.0,6/121,2.30%,PTPN2;RHOQ;PKLR;BCAR1;HDAC9;LPIN3
prerank,GO_Biological_Process_2021__hexose transmembrane transport (GO:0008645),-0.4901541885540083,-0.7365604577438097,0.6639344262295082,0.9423595957112256,1.0,1/22,0.99%,SLC2A10
prerank,GO_Biological_Process_2021__mRNA polyadenylation (GO:0006378),0.49326859636627546,0.73618540315285,0.6363636363636364,0.8778974262502424,1.0,1/25,0.68%,TENT2
prerank,GO_Biological_Process_2021__RNA polyadenylation (GO:0043631),0.49326859636627546,0.73618540315285,0.6363636363636364,0.8778974262502424,1.0,1/25,0.68%,TENT2
prerank,TRRUST_Transcription_Factors_2019__NFIC human,-0.4809984519075359,-0.736176125142612,0.656,0.9422540123471137,1.0,1/25,1.91%,MATN1
prerank,Reactome_2022__Cytoprotection By HMOX1 R-HSA-9707564,-0.5584120230797427,-0.7359232324948235,0.8629032258064516,0.94208249697927,1.0,4/57,1.32%,COX16;NCOA1;CREBBP;LIN9
prerank,Elsevier_Pathway_Collection__Proteins Involved in Helicobacter Infections,-0.5390489743213358,-0.735540761655948,0.8429752066115702,0.9420085581035591,1.0,3/55,2.36%,SOD2;SHH;IRAK3
prerank,TRRUST_Transcription_Factors_2019__USF1 human,0.5583779499886279,0.7353564651515749,0.8205128205128205,0.8783386275701959,1.0,4/63,2.07%,SLC19A1;PKLR;PTGS2;SERPINE1
prerank,GO_Biological_Process_2021__response to cytokine (GO:0034097),-0.49844030336660355,-0.7350990223759812,0.926829268292683,0.9419488209209479,1.0,9/143,2.36%,ADAM10;APP;GGT5;SMPD1;PTPN18;PML;CD274;CIITA;IRAK3
prerank,Elsevier_Pathway_Collection__CUL4/CRL (SCF4) Complex,0.4923076169010255,0.7349841525049537,0.626984126984127,0.878348756413178,1.0,1/23,0.77%,MSH2
prerank,Elsevier_Pathway_Collection__rRNA Transcription and Processing,0.49223238971834704,0.7348181470555746,0.5916666666666667,0.8782086260719631,1.0,1/18,0.78%,TAF1B
prerank,Elsevier_Pathway_Collection__Osteoclast Activation in Rheumatoid Arthritis,-0.531175885253523,-0.7345542554765441,0.8,0.9420147330121988,1.0,2/57,0.23%,PTK2B;MAP2K6
prerank,GO_Biological_Process_2021__carbohydrate catabolic process (GO:0016052),0.5562441147142765,0.7343613674709158,0.7661290322580645,0.8782962156314551,1.0,4/37,2.28%,MANBA;PKLR;HK2;HKDC1
prerank,Elsevier_Pathway_Collection__CD38 -> cADPR/Calcium Signaling,0.5329393017285999,0.7342457222090861,0.6666666666666666,0.8780818995500352,1.0,2/25,2.27%,SYK;FN1
prerank,Reactome_2022__Synthesis Of Bile Acids And Bile Salts Via 7Alpha-Hydroxycholesterol R-HSA-193368,-0.49226892148848733,-0.7341115675424519,0.664,0.9419770157704939,1.0,1/24,0.78%,NCOA1
prerank,GO_Biological_Process_2021__atrioventricular valve morphogenesis (GO:0003181),0.4813876898674194,0.7339659174006832,0.5739130434782609,0.8780286597921697,1.0,1/19,1.86%,ZFPM1
prerank,MSigDB_Oncogenic_Signatures__EIF4E DN,0.513906503953555,0.7338027263363134,0.8648648648648649,0.8778857388718726,1.0,7/92,1.82%,FNDC3B;LMO7;UPF2;SORT1;SVIL;TSPAN6;PTGS2
prerank,GO_Biological_Process_2021__amino acid import (GO:0043090),0.4821946800449399,0.7337573454624262,0.625,0.8776192101859324,1.0,2/21,1.79%,SLC47A1;SLC7A1
prerank,GO_Biological_Process_2021__gonad development (GO:0008406),0.5791788395175672,0.7332784265660611,0.7777777777777778,0.877745496716817,1.0,3/41,2.09%,MSH2;SALL1;COL9A3
prerank,GO_Biological_Process_2021__T cell activation (GO:0042110),0.5116324408785775,0.7332495321252043,0.8449612403100775,0.8774699279857829,1.0,3/73,1.23%,PIK3CD;PTPN2;CD4
prerank,WikiPathway_2021_Human__miRNA regulation of DNA damage response WP1530,0.5416676782473687,0.733142427163337,0.8055555555555556,0.8772625169179671,1.0,4/70,1.02%,CREB1;CDK6;TLK2;ATR
prerank,GO_Biological_Process_2021__negative regulation of apoptotic signaling pathway (GO:2001234),0.5190059753283213,0.7331034471430865,0.8207547169811321,0.8770042897654453,1.0,5/76,2.28%,PLAUR;CX3CL1;LGALS3;SH3RF1;HGF
prerank,KEGG_2021_Human__Insulin resistance,0.4891202131054872,0.7330445495615602,0.952755905511811,0.8767446963570649,1.0,5/104,1.10%,PPARA;PIK3CD;CREB1;SLC27A2;PRKAA2
prerank,KEGG_2021_Human__Apoptosis,0.47867664370973284,0.732893754258661,1.0,0.8765716971083601,1.0,7/137,2.15%,ERN1;TNFRSF10A;PIK3CD;CASP7;BOK;CTSH;TUBA1A
prerank,GO_Biological_Process_2021__cellular response to amyloid-beta (GO:1904646),-0.5633473547405705,-0.7328645293393067,0.8,0.9426577303324355,1.0,1/34,0.81%,APP
prerank,Elsevier_Pathway_Collection__Synaptic Exocytosis in Dementia,-0.5230777039359352,-0.732863306678961,0.6693548387096774,0.9422403391991987,1.0,2/23,1.55%,STXBP5;SNPH
prerank,GO_Biological_Process_2021__ubiquitin-dependent protein catabolic process via the multivesicular body sorting pathway (GO:0043162),0.49519233735194396,0.7327956972461215,0.6532258064516129,0.876357166146826,1.0,1/22,0.48%,TOM1L1
prerank,GO_Biological_Process_2021__positive regulation of telomere maintenance via telomerase (GO:0032212),-0.5359128765720207,-0.732552197344475,0.7142857142857143,0.942077199079455,1.0,3/33,0.97%,HMBOX1;NEK7;TNKS
prerank,GO_Biological_Process_2021__cell morphogenesis involved in differentiation (GO:0000904),0.5330528427490088,0.7325398228150055,0.847457627118644,0.8762584385295515,1.0,6/72,2.27%,ABI2;TBCD;SIPA1L3;ITGA4;PROX1;FN1
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> NF-kB Signaling,-0.5212099006301154,-0.7324817017745088,0.7238805970149254,0.941713696246494,1.0,3/39,2.44%,GRAP2;VAV1;ZAP70
prerank,GO_Biological_Process_2021__negative regulation of ERBB signaling pathway (GO:1901185),-0.534813069884107,-0.7322471732137847,0.7398373983739838,0.9415055273594363,1.0,3/39,2.09%,ITGA1;PTPRJ;PTPN18
prerank,Elsevier_Pathway_Collection__MicroRNAs Role in Melanoma,-0.5235398228967526,-0.732088035753085,0.648854961832061,0.9412380703077258,1.0,2/22,1.50%,ZEB1;BMP4
prerank,Elsevier_Pathway_Collection__Sebocyte Proliferation in Acne Vulgaris,0.5291380684862343,0.7319752865679661,0.7027027027027027,0.876414134788223,1.0,2/40,0.43%,PPARA;CREB1
prerank,Reactome_2022__Amino Acid Transport Across Plasma Membrane R-HSA-352230,-0.5363443388058717,-0.7319357491780887,0.6984126984126984,0.9409692860868591,1.0,3/28,1.38%,SLC7A9;SLC36A4;SLC7A8
prerank,GO_Biological_Process_2021__regulation of secretion by cell (GO:1903530),-0.538961328925908,-0.7319249771294021,0.8527131782945736,0.9405584445248526,1.0,3/51,1.67%,RIC1;STXBP5;CPLANE2
prerank,GO_Biological_Process_2021__regulation of mitotic metaphase/anaphase transition (GO:0030071),0.5382084105487672,0.7318165326858851,0.696969696969697,0.8762384041637791,1.0,3/26,1.74%,NEK6;CENPE;UBE2C
prerank,GO_Biological_Process_2021__regulation of brown fat cell differentiation (GO:0090335),0.4818131784515945,0.7316748508581684,0.5833333333333334,0.8760797394760709,1.0,1/16,1.82%,PTGS2
prerank,TRRUST_Transcription_Factors_2019__HNF4A human,-0.5604976014518918,-0.7316532056610677,0.8035714285714286,0.9403699123652516,1.0,2/42,1.10%,CYP2C8;GPR39
prerank,Elsevier_Pathway_Collection__ERK/MAPK Canonical Signaling,0.560803658819134,0.7315050152046928,0.8151260504201681,0.8759535228543961,1.0,3/47,1.07%,CREB1;PTK2;KSR1
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> AP-1 Signaling,-0.5471525033873634,-0.7313965933713004,0.7416666666666667,0.9401378027073859,1.0,2/31,2.44%,GRAP2;ZAP70
prerank,WikiPathway_2021_Human__Monoamine Transport WP727,-0.5320098941292726,-0.7313121095776419,0.7107438016528925,0.9397825312327264,1.0,2/32,2.36%,TGFB1I1;FBXO32
prerank,GO_Biological_Process_2021__cellular response to chemical stress (GO:0062197),0.5146620163342599,0.7312167123580927,0.872,0.8759259168665969,1.0,5/99,2.39%,ETV5;PRKAA2;TXNRD2;CYBA;PYCR1
prerank,KEGG_2021_Human__Vitamin digestion and absorption,0.4946153912076869,0.7308012978460221,0.6299212598425197,0.8759768143351624,1.0,1/22,0.54%,SLC19A1
prerank,GO_Biological_Process_2021__fatty acid oxidation (GO:0019395),-0.5376480897928583,-0.7306409724998478,0.8013698630136986,0.9399286296693553,1.0,3/57,1.80%,ABCD3;CYP4V2;HAO1
prerank,MSigDB_Oncogenic_Signatures__SIRNA EIF4GI UP,-0.5166033947352329,-0.730577898111802,0.8852459016393442,0.9395597228966138,1.0,4/84,2.20%,GIN1;SLCO1A2;THADA;HLA-B
prerank,GO_Biological_Process_2021__apical junction assembly (GO:0043297),0.5114480904024106,0.7304809826553984,0.8220338983050848,0.875938450574246,1.0,3/56,1.24%,TBCD;DLG1;CRB3
prerank,GO_Biological_Process_2021__regulation of lipid metabolic process (GO:0019216),-0.5089620956217535,-0.7304143774258532,0.8852459016393442,0.9392363689751089,1.0,5/92,2.45%,PLPP1;NCOA1;CREBBP;RORC;TM6SF2
prerank,GO_Biological_Process_2021__intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress (GO:0070059),0.4989221516201023,0.7303921217641411,0.6178861788617886,0.8757201835243675,1.0,1/29,0.11%,ERN1
prerank,GO_Biological_Process_2021__negative regulation of ion transmembrane transporter activity (GO:0032413),0.49227054845711077,0.7303864312051276,0.6209677419354839,0.8754251991561862,1.0,1/19,0.78%,CAB39
prerank,Reactome_2022__Receptor-type Tyrosine-Protein Phosphatases R-HSA-388844,0.4808109838837599,0.7298895796725143,0.5928571428571429,0.8755607226537823,1.0,1/19,1.92%,PPFIA4
prerank,MSigDB_Oncogenic_Signatures__KRAS.AMP.LUNG UP.V1 DN,-0.49466668876385667,-0.7298075975061789,0.9022556390977443,0.9393248375781523,1.0,5/110,2.27%,ADAMTS5;PDE11A;GRIK5;RAPGEF3;GPR17
prerank,GO_Biological_Process_2021__amino acid import across plasma membrane (GO:0089718),0.482195414876179,0.7294907532571006,0.6307692307692307,0.8755855411753394,1.0,2/20,1.79%,SLC47A1;SLC7A1
prerank,MSigDB_Oncogenic_Signatures__CAHOY OLIGODENDROCUTIC,-0.5227873521117228,-0.7293749885835382,0.8904109589041096,0.9392807841918143,1.0,2/82,2.27%,KIAA1958;GPR17
prerank,Elsevier_Pathway_Collection__BMP/TGF-beta Signaling Impairment in Pulmonary Hypertension,0.551541489857079,0.7293447950745295,0.7480314960629921,0.8754214446163864,1.0,2/27,1.99%,SMAD9;APOE
prerank,KEGG_2021_Human__Carbohydrate digestion and absorption,-0.5365848629897809,-0.7292808905998077,0.7803030303030303,0.9389548667556822,1.0,3/37,1.91%,AKT3;PIK3CB;PLCB4
prerank,Elsevier_Pathway_Collection__Effector T-cell Inactivation in Cancer Immune Escape,-0.5358158330556196,-0.7292187453816823,0.7692307692307693,0.9386027715903007,1.0,5/57,2.44%,PTK2B;TNFRSF10B;CD274;CIITA;ZAP70
prerank,WikiPathway_2021_Human__Drug Induction of Bile Acid Pathway WP2289,0.48085117100085595,0.7291968865792058,0.6230769230769231,0.8752605306482562,1.0,1/17,1.92%,NR1I2
prerank,GO_Biological_Process_2021__protein N-linked glycosylation (GO:0006487),0.5118667559652339,0.7291487186444917,0.8373983739837398,0.875001505280159,1.0,3/66,1.20%,ST3GAL1;DAD1;ASGR2
prerank,KEGG_2021_Human__Natural killer cell mediated cytotoxicity,0.49368338828893243,0.7288411284568403,0.898989898989899,0.8749421007092743,1.0,6/104,2.00%,TNFRSF10A;PIK3CD;SYK;ITGAL;CD48;NFATC2
prerank,"GO_Biological_Process_2021__G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger (GO:0007187)",0.5549974150419986,0.7287238711554612,0.7928571428571428,0.8747615775122639,1.0,2/36,1.65%,ANXA1;DRD4
prerank,TRRUST_Transcription_Factors_2019__JUN mouse,-0.4999225403823437,-0.728592715812772,0.9285714285714286,0.9386944757840247,1.0,4/110,2.40%,NR3C1;CCND2;MMP2;SPI1
prerank,Elsevier_Pathway_Collection__WNT Signaling in Melanoma,0.48296171855470454,0.728523465151667,0.6495726495726496,0.8746103071038869,1.0,1/23,1.71%,CDH1
prerank,Reactome_2022__p130Cas Linkage To MAPK Signaling For Integrins R-HSA-372708,-0.4880044206407577,-0.7283376044465414,0.5982142857142857,0.9384905703159784,1.0,2/15,1.21%,RAP1B;RAP1A
prerank,Reactome_2022__Collagen Biosynthesis And Modifying Enzymes R-HSA-1650814,0.5316711320414835,0.7283318397502307,0.8059701492537313,0.8744928573957952,1.0,6/66,2.41%,PLOD2;COL12A1;P3H3;COL9A3;COL9A2;COL4A5
prerank,GO_Biological_Process_2021__regulation of cell junction assembly (GO:1901888),-0.5213320056385253,-0.7282864253352049,0.7022900763358778,0.9381158243677347,1.0,2/27,1.21%,RAP1B;RAP1A
prerank,GO_Biological_Process_2021__regulation of calcium ion-dependent exocytosis (GO:0017158),0.5219492242881216,0.7282430787281888,0.6796875,0.8742881585462601,1.0,2/30,2.36%,RAB3GAP1;STX1A
prerank,Reactome_2022__Signaling By WNT In Cancer R-HSA-4791275,0.49569019606710873,0.728133953401815,0.6774193548387096,0.8740912570802455,1.0,1/32,0.43%,LRP5
prerank,GO_Biological_Process_2021__inorganic cation import across plasma membrane (GO:0098659),0.5352489690702293,0.7281208263143962,0.8083333333333333,0.8738164063543747,1.0,2/70,2.03%,KCNJ10;TRPV1
prerank,MSigDB_Oncogenic_Signatures__ATM DN.V1 UP,-0.4939254428975873,-0.7280755828024317,0.9435483870967742,0.9378455295599091,1.0,5/119,2.34%,PTK2B;MYOM1;LIPE;CIITA;PARP3
prerank,GO_Biological_Process_2021__organic acid transport (GO:0015849),-0.49990099626633244,-0.727971313333504,0.9069767441860465,0.9375117850326049,1.0,5/92,1.38%,SLC23A2;SLC7A9;NCOA1;SLCO1A2;SLC7A8
prerank,GO_Biological_Process_2021__positive regulation of translation (GO:0045727),0.5244242698643904,0.7279453836561648,0.8672566371681416,0.8736381660111272,1.0,2/92,0.90%,YTHDF3;PLD1
prerank,GO_Biological_Process_2021__negative regulation of telomere maintenance via telomere lengthening (GO:1904357),-0.49038439552593094,-0.727884665868277,0.6583333333333333,0.9371674655604082,1.0,1/24,0.97%,TNKS
prerank,GO_Biological_Process_2021__negative regulation of protein metabolic process (GO:0051248),-0.5320717608025775,-0.7274000489427822,0.7966101694915254,0.9371260877275435,1.0,2/48,2.36%,INHBB;IRAK3
prerank,Reactome_2022__Hyaluronan Metabolism R-HSA-2142845,0.4850435148372177,0.7273613735729854,0.5864661654135338,0.8738593783864338,1.0,1/15,1.50%,HAS3
prerank,GO_Biological_Process_2021__enzyme linked receptor protein signaling pathway (GO:0007167),0.48481965256563475,0.7272323605365535,0.928,0.8736781857826125,1.0,6/135,1.53%,LMTK2;PTK2;ERBB3;CD4;SYK;BCAR1
prerank,GO_Biological_Process_2021__regulation of DNA repair (GO:0006282),0.5517973653754694,0.7271926379714555,0.7916666666666666,0.8734252551743807,1.0,3/45,1.97%,SMCHD1;WRAP53;AXIN2
prerank,Elsevier_Pathway_Collection__Ca2+ Toxicity in Neurons,-0.49192241641147405,-0.7270009207391454,0.676923076923077,0.9370630279368799,1.0,1/25,0.81%,APP
prerank,KEGG_2021_Human__Fc gamma R-mediated phagocytosis,0.48507519433615814,0.726048603200161,0.937007874015748,0.8740727500937006,1.0,5/94,1.51%,PIK3CD;ACTR3;PLD1;SYK;ASAP2
prerank,Elsevier_Pathway_Collection__ADRA1 -> Ion Channels,0.4796985679703272,0.7260444337385824,0.6101694915254238,0.8737801312991531,1.0,1/16,2.03%,TRPV1
prerank,Elsevier_Pathway_Collection__CD38/CD19 -> JUN/FOS/NF-kB Signaling in B-cell Proliferation,-0.5211713979445587,-0.7257594659560206,0.752,0.9376202751086764,1.0,2/39,2.44%,PTK2B;ZAP70
prerank,GO_Biological_Process_2021__glycoprotein metabolic process (GO:0009100),-0.509987400435266,-0.725758500702479,0.7878787878787878,0.937209865357113,1.0,3/51,1.39%,GANC;FBXO27;ADAMTS9
prerank,Elsevier_Pathway_Collection__Dendritic Cells Function in Atherosclerosis,-0.5270570513012388,-0.7250812399540589,0.7709923664122137,0.9373002292714104,1.0,2/42,1.85%,MAP2K6;TICAM2
prerank,WikiPathway_2021_Human__Common Pathways Underlying Drug Addiction WP2636,-0.5594228350180641,-0.7248102538431924,0.7801418439716312,0.937119511173379,1.0,2/36,1.21%,RAP1B;RAP1A
prerank,Reactome_2022__Signaling By PDGF R-HSA-186797,-0.5345339435437797,-0.7248075603566063,0.8275862068965517,0.9367083134940576,1.0,4/51,2.12%,PIK3CB;STAT5A;COL4A4;THBS4
prerank,Reactome_2022__Activation Of Gene Expression By SREBF (SREBP) R-HSA-2426168,0.5523004154544638,0.7247228729537367,0.7985611510791367,0.8745843881220641,1.0,5/42,1.93%,TBL1X;PPARA;ACACA;PKMYT1;ELOVL6
prerank,GO_Biological_Process_2021__peripheral nervous system development (GO:0007422),-0.4820393378606124,-0.7247177038120314,0.6451612903225806,0.9363810268432715,1.0,2/23,1.81%,PMP22;NTF3
prerank,Elsevier_Pathway_Collection__Th2-Cell Function in Ulcerative Colitis,0.5326457735605316,0.7246212180910413,0.782608695652174,0.8743696655151383,1.0,2/52,2.29%,CD4;CD86
prerank,WikiPathway_2021_Human__DNA damage response WP707,0.5416688646256931,0.7245387795965199,0.8130841121495327,0.8741764579206969,1.0,4/67,1.02%,CREB1;CDK6;TLK2;ATR
prerank,Reactome_2022__Regulation Of IGF Transport And Uptake By IGFBPs R-HSA-381426,-0.48958191581848687,-0.7244959730194933,0.96875,0.9361622856601772,1.0,6/117,2.41%,EVA1A;ADAM10;APP;BMP4;MMP2;PRSS23
prerank,GO_Biological_Process_2021__positive regulation of leukocyte activation (GO:0002696),-0.4841956102492333,-0.7242881570791647,0.59375,0.9359267315920325,1.0,1/18,1.59%,CD2
prerank,Reactome_2022__Signaling By NOTCH1 R-HSA-1980143,-0.5333545291807922,-0.7242581809414219,0.8832116788321168,0.9355260479966353,1.0,3/73,1.22%,ADAM10;TLE4;CREBBP
prerank,Reactome_2022__Nuclear Events Mediated By NFE2L2 R-HSA-9759194,-0.5211929967816534,-0.7241251075455033,0.8623188405797102,0.9352276534920846,1.0,2/76,1.22%,GSTA1;CREBBP
prerank,TRRUST_Transcription_Factors_2019__SREBF1 mouse,0.5680037246097532,0.7239660304870813,0.7819548872180451,0.8743617920724239,1.0,1/31,0.35%,ACACA
prerank,GO_Biological_Process_2021__negative regulation of microtubule polymerization or depolymerization (GO:0031111),0.5242648288327502,0.7235968395137572,0.7226890756302521,0.8743807393248665,1.0,2/32,1.43%,TBCD;CAMSAP3
prerank,GO_Biological_Process_2021__cellular nitrogen compound biosynthetic process (GO:0044271),0.4843792007717635,0.7231641190297479,0.7008547008547008,0.8744530421878772,1.0,1/31,1.56%,MTARC2
prerank,GO_Biological_Process_2021__fatty acid metabolic process (GO:0006631),-0.4942220911955316,-0.7229128821998049,0.9632352941176471,0.9358295804534776,1.0,7/120,1.62%,AASDH;ABCD3;GGT5;SGPL1;ACSM2B;ECHDC3;LIPG
prerank,WikiPathway_2021_Human__Heart Development WP1591,-0.5305243732678745,-0.722671603201365,0.7874015748031497,0.9356053862651798,1.0,2/36,1.50%,SHH;BMP4
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Inhibitory Receptor Signaling,-0.5212769153716126,-0.7225903611538623,0.8527131782945736,0.9352780411330797,1.0,5/50,2.44%,RAP1A;LAIR1;HLA-B;VAV1;ZAP70
prerank,GO_Biological_Process_2021__positive regulation of cyclin-dependent protein kinase activity (GO:1904031),0.48565592478236447,0.7223930234780741,0.6222222222222222,0.8747630862013062,1.0,1/20,1.44%,PROX1
prerank,WikiPathway_2021_Human__Adipogenesis WP236,-0.4830901254592003,-0.7223458601083993,0.9826086956521739,0.9350989967103623,1.0,6/122,1.71%,NR3C1;NCOA1;RB1;LIPE;BMP4;STAT5A
prerank,GO_Biological_Process_2021__muscle cell differentiation (GO:0042692),0.49018926291730075,0.7220524258285581,0.7327586206896551,0.8747605451908032,1.0,1/31,0.98%,MRTFA
prerank,GO_Biological_Process_2021__establishment of protein localization to organelle (GO:0072594),0.5165733047199568,0.722029068815331,0.8125,0.874491434921918,1.0,3/73,2.19%,SYK;LAMP2;HK2
prerank,GO_Biological_Process_2021__phosphatidylinositol metabolic process (GO:0046488),-0.47954973304177756,-0.7219724350768103,0.9758064516129032,0.9349848368101207,1.0,3/107,2.05%,PIK3CB;PLAAT3;PIK3R6
prerank,GO_Biological_Process_2021__metal ion homeostasis (GO:0055065),0.5287908328712728,0.7219574054139252,0.717948717948718,0.8742529619701247,1.0,2/39,1.67%,TMTC2;CYP27B1
prerank,MSigDB_Oncogenic_Signatures__IL21 UP.V1 DN,0.4773210493185255,0.7218223410827419,0.9925925925925926,0.8740603175072214,1.0,7/141,2.28%,ZNF286A;PROX1;RIN2;ITGA2;ASPHD1;TIMP3;HKDC1
prerank,Elsevier_Pathway_Collection__MEN1 Mutation in Hyperparathyroidism,0.49334648795930064,0.7217997757864669,0.6481481481481481,0.8737856308949737,1.0,1/21,0.67%,CDK6
prerank,GO_Biological_Process_2021__regulation of interleukin-12 production (GO:0032655),0.5259495771344849,0.7216343659851308,0.7894736842105263,0.873631305067057,1.0,2/48,1.26%,MEFV;SYK
prerank,KEGG_2021_Human__Glucagon signaling pathway,0.4789412396185984,0.7215189111482939,0.9553571428571429,0.8734314631302931,1.0,6/97,2.12%,PPARA;ACACA;CREB1;PHKA2;PRKAA2;PHKA1
prerank,Reactome_2022__CD28 Co-Stimulation R-HSA-389356,-0.5481516775854376,-0.7214236691390236,0.8071428571428572,0.9350217428547279,1.0,3/33,2.34%,AKT3;GRAP2;VAV1
prerank,GO_Biological_Process_2021__epithelial structure maintenance (GO:0010669),-0.4836600560452514,-0.7213264989971505,0.6029411764705882,0.9346952240098119,1.0,2/15,1.64%,MUC6;PIWIL4
prerank,WikiPathway_2021_Human__Lipid Metabolism Pathway WP3965,0.5223701205096527,0.7212429813751021,0.6851851851851852,0.8733700919543148,1.0,2/28,1.10%,ACACA;PRKAA2
prerank,Reactome_2022__MAP2K And MAPK Activation R-HSA-5674135,-0.5594228543496553,-0.7209745962050085,0.796875,0.9345567636573893,1.0,2/36,1.21%,RAP1B;RAP1A
prerank,Reactome_2022__Regulation Of Lipid Metabolism By PPARalpha R-HSA-400206,-0.486953429735618,-0.7207463370961378,0.975,0.9343399627958747,1.0,4/116,1.32%,CDK19;NCOA1;CREBBP;LIN9
prerank,GO_Biological_Process_2021__negative regulation of developmental process (GO:0051093),-0.517852754138416,-0.7207272196961422,0.8529411764705882,0.9339465055867004,1.0,5/73,2.40%,SHH;BMP4;RAPGEF3;PARP3;SPI1
prerank,GO_Biological_Process_2021__neural crest cell development (GO:0014032),-0.5490652758872168,-0.7206926868084818,0.8095238095238095,0.9335795222266632,1.0,3/44,2.25%,SHH;NRG1;SEMA4D
prerank,GO_Biological_Process_2021__positive regulation of glycolytic process (GO:0045821),-0.4919244618184304,-0.7206764804703294,0.6330935251798561,0.9327850830112288,1.0,1/19,0.81%,APP
prerank,GO_Biological_Process_2021__positive regulation of purine nucleotide metabolic process (GO:1900544),-0.4919244618184304,-0.7206764804703294,0.6330935251798561,0.9327850830112288,1.0,1/19,0.81%,APP
prerank,GO_Biological_Process_2021__organophosphate biosynthetic process (GO:0090407),0.5220189247640752,0.72059144106254,0.7394957983193278,0.8736263705552523,1.0,2/38,2.35%,AGPAT3;GK
prerank,Elsevier_Pathway_Collection__Adherens Junction Assembly (Nectin),0.496961030888852,0.7204688899751096,0.696,0.8734631923990704,1.0,2/27,0.31%,TJP1;LMO7
prerank,GO_Biological_Process_2021__very long-chain fatty acid metabolic process (GO:0000038),0.5102138939102809,0.7204519477284859,0.7203389830508474,0.8731907832014533,1.0,3/32,1.93%,SLC27A2;ELOVL2;ELOVL6
prerank,Reactome_2022__Triglyceride Metabolism R-HSA-8979227,0.5220647313032972,0.7204387555537064,0.7230769230769231,0.8729033768981928,1.0,3/30,2.35%,MOGAT2;LPIN3;GK
prerank,GO_Biological_Process_2021__cellular response to chemokine (GO:1990869),-0.5267091231379577,-0.7203294472854199,0.8333333333333334,0.9326263238665573,1.0,2/56,0.67%,PTK2B;CCL23
prerank,GO_Biological_Process_2021__response to interleukin-1 (GO:0070555),0.5003414801633839,0.7202334322679528,0.9083333333333333,0.8727770307348395,1.0,5/81,1.98%,IRAK2;CX3CL1;ANXA1;CCL14;MAPK13
prerank,GO_Biological_Process_2021__carbohydrate homeostasis (GO:0033500),0.5343722920380536,0.7202165302637183,0.84251968503937,0.8724960265468769,1.0,3/60,2.12%,PTPN2;PRKAA2;RBP4
prerank,TRRUST_Transcription_Factors_2019__FOS human,0.5475556299649806,0.7201253977849392,0.8442622950819673,0.8722864912716871,1.0,3/53,2.39%,PLAUR;PTGS2;MELTF
prerank,GO_Biological_Process_2021__regulation of ion transmembrane transport (GO:0034765),-0.5222918407294708,-0.7200492399391601,0.71900826446281,0.9324431517725551,1.0,2/31,1.11%,WNK3;NEDD4
prerank,Reactome_2022__Long-term Potentiation R-HSA-9620244,-0.5233090298236436,-0.7199482175590894,0.676923076923077,0.9320975588985024,1.0,2/22,1.53%,GRIN2B;NRG1
prerank,GO_Biological_Process_2021__DNA modification (GO:0006304),0.47849861546668265,0.7199235344687905,0.6567164179104478,0.8721256115545505,1.0,1/25,2.15%,ACD
prerank,WikiPathway_2021_Human__ncRNAs involved in Wnt signaling in hepatocellular carcinoma WP4336,0.5278385993932956,0.7198675224902711,0.8467741935483871,0.8718723914083162,1.0,2/80,1.76%,LRP5;FOSL1
prerank,Reactome_2022__PPARA Activates Gene Expression R-HSA-1989781,-0.4869544422159195,-0.7198319153355669,0.9672131147540983,0.9317859947762313,1.0,4/114,1.32%,CDK19;NCOA1;CREBBP;LIN9
prerank,GO_Biological_Process_2021__regulation of proteasomal ubiquitin-dependent protein catabolic process (GO:0032434),-0.4883497393341243,-0.7195786456935401,0.9763779527559056,0.9315697127227466,1.0,2/99,1.17%,RNF217;RNF180
prerank,Elsevier_Pathway_Collection__Clear Cell Endometrial Cancer and Papillary Serous Endometrial Cancer,0.4830504247144538,0.7192483221660138,0.9008264462809917,0.8721299123620008,1.0,4/65,1.71%,CREB1;CDK6;ERBB3;CDH1
prerank,GO_Biological_Process_2021__positive regulation of ubiquitin-dependent protein catabolic process (GO:2000060),-0.48836057182092407,-0.7189201043245155,0.9459459459459459,0.9316860139273886,1.0,2/76,1.17%,RNF217;RNF180
prerank,Elsevier_Pathway_Collection__Cardiovascular Effects in Hyperthyroidism,0.49141763248112036,0.7187763868359657,0.7166666666666667,0.8722539806525283,1.0,1/38,0.86%,PTK2
prerank,Reactome_2022__FOXO-mediated Transcription Of Cell Cycle Genes R-HSA-9617828,0.48396623465936955,0.7186759314537795,0.6062992125984252,0.872053964067679,1.0,1/16,1.61%,PCBP4
prerank,TRRUST_Transcription_Factors_2019__RUNX1 human,0.5129002565150012,0.7185096488923562,0.7345132743362832,0.871914622807036,1.0,3/37,2.05%,PIK3CD;FHL2;LGALS3
prerank,Elsevier_Pathway_Collection__AGE Related Insulin Resistance in Skeletal Muscles,0.49576913002761297,0.71845597053903,0.6434108527131783,0.8716634130024141,1.0,1/22,0.43%,CREB1
prerank,KEGG_2021_Human__Oxidative phosphorylation,-0.4916994992640693,-0.7184106897296374,0.9461538461538461,0.931702691938384,1.0,1/112,0.83%,NDUFS4
prerank,GO_Biological_Process_2021__positive regulation of cellular protein localization (GO:1903829),0.533015556309638,0.7182547357679963,0.8099173553719008,0.8715424469470578,1.0,3/70,2.26%,NDC80;PRKAA2;GPD1L
prerank,TRRUST_Transcription_Factors_2019__GATA2 human,0.47946706901335484,0.7182217783659206,0.6417910447761194,0.8712869954601139,1.0,1/17,2.06%,DPYSL2
prerank,GO_Biological_Process_2021__neural crest cell migration (GO:0001755),-0.5331614476368721,-0.7180364921953531,0.7769230769230769,0.9315923283694767,1.0,2/35,2.25%,SHH;SEMA4D
prerank,Elsevier_Pathway_Collection__Proteins Involved in Astrocytoma,-0.4996636211760956,-0.7179671952301062,0.9090909090909091,0.9312265866892432,1.0,4/89,1.90%,GLG1;APP;SOD2;TEK
prerank,WikiPathway_2021_Human__Photodynamic therapy-induced NF-kB survival signaling WP3617,0.4818003554897111,0.7176155943064005,0.6904761904761905,0.8715456184569812,1.0,1/33,1.82%,PTGS2
prerank,KEGG_2021_Human__Th17 cell differentiation,-0.5090713205214057,-0.7175943561026376,0.9375,0.9310905301264202,1.0,4/98,2.44%,STAT5A;RORC;IL21R;ZAP70
prerank,WikiPathway_2021_Human__EGFR Tyrosine Kinase Inhibitor Resistance WP4806,-0.5348498390314284,-0.7173268329896222,0.9206349206349206,0.9309010954413591,1.0,3/83,1.53%,AKT3;PIK3CB;NRG1
prerank,Reactome_2022__Signaling By RAF1 Mutants R-HSA-9656223,-0.5594224130201578,-0.7168531951441381,0.7751937984496124,0.9308034925892874,1.0,2/37,1.21%,RAP1B;RAP1A
prerank,MSigDB_Oncogenic_Signatures__BCAT.100 UP.V1 UP,-0.5331532449982939,-0.7168035528437395,0.7543859649122807,0.9304433071186431,1.0,4/45,2.26%,SLC7A8;BMP4;DUSP4;CD9
prerank,Elsevier_Pathway_Collection__Diffuse Large-B-Cell Lymphoma,-0.5036837619520148,-0.7167460196973964,0.8863636363636364,0.9300986980982116,1.0,4/87,2.27%,CREBBP;IL10RA;CD274;CIITA
prerank,GO_Biological_Process_2021__regulation of cell killing (GO:0031341),-0.4823898750357109,-0.7164719153884438,0.5855855855855856,0.9299023910809785,1.0,1/16,1.77%,NOXA1
prerank,GO_Biological_Process_2021__L-alpha-amino acid transmembrane transport (GO:1902475),-0.48630795823540796,-0.7163585472192663,0.689922480620155,0.929599493045817,1.0,2/24,1.38%,SLC36A4;SLC7A8
prerank,WikiPathway_2021_Human__miRNA targets in ECM and membrane receptors WP2911,-0.4973459146464093,-0.7161859362539604,0.6611570247933884,0.9293364936668229,1.0,1/22,0.27%,ITGA1
prerank,GO_Biological_Process_2021__positive regulation of nitric oxide biosynthetic process (GO:0045429),0.48180554808781123,0.7158822466676235,0.6507936507936508,0.872807351684864,1.0,1/26,1.82%,PTGS2
prerank,Reactome_2022__Regulation Of Cholesterol Biosynthesis By SREBP (SREBF) R-HSA-1655829,0.5522907036422423,0.7157004126189035,0.8428571428571429,0.8726906951424048,1.0,5/55,1.93%,TBL1X;PPARA;ACACA;PKMYT1;ELOVL6
prerank,Reactome_2022__Sensory Processing Of Sound By Outer Hair Cells Of Cochlea R-HSA-9662361,0.5324587129921636,0.7155465353951405,0.7661290322580645,0.8725393880406564,1.0,2/46,2.31%,ESPN;MYO7A
prerank,Reactome_2022__SHC1 Events In ERBB2 Signaling R-HSA-1250196,0.4881551210900634,0.7151070081462132,0.6410256410256411,0.8725859202078406,1.0,1/21,1.19%,ERBB3
prerank,TRRUST_Transcription_Factors_2019__TCF4 human,0.49107708312812176,0.7151028100356275,0.6640625,0.8722959273703698,1.0,1/23,0.90%,PLD1
prerank,Reactome_2022__Signaling By BMP R-HSA-201451,-0.49622945245524547,-0.7145898051766185,0.6854838709677419,0.9302074555526179,1.0,1/27,0.38%,ZFYVE16
prerank,Elsevier_Pathway_Collection__Th1-Cell Differentiation,-0.521187909189087,-0.714573927853981,0.8759124087591241,0.9298149506423189,1.0,3/62,2.44%,GRAP2;IL12RB2;ZAP70
prerank,Reactome_2022__Toll Like Receptor 7/8 (TLR7/8) Cascade R-HSA-168181,0.491088688122317,0.7145461177492245,0.956140350877193,0.8724903365624331,1.0,3/100,0.90%,CREB1;IRAK2;NOD2
prerank,GO_Biological_Process_2021__positive regulation of osteoblast differentiation (GO:0045669),-0.5235279849234381,-0.7144028366222765,0.8059701492537313,0.9295659014858068,1.0,2/42,1.50%,ZHX3;BMP4
prerank,WikiPathway_2021_Human__Melanoma WP4685,-0.5219696747682997,-0.714278177926493,0.8666666666666667,0.9292668457029624,1.0,4/64,1.15%,POLK;AKT3;PIK3CB;RB1
prerank,KEGG_2021_Human__Arachidonic acid metabolism,-0.5337100639857312,-0.7142041593433719,0.813953488372093,0.9289193691930652,1.0,3/54,1.19%,CYP2C8;GGT5;PLAAT3
prerank,Reactome_2022__Toll Like Receptor 9 (TLR9) Cascade R-HSA-168138,0.4910876030182417,0.7140401790446566,0.963963963963964,0.8726167585235121,1.0,3/103,0.90%,CREB1;IRAK2;NOD2
prerank,Reactome_2022__Platelet Aggregation (Plug Formation) R-HSA-76009,-0.5447240033764067,-0.7138205598809809,0.7857142857142857,0.9288291655133302,1.0,4/36,1.54%,RAP1B;RAP1A;RASGRP2;RAPGEF3
prerank,GO_Biological_Process_2021__monocarboxylic acid biosynthetic process (GO:0072330),-0.5223996984973295,-0.7138050605743606,0.8387096774193549,0.9284335402983956,1.0,4/62,1.62%,CYP39A1;ABCD3;ACSM2B;LIPG
prerank,GO_Biological_Process_2021__cyclic-nucleotide-mediated signaling (GO:0019935),0.5255638873168412,0.713793948737402,0.7478260869565218,0.872548638222561,1.0,2/32,1.99%,KSR1;APOE
prerank,GO_Biological_Process_2021__positive regulation of telomere maintenance via telomere lengthening (GO:1904358),-0.5359117465235076,-0.7137922662147861,0.7664233576642335,0.9280504097840769,1.0,3/36,0.97%,HMBOX1;NEK7;TNKS
prerank,Reactome_2022__Mitochondrial Biogenesis R-HSA-1592230,0.48908795250029086,0.7136494077065606,0.9302325581395349,0.8723615172029355,1.0,4/89,1.10%,TBL1X;PPARA;CREB1;PRKAA2
prerank,WikiPathway_2021_Human__Angiogenesis WP1539,0.4815388193290285,0.713318457375437,0.6727272727272727,0.8723447461261422,1.0,2/24,1.85%,PTK2;TIMP3
prerank,Elsevier_Pathway_Collection__Treg-Cell Function in Diabetes Mellitus Type 1,-0.5211936370489537,-0.7132980457134113,0.8333333333333334,0.9280168844301273,1.0,3/56,2.44%,GRAP2;STAT5A;ZAP70
prerank,GO_Biological_Process_2021__T cell differentiation (GO:0030217),-0.5115855684261458,-0.7130627652538583,0.7647058823529411,0.927817933030891,1.0,6/39,2.44%,RABL3;SHH;GLI3;RHOH;SPI1;ZAP70
prerank,Reactome_2022__Signaling By MET R-HSA-6806834,0.5491262102630967,0.7130276506297057,0.8790322580645161,0.8723053976919438,1.0,5/63,2.24%,ITGA3;PTPN2;PTK2;ITGA2;LRIG1
prerank,GO_Biological_Process_2021__positive regulation of cytokine production involved in immune response (GO:0002720),0.49103498755252145,0.7130162269363194,0.706766917293233,0.8720191896861643,1.0,1/32,0.90%,NOD2
prerank,Reactome_2022__NS1 Mediated Effects On Host Pathways R-HSA-168276,-0.4959576039609108,-0.7129213703035823,0.8134328358208955,0.927526598573266,1.0,1/42,0.41%,KPNA3
prerank,GO_Biological_Process_2021__response to ionizing radiation (GO:0010212),0.5392558709216522,0.7129067921968066,0.889763779527559,0.8718159427644642,1.0,3/72,1.64%,BRSK1;MSH2;ANXA1
prerank,GO_Biological_Process_2021__positive regulation of nitric oxide metabolic process (GO:1904407),0.4818047542312033,0.7126895416721339,0.6693548387096774,0.8717196439099394,1.0,1/27,1.82%,PTGS2
prerank,GO_Biological_Process_2021__bicellular tight junction assembly (GO:0070830),0.5114515160631963,0.7125807243861282,0.7804878048780488,0.8715346799671345,1.0,3/49,1.24%,TBCD;DLG1;CRB3
prerank,GO_Biological_Process_2021__substantia nigra development (GO:0021762),-0.549837960996291,-0.7123388850401832,0.8174603174603174,0.9275691731396839,1.0,4/41,2.17%,CCDC14;ZNF148;BASP1;MAOB
prerank,Reactome_2022__Signaling By High-Kinase Activity BRAF Mutants R-HSA-6802948,-0.5594248230521875,-0.71195127066579,0.7886178861788617,0.9274419215906152,1.0,2/32,1.21%,RAP1B;RAP1A
prerank,Reactome_2022__HATs Acetylate Histones R-HSA-3214847,0.4939450552977456,0.7118196167695605,0.8869565217391304,0.8718985762093522,1.0,3/92,0.61%,SUPT3H;ING5;ELP3
prerank,GO_Biological_Process_2021__glial cell development (GO:0021782),0.4933453484490004,0.7117587458229835,0.6724137931034483,0.8716550636432353,1.0,1/25,0.67%,CDK6
prerank,Elsevier_Pathway_Collection__B-Cell Chronic Lymphocytic Leukemia,-0.5051188009675739,-0.7117419725127639,0.8854961832061069,0.9271950685551398,1.0,3/90,2.44%,PTK2B;CCND2;ZAP70
prerank,WikiPathway_2021_Human__Oxidative Stress WP408,0.5352030665054566,0.7113933866988442,0.7936507936507936,0.8716656164962827,1.0,2/32,2.04%,MAOA;TXNRD2
prerank,GO_Biological_Process_2021__regulation of focal adhesion assembly (GO:0051893),-0.5477872872309002,-0.7112975498671481,0.8387096774193549,0.9271453353898128,1.0,5/53,2.38%,PEAK1;PTPRJ;BCAS3;TEK;HRG
prerank,GO_Biological_Process_2021__ephrin receptor signaling pathway (GO:0048013),0.48939987341610947,0.7112214139153199,0.9464285714285714,0.8715124573698197,1.0,3/80,1.07%,ACTR3;PTK2;ARHGEF7
prerank,Reactome_2022__Post-translational Protein Phosphorylation R-HSA-8957275,0.4905233049005938,0.7110141423025769,0.9444444444444444,0.8713654061012562,1.0,7/101,2.39%,CDH2;IGFBP3;CKAP4;APOE;QSOX1;FN1;MELTF
prerank,GO_Biological_Process_2021__positive regulation of muscle cell differentiation (GO:0051149),-0.5152312462250352,-0.7108833495753109,0.6974789915966386,0.9270744485500783,1.0,3/24,2.34%,NRG1;BOC;OLFM2
prerank,TRRUST_Transcription_Factors_2019__HDAC3 human,0.4830016263437895,0.7108793701268975,0.6771653543307087,0.8711884355275281,1.0,2/22,1.71%,GTF2I;CDH1
prerank,Reactome_2022__Hh Mutants Are Degraded By ERAD R-HSA-5362768,0.4880236415366865,0.7108507683386058,0.8442622950819673,0.870912558337402,1.0,1/53,1.20%,PSMB9
prerank,KEGG_2021_Human__Morphine addiction,-0.4844277002754,-0.7103866462901118,0.9153846153846154,0.9270323766842307,1.0,2/79,1.56%,PDE11A;ADCY3
prerank,KEGG_2021_Human__Melanoma,-0.5219687905532568,-0.7102107361679291,0.8646616541353384,0.9267543554092602,1.0,4/66,1.15%,POLK;AKT3;PIK3CB;RB1
prerank,KEGG_2021_Human__NF-kappa B signaling pathway,-0.4975123788489535,-0.7101737548267417,0.9609375,0.9263797994096208,1.0,5/102,2.44%,ERC1;TICAM2;CARD10;TNFSF14;ZAP70
prerank,WikiPathway_2021_Human__B Cell Receptor Signaling Pathway WP23,-0.49060421015333333,-0.7101107222994781,0.9495798319327731,0.9260312586976205,1.0,7/97,2.39%,MAP2K6;TEC;MAPK4;RASGRP3;PTPN18;VAV1;MAP4K1
prerank,Elsevier_Pathway_Collection__Neutrophil Chemotaxis,0.5340283850620049,0.7100248453428483,0.8403361344537815,0.8712983101285463,1.0,2/56,2.16%,ITGA4;CYBA
prerank,Elsevier_Pathway_Collection__CD4+ T-Cell Function Decline in HIV,0.532646768964146,0.7099982674424966,0.7807017543859649,0.8710435716208758,1.0,2/51,2.29%,CD4;CD86
prerank,Reactome_2022__TP53 Regulates Metabolic Genes R-HSA-5628897,-0.4953734080949897,-0.7099726749016242,0.8818897637795275,0.9257298508243678,1.0,2/81,0.47%,COX16;AKT3
prerank,GO_Biological_Process_2021__negative regulation of smooth muscle cell proliferation (GO:0048662),0.5316253482239606,0.7097016590358173,0.71900826446281,0.8710183308179563,1.0,2/32,2.40%,IGFBP3;TAFA5
prerank,"Elsevier_Pathway_Collection__Hypoparathyroidism, Primary",-0.4987691117554546,-0.7095988945673668,0.6466165413533834,0.9256099174724126,1.0,1/18,0.13%,PTK2B
prerank,Elsevier_Pathway_Collection__TNF-alpha/TNFRSF1A Signaling,-0.4978061258707885,-0.7095297983817382,0.6666666666666666,0.9252651725948897,1.0,1/32,0.23%,MAP2K6
prerank,Elsevier_Pathway_Collection__Acute Phase in Atopic Dermatitis,0.5326603570899531,0.7093346065528096,0.7565217391304347,0.8710530418276429,1.0,2/36,2.29%,CD4;CD86
prerank,GO_Biological_Process_2021__embryonic skeletal system development (GO:0048706),0.5484218342038727,0.7092028044971013,0.752,0.8708570569410101,1.0,3/32,2.31%,MEGF8;RBP4;HOXD3
prerank,Elsevier_Pathway_Collection__Glioma Stem Cell Program Activation,-0.5248420924356101,-0.7090513280004349,0.8898305084745762,0.925214947476568,1.0,5/69,2.08%,SHH;BMP4;CD44;KLF4;GLI3
prerank,Reactome_2022__Sulfur Amino Acid Metabolism R-HSA-1614635,0.49034549936937977,0.7083753032390182,0.6915887850467289,0.8712302055137475,1.0,1/25,0.97%,MTAP
prerank,Elsevier_Pathway_Collection__TLR2 Signaling in Treg-Cell in Type 1 Diabetes (Animal Model),-0.5211936454961836,-0.7083446660250097,0.7862595419847328,0.9253789297495852,1.0,3/56,2.44%,GRAP2;STAT5A;ZAP70
prerank,Elsevier_Pathway_Collection__Proteins Involved in Congenital Hypothyroidism,-0.4843111008094169,-0.7081857305425735,0.6417910447761194,0.9251221638012324,1.0,1/18,1.58%,PAX8
prerank,Elsevier_Pathway_Collection__Extraocular Muscles Weakness in Myasthenia Gravis,-0.4231506980205353,-0.7081051980776201,0.5483870967741935,0.9247947923620825,1.0,8/15,22.69%,MYLK;LRP4;PAK1;RAC1;AGRN;RAPSN;CD59;DGKZ
prerank,TRRUST_Transcription_Factors_2019__SOX9 mouse,0.48300032011369154,0.7080447187473663,0.6779661016949152,0.87123637059245,1.0,2/24,1.71%,WWP2;CDH1
prerank,GO_Biological_Process_2021__negative regulation of interleukin-8 production (GO:0032717),0.48369709117006765,0.708030035195604,0.6190476190476191,0.8709627087561587,1.0,2/17,1.64%,CD33;ANXA1
prerank,GO_Biological_Process_2021__regulation of cell motility (GO:2000145),-0.47872680385986294,-0.7079696843303268,0.9927536231884058,0.9245023446614168,1.0,6/123,2.14%,LDB2;TTBK2;AMOTL1;SGK3;NRG1;MGAT3
prerank,Elsevier_Pathway_Collection__Treg-Cell Differentiation,-0.5211945848306804,-0.707696808194289,0.8333333333333334,0.9243321022616278,1.0,3/55,2.44%,GRAP2;STAT5A;ZAP70
prerank,Reactome_2022__TRAF6 Mediated Induction Of NFkB And MAP Kinases Upon TLR7/8 Or 9 Activation R-HSA-975138,0.491089381900885,0.7075843614713193,0.9557522123893806,0.8710631992504835,1.0,3/98,0.90%,CREB1;IRAK2;NOD2
prerank,Elsevier_Pathway_Collection__Cholesteatoma,0.5350574917971791,0.7075608079767263,0.8796296296296297,0.870789777179588,1.0,2/69,2.05%,ERBB3;LGALS3
prerank,GO_Biological_Process_2021__vesicle organization (GO:0016050),-0.49622636662443736,-0.7072909042702373,0.8461538461538461,0.924249294143708,1.0,1/46,0.38%,ZFYVE16
prerank,Reactome_2022__Paradoxical Activation Of RAF Signaling By Kinase Inactive BRAF R-HSA-6802955,-0.5594214642313526,-0.7071897407979735,0.7936507936507936,0.9239348880776135,1.0,2/39,1.21%,RAP1B;RAP1A
prerank,Elsevier_Pathway_Collection__Aldosterone Synthesis Chronic Regulation,-0.49876828909007925,-0.7071782907251117,0.6737588652482269,0.9235455650399206,1.0,1/29,0.13%,PTK2B
prerank,GO_Biological_Process_2021__toll-like receptor signaling pathway (GO:0002224),0.47944841017096795,0.7070104591764509,0.9758064516129032,0.870924640703892,1.0,3/89,2.06%,TRAF3;IRAK2;PIK3AP1
prerank,GO_Biological_Process_2021__regulation of endothelial cell migration (GO:0010594),-0.48737546128396203,-0.7069389697736529,0.9523809523809523,0.9233324317212009,1.0,7/89,2.45%,PTK2B;PIK3CB;BCAS3;ADAMTS9;BMP4;TEK;DNAJA4
prerank,GO_Biological_Process_2021__negative regulation of MAPK cascade (GO:0043409),-0.4917866249315361,-0.7069224272358636,0.9577464788732394,0.9229497065645268,1.0,6/88,2.36%,PIK3CB;PTPRJ;BMP4;DUSP4;SMPD1;IRAK3
prerank,Reactome_2022__MyD88 Dependent Cascade Initiated On Endosome R-HSA-975155,0.49108903507633384,0.7068760371292042,0.9646017699115044,0.8707426042447018,1.0,3/99,0.90%,CREB1;IRAK2;NOD2
prerank,GO_Biological_Process_2021__organic hydroxy compound biosynthetic process (GO:1901617),-0.49788127099272766,-0.7067083694775471,0.8208955223880597,0.922708474563245,1.0,1/50,0.22%,CYP39A1
prerank,GO_Biological_Process_2021__negative regulation of epithelial cell migration (GO:0010633),-0.5311614154296642,-0.7066103518580859,0.7777777777777778,0.9223788805668783,1.0,2/34,2.45%,ADAMTS9;DNAJA4
prerank,GO_Biological_Process_2021__regulation of protein transport (GO:0051223),0.4904219278840734,0.7065728538959507,0.6976744186046512,0.8707160535183435,1.0,1/26,0.96%,WWP2
prerank,WikiPathway_2021_Human__Differentiation Pathway WP2848,-0.5850667291119547,-0.7064932448277538,0.8064516129032258,0.9220825780039841,1.0,2/41,1.50%,SHH;BMP4
prerank,GO_Biological_Process_2021__regulation of intrinsic apoptotic signaling pathway in response to DNA damage (GO:1902229),0.4408876544009628,0.7063475797649788,0.5619834710743802,0.8706208242763296,1.0,10/16,30.51%,TPT1;SNAI2;CLU;BCL2L1;DDIAS;SNAI1;TMEM161A;SFRP2;FBH1;ACKR3
prerank,KEGG_2021_Human__Galactose metabolism,-0.49996095102494004,-0.7062581840899539,0.6766917293233082,0.9218780191139971,1.0,1/26,0.01%,GANC
prerank,GO_Biological_Process_2021__regulation of oxidative phosphorylation (GO:0002082),-0.43721987961625697,-0.706216119407579,0.5423728813559322,0.92150422147162,1.0,9/15,28.15%,PPIF;COX7A2;ATP7A;MLXIPL;ABCD1;COX7A2L;VCP;UQCC2;SHMT2
prerank,Elsevier_Pathway_Collection__Natural Killer T-Cell Roles in Diabetes Mellitus Type 1,0.5326393751063716,0.7061366688663502,0.8495575221238938,0.8705376014992209,1.0,2/59,2.29%,CD4;CD86
prerank,GO_Biological_Process_2021__regulation of myoblast differentiation (GO:0045661),-0.48272677921016166,-0.7060384487472945,0.7142857142857143,0.9212461328341865,1.0,2/30,1.74%,BMP4;BOC
prerank,GO_Biological_Process_2021__regulation of DNA biosynthetic process (GO:2000278),-0.5103462079487874,-0.7059943953980846,0.689922480620155,0.9208923943547457,1.0,3/28,1.36%,HMBOX1;TNKS;SMG6
prerank,GO_Biological_Process_2021__positive regulation of cation transmembrane transport (GO:1904064),0.5151394983431562,0.7059940383750696,0.8,0.8703648898277097,1.0,3/40,2.34%,KCNJ10;FLNA;GNG2
prerank,GO_Biological_Process_2021__amino acid transport (GO:0006865),-0.5363362463559556,-0.705700364998875,0.8120300751879699,0.9207306128308922,1.0,3/43,1.38%,SLC7A9;SLC36A4;SLC7A8
prerank,TRRUST_Transcription_Factors_2019__RELA mouse,0.4957184523482624,0.7056137155037613,0.9022556390977443,0.8703937003385331,1.0,6/103,2.29%,PPARA;PTGS2;APOE;FN1;HGF;CD86
prerank,GO_Biological_Process_2021__vascular endothelial growth factor receptor signaling pathway (GO:0048010),-0.5151926154823978,-0.7054832496303804,0.8880597014925373,0.9205076046038126,1.0,4/67,2.34%,PTK2B;PAK2;PIK3CB;VAV1
prerank,Elsevier_Pathway_Collection__Endometrioid Ovarian Carcinoma,-0.5247096565223185,-0.7054516344152764,0.8870967741935484,0.9201381728494008,1.0,4/76,1.71%,NCOA1;CREBBP;NRG1;STAT5A
prerank,GO_Biological_Process_2021__chordate embryonic development (GO:0043009),0.5343388812541116,0.704999947292065,0.782258064516129,0.8706089182565013,1.0,2/53,2.12%,PROX1;RBP4
prerank,"Reactome_2022__BMAL1:CLOCK,NPAS2 Activates Circadian Gene Expression R-HSA-1368108",0.4994613914055275,0.7049467903739163,0.6589147286821705,0.8703603180440639,1.0,4/25,2.07%,TBL1X;PPARA;F7;SERPINE1
prerank,GO_Biological_Process_2021__regulation of gluconeogenesis (GO:0006111),0.4943065202918423,0.7049411804957219,0.6842105263157895,0.8700761125904274,1.0,1/27,0.57%,PTPN2
prerank,Reactome_2022__MyD88 Cascade Initiated On Plasma Membrane R-HSA-975871,0.4910904456050673,0.7048033780559648,0.990990990990991,0.8698978805431955,1.0,3/95,0.90%,CREB1;IRAK2;NOD2
prerank,Elsevier_Pathway_Collection__CFTR Expression in Epithelial Cells (Class I Mutations),-0.49780739265033147,-0.7045380226490672,0.664179104477612,0.9204644216033724,1.0,1/22,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__regulation of viral entry into host cell (GO:0046596),-0.548763815073445,-0.7045034770839002,0.7777777777777778,0.9200998055642822,1.0,2/36,2.27%,TMPRSS2;CIITA
prerank,Elsevier_Pathway_Collection__ADRA1A -> IL6 Production,-0.497806481461293,-0.7041743811772633,0.7073170731707317,0.9199611145548973,1.0,1/30,0.23%,MAP2K6
prerank,Reactome_2022__Oncogenic MAPK Signaling R-HSA-6802957,0.5068669804021327,0.7041323666941429,0.8699186991869918,0.8701248929421063,1.0,5/76,2.27%,TRAK1;TRIM24;PAPSS1;KSR1;FN1
prerank,KEGG_2021_Human__Gap junction,0.5048856867609425,0.7040842547072675,0.952755905511811,0.869867848950843,1.0,3/79,2.15%,TJP1;LPAR1;TUBA1A
prerank,"GO_Biological_Process_2021__nuclear-transcribed mRNA catabolic process, exonucleolytic (GO:0000291)",0.49776736334334315,0.7039749562997453,0.7456140350877193,0.8696645593789049,1.0,1/35,0.23%,DIS3L2
prerank,Elsevier_Pathway_Collection__Circadian Clock Genes in Suprachiasmatic Nuclei Neurons,-0.49780520451744875,-0.7037856375366854,0.7741935483870968,0.9198882556057241,1.0,1/39,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__histone lysine methylation (GO:0034968),-0.4991528245247722,-0.7036882957677503,0.736,0.9195810758235178,1.0,1/31,0.09%,KDM6A
prerank,GO_Biological_Process_2021__positive regulation of cellular protein metabolic process (GO:0032270),-0.4996317959941215,-0.7034552523693889,0.9111111111111111,0.9193711522153034,1.0,4/101,2.05%,CPEB3;ATG10;NIBAN1;KLF4
prerank,WikiPathway_2021_Human__Initiation of transcription and translation elongation at the HIV-1 LTR WP3414,-0.4878818522878597,-0.7032437275351062,0.7109375,0.9191778139488508,1.0,2/30,1.22%,NELFA;CREBBP
prerank,Elsevier_Pathway_Collection__ICAM1 -> AP-1/CREB/ELK/SRF Signaling,-0.4978071980026467,-0.7030759447749443,0.6666666666666666,0.9189041256937384,1.0,1/23,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__hydrogen peroxide metabolic process (GO:0042743),0.47846110036055134,0.7030119552186167,0.6666666666666666,0.8701994302817014,1.0,1/24,2.16%,CYBA
prerank,GO_Biological_Process_2021__regulation of cell division (GO:0051302),-0.5096661298556497,-0.7028841510097569,0.860655737704918,0.9186902830653738,1.0,3/75,1.43%,UVRAG;BIRC6;SHH
prerank,GO_Biological_Process_2021__positive regulation of toll-like receptor signaling pathway (GO:0034123),-0.48157625855236547,-0.7028548441394551,0.6470588235294118,0.918314240481478,1.0,1/24,1.85%,TICAM2
prerank,Reactome_2022__RHOBTB1 GTPase Cycle R-HSA-9013422,-0.49953783145346914,-0.7027805393774887,0.6746031746031746,0.9179831884006086,1.0,1/23,0.05%,PDE5A
prerank,TRRUST_Transcription_Factors_2019__PPARG mouse,-0.5067409494873606,-0.702776037615924,0.8064516129032258,0.9175973421947643,1.0,3/44,2.28%,SOD2;LIPE;PLIN4
prerank,GO_Biological_Process_2021__lipid homeostasis (GO:0055088),-0.514118667285803,-0.7024652977634217,0.8181818181818182,0.9174305346786154,1.0,5/62,2.45%,TLCD4;THADA;LIPG;TLCD2;TM6SF2
prerank,GO_Biological_Process_2021__organic anion transport (GO:0015711),-0.4891433765662078,-0.7023332410224372,0.9761904761904762,0.9171493520413363,1.0,6/91,2.46%,SLC35A3;SLC2A10;SLCO1A2;SLCO3A1;SLC4A5;SLC16A2
prerank,MSigDB_Oncogenic_Signatures__CRX DN.V1 DN,-0.47722284736310827,-0.7022798933723039,1.0,0.9168000232009273,1.0,6/121,2.29%,ZDHHC14;DHX32;INHBB;CD44;PCOLCE;SEL1L3
prerank,GO_Biological_Process_2021__positive regulation of potassium ion transmembrane transport (GO:1901381),-0.5639091283134121,-0.7016627223458468,0.8571428571428571,0.9168819184621158,1.0,3/44,2.44%,KCNN2;WNK3;KCNE1
prerank,GO_Biological_Process_2021__negative regulation of tumor necrosis factor superfamily cytokine production (GO:1903556),0.5242971233236717,0.7015312915435878,0.7983870967741935,0.8711504366657931,1.0,2/43,1.42%,CD33;CX3CL1
prerank,WikiPathway_2021_Human__Integrated Cancer Pathway WP1971,-0.5380036738883797,-0.7011512535048877,0.8148148148148148,0.9169251259402207,1.0,3/44,1.77%,POU2F1;RB1;NOXA1
prerank,Reactome_2022__Detoxification Of Reactive Oxygen Species R-HSA-3299685,-0.493959102103698,-0.7009598668999433,0.7603305785123967,0.9166862013815142,1.0,1/32,0.61%,GLYAT
prerank,Reactome_2022__Degradation Of GLI1 By Proteasome R-HSA-5610780,0.48802223927711696,0.7005636179827084,0.8524590163934426,0.8716755400736352,1.0,1/56,1.20%,PSMB9
prerank,GO_Biological_Process_2021__hyaluronan metabolic process (GO:0030212),0.4850390153381211,0.7004683421211992,0.6564885496183206,0.8714793539064986,1.0,1/22,1.50%,HAS3
prerank,WikiPathway_2021_Human__Glycolysis and Gluconeogenesis WP534,0.5336545977284645,0.7001542822583594,0.8110236220472441,0.8714541860131658,1.0,2/43,2.19%,PKLR;HK2
prerank,GO_Biological_Process_2021__regulation of sprouting angiogenesis (GO:1903670),0.5026936874714961,0.7000082004605758,0.688,0.871307224095624,1.0,3/32,2.37%,TJP1;PPP1R16B;FGF1
prerank,KEGG_2021_Human__Aldosterone-regulated sodium reabsorption,0.49611316949365714,0.6999261706067816,0.7203389830508474,0.8710831390512201,1.0,1/33,0.39%,PIK3CD
prerank,Reactome_2022__Signaling By ERBB2 In Cancer R-HSA-1227990,0.4881531179098473,0.6997703661118121,0.6666666666666666,0.8709319432702713,1.0,1/25,1.19%,ERBB3
prerank,Elsevier_Pathway_Collection__G-cell: Gastrin Secretion,-0.4398242072891348,-0.6996784939641183,0.5588235294117647,0.9172948929116548,1.0,5/16,20.08%,GNA12;CPB2;PCSK2;GNA13;SP1
prerank,Elsevier_Pathway_Collection__Glutamine in Cancer Metabolism,-0.4885372766052935,-0.6992397169749263,0.6774193548387096,0.9172251288512033,1.0,1/26,1.15%,RB1
prerank,Elsevier_Pathway_Collection__Androgens in Sebocyte Maturation,-0.5031624985602293,-0.6992176994785791,0.8503937007874016,0.916861820771926,1.0,4/64,2.08%,SUFU;SHH;BMP4;GLI3
prerank,Elsevier_Pathway_Collection__CDH2 Activation Promotes Cancer Cell Migration and Survival,-0.541219316224471,-0.6991095600417109,0.8270676691729323,0.9165729289294811,1.0,3/49,0.44%,PTK2B;ADAM10;ZEB1
prerank,TRRUST_Transcription_Factors_2019__MEF2C mouse,-0.4953842871192118,-0.6990192907126603,0.7,0.9162620558083439,1.0,1/24,0.47%,MYOM1
prerank,KEGG_2021_Human__Adherens junction,-0.48790088663938624,-0.6988572278854377,0.9206349206349206,0.9159929109834465,1.0,3/71,1.22%,PTPRJ;PARD3;CREBBP
prerank,Elsevier_Pathway_Collection__MTOR/TORC in Cancer Cell Motility and Invasion,-0.480767840836194,-0.6987331656101069,0.6722689075630253,0.9157136295768453,1.0,1/25,1.93%,MMP2
prerank,Reactome_2022__Neurexins And Neuroligins R-HSA-6794361,-0.5416886730780781,-0.6985845132189058,0.8368794326241135,0.9154479000526953,1.0,4/56,2.37%,SIPA1L1;GRIN2B;SYT2;SYT7
prerank,Elsevier_Pathway_Collection__Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma,0.5326399721055368,0.6981978251675897,0.8620689655172413,0.8719324500906814,1.0,2/58,2.29%,SYK;CD86
prerank,GO_Biological_Process_2021__receptor internalization (GO:0031623),-0.5229728780507064,-0.6981380611066553,0.8292682926829268,0.9154220093998887,1.0,2/47,2.26%,NEDD4;CD9
prerank,Elsevier_Pathway_Collection__Endothelin Signaling in Arterial Hypertension,-0.49876863159352086,-0.6981303520157853,0.7272727272727273,0.9150442594890759,1.0,1/26,0.13%,PTK2B
prerank,Reactome_2022__Epigenetic Regulation Of Gene Expression R-HSA-212165,0.49220392583256306,0.6979644820485932,0.968,0.871852283390552,1.0,1/105,0.78%,TAF1B
prerank,GO_Biological_Process_2021__posttranscriptional regulation of gene expression (GO:0010608),0.49749702108342414,0.6979285262583439,0.8267716535433071,0.871597170344027,1.0,1/44,0.25%,EIF2A
prerank,Elsevier_Pathway_Collection__Pancreatic Neuroendocrine Tumors,0.4881708073299615,0.6979274187587254,0.8677685950413223,0.8713096094168267,1.0,2/70,1.19%,CDK6;ERBB3
prerank,GO_Biological_Process_2021__positive regulation of cytoskeleton organization (GO:0051495),-0.5090075788274132,-0.6978610345345619,0.8818897637795275,0.914845648600624,1.0,6/79,1.90%,PTK2B;CARMIL1;BCAS3;HCK;NTF3;TEK
prerank,Reactome_2022__Inflammasomes R-HSA-622312,-0.4919236561353846,-0.6974881291024658,0.7111111111111111,0.9147506117742659,1.0,1/21,0.81%,APP
prerank,Elsevier_Pathway_Collection__TNFRSF1A -> CREB/ELK-SRF Signaling,-0.49780647718716764,-0.6974664951153762,0.7,0.9143883836101497,1.0,1/29,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__amino acid transmembrane transport (GO:0003333),-0.5408183047819782,-0.6974289280506598,0.8111888111888111,0.9140294105997692,1.0,4/40,2.46%,SLC7A9;SLC36A4;SLC7A8;SLC16A2
prerank,GO_Biological_Process_2021__negative regulation of cellular protein metabolic process (GO:0032269),-0.4918253064284522,-0.6972130836224607,0.9393939393939394,0.9138138516250951,1.0,2/87,0.83%,CPEB3;RIC1
prerank,Reactome_2022__Nuclear Envelope Breakdown R-HSA-2980766,0.5326454315796265,0.696878676269647,0.8174603174603174,0.8719055497057903,1.0,3/53,2.30%,NEK6;NUP210;LPIN3
prerank,Elsevier_Pathway_Collection__mRNA Degradation,-0.49346043872538786,-0.6968783329928527,0.6942148760330579,0.9136869598539964,1.0,1/26,0.66%,EDC3
prerank,Reactome_2022__Plasma Lipoprotein Remodeling R-HSA-8963899,-0.4838394922290177,-0.6967817158838118,0.7350427350427351,0.9133670583175347,1.0,1/33,1.62%,LIPG
prerank,Reactome_2022__Degradation Of GLI2 By Proteasome R-HSA-5610783,0.4880221627197042,0.6967088091737073,0.8617886178861789,0.8717677160712382,1.0,1/56,1.20%,PSMB9
prerank,WikiPathway_2021_Human__Endometrial cancer WP4155,-0.5400999501229065,-0.6965124948661986,0.8257575757575758,0.9131417312832769,1.0,3/63,0.55%,POLK;AKT3;PIK3CB
prerank,Reactome_2022__Hh Mutants Abrogate Ligand Secretion R-HSA-5387390,0.48802214789519033,0.6964582009068099,0.864406779661017,0.871665519440611,1.0,1/56,1.20%,PSMB9
prerank,GO_Biological_Process_2021__positive regulation of endothelial cell proliferation (GO:0001938),0.5042591121051342,0.6964107379342845,0.8990825688073395,0.8714123688172467,1.0,4/76,1.44%,PIK3CD;PPP1R16B;ITGA4;PROX1
prerank,KEGG_2021_Human__Phosphatidylinositol signaling system,-0.48094944198835576,-0.6961328460442741,0.9769230769230769,0.9130226437703849,1.0,2/92,1.91%,PIK3CB;PLCB4
prerank,GO_Biological_Process_2021__regulation of centrosome cycle (GO:0046605),-0.4548504744059511,-0.6961129223965645,0.6129032258064516,0.9126592504159734,1.0,11/21,23.95%,CHMP2B;MARK4;CHMP4B;PDCD6IP;NAT10;CHMP1A;XRCC3;NPM1;CHMP3;FBXW5;CHMP1B
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer Metabolic Reprogramming,-0.5002927556653827,-0.6960872994267442,0.9285714285714286,0.9122917451487788,1.0,4/85,2.36%,RB1;LIPE;CD44;FBXO32
prerank,WikiPathway_2021_Human__Pathways affected in adenoid cystic carcinoma WP3651,-0.5211997353493106,-0.6960565121119612,0.872,0.9119304307626244,1.0,2/62,1.22%,KDM6A;CREBBP
prerank,Elsevier_Pathway_Collection__Oxidation of Fatty Acid in non-Alcoholic Fatty Liver Disease,0.4980760257372747,0.6958638337208123,0.7241379310344828,0.871569376447082,1.0,1/27,0.20%,PPARA
prerank,GO_Biological_Process_2021__positive regulation of neuron projection development (GO:0010976),-0.521305655747558,-0.6955433875060821,0.9173553719008265,0.9119693880473255,1.0,2/82,1.21%,PTK2B;RAP1A
prerank,WikiPathway_2021_Human__G1 to S cell cycle control WP45,0.5071154809316392,0.6955049062821314,0.8166666666666667,0.8715694402913002,1.0,4/63,0.91%,CDC45;CREB1;CDK6;TFDP2
prerank,GO_Biological_Process_2021__regulation of cellular amide metabolic process (GO:0034248),0.49749876477978294,0.6953435998142932,0.7142857142857143,0.8714393398375043,1.0,1/31,0.25%,EIF2A
prerank,Reactome_2022__Regulation Of Necroptotic Cell Death R-HSA-5675482,-0.4969602488953643,-0.6952356861924508,0.7049180327868853,0.9118025315022039,1.0,1/29,0.31%,TNFRSF10B
prerank,Elsevier_Pathway_Collection__Osteoblast Function Decline in Gout,0.4831925342643597,0.6952040488722496,0.7333333333333333,0.8712738373429935,1.0,2/24,1.69%,CREB1;SMAD9
prerank,Elsevier_Pathway_Collection__Apoptosis,0.49870434908516936,0.6949548479996519,0.8870967741935484,0.8711867865378967,1.0,5/76,1.87%,TNFRSF10A;CASP7;TNFRSF25;TNFRSF10D;BOK
prerank,WikiPathway_2021_Human__mBDNF and proBDNF regulation of GABA neurotransmission WP4829,0.4957667623343052,0.6948738285244904,0.7652173913043478,0.870966801777427,1.0,1/34,0.43%,CREB1
prerank,Elsevier_Pathway_Collection__EGFR Nuclear Signaling in Colorectal Cancer,-0.48296218486820996,-0.694416541192512,0.6428571428571429,0.9120677748299693,1.0,1/22,1.71%,STAT5A
prerank,GO_Biological_Process_2021__negative regulation of axon extension involved in axon guidance (GO:0048843),0.48404063718285717,0.6942037589042156,0.6796875,0.8712506849104577,1.0,1/20,1.60%,SEMA3G
prerank,GO_Biological_Process_2021__neurotrophin signaling pathway (GO:0038179),0.4847333421045543,0.6941604185726495,0.6637931034482759,0.8710071963936253,1.0,2/20,1.53%,SORT1;BCAR1
prerank,TRRUST_Transcription_Factors_2019__ESR1 mouse,-0.48295858283172394,-0.6941213000449357,0.7096774193548387,0.9119054221849133,1.0,1/27,1.71%,STAT5A
prerank,GO_Biological_Process_2021__cellular metal ion homeostasis (GO:0006875),-0.4933262508607725,-0.6938439742551116,0.9562043795620438,0.9117226522188379,1.0,1/91,0.67%,CCL23
prerank,GO_Biological_Process_2021__positive regulation of ossification (GO:0045778),0.48749287755085996,0.6930062521807441,0.7889908256880734,0.8717307944155834,1.0,1/37,1.25%,PKDCC
prerank,GO_Biological_Process_2021__regulation of T cell activation (GO:0050863),0.5509875272563864,0.6929778210651669,0.8739495798319328,0.8714695992866685,1.0,3/47,2.05%,CD4;THY1;LGALS3
prerank,WikiPathway_2021_Human__Signal transduction through IL1R WP4496,0.48415029980127633,0.6924542227447036,0.7230769230769231,0.8716821323424433,1.0,2/30,1.59%,IRAK2;IL1RN
prerank,KEGG_2021_Human__DNA replication,0.491495669745055,0.6923806176497671,0.75,0.8714786406699185,1.0,1/35,0.85%,POLE4
prerank,KEGG_2021_Human__beta-Alanine metabolism,0.4993069470305272,0.6923357448036697,0.71900826446281,0.8712487453659519,1.0,1/29,0.07%,SMOX
prerank,"WikiPathway_2021_Human__GPCRs, Class B Secretin-like WP334",0.4776550381885668,0.6922949625290452,0.6893939393939394,0.8709924724098463,1.0,1/22,2.24%,ADGRG2
prerank,KEGG_2021_Human__Nicotinate and nicotinamide metabolism,-0.4956517702230005,-0.6919170927190711,0.7121212121212122,0.9127741355316783,1.0,1/33,0.44%,NT5C1B
prerank,GO_Biological_Process_2021__protein monoubiquitination (GO:0006513),-0.49930610142727283,-0.69191173355368,0.7518796992481203,0.9123960704776318,1.0,1/39,0.08%,UBE3D
prerank,GO_Biological_Process_2021__receptor metabolic process (GO:0043112),-0.503863431902698,-0.6918418771884143,0.8666666666666667,0.9120681705394663,1.0,3/58,2.26%,UVRAG;NEDD4;CD9
prerank,GO_Biological_Process_2021__response to UV (GO:0009411),0.4802907780166233,0.6914124620105296,0.9763779527559056,0.8715039670695496,1.0,4/97,1.98%,BRSK1;MSH2;ATR;MAPK13
prerank,Reactome_2022__Hedgehog Ligand Biogenesis R-HSA-5358346,0.48801917003920986,0.6914111443483204,0.9035087719298246,0.8712212673917884,1.0,1/62,1.20%,PSMB9
prerank,GO_Biological_Process_2021__positive regulation of vascular endothelial growth factor production (GO:0010575),-0.48223094477499,-0.6909690192825009,0.6821705426356589,0.9123282455495523,1.0,1/23,1.78%,CYP1B1
prerank,Reactome_2022__Signaling By BRAF And RAF1 Fusions R-HSA-6802952,0.5068801268933137,0.6908808360656925,0.8211382113821138,0.8713995998433792,1.0,5/61,2.27%,TRAK1;TRIM24;PAPSS1;KSR1;FN1
prerank,Elsevier_Pathway_Collection__Endosomal Recycling,0.4910736953851192,0.6903302397677648,0.717948717948718,0.8715807592144973,1.0,1/32,0.90%,PLD1
prerank,Elsevier_Pathway_Collection__Treg-Cell Activation in Diabetes Mellitus,-0.521195538475903,-0.6902986204445068,0.8666666666666667,0.9125016705170835,1.0,3/54,2.44%,GRAP2;STAT5A;ZAP70
prerank,GO_Biological_Process_2021__regulation of postsynapse organization (GO:0099175),0.4987297154765378,0.6902931545501128,0.7016129032258065,0.8713439251835265,1.0,1/28,0.13%,ABI2
prerank,Elsevier_Pathway_Collection__SCF/SKP2 Complex,0.4933456569623963,0.690158021553415,0.7241379310344828,0.8711704952598525,1.0,1/25,0.67%,CDK6
prerank,WikiPathway_2021_Human__Unfolded protein response WP4925,0.4989224219477781,0.6901443901593278,0.6910569105691057,0.8708971897970318,1.0,1/24,0.11%,ERN1
prerank,GO_Biological_Process_2021__negative regulation of cell-matrix adhesion (GO:0001953),-0.48972849726614986,-0.6901330736653708,0.7463768115942029,0.9122488182367955,1.0,1/29,1.03%,BCAS3
prerank,Elsevier_Pathway_Collection__Alzheimer's Disease,-0.4919481804964647,-0.6900195420988015,0.9545454545454546,0.9119595815958477,1.0,2/65,0.81%,ADAM10;APP
prerank,GO_Biological_Process_2021__positive regulation of bone mineralization (GO:0030501),0.4874944158698901,0.6899424193333404,0.7931034482758621,0.8707798774230514,1.0,1/34,1.25%,PKDCC
prerank,GO_Biological_Process_2021__histone lysine demethylation (GO:0070076),-0.4991532534634336,-0.6895964723240726,0.75,0.9118754273896933,1.0,1/25,0.09%,KDM6A
prerank,TRRUST_Transcription_Factors_2019__CEBPA human,0.5107365154050285,0.6894613607063487,0.7933884297520661,0.8709183287488377,1.0,3/47,2.27%,HSD17B11;HOMER3;FN1
prerank,Elsevier_Pathway_Collection__Leukocyte Adhesion to Endothelial Cell,0.4863428918392758,0.6893776674453006,0.7586206896551724,0.8707305748843428,1.0,2/30,1.37%,ITGA4;ITGAL
prerank,GO_Biological_Process_2021__tight junction assembly (GO:0120192),0.5114500485414089,0.6893335211732841,0.8482142857142857,0.8704871405471518,1.0,3/52,1.24%,TBCD;DLG1;CRB3
prerank,Elsevier_Pathway_Collection__Vascular Smooth Muscle Cell/Pericyte Differentiation and Proliferation,-0.4795798130062682,-0.6893090814453272,0.68,0.9117196778110099,1.0,1/20,2.05%,KLF4
prerank,GO_Biological_Process_2021__positive regulation of carbohydrate metabolic process (GO:0045913),-0.49192341099660725,-0.6892190887365235,0.706766917293233,0.9114178625233147,1.0,1/22,0.81%,APP
prerank,Reactome_2022__PLC Beta Mediated Events R-HSA-112043,0.49576465276467424,0.6890479062276673,0.7264957264957265,0.8704229643387074,1.0,1/45,0.43%,CREB1
prerank,GO_Biological_Process_2021__ERBB signaling pathway (GO:0038127),0.5286972273654935,0.688949878143402,0.8145161290322581,0.8702296860214248,1.0,4/65,2.14%,PTK2;ERBB3;BCAR1;SLC30A10
prerank,Reactome_2022__Signaling By ERBB2 KD Mutants R-HSA-9664565,0.48815359835496874,0.6888219063376974,0.6585365853658537,0.8700380009727495,1.0,1/24,1.19%,ERBB3
prerank,Reactome_2022__Visual Phototransduction R-HSA-2187338,-0.4797612815057668,-0.6887538548237986,0.9701492537313433,0.911399797715024,1.0,3/83,2.03%,CYP4V2;SDC3;HSD17B6
prerank,Reactome_2022__Activation Of Pre-Replicative Complex R-HSA-68962,0.4915360815426052,0.6884216253662974,0.75,0.8701118934420266,1.0,2/31,0.85%,CDC45;POLE4
prerank,GO_Biological_Process_2021__regulation of intracellular pH (GO:0051453),0.49403599027384304,0.6883899778425834,0.7421875,0.8698573292034484,1.0,1/32,0.60%,SLC4A7
prerank,GO_Biological_Process_2021__maintenance of blood-brain barrier (GO:0035633),0.49788349217084454,0.6880383323688777,0.7165354330708661,0.8698843322021811,1.0,1/30,0.22%,TJP1
prerank,GO_Biological_Process_2021__myotube differentiation (GO:0014902),-0.49019404185789517,-0.6874651516894144,0.656,0.9119704249942205,1.0,1/19,0.99%,ADAMTS5
prerank,Reactome_2022__Formation Of HIV-1 Elongation Complex Containing HIV-1 Tat R-HSA-167200,-0.4930331260093823,-0.6873336888668763,0.7986111111111112,0.911715604936774,1.0,1/41,0.70%,NELFA
prerank,WikiPathway_2021_Human__Host-pathogen interaction of human coronaviruses - interferon induction WP4880,0.4979215379190536,0.6869093212976315,0.7175572519083969,0.8705677062616503,1.0,1/33,0.21%,TRAF3
prerank,GO_Biological_Process_2021__peptide hormone secretion (GO:0030072),0.48365546091869266,0.6868250633388429,0.7142857142857143,0.8703586473223895,1.0,1/21,1.64%,ANXA1
prerank,Reactome_2022__HDMs Demethylate Histones R-HSA-3214842,-0.49915326131625637,-0.6861638650165157,0.7235772357723578,0.9123075223055322,1.0,1/25,0.09%,KDM6A
prerank,WikiPathway_2021_Human__Head and Neck Squamous Cell Carcinoma WP4674,0.48905601681603506,0.6860652465373173,0.9032258064516129,0.870725154621677,1.0,3/73,1.10%,TRAF3;CDK6;PRKAA2
prerank,WikiPathway_2021_Human__Pathways in clear cell renal cell carcinoma WP4018,-0.4986734659554794,-0.6859715367331085,0.8870967741935484,0.9120848699548284,1.0,5/83,1.58%,ALDOB;ZEB1;CREBBP;DEPTOR;GRB10
prerank,GO_Biological_Process_2021__positive regulation of gene silencing by miRNA (GO:2000637),0.4859213947052313,0.6856269366155914,0.7196969696969697,0.8708689374807961,1.0,1/26,1.41%,MYCN
prerank,GO_Biological_Process_2021__positive regulation of lipid catabolic process (GO:0050996),0.4980764794854316,0.6854928619684929,0.6923076923076923,0.8707126614948268,1.0,1/22,0.20%,PPARA
prerank,Elsevier_Pathway_Collection__Intraflagellar Transport: Anterograde Transport,-0.47675602519517013,-0.6854665704041106,0.75,0.9120636501054091,1.0,1/37,2.33%,BBS5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Insulin Resistance,-0.4968774169927638,-0.6853180052705156,0.9043478260869565,0.911796093242247,1.0,2/77,0.32%,ALDOB;NR3C1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Breast Cancer Related to NOTCH Signaling Pathway,0.4829560840071446,0.6851707350079699,0.7383177570093458,0.8707144662588091,1.0,1/31,1.71%,CDH1
prerank,GO_Biological_Process_2021__peptidyl-tyrosine phosphorylation (GO:0018108),0.49540281871961356,0.6850170110284373,0.8976377952755905,0.8705641914194827,1.0,5/67,2.09%,ABI2;PTK2;PKDCC;SYK;PRLR
prerank,GO_Biological_Process_2021__collagen fibril organization (GO:0030199),0.4960565087963544,0.6845504999564377,0.9545454545454546,0.8707107631797033,1.0,5/88,2.41%,PLOD2;COL12A1;COL9A3;COL9A2;COL4A5
prerank,GO_Biological_Process_2021__branching morphogenesis of an epithelial tube (GO:0048754),-0.5177076756772548,-0.6845158583455699,0.8043478260869565,0.912126175428751,1.0,3/41,1.58%,SHH;BMP4;PAX8
prerank,Elsevier_Pathway_Collection__NFKB Canonical Signaling Activation in Cancer,-0.5110628254422699,-0.6845107316733998,0.8992248062015504,0.9117568576035328,1.0,3/70,2.24%,EXOC2;TNFRSF14;TNFSF14
prerank,GO_Biological_Process_2021__regulation of production of miRNAs involved in gene silencing by miRNA (GO:1903798),0.4859268316311753,0.6844634053368307,0.656934306569343,0.8705021336243958,1.0,1/17,1.41%,MYCN
prerank,GO_Biological_Process_2021__negative regulation of endothelial cell apoptotic process (GO:2000352),-0.4810753746160852,-0.6844114585813785,0.7307692307692307,0.9114402575395409,1.0,1/25,1.90%,TEK
prerank,Elsevier_Pathway_Collection__Th2-Cell Differentiation,-0.521197535002519,-0.6842776396556466,0.8484848484848485,0.9107860200474889,1.0,3/52,2.44%,GRAP2;STAT5A;ZAP70
prerank,Elsevier_Pathway_Collection__Th2-Cell Response in Asthma,-0.521197535002519,-0.6842776396556466,0.8484848484848485,0.9107860200474889,1.0,3/52,2.44%,GRAP2;STAT5A;ZAP70
prerank,GO_Biological_Process_2021__DNA replication initiation (GO:0006270),0.491533708606847,0.6842483298919521,0.823076923076923,0.870420735097593,1.0,2/38,0.85%,CDC45;POLE4
prerank,WikiPathway_2021_Human__Complement and Coagulation Cascades WP558,0.5028976993610279,0.6841277178888207,0.8449612403100775,0.8702634491126601,1.0,4/58,2.10%,PLAUR;F7;SERPINE1;SERPINA5
prerank,Reactome_2022__Activation Of ATR In Response To Replication Stress R-HSA-176187,0.4981137980098947,0.6840924314217803,0.7543859649122807,0.8700011512901867,1.0,1/35,0.19%,CDC45
prerank,Reactome_2022__G-protein Mediated Events R-HSA-112040,0.4957639083053096,0.6839634370607919,0.7606837606837606,0.8698499415170815,1.0,1/49,0.43%,CREB1
prerank,WikiPathway_2021_Human__Development of ureteric collection system WP5053,-0.5507587884121826,-0.6839149539011465,0.8571428571428571,0.9106796040877649,1.0,3/44,2.08%,SHH;BMP4;GLI3
prerank,GO_Biological_Process_2021__positive regulation of cellular metabolic process (GO:0031325),0.480095273069064,0.6836638806304208,0.975,0.8698666113891695,1.0,3/100,1.99%,PPARA;ACACA;APOE
prerank,GO_Biological_Process_2021__negative regulation of mRNA catabolic process (GO:1902373),-0.48349744895672286,-0.6836330865066219,0.7352941176470589,0.9105427520095278,1.0,1/27,1.66%,TENT5C
prerank,Elsevier_Pathway_Collection__Peripheral T-Cell Tolerance,0.49444273611825795,0.6834878772839869,0.8346456692913385,0.8697359623791241,1.0,5/58,2.29%,TNFRSF10A;TNFRSF21;TNFRSF25;NFATC2;CD86
prerank,GO_Biological_Process_2021__muscle cell development (GO:0055001),0.48280372084658696,0.6834776366832233,0.7678571428571429,0.8694625119535176,1.0,1/29,1.72%,MYOF
prerank,Elsevier_Pathway_Collection__ERBB2/3 -> EP300/ETS/ETV/SP1 Signaling,0.4881517881663688,0.6833116781209666,0.6929824561403509,0.8693481118158904,1.0,1/28,1.19%,ERBB3
prerank,WikiPathway_2021_Human__Microglia Pathogen Phagocytosis Pathway WP3937,0.5003033353221242,0.6832947565380517,0.7862595419847328,0.869079335718022,1.0,4/40,2.16%,PIK3CD;SYK;SIGLEC7;CYBA
prerank,GO_Biological_Process_2021__ventricular septum morphogenesis (GO:0060412),0.4814217978059897,0.6831117849153434,0.7317073170731707,0.868972416974904,1.0,2/26,1.86%,PROX1;ZFPM1
prerank,GO_Biological_Process_2021__purine-containing compound biosynthetic process (GO:0072522),-0.48226776135806027,-0.6830927446911772,0.7131782945736435,0.9105309634533088,1.0,1/25,1.78%,GMPR
prerank,Reactome_2022__CTNNB1 S33 Mutants Not Phosphorylated R-HSA-5358747,0.4028850330078507,0.682815110769486,0.544,0.8689558477438748,1.0,5/15,16.00%,PPP2R5B;CSNK1A1;PPP2R5D;AMER1;PPP2R5E
prerank,Reactome_2022__Circadian Clock R-HSA-400253,0.4946195242468895,0.6822805892055674,0.8770491803278688,0.8691954855610541,1.0,5/65,2.07%,TBL1X;PPARA;CREB1;F7;SERPINE1
prerank,GO_Biological_Process_2021__negative regulation of hydrolase activity (GO:0051346),-0.4897181640198916,-0.6818293395232399,0.8740157480314961,0.9112192019050068,1.0,1/53,1.03%,BCAS3
prerank,GO_Biological_Process_2021__regulation of viral genome replication (GO:0045069),0.5241315502218239,0.6816562439969697,0.859375,0.8695339210569398,1.0,2/63,1.44%,PPARA;PROX1
prerank,Elsevier_Pathway_Collection__non-Suppressive Treg-Cell in Diabetes Mellitus Type 1,-0.5212032259839269,-0.6815426214174439,0.8134328358208955,0.911073586400892,1.0,3/46,2.44%,GRAP2;STAT5A;ZAP70
prerank,GO_Biological_Process_2021__positive regulation of cell cycle phase transition (GO:1901989),-0.43337957746870454,-0.6814870241167181,0.6083333333333333,0.9107379935536893,1.0,10/16,30.42%,DDRGK1;STXBP4;CUL3;PHB2;NPM1;CDC73;FAM83D;ZNF16;ATAD5;GLI1
prerank,Elsevier_Pathway_Collection__P38 MAPK/MAPK14 Signaling,-0.4978054756489542,-0.681451132220065,0.775,0.9103867208954849,1.0,1/37,0.23%,MAP2K6
prerank,Elsevier_Pathway_Collection__Bone Remodeling in Hyperthyroidism,0.5095259306500753,0.6814296812417575,0.8230088495575221,0.8694531785331852,1.0,3/56,1.69%,CREB1;LRP5;SMAD9
prerank,GO_Biological_Process_2021__protein polymerization (GO:0051258),0.48054999343404353,0.6813673423638031,0.8956521739130435,0.8692212465186888,1.0,2/59,1.95%,UBE2C;SPIRE2
prerank,Reactome_2022__Protein-protein Interactions At Synapses R-HSA-6794362,0.4927282091589103,0.6813579632066435,0.954954954954955,0.8689429437052633,1.0,6/85,2.36%,DLG1;LIN7A;HOMER3;PPFIA4;GPRIN1;STX1A
prerank,TRRUST_Transcription_Factors_2019__PPARG human,-0.49742804329679513,-0.6809878342859376,0.889763779527559,0.9103416722986757,1.0,5/63,2.27%,POU2F1;LIPE;KLF4;CD83;CIITA
prerank,GO_Biological_Process_2021__dicarboxylic acid metabolic process (GO:0043648),0.49310617150158437,0.6808566253668218,0.8823529411764706,0.8691066262214184,1.0,2/57,0.70%,SLC19A1;MTHFS
prerank,GO_Biological_Process_2021__regulation of smoothened signaling pathway (GO:0008589),0.49122225176185175,0.680735309327796,0.875968992248062,0.8689404088782138,1.0,3/49,0.89%,MEGF8;HERC4;TTC23
prerank,GO_Biological_Process_2021__regulation of MAP kinase activity (GO:0043405),-0.4917856890363473,-0.6803783710037711,0.9375,0.9104372461794947,1.0,6/89,2.36%,PIK3CB;PTPRJ;BMP4;PIK3R6;SMPD1;IRAK3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Migraine,-0.4893026631072197,-0.6802021508193672,0.8173913043478261,0.9102067751849462,1.0,1/35,1.08%,GRIN2B
prerank,Elsevier_Pathway_Collection__VEGFA/NOTCH1/WNT Cross-talk in Blood Vessel Sprouting and Branching in Cancer,-0.49653563387084554,-0.6800629812977766,0.7857142857142857,0.9099373935036729,1.0,1/38,0.35%,ADAM10
prerank,Reactome_2022__Recruitment And ATM-mediated Phosphorylation Of Repair And Signal Proteins At DNA Double Strand Breaks R-HSA-5693565,0.4964176084895285,0.6796964440627252,0.8372093023255814,0.8695861724242046,1.0,1/54,0.36%,HERC2
prerank,Elsevier_Pathway_Collection__Intraflagellar Transport: Retrograde Transport,-0.4767569858749294,-0.6796595996337343,0.7573529411764706,0.9098477291599321,1.0,1/36,2.33%,BBS5
prerank,GO_Biological_Process_2021__positive regulation of ATPase activity (GO:0032781),-0.49792050597178555,-0.6794365642108664,0.8059701492537313,0.9096698740102583,1.0,1/41,0.22%,ALDOB
prerank,GO_Biological_Process_2021__cellular response to retinoic acid (GO:0071300),-0.4987675112267323,-0.6792854280238696,0.7708333333333334,0.9094155074383407,1.0,1/40,0.13%,PTK2B
prerank,WikiPathway_2021_Human__Mitochondrial CIV Assembly WP4922,0.49734458476787774,0.6791378321100772,0.7251908396946565,0.869791593503178,1.0,1/32,0.27%,CMC1
prerank,GO_Biological_Process_2021__positive regulation of smooth muscle cell proliferation (GO:0048661),-0.514163308275126,-0.6790757136200427,0.8712121212121212,0.90920472248513,1.0,3/46,1.93%,BMP4;RBPMS2;MMP2
prerank,TRRUST_Transcription_Factors_2019__DNMT1 human,-0.4885743269320244,-0.6790624655431602,0.7368421052631579,0.9088438116788683,1.0,2/30,1.15%,TNFRSF10B;RB1
prerank,WikiPathway_2021_Human__Apoptosis-related network due to altered Notch3 in ovarian cancer WP2864,0.5052476385477181,0.6789036187527074,0.8181818181818182,0.8697124017385738,1.0,6/53,1.99%,ERN1;PTK2;TNFRSF21;CASP7;ERBB3;APOE
prerank,Reactome_2022__Pausing And Recovery Of Tat-mediated HIV Elongation R-HSA-167238,-0.4930365995797247,-0.6788753720737996,0.7777777777777778,0.9086421009881335,1.0,1/29,0.70%,NELFA
prerank,GO_Biological_Process_2021__mitotic chromosome condensation (GO:0007076),0.49407554367907847,0.6787761675301685,0.7089552238805971,0.8695462034763687,1.0,1/27,0.60%,NCAPG
prerank,GO_Biological_Process_2021__Golgi to plasma membrane transport (GO:0006893),-0.510032298713131,-0.6787601153061076,0.8760330578512396,0.9083611356887739,1.0,3/47,1.64%,EXOC2;EXOC6B;VPS35L
prerank,GO_Biological_Process_2021__positive regulation of biomineral tissue development (GO:0070169),0.4874934587328616,0.6787358110251244,0.8018867924528302,0.8693003354321993,1.0,1/36,1.25%,PKDCC
prerank,GO_Biological_Process_2021__positive regulation of epithelial cell migration (GO:0010634),-0.48118025747686,-0.6784303007607433,0.9836065573770492,0.9082637126809253,1.0,5/94,1.90%,PTK2B;PIK3CB;BCAS3;BMP4;TEK
prerank,WikiPathway_2021_Human__Hair Follicle Development: Organogenesis - Part 2 of 3 WP2839,-0.5141386301275521,-0.6784238128958912,0.7615384615384615,0.9078951203080906,1.0,3/31,1.54%,SHH;BMP4;CCND2
prerank,WikiPathway_2021_Human__Electron Transport Chain (OXPHOS system in mitochondria) WP111,-0.49170749488552945,-0.6783624899804069,0.9333333333333333,0.9075773071682882,1.0,1/89,0.83%,NDUFS4
prerank,MSigDB_Oncogenic_Signatures__BCAT BILD ET AL UP,0.5137051588392771,0.6782640370029137,0.7777777777777778,0.8694301823411039,1.0,3/41,1.97%,SLC27A2;SLC35C2;AXIN2
prerank,GO_Biological_Process_2021__selective autophagy (GO:0061912),-0.49768758191675344,-0.678251553077306,0.852112676056338,0.9072813783090459,1.0,1/58,0.24%,KLHL3
prerank,KEGG_2021_Human__RNA degradation,-0.4934463519146808,-0.6781419049729416,0.9193548387096774,0.9069943374976052,1.0,1/76,0.66%,EDC3
prerank,GO_Biological_Process_2021__apoptotic cell clearance (GO:0043277),0.4836473789225894,0.678038464574173,0.7913043478260869,0.8693628057955644,1.0,1/32,1.64%,ANXA1
prerank,Elsevier_Pathway_Collection__Natural Killer Cell Activation through C-Type Lectin-like Receptors,0.48002961965005714,0.6780305535070932,0.8037383177570093,0.869092600239284,1.0,1/34,2.00%,NFATC2
prerank,GO_Biological_Process_2021__regulation of centrosome duplication (GO:0010824),-0.4951137934504289,-0.6779348180416157,0.7704918032786885,0.9067925180965667,1.0,1/29,0.50%,CEP120
prerank,Elsevier_Pathway_Collection__CFTR Facilitates Oxidative Stress in Airway Epithelium in CF,0.5247897344543909,0.6778199286762269,0.8888888888888888,0.8689964035238518,1.0,2/57,1.37%,CREB1;ITGAL
prerank,Elsevier_Pathway_Collection__Th2-Cells Function in Systemic Scleroderma,-0.5211946975923386,-0.6777140030490082,0.8538461538461538,0.9065822242283862,1.0,3/55,2.44%,GRAP2;STAT5A;ZAP70
prerank,GO_Biological_Process_2021__carbohydrate derivative biosynthetic process (GO:1901137),-0.4960378849430963,-0.6773842933329881,0.7142857142857143,0.9064786088377409,1.0,1/26,0.40%,ALG6
prerank,GO_Biological_Process_2021__positive regulation of protein secretion (GO:0050714),0.47880948848956223,0.6771648200383925,0.967479674796748,0.8693289227046452,1.0,3/69,2.12%,CD2AP;CD33;RBP4
prerank,WikiPathway_2021_Human__MTHFR deficiency WP4288,-0.4832693235429306,-0.6770899339104607,0.6865671641791045,0.9063391105829157,1.0,1/23,1.68%,BHMT
prerank,Elsevier_Pathway_Collection__Cancer Cells Inhibit Adipocyte Differentiation,-0.4828065498870305,-0.6768306598714349,0.7264150943396226,0.9061724020003525,1.0,1/25,1.73%,IL11RA
prerank,GO_Biological_Process_2021__anion transmembrane transport (GO:0098656),-0.4863636951232176,-0.6767845107841233,0.9130434782608695,0.9058548894077694,1.0,4/64,1.38%,SLC23A2;SLC35A3;SLC36A4;SLC7A8
prerank,GO_Biological_Process_2021__regulation of protein targeting to membrane (GO:0090313),0.4842661184804681,0.676467015313638,0.7652173913043478,0.8696612276333893,1.0,1/28,1.58%,MTCL1
prerank,GO_Biological_Process_2021__negative regulation of wound healing (GO:0061045),-0.491421028647101,-0.67631107821023,0.768,0.905835081458381,1.0,1/29,0.86%,TFPI
prerank,GO_Biological_Process_2021__homotypic cell-cell adhesion (GO:0034109),-0.4945719170099584,-0.6761289292693073,0.8088235294117647,0.9056098913010298,1.0,1/44,0.55%,PIK3CB
prerank,GO_Biological_Process_2021__actomyosin structure organization (GO:0031032),0.4820815158346747,0.6758751046676601,0.9338842975206612,0.8699701629609683,1.0,2/72,1.79%,TJP1;ITGB5
prerank,Reactome_2022__FCERI Mediated NF-kB Activation R-HSA-2871837,0.4880121924736085,0.6757757879481625,0.9322033898305084,0.8697870022138364,1.0,1/76,1.20%,PSMB9
prerank,Elsevier_Pathway_Collection__Angiogenesis in Endometriosis,0.4818614776869955,0.67571367557791,0.9067796610169492,0.8695663558112925,1.0,3/57,1.82%,PTK2;BCAR1;PTGS2
prerank,GO_Biological_Process_2021__inositol lipid-mediated signaling (GO:0048017),-0.4809808457969401,-0.6753590401292253,0.8368794326241135,0.9058314081161558,1.0,2/50,1.91%,PIK3CB;PLCB4
prerank,GO_Biological_Process_2021__phosphatidylcholine metabolic process (GO:0046470),-0.48820883497061707,-0.6752295797831794,0.952,0.9055647823679609,1.0,2/71,1.19%,ABHD3;PLAAT3
prerank,Elsevier_Pathway_Collection__Proteins Involved in Polycystic Ovary Syndrome,0.4788678478879229,0.6749963386496708,0.9769230769230769,0.8699126149222367,1.0,5/92,2.12%,NEK4;FBN3;AMH;SERPINE1;RBP4
prerank,Elsevier_Pathway_Collection__NOTCH1 Signaling in Breast Cancer,0.48299290935431083,0.6748613013607822,0.8090909090909091,0.8697383215861502,1.0,2/35,1.71%,CREB1;CDH1
prerank,Elsevier_Pathway_Collection__Neurotrophic Factor Deprivation in Retinal Ganglion Cell Death,-0.48203165228152983,-0.6747432504355989,0.7709923664122137,0.9056111162014676,1.0,2/34,1.81%,MAP2K6;NTF3
prerank,Elsevier_Pathway_Collection__T-Cell Receptor -> ATF/CREB Signaling,0.5065590964234041,0.6746736369331386,0.696,0.8696421646946334,1.0,3/32,2.29%,CREB1;CD4;CD86
prerank,GO_Biological_Process_2021__negative regulation of phosphatase activity (GO:0010923),0.4792286301326646,0.6745961693904149,0.7416666666666667,0.8694232929781194,1.0,1/26,2.08%,SH3RF2
prerank,GO_Biological_Process_2021__phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200),0.4789297176134778,0.6745768423431243,0.9333333333333333,0.8691641308504079,1.0,2/63,2.11%,LPAR1;GPR35
prerank,Reactome_2022__DNA Double Strand Break Response R-HSA-5693606,0.49641743569941005,0.6745622190528549,0.8515625,0.8688964742073078,1.0,1/55,0.36%,HERC2
prerank,GO_Biological_Process_2021__positive regulation of tumor necrosis factor superfamily cytokine production (GO:1903557),0.4944285313550668,0.6744059692695601,0.9253731343283582,0.8687689643043989,1.0,5/74,2.29%,LILRA2;NOD2;SYK;CYBA;CD86
prerank,Reactome_2022__HSF1-dependent Transactivation R-HSA-3371571,0.4904572606223771,0.6742558830177471,0.7478991596638656,0.8686343233884101,1.0,1/34,0.96%,TNFRSF21
prerank,Reactome_2022__Arachidonic Acid Metabolism R-HSA-2142753,0.4819009939982404,0.6740986441047789,0.8584070796460177,0.8685084215714236,1.0,4/56,1.82%,EPHX2;CYP4F3;PTGR1;PTGS2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Gout,0.5057714883933504,0.6739704034434528,0.75,0.8683350260665977,1.0,4/32,2.07%,PLAUR;IL1RN;HPRT1;SERPINE1
prerank,GO_Biological_Process_2021__regulation of transcription regulatory region DNA binding (GO:2000677),0.4920762169668998,0.6734245729036307,0.7217391304347827,0.8685537450008122,1.0,1/25,0.80%,NIBAN2
prerank,GO_Biological_Process_2021__transcription-coupled nucleotide-excision repair (GO:0006283),-0.49587498317413625,-0.6733632446708853,0.8907563025210085,0.9063643824916824,1.0,1/73,0.42%,POLK
prerank,GO_Biological_Process_2021__regulation of vascular endothelial growth factor production (GO:0010574),-0.4822294436830957,-0.6731358181326184,0.7142857142857143,0.9061666700182825,1.0,1/25,1.78%,CYP1B1
prerank,KEGG_2021_Human__IL-17 signaling pathway,0.4803029093965886,0.6724042309987309,0.9739130434782609,0.8691901342922015,1.0,4/81,1.98%,TRAF3;FOSL1;PTGS2;MAPK13
prerank,KEGG_2021_Human__Allograft rejection,-0.47806811244852243,-0.6722956933049388,0.7794117647058824,0.9064491234300206,1.0,1/33,2.20%,HLA-B
prerank,GO_Biological_Process_2021__aerobic electron transport chain (GO:0019646),-0.4917143398876312,-0.6722814776796487,0.9365079365079365,0.9060911228780191,1.0,1/70,0.83%,NDUFS4
prerank,GO_Biological_Process_2021__mitochondrial ATP synthesis coupled electron transport (GO:0042775),-0.49171399317629777,-0.6721266923337763,0.9435483870967742,0.9058622648790239,1.0,1/71,0.83%,NDUFS4
prerank,GO_Biological_Process_2021__regulation of ceramide biosynthetic process (GO:2000303),-0.4193540990725697,-0.6719939112110882,0.5925925925925926,0.9055978148728266,1.0,9/16,37.99%,RACK1;SAMD8;ORMDL3;SPHK1;TNF;PRKCD;PLA2G6;ENPP7;ORMDL1
prerank,GO_Biological_Process_2021__regulation of biomineral tissue development (GO:0070167),0.48330701247197616,0.671893340050905,0.7388059701492538,0.8693479478415717,1.0,1/24,1.67%,CYP27B1
prerank,GO_Biological_Process_2021__platelet aggregation (GO:0070527),-0.49457378299743715,-0.6718893330641431,0.7954545454545454,0.9053164130148093,1.0,1/36,0.55%,PIK3CB
prerank,Reactome_2022__IKK Complex Recruitment Mediated By RIP1 R-HSA-937041,-0.4101875325406863,-0.6718583298882244,0.5877862595419847,0.9049851911261738,1.0,10/22,26.62%,RIPK1;UBE2D3;UBB;UBE2D2;UBA52;BIRC2;TICAM1;TRAF6;LY96;UBE2V1
prerank,Elsevier_Pathway_Collection__Clear Cell Ovarian Carcinoma,-0.48300109574083827,-0.6717817226031026,0.9322033898305084,0.9046928305903049,1.0,3/81,1.71%,NCOA1;CREBBP;STAT5A
prerank,GO_Biological_Process_2021__striated muscle contraction (GO:0006941),0.4825199526252868,0.6716240381097534,0.8548387096774194,0.8692968888282865,1.0,1/48,1.75%,TNNC2
prerank,GO_Biological_Process_2021__chloride transport (GO:0006821),0.4788071250469341,0.6713880971079264,0.940677966101695,0.8692185150299073,1.0,1/68,2.12%,CLCN4
prerank,Reactome_2022__Formation Of HIV Elongation Complex In Absence Of HIV Tat R-HSA-167152,-0.49303249414567557,-0.6704921375225538,0.8222222222222222,0.9052665531384358,1.0,1/43,0.70%,NELFA
prerank,Reactome_2022__Transcriptional Activation Of Mitochondrial Biogenesis R-HSA-2151201,0.4958414699977537,0.6701568315398585,0.8449612403100775,0.8699186260000527,1.0,3/52,0.43%,TBL1X;PPARA;CREB1
prerank,WikiPathway_2021_Human__Matrix Metalloproteinases WP129,0.4814979587788974,0.6700980902104241,0.7565217391304347,0.8696933844837497,1.0,1/26,1.85%,TIMP3
prerank,Elsevier_Pathway_Collection__Hashimoto's Thyroiditis,0.4874889833176733,0.6697437684200936,0.872,0.8697141782880358,1.0,2/46,1.26%,CD4;SYK
prerank,WikiPathway_2021_Human__NO/cGMP/PKG mediated Neuroprotection WP4008,0.4957650620444839,0.6696866576205063,0.8448275862068966,0.8694963337827037,1.0,1/43,0.43%,CREB1
prerank,Reactome_2022__HIV Elongation Arrest And Recovery R-HSA-167287,-0.4930359682108573,-0.6694242935161445,0.7851239669421488,0.9057626877534499,1.0,1/31,0.70%,NELFA
prerank,GO_Biological_Process_2021__RNA biosynthetic process (GO:0032774),0.4995759771671563,0.6693830406242419,0.7457627118644068,0.8695085550613846,1.0,1/31,0.05%,TAF4
prerank,KEGG_2021_Human__Inositol phosphate metabolism,-0.48096366651798983,-0.6693514139268822,0.959349593495935,0.90545038066043,1.0,2/73,1.91%,PIK3CB;PLCB4
prerank,Reactome_2022__SUMOylation Of Transcription Cofactors R-HSA-3899300,-0.5212093044593535,-0.6686240831843591,0.8278688524590164,0.9057219918356755,1.0,2/42,1.22%,NCOA1;CREBBP
prerank,Elsevier_Pathway_Collection__Smooth Muscle Cell Dysfunction in Arterial Hypertension,-0.49876677924261126,-0.6685577212126504,0.835820895522388,0.9054028213812944,1.0,1/49,0.13%,PTK2B
prerank,WikiPathway_2021_Human__Envelope proteins and their potential roles in EDMD physiopathology WP4535,0.47940626671205167,0.6684514275809658,0.8771929824561403,0.8700307547516671,1.0,2/45,2.06%,MAP3K9;SYNE3
prerank,Reactome_2022__SUMOylation Of Intracellular Receptors R-HSA-4090294,0.48088116947930426,0.6684463604089554,0.75,0.8697627536717752,1.0,2/29,1.92%,PPARA;NR1I2
prerank,"GO_Biological_Process_2021__mitochondrial electron transport, NADH to ubiquinone (GO:0006120)",-0.49172504204605655,-0.6683544960012872,0.8099173553719008,0.9052236473031513,1.0,1/39,0.83%,NDUFS4
prerank,GO_Biological_Process_2021__regulation of autophagy of mitochondrion (GO:1903146),0.45374009816978467,0.6683245510645094,0.6666666666666666,0.8695710139762249,1.0,13/19,32.73%,HTT;CSNK2A2;HTRA2;FBXO7;HAX1;SREBF1;CAMKK2;PINK1;DNM1L;HDAC6;PRKN;USP36;GSK3A
prerank,"WikiPathway_2021_Human__Non-genomic actions of 1,25 dihydroxyvitamin D3 WP4341",0.4802749769045115,0.6682007437612585,0.9836065573770492,0.869412406461103,1.0,3/67,1.98%,NOD2;CYP27B1;MAPK13
prerank,GO_Biological_Process_2021__negative regulation of cell projection organization (GO:0031345),0.5042572156276028,0.6681626538514642,0.7910447761194029,0.8691807281715304,1.0,4/48,2.22%,LPAR1;APOE;DPYSL3;GFI1
prerank,KEGG_2021_Human__Mucin type O-glycan biosynthesis,0.49680574847452696,0.6679336107728533,0.7619047619047619,0.869134220962637,1.0,1/34,0.32%,ST3GAL1
prerank,WikiPathway_2021_Human__Structural Pathway of Interleukin 1 (IL-1) WP2637,-0.4978043636623795,-0.66790978662346,0.8770491803278688,0.9051900012105677,1.0,1/48,0.23%,MAP2K6
prerank,Reactome_2022__Assembly Of Collagen Fibrils And Other Multimeric Structures R-HSA-2022090,-0.47616382856735123,-0.6677629838314255,0.888,0.9049241480753869,1.0,3/55,2.39%,PCOLCE;COL4A4;COL7A1
prerank,Reactome_2022__Signaling By NOTCH2 R-HSA-1980145,-0.4965368536176571,-0.667175033740806,0.7555555555555555,0.9050017356825675,1.0,1/31,0.35%,ADAM10
prerank,KEGG_2021_Human__Autoimmune thyroid disease,-0.4780682113543122,-0.6665652334751612,0.781021897810219,0.905110579866377,1.0,1/33,2.20%,HLA-B
prerank,GO_Biological_Process_2021__ventricular cardiac muscle tissue morphogenesis (GO:0055010),0.4856508746631821,0.6663148128583202,0.765625,0.8702018298114591,1.0,1/28,1.44%,PROX1
prerank,WikiPathway_2021_Human__Metabolic reprogramming in colon cancer WP4290,-0.4979596661261192,-0.6662467732968637,0.7868852459016393,0.9049930751611897,1.0,2/42,0.22%,SUCLG2;ALDOB
prerank,Reactome_2022__Collagen Degradation R-HSA-1442490,-0.510282779647321,-0.6659606807276606,0.796875,0.9048500610848368,1.0,3/38,2.32%,ADAM10;MMP2;COL26A1
prerank,GO_Biological_Process_2021__regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0000079),0.4844654715966006,0.6656475365154744,0.9682539682539683,0.8704460013298722,1.0,2/80,1.56%,PROX1;PKMYT1
prerank,WikiPathway_2021_Human__Nuclear Receptors in Lipid Metabolism and Toxicity WP299,0.4809175917375599,0.6654676221964181,0.8048780487804879,0.8703160260062112,1.0,3/32,1.92%,PPARA;CYP27B1;NR1I2
prerank,GO_Biological_Process_2021__protein catabolic process (GO:0030163),0.5019064159460984,0.6653283473441627,0.8120300751879699,0.8701517545231646,1.0,4/57,1.99%,MANBA;TRIM24;LAMP2;APOE
prerank,Reactome_2022__IRS-mediated Signaling R-HSA-112399,-0.4945725356349855,-0.6652412496919433,0.8062015503875969,0.9050256630791655,1.0,1/40,0.55%,PIK3CB
prerank,GO_Biological_Process_2021__negative regulation of blood vessel morphogenesis (GO:2000181),0.482003777488085,0.6650949923405077,0.943089430894309,0.8700534598718663,1.0,3/74,1.81%,GTF2I;NIBAN2;PTPRM
prerank,TRRUST_Transcription_Factors_2019__ESR1 human,-0.4822756116062684,-0.6650433393605257,0.9710144927536232,0.9048344267230114,1.0,3/71,1.78%,ZEB1;MTA3;CYP1B1
prerank,GO_Biological_Process_2021__regulation of vascular associated smooth muscle cell proliferation (GO:1904705),-0.4807991066290203,-0.6649011308366244,0.7857142857142857,0.9045723077430998,1.0,2/36,1.93%,SOD2;MMP2
prerank,GO_Biological_Process_2021__sodium ion transmembrane transport (GO:0035725),0.48454214327444595,0.6647807305286336,0.9461538461538461,0.8700382575575167,1.0,1/76,1.54%,SLC6A4
prerank,GO_Biological_Process_2021__regulation of nitric oxide biosynthetic process (GO:0045428),0.481795726883607,0.6644177745684454,0.8411214953271028,0.8700731531041473,1.0,1/39,1.82%,PTGS2
prerank,GO_Biological_Process_2021__zymogen activation (GO:0031638),-0.4837563097057044,-0.6637087437520299,0.8770491803278688,0.9050829675301694,1.0,1/42,1.63%,C1R
prerank,GO_Biological_Process_2021__regulation of dendritic spine morphogenesis (GO:0061001),0.4987295874008397,0.663231138100143,0.743801652892562,0.870740367182304,1.0,1/31,0.13%,ABI2
prerank,Elsevier_Pathway_Collection__DRD2 Expression Targets,-0.497805503445027,-0.662927460288044,0.8046875,0.9052979416536646,1.0,1/38,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__epithelial cell migration (GO:0010631),0.4834896172974131,0.6627642969800538,0.8692307692307693,0.8708608278485659,1.0,2/40,1.66%,PLEKHG5;ANLN
prerank,GO_Biological_Process_2021__regulation of protein localization (GO:0032880),0.4842467798636545,0.6627635967296731,0.9098360655737705,0.8705837483614999,1.0,2/60,1.58%,DLG1;DZIP1L
prerank,GO_Biological_Process_2021__fatty acid catabolic process (GO:0009062),-0.48208430679616787,-0.6625384566838672,0.9496402877697842,0.9052090728222301,1.0,3/69,1.80%,ABCD3;ABHD3;HAO1
prerank,Reactome_2022__Selective Autophagy R-HSA-9663891,-0.49271956565092717,-0.6624626614437035,0.8852459016393442,0.9048989975460254,1.0,1/59,0.73%,TOMM70
prerank,GO_Biological_Process_2021__positive regulation of endopeptidase activity (GO:0010950),-0.489306059660338,-0.6622564455176096,0.7295081967213115,0.904696930257102,1.0,1/27,1.08%,GRIN2B
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hypoxia-Induced Pulmonary Hypertension,0.4845776969171633,0.6618191355518,0.728,0.8710329143308109,1.0,1/22,1.54%,SLC6A4
prerank,GO_Biological_Process_2021__regulation of cellular respiration (GO:0043457),-0.41655412640771283,-0.6618010615070151,0.5968992248062015,0.9046225830903485,1.0,8/15,28.15%,NOA1;NOP53;IFNAR1;PRDM16;IL10RB;VCP;IDE;SHMT2
prerank,GO_Biological_Process_2021__negative regulation of cysteine-type endopeptidase activity (GO:2000117),0.4773228846415656,0.6617543536359289,0.9133858267716536,0.8708202530321205,1.0,4/51,2.28%,FNIP1;NAIP;SH3RF1;HGF
prerank,WikiPathway_2021_Human__T-Cell Receptor and Co-stimulatory Signaling WP2583,0.4800346099112708,0.6613564468993398,0.7741935483870968,0.8708776872414993,1.0,1/28,2.00%,NFATC2
prerank,Elsevier_Pathway_Collection__Mast-Cells De Novo Synthesized Mediators via IgE Independent Signaling,0.4818439264325738,0.660450953570114,0.9752066115702479,0.8713249037154502,1.0,3/82,1.82%,CREB1;PLAUR;PTGS2
prerank,Reactome_2022__RHOBTB GTPase Cycle R-HSA-9706574,-0.49953724622247425,-0.6604096522536458,0.8076923076923077,0.9052410810976119,1.0,1/35,0.05%,PDE5A
prerank,Reactome_2022__RNA Polymerase III Chain Elongation R-HSA-73780,0.3986734975640641,0.6602951369856069,0.5939849624060151,0.8711751603009247,1.0,7/17,23.38%,POLR3E;POLR3B;CRCP;POLR3C;POLR3D;POLR2K;POLR3F
prerank,Reactome_2022__PI3K Cascade R-HSA-109704,-0.49457321850227515,-0.6599068684045125,0.8062015503875969,0.9052288866758184,1.0,1/37,0.55%,PIK3CB
prerank,GO_Biological_Process_2021__regulation of cellular protein metabolic process (GO:0032268),0.4800977486732,0.6598625953255993,0.8676470588235294,0.871215303080892,1.0,2/47,1.99%,EIF2A;APOE
prerank,Reactome_2022__RIPK1-mediated Regulated Necrosis R-HSA-5213460,-0.4969599588861932,-0.65973372831235,0.7542372881355932,0.9049675560630283,1.0,1/31,0.31%,TNFRSF10B
prerank,Reactome_2022__Role Of Nef In HIV-1 Replication And Disease Pathogenesis R-HSA-164952,0.4877672281208031,0.6594970789571166,0.7596153846153846,0.8711926522766056,1.0,1/27,1.23%,CD4
prerank,GO_Biological_Process_2021__regulation of NIK/NF-kappaB signaling (GO:1901222),0.4943102669638033,0.6586632292490892,0.911504424778761,0.8715465049095281,1.0,5/77,2.31%,DLG1;NOD2;TSPAN6;CD86;UACA
prerank,GO_Biological_Process_2021__double-strand break repair via nonhomologous end joining (GO:0006303),0.49029410256823047,0.6586608948224992,0.9076923076923077,0.8712728503236495,1.0,3/60,0.98%,HERC2;DCLRE1C;SMC5
prerank,GO_Biological_Process_2021__nucleosome organization (GO:0034728),0.4976855071777591,0.6583853271586694,0.9421487603305785,0.8712388012968099,1.0,1/75,0.23%,NAA60
prerank,Elsevier_Pathway_Collection__Growth Factor Signaling in Hepatocellular Carcinoma,-0.4829615275659205,-0.6581266326855416,0.9752066115702479,0.9056375276817465,1.0,2/81,1.71%,NRG1;STAT5A
prerank,GO_Biological_Process_2021__positive regulation of blood vessel endothelial cell migration (GO:0043536),-0.482984720652093,-0.65800484778905,0.8936170212765957,0.9053521968487757,1.0,2/47,1.71%,AKT3;STAT5A
prerank,KEGG_2021_Human__Fructose and mannose metabolism,-0.4979216914402294,-0.6579498019315789,0.8244274809160306,0.9050260916373336,1.0,1/33,0.22%,ALDOB
prerank,Elsevier_Pathway_Collection__PI3K/RAC1 Signaling,-0.4766818476963453,-0.657837522434925,0.8068965517241379,0.9047426477347554,1.0,2/36,2.34%,PIK3CB;VAV1
prerank,GO_Biological_Process_2021__positive regulation of phagocytosis (GO:0050766),-0.49021932322255657,-0.6578258257309166,0.9016393442622951,0.9043873797151382,1.0,1/51,0.98%,PTPRJ
prerank,GO_Biological_Process_2021__positive regulation of apoptotic signaling pathway (GO:2001235),0.4813605393285093,0.6576954885560309,0.9534883720930233,0.8714996947226722,1.0,2/57,1.87%,ING5;BOK
prerank,GO_Biological_Process_2021__kidney development (GO:0001822),-0.4843590186363168,-0.657444503076963,0.9538461538461539,0.9042823558882334,1.0,3/66,1.58%,SHH;BMP4;PAX8
prerank,Elsevier_Pathway_Collection__Necrosis,0.48368309328653625,0.6573974737895103,0.8195488721804511,0.8714442310768167,1.0,1/36,1.63%,LAMP2
prerank,GO_Biological_Process_2021__recombinational repair (GO:0000725),-0.4961448941829358,-0.6570358099898153,0.9590163934426229,0.9041661230190129,1.0,2/78,0.40%,REV3L;NSMCE2
prerank,Elsevier_Pathway_Collection__Vascular Endothelial Cell Vasodilation in Brain,-0.4799187003672343,-0.6567511783299038,0.7647058823529411,0.9039907181028474,1.0,1/29,2.01%,BDKRB2
prerank,KEGG_2021_Human__Graft-versus-host disease,-0.4780663923085226,-0.6565907152574192,0.8188976377952756,0.9037406965296167,1.0,1/35,2.20%,HLA-B
prerank,GO_Biological_Process_2021__DNA double-strand break processing (GO:0000729),-0.4249776244178315,-0.6565253586696259,0.5915492957746479,0.903426017377587,1.0,6/18,22.98%,BLM;DNA2;RAD52;BRCA1;RAD50;UBE2V2
prerank,Elsevier_Pathway_Collection__Neutrophil Degranulation via FPR1 Signaling,0.4785071765836407,0.6563596270904442,0.9734513274336283,0.8719113502391546,1.0,3/62,2.16%,PLD1;SYK;CYBA
prerank,Elsevier_Pathway_Collection__Complement Activation in Macular Degeneration,-0.48376518018961706,-0.6562333601378615,0.7480314960629921,0.9032609840492122,1.0,1/29,1.63%,C1R
prerank,Elsevier_Pathway_Collection__TLR4 Signaling in Leukocytes,-0.48159381465813994,-0.6561019461289612,0.8849557522123894,0.9030087358137104,1.0,2/54,1.85%,MAP2K6;TICAM2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Low-Grade Serous Ovarian Carcinoma,0.48729531895923306,0.6560849726049255,0.8444444444444444,0.8718244768750081,1.0,1/47,1.27%,NOTCH3
prerank,Elsevier_Pathway_Collection__NFKB Signaling Activation by Blocking of Tumor Suppressors,0.4979192854120896,0.6559506349620904,0.8403361344537815,0.871660820100725,1.0,1/53,0.21%,TRAF3
prerank,Reactome_2022__Metabolism Of Non-Coding RNA R-HSA-194441,0.48952590934115986,0.6558613732019047,0.8548387096774194,0.8714389451194268,1.0,1/52,1.05%,NUP210
prerank,TRRUST_Transcription_Factors_2019__CEBPA mouse,0.48180927091402254,0.6555470529394449,0.7,0.8714106070890532,1.0,1/21,1.82%,PTGS2
prerank,KEGG_2021_Human__Cysteine and methionine metabolism,0.5111636099438774,0.6555199961212826,0.860655737704918,0.8711548336453487,1.0,3/49,1.83%,MTAP;CBS;SMS
prerank,GO_Biological_Process_2021__regulation of sodium ion transport (GO:0002028),-0.4889576478030675,-0.6544171198458523,0.8130081300813008,0.9036974037873491,1.0,2/33,1.11%,WNK3;NEDD4
prerank,WikiPathway_2021_Human__Prader-Willi and Angelman Syndrome WP3998,-0.48471496554515214,-0.6527581853399629,0.9185185185185185,0.9043376605580155,1.0,3/51,1.54%,RB1;FEZ1;CCND2
prerank,GO_Biological_Process_2021__glycosphingolipid biosynthetic process (GO:0006688),-0.4164403270373034,-0.6518982180150308,0.5691056910569106,0.9045355670270252,1.0,9/15,28.75%,B4GALT6;A4GALT;ST8SIA3;ST8SIA1;ST6GALNAC3;ST6GALNAC6;LARGE1;ST8SIA6;ST8SIA5
prerank,GO_Biological_Process_2021__negative regulation of cell cycle G2/M phase transition (GO:1902750),0.48802280752503113,0.6511148993785991,0.907563025210084,0.8738196519625295,1.0,1/55,1.20%,PSMB9
prerank,Reactome_2022__Elastic Fibre Formation R-HSA-1566948,0.48210500518765353,0.650756151856306,0.8245614035087719,0.873773539922016,1.0,2/39,1.79%,FBN3;ITGB5
prerank,"GO_Biological_Process_2021__nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay (GO:0000288)",-0.49345206421721627,-0.6507227731617548,0.890625,0.9048472479424524,1.0,1/56,0.66%,EDC3
prerank,Reactome_2022__IRS-related Events Triggered By IGF1R R-HSA-2428928,-0.4945717950904445,-0.6499549804098931,0.8449612403100775,0.9049295006827153,1.0,1/43,0.55%,PIK3CB
prerank,GO_Biological_Process_2021__negative regulation of G2/M transition of mitotic cell cycle (GO:0010972),0.48801879776092283,0.6497693349200476,0.9256198347107438,0.8741393253233415,1.0,1/63,1.20%,PSMB9
prerank,GO_Biological_Process_2021__positive regulation of tumor necrosis factor production (GO:0032760),-0.5027977693439044,-0.649735548525683,0.9401709401709402,0.9046800015842174,1.0,4/71,1.59%,OAS1;APP;PTPRJ;CD2
prerank,GO_Biological_Process_2021__negative regulation of cysteine-type endopeptidase activity involved in apoptotic process (GO:0043154),0.47735892722923795,0.6495621211899105,0.9495798319327731,0.8739866574115709,1.0,5/54,2.28%,FNIP1;PLAUR;NAIP;SH3RF1;HGF
prerank,GO_Biological_Process_2021__positive regulation of actin filament polymerization (GO:0030838),-0.48521784110156996,-0.6489094181605201,0.8870967741935484,0.9047805189951406,1.0,3/47,1.49%,PTK2B;CARMIL1;HCK
prerank,GO_Biological_Process_2021__regulation of epidermal growth factor-activated receptor activity (GO:0007176),0.49269133033118157,0.6485425334207147,0.7586206896551724,0.874291112879851,1.0,1/26,0.73%,ZGPAT
prerank,GO_Biological_Process_2021__heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules (GO:0007157),0.48629926541237023,0.6474658861141799,0.8333333333333334,0.8746124027625242,1.0,1/38,1.37%,ITGAL
prerank,GO_Biological_Process_2021__positive regulation of DNA biosynthetic process (GO:2000573),-0.47966375662732463,-0.6471069292024478,0.924812030075188,0.9053794940336283,1.0,4/61,2.05%,HMBOX1;NEK7;TNKS;KLF4
prerank,Reactome_2022__IGF1R Signaling Cascade R-HSA-2428924,-0.49457158253465616,-0.6462836451826995,0.8484848484848485,0.9054403474641807,1.0,1/44,0.55%,PIK3CB
prerank,GO_Biological_Process_2021__fibroblast growth factor receptor signaling pathway (GO:0008543),-0.4770761591908462,-0.6459418195428345,0.96875,0.9052696221367307,1.0,2/68,2.30%,FLRT2;GALNT3
prerank,Reactome_2022__Signaling By Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) R-HSA-2404192,-0.49457132133509374,-0.6458983719828592,0.849624060150376,0.9049265058522232,1.0,1/45,0.55%,PIK3CB
prerank,Reactome_2022__ZBP1(DAI) Mediated Induction Of Type I IFNs R-HSA-1606322,-0.42386203521786137,-0.645417944744673,0.6583333333333333,0.9048094002199912,1.0,8/20,16.49%,RIPK1;NFKB1;RELA;DHX9;MYD88;TICAM1;NKIRAS2;TLR3
prerank,Reactome_2022__RMTs Methylate Histone Arginines R-HSA-3214858,0.49946017613390514,0.6454016830538988,0.8373983739837398,0.8754356183741026,1.0,1/40,0.06%,ARID1B
prerank,GO_Biological_Process_2021__connective tissue development (GO:0061448),-0.480759889688815,-0.645287569689372,0.847457627118644,0.9045185964642232,1.0,3/37,1.94%,CREB3L2;CD44;RORC
prerank,GO_Biological_Process_2021__icosanoid metabolic process (GO:0006690),-0.48232597041226766,-0.6452268033669146,0.9473684210526315,0.9041817911792099,1.0,4/54,1.78%,CYP2C8;GGT5;CYP4F22;CYP1B1
prerank,"KEGG_2021_Human__Glycine, serine and threonine metabolism",0.48164339908619735,0.6450538076733979,0.8934426229508197,0.8753522158485691,1.0,3/39,1.84%,MAOA;CBS;CHDH
prerank,Elsevier_Pathway_Collection__Synaptic Potentiation by PKMZ in LTP Maintenance - Active State,0.48065477823367897,0.6449809079215747,0.7540983606557377,0.8751015953552352,1.0,1/22,1.94%,IQSEC1
prerank,GO_Biological_Process_2021__cellular response to estradiol stimulus (GO:0071392),0.42116984134182806,0.6447491293535607,0.6083333333333333,0.8749106511455993,1.0,8/18,30.50%,LCOR;CCDC62;SSTR2;RUVBL2;EGFR;SFRP1;POU4F1;ZNF703
prerank,GO_Biological_Process_2021__regulation of bone mineralization (GO:0030500),0.483365444654691,0.644495431348417,0.9126984126984127,0.8747439104401526,1.0,3/54,1.67%,BCOR;PKDCC;CYP27B1
prerank,GO_Biological_Process_2021__blood circulation (GO:0008015),0.4827917530099534,0.6441232947018729,0.8717948717948718,0.8746664958813625,1.0,1/45,1.72%,MYOF
prerank,GO_Biological_Process_2021__regulation of smooth muscle cell proliferation (GO:0048660),0.48583223148452837,0.6440559805334227,0.8596491228070176,0.874417823033602,1.0,2/49,1.42%,IGFBP3;CX3CL1
prerank,WikiPathway_2021_Human__Immune response to tuberculosis WP4197,-0.49523054632953967,-0.6439536537470835,0.8050847457627118,0.9044852493407777,1.0,1/23,0.48%,OAS1
prerank,WikiPathway_2021_Human__Interactions between immune cells and microRNAs in tumor microenvironment WP4559,-0.47753528437271653,-0.6436789445052254,0.7786259541984732,0.9042537150870921,1.0,1/27,2.25%,CD274
prerank,WikiPathway_2021_Human__Oxidative phosphorylation WP623,-0.4917203859175721,-0.6426028001712136,0.896551724137931,0.9043721940051707,1.0,1/52,0.83%,NDUFS4
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Cancer-Associated Resisting to Cell Death,0.4901062961674207,0.6422223690407144,0.8805970149253731,0.8750057579923614,1.0,2/47,1.00%,TNFRSF10A;CASP7
prerank,GO_Biological_Process_2021__positive regulation of exocytosis (GO:0045921),0.49161025661256336,0.6421025178558781,0.8412698412698413,0.8747783579595362,1.0,1/37,0.84%,RAB7A
prerank,Elsevier_Pathway_Collection__Astrocytoma,0.49334108338077626,0.6420183144138101,0.84,0.8745440289605529,1.0,1/41,0.67%,CDK6
prerank,Elsevier_Pathway_Collection__MITF as a Regulator of Melanoma Cell Development,-0.4878708787340983,-0.6419237785765938,0.9051094890510949,0.904322727394367,1.0,2/53,1.22%,AKT3;CREBBP
prerank,Reactome_2022__Golgi Associated Vesicle Biogenesis R-HSA-432722,0.48994908768976453,0.6404141714433913,0.9504132231404959,0.87500976701237,1.0,2/55,1.01%,IGF2R;SORT1
prerank,Reactome_2022__RNA Polymerase I Promoter Clearance R-HSA-73854,0.492216001765692,0.6401753640117996,0.944,0.874856084090837,1.0,1/68,0.78%,TAF1B
prerank,Reactome_2022__Regulated Necrosis R-HSA-5218859,-0.4969562897392185,-0.6398402250975137,0.8846153846153846,0.9049094849545857,1.0,1/55,0.31%,TNFRSF10B
prerank,GO_Biological_Process_2021__positive regulation of cholesterol transport (GO:0032376),-0.4838408940001636,-0.6396974224852934,0.8145161290322581,0.9046096644704918,1.0,1/31,1.62%,LIPG
prerank,Reactome_2022__RNA Polymerase I Transcription Initiation R-HSA-73762,0.49222330470079917,0.639292975630957,0.8870967741935484,0.874956853963531,1.0,1/46,0.78%,TAF1B
prerank,Reactome_2022__Signaling By FGFR3 R-HSA-5654741,-0.47706613858674646,-0.6385161271096951,0.8278688524590164,0.9047459770448455,1.0,1/35,2.30%,GALNT3
prerank,GO_Biological_Process_2021__cellular response to decreased oxygen levels (GO:0036294),0.481773959306088,0.6383498764631074,0.9624060150375939,0.8750448466700081,1.0,1/67,1.82%,PTGS2
prerank,Elsevier_Pathway_Collection__Proteins Involved in Psoriasis,0.4817880103942634,0.6374437378957649,0.8934426229508197,0.8751384328758653,1.0,1/49,1.82%,PTGS2
prerank,GO_Biological_Process_2021__chromosome condensation (GO:0030261),0.4940719444757537,0.6374369991449493,0.8650793650793651,0.8748663150050969,1.0,1/41,0.60%,NCAPG
prerank,Elsevier_Pathway_Collection__Methylases in Histone Methylation Cancer,-0.3917995275048919,-0.6371623498876736,0.5583333333333333,0.9049059230096196,1.0,8/17,22.61%,PRMT1;NSD2;KMT2C;SUZ12;PRDM2;PRDM12;PRDM16;MECOM
prerank,GO_Biological_Process_2021__positive regulation of Notch signaling pathway (GO:0045747),0.49103081159270023,0.6370809543187096,0.8818897637795275,0.8747058619017376,1.0,1/44,0.90%,NOD2
prerank,GO_Biological_Process_2021__regulation of embryonic development (GO:0045995),-0.49369023674244517,-0.6369262701133532,0.8203125,0.9046413597622286,1.0,2/32,0.64%,WDPCP;NR2C2
prerank,Reactome_2022__Positive Epigenetic Regulation Of rRNA Expression R-HSA-5250913,0.4922176735990668,0.6366119283153127,0.9302325581395349,0.874589246564349,1.0,1/63,0.78%,TAF1B
prerank,GO_Biological_Process_2021__positive regulation of actin filament bundle assembly (GO:0032233),0.48583164661681155,0.6350264634429302,0.9310344827586207,0.874840826262862,1.0,2/50,1.42%,LPAR1;CX3CL1
prerank,GO_Biological_Process_2021__regulation of toll-like receptor signaling pathway (GO:0034121),0.4778448609067309,0.6339219848594013,0.7424242424242424,0.8749174098292645,1.0,1/25,2.22%,GFI1
prerank,Elsevier_Pathway_Collection__Dendritic Cells Function in Psoriasis,0.49792091085849677,0.6337965226509947,0.8373983739837398,0.874679617120052,1.0,1/39,0.21%,TRAF3
prerank,Elsevier_Pathway_Collection__VEGFR -> ATF/CREB/ELK-SRF Signaling,-0.4978056300667285,-0.6305769506225329,0.8270676691729323,0.9063836532226895,1.0,1/37,0.23%,MAP2K6
prerank,GO_Biological_Process_2021__ATP synthesis coupled proton transport (GO:0015986),0.4377073748376746,0.6299607397508018,0.6666666666666666,0.875542481919877,1.0,8/18,21.27%,VPS9D1;ATP5MC3;ATP5F1A;ATP5F1D;ATP5PB;DMAC2L;ATP5MC1;ATP5MG
prerank,TRRUST_Transcription_Factors_2019__STAT6 human,0.4818000296281062,0.628514822978746,0.8067226890756303,0.8756708939260016,1.0,1/33,1.82%,PTGS2
prerank,Reactome_2022__Deadenylation-dependent mRNA Decay R-HSA-429914,-0.49345323426149074,-0.6269602048183408,0.8968253968253969,0.9070505023927392,1.0,1/52,0.66%,EDC3
prerank,GO_Biological_Process_2021__positive regulation of DNA replication (GO:0045740),-0.41946734251018264,-0.6269593645197798,0.6190476190476191,0.9066919844076038,1.0,8/17,25.59%,NPM2;DHX9;BCAR3;EGF;DNA2;BRPF3;PCNA;ATAD5
prerank,GO_Biological_Process_2021__myeloid cell differentiation (GO:0030099),0.48140282754680297,0.6242362409465435,0.8955223880597015,0.8764089840420022,1.0,2/52,1.86%,PTPN2;ZFPM1
prerank,GO_Biological_Process_2021__positive regulation of DNA metabolic process (GO:0051054),0.47727452651636887,0.624235185961205,0.972972972972973,0.8761344198239439,1.0,3/62,2.28%,SMCHD1;WRAP53;HGF
prerank,GO_Biological_Process_2021__positive regulation of cell-matrix adhesion (GO:0001954),0.48533563621447134,0.6202682554696387,0.9203539823008849,0.876677690030358,1.0,4/43,1.48%,CDK6;THY1;CX3CL1;RIN2
prerank,GO_Biological_Process_2021__negative regulation of nervous system development (GO:0051961),-0.39974078053026585,-0.6194811448802152,0.6173913043478261,0.9080355663780459,1.0,9/17,35.27%,CCL11;NOTCH1;PCM1;APPL2;ELAPOR2;TNF;IL1B;DYNLT1;IL6
prerank,GO_Biological_Process_2021__ribosomal small subunit assembly (GO:0000028),0.41381125018424747,0.6191500543620394,0.6412213740458015,0.8766058066007427,1.0,9/16,31.20%,RPS14;RPS27L;RPS27;PWP2;MRPS11;XRCC5;MRPS7;RPS15;PRKDC
prerank,GO_Biological_Process_2021__positive regulation of activated T cell proliferation (GO:0042104),-0.39970835497103613,-0.6182311016760689,0.6433566433566433,0.9079235457978638,1.0,11/19,31.80%,IL12B;IGF1;FADD;HMGB1;HHLA2;IGF2;IGFBP2;TMIGD2;IL12RB1;CD24;RPS3
prerank,WikiPathway_2021_Human__Kisspeptin/kisspeptin receptor system in the ovary WP4871,0.48360789158932815,0.616457739515845,0.8548387096774194,0.8768110398889761,1.0,2/36,1.64%,PIK3CD;AMH
prerank,GO_Biological_Process_2021__heart looping (GO:0001947),-0.4767971913935387,-0.6144386830531581,0.8976377952755905,0.9082837351456814,1.0,2/36,2.33%,SHH;BBS5
prerank,Reactome_2022__Signaling By ALK Fusions And Activated Point Mutants R-HSA-9725370,-0.48298064080702635,-0.6137370871691489,0.9465648854961832,0.9080659024702308,1.0,2/53,1.71%,BIRC6;STAT5A
prerank,GO_Biological_Process_2021__positive regulation of isotype switching (GO:0045830),0.3598656149818915,0.6117785719226654,0.5688073394495413,0.8773184380495724,1.0,8/15,32.19%,CD40;PAXIP1;HMCES;KMT5C;CLCF1;TP53BP1;TNFSF13;MAD2L2
prerank,GO_Biological_Process_2021__regulation of protein localization to cell surface (GO:2000008),-0.4818010874437587,-0.6102198436163723,0.859375,0.9083158158816299,1.0,1/32,1.83%,KCNAB2
prerank,GO_Biological_Process_2021__positive regulation of TOR signaling (GO:0032008),0.49357290836104634,0.6079658882292331,0.888,0.8776371716618234,1.0,2/39,0.65%,CLEC16A;FNIP1
prerank,WikiPathway_2021_Human__Glycosaminoglycan degradation WP4815,-0.3608360150356915,-0.605022914740434,0.5833333333333334,0.9088437404457043,1.0,7/17,23.55%,HYAL2;GLB1;HPSE;NAGLU;HYAL1;HGSNAT;SGSH
prerank,Reactome_2022__Formation Of ATP By Chemiosmotic Coupling R-HSA-163210,0.40322852279468924,0.6039023530312576,0.6466165413533834,0.8779767829818373,1.0,7/16,21.27%,ATP5MC3;ATP5F1A;ATP5F1D;ATP5PB;DMAC2L;ATP5MC1;ATP5MG
prerank,Reactome_2022__RNA Polymerase III Transcription Initiation From Type 1 Promoter R-HSA-76061,0.39523018117469305,0.6004474636982481,0.7007874015748031,0.8782262813822889,1.0,11/27,23.38%,GTF3C2;POLR3E;GTF3C5;POLR3B;CRCP;POLR3C;POLR3D;POLR2K;GTF3C4;GTF3A;POLR3F
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA damage recognition (GO:0000715)",-0.41165631569630334,-0.5958335729475674,0.6944444444444444,0.9100414664193137,1.0,12/23,28.35%,UBB;COPS4;CETN2;CUL4A;UBA52;COPS2;COPS6;GPS1;RAD23B;DDB2;DDB1;XPA
prerank,GO_Biological_Process_2021__B cell proliferation (GO:0042100),0.36524564517242075,0.592102401082523,0.625,0.8792437528884792,1.0,8/16,30.94%,CD40;CD40LG;GAPT;PTPRC;HSPD1;BCL2;MEF2C;MS4A1
prerank,GO_Biological_Process_2021__tRNA metabolic process (GO:0006399),0.3816577889668178,0.5913912204682242,0.6229508196721312,0.8790799767656429,1.0,9/18,29.20%,RPP21;KARS1;POP5;SLFN13;POP7;FARS2;ADAT1;AARS1;SARS1
prerank,GO_Biological_Process_2021__sulfur compound transport (GO:0072348),0.42937053766587047,0.5900439303491916,0.7796610169491526,0.8790285733976612,1.0,11/28,20.30%,SLC35F3;SLC19A2;SLC26A6;SLC25A14;SLC26A8;SLC25A26;SLC6A13;SLC9A3R1;SLC26A11;MGST1;SLC35B2
prerank,GO_Biological_Process_2021__positive regulation of natural killer cell mediated cytotoxicity (GO:0045954),-0.3894771462479768,-0.5891878398458988,0.635036496350365,0.9109143913605724,1.0,12/18,39.79%,AP1G1;LAMP1;IL12B;CD226;HLA-E;HLA-F;RAET1E;NCR3;SLAMF6;KLRK1;IL12A;NECTIN2
prerank,GO_Biological_Process_2021__electron transport chain (GO:0022900),0.38321989239324994,0.5890675979271164,0.6821705426356589,0.8789056520546957,1.0,7/15,20.33%,SDHB;ENOX2;ETFRF1;PPARGC1A;NDOR1;POR;NDUFA5
prerank,GO_Biological_Process_2021__midbody abscission (GO:0061952),-0.3610424713223684,-0.5885306076576122,0.6333333333333333,0.9106528802330192,1.0,10/17,30.94%,CHMP2B;CHMP4B;PDCD6IP;CHMP1A;CHMP6;CEP55;CHMP3;CHMP1B;MITD1;VPS4B
prerank,GO_Biological_Process_2021__mitochondrial ATP synthesis coupled proton transport (GO:0042776),0.3997770872712474,0.5858303222813996,0.6641221374045801,0.8791839237904265,1.0,7/17,21.27%,ATP5MC3;ATP5F1A;ATP5F1D;ATP5PB;DMAC2L;ATP5MC1;ATP5MG
prerank,TRRUST_Transcription_Factors_2019__NFKBIA human,-0.3884515896917807,-0.5842306306989767,0.6666666666666666,0.9111109996358497,1.0,9/18,28.16%,NFKB1;PON2;RELA;ICAM1;MMP1;FAS;TRAF1;IL1B;S100A6
prerank,GO_Biological_Process_2021__non-motile cilium assembly (GO:1905515),-0.40902601660071924,-0.5833446549156517,0.7333333333333333,0.9109107023446527,1.0,13/29,19.76%,BBS4;BBS1;TMEM17;DISC1;ARL13B;TOGARAM1;TMEM216;GORAB;CSNK1D;CEP290;PCM1;VANGL2;IFT57
prerank,GO_Biological_Process_2021__positive regulation by host of viral transcription (GO:0043923),-0.35372036577587773,-0.5833111596569502,0.6267605633802817,0.9105579092761459,1.0,8/16,35.66%,ZNF639;CHD1;SP1;HPN;SMARCA4;TFAP4;LEF1;RRP1B
prerank,Reactome_2022__Membrane Binding And Targetting Of GAG Proteins R-HSA-174490,-0.3783705626255527,-0.5817446185136211,0.680672268907563,0.9105022570742709,1.0,7/15,25.68%,UBB;UBA52;VPS37A;TSG101;VPS28;VPS37B;SGIP1
prerank,WikiPathway_2021_Human__MAP3K1 role in promoting and blocking gonadal determination WP4872,0.3233272447502849,0.580296404559183,0.5772357723577236,0.8799261060933758,1.0,3/15,6.67%,RHOA;MAPK1;GADD45G
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA duplex unwinding (GO:0000717)",-0.37602690679521883,-0.5799034224494259,0.6484375,0.9104827019630819,1.0,10/22,28.35%,UBB;CETN2;CUL4A;GTF2H2;UBA52;ERCC3;RAD23B;DDB2;DDB1;XPA
prerank,GO_Biological_Process_2021__protein peptidyl-prolyl isomerization (GO:0000413),-0.4006948950875121,-0.5762599999168587,0.6612903225806451,0.9108582069960905,1.0,8/20,25.10%,PPWD1;PPIF;NKTR;PPIG;PPIL2;FKBP1B;PPIA;FKBP1A
prerank,"GO_Biological_Process_2021__positive regulation of mRNA splicing, via spliceosome (GO:0048026)",0.3496552211457027,0.5724645660588071,0.6416666666666667,0.881165403976313,1.0,6/16,25.46%,TRA2A;RBMX;THRAP3;CELF4;RBMXL1;CELF3
prerank,GO_Biological_Process_2021__autophagy of nucleus (GO:0044804),0.3335283328427945,0.5719275695269695,0.6147540983606558,0.8809943290945429,1.0,8/16,37.84%,WDR45;ATG12;ATG7;ATG5;ATG13;ULK1;WDR45B;ATG2A
prerank,GO_Biological_Process_2021__positive regulation of G2/M transition of mitotic cell cycle (GO:0010971),0.4048524132113394,0.5717837099103986,0.6637931034482759,0.880742117022431,1.0,10/19,33.01%,CDK1;DBF4B;MECP2;STOX1;DTL;RCC2;FBXO5;RAB11A;CDC25A;CDC25B
prerank,Reactome_2022__TNFR1-induced NFkappaB Signaling Pathway R-HSA-5357956,-0.39710565897571126,-0.5699151499101563,0.717948717948718,0.9118957231417673,1.0,11/26,23.40%,RIPK1;TAB2;USP4;TRADD;RACK1;RBCK1;BIRC2;TNFAIP3;SHARPIN;TRAF1;TNF
prerank,Reactome_2022__Regulation Of TP53 Activity Thru Methylation R-HSA-6804760,0.3614574677067851,0.5695684391995706,0.6186440677966102,0.8808821515863248,1.0,7/19,19.87%,PRMT5;EHMT1;SETD9;CHEK2;TTC5;JMY;L3MBTL1
prerank,Reactome_2022__RNA Polymerase III Transcription Initiation From Type 2 Promoter R-HSA-76066,0.37784702289222777,0.5691938259655519,0.717741935483871,0.8806861269304286,1.0,10/26,23.38%,GTF3C2;POLR3E;GTF3C5;POLR3B;CRCP;POLR3C;POLR3D;POLR2K;GTF3C4;POLR3F
prerank,KEGG_2021_Human__Glycosaminoglycan degradation,-0.3430655651239579,-0.5688532387560938,0.6074766355140186,0.9117703814100298,1.0,7/18,23.55%,HYAL2;GLB1;HPSE;NAGLU;HYAL1;HGSNAT;SGSH
prerank,GO_Biological_Process_2021__purine ribonucleoside monophosphate biosynthetic process (GO:0009168),-0.3743504323389872,-0.568783808515166,0.6259541984732825,0.911422235170799,1.0,8/16,29.41%,AMPD1;PAICS;PFAS;IMPDH2;GMPS;ATIC;ADSS2;AMPD3
prerank,GO_Biological_Process_2021__regulation of glycogen biosynthetic process (GO:0005979),-0.3797402712816243,-0.5665889220448633,0.6752136752136753,0.9115462879743466,1.0,9/23,18.44%,IRS2;DYRK2;PPP1R3G;IGF1;INSR;PPP1R3E;IRS1;IGF2;SELENOS
prerank,Elsevier_Pathway_Collection__Proteins with Altered Expression in Aging,-0.37601904366007244,-0.5661786421495465,0.6517857142857143,0.9112718230900437,1.0,8/19,25.06%,IGF1;GLB1;SPRY2;BECN1;ELN;NF1;TNF;COL1A1
prerank,GO_Biological_Process_2021__neuron cell-cell adhesion (GO:0007158),0.3566262141981997,0.5651004758644929,0.6206896551724138,0.8813005043262284,1.0,7/16,21.78%,NLGN2;NINJ2;NLGN3;NRXN1;NCAM2;CDK5R1;NRXN3
prerank,GO_Biological_Process_2021__fatty acid beta-oxidation using acyl-CoA oxidase (GO:0033540),0.31410198150043067,0.5628054785483931,0.6446280991735537,0.881533968028159,1.0,3/15,6.69%,DECR2;CRAT;CROT
prerank,Reactome_2022__MAP3K8 (TPL2)-dependent MAPK1/3 Activation R-HSA-5684264,-0.33429840979319914,-0.5614593308737608,0.608,0.9120250397339446,1.0,4/16,15.19%,NFKB1;UBB;UBA52;CUL1
prerank,Reactome_2022__RNA Polymerase I Promoter Opening R-HSA-73728,-0.37461129130918935,-0.5601255004804178,0.6747967479674797,0.9119662442633624,1.0,8/22,20.41%,H2BC9;H2BC17;H2BC5;H2BC13;H2AC6;UBTF;H2AZ1;H2AZ2
prerank,GO_Biological_Process_2021__regulation of calcium ion transmembrane transporter activity (GO:1901019),-0.39987124651565553,-0.5551451724946286,0.7603305785123967,0.9127614339752576,1.0,12/27,25.10%,JPH1;JPH3;CACNB2;STRIT1;HPCA;FKBP1B;CACNB4;PRKACA;NOS1;HRC;PDE4D;FKBP1A
prerank,WikiPathway_2021_Human__Mitochondrial LC-Fatty Acid Beta-Oxidation WP368,-0.36068499340977533,-0.5546797092898349,0.7054263565891473,0.9125269790555154,1.0,4/17,9.76%,CPT2;ACADM;SCP2;PECR
prerank,GO_Biological_Process_2021__positive regulation of muscle hypertrophy (GO:0014742),-0.3523366794884908,-0.5529574782663547,0.6666666666666666,0.912560562858492,1.0,10/17,30.95%,MEF2A;IGF1;PDE9A;NR4A3;HAND2;ROCK1;MYMK;SLC9A1;PRKCA;MTPN
prerank,GO_Biological_Process_2021__positive regulation of T cell cytokine production (GO:0002726),-0.34012944095237857,-0.550409056625089,0.6328125,0.9128577303146186,1.0,11/20,31.22%,TNFSF4;XCL1;RSAD2;TRAF6;FZD5;IL1B;MALT1;IL1R1;HLA-A;CD55;CD81
prerank,WikiPathway_2021_Human__Kallmann's Syndrome WP5074,0.36917124516525546,0.5492724200908397,0.6694915254237288,0.8844036024132292,1.0,9/19,27.85%,FGFR1;MAPK1;FRS2;SOX10;GRB2;PTPN11;PRKCQ;AKT1;PLXND1
prerank,GO_Biological_Process_2021__negative regulation of small molecule metabolic process (GO:0062014),-0.3330531245989354,-0.5467783601197391,0.6194029850746269,0.9134664587677717,1.0,6/18,24.15%,CLK2;PGP;BCKDK;C1QTNF3;DKKL1;SIK1
prerank,Reactome_2022__Constitutive Signaling By Ligand-Responsive EGFR Cancer Variants R-HSA-1236382,-0.3559170127464374,-0.5446940815845264,0.65,0.9136458181404054,1.0,5/18,14.84%,UBB;PIGU;UBA52;EGF;NRAS
prerank,WikiPathway_2021_Human__Platelet-mediated interactions with vascular and circulating cells WP4462,0.3564094208974728,0.5444782660749526,0.6904761904761905,0.8852846927565862,1.0,6/17,19.80%,CD40;TLR4;CD40LG;SELE;CCL5;VCAM1
prerank,WikiPathway_2021_Human__Leptin Insulin Overlap WP3935,-0.31864371364710575,-0.5429515923193942,0.6615384615384615,0.91376989578551,1.0,6/15,22.69%,IRS2;SOCS2;INSR;PIK3R3;IRS1;DGKZ
prerank,WikiPathway_2021_Human__Interactome of polycomb repressive complex 2 (PRC2)  WP2916,0.3411926307033549,0.5415863792487784,0.6722689075630253,0.8857207644481037,1.0,9/16,30.07%,RBBP7;RBBP4;THRAP3;EED;STK38;MORC3;MTF2;EZH1;TRIM35
prerank,Reactome_2022__Assembly Of HIV Virion R-HSA-175474,-0.36090503974860133,-0.5413665637622289,0.7583333333333333,0.9138277324846412,1.0,8/17,25.68%,UBB;UBA52;VPS37A;TSG101;VPS28;PPIA;VPS37B;SGIP1
prerank,GO_Biological_Process_2021__regulation of steroid biosynthetic process (GO:0050810),0.31341791618608233,0.537704979482234,0.6587301587301587,0.8865044855516251,1.0,15/15,68.68%,BMP5;AKR1C3;ASAH1;CYP7A1;NR5A1;CES1;DGKQ;NR1H4;SIRT1;FGFR4;WNT4;CGA;EGR1;STAR;BMP2
prerank,WikiPathway_2021_Human__Mitochondrial complex III assembly WP4921,-0.34644026617476037,-0.5360445989475086,0.7196969696969697,0.9148993361542646,1.0,7/15,28.73%,TTC19;UQCC1;UQCRC2;UQCC3;UQCC2;UQCRB;LYRM7
prerank,Reactome_2022__mTORC1-mediated Signaling R-HSA-166208,-0.36821941142358827,-0.5348907436928267,0.7063492063492064,0.9148988560318233,1.0,8/24,13.21%,RRAGC;EIF4G1;RPS6;RHEB;EIF4B;LAMTOR2;LAMTOR3;SLC38A9
prerank,GO_Biological_Process_2021__regulation of early endosome to late endosome transport (GO:2000641),0.31520091717162313,0.5341650829956589,0.6239316239316239,0.8871606072372986,1.0,7/18,19.13%,MAPK1;VPS11;DENND10;SNX12;MSN;EZR;DAB2
prerank,WikiPathway_2021_Human__Proteoglycan biosynthesis WP4784,-0.31397041735275716,-0.5340396788428514,0.6456692913385826,0.9147868889158948,1.0,4/17,10.79%,B3GAT3;EXT1;EXTL3;PAPSS2
prerank,GO_Biological_Process_2021__peptidyl-proline modification (GO:0018208),-0.3760427142289864,-0.5335974305179177,0.7076923076923077,0.9145566859992362,1.0,7/25,14.72%,PPWD1;PPIF;NKTR;PPIG;PPIL2;FKBP10;FKBP1B
prerank,Elsevier_Pathway_Collection__APC/C-FZR1 Complex,0.3564651292657604,0.5324321612288357,0.7218045112781954,0.8873596973336815,1.0,12/23,31.57%,CDK1;ANAPC5;CDC23;ANAPC11;ANAPC7;ANAPC4;AURKA;ANAPC13;ANAPC2;CDC16;CDC25A;ANAPC10
prerank,GO_Biological_Process_2021__cellular glucuronidation (GO:0052695),-0.35074945823653253,-0.5313384482080347,0.6985294117647058,0.9147846421582099,1.0,8/16,30.06%,UGT2A3;UGT2B17;UGT1A1;ABHD10;UGT2B28;UGT2B4;UGT2B15;UGT1A5
prerank,GO_Biological_Process_2021__acidic amino acid transport (GO:0015800),0.31080921003500595,0.5306242708152961,0.6476190476190476,0.8875670395488796,1.0,6/17,20.98%,SLC6A13;ARL6IP5;SLC9A3R1;SLC25A13;SLC25A12;SLC1A1
prerank,"Reactome_2022__Tristetraprolin (TTP, ZFP36) Binds And Destabilizes mRNA R-HSA-450513",0.3226871701152159,0.5262275441401942,0.6747967479674797,0.8885431931774861,1.0,9/17,31.05%,EXOSC4;EXOSC9;XRN1;MAPKAPK2;YWHAB;DCP2;EXOSC2;DCP1A;EXOSC7
prerank,Reactome_2022__Assembly Of Active LPL And LIPC Lipase Complexes R-HSA-8963889,0.35222056690816017,0.5224404815473398,0.6946564885496184,0.8893485381843366,1.0,11/19,32.85%,MBTPS2;FGF21;LMF2;ANGPTL8;LPL;FURIN;ANGPTL3;APOA4;CIDEC;PCSK6;PCSK5
prerank,Reactome_2022__Meiotic Recombination R-HSA-912446,-0.36604412440533324,-0.5197131274307237,0.8571428571428571,0.9178980798301266,1.0,16/42,24.50%,H2BC9;H2BC17;H2BC5;CDK2;HID1;H2BC13;H2AC6;POLR1A;BLM;PSMC3IP;H2AZ1;BRCA1;RAD50;H2AZ2;BRCA2;MSH5
prerank,GO_Biological_Process_2021__homologous chromosome segregation (GO:0045143),0.33884820960340817,0.5194582645141662,0.6610169491525424,0.8899246574903638,1.0,7/17,25.93%,CENPC;MEI4;SIRT7;KASH5;ANKRD31;SGO1;RNF212B
prerank,Elsevier_Pathway_Collection__SOCS in Negative Feedback Regulation in Myocarditis,0.3198692151283915,0.5183904786482869,0.7111111111111111,0.8899678208452187,1.0,6/17,21.61%,STAT3;SOCS1;TYK2;IFNGR2;IFNGR1;IFNG
prerank,Elsevier_Pathway_Collection__Insulin Resistance in Myocytes Induced by Obesity,0.4079501842460852,0.517522272840728,0.872,0.8899203601433556,1.0,21/39,28.63%,APPL1;ACSL1;FABP3;TLR4;STAT3;SOCS1;PPARGC1A;SREBF1;MAP3K7;SLC2A1;CAMKK2;SLC2A4;RPS6KB1;MAPK8;STK11;PRKCQ;AKT1;PIK3R1;SOCS6;CXCL5;CXCR2
prerank,Reactome_2022__VLDLR Internalisation And Degradation R-HSA-8866427,-0.3113595258135359,-0.5172507329782122,0.6666666666666666,0.9183760430925314,1.0,5/16,16.20%,UBB;UBA52;AP2M1;NR1H2;NR1H3
prerank,Reactome_2022__Beta-catenin Phosphorylation Cascade R-HSA-196299,0.30832975868956225,0.5171450297370845,0.6611570247933884,0.8897712127092055,1.0,5/17,16.00%,PPP2R5B;CSNK1A1;PPP2R5D;AMER1;PPP2R5E
prerank,GO_Biological_Process_2021__vasculature development (GO:0001944),0.35439491507397536,0.5166893260385804,0.7,0.8896263365615397,1.0,7/17,22.80%,FLT4;FOXF1;STRA6;CDH5;STK11;ERRFI1;ACVR2B
prerank,Reactome_2022__DNA Methylation R-HSA-5334118,-0.34061564069891265,-0.5161455132302307,0.704,0.9183783313561676,1.0,8/24,20.41%,H2BC9;H2BC17;H2BC5;H2BC13;H2AC6;UHRF1;H2AZ1;H2AZ2
prerank,Reactome_2022__Signaling By ERBB2 ECD Mutants R-HSA-9665348,-0.31630874635435124,-0.5160253679202331,0.7094017094017094,0.9180647881277695,1.0,4/15,14.84%,PIGU;EGF;ERBIN;NRAS
prerank,Reactome_2022__Diseases Associated With Glycosylation Precursor Biosynthesis R-HSA-5609975,-0.34767215532776863,-0.5150802998225591,0.6764705882352942,0.9180191533794156,1.0,6/15,21.20%,PMM2;DPM1;NUS1;GALE;DPM3;GNE
prerank,GO_Biological_Process_2021__cilium-dependent cell motility (GO:0060285),0.3263495912977806,0.5143424156457607,0.6640625,0.8900510862032389,1.0,10/21,27.06%,DNAH3;DNAH8;DNAH1;DNAAF2;TEKT1;CFAP54;CCDC65;EFHC1;DNAH7;RSPH9
prerank,GO_Biological_Process_2021__regulation of T cell cytokine production (GO:0002724),-0.3283246968706707,-0.5138900557661865,0.7109375,0.9180270662043596,1.0,11/19,30.41%,TNFSF4;TRPM4;SMAD7;XCL1;TRAF6;FZD5;HLA-F;MALT1;HLA-A;CLC;CD55
prerank,Reactome_2022__RNA Polymerase III Transcription Termination R-HSA-73980,0.3278819352251401,0.5127842213971213,0.7,0.8902904264152877,1.0,7/21,23.38%,POLR3E;POLR3B;CRCP;POLR3C;POLR3D;POLR2K;POLR3F
prerank,Elsevier_Pathway_Collection__Transcription Factors in beta-Cell Neogenesis (Rodent Model),0.3118031393687595,0.5120932362148151,0.717391304347826,0.8902582474025386,1.0,5/15,18.40%,FOXA2;MNX1;ONECUT1;NEUROD1;MAFB
prerank,GO_Biological_Process_2021__positive regulation of cell communication (GO:0010647),0.3542836609765588,0.511609306781833,0.6982758620689655,0.8901356593265932,1.0,11/20,31.88%,ANK3;ILK;DLG4;EDN1;NMB;LGI1;HOMER1;RIMS3;GRIK2;CDKN2AIP;GATA3
prerank,GO_Biological_Process_2021__regulation of transport (GO:0051049),0.36681562597451617,0.5112718551921518,0.8728813559322034,0.8899575157482498,1.0,13/35,19.37%,WWC1;TMEM102;ACTG1;EPB41;DISP3;TRAT1;CDK5;NRP1;YRDC;ARL6IP5;PINK1;SNCA;CLDN19
prerank,Reactome_2022__VEGFR2 Mediated Cell Proliferation R-HSA-5218921,-0.3261258463848919,-0.5106528524553184,0.6717557251908397,0.9187481897837242,1.0,8/18,30.07%,AHCYL1;ITPR3;NRAS;SPHK1;SRC;PRKCD;PLCG1;PRKCA
prerank,Reactome_2022__Spry Regulation Of FGF Signaling R-HSA-1295596,-0.2998254683502566,-0.5099934065729888,0.6842105263157895,0.9185912885674481,1.0,4/16,11.41%,UBB;PPP2CB;UBA52;SPRY2
prerank,GO_Biological_Process_2021__sarcomere organization (GO:0045214),0.3535582244261512,0.50991762783573,0.7338709677419355,0.8901326324004432,1.0,9/25,20.10%,TCAP;WDR1;MYLK3;MYOM2;CSRP2;LMOD2;BMP10;KRT19;MYOZ2
prerank,TRRUST_Transcription_Factors_2019__VHL human,0.3434500900771314,0.5095974548356627,0.7286821705426356,0.8899712790526606,1.0,11/19,40.53%,CXCR4;CA12;BHLHE40;DAB2;KLF10;CA9;TP53;VEGFA;IGF1R;AR;HIF1A
prerank,WikiPathway_2021_Human__Imatinib and Chronic Myeloid Leukemia WP3640,0.3270379649057225,0.5090590783912885,0.6771653543307087,0.8898711632470966,1.0,4/20,7.69%,PIM2;BCR;CSF1R;ABCB1
prerank,GO_Biological_Process_2021__protein localization to endoplasmic reticulum (GO:0070972),-0.3200298665642002,-0.5082057784010203,0.7401574803149606,0.9188100277059287,1.0,5/16,14.78%,DDRGK1;GBF1;RYR2;LRRK2;MIA3
prerank,Elsevier_Pathway_Collection__Ca2+ Toxicity in Lens Cells,-0.34106288395480233,-0.507956202567556,0.712,0.9185395165785293,1.0,10/24,25.01%,RYR3;PDGFRB;CASR;ATP2A3;EGF;ATP2B1;CRYGS;MCU;CAPN10;SRC
prerank,WikiPathway_2021_Human__Cholesterol Biosynthesis Pathway WP197,-0.319520888083817,-0.5066441028361562,0.7345132743362832,0.9186471812485154,1.0,5/15,17.88%,HMGCS1;CYP51A1;MVD;DHCR7;HMGCR
prerank,WikiPathway_2021_Human__Inhibition of exosome biogenesis and secretion by Manumycin A in CRPC cells WP4301,-0.3160685460948077,-0.5065047637496247,0.6744186046511628,0.9183386137816947,1.0,8/18,29.28%,RAB5C;PDCD6IP;NRAS;RAB5B;RAB27A;ARAF;RAF1;HNRNPH1
prerank,Reactome_2022__Listeria Monocytogenes Entry Into Host Cells R-HSA-8876384,-0.34398940307764925,-0.5057033355437146,0.6721311475409836,0.9182683836114759,1.0,10/19,31.42%,UBB;SH3GL2;FZR1;UBA52;CBLL1;SH3GL1;SRC;SH3KBP1;RNMT;SH3GL3
prerank,GO_Biological_Process_2021__resolution of meiotic recombination intermediates (GO:0000712),-0.31916389503968495,-0.5054953872899438,0.7007874015748031,0.9179834557343882,1.0,5/16,17.30%,FANCM;HFM1;MUS81;TOP2B;SHOC1
prerank,Reactome_2022__Regulation Of TNFR1 Signaling R-HSA-5357905,-0.3821144230411088,-0.5034527054634366,0.8245614035087719,0.9182894301260488,1.0,15/35,25.48%,RIPK1;MADD;USP4;TRADD;RACK1;UBB;UBA52;RBCK1;FADD;BIRC2;TNFAIP3;SHARPIN;TRAF1;TNF;SPPL2B
prerank,GO_Biological_Process_2021__neuronal action potential (GO:0019228),0.32696853863987824,0.5033372219592899,0.7230769230769231,0.8913935371973534,1.0,6/19,15.46%,KCNMB2;CACNA1I;ANK3;SCN11A;CACNA1G;SCN3A
prerank,GO_Biological_Process_2021__positive regulation of heart rate (GO:0010460),-0.3066692478752443,-0.503260261010169,0.6693548387096774,0.9179924137887863,1.0,7/16,28.05%,TRPM4;RYR2;ADRB1;HRC;PDE4D;KCNQ1;TPM1
prerank,Elsevier_Pathway_Collection__Leptin Role in Endometriosis,0.2979244965464053,0.5012808994075781,0.734375,0.8917985071499794,1.0,7/17,28.45%,MAPK1;STAT3;MYC;GRB2;PTPN11;LEPR;LEP
prerank,WikiPathway_2021_Human__Airway smooth muscle cell contraction WP4962,0.29384706953299744,0.5005389512740979,0.6637168141592921,0.8917465068829293,1.0,3/15,8.75%,PPP1CB;RHOA;RYR1
prerank,Reactome_2022__Aggrephagy R-HSA-9646399,-0.34246768264526367,-0.4984346365490738,0.6791044776119403,0.9193187431239173,1.0,10/23,30.28%,UBB;ARL13B;UBA52;DYNLL2;PARK7;DYNC1LI2;VCP;UBE2V1;DYNC1I1;HSP90AA1
prerank,GO_Biological_Process_2021__negative regulation of androgen receptor signaling pathway (GO:0060766),0.3106657579504311,0.49542643368319356,0.7288135593220338,0.8932002778465381,1.0,5/15,22.96%,FOXH1;HEYL;DAB2;HDAC1;SFRP1
prerank,Elsevier_Pathway_Collection__TRRAP/TIP60 in Chromatin Remodeling,0.32316205306324197,0.49358814428095094,0.672566371681416,0.8935918287573313,1.0,7/22,20.90%,KAT2A;MRGBP;RUVBL1;TRRAP;RUVBL2;MAD2L1;NPAT
prerank,Elsevier_Pathway_Collection__Oxygen Shortage in Myocardial Ischemia,-0.31197296998611285,-0.49256431065376527,0.6850393700787402,0.9211329768253834,1.0,5/16,9.18%,SLC2A12;TNNC1;CACNB2;MYBPC3;RYR2
prerank,GO_Biological_Process_2021__global genome nucleotide-excision repair (GO:0070911),-0.33958223199521953,-0.4896845048426717,0.7235772357723578,0.9218509147572932,1.0,14/26,33.45%,UBB;CETN2;CUL4A;GTF2H2;UBA52;ERCC3;ERCC1;RAD23B;DDB2;DDB1;XPA;USP45;ERCC2;RNF111
prerank,GO_Biological_Process_2021__neuron projection extension (GO:1990138),0.36410862035990843,0.4891676844937484,0.8198198198198198,0.8948347076668012,1.0,18/32,33.07%,LLPH;USP9X;NLGN3;IQGAP1;CDK5;NRP1;SEMA3F;ALCAM;CYFIP1;FLRT1;NRP2;SEMA3A;FLRT3;MAP1B;HSP90AB1;ULK1;EIF2AK4;SLC9A6
prerank,GO_Biological_Process_2021__regulation of calcium-mediated signaling (GO:0050848),0.3189406628475296,0.484631014077414,0.7142857142857143,0.8962542907590109,1.0,10/25,21.49%,HTT;P2RX5;TRAT1;CMKLR1;CDH13;P2RX4;P2RX2;PLCG2;CLEC7A;SLC8A2
prerank,GO_Biological_Process_2021__endoplasmic reticulum to cytosol transport (GO:1903513),-0.2923882502219749,-0.4844209391886171,0.6551724137931034,0.9235303919201172,1.0,8/15,29.83%,HERPUD1;DERL2;SEL1L;SELENOS;UFD1;VCP;TMEM129;NPLOC4
prerank,GO_Biological_Process_2021__metallo-sulfur cluster assembly (GO:0031163),0.3217836828410445,0.4841586451492129,0.7456140350877193,0.8961566421928263,1.0,15/22,39.25%,ISCA1;FXN;LYRM4;CIAO1;HSPA9;NDOR1;CIAPIN1;NFU1;NFS1;ISCU;ABCB7;NUBP1;NUBP2;GLRX5;CIAO2B
prerank,GO_Biological_Process_2021__mucosal immune response (GO:0002385),0.3112786372681781,0.48379493092235853,0.6971830985915493,0.8960382692727975,1.0,10/20,32.75%,DEFB1;DEFA3;IFNL2;LTF;PLA2G1B;CAMP;APOA4;IFNLR1;RAB17;PIGR
prerank,GO_Biological_Process_2021__negative regulation of ubiquitin-protein transferase activity (GO:0051444),0.32568656643053256,0.4837545286178392,0.7520661157024794,0.89578283342427,1.0,8/15,32.19%,RPL23;BAG5;BAG2;RPL5;MAD2L1;FBXO5;ABL1;MAD2L2
prerank,GO_Biological_Process_2021__protein exit from endoplasmic reticulum (GO:0032527),-0.32558212286836624,-0.48272474439869717,0.76,0.9238130492233066,1.0,13/24,29.83%,HERPUD1;DERL2;SEL1L;TECPR2;SELENOS;UFD1;SURF4;VCP;TMED9;MAP1LC3C;TMEM129;LMAN1;NPLOC4
prerank,Reactome_2022__MyD88 Deficiency (TLR2/4) R-HSA-5602498,-0.2962294595092223,-0.4825890870911436,0.6967213114754098,0.9235145866080875,1.0,7/17,26.14%,FGB;TIRAP;MYD88;BTK;HMGB1;FGG;LY96
prerank,Reactome_2022__Glucuronidation R-HSA-156588,-0.3349337315838612,-0.4819181311789759,0.7785714285714286,0.9233990088919936,1.0,11/22,30.06%,UGT2A3;UGT3A2;UGP2;UGT2B17;UGT1A1;ABHD10;UGT2B28;UGT2B4;UGT2B15;UGT2B10;UGT1A5
prerank,Elsevier_Pathway_Collection__NF-kB Signaling Activation in Huntington Disease,0.299982450676827,0.4816771670466033,0.717741935483871,0.8963459625408279,1.0,3/15,7.83%,HTT;CASP3;BCL2L1
prerank,Reactome_2022__PKA Activation In Glucagon Signaling R-HSA-164378,0.3007529303124334,0.4814084300119845,0.7083333333333334,0.8961916473982333,1.0,8/15,34.32%,ADCY5;PRKAR2B;GNAS;ADCY6;ADCY1;PRKACB;ADCY9;ADCY8
prerank,GO_Biological_Process_2021__iron-sulfur cluster assembly (GO:0016226),0.3175967327241335,0.4807146211620034,0.7350427350427351,0.8961938115496685,1.0,15/23,39.25%,ISCA1;FXN;LYRM4;CIAO1;HSPA9;NDOR1;CIAPIN1;NFU1;NFS1;ISCU;ABCB7;NUBP1;NUBP2;GLRX5;CIAO2B
prerank,GO_Biological_Process_2021__tRNA 5'-end processing (GO:0099116),0.2755769365878881,0.47796502850285194,0.7716535433070866,0.8969250816446572,1.0,4/15,12.74%,RPP21;POP5;POP7;RPP14
prerank,GO_Biological_Process_2021__membrane depolarization during cardiac muscle cell action potential (GO:0086012),-0.31060418297025005,-0.4778025140866839,0.7175572519083969,0.9246597110179122,1.0,5/17,9.65%,KCNJ2;CACNA1D;CACNB2;TRPM4;SCN4B
prerank,GO_Biological_Process_2021__membrane depolarization (GO:0051899),0.3475237988152907,0.4777265610632717,0.8189655172413793,0.8967444522358992,1.0,18/28,37.42%,YWHAH;CACNA1I;SCN1B;SCN11A;CHRNA4;P2RX4;CACNA1G;SCN3A;KCNH2;SCN5A;ABL1;CACNG4;SCN8A;SCN3B;ATP5IF1;SCN4A;CACNA1E;P2RX7
prerank,GO_Biological_Process_2021__dendritic cell chemotaxis (GO:0002407),0.2907133784893593,0.47603833876939305,0.6964285714285714,0.897123908805099,1.0,6/16,20.21%,CXCR4;CCL19;TRPM2;CCL5;CCR2;CCR5
prerank,Elsevier_Pathway_Collection__FXN Role in Friedreich Ataxia Progression,0.3161605950761336,0.47589477473973896,0.7741935483870968,0.8969018625025719,1.0,9/17,33.41%,SDHB;FXN;LYRM4;HSPA9;HSPD1;NFS1;TP53;ISCU;EPAS1
prerank,Elsevier_Pathway_Collection__NOTCH -> RBPJ/HES/HEY Signaling,0.29363358034290765,0.4742734925618685,0.7131782945736435,0.8972478740145625,1.0,6/16,23.75%,ADAM17;DVL1;CIR1;HEY1;HDAC1;DLL1
prerank,Elsevier_Pathway_Collection__P2RY1/2/4/6 -> Potassium Channels,-0.32439503958135074,-0.4742457549429437,0.7589285714285714,0.9258036663287711,1.0,5/16,18.02%,KCNJ2;P2RY1;KCNJ5;P2RY2;KCNJ4
prerank,GO_Biological_Process_2021__rRNA catabolic process (GO:0016075),0.29812350906910123,0.4733370573118359,0.7416666666666667,0.8973118715254887,1.0,5/18,15.24%,EXOSC4;SLFN13;DIS3L;EXOSC9;XRN1
prerank,GO_Biological_Process_2021__myofibril assembly (GO:0030239),0.3541587760062448,0.47305561988742856,0.8412698412698413,0.8971327817547986,1.0,15/38,22.34%,TCAP;WDR1;KLHL41;TMOD1;MYLK3;PGM5;MYOM2;CSRP2;LMOD2;BMP10;KRT19;LMOD1;MYOZ2;TMOD2;FLII
prerank,GO_Biological_Process_2021__positive regulation of smooth muscle cell migration (GO:0014911),-0.31483788560470605,-0.47265052775695,0.7153284671532847,0.9260658396147374,1.0,6/17,19.72%,DOCK7;PDGFRB;IGF1;MDK;NR4A3;AIF1
prerank,Elsevier_Pathway_Collection__SELE -> ELK-SRF Signaling,0.29445750340540333,0.47228620434650315,0.7,0.897185731061841,1.0,6/17,21.12%,MAPK1;SELE;ELK1;MAPKAPK2;GRB2;PTPN11
prerank,Elsevier_Pathway_Collection__Proteins Involved in Graves Disease,-0.31152208258144576,-0.47183407375780645,0.6814814814814815,0.9260637789603953,1.0,9/18,30.29%,TAB2;ICAM1;IGF1;CXCL10;FAS;TNF;IL1B;TSHR;IFIH1
prerank,GO_Biological_Process_2021__beta-catenin destruction complex disassembly (GO:1904886),0.3135227876818442,0.47160399685050775,0.7,0.8971944844529945,1.0,6/19,18.12%,CSNK1A1;WNT1;APC;DVL1;AMER1;LRP6
prerank,KEGG_2021_Human__Phototransduction,-0.3298912523177693,-0.4703566150660291,0.7463768115942029,0.9263501380507183,1.0,7/19,20.02%,GNAT2;PDE6A;PDE6G;RCVRN;GNAT1;RGS9;GUCA1B
prerank,Reactome_2022__IRAK4 Deficiency (TLR2/4) R-HSA-5603041,-0.29115751609670043,-0.46836457095249046,0.7295081967213115,0.9268416270735299,1.0,7/18,26.14%,FGB;TIRAP;MYD88;BTK;HMGB1;FGG;LY96
prerank,GO_Biological_Process_2021__protein quality control for misfolded or incompletely synthesized proteins (GO:0006515),-0.3167811201870365,-0.46808383427271,0.7355371900826446,0.9266136070446975,1.0,13/25,29.75%,FBXL17;NGLY1;ATXN3;STUB1;CUL3;CLPP;LONP1;UFD1;ZER1;VCP;RNF185;KLHL15;TOR1A
prerank,Elsevier_Pathway_Collection__Endothelial Cell Dysfunction in Progressive Diabetic Nephropathy,0.3226502252957979,0.467010248917051,0.7567567567567568,0.8987691718303493,1.0,8/26,19.23%,KDR;SMAD4;FLT4;MAPK1;STAT3;MYC;GRB2;TGFBR2
prerank,Elsevier_Pathway_Collection__Androgen Induced Sebocyte Hyperfunction,-0.27337953610912735,-0.46630138132239995,0.7603305785123967,0.9270638492017386,1.0,6/16,28.26%,SRD5A1;FGF10;IGF1;IRS1;HSD3B2;FGF7
prerank,Reactome_2022__Zinc Transporters R-HSA-435354,0.30516658222901955,0.4641283776723371,0.7586206896551724,0.8997084335093155,1.0,5/16,15.60%,SLC39A8;SLC30A3;SLC39A3;SLC30A1;SLC39A14
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, preincision complex assembly (GO:0006294)",-0.3235216766623064,-0.4620150353694034,0.8095238095238095,0.9285800631521817,1.0,12/29,29.05%,UBB;CETN2;CUL4A;GTF2H2;UBA52;RPA2;ERCC3;RAD23B;DDB2;DDB1;XPA;CCNH
prerank,Elsevier_Pathway_Collection__TNFRSF6 -> HSF1 Signaling,-0.2656211677020321,-0.4617128806931421,0.8270676691729323,0.9283434902136911,1.0,5/15,20.09%,MAP2K7;TRADD;MAP3K1;MAP2K2;FAS
prerank,GO_Biological_Process_2021__cellular response to zinc ion (GO:0071294),-0.2777309226426703,-0.4610155910886195,0.7902097902097902,0.9282998390851205,1.0,7/15,26.12%,MT1A;MT1HL1;MT1B;MT3;ATP13A2;HVCN1;MT1H
prerank,Reactome_2022__Late Endosomal Microautophagy R-HSA-9615710,-0.3162965770881827,-0.4601205972665687,0.7685185185185185,0.9283851175544386,1.0,12/29,24.90%,CHMP2B;UBB;CHMP4B;ARL13B;UBA52;VPS37A;CHMP6;TSG101;VPS28;PARK7;PLIN2;VPS37B
prerank,GO_Biological_Process_2021__positive regulation of signaling (GO:0023056),0.32568500984317067,0.45926700326848546,0.8035714285714286,0.9015681809354786,1.0,14/29,32.07%,NSF;ILK;DLG4;SNCA;ECE1;EDN1;NMB;LGI1;HOMER1;RIMS3;GRIK2;CDKN2AIP;GATA3;VAMP3
prerank,GO_Biological_Process_2021__neuromuscular process (GO:0050905),-0.27255893113036145,-0.459130794399158,0.72,0.9284879620715124,1.0,7/15,28.50%,CHRND;UBA5;TIFAB;PRRT2;MYCBP2;CLN3;AGTPBP1
prerank,Reactome_2022__Budding And Maturation Of HIV Virion R-HSA-162588,-0.3249354556670764,-0.45834065108748806,0.7719298245614035,0.9284809111952013,1.0,12/27,25.68%,CHMP2B;UBB;CHMP4B;PDCD6IP;UBA52;VPS37A;CHMP6;TSG101;VPS28;PPIA;VPS37B;SGIP1
prerank,GO_Biological_Process_2021__natural killer cell mediated immunity (GO:0002228),-0.29970978417298927,-0.4582941328870558,0.7627118644067796,0.9281458985089183,1.0,11/18,37.64%,PLEKHM2;TUBB4B;SLAMF7;KIR3DL1;ULBP1;ULBP2;KIF5B;GZMB;RAET1E;ARL8B;KLRK1
prerank,GO_Biological_Process_2021__positive regulation of lipid storage (GO:0010884),0.32543387451615785,0.45811574678333333,0.7627118644067796,0.9018209367211538,1.0,8/19,22.44%,PLIN3;EHD1;FITM2;C3;OSBPL11;HILPDA;MSR1;LPL
prerank,GO_Biological_Process_2021__nucleocytoplasmic transport (GO:0006913),-0.31873947915106615,-0.45658928955235767,0.8064516129032258,0.9285345614904897,1.0,19/39,29.24%,RITA1;SNRPF;SNRPD1;XPO1;RGS14;RSRC1;NPM1;HTATIP2;BACH2;ANP32A;GEMIN7;NUP205;SNUPN;SNRPG;ATXN1;MALT1;SNRPD2;NXT1;DDX20
prerank,KEGG_2021_Human__Asthma,-0.3099680590275644,-0.4535443888237691,0.775,0.9295851279127543,1.0,12/23,30.45%,CCL11;HLA-DMB;HLA-DRA;FCER1A;HLA-DRB1;HLA-DOB;TNF;HLA-DQB1;EPX;MS4A2;FCER1G;HLA-DRB5
prerank,GO_Biological_Process_2021__mRNA methylation (GO:0080009),-0.2865722787468754,-0.45268526477439397,0.822429906542056,0.9296101550759155,1.0,7/15,23.68%,CMTR1;TRMT61A;CBLL1;NSUN2;METTL14;PCIF1;ZC3H13
prerank,WikiPathway_2021_Human__Simplified Depiction of MYD88 Distinct Input-Output Pathway WP3877,-0.28724150329257314,-0.45266597910462325,0.7445255474452555,0.9292603385234316,1.0,7/16,32.47%,TLR10;NFKB1;MYD88;TRAF6;UBE2V1;TLR5;IRAK1
prerank,GO_Biological_Process_2021__regulation of stem cell proliferation (GO:0072091),0.26960213795981186,0.4520575796028145,0.75,0.9043568667772011,1.0,8/15,33.41%,ZFP36L1;EPCAM;PTPRC;YAP1;TERT;AGO3;HMGA2;KDM1A
prerank,GO_Biological_Process_2021__positive regulation of signaling receptor activity (GO:2000273),0.32718546808334853,0.4517234609359855,0.8442622950819673,0.9042104956915701,1.0,14/36,23.62%,ADAM17;NLGN3;TAF1;BTC;NRP1;HDAC2;CCR2;HDAC1;BUD31;IFNG;ARC;ADRA2A;ADRB2;EDN1
prerank,GO_Biological_Process_2021__negative regulation of sequestering of calcium ion (GO:0051283),-0.3083663431124214,-0.45162466196884077,0.732824427480916,0.9293774504306364,1.0,10/23,21.46%,RYR3;HTR2A;ITPR3;XCL1;RYR2;CCL21;CHERP;CCR7;IBTK;ANXA6
prerank,Reactome_2022__Synthesis Of PIPs At Golgi Membrane R-HSA-1660514,0.28800998897287694,0.45148078349612464,0.7727272727272727,0.9040380485609136,1.0,8/16,35.47%,PIK3C2A;PIK3C3;PI4KB;TPTE2;PIK3R4;PIK3C2G;ARF3;INPP5E
prerank,Elsevier_Pathway_Collection__Li-Fraumeni Syndrome,0.2872714866033389,0.45027145679874464,0.6991869918699187,0.9043750947467271,1.0,10/19,32.74%,APAF1;CASP3;BCL2L1;CHEK2;CCNE1;BBC3;BCL2;CYCS;CDC25A;TP53
prerank,GO_Biological_Process_2021__mesenchyme morphogenesis (GO:0072132),-0.2812005932494007,-0.44989103877403364,0.7565217391304347,0.9298284461523467,1.0,10/16,36.19%,NOTCH1;SOX9;NOS3;SMAD2;ACVRL1;NOG;BMP2;ACVR1;MDM4;TGFB2
prerank,Reactome_2022__InlB-mediated Entry Of Listeria Monocytogenes Into Host Cell R-HSA-8875360,-0.2685022586643828,-0.44984141022251095,0.7258064516129032,0.929491112467116,1.0,4/15,14.71%,UBB;SH3GL2;UBA52;SH3GL1
prerank,GO_Biological_Process_2021__calcium-independent cell-cell adhesion via plasma membrane cell-adhesion molecules (GO:0016338),0.2876910206576543,0.44945523378771973,0.7424242424242424,0.9044352978270335,1.0,7/18,35.00%,CLDN18;CLDN19;CLDN4;CLDN1;CLDN10;CLDN6;CLDN12
prerank,WikiPathway_2021_Human__Serotonin Receptor 2 and ELK-SRF/GATA4 signaling WP732,-0.29105268225112185,-0.4486857339959969,0.7049180327868853,0.9296512361199876,1.0,5/19,15.70%,HTR2A;ELK4;RASGRF1;NRAS;MAP2K2
prerank,GO_Biological_Process_2021__vacuolar acidification (GO:0007035),0.30239496081486483,0.44820631514356213,0.7962962962962963,0.9047307395747154,1.0,7/20,26.36%,ATP6V0D1;SLC11A1;CCDC115;ATP6AP2;CLN5;ATP6V0A1;DMXL2
prerank,GO_Biological_Process_2021__chaperone-mediated protein complex assembly (GO:0051131),-0.28620829205459075,-0.44820098991547525,0.7730496453900709,0.9295195147322336,1.0,6/21,11.67%,CCT2;PFDN6;BBS12;PTGES3;APCS;PTGES3L
prerank,GO_Biological_Process_2021__protein deacylation (GO:0035601),-0.28007817836934124,-0.44773758878775965,0.7443609022556391,0.9294148951637586,1.0,9/23,30.72%,LYPLA2;ABHD17B;SIRT6;SIRT2;ABHD10;HDAC3;LYPLA1;HDAC4;ABHD17A
prerank,GO_Biological_Process_2021__release of sequestered calcium ion into cytosol (GO:0051209),-0.31713571098043747,-0.44701926257113156,0.7666666666666667,0.9294007743848741,1.0,11/25,21.39%,SLC8B1;RYR3;HTR2A;ITPR3;XCL1;RYR2;CCL21;CHERP;CCR7;LETM1;IBTK
prerank,Elsevier_Pathway_Collection__Toll-like Receptors in Pyelonephritis,-0.2965553012304416,-0.44692191322278185,0.7899159663865546,0.9290925786085323,1.0,11/18,35.86%,NFKB1;TIRAP;MYD88;TRAF6;TNF;IL1B;TLR5;IRAK1;NFKBIA;IL6;CD14
prerank,GO_Biological_Process_2021__regulation of programmed necrotic cell death (GO:0062098),-0.290655735686674,-0.4465556982947621,0.7777777777777778,0.9289316051454578,1.0,5/20,14.57%,RIPK1;PDCD6IP;PELI1;BIRC2;STUB1
prerank,WikiPathway_2021_Human__Overview of interferons-mediated signaling pathway WP4558,0.2898496637730592,0.44514961682094273,0.7461538461538462,0.9058526514196147,1.0,9/19,29.81%,IFNL2;TYK2;IFNGR2;IFNGR1;IFNG;PIK3R1;IFNL1;IFNAR2;IFNLR1
prerank,Reactome_2022__Cytosolic tRNA Aminoacylation R-HSA-379716,0.3063068630291498,0.44332143755663883,0.7913669064748201,0.9065214890647352,1.0,12/24,29.69%,AIMP2;KARS1;NARS1;RARS1;AIMP1;EEF1E1;YARS1;EPRS1;CARS1;AARS1;SARS1;MARS1
prerank,GO_Biological_Process_2021__antibacterial humoral response (GO:0019731),0.3087149952562509,0.4427910802670391,0.8031496062992126,0.906477865565082,1.0,9/28,18.19%,DEFB1;DEFA3;CTSG;LTF;SLPI;SFTPD;PLA2G1B;WFDC3;CAMP
prerank,Reactome_2022__Synthesis Of PIPs At Early Endosome Membrane R-HSA-1660516,-0.29453041924470014,-0.44198046787682754,0.8016528925619835,0.9307482508317269,1.0,9/16,35.75%,VAC14;MTM1;MTMR2;MTMR12;INPP4B;MTMR4;PIKFYVE;INPP4A;PI4K2A
prerank,GO_Biological_Process_2021__regulation of catabolic process (GO:0009894),-0.28689351821056197,-0.4416981767774716,0.7480314960629921,0.9305328690618156,1.0,8/18,26.74%,ZDHHC2;HPGD;ITGB1;CHMP6;RARRES2;CENATAC;FAM83D;SNF8
prerank,GO_Biological_Process_2021__regulation of triglyceride biosynthetic process (GO:0010866),-0.25056821165241117,-0.4411374823786554,0.8305084745762712,0.9304712048735173,1.0,6/15,25.83%,CNEP1R1;NR1H2;NR1H3;GPLD1;SIK1;MFSD2A
prerank,"GO_Biological_Process_2021__maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000466)",-0.2734203944946939,-0.4410166084456368,0.7007874015748031,0.9301833853401694,1.0,8/22,23.42%,UTP20;NOP9;EXOSC8;EXOSC3;RPS21;RPP40;FTSJ3;NOP14
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Systemic Scleroderma,-0.2637535214874902,-0.44035576346357236,0.7967479674796748,0.9301649712814778,1.0,6/15,25.51%,TNFSF4;NOS3;PTPN22;TNF;CD19;TGFB1
prerank,WikiPathway_2021_Human__Physiological and pathological hypertrophy of the heart WP1528,0.30711366882319785,0.4398070663964015,0.7983870967741935,0.90766417531327,1.0,12/25,30.75%,RHOA;MAPK1;STAT3;CTF1;PRKCE;MAPK8;CAMK2D;PPP3CA;EDN1;AGT;LIFR;CALM2
prerank,GO_Biological_Process_2021__rRNA methylation (GO:0031167),-0.2997673854137697,-0.43680459032956925,0.78125,0.9316090383768705,1.0,8/22,26.16%,EMG1;TRMT112;METTL15;MRM1;TFB1M;FTSJ3;MRM3;FBL
prerank,GO_Biological_Process_2021__regulation of ryanodine-sensitive calcium-release channel activity (GO:0060314),-0.294272715850882,-0.43630075298269855,0.7426470588235294,0.9315336089129099,1.0,10/24,26.37%,JPH1;JPH3;FKBP1B;PRKACA;SRI;NOS1;HRC;PDE4D;FKBP1A;CASQ2
prerank,Elsevier_Pathway_Collection__IL6R -> CEBP/ELK/SRF Signaling,0.2824785835863458,0.43607427340788574,0.7768595041322314,0.9091739711227426,1.0,5/17,21.12%,MAPK1;ELK1;MAPKAPK2;GRB2;PTPN11
prerank,GO_Biological_Process_2021__rRNA modification (GO:0000154),-0.28351044530130987,-0.43542143750432033,0.7681159420289855,0.9316128418430736,1.0,8/21,27.97%,TSR3;TRMT112;NAT10;NOP10;TFB1M;FTSJ3;FBL;NHP2
prerank,GO_Biological_Process_2021__negative regulation of response to endoplasmic reticulum stress (GO:1903573),-0.2954185582175609,-0.4351687914847108,0.8145161290322581,0.9313882979084109,1.0,9/25,19.20%,HERPUD1;RACK1;LRRK2;UBXN1;NR1H2;ALOX5;NR1H3;SELENOS;PARK7
prerank,GO_Biological_Process_2021__DNA unwinding involved in DNA replication (GO:0006268),0.27497106837554813,0.43470097831781945,0.8145161290322581,0.9095347173651089,1.0,7/16,24.76%,RPA1;RECQL4;MCMDC2;PURA;SSBP1;TWNK;RECQL
prerank,WikiPathway_2021_Human__GABA receptor Signaling WP4159,0.29163043145746353,0.4324376884598517,0.776,0.9103936195568924,1.0,9/25,24.25%,AP2A2;GABBR2;GABRE;GABRQ;AP2A1;GABRA4;SLC6A11;GABRG3;GABRB3
prerank,"Reactome_2022__Sensory Perception Of Sweet, Bitter, And Umami (Glutamate) Taste R-HSA-9717207",-0.2709191642102316,-0.4324321655796363,0.8260869565217391,0.932540875699437,1.0,6/20,17.83%,ITPR3;TRPM4;SCN4B;GNB3;SCN2A;PLCB2
prerank,GO_Biological_Process_2021__positive regulation of cell cycle G2/M phase transition (GO:1902751),0.30700473487618046,0.43184436665377063,0.7560975609756098,0.9104202509420057,1.0,10/22,33.01%,CDK1;DBF4B;MECP2;STOX1;DTL;RCC2;FBXO5;RAB11A;CDC25A;CDC25B
prerank,Elsevier_Pathway_Collection__SIRT7 Signaling in Aging,0.2864022721845854,0.4312565342802284,0.7984496124031008,0.9104317729717053,1.0,5/15,15.80%,CDK1;PPARGC1A;POLR1E;SIRT7;MYBBP1A
prerank,Elsevier_Pathway_Collection__FAS Mediated Apoptosis in Systemic Scleroderma,-0.2874005234033621,-0.4309426071497642,0.8015873015873016,0.9329298342639676,1.0,7/15,27.17%,RIPK1;MAP2K7;BAX;CASP2;FAS;TNF;IL1B
prerank,GO_Biological_Process_2021__positive regulation of mRNA processing (GO:0050685),0.2982410503473524,0.4302524777225637,0.7699115044247787,0.910636694908746,1.0,7/21,25.46%,TRA2A;RBMX;THRAP3;PAF1;CELF4;RBMXL1;CELF3
prerank,WikiPathway_2021_Human__Cori Cycle WP1946,0.2715597195198061,0.4300254536216297,0.7795275590551181,0.9104739936009432,1.0,4/15,18.68%,TPI1;SLC2A1;SLC2A4;PGK1
prerank,"GO_Biological_Process_2021__positive regulation of DNA-templated transcription, elongation (GO:0032786)",0.32023896010125896,0.42826056435731397,0.8064516129032258,0.9110790639417709,1.0,6/23,13.28%,SUPT6H;ELL3;SUPT5H;SCAF8;CCNK;CCNT2
prerank,GO_Biological_Process_2021__positive regulation of immunoglobulin mediated immune response (GO:0002891),-0.25824045697291886,-0.42807761364212554,0.7463768115942029,0.9340675248794085,1.0,5/15,22.63%,TNFSF4;XCL1;CD226;TFRC;KMT5B
prerank,Elsevier_Pathway_Collection__Genes with Mutations Associated with Cataract,0.28475249323197405,0.42773136760919034,0.8429752066115702,0.9110341835528585,1.0,7/16,25.11%,CRYBA4;MIP;BFSP2;EPHA2;GALK1;CRYAA;HSF4
prerank,Reactome_2022__Platelet Sensitization By LDL R-HSA-432142,0.27465538072714235,0.4269640768411474,0.768595041322314,0.9111742815635275,1.0,11/17,37.50%,PPP2R5B;PPP2R5D;PPP2R5E;PECAM1;PTPN11;APOB;PPP2R1B;PPP2R1A;PPP2CA;MAPK14;PLA2G4A
prerank,GO_Biological_Process_2021__mitotic cytokinetic process (GO:1902410),-0.2724271930893582,-0.4261774945872617,0.744,0.9347843560831367,1.0,10/20,30.94%,CHMP2B;CHMP4B;PDCD6IP;CHMP1A;CHMP6;CEP55;CHMP3;CHMP1B;MITD1;VPS4B
prerank,Reactome_2022__TNF Signaling R-HSA-75893,-0.31425009619954886,-0.42366595645840766,0.8803418803418803,0.9358359730188428,1.0,16/44,25.48%,RIPK1;TAB2;MADD;USP4;TRADD;RACK1;UBB;UBA52;RBCK1;FADD;BIRC2;TNFAIP3;SHARPIN;TRAF1;TNF;SPPL2B
prerank,GO_Biological_Process_2021__poly(A)+ mRNA export from nucleus (GO:0016973),-0.26938900917435715,-0.42270971689769926,0.7903225806451613,0.9360246474127222,1.0,8/19,29.80%,THOC2;ZC3H11B;NUP93;ENY2;NXF5;NXF3;NXF1;SARNP
prerank,GO_Biological_Process_2021__post-transcriptional gene silencing by RNA (GO:0035194),0.2873741874360466,0.42154849148558715,0.788135593220339,0.913759012498705,1.0,9/20,27.51%,AJUBA;TNRC6B;WTIP;TNRC6A;AGO1;TNRC6C;CNOT7;CNOT6;AGO3
prerank,GO_Biological_Process_2021__G protein-coupled acetylcholine receptor signaling pathway (GO:0007213),-0.2524693493632357,-0.4204047809570115,0.8188976377952756,0.9368699274755723,1.0,3/15,11.57%,CHRM4;GRK2;AGRN
prerank,GO_Biological_Process_2021__positive regulation of transcription by RNA polymerase I (GO:0045943),-0.28952697450209364,-0.4195983843705208,0.7317073170731707,0.9370205516003117,1.0,11/23,38.71%,BNC1;PWP1;UBTF;EIF2AK3;HEATR1;SMARCA4;PIH1D1;DHX33;RASL11A;UTP15;IPPK
prerank,Elsevier_Pathway_Collection__Renin-Angiotensin-Aldosterone System in Myocardial ischemia,-0.25316324899616593,-0.4193517148397549,0.8650793650793651,0.9368014182914673,1.0,6/15,23.73%,ACE2;NPR1;CYP21A2;NR3C2;CYP11A1;HSD3B2
prerank,Elsevier_Pathway_Collection__Gluconeogenesis Impairment in non-Alcoholic Fatty Liver Disease,-0.2381776239907728,-0.4191158482454349,0.8582677165354331,0.9365918227550963,1.0,15/15,76.20%,IRS2;INSR;G6PC;RETN;CEBPA;LDLR;PCK1;PPARG;FOXO1;PDPK1;IGF1R;LPIN1;LEP;PIK3R1;AKT1
prerank,"Elsevier_Pathway_Collection__Oxidative Stress, All-Trans-Retinal and Lipofuscin Toxicity in AMD",-0.28223948498662205,-0.4181391191784588,0.7923076923076923,0.9367517488510788,1.0,4/18,15.40%,ABCA4;HTR2A;NFE2L2;CUL3
prerank,"Elsevier_Pathway_Collection__L-cell: GCG, PYY and 5-HT Release",-0.2581432084542643,-0.417632366504915,0.7661290322580645,0.9366413255639366,1.0,7/19,24.83%,GPR119;PCSK2;CASR;PLCB2;FFAR2;DPP4;SLC5A1
prerank,Elsevier_Pathway_Collection__Tamoxifen Induced Endometrial Cancer,0.2749960173011773,0.41647086469906125,0.8091603053435115,0.9161696525668106,1.0,6/16,23.81%,MYC;ILK;GRB2;PELP1;EGFR;AKT1
prerank,GO_Biological_Process_2021__positive regulation of cardiac muscle hypertrophy (GO:0010613),-0.26636839438394455,-0.41620175962731704,0.8270676691729323,0.9371180412487583,1.0,9/18,30.95%,MEF2A;IGF1;PDE9A;NR4A3;HAND2;ROCK1;SLC9A1;PRKCA;MTPN
prerank,Elsevier_Pathway_Collection__Spindle Assembly,0.2567694618680325,0.4161456316246294,0.753731343283582,0.9160808448414747,1.0,7/16,26.31%,CDK1;NEK2;PLK1;MAD2L1;ESPL1;MXD1;NUMA1
prerank,GO_Biological_Process_2021__ceramide catabolic process (GO:0046514),0.25925835420164967,0.4146874310655839,0.8070175438596491,0.9166133170842831,1.0,3/15,9.32%,NEU3;GBA3;ASAH2B
prerank,GO_Biological_Process_2021__regulation of single stranded viral RNA replication via double stranded DNA intermediate (GO:0045091),0.2381894759215199,0.4146755250286716,0.8083333333333333,0.9163383909224097,1.0,4/17,12.30%,APOBEC3C;RESF1;TASOR;APOBEC3A
prerank,GO_Biological_Process_2021__negative regulation of reproductive process (GO:2000242),-0.26437799199790474,-0.4145761661542482,0.831858407079646,0.9376532126034673,1.0,5/16,22.86%,ZP3;IGF1;DUSP1;NPPC;WDR77
prerank,GO_Biological_Process_2021__transcription by RNA polymerase III (GO:0006383),0.2936397749922197,0.41364622934240564,0.8305084745762712,0.9166625997728611,1.0,10/28,25.54%,GTF3C2;ZC3H8;GTF3C5;RO60;SNAPC3;CRCP;POLR2K;GTF3C4;GTF3A;SNAPC4
prerank,Elsevier_Pathway_Collection__Protein Nuclear Import and Export,-0.27176125987520827,-0.4135476292575015,0.7956204379562044,0.9378712890214079,1.0,8/17,29.29%,KPNA1;TNPO1;RAN;XPO1;RANBP1;NXF1;NXT1;XPOT
prerank,GO_Biological_Process_2021__negative regulation of immune system process (GO:0002683),0.2529881509028625,0.4127447684042456,0.7709923664122137,0.9169387632030052,1.0,8/18,30.95%,COL3A1;LILRB4;IL17D;ADTRP;PDCD1;FOXP3;FCRLB;LYN
prerank,Reactome_2022__Activated PKN1 Stimulates Transcription Of Androgen Receptor Regulated KLK2 And KLK3 R-HSA-5625886,-0.29130412896371444,-0.41091224078717586,0.8173913043478261,0.9390202087526921,1.0,5/26,6.77%,H2BC9;H2BC17;H2BC5;H2BC13;H2AC6
prerank,GO_Biological_Process_2021__response to interferon-alpha (GO:0035455),-0.2934509909150531,-0.4102487808124649,0.8062015503875969,0.9390399884747996,1.0,6/18,18.95%,KLHL20;IFNAR1;IFITM1;EIF2AK2;BST2;TPR
prerank,GO_Biological_Process_2021__regulation of intracellular transport (GO:0032386),-0.2924757642879735,-0.4096644380361566,0.7636363636363637,0.939055749051582,1.0,15/37,25.42%,MLC1;MYBPC3;LAMP1;LRRK2;RNF139;ANTKMT;HAP1;RAB11B;MAP2;GRIPAP1;CAPN10;REEP5;ATP13A2;MYLK2;NDEL1
prerank,GO_Biological_Process_2021__regulation of protein localization to cell periphery (GO:1904375),0.2639865146048309,0.40926469954619704,0.816,0.9186525000178358,1.0,5/19,19.08%,APPL1;STX8;CDK5;PLK1;ZDHHC7
prerank,WikiPathway_2021_Human__nsp1 from SARS-CoV-2 inhibits translation initiation in the host cell WP5027,0.2732418498046403,0.4091666641333686,0.7933884297520661,0.91842647352932,1.0,7/17,31.60%,EIF3CL;EIF3C;EIF3A;EIF5;EIF3E;EIF1AX;EIF2S1
prerank,Reactome_2022__Formation Of Incision Complex In GG-NER R-HSA-5696395,-0.31090600886157027,-0.4081002910026834,0.9166666666666666,0.9396678945318112,1.0,20/42,33.45%,SUMO1;UBB;POLR1A;CETN2;CUL4A;GTF2H2;UBA52;PARP2;ERCC3;ERCC1;RAD23B;UBE2V2;DDB2;DDB1;UBE2I;XPA;CCNH;USP45;ERCC2;RNF111
prerank,WikiPathway_2021_Human__LTF danger signal response pathway WP4478,-0.2575862372695552,-0.40486987457722917,0.8666666666666667,0.9411958404834644,1.0,9/16,35.86%,NFKB1;MYD88;TRAF6;TREM1;TNF;IL1B;IRAK1;IL6;CD14
prerank,GO_Biological_Process_2021__positive regulation of heart contraction (GO:0045823),-0.25480385642940073,-0.4048507610357935,0.8151260504201681,0.9408454681787466,1.0,7/17,31.02%,TRPM4;RYR2;RGS2;HRC;ATP1A2;KCNQ1;APELA
prerank,GO_Biological_Process_2021__integrated stress response signaling (GO:0140467),0.24656315694665126,0.4034112371872919,0.8547008547008547,0.9214690479347816,1.0,8/15,32.88%,EIF2AK1;HSPA5;IGFBP1;OMA1;CXCL8;EIF2S1;EIF2AK4;QRICH1
prerank,"GO_Biological_Process_2021__RNA splicing, via transesterification reactions (GO:0000375)",-0.28328915119009596,-0.4029303938788051,0.7931034482758621,0.9416348267447852,1.0,6/25,10.53%,SF3B3;WDR83;MPHOSPH10;SRSF4;DBR1;SCAF11
prerank,Elsevier_Pathway_Collection__Single-Strand Nucleotide Excision,0.28243934042429214,0.4024832673584353,0.8102189781021898,0.9217051832260734,1.0,5/18,15.82%,ERCC4;TENT4A;POLE;XAB2;XPC
prerank,GO_Biological_Process_2021__positive regulation of leukocyte adhesion to vascular endothelial cell (GO:1904996),-0.26633255151597673,-0.40203992768339303,0.8015873015873016,0.9418094423158465,1.0,10/16,35.27%,RELA;MDK;ST3GAL4;ALOX5;TRAF6;TNF;FUT4;IRAK1;ETS1;IL6
prerank,Elsevier_Pathway_Collection__Alveolar Epithelial Cell Apoptosis in COPD,-0.26711010894266807,-0.401544077637786,0.8013698630136986,0.941754873181076,1.0,12/25,32.07%,MAP1LC3B;PRF1;DFFA;BAX;FADD;TOP2B;FAS;CASP9;TNF;BID;GZMB;CAV1
prerank,GO_Biological_Process_2021__membrane depolarization during action potential (GO:0086010),0.284004073215868,0.4013571354453613,0.8153846153846154,0.9221336419893963,1.0,8/25,15.46%,YWHAH;CACNA1I;SCN1B;HCN2;SCN11A;SLC8A1;CACNA1G;SCN3A
prerank,GO_Biological_Process_2021__regulation of mitochondrion organization (GO:0010821),0.2946946200637443,0.40118465478068477,0.916030534351145,0.9219586876898154,1.0,22/47,32.73%,TMEM102;CSNK2A2;RHOT1;INF2;HTRA2;MGARP;HAX1;PPARGC1A;SIRT7;SREBF1;STOX1;PINK1;CYRIB;DNM1L;OMA1;FIS1;PISD;HDAC6;PRMT6;PRKN;USP36;GSK3A
prerank,GO_Biological_Process_2021__negative regulation of leukocyte mediated cytotoxicity (GO:0001911),-0.2474888174537389,-0.40098281181801687,0.8484848484848485,0.9417442748374075,1.0,5/15,23.63%,CX3CR1;HLA-E;HLA-G;FCGR2B;HLA-F
prerank,GO_Biological_Process_2021__regulation of adenylate cyclase activity (GO:0045761),-0.2649951922070778,-0.40002840482959084,0.8067226890756303,0.9419279664058453,1.0,5/17,18.15%,PALM;CACNA1D;NF1;AKAP5;GRM2
prerank,Elsevier_Pathway_Collection__GDNF -> HSF1 Signaling,-0.2609737701812078,-0.39967197050645625,0.7786259541984732,0.9418135554756608,1.0,12/29,31.29%,RAC1;MAP2K7;MAP3K1;RASGRF1;MAP2K2;RET;SRC;CDC42;VAV2;RAF1;PLCG1;MAP2K1
prerank,Elsevier_Pathway_Collection__SIRT2 Signaling in Aging,-0.26502323327584754,-0.39921538223169734,0.7542372881355932,0.9417577373709805,1.0,5/22,16.45%,RIPK1;RELA;NMNAT1;CDK9;SIRT2
prerank,GO_Biological_Process_2021__cellular monovalent inorganic cation homeostasis (GO:0030004),-0.24576783096671834,-0.39636222523972636,0.8217054263565892,0.9431241987782633,1.0,8/18,28.66%,ATP1A3;KCNJ2;ATP12A;KCNMA1;ATP1B3;LACC1;ATP1A2;SLC9A1
prerank,GO_Biological_Process_2021__aggrephagy (GO:0035973),-0.28129970491165046,-0.3957884483389807,0.8283582089552238,0.9431144333335295,1.0,12/28,30.67%,UBB;WDR81;ARL13B;UBA52;SQSTM1;DYNLL2;PARK7;DYNC1LI2;MAP1LC3C;UBE2V1;DYNC1I1;ACBD5
prerank,GO_Biological_Process_2021__regulation of protein modification by small protein conjugation or removal (GO:1903320),0.2676773202668419,0.3956037322472593,0.8048780487804879,0.9249896741665178,1.0,11/20,33.41%,DCUN1D3;DCUN1D2;UBQLN1;PINK1;WASHC1;ITCH;DAXX;HSP90AB1;PRKN;ZMIZ1;EPAS1
prerank,GO_Biological_Process_2021__positive regulation of calcium ion transmembrane transporter activity (GO:1901021),0.27968450347767526,0.3953753020799439,0.8130081300813008,0.9248698738899812,1.0,11/20,32.17%,HTT;ATP1B1;VMP1;JPH2;ATP2A1;GSTM2;AKAP6;ANK2;CALM2;CALM3;PKD2
prerank,Elsevier_Pathway_Collection__CD157 -> cADPR/Calcium Signaling,-0.27877762638683884,-0.39536699291121863,0.7633587786259542,0.9430183426987118,1.0,11/21,31.29%,MYLK;RYR3;CNN1;RYR2;RASGRF1;MAP2K2;ROCK1;LIMK2;RAF1;PLCG1;MAP2K1
prerank,KEGG_2021_Human__Ascorbate and aldarate metabolism,-0.28986784046885383,-0.3953499485686209,0.8308823529411765,0.9426687350131647,1.0,13/27,31.14%,UGT2A3;KL;UGT2B17;UGT1A1;UGT2B28;MIOX;UGT2B4;UGT2B15;UGT2B10;ALDH2;UGT1A5;ALDH1B1;ALDH9A1
prerank,GO_Biological_Process_2021__regulation of mitochondrial fission (GO:0090140),0.28469683675856083,0.3952663969726824,0.773109243697479,0.9246492578799539,1.0,9/25,22.85%,KDR;RALA;INF2;DCN;PINK1;CYRIB;AURKA;DNM1L;FIS1
prerank,Reactome_2022__RHOBTB2 GTPase Cycle R-HSA-9013418,0.27403054140205396,0.39505866174369625,0.8205128205128205,0.924524181751552,1.0,12/23,31.45%,SRRM1;ACTG1;TWF1;RBMX;TXNL1;STK38;MYO6;HSP90AB1;MSI2;CDC37;TMOD3;CCT6A
prerank,GO_Biological_Process_2021__negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway (GO:1902236),0.2444106366365503,0.3938123959554966,0.8650793650793651,0.9250204953146034,1.0,4/15,14.65%,BCL2L1;MAGEA3;OPA1;XBP1
prerank,Elsevier_Pathway_Collection__Alveolar Epithelial Cell Autophagy in COPD,-0.24971711761601817,-0.3936622277013881,0.7692307692307693,0.9433466382234419,1.0,8/24,20.09%,MAP1LC3B;NFE2L2;EIF2AK3;BECN1;ATF6;HMGB1;ATG4B;FAS
prerank,"GO_Biological_Process_2021__retrograde protein transport, ER to cytosol (GO:0030970)",-0.2586544916629909,-0.39339677797054134,0.7652173913043478,0.9431563733682261,1.0,8/17,29.83%,HERPUD1;DERL2;SEL1L;SELENOS;UFD1;VCP;TMEM129;NPLOC4
prerank,Elsevier_Pathway_Collection__Sarcomere in Cardiomyocyte in Dilated Cardiomyopathy,0.2697051951822762,0.3929832288036766,0.788135593220339,0.9252686026342037,1.0,4/19,12.27%,TNNI3;ACTG1;TCAP;LAMA2
prerank,GO_Biological_Process_2021__negative regulation of epithelial to mesenchymal transition (GO:0010719),0.28039116034280726,0.3929658237183954,0.8189655172413793,0.9250018352549509,1.0,17/28,37.79%,FOXA2;USF3;DAB2IP;BMP5;SPRY1;EFNA1;SPRED2;SFRP1;SFRP2;FOXA1;GATA3;MAD2L2;IL17RD;OVOL2;PPP2CA;SPRED3;SPRED1
prerank,GO_Biological_Process_2021__positive regulation of mitochondrial fission (GO:0090141),0.2736038135605493,0.3927671833850925,0.8048780487804879,0.9248359651168062,1.0,7/19,22.85%,KDR;RALA;DCN;PINK1;AURKA;DNM1L;FIS1
prerank,GO_Biological_Process_2021__positive regulation of vasoconstriction (GO:0045907),-0.2358068003002537,-0.3913473727611998,0.9098360655737705,0.9439874222548298,1.0,3/15,8.18%,FGB;AVPR2;TRPM4
prerank,GO_Biological_Process_2021__positive regulation of natural killer cell mediated immunity (GO:0002717),-0.27744366445115065,-0.3906242360500565,0.8515625,0.9440953414918491,1.0,12/21,39.79%,AP1G1;LAMP1;CD226;HLA-E;HLA-G;HLA-F;RAET1E;NCR3;SLAMF6;KLRK1;IL12A;NECTIN2
prerank,Elsevier_Pathway_Collection__Single Strand Nucleotide Excision DNA Repair Suppression in Cancer,0.2654036277514327,0.38918094454683944,0.7986111111111112,0.9267237630680777,1.0,5/19,15.82%,ERCC4;TENT4A;POLE;XAB2;XPC
prerank,GO_Biological_Process_2021__regulation of AMPA receptor activity (GO:2000311),0.26503421358864276,0.387930745249226,0.8214285714285714,0.9271656011456849,1.0,11/21,31.61%,NLGN2;NLGN3;SHISA8;MAPK8IP2;PRRT1;ARC;ADRB2;SHANK1;MEF2C;CACNG4;CACNG5
prerank,GO_Biological_Process_2021__regulation of mitochondrial membrane permeability (GO:0046902),0.2550854481399881,0.3877188526221792,0.816,0.9270250677876897,1.0,5/18,13.18%,TMEM102;SPG7;SLC25A4;BCL2L1;THEM4
prerank,Elsevier_Pathway_Collection__Age-Related Cataract,-0.25476592211361165,-0.38753019670194394,0.8345864661654135,0.9457072808587783,1.0,5/19,12.66%,CAST;GSR;GJA3;CASR;ATP2B1
prerank,GO_Biological_Process_2021__mRNA modification (GO:0016556),0.2873534090431746,0.38649366048667594,0.8449612403100775,0.9274828630575648,1.0,7/22,14.14%,PUS7;METTL8;TRMT6;TRUB1;METTL16;DKC1;WTAP
prerank,GO_Biological_Process_2021__establishment of vesicle localization (GO:0051650),-0.23505392642060952,-0.38588390350811574,0.8359375,0.9464304594869691,1.0,9/18,31.12%,SYT11;SNAPIN;RAB27A;DNM2;LIMK2;KIF5B;TOR1A;KIF5A;F8A1
prerank,Reactome_2022__DARPP-32 Events R-HSA-180024,0.2773121960219068,0.38557547131446435,0.8333333333333334,0.9278180503871981,1.0,10/23,31.08%,PRKAR2B;PDE4C;PPP2R5D;CDK5;PPP1R1B;PPP3CA;PPP3CC;PRKACB;PPP2R1B;PPP2R1A
prerank,"GO_Biological_Process_2021__mRNA cis splicing, via spliceosome (GO:0045292)",-0.22775818087045102,-0.3850750025423174,0.8787878787878788,0.9466128197887067,1.0,4/16,31.28%,SNRNP200;DDX23;DCPS;SFSWAP
prerank,GO_Biological_Process_2021__presynapse assembly (GO:0099054),0.2382882256820422,0.38441648582995475,0.8582089552238806,0.9283092995592839,1.0,4/17,14.87%,NLGN2;NLGN3;WNT5A;DVL1
prerank,GO_Biological_Process_2021__regulation of ubiquitin-protein transferase activity (GO:0051438),-0.26303436786271106,-0.38397573014325675,0.7586206896551724,0.9469605066751162,1.0,10/27,20.88%,ARRDC4;UBE2L3;SMAD7;TRIB3;TOPORS;DCUN1D4;ARRDC3;DCUN1D1;PARK7;BMI1
prerank,Elsevier_Pathway_Collection__Single-Strand Base Excision,0.2362813331823881,0.38358645909550465,0.8120300751879699,0.9282574684372313,1.0,4/15,19.88%,XRCC1;APEX1;POLE;TDG
prerank,Elsevier_Pathway_Collection__Single Strand Base Excision DNA Repair Impairment in Cancer,0.2362813331823881,0.38358645909550465,0.8120300751879699,0.9282574684372313,1.0,4/15,19.88%,XRCC1;APEX1;POLE;TDG
prerank,GO_Biological_Process_2021__nuclear envelope organization (GO:0006998),0.2614955811756536,0.3830403754666597,0.8305084745762712,0.9283123530093553,1.0,4/20,10.99%,NEMP1;SUN1;NUP155;REEP4
prerank,GO_Biological_Process_2021__mammary gland epithelium development (GO:0061180),-0.23758062428629717,-0.3828978964432745,0.8731343283582089,0.9472788220889551,1.0,5/15,21.13%,LATS1;IRF6;WNT7B;WNT2;ID2
prerank,GO_Biological_Process_2021__positive regulation of myeloid leukocyte cytokine production involved in immune response (GO:0061081),0.24535482708461784,0.3828386376906726,0.8405797101449275,0.928160912970829,1.0,8/16,32.01%,WNT5A;LILRB1;PLCG2;GPRC5B;LAPTM5;MAVS;DDX58;SEMA7A
prerank,GO_Biological_Process_2021__regulation of lipid catabolic process (GO:0050994),-0.2691175558134645,-0.3822645001844521,0.864,0.9473363239672915,1.0,10/20,29.61%,PDE3B;TYSND1;LONP2;APOA5;RARRES2;ABCB11;ABCD1;TNF;IL1B;ALK
prerank,GO_Biological_Process_2021__negative regulation of lipid catabolic process (GO:0050995),0.2573541371023719,0.38200868711524677,0.85,0.9283663951195024,1.0,7/17,25.25%,APOA2;HCAR2;PRKAA1;ADRA2A;SORL1;AKT1;BSCL2
prerank,Elsevier_Pathway_Collection__Androgens in Adipocyte Activation,-0.232917759354212,-0.3820000364422615,0.8608695652173913,0.9471703277134266,1.0,2/16,7.37%,SRD5A1;SHBG
prerank,GO_Biological_Process_2021__cellular response to epidermal growth factor stimulus (GO:0071364),0.2781014244481938,0.3800929788645134,0.8490566037735849,0.9292797738402002,1.0,11/28,23.57%,SNAI2;ZFP36L1;IQGAP1;DAB2IP;PDE8A;DUSP22;SYAP1;PTPN11;EGFR;STAT5B;ZFP36L2
prerank,GO_Biological_Process_2021__eye morphogenesis (GO:0048592),0.23544853220633236,0.37999007489655345,0.8785046728971962,0.92906309327482,1.0,8/19,28.84%,SKI;TENM3;STAT3;FBN1;MFAP5;MFAP2;COL5A2;IFT122
prerank,GO_Biological_Process_2021__response to hexose (GO:0009746),-0.25960202424686607,-0.37977639613972924,0.8062015503875969,0.9482349806107767,1.0,7/23,19.70%,EIF2B2;IRS2;GCKR;THBS1;GPLD1;SELENOS;ZBED3
prerank,GO_Biological_Process_2021__DNA biosynthetic process (GO:0071897),0.23643868100299137,0.37902611943471365,0.7931034482758621,0.9293914717306603,1.0,6/17,28.39%,POLD1;POLE;TYMS;POLH;TERT;POLA1
prerank,GO_Biological_Process_2021__dendritic spine morphogenesis (GO:0060997),-0.25744980885799507,-0.37831019328070636,0.8560606060606061,0.9488443333526932,1.0,6/16,25.74%,SHANK3;CTNND2;PAK3;EPHB1;DIP2A;CDC42
prerank,Reactome_2022__EGR2 And SOX10-mediated Initiation Of Schwann Cell Myelination R-HSA-9619665,0.2575392847905155,0.3782443736764724,0.7619047619047619,0.9296234375991301,1.0,11/29,23.17%,EGR2;PLPPR3;LAMA2;NAB2;MPZ;HDAC2;SOX10;NAB1;POU3F1;YAP1;MAG
prerank,GO_Biological_Process_2021__osteoclast differentiation (GO:0030316),0.25799710564331374,0.3769839560039107,0.8114754098360656,0.9301898808478927,1.0,5/21,19.69%,CSF1R;TNFSF11;CSF1;GLO1;EPHA2
prerank,GO_Biological_Process_2021__positive regulation of hormone secretion (GO:0046887),-0.22303212381781512,-0.37683791543761347,0.8951612903225806,0.9494466261514297,1.0,2/15,3.77%,TFR2;FGB
prerank,GO_Biological_Process_2021__dendritic cell migration (GO:0036336),0.24477988800274308,0.37429551429241664,0.8796296296296297,0.9316430605525159,1.0,6/18,20.21%,CXCR4;CCL19;TRPM2;CCL5;CCR2;CCR5
prerank,Elsevier_Pathway_Collection__mTOR Hyperactivation after Status Epilepticus,-0.2516126090271501,-0.37262048040214735,0.8646616541353384,0.95188360135247,1.0,3/16,10.62%,RPS6;RHEB;SHANK2
prerank,GO_Biological_Process_2021__phosphatidylinositol dephosphorylation (GO:0046856),-0.2540017495519413,-0.37255035555882365,0.8549618320610687,0.951567083138908,1.0,7/24,23.90%,MTMR3;SYNJ2;MTM1;PIP4P1;MTMR8;MTMR2;MTMR12
prerank,GO_Biological_Process_2021__protein kinase B signaling (GO:0043491),0.2667571895629753,0.3724192759797759,0.8521739130434782,0.9325849407615454,1.0,9/24,23.81%,KDR;ZFP36L1;GAS6;NKX3-1;THEM4;CCL5;EPHA2;ADTRP;AKT1
prerank,TRRUST_Transcription_Factors_2019__PAX3 mouse,0.2207828835635896,0.3721215983543519,0.8421052631578947,0.9324624013630838,1.0,5/15,29.09%,WNT1;SPRY1;MSX2;TYRP1;MBP
prerank,Elsevier_Pathway_Collection__Osteoclasts Function in Osteopetrosis,0.24913092000879072,0.37131717892970983,0.8034188034188035,0.9327188020759122,1.0,4/19,13.39%,ITGB3;ACP5;TNFSF11;MAP3K7
prerank,TRRUST_Transcription_Factors_2019__FOXA1 human,-0.251849186099113,-0.3699804903361862,0.8805970149253731,0.9529434023158195,1.0,10/20,32.22%,UGT2B17;NF1;TFF1;AGR2;BRCA1;RET;UGT2B15;SERPINC1;NKX2-1;SFTPB
prerank,Elsevier_Pathway_Collection__FOXA2 Signaling in Prostate Cancer,-0.23498859175261977,-0.36978234889837597,0.8632478632478633,0.9527335440499273,1.0,5/18,20.41%,HIPK2;SOX9;AGR2;SIAH1;VHL
prerank,Elsevier_Pathway_Collection__G-Proteins Signaling in Insulin Secretion in beta-Cell,-0.24504377026589075,-0.36969754191555154,0.8928571428571429,0.9524394735872225,1.0,4/19,16.03%,GPR119;TRPM4;RASGRF1;GLP1R
prerank,GO_Biological_Process_2021__positive regulation of microtubule polymerization (GO:0031116),-0.2629132943577198,-0.3696120531564324,0.7804878048780488,0.9521403517306907,1.0,5/27,10.37%,MAPRE1;PAK1;RAC1;HSPA1B;TOGARAM1
prerank,GO_Biological_Process_2021__cytoplasmic translational initiation (GO:0002183),0.2563299968142677,0.36920257395205125,0.8449612403100775,0.9338799958041404,1.0,7/19,25.18%,EIF4A2;DHX29;EIF3A;RBM4;EIF3M;EIF5;EIF4A1
prerank,Elsevier_Pathway_Collection__Histone Methylation,0.25944728362872127,0.3688953923535354,0.8070175438596491,0.9337977456974189,1.0,9/28,21.19%,RBBP7;MECP2;DNMT3A;RBBP4;HDAC2;CBX5;KDM3A;HDAC1;KDM4A
prerank,Elsevier_Pathway_Collection__IGF1R -> ELK/SRF/HIF1A/MYC/SREBF Signaling,0.23386324000057115,0.36854882878989675,0.8359375,0.9337777312270612,1.0,6/20,19.14%,MAPK1;SREBF1;ELK1;MAPKAPK2;MYC;GRB2
prerank,GO_Biological_Process_2021__positive regulation of interferon-alpha production (GO:0032727),-0.2491126100825029,-0.3678974232093479,0.8512396694214877,0.9529387489712072,1.0,3/19,6.68%,SETD2;DDX3X;DHX9
prerank,Reactome_2022__PRC2 Methylates Histones And DNA R-HSA-212300,-0.2539558609744441,-0.36753951001866,0.8050847457627118,0.9528016292333704,1.0,10/32,20.70%,H2BC9;H2BC17;H2BC5;H2BC13;H2AC6;SUZ12;H2AZ1;H2AZ2;JARID2;PHF19
prerank,GO_Biological_Process_2021__DNA methylation (GO:0006306),0.2588731146770777,0.36633789356868135,0.8467741935483871,0.9350443246164484,1.0,11/23,32.17%,PICK1;MTRR;DNMT3A;EHMT1;KMT2E;ZFP57;N6AMT1;HELLS;TEX15;BEND3;PPM1D
prerank,Elsevier_Pathway_Collection__CHRM1/2/3 -> Vascular Motility,-0.24930713497221924,-0.3652721609181519,0.8809523809523809,0.9539730127441207,1.0,7/20,31.29%,MYLK;ACTA2;RASGRF1;MAP2K2;NOS3;RAF1;MAP2K1
prerank,Reactome_2022__Sensory Perception Of Taste R-HSA-9717189,-0.25835342251192794,-0.36486029853821483,0.8636363636363636,0.9539000841001499,1.0,9/25,25.14%,KCNJ2;ITPR3;TRPM4;SCN4B;GNB3;SCN2A;PLCB2;TAS2R5;SCNN1A
prerank,GO_Biological_Process_2021__positive regulation of CREB transcription factor activity (GO:0032793),-0.22337356550611653,-0.36399655177667756,0.8518518518518519,0.9541126336577622,1.0,2/17,4.35%,TSSK4;RPS6KA4
prerank,Reactome_2022__Regulation Of TLR By Endogenous Ligand R-HSA-5686938,0.24365355063305694,0.36333162089926885,0.8333333333333334,0.9367708677880748,1.0,4/18,16.68%,TLR1;TLR4;NDUFA2;S100A9
prerank,Reactome_2022__RA Biosynthesis Pathway R-HSA-5365859,0.25816624707778013,0.36262504147425584,0.8913043478260869,0.9370106539091053,1.0,10/20,30.75%,RDH16;RDH14;ADH7;ADH1A;AKR1C3;RDH13;CYP26B1;ALDH1A1;CYP26A1;CYP26C1
prerank,Elsevier_Pathway_Collection__Proteins Involved in Hypogonadotropic Hypogonadism,0.24975383042486649,0.3624718710869099,0.8455284552845529,0.9368344195655566,1.0,5/20,14.07%,KISS1R;FGFR1;WDR11;POLR3B;PCSK1
prerank,Elsevier_Pathway_Collection__SOCS3 and PTPN1 in Hypothalamic Neuron Insensitivity to Insulin and Leptin,-0.2194370804396456,-0.36100025980151385,0.9140625,0.9558883539477191,1.0,4/15,18.29%,IRS2;PDE3B;INSR;IRS1
prerank,GO_Biological_Process_2021__regulation of fibroblast growth factor receptor signaling pathway (GO:0040036),-0.2409097313970277,-0.35907276405763494,0.8272727272727273,0.9569070072641843,1.0,4/19,12.69%,SPRY2;NPTN;FGFBP3;THBS1
prerank,Elsevier_Pathway_Collection__PTGER1/4 -> Vascular Motility,0.21822731626997977,0.3587143756002714,0.8907563025210085,0.9391851959383161,1.0,3/18,6.08%,MYL9;RHOA;MAPK1
prerank,Reactome_2022__Signaling By EGFR In Cancer R-HSA-1643713,-0.25777925201298346,-0.3582058229880149,0.8918918918918919,0.9571563010169976,1.0,5/23,14.84%,UBB;PIGU;UBA52;EGF;NRAS
prerank,Elsevier_Pathway_Collection__GCG and PPY Regulate Metabolism and Satiety,0.20195747417149257,0.3576159713504336,0.9298245614035088,0.939695277843309,1.0,6/15,30.61%,PYY;PCSK1;GCG;GNAS;PLCB3;GLP2R
prerank,Elsevier_Pathway_Collection__Conventional Dendritic Cell Role in Diabetes Mellitus Type 1,0.2335188337286952,0.357162681560541,0.8205128205128205,0.9397423355584078,1.0,5/21,13.39%,NLRP3;CASP1;TLR4;CTSB;MAP3K7
prerank,GO_Biological_Process_2021__positive regulation of histone acetylation (GO:0035066),0.24142371328946155,0.3567946388178799,0.8671875,0.9397044015276005,1.0,6/23,19.81%,SMAD4;PAXIP1;RPS6KA5;PPARGC1A;RUVBL2;LIF
prerank,GO_Biological_Process_2021__natural killer cell mediated cytotoxicity (GO:0042267),-0.2287921894365942,-0.35679419349480124,0.8837209302325582,0.9577770895606355,1.0,10/20,34.68%,PLEKHM2;TUBB4B;SLAMF7;KIR3DL1;ULBP1;ULBP2;KIF5B;GZMB;RAET1E;ARL8B
prerank,"GO_Biological_Process_2021__alternative mRNA splicing, via spliceosome (GO:0000380)",0.21640520290278314,0.35535110160447025,0.926605504587156,0.9403999232207345,1.0,7/16,30.05%,SFPQ;DDX5;CELF4;CDK13;SCNM1;SLU7;RBM17
prerank,GO_Biological_Process_2021__ganglioside metabolic process (GO:0001573),-0.25213992060559376,-0.35528554394300854,0.8859649122807017,0.9584026675144383,1.0,5/18,16.06%,NEU4;ST8SIA3;ST6GALNAC3;ST6GALNAC6;GM2A
prerank,GO_Biological_Process_2021__modulation by host of viral genome replication (GO:0044827),0.23603341188643903,0.3550136255568945,0.9083333333333333,0.9403631625269124,1.0,4/15,13.12%,PPIB;NUCKS1;VAPA;CCNK
prerank,GO_Biological_Process_2021__regulation of protein localization to membrane (GO:1905475),0.2592560289135025,0.35448160893908764,0.8677685950413223,0.9404638600887447,1.0,6/29,12.21%,APPL1;GPC2;STX8;CDK5;FYN;GPC4
prerank,GO_Biological_Process_2021__spliceosomal snRNP assembly (GO:0000387),0.2576263294638976,0.35388106799635183,0.88,0.9406170306674133,1.0,12/38,21.74%,LSM2;LSM4;TGS1;STRAP;GEMIN2;COIL;SMN1;PRMT5;CD2BP2;GEMIN4;SNRPC;SART3
prerank,GO_Biological_Process_2021__multivesicular body organization (GO:0036257),-0.2428119093138601,-0.35371075244032407,0.8461538461538461,0.9591183343082875,1.0,13/31,26.74%,CHMP2B;CHMP4B;PDCD6IP;CHMP1A;VPS37A;CHMP6;TSG101;VPS28;CHMP3;CHMP1B;RAB27A;VPS37B;SNF8
prerank,Reactome_2022__PKA Activation R-HSA-163615,0.22725213782967557,0.3534354482308888,0.8677685950413223,0.9406260225742429,1.0,2/16,3.20%,ADCY5;PRKAR2B
prerank,GO_Biological_Process_2021__regulation of rhodopsin mediated signaling pathway (GO:0022400),0.25484693969482575,0.3528650874091713,0.8495575221238938,0.9407427053213919,1.0,5/20,15.03%,SAG;FNTA;GUCY2D;CNGB1;METAP2
prerank,Elsevier_Pathway_Collection__WNT Planar Cell Polarity (PCP) non-Canonical Signaling,-0.2301830032395668,-0.35283350017173154,0.8347107438016529,0.9593493802555204,1.0,5/22,12.44%,RAC1;MAP2K7;PFN1;ROR2;MAP3K1
prerank,GO_Biological_Process_2021__positive regulation of amyloid-beta formation (GO:1902004),0.2038234451118763,0.3524418117572375,0.9504132231404959,0.9407691495995789,1.0,8/18,29.05%,CLU;SLC2A13;CASP3;IFNGR1;IFNG;EFNA1;PICALM;ABCA2
prerank,GO_Biological_Process_2021__positive regulation of JUN kinase activity (GO:0043507),-0.22561838527361067,-0.35235489670709663,0.8968253968253969,0.9593756751775856,1.0,9/22,31.80%,PAK1;SASH1;DVL2;TRAF6;TNF;MAP3K11;ARHGEF5;MAP3K4;RPS3
prerank,GO_Biological_Process_2021__histone ubiquitination (GO:0016574),-0.24067852816024488,-0.3514307859034794,0.8173913043478261,0.959626117548262,1.0,9/20,29.37%,USP22;UHRF1;RNF20;UBE2E1;PHC1;CDC73;RAG1;RNF8;DTX3L
prerank,GO_Biological_Process_2021__acetylcholine receptor signaling pathway (GO:0095500),-0.22340141599392926,-0.3514179252491828,0.8549618320610687,0.9592735755438422,1.0,3/17,11.57%,CHRM4;GRK2;AGRN
prerank,GO_Biological_Process_2021__regulation of activin receptor signaling pathway (GO:0032925),-0.20876181698513613,-0.351000375327656,0.8992248062015504,0.9591937638173342,1.0,3/15,8.86%,ACVR2A;ACVR1B;SMAD7
prerank,Elsevier_Pathway_Collection__CR3 Mediated Phagocytosis in Neutrophils and Macrophages,0.20433695610947844,0.35095924658422756,0.8833333333333333,0.9415449640267805,1.0,3/17,12.46%,RHOA;IQGAP1;C3
prerank,GO_Biological_Process_2021__regulation of interferon-alpha production (GO:0032647),-0.23607957049574657,-0.35090392970655065,0.8740157480314961,0.9588966412712816,1.0,4/24,9.88%,SETD2;DDX3X;DHX9;LILRA4
prerank,Elsevier_Pathway_Collection__InsulinR -> ELK/SRF/SREBF Signaling,-0.21287913984122359,-0.3507589442952306,0.88,0.958621991754707,1.0,5/20,18.29%,IRS2;ELK4;INSR;MAP2K2;IRS1
prerank,GO_Biological_Process_2021__regulation of cardiac muscle hypertrophy (GO:0010611),-0.2465800329965946,-0.350640231535018,0.8294573643410853,0.9583331526287046,1.0,11/23,30.95%,MEF2A;NOTCH1;IGF1;PDE9A;NR4A3;RGS2;HAND2;ROCK1;SLC9A1;PRKCA;MTPN
prerank,GO_Biological_Process_2021__microtubule nucleation (GO:0007020),-0.24871560581749583,-0.3489275210562281,0.8916666666666667,0.9591484811194927,1.0,12/20,42.11%,CSNK1D;CCDC57;TUBGCP3;GOLGA2;NDEL1;TUBGCP2;CLASP1;RANBP9;TUBGCP6;NDE1;TPPP;TUBGCP4
prerank,GO_Biological_Process_2021__mitotic cell cycle checkpoint signaling (GO:0007093),-0.251301157682913,-0.34869920685348477,0.9166666666666666,0.9589315743949502,1.0,3/22,5.23%,BUB1B;PRCC;ZW10
prerank,GO_Biological_Process_2021__response to cholesterol (GO:0070723),-0.21284859526325695,-0.3484750080107533,0.9298245614035088,0.9587435831152206,1.0,8/19,29.03%,MLC1;CCL3;SMO;GPLD1;GRAMD1B;SMAD2;TGFB1;TGFBR1
prerank,WikiPathway_2021_Human__Farnesoid X receptor pathway WP2879,-0.22986514456408585,-0.34762915164282254,0.8695652173913043,0.9589372432070359,1.0,5/19,20.54%,SLC27A5;IRS2;CYP8B1;ABCB11;UGT2B4
prerank,GO_Biological_Process_2021__regulation of protein processing (GO:0070613),0.24310290801432033,0.34723683649974785,0.8706896551724138,0.9437433177348906,1.0,7/20,20.62%,SNX12;BAG2;NKD2;MAGEA3;ANGPTL8;PRNP;NLRC4
prerank,WikiPathway_2021_Human__Canonical and non-canonical TGF-B signaling WP3874,0.2250163567348702,0.3471944133096984,0.8362068965517241,0.9434931991486862,1.0,5/17,19.30%,SMAD4;BMP1;LOXL4;TGFBR2;MAPK8
prerank,GO_Biological_Process_2021__cellular response to dsRNA (GO:0071359),-0.21841545454535263,-0.3464231101919178,0.8571428571428571,0.9594442154098565,1.0,7/17,32.07%,DHX9;NPM1;FLOT1;MUL1;IFIH1;STING1;CAV1
prerank,WikiPathway_2021_Human__Glucuronidation WP698,-0.25326820933793176,-0.3461972704433443,0.8591549295774648,0.9592222980155907,1.0,10/23,30.06%,UGT2A3;UGP2;UGT2B17;UGT1A1;PGM2;UGT2B28;UGT2B4;UGT2B15;UGT2B10;UGT1A5
prerank,GO_Biological_Process_2021__dendritic cell differentiation (GO:0097028),0.22032057370046343,0.3449211909662159,0.8548387096774194,0.9448145875893293,1.0,11/22,35.64%,GAS6;CCL19;TRPM2;LILRB1;TGFBR2;LGALS9;BATF;LYN;IRF8;PRTN3;F2RL1
prerank,Elsevier_Pathway_Collection__ADRA1 -> Vasoconstriction,-0.2244531653769001,-0.34465735608314924,0.8646616541353384,0.9599702328164663,1.0,4/19,15.70%,MYLK;ACTA2;RASGRF1;MAP2K2
prerank,Elsevier_Pathway_Collection__IL2R -> ELK/SRF/MYC Signaling,0.22437418851813554,0.3446133975496538,0.832,0.9447524284776215,1.0,5/19,19.14%,MAPK1;ELK1;MAPKAPK2;MYC;GRB2
prerank,Elsevier_Pathway_Collection__Insulin Influence on Protein Synthesis,-0.2519921601275045,-0.3445708989441899,0.8705035971223022,0.9596713127095265,1.0,11/31,31.29%,IRS2;RPS6;RHEB;IGF1;INSR;MAP2K2;IRS1;IDE;RAF1;TSC2;MAP2K1
prerank,Reactome_2022__NRIF Signals Cell Death From Nucleus R-HSA-205043,0.22133455003834063,0.34438970286568615,0.9181818181818182,0.9446191070900973,1.0,5/16,19.86%,ITGB3BP;APH1B;MAPK8;PSEN1;PSENEN
prerank,GO_Biological_Process_2021__apoptotic DNA fragmentation (GO:0006309),-0.2309808113171031,-0.34357820941058814,0.9357142857142857,0.9599881645285876,1.0,4/15,17.27%,KPNA1;DFFA;HMGB1;HMGB2
prerank,GO_Biological_Process_2021__negative regulation of cyclin-dependent protein kinase activity (GO:1904030),-0.23615743684068052,-0.3423937025654464,0.9,0.9604768641410587,1.0,12/22,38.21%,NR2F2;LATS1;HEXIM2;IPO7;CDKN1A;CDKN1C;TFAP4;CEBPA;CDKN1B;LATS2;CDKN2A;INCA1
prerank,GO_Biological_Process_2021__regulation of necroptotic process (GO:0060544),-0.22347532929981084,-0.3423133105711894,0.8699186991869918,0.9601793913224627,1.0,6/23,19.73%,RIPK1;PDCD6IP;PELI1;BIRC2;STUB1;ARHGEF2
prerank,Reactome_2022__WNT Ligand Biogenesis And Trafficking R-HSA-3238698,0.24331252995816216,0.3420004984794894,0.8504672897196262,0.9460880455349083,1.0,8/24,27.78%,TMED5;WNT1;WNT3;WNT5A;PORCN;WNT10B;VPS29;WNT10A
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, DNA incision, 3'-to lesion (GO:0006295)",-0.21823592967531674,-0.3417698479407082,0.8615384615384616,0.9598221063338562,1.0,8/21,28.35%,CUL4A;GTF2H2;RPA2;ERCC3;ERCC1;DDB2;DDB1;XPA
prerank,"GO_Biological_Process_2021__nucleotide-excision repair, preincision complex stabilization (GO:0006293)",-0.21823592967531674,-0.3417698479407082,0.8615384615384616,0.9598221063338562,1.0,8/21,28.35%,CUL4A;GTF2H2;RPA2;ERCC3;ERCC1;DDB2;DDB1;XPA
prerank,GO_Biological_Process_2021__positive regulation of macrophage activation (GO:0043032),0.22466071395021106,0.34157792561376266,0.8583333333333333,0.9460859778929762,1.0,6/15,26.42%,KARS1;TLR4;WNT5A;HSPD1;STAP1;TTBK1
prerank,GO_Biological_Process_2021__regulation of cardiac muscle contraction by calcium ion signaling (GO:0010882),0.2281422348340389,0.34068817328577017,0.9044117647058824,0.9464503271537655,1.0,10/21,31.21%,TNNI3;CLIC2;SLC8A1;ATP1B1;CAMK2D;GSTM2;ANK2;ATP2A2;CALM2;CALM3
prerank,GO_Biological_Process_2021__negative regulation of cyclin-dependent protein serine/threonine kinase activity (GO:0045736),-0.2173738444012043,-0.3403093801437874,0.8861788617886179,0.9605210256912906,1.0,11/20,38.21%,NR2F2;LATS1;HEXIM2;IPO7;CDKN1C;TFAP4;CEBPA;CDKN1B;LATS2;CDKN2A;INCA1
prerank,GO_Biological_Process_2021__regulation of transcription by RNA polymerase III (GO:0006359),0.24734033823260934,0.3401021441552127,0.8955223880597015,0.9465326847837338,1.0,10/21,32.21%,ZC3H8;ZNF143;NAB2;POLR3C;RPTOR;POLR3F;ZNF76;ZNF345;DHX36;MAF1
prerank,Reactome_2022__Protein Methylation R-HSA-8876725,-0.210127653029837,-0.33997853036618836,0.897196261682243,0.9603905351080798,1.0,17/17,79.00%,METTL22;METTL21A;ETFB;VCP;KIN;CALM1;VCPKMT;EEF1A1;PRMT3;EEF1AKMT2;HSPA8;CAMKMT;EEF2KMT;EEF1AKMT1;EEF2;RPS2;ETFBKMT
prerank,GO_Biological_Process_2021__intermediate filament organization (GO:0045109),-0.21524616714777456,-0.33940714920014986,0.92,0.9604422481598881,1.0,6/15,32.52%,MTM1;GFAP;DSP;KRT14;NEFL;DNAJB6
prerank,KEGG_2021_Human__Nitrogen metabolism,-0.20894567366155867,-0.33934791227494154,0.928,0.9601415451205926,1.0,5/15,23.56%,CA4;CPS1;CA3;CA1;CA13
prerank,GO_Biological_Process_2021__positive regulation of amyloid precursor protein catabolic process (GO:1902993),0.21390219015577888,0.33913271202773293,0.8974358974358975,0.9469100969835343,1.0,11/22,32.73%,CLU;SLC2A13;CASP3;IFNGR1;IFNG;EFNA1;PICALM;ABCA2;LYN;EFNA3;GSK3A
prerank,GO_Biological_Process_2021__positive regulation of macrophage derived foam cell differentiation (GO:0010744),0.21189866834738696,0.3383571625068138,0.9035087719298246,0.9471907333455792,1.0,7/17,30.69%,CSF1;PLA2G2A;AGTR1;MSR1;LPL;AGT;APOB
prerank,Elsevier_Pathway_Collection__Sarcomere Disorganization and Intracellular Calcium Overload,0.24327118472443654,0.3379476847218105,0.872,0.947203086206812,1.0,12/23,34.27%,TNNI3;ACTG1;TCAP;SLC8A1;TLN1;JPH2;MYOZ2;PLN;ATP2A2;MYL3;MYH6;TTN
prerank,Reactome_2022__Processing Of Intronless Pre-mRNAs R-HSA-77595,0.23839211219263745,0.33730229644671816,0.860655737704918,0.9474097578676948,1.0,8/20,30.98%,CPSF3;CSTF1;CPSF7;CSTF2T;CSTF3;PCF11;PABPN1;SYMPK
prerank,GO_Biological_Process_2021__positive regulation of cardiac muscle tissue growth (GO:0055023),-0.21751414702313804,-0.33668628079417506,0.9230769230769231,0.9616685945718767,1.0,3/17,9.60%,TGFBR3;NOTCH1;IGF1
prerank,GO_Biological_Process_2021__ribosomal large subunit assembly (GO:0000027),-0.2364800246226307,-0.33661910912056625,0.8671875,0.9613637633624217,1.0,11/24,36.33%,NOP53;RPLP0;TRAF7;RPL23A;MDN1;RPL3;PPAN;RSL24D1;FASTKD2;DDX28;RPL11
prerank,Elsevier_Pathway_Collection__TNFR/NF-kB Classical Pathway in Multiple Myeloma Plasma Cells,-0.2506063519267859,-0.3365864083549089,0.875968992248062,0.9610292830402155,1.0,6/29,6.97%,RIPK1;NFKB1;TRADD;RELA;MCL1;ICAM1
prerank,GO_Biological_Process_2021__cardiac muscle cell development (GO:0055013),0.2292773154695618,0.3365320241068624,0.8615384615384616,0.9476658781826466,1.0,9/18,34.27%,TCAP;MYLK3;BMP10;SLC8A1;ALPK3;ALPK2;MYH6;VEGFA;TTN
prerank,WikiPathway_2021_Human__STING pathway in Kawasaki-like disease and COVID-19 WP4961,0.22198839340295828,0.33544636610519074,0.8717948717948718,0.9481415043925041,1.0,12/20,38.53%,NLRP3;FCGR2A;FCGR2C;REL;IRF3;IKBKG;NLRX1;CGAS;IKBKE;IKBKB;GSDMD;TBK1
prerank,GO_Biological_Process_2021__positive regulation of histone methylation (GO:0031062),-0.238864735765777,-0.33498434079717604,0.8257575757575758,0.9617973679545302,1.0,8/26,20.70%,MYB;CHTOP;BRCA1;TET1;WDR61;PRDM12;JARID2;PHF19
prerank,GO_Biological_Process_2021__retina homeostasis (GO:0001895),-0.2229728372282095,-0.3342204522375602,0.8872180451127819,0.9620132820065951,1.0,6/25,19.66%,BBS4;ZG16B;SLC28A2;PRDX1;ALB;OPRPN
prerank,GO_Biological_Process_2021__regulation of mRNA processing (GO:0050684),0.24777076826090327,0.3335322590220748,0.9298245614035088,0.9492314400996996,1.0,8/34,11.38%,SUPT6H;RBM23;SRPK3;ZFP36L1;IWS1;SF1;PTCD2;METTL16
prerank,GO_Biological_Process_2021__regulation of glucose transmembrane transport (GO:0010827),0.21616124359371605,0.3331208142078604,0.9090909090909091,0.9492123792437475,1.0,7/17,27.73%,APPL1;C3;PLA2G1B;SLC2A1;RTN2;C1QTNF12;INPP5K
prerank,WikiPathway_2021_Human__Intraflagellar transport proteins binding to dynein WP4532,-0.23155878123323442,-0.3328491163431741,0.8455284552845529,0.9626714569043601,1.0,7/25,23.00%,DYNC2H1;DYNC2LI1;IFT43;HSPB11;DYNLL2;DYNC1LI2;IFT80
prerank,GO_Biological_Process_2021__regulation of neuron projection arborization (GO:0150011),0.21527853318219053,0.3325554258864848,0.95,0.9492963699825484,1.0,5/15,21.08%,FZD4;WNT5A;DVL1;DLG4;NTNG2
prerank,Elsevier_Pathway_Collection__Apoptosis Block in Acute Myeloid Leukemia Cell,0.24649508334966416,0.332068095843986,0.8770491803278688,0.949334825968382,1.0,11/32,25.41%,PIM2;XIAP;BCL2L1;STAT3;FLT3LG;KMT2A;BIRC5;GRB2;AKT1;BBC3;BCL2
prerank,GO_Biological_Process_2021__diol biosynthetic process (GO:0034312),0.19555240083163977,0.3319657224287592,0.936,0.9491298543702901,1.0,6/17,32.41%,GCH1;ASAH2B;ASAH1;ABCA2;DHFR;SPR
prerank,GO_Biological_Process_2021__histone H4-K16 acetylation (GO:0043984),0.22661463745990107,0.330891848829734,0.8785046728971962,0.9495908260176523,1.0,6/19,21.84%,JADE1;KMT2A;MSL1;HCFC1;MSL2;KANSL1
prerank,GO_Biological_Process_2021__modulation by host of symbiont process (GO:0051851),-0.22959681787224545,-0.3297293066898553,0.8592592592592593,0.9644730501459996,1.0,10/32,25.64%,CX3CR1;ZNF639;CHD1;SAP30;CCL3;POU2F3;SP1;CARD9;HPN;SMARCA4
prerank,KEGG_2021_Human__Collecting duct acid secretion,-0.22582656507579899,-0.3296908027369088,0.9,0.9641484134692281,1.0,4/23,10.82%,ATP6V0C;SLC12A7;ATP6V1G1;ATP6V0D2
prerank,TRRUST_Transcription_Factors_2019__HDAC1 mouse,-0.223522497933057,-0.3288110664008008,0.8992248062015504,0.9644188740172257,1.0,12/25,35.27%,IL12B;NFYA;SP1;FAS;CDKN1A;COMP;AKAP12;STAR;NFKBIA;CDKN1B;RBL2;IL6
prerank,GO_Biological_Process_2021__positive regulation of protein ubiquitination (GO:0031398),-0.2384456743043082,-0.3285119024115371,0.9923664122137404,0.9642836405023301,1.0,28/79,20.88%,BIRC7;ARRDC4;FANCM;UBE2L3;HSPBP1;UBB;SMAD7;TRIB3;TOPORS;LRRK2;PHF23;BIRC2;FANCI;STUB1;MARCHF7;PSMD10;CUL3;FAM107A;DCUN1D4;TRAF6;HDAC3;MYCBP2;ARRDC3;SPHK1;DCUN1D1;BRCA1;PEF1;BMI1
prerank,GO_Biological_Process_2021__regulation of release of sequestered calcium ion into cytosol by sarcoplasmic reticulum (GO:0010880),-0.2443243312255231,-0.32820799891681457,0.8846153846153846,0.9641498013147398,1.0,9/22,26.37%,RYR2;FKBP1B;PRKACA;SRI;HRC;PDE4D;CACNA1C;ATP1A2;CASQ2
prerank,GO_Biological_Process_2021__positive regulation of histone modification (GO:0031058),-0.23996612433606224,-0.32769601014515537,0.8872180451127819,0.9641701131964449,1.0,11/32,27.17%,RPS6KA4;BRD7;CHTOP;FMR1;CDK9;NOS1;BRCA1;TET1;AKAP8L;CTBP1;IL1B
prerank,GO_Biological_Process_2021__positive regulation of glial cell differentiation (GO:0045687),0.2036715180217969,0.3274639120786173,0.9224806201550387,0.9518078064250483,1.0,6/18,22.22%,TENM4;CXCR4;EGR2;DICER1;CLCF1;ZNF365
prerank,GO_Biological_Process_2021__positive regulation of cation channel activity (GO:2001259),0.22712367201974185,0.3267797291634498,0.8879310344827587,0.9520405544137581,1.0,14/36,23.82%,HTT;TMSB4X;ANK3;NLGN3;ATPSCKMT;CTSS;CCR2;JPH2;IFNG;ARC;ADRB2;GSTM2;AKAP6;ANK2
prerank,GO_Biological_Process_2021__multivesicular body assembly (GO:0036258),-0.22714548639774623,-0.32663787826330687,0.8515625,0.9645553426465093,1.0,12/30,26.74%,CHMP2B;CHMP4B;PDCD6IP;CHMP1A;VPS37A;CHMP6;TSG101;VPS28;CHMP3;CHMP1B;VPS37B;SNF8
prerank,Elsevier_Pathway_Collection__Penile Detumescense Augmentation Mechanisms,0.20821969554084946,0.3255317598613856,0.9,0.9525777260139723,1.0,5/16,25.79%,RHOA;AGTR1;EDN1;GNAI1;ADRA1B
prerank,Elsevier_Pathway_Collection__Hypoxia-Induced Cell Death Evasion in Cancer,-0.21893773712055248,-0.3251107738078145,0.8444444444444444,0.9652830968075601,1.0,8/23,23.95%,HIPK2;BAX;IGF1;BNIP3;BECN1;IRS1;CASP9;BAD
prerank,GO_Biological_Process_2021__DNA methylation or demethylation (GO:0044728),0.21277970024578557,0.32478290734182363,0.896,0.9525657530397056,1.0,8/19,32.17%,MTRR;DNMT3A;EHMT1;KMT2E;HELLS;TEX15;BEND3;PPM1D
prerank,GO_Biological_Process_2021__DNA alkylation (GO:0006305),0.21277970024578557,0.32478290734182363,0.896,0.9525657530397056,1.0,8/19,32.17%,MTRR;DNMT3A;EHMT1;KMT2E;HELLS;TEX15;BEND3;PPM1D
prerank,Elsevier_Pathway_Collection__Actin Cytoskeleton,0.21271530948902853,0.3247153208936166,0.9223300970873787,0.9523095328879859,1.0,6/15,31.04%,TMOD1;DSTN;AKT1;CFL1;VASP;FSCN1
prerank,GO_Biological_Process_2021__positive regulation of neuron apoptotic process (GO:0043525),-0.23370057702408542,-0.32460516996109945,0.8814814814814815,0.9652977983691267,1.0,7/23,26.70%,MCL1;CCL3;BAX;NF1;SRPK2;TNF;TFAP2A
prerank,Reactome_2022__EPHA-mediated Growth Cone Collapse R-HSA-3928663,0.21204476477384326,0.3245531316710779,0.9215686274509803,0.952114838625626,1.0,3/15,11.90%,MYL9;RHOA;FYN
prerank,GO_Biological_Process_2021__positive regulation of erythrocyte differentiation (GO:0045648),-0.22624877377447983,-0.3240408174116865,0.8661417322834646,0.9653409277683543,1.0,4/27,7.27%,ACVR2A;PRMT1;HSPA1B;ACVR1B
prerank,GO_Biological_Process_2021__regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion (GO:0010881),-0.22840736568807884,-0.3236793915521664,0.9586776859504132,0.9652082876387896,1.0,7/17,26.37%,RYR2;FKBP1B;PRKACA;HRC;CACNA1C;ATP1A2;CASQ2
prerank,Reactome_2022__Transferrin Endocytosis And Recycling R-HSA-917977,-0.24028916304324263,-0.32312061641612827,0.8709677419354839,0.9653276295625081,1.0,10/28,26.59%,TFR2;ATP6V0C;ATP6V1G1;ATP6V0D2;ATP6V0B;MCOLN1;TFRC;STEAP2;TCIRG1;ATP6V1C1
prerank,TRRUST_Transcription_Factors_2019__REST human,0.21617811082536514,0.32290424065322354,0.9217391304347826,0.9529859786913772,1.0,7/20,24.61%,TH;NRP1;TAC1;PCSK1;CHGB;GABRB3;TPH2
prerank,Reactome_2022__Insulin Receptor Recycling R-HSA-77387,-0.22204388205859943,-0.3225669483910724,0.8861788617886179,0.9653681181928885,1.0,5/22,14.56%,ATP6V0C;ATP6V1G1;ATP6V0D2;ATP6V0B;INSR
prerank,TRRUST_Transcription_Factors_2019__RFX5 human,-0.205015502190889,-0.322175440836946,0.9508196721311475,0.965309187730838,1.0,4/16,15.18%,HLA-DMB;HLA-DRA;HLA-DRB1;HLA-DOB
prerank,"Reactome_2022__Synthesis, Secretion, And Inactivation Of Glucagon-like Peptide-1 (GLP-1) R-HSA-381771",-0.20485911441146437,-0.32139472900967075,0.9453125,0.9655212634050099,1.0,5/16,24.14%,GPR119;GNB3;SPCS3;DPP4;SEC11C
prerank,GO_Biological_Process_2021__response to zinc ion (GO:0010043),-0.22520260905742184,-0.32114179550832045,0.904,0.9653359168631817,1.0,10/25,26.12%,MT1A;MT1HL1;SLC30A2;MT1B;MT3;D2HGDH;ATP13A2;HVCN1;SLC30A4;MT1H
prerank,Elsevier_Pathway_Collection__Eicosanoids in Myeloid Cell Activation,0.22267234699841137,0.31975725872659544,0.8760330578512396,0.9550100099856184,1.0,8/23,25.69%,GNA15;MAPK1;PRKCE;GNAS;CYSLTR2;AKT1;GNAI1;PTGDR2
prerank,GO_Biological_Process_2021__regulation of epithelial cell differentiation (GO:0030856),-0.20718422042475887,-0.31947049838194025,0.9553571428571429,0.9661460893556054,1.0,8/17,35.40%,KIAA1109;SOX9;PRKX;KLF7;CD24;CAV1;OSR1;AJAP1
prerank,GO_Biological_Process_2021__cellular response to drug (GO:0035690),-0.2181809675303084,-0.3179833601123323,0.8897058823529411,0.9668319367922058,1.0,10/24,27.74%,DPEP1;PPM1E;AIM2;SLAMF8;GPLD1;TFRC;CERS1;IL1B;FBP1;KCNQ1
prerank,Reactome_2022__Regulation Of NF-kappa B Signaling R-HSA-9758274,-0.20092486625546008,-0.3178952139472889,0.9252336448598131,0.9665329341064166,1.0,4/18,18.36%,UBB;UBA52;LRRC14;TRAF6
prerank,Elsevier_Pathway_Collection__Acetaminophen Induced Hepatotoxicity,-0.20492623746336386,-0.3160054465350965,0.9285714285714286,0.9675259582906751,1.0,6/15,27.22%,AIFM1;BAX;ATP2B1;CASP9;CYP2E1;BID
prerank,GO_Biological_Process_2021__protein export from nucleus (GO:0006611),-0.21988297479626445,-0.31541270094852253,0.8947368421052632,0.9675964257880006,1.0,8/27,18.95%,STYX;RANBP3;SMURF1;RAN;XPO1;DUSP16;RANBP3L;TPR
prerank,Reactome_2022__Signaling By NODAL R-HSA-1181150,0.2098425915001541,0.31416070396607215,0.8677685950413223,0.95867645946379,1.0,4/21,9.15%,SMAD4;TDGF1P3;MAPK1;FOXH1
prerank,GO_Biological_Process_2021__positive regulation of microtubule polymerization or depolymerization (GO:0031112),-0.22955531579287547,-0.314095838903104,0.859504132231405,0.9682356980529738,1.0,4/25,10.37%,MAPRE1;PAK1;RAC1;TOGARAM1
prerank,GO_Biological_Process_2021__positive regulation of telomerase RNA localization to Cajal body (GO:1904874),-0.1993434871301731,-0.31363078583413706,0.9618320610687023,0.9682273766413608,1.0,9/15,38.14%,CCT2;CCT4;NOP10;CCT7;SHQ1;NHP2;CCT3;NAF1;CCT5
prerank,GO_Biological_Process_2021__negative regulation of mitotic metaphase/anaphase transition (GO:0045841),0.20905746476393997,0.312955583503648,0.8879310344827587,0.9592450370471026,1.0,7/22,22.90%,KLHL22;APC;PLK1;ZNF207;TRIP13;MAD2L1;FBXO5
prerank,WikiPathway_2021_Human__Extracellular vesicles in the crosstalk of cardiac cells WP4300,0.20982754547224078,0.311909673114696,0.9193548387096774,0.9597226855872353,1.0,9/19,35.14%,KDR;TLR4;STAT3;BIRC5;EGFR;ETS2;MMP9;SPP1;SOD1
prerank,Reactome_2022__TP53 Regulates Transcription Of Additional Cell Cycle Genes With Uncertain Roles In P53 Pathway R-HSA-6804115,-0.2260610631297044,-0.3111899263291096,0.8968253968253969,0.969520560646978,1.0,5/21,21.15%,CNOT3;BTG2;CNOT8;NPM1;CNOT1
prerank,GO_Biological_Process_2021__sensory perception of pain (GO:0019233),-0.20587706971357916,-0.3106339158538283,0.9508196721311475,0.9695426314049823,1.0,4/16,19.79%,PROK2;RETREG1;NIPSNAP1;PRDM12
prerank,GO_Biological_Process_2021__sodium ion homeostasis (GO:0055078),0.2163173307220298,0.31054725573238573,0.9145299145299145,0.9604344546733901,1.0,6/22,18.96%,ATP1A1;SCNN1B;SLC8A1;TMPRSS3;ATP1B1;SLC12A3
prerank,WikiPathway_2021_Human__Purinergic signaling WP4900,-0.2297500491104722,-0.31004350689791266,0.9090909090909091,0.9695903886728174,1.0,10/31,23.41%,GNAT2;P2RY1;P2RY2;P2RX6;P2RY10;ADORA3;P2RY12;GNAT1;P2RX3;P2RY13
prerank,Reactome_2022__Ion Homeostasis R-HSA-5578775,-0.24546881783218413,-0.3096982776635624,0.946969696969697,0.9694646818515079,1.0,14/45,17.52%,ATP1A3;RYR3;AHCYL1;ITPR3;NANOS1;RYR2;ATP2A3;KCNJ11;ATP2B1;FKBP1B;ATP1B3;SRI;FXYD2;ATP2B3
prerank,Elsevier_Pathway_Collection__SCF/FBXW7 Complex,0.2164366996247355,0.308978172778561,0.907563025210084,0.9612230257501245,1.0,7/20,24.16%,JUNB;TRIM17;HUWE1;MYC;AURKA;NFKB2;CCNE1
prerank,Elsevier_Pathway_Collection__SOD1 Mutation,0.20704758807787185,0.30890015534045734,0.916030534351145,0.9609902142434715,1.0,18/28,40.07%,CASP1;XIAP;CASP3;BCL2L1;HSPA5;DERL1;CHGB;BCL2;KIFAP3;CYCS;TP53;VEGFA;HSPB8;SOD1;CRYAB;HSPA1A;CYBB;HSPB1
prerank,Reactome_2022__rRNA Modification In Nucleus And Cytosol R-HSA-6790901,-0.2336565934313565,-0.3084035943751906,0.9747899159663865,0.9700312470469851,1.0,11/59,10.72%,EMG1;MPHOSPH10;TSR3;TRMT112;BMS1;UTP20;RPS6;KRR1;NAT10;IMP4;PNO1
prerank,GO_Biological_Process_2021__intracellular cholesterol transport (GO:0032367),0.18779182781332598,0.30802568146075815,0.952755905511811,0.9613483518549262,1.0,2/15,5.41%,SERAC1;ABCA1
prerank,Reactome_2022__Mitochondrial Fatty Acid Beta-Oxidation R-HSA-77289,-0.22345201326607395,-0.30692912058489763,0.9253731343283582,0.970750163354203,1.0,19/36,36.67%,DECR1;ACADM;ACAA2;HADHB;ACOT7;PCCA;ACSM6;ACOT12;ACOT11;ACOT1;ECI1;ACBD6;ACADS;ACSF2;ACAD10;ACOT13;PCCB;HADH;ACOT2
prerank,Elsevier_Pathway_Collection__Apoptosis of Mantle Cell Deregulation,-0.1985815134679316,-0.30667790713705895,0.926829268292683,0.970597223376921,1.0,6/17,27.22%,MCL1;BAX;FADD;CASP9;BAD;BID
prerank,WikiPathway_2021_Human__Regucalcin in proximal tubule epithelial kidney cells WP4838,0.22127851546058103,0.30622844186029746,0.8991596638655462,0.9623926926284684,1.0,5/30,7.71%,SMAD4;APAF1;MAPK1;TNFSF11;CASP3
prerank,Reactome_2022__Iron Uptake And Transport R-HSA-917937,-0.2298249307171765,-0.304336351635226,0.9672131147540983,0.9718798399143472,1.0,12/55,18.23%,TFR2;ATP6V0C;UBB;UBA52;ATP6V1G1;ATP6V0D2;ATP6V0B;CYBRD1;CUL1;MCOLN1;FTH1;TFRC
prerank,GO_Biological_Process_2021__phosphatidylglycerol metabolic process (GO:0046471),0.20951838655250626,0.30247760629225157,0.9243697478991597,0.9646412759791353,1.0,6/21,25.45%,SERAC1;PLA2G1B;PLA2G2A;LPCAT1;PLA2G2D;PLA2G4F
prerank,GO_Biological_Process_2021__dendrite morphogenesis (GO:0048813),-0.24712244138152636,-0.3015908152786506,0.967479674796748,0.9733654139124718,1.0,11/36,20.45%,MINK1;LRP4;MEF2A;SDC2;SHANK3;TAOK2;CTNND2;PAK3;EPHB1;MAP2;DIP2A
prerank,Elsevier_Pathway_Collection__IL6/IL12 Signaling Activates Immune System in Multiple Sclerosis,0.18521105190565945,0.30097903428910266,0.9186991869918699,0.965356973740036,1.0,3/18,11.77%,CXCL11;STAT3;TYK2
prerank,WikiPathway_2021_Human__IL1 and megakaryocytes in obesity WP2865,-0.20312220459627245,-0.30021949417083266,0.975609756097561,0.9739936253541204,1.0,5/24,14.37%,NFKB1;ICAM1;MYD88;PLA2G7;FCER1A
prerank,GO_Biological_Process_2021__positive regulation of nervous system development (GO:0051962),-0.21688923010526262,-0.29769320117649456,0.9140625,0.975468382535214,1.0,13/40,24.28%,CX3CR1;IL1RAP;LRRC4B;NAP1L1;RGS14;BDNF;CLSTN1;SLITRK2;EPHB1;SERPINF1;SRPX2;NLGN1;FAIM
prerank,GO_Biological_Process_2021__cellular iron ion homeostasis (GO:0006879),0.22110192106161777,0.29752173802332793,0.9672131147540983,0.9674305695982122,1.0,13/56,19.65%,SMAD4;ATP6V0D1;HJV;ATP6AP1;ALAS2;FXN;SLC11A1;IREB2;CCDC115;FRRS1;SLC39A14;MYC;HEPH
prerank,GO_Biological_Process_2021__positive regulation of tyrosine phosphorylation of STAT protein (GO:0042531),0.2249914411602591,0.2969821640113856,0.9327731092436975,0.9675045914300303,1.0,14/48,24.34%,TNFSF18;STAP2;CSF1R;CD40;STAT3;CTF1;PTK6;CCL5;IL23R;LIF;IL31RA;IFNG;CLCF1;IFNL1
prerank,Reactome_2022__Endosomal Sorting Complex Required For Transport (ESCRT) R-HSA-917729,-0.21844854665779906,-0.2963098966052371,0.9152542372881356,0.9760851267161849,1.0,8/29,18.34%,CHMP2B;UBB;CHMP4B;UBA52;VPS37A;CHMP6;TSG101;VPS28
prerank,GO_Biological_Process_2021__histone H4-K5 acetylation (GO:0043981),-0.1883056545492296,-0.2952683210329903,0.9507042253521126,0.9760974321937752,1.0,5/15,28.40%,KANSL2;PHF20;JADE2;KANSL3;MEAF6
prerank,GO_Biological_Process_2021__histone H4-K8 acetylation (GO:0043982),-0.1883056545492296,-0.2952683210329903,0.9507042253521126,0.9760974321937752,1.0,5/15,28.40%,KANSL2;PHF20;JADE2;KANSL3;MEAF6
prerank,TRRUST_Transcription_Factors_2019__POU5F1 mouse,0.18345776001065436,0.29482224662971634,0.9609375,0.9686637872704796,1.0,2/17,6.46%,TPT1;MESP1
prerank,GO_Biological_Process_2021__gene silencing by miRNA (GO:0035195),0.21192995453914615,0.29446285638812936,0.9312977099236641,0.9686006268778105,1.0,13/31,28.58%,AJUBA;TNRC6B;WTIP;RBM4;TNRC6A;AGO1;DICER1;TNRC6C;XPO5;CNOT7;CNOT6;AGO3;ADAR
prerank,TRRUST_Transcription_Factors_2019__POU2F1 human,0.20497963135523317,0.2943740532384107,0.9444444444444444,0.9683941326029869,1.0,10/32,23.87%,SNAI2;SDC4;RRM2B;TWIST1;RPTOR;TXNRD1;VCAM1;CAPN6;MAD2L1;GATA1
prerank,TRRUST_Transcription_Factors_2019__SREBF2 human,-0.20429013344534105,-0.29414432235373544,0.9193548387096774,0.9764765629601801,1.0,9/19,33.76%,PON2;ACOT7;HMGCR;FAS;LIPC;FDFT1;HNF4A;NPC1L1;LDLR
prerank,WikiPathway_2021_Human__Amplification and Expansion of Oncogenic Pathways as Metastatic Traits WP3678,-0.18389107813031394,-0.2936641698761926,0.9407407407407408,0.9764653018377907,1.0,5/17,25.01%,NOTCH1;CYTIP;VHL;WNT2;SRC
prerank,GO_Biological_Process_2021__mitotic spindle assembly checkpoint signaling (GO:0007094),0.2009920841086921,0.29249383122762723,0.9298245614035088,0.9687741118915973,1.0,6/21,20.71%,KLHL22;APC;PLK1;ZNF207;TRIP13;MAD2L1
prerank,GO_Biological_Process_2021__mitotic spindle checkpoint signaling (GO:0071174),0.2009920841086921,0.29249383122762723,0.9298245614035088,0.9687741118915973,1.0,6/21,20.71%,KLHL22;APC;PLK1;ZNF207;TRIP13;MAD2L1
prerank,GO_Biological_Process_2021__spindle assembly checkpoint signaling (GO:0071173),0.2009920841086921,0.29249383122762723,0.9298245614035088,0.9687741118915973,1.0,6/21,20.71%,KLHL22;APC;PLK1;ZNF207;TRIP13;MAD2L1
prerank,GO_Biological_Process_2021__cellular response to cadmium ion (GO:0071276),0.19491424876942054,0.29231762576793585,0.954954954954955,0.9686128922540781,1.0,9/26,25.84%,MT1X;MAPK1;MT2A;MAPK8;EGFR;MT1G;AKT1;AKR1C3;DAXX
prerank,GO_Biological_Process_2021__error-free translesion synthesis (GO:0070987),-0.1878986135656764,-0.2907444278451017,0.9365079365079365,0.9780817173599985,1.0,6/22,23.58%,UBB;UBA52;RPA2;UFD1;PCNA;VCP
prerank,Elsevier_Pathway_Collection__Golgi Transport,-0.20141949249421567,-0.2898487266222258,0.9534883720930233,0.9783203992650195,1.0,4/20,12.47%,SEC31B;GBF1;TRAPPC3;RAB2A
prerank,GO_Biological_Process_2021__cellular response to amino acid starvation (GO:0034198),-0.22091325172920703,-0.28965195440113545,0.991304347826087,0.9780899989079347,1.0,16/71,16.25%,RRAGC;ATP6V0C;SZT2;RHEB;SESN1;FLCN;LAMTOR2;ATP6V1G1;ATP6V0D2;ATP6V0B;EIF2AK3;LAMTOR3;TFEB;SLC38A9;EIF2AK2;CASTOR1
prerank,GO_Biological_Process_2021__heme biosynthetic process (GO:0006783),-0.20606824213135805,-0.2888729352794558,0.9097744360902256,0.9782301590722926,1.0,6/22,23.03%,NFE2L1;COX10;UROD;CPOX;ALB;ALAS1
prerank,GO_Biological_Process_2021__response to amino acid starvation (GO:1990928),-0.217186966753288,-0.28850750653759183,0.9915254237288136,0.978160829576667,1.0,16/72,16.25%,RRAGC;ATP6V0C;SZT2;RHEB;SESN1;FLCN;LAMTOR2;ATP6V1G1;ATP6V0D2;ATP6V0B;EIF2AK3;LAMTOR3;TFEB;SLC38A9;EIF2AK2;CASTOR1
prerank,KEGG_2021_Human__RNA polymerase,-0.20140908349218734,-0.28768630993479566,0.9137931034482759,0.9783417041500713,1.0,10/31,25.48%,POLR1A;POLR2C;POLR1H;POLR2J2;POLR2A;POLR3H;POLR2J3;POLR3G;POLR2G;POLR2F
prerank,GO_Biological_Process_2021__negative regulation of striated muscle cell differentiation (GO:0051154),0.18966365675634986,0.28729256946685533,0.9487179487179487,0.9715668175863976,1.0,6/18,24.22%,XBP1;FRS2;BHLHE41;BHLHA15;HDAC1;SOX6
prerank,GO_Biological_Process_2021__regulation of non-canonical Wnt signaling pathway (GO:2000050),0.1767866459534897,0.2871152180356042,0.9857142857142858,0.9713863172004386,1.0,4/15,22.96%,RSPO3;SPEF1;NPHP3;SFRP1
prerank,Reactome_2022__Platelet Calcium Homeostasis R-HSA-418360,-0.2050154633409774,-0.2859323221921241,0.9166666666666666,0.9790761597757611,1.0,8/25,22.42%,ITPR3;ATP2A3;P2RX6;ATP2B1;SRI;ATP2B3;P2RX3;SLC8A3
prerank,GO_Biological_Process_2021__negative regulation of cell development (GO:0010721),-0.20545054570055582,-0.2858894554778292,0.9322033898305084,0.9787489743570248,1.0,11/23,35.27%,CCL11;NOTCH1;IGF1;PCM1;APPL2;RFLNA;TNF;IL1B;DYNLT1;PTHLH;IL6
prerank,Reactome_2022__Postmitotic Nuclear Pore Complex (NPC) Reformation R-HSA-9615933,-0.2034574657650865,-0.2838286525959467,0.9478260869565217,0.9796535900883334,1.0,11/27,30.16%,SUMO1;NUP188;TNPO1;RAN;NUP93;NUP205;NUP62;NUP85;NUP35;UBE2I;NUP107
prerank,GO_Biological_Process_2021__regulation of water loss via skin (GO:0033561),-0.1900257622947668,-0.2832985353581136,0.957983193277311,0.9792797891218954,1.0,18/18,81.01%,HRNR;ALOX12B;MET;TP63;LSR;KDF1;KRT16;FLG2;ABCA12;ALOX12;SFN;CLDN1;CLDN4;FA2H;FLG;TMEM79;STMN1;UGCG
prerank,GO_Biological_Process_2021__establishment of skin barrier (GO:0061436),-0.1900257622947668,-0.2832985353581136,0.957983193277311,0.9792797891218954,1.0,18/18,81.01%,HRNR;ALOX12B;MET;TP63;LSR;KDF1;KRT16;FLG2;ABCA12;ALOX12;SFN;CLDN1;CLDN4;FA2H;FLG;TMEM79;STMN1;UGCG
prerank,"GO_Biological_Process_2021__regulation of alternative mRNA splicing, via spliceosome (GO:0000381)",0.20128906752018005,0.28284000282876626,0.9357798165137615,0.9738859360946337,1.0,15/48,26.63%,NSRP1;CELF2;MBNL2;RBM4;WTAP;RBMX;MBNL1;THRAP3;DDX5;RBM24;PTBP1;CELF4;CELF3;RBM7;RBM15
prerank,Elsevier_Pathway_Collection__Neutrophil Recruitment in Sinovium in Gout,-0.2000664339884336,-0.28282012901236514,0.9719626168224299,0.9792446412332266,1.0,6/36,8.91%,TRADD;ICAM1;MYD88;C5;IL1RAP;CCL3
prerank,GO_Biological_Process_2021__late endosome to vacuole transport via multivesicular body sorting pathway (GO:0032511),-0.18109108568625507,-0.2826749406644731,0.9776119402985075,0.9789841850942587,1.0,6/16,26.74%,CHMP4B;CHMP6;VPS28;LEPROTL1;TMEM50A;SNF8
prerank,Reactome_2022__rRNA Processing R-HSA-72312,-0.1766834014419827,-0.28257172289257426,1.0,0.9786959194099,1.0,58/196,26.16%,EMG1;MPHOSPH10;TSR3;TRMT112;BMS1;UTP20;RPL39;RPS6;RPLP0;RPL28;KRR1;RPP38;RPL36AL;NAT10;RPS8;MPHOSPH6;DDX56;RPS15A;UBA52;IMP4;RPL10A;PNO1;MRM1;LTV1;GNL3;RPS17;PRORP;CSNK1D;RPL23A;NOP10;EXOSC8;EXOSC3;RPL30;HEATR1;RPL41;RPS21;CSNK1E;RPL36;RPP40;RIOK2;RPL37;C1D;RPL8;TFB1M;UTP25;FTSJ3;RPL3;MRM3;HSD17B10;RPLP1;BYSL;NOP14;SENP3;RPP25;RPS28;RPS10;RPL21;FBL
prerank,GO_Biological_Process_2021__regulation of acute inflammatory response (GO:0002673),-0.18708251240633222,-0.2799417396028791,0.9669421487603306,0.9799942365518185,1.0,7/18,35.27%,APCS;GSTP1;FFAR2;DNASE1;DNASE1L3;F12;IL6
prerank,GO_Biological_Process_2021__RNA splicing (GO:0008380),-0.18858289607051726,-0.2788151174862572,0.992,0.9803531070894788,1.0,32/97,28.52%,SF3B3;RRAGC;WDR83;SRPK1;MPHOSPH10;SNRPF;SRSF4;SNRPD1;DBR1;WT1;PPIG;RNF113A;SCAF11;DHX15;RSRC1;SNRPA1;DDX23;SRPK2;USB1;RNPS1;FUS;SRSF2;SF3B2;SF3B4;PRPF18;BCAS2;SNRPG;NOL3;RBM8A;SRSF11;YJU2;SNRPD2
prerank,Reactome_2022__Pyroptosis R-HSA-5620971,-0.20355769865050521,-0.2781093836637662,0.9173553719008265,0.9804434881362801,1.0,6/24,16.03%,CHMP2B;CHMP4B;IRF2;BAX;CHMP6;HMGB1
prerank,Elsevier_Pathway_Collection__Mitochondrial DNA Replication and Transcription,0.19335837573039139,0.2769842031705093,0.9461538461538461,0.9772714169357505,1.0,5/16,22.23%,POLRMT;PPARGC1A;SSBP1;ENDOG;MTERF1
prerank,KEGG_2021_Human__Cytosolic DNA-sensing pathway,0.20558884841654634,0.2763429390304988,0.9285714285714286,0.9773714053683644,1.0,22/47,35.24%,POLR3E;CASP1;POLR3B;CCL5;CCL4L2;POLR3C;POLR3D;POLR2K;NFKBIB;IRF3;POLR3F;IKBKG;PYCARD;ADAR;POLR1C;CGAS;MAVS;DDX58;ZBP1;RIPK3;IKBKE;POLR3K
prerank,Reactome_2022__Class C/3 (Metabotropic Glutamate/Pheromone Receptors) R-HSA-420499,0.1793081475896274,0.2759946400282731,0.9710144927536232,0.9772847071684676,1.0,7/16,32.59%,GABBR2;TAS2R4;TAS2R31;TAS2R20;GRM1;GRM7;TAS2R60
prerank,GO_Biological_Process_2021__negative regulation of neuron differentiation (GO:0045665),-0.17051711608009418,-0.2743413796316878,0.9745762711864406,0.9825035104260447,1.0,6/19,29.14%,SOX2;SOX9;MED1;DLX1;CNTN4;HES5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Pulmonary Emphysema,0.20700340071181797,0.2742601762483744,0.9375,0.9780303598491903,1.0,6/35,9.07%,KDR;ELANE;CD40;CTSG;SLPI;TLR4
prerank,GO_Biological_Process_2021__response to cadmium ion (GO:0046686),0.18765218197595046,0.2740796058971968,0.9568965517241379,0.9778615037703118,1.0,9/28,25.84%,MT1X;MAPK1;MT2A;MAPK8;EGFR;MT1G;AKT1;AKR1C3;DAXX
prerank,GO_Biological_Process_2021__porphyrin-containing compound biosynthetic process (GO:0006779),-0.1996578747846686,-0.27389501540295424,0.9541984732824428,0.9824228290460778,1.0,7/24,23.03%,NFE2L1;COX10;UROD;CPOX;ALB;SUCLA2;ALAS1
prerank,GO_Biological_Process_2021__homologous chromosome pairing at meiosis (GO:0007129),0.19752339341811775,0.27263995469871943,0.9112903225806451,0.9785192672929348,1.0,8/24,25.93%,MEI4;SIRT7;TRIP13;RAD21;KASH5;ANKRD31;BAG6;RNF212B
prerank,GO_Biological_Process_2021__regulation of osteoblast proliferation (GO:0033688),-0.16622541980245442,-0.27237121600309466,0.9794520547945206,0.9830520593976559,1.0,3/16,14.99%,MN1;EIF2AK2;HPSE
prerank,Elsevier_Pathway_Collection__SIRT6 Signaling in Aging,-0.16975231714392383,-0.2712656059219936,0.9781021897810219,0.9833292113134428,1.0,4/20,17.12%,NFKB1;RELA;SIRT6;WRN
prerank,GO_Biological_Process_2021__regulation of cell cycle G1/S phase transition (GO:1902806),-0.1977789846943414,-0.26794315232531085,0.9636363636363636,0.9848789205270196,1.0,12/34,24.30%,TMEM14B;DDRGK1;MN1;STXBP4;PHB2;PSME1;APPL2;ID2;CDC73;CDKN1A;FAM83D;TRIM39
prerank,Elsevier_Pathway_Collection__Translation,0.17936915526559544,0.26755438298419887,0.968503937007874,0.981265472164996,1.0,8/24,29.66%,TPT1;EEF1B2;RPS6KB1;FARS2;EEF2;EIF4A1;MARS2;PABPC1
prerank,GO_Biological_Process_2021__endosome organization (GO:0007032),-0.19138952024533676,-0.26608565323736993,0.9734513274336283,0.9855877725156587,1.0,13/41,24.43%,PLEKHJ1;RAB22A;CHMP2B;ALS2CL;EEA1;USP50;RILP;SQSTM1;CLCN3;TMCC1;DNM1;RAB27A;DNAJC13
prerank,Elsevier_Pathway_Collection__IL22 Induces Keratinocyte Proliferation in Psoriasis,0.19012376974764247,0.26543710525438463,0.9541984732824428,0.9822575478295301,1.0,17/33,38.69%,MAPK1;STAT3;TYK2;S100A9;GRB2;MAPK8;PTPN11;AKT1;FLG;KRT10;S100A8;MMP9;TP53;PDPK1;MAPK14;MMP12;MTOR
prerank,Reactome_2022__rRNA Processing In Nucleus And Cytosol R-HSA-8868773,-0.16486523414942375,-0.2649913722613904,1.0,0.9858345492260118,1.0,62/186,30.40%,EMG1;MPHOSPH10;TSR3;TRMT112;BMS1;UTP20;RPL39;RPS6;RPLP0;RPL28;KRR1;RPP38;RPL36AL;NAT10;RPS8;MPHOSPH6;DDX56;RPS15A;UBA52;IMP4;RPL10A;PNO1;LTV1;GNL3;RPS17;CSNK1D;RPL23A;NOP10;EXOSC8;EXOSC3;RPL30;HEATR1;RPL41;RPS21;CSNK1E;RPL36;RPP40;RIOK2;RPL37;C1D;RPL8;UTP25;FTSJ3;RPL3;RPLP1;BYSL;NOP14;SENP3;RPP25;RPS28;RPS10;RPL21;FBL;RPS11;RRP7A;NHP2;NOL12;TSR1;EXOSC5;TEX10;RPL29;RPL7A
prerank,Elsevier_Pathway_Collection__RAS/RAF/MAPK Signaling Activation in Cancer,-0.18439465829246016,-0.2647388036798341,0.96875,0.9856298894184943,1.0,6/29,15.70%,PAK1;RAC1;MAP2K7;MAP3K1;NRAS;MAP2K2
prerank,GO_Biological_Process_2021__regulation of mitochondrial translation (GO:0070129),-0.17697768782624176,-0.2644636945469972,0.992,0.9854253766367005,1.0,2/21,4.82%,MRPS27;MTG2
prerank,WikiPathway_2021_Human__Cytosolic DNA-sensing pathway WP4655,0.19345875576946306,0.2637278963800956,0.967741935483871,0.9829491127468436,1.0,26/57,35.24%,POLR3E;CASP1;ATG12;POLR3B;CCL5;CCL4L2;POLR3C;POLR3D;POLR2K;NFKBIB;IRF3;POLR3F;ATG5;IKBKG;NLRX1;PYCARD;CYLD;ADAR;POLR1C;CGAS;MAVS;DDX58;ZBP1;RIPK3;IKBKE;POLR3K
prerank,WikiPathway_2021_Human__NAD+ metabolism WP3644,-0.1492602880233467,-0.2636088067846595,0.9848484848484849,0.9855541453666566,1.0,3/16,16.45%,NMNAT1;SIRT6;SIRT2
prerank,Reactome_2022__FGFR2 Alternative Splicing R-HSA-6803529,-0.18813309415796758,-0.26333734477603504,0.9657534246575342,0.9853333457659342,1.0,14/26,40.21%,HNRNPF;POLR2C;POLR2A;POLR2G;POLR2F;HNRNPM;HNRNPH1;ESRP1;POLR2I;RBFOX2;ESRP2;TIA1;HNRNPA1;POLR2H
prerank,Reactome_2022__Metabolism Of Angiotensinogen To Angiotensins R-HSA-2022377,-0.1616316389818516,-0.2620192671760722,0.9851851851851852,0.9857076130678739,1.0,8/18,34.25%,ACE2;CPB2;ENPEP;CTSD;ANPEP;CPB1;CMA1;KCTD11
prerank,Elsevier_Pathway_Collection__Blood-Brain Barrier Disruption in Epileptiform Disorders,-0.18606307623659507,-0.2612842715175118,0.9848484848484849,0.985739978546602,1.0,10/24,36.34%,RPS6;RHEB;ALB;IL1B;GJA1;TGFBR1;TSC2;SLC1A2;IL6;ITPR1
prerank,GO_Biological_Process_2021__proton transmembrane transport (GO:1902600),-0.19231042678921473,-0.26114646873051345,0.9465648854961832,0.9854535773600138,1.0,10/29,28.66%,ATP6V0C;ATP1A3;ATP12A;ATP5PO;NOX5;HVCN1;UCP2;ATP1A2;SLC4A11;SLC9A1
prerank,Reactome_2022__Phase 0 - Rapid Depolarisation R-HSA-5576892,0.1773256224428695,0.26111673763601906,0.959349593495935,0.984136921024393,1.0,11/28,30.82%,SCN1B;CAMK2G;SCN11A;RANGRF;SCN3A;CAMK2D;FGF13;CACNA2D2;SCN5A;CACNG4;SCN8A
prerank,Elsevier_Pathway_Collection__Inherited Channelopathies,-0.18073030347877583,-0.2609601198401592,0.9624060150375939,0.9852217507490617,1.0,12/22,37.01%,KCNJ11;KCNQ3;KCNMA1;CACNB4;SCN2A;HCN1;CHRNB2;GABRD;SCN1A;ADAM22;CHRNA7;GABRB2
prerank,GO_Biological_Process_2021__positive regulation of myeloid cell differentiation (GO:0045639),-0.18812866631783337,-0.26090591991852413,0.9236641221374046,0.9849016138603308,1.0,5/37,7.27%,ACVR2A;PRMT1;THPO;HSPA1B;ACVR1B
prerank,Reactome_2022__mRNA Splicing - Minor Pathway R-HSA-72165,-0.1975236045546865,-0.2602600463522459,0.9833333333333333,0.9849013707584684,1.0,14/49,25.73%,SF3B3;SF3B6;SNRPF;SNRNP200;POLR2C;YBX1;POLR2A;DDX23;SRSF2;SF3B2;POLR2G;SF3B4;POLR2F;SNRPG
prerank,Elsevier_Pathway_Collection__Proteins Involved in T-Cell Acute Lymphoblastic Leukemia,-0.1885424226130355,-0.25976668767356836,0.9618320610687023,0.98480892565376,1.0,10/37,26.47%,MYB;NOTCH1;SET;CCND3;CXCL12;IL7;LMO2;RBPJ;TGFB1;TLX3
prerank,TRRUST_Transcription_Factors_2019__FOXO1 human,-0.17671122730063088,-0.25874153469474687,0.96875,0.9850195686743984,1.0,10/20,37.34%,IRS2;TXNIP;PDGFA;RAG1;HYOU1;LHB;CDKN1B;IL6;EGR1;KLF2
prerank,WikiPathway_2021_Human__Ebstein-Barr virus LMP1 signaling WP262,-0.16714011716396548,-0.2584817549383582,0.9609375,0.9847958848988813,1.0,3/22,6.36%,NFKB1;TRADD;RELA
prerank,GO_Biological_Process_2021__regulation of G protein-coupled receptor signaling pathway (GO:0008277),0.17824809210169926,0.2559085878854667,0.9833333333333333,0.9866682893211651,1.0,20/73,23.65%,CALCR;SAG;CRY1;FNTA;ZDHHC3;ADCYAP1;GRK6;GUCY2D;CNGB1;C3;METAP2;SLC39A14;SYP;CCL5;YWHAB;ZDHHC7;FRMPD1;MRAP;EDN1;RIC8B
prerank,"Reactome_2022__Incretin Synthesis, Secretion, And Inactivation R-HSA-400508",-0.17531056033080408,-0.2553209974237627,0.9758064516129032,0.9861053124380448,1.0,7/18,32.65%,GPR119;GNB3;SPCS3;DPP4;SEC11C;GATA4;FFAR4
prerank,Reactome_2022__GAB1 Signalosome R-HSA-180292,0.16224204003053944,0.25467840619507187,0.9703703703703703,0.9870490452749119,1.0,5/16,24.11%,BTC;GRB2;PTPN11;EGFR;PIK3R1
prerank,"Elsevier_Pathway_Collection__Myocarditis, Acute Viral Overiew",-0.17357415362016776,-0.2541492106381722,0.9784172661870504,0.9863896790327289,1.0,2/20,4.72%,RAC1;EIF4G1
prerank,GO_Biological_Process_2021__histone H2A acetylation (GO:0043968),-0.15405286465167373,-0.25325317782697304,1.0,0.9864885067517714,1.0,5/16,30.97%,EP400;ING3;MSL3;MEAF6;MORF4L2
prerank,Elsevier_Pathway_Collection__Lipids Enhance Apoptotic Cell Engulfment and Reduce Inflammation,-0.19141102099655935,-0.2530683917288924,0.957983193277311,0.9862431921179741,1.0,8/25,27.17%,THBS1;NR4A1;MERTK;NR1H2;NR1H3;STAB2;TNF;IL1B
prerank,GO_Biological_Process_2021__hydrogen peroxide catabolic process (GO:0042744),0.15390888570359013,0.2524803256498166,1.0,0.9878835590923677,1.0,5/16,29.55%,HBA1;HBM;GPX3;APOA4;HBD
prerank,GO_Biological_Process_2021__clathrin coat assembly (GO:0048268),0.15280230352236307,0.24925333238762493,0.9682539682539683,0.9892162881957725,1.0,5/15,28.31%,PIK3C2A;FCHO2;NSG1;PICALM;EPS15
prerank,"GO_Biological_Process_2021__DNA catabolic process, endonucleolytic (GO:0000737)",-0.184437385682282,-0.24875548796705335,0.9847328244274809,0.9879370171255256,1.0,5/22,17.27%,KPNA1;DFFA;MUS81;HMGB1;HMGB2
prerank,Elsevier_Pathway_Collection__Reperfusion Injury in Myocardial ischemia,0.16625628606869625,0.24709700332673337,0.9344262295081968,0.9899599881658449,1.0,10/27,28.06%,APAF1;SLC25A4;CASP3;CACNA2D1;HDAC1;ENDOG;BBC3;BCL2;PARP1;CYCS
prerank,GO_Biological_Process_2021__regulation of rRNA processing (GO:2000232),-0.15312078139313187,-0.24698276506912187,1.0,0.9884596165418595,1.0,4/16,27.09%,TRMT112;HEATR1;RIOK2;SHQ1
prerank,GO_Biological_Process_2021__RNA transport (GO:0050658),-0.17847200121605192,-0.24671007863532454,0.9851851851851852,0.9882340048784092,1.0,24/71,29.80%,POM121C;SRSF4;NUP188;CHTOP;SIDT2;FMR1;NUP62CL;THOC2;YBX1;DHX38;ALYREF;TPR;RNPS1;NXF5;THOC5;SRSF2;FLOT1;NUP62;RBM8A;SRSF11;NXF1;RTRAF;ZFP36;SARNP
prerank,Reactome_2022__Major Pathway Of rRNA Processing In Nucleolus And Cytosol R-HSA-6791226,-0.15333820054704728,-0.24636132528057816,1.0,0.9880626713052115,1.0,49/176,26.16%,EMG1;MPHOSPH10;BMS1;UTP20;RPL39;RPS6;RPLP0;RPL28;KRR1;RPP38;RPL36AL;RPS8;MPHOSPH6;DDX56;RPS15A;UBA52;IMP4;RPL10A;PNO1;LTV1;GNL3;RPS17;CSNK1D;RPL23A;EXOSC8;EXOSC3;RPL30;HEATR1;RPL41;RPS21;CSNK1E;RPL36;RPP40;RIOK2;RPL37;C1D;RPL8;UTP25;FTSJ3;RPL3;RPLP1;BYSL;NOP14;SENP3;RPP25;RPS28;RPS10;RPL21;FBL
prerank,Elsevier_Pathway_Collection__AHR Signaling in M1 Macrophages Function,-0.16402527946885886,-0.24622811365119707,0.9761904761904762,0.9877593606312265,1.0,10/22,35.86%,TIRAP;MYD88;IL12B;TRAF6;TNF;JAK1;IRAK1;NFKBIA;IL6;CD14
prerank,GO_Biological_Process_2021__regulation of viral life cycle (GO:1903900),0.17290977617106373,0.24449152054009174,0.9652173913043478,0.9908377439931002,1.0,23/23,82.72%,TRIM22;TRIM6;TRIM38;KPNA2;KPNA6;TRIM34;VPS4A;TRIM5;TRIM27;TYRO3;AXL;TRIM31;LAMP3;CD209;NECTIN2;TRIM25;TRIM68;TRIM21;PPIA;TRIM14;TRIM62;TSG101;HS3ST5
prerank,"GO_Biological_Process_2021__base-excision repair, gap-filling (GO:0006287)",0.16849658020365818,0.24421007618666504,0.9632352941176471,0.9906815433528027,1.0,6/35,14.51%,POLD1;XRCC1;SMUG1;APEX1;RPA1;POLE
prerank,Elsevier_Pathway_Collection__Alcoholic Dilated Cardiomyopathy (Mouse Model),0.17233014581245187,0.24395962596877352,0.943089430894309,0.9904951254174175,1.0,5/26,14.90%,TNNI3;ACTG1;TCAP;LAMA2;SLC8A1
prerank,"GO_Biological_Process_2021__mitochondrial electron transport, cytochrome c to oxygen (GO:0006123)",-0.1576644753845841,-0.2429454198522104,0.9763779527559056,0.9889365086484158,1.0,4/17,23.33%,COX7C;COX10;NDUFA4;COX7A2L
prerank,GO_Biological_Process_2021__rRNA metabolic process (GO:0016072),0.15714410856213518,0.24279223646340295,1.0,0.990765951911536,1.0,38/162,20.65%,RPL15;RPL19;EXOSC4;RPS14;RPL22;WDR36;RPL13A;RPL23;NOB1;POP5;IMP3;LAS1L;RPL12;RPL18;RPS27;SLFN13;RPL34;DKC1;DIS3L;EXOSC9;NOL6;PWP2;RPL37A;RCL1;XRN1;LYAR;RRP1;RPL5;UTP18;WDR55;RRP12;NOL8;DDX52;RPL26;RPL4;DDX10;RPL27;PELP1
prerank,GO_Biological_Process_2021__positive regulation of dendrite morphogenesis (GO:0050775),-0.15693043110771093,-0.24162423410630776,0.991304347826087,0.9891912959602547,1.0,6/19,24.76%,SS18L1;LRP8;OBSL1;CAMK2B;CDKL5;RELN
prerank,GO_Biological_Process_2021__nuclear export (GO:0051168),-0.16967233206757731,-0.2412767004805673,1.0,0.9889871901565298,1.0,26/81,27.39%,POM121C;RITA1;SRSF4;NUP188;CHTOP;RANBP3;SMURF1;NUP62CL;RAN;XPO1;THOC2;DHX38;RANBP3L;ALYREF;TPR;RNPS1;THOC5;SRSF2;TGFB1;NUP62;ATXN1;XPO4;RBM8A;SRSF11;NXF1;MALT1
prerank,KEGG_2021_Human__Porphyrin and chlorophyll metabolism,-0.1788353019475201,-0.23862497662712132,0.9921259842519685,0.9898058550719425,1.0,14/40,30.06%,UGT2A3;COX10;UGT2B17;UROD;UGT1A1;CPOX;HCCS;HEPHL1;UGT2B28;UGT2B4;ALAS1;UGT2B15;UGT2B10;UGT1A5
prerank,Reactome_2022__Formation Of A Pool Of Free 40S Subunits R-HSA-72689,0.1705192512713769,0.23708739800706807,1.0,0.9930911493079398,1.0,36/96,31.95%,RPL15;RPL19;RPS14;RPL22;EIF3C;RPL13A;RPL23;RPS27L;RPL12;RPL18;RPS27;RPL34;EIF3A;RPL39L;RPL37A;RPL5;RPL26;RPL4;RPL27;EIF3M;RPL3L;RPS2;EIF3K;RPL9;RPL31;MRPL13;RPS23;EIF3E;RPS9;RPS4Y1;RPL7;RPS15;EIF1AX;EIF3L;RPS20;RPL22L1
prerank,Reactome_2022__L13a-mediated Translational Silencing Of Ceruloplasmin Expression R-HSA-156827,0.16973700084644802,0.23657117062780944,1.0,0.993027951533173,1.0,40/106,31.95%,RPL15;EIF4A2;RPL19;RPS14;RPL22;EIF3C;RPL13A;RPL23;RPS27L;RPL12;RPL18;RPS27;RPL34;EIF3A;RPL39L;RPL37A;RPL5;RPL26;RPL4;RPL27;EIF3M;RPL3L;RPS2;EIF4A1;EIF3K;RPL9;RPL31;MRPL13;RPS23;EIF3E;RPS9;RPS4Y1;PABPC1;RPL7;RPS15;EIF1AX;EIF3L;EIF2S1;RPS20;RPL22L1
prerank,GO_Biological_Process_2021__nucleic acid metabolic process (GO:0090304),-0.1780537093955203,-0.23647866428111292,1.0,0.9903840698930556,1.0,26/69,33.72%,HNRNPF;MMS19;POLG;POLR2C;DNA2;DDX54;RAN;DXO;HNRNPL;POLR2A;HNRNPK;WRN;HNRNPU;METTL14;RAD50;POLR2G;DDX24;POLR2F;HNRNPM;HNRNPH1;ANKLE1;POLR2I;HNRNPD;DNASE1L3;RBFOX2;RECQL5
prerank,Elsevier_Pathway_Collection__mTOR Signaling Activation by Taste Sensor Receptors (Rodent Model),0.16711099160448462,0.2330437733235984,0.9694656488549618,0.9941467695007379,1.0,15/29,38.84%,GNA15;MAPK1;RPTOR;RPS6KB1;STK11;GNAI1;ATG13;AKT1S1;EIF4EBP1;ULK1;GNB1;SLC1A5;TAS1R3;MTOR;TAS1R1
prerank,GO_Biological_Process_2021__nucleotide metabolic process (GO:0009117),-0.16616587076178155,-0.23280697078219664,0.9736842105263158,0.9915268042223092,1.0,10/23,36.60%,CTPS2;NMNAT1;AK7;PARK7;REXO2;GUK1;CMPK1;NME2;NMNAT2;NUDT5
prerank,Elsevier_Pathway_Collection__Proteins Involved in Cholesteatoma,0.17470990462473754,0.23278003597147745,0.983739837398374,0.9939688207423071,1.0,7/34,18.19%,DEFB1;TNFSF11;TLR4;HSP90B1;HSPA5;MYC;CAMP
prerank,Reactome_2022__GTP Hydrolysis And Joining Of 60S Ribosomal Subunit R-HSA-72706,0.16617619474170478,0.23037411363803442,1.0,0.9947262710912299,1.0,40/107,31.95%,RPL15;EIF4A2;RPL19;RPS14;RPL22;EIF3C;RPL13A;RPL23;RPS27L;RPL12;RPL18;RPS27;RPL34;EIF3A;RPL39L;RPL37A;RPL5;RPL26;RPL4;RPL27;EIF3M;EIF5;RPL3L;RPS2;EIF4A1;EIF3K;RPL9;RPL31;MRPL13;RPS23;EIF3E;RPS9;RPS4Y1;RPL7;RPS15;EIF1AX;EIF3L;EIF2S1;RPS20;RPL22L1
prerank,Elsevier_Pathway_Collection__MTHFR Activity Regulation,0.1512072137975337,0.226351335453222,1.0,0.9958751716543989,1.0,10/19,39.73%,MAP3K14;SREBF1;TRAF2;AKT1;TNFRSF1A;IGF1R;SOD1;PDPK1;MTHFR;MAP3K5
prerank,GO_Biological_Process_2021__cardiac muscle contraction (GO:0060048),-0.1719668559077885,-0.22587419947641582,0.9836065573770492,0.9936287666384077,1.0,11/31,28.05%,TNNC1;GRK2;MYBPC3;RYR2;SCN4B;TNNI1;MYLK2;ATP1A2;CASQ2;KCNQ1;TPM1
prerank,GO_Biological_Process_2021__apoptotic nuclear changes (GO:0030262),0.15744126455552596,0.2255885002682214,1.0,0.9958559514162811,1.0,10/23,35.12%,CASP3;DICER1;DNASE2;ENDOG;ACIN1;EXOG;H1-0;DEDD2;CECR2;BLCAP
prerank,GO_Biological_Process_2021__ribonucleoprotein complex biogenesis (GO:0022613),-0.1621884659714637,-0.22550814231805663,1.0,0.9934184276683031,1.0,15/60,27.09%,EMG1;RPS6;CUL4A;XPO1;LTV1;SURF6;RPS17;NPM1;RIOK2;NOP16;PAK1IP1;BYSL;NOP14;RPS28;SHQ1
prerank,GO_Biological_Process_2021__heart contraction (GO:0060047),-0.16780727685004287,-0.22541555069428196,0.9770992366412213,0.9930991347238248,1.0,11/34,28.05%,TNNC1;GRK2;MYBPC3;RYR2;SCN4B;TNNI1;MYLK2;ATP1A2;CASQ2;KCNQ1;TPM1
prerank,"GO_Biological_Process_2021__maturation of SSU-rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) (GO:0000462)",-0.17128680734722251,-0.2244190744607545,0.9917355371900827,0.9930859514595521,1.0,7/29,18.97%,BMS1;UTP20;NOP9;RPS8;HEATR1;RPS21;RPP40
prerank,Reactome_2022__Cap-dependent Translation Initiation R-HSA-72737,0.1580058933083066,0.2233982758597034,0.9919354838709677,0.9963112082489979,1.0,42/114,31.95%,RPL15;EIF4A2;RPL19;RPS14;RPL22;EIF3C;RPL13A;RPL23;RPS27L;RPL12;RPL18;RPS27;RPL34;EIF3A;RPL39L;RPL37A;RPL5;RPL26;RPL4;RPL27;EIF3M;EIF5;RPL3L;RPS2;EIF4A1;EIF3K;RPL9;RPL31;MRPL13;RPS23;EIF3E;RPS9;RPS4Y1;PABPC1;EIF4EBP1;RPL7;RPS15;EIF1AX;EIF3L;EIF2S1;RPS20;RPL22L1
prerank,GO_Biological_Process_2021__ribosomal small subunit biogenesis (GO:0042274),-0.16446415361315644,-0.22173499026562485,0.975609756097561,0.993615401248457,1.0,12/39,29.48%,EMG1;TSR3;RPS6;LTV1;SURF6;RPS17;NPM1;RIOK2;NOP14;RPS28;RRP7A;LSM6
prerank,TRRUST_Transcription_Factors_2019__SMAD1 mouse,0.15022697464741233,0.2216869101370459,1.0,0.9965901328365672,1.0,10/21,35.69%,SMAD6;TNFSF11;HEY1;RUNX2;MSX2;SPP1;COL4A1;OVOL2;TBX20;ID3
prerank,"Reactome_2022__mRNA Activation Upon Binding Of Cap-Binding Complex And eIFs, Subsequent Binding To 43S R-HSA-72662",0.1653445613224136,0.22022307078493025,1.0,0.9967624975050823,1.0,24/57,35.50%,EIF4A2;RPS14;EIF3C;RPS27L;RPS27;EIF3A;EIF3M;RPS2;EIF4A1;EIF3K;RPS23;EIF3E;RPS9;RPS4Y1;PABPC1;EIF4EBP1;RPS15;EIF1AX;EIF3L;EIF2S1;RPS20;RPS25;EIF4H;RPS4X
prerank,Reactome_2022__Nonsense Mediated Decay (NMD) Independent Of Exon Junction Complex (EJC) R-HSA-975956,0.15543529976213186,0.21779960879635657,1.0,0.9971724429496265,1.0,32/90,31.95%,RPL15;RPL19;RPS14;RPL22;RPL13A;RPL23;RPS27L;RPL12;UPF1;RPL18;RPS27;RPL34;RPL39L;RPL37A;GSPT2;RPL5;RPL26;RPL4;RPL27;RPL3L;RPS2;RPL9;RPL31;MRPL13;RPS23;RPS9;RPS4Y1;PABPC1;RPL7;RPS15;RPS20;RPL22L1
prerank,GO_Biological_Process_2021__negative regulation of RNA metabolic process (GO:0051253),-0.1488531512914424,-0.21713562673759645,1.0,0.9946317859927554,1.0,6/19,32.79%,ZC3H12A;TNF;TGFB1;SHQ1;FCN3;PTBP2
prerank,Elsevier_Pathway_Collection__Keratinocyte Activation in Psoriatic Arthritis,-0.16557660675824012,-0.2160951476374523,0.9916666666666667,0.9945692336681603,1.0,12/40,26.36%,MAP2K7;IL22RA1;IL17RC;MMP1;MAP3K1;MAP2K2;TRAF3IP2;TRAF6;IL10RB;TNF;IL17RA;JAK1
prerank,Reactome_2022__Eukaryotic Translation Elongation R-HSA-156842,0.15651815900786104,0.2146289240874353,1.0,0.997843390879125,1.0,31/87,31.95%,RPL15;RPL19;RPS14;RPL22;RPL13A;RPL23;RPS27L;RPL12;RPL18;RPS27;EEF1B2;RPL34;RPL39L;RPL37A;RPL5;RPL26;RPL4;RPL27;RPL3L;RPS2;EEF2;RPL9;RPL31;MRPL13;RPS23;RPS9;RPS4Y1;RPL7;RPS15;RPS20;RPL22L1
prerank,GO_Biological_Process_2021__mitotic nuclear membrane organization (GO:0101024),0.1514637808485108,0.21184622225908248,0.9859154929577465,0.9980715291378742,1.0,12/51,21.13%,NDC1;CDK1;CHMP4A;NUP37;CHMP2A;NUP155;REEP4;NUP160;SEH1L;ANKLE2;SPAST;CHMP4C
prerank,GO_Biological_Process_2021__mitotic nuclear membrane reassembly (GO:0007084),0.1514637808485108,0.21184622225908248,0.9859154929577465,0.9980715291378742,1.0,12/51,21.13%,NDC1;CDK1;CHMP4A;NUP37;CHMP2A;NUP155;REEP4;NUP160;SEH1L;ANKLE2;SPAST;CHMP4C
prerank,"Reactome_2022__Formation Of Ternary Complex, And Subsequently, 43S Complex R-HSA-72695",0.15998269691572456,0.21070069453184398,1.0,0.9981120474168262,1.0,18/49,33.24%,RPS14;EIF3C;RPS27L;RPS27;EIF3A;EIF3M;RPS2;EIF3K;RPS23;EIF3E;RPS9;RPS4Y1;RPS15;EIF1AX;EIF3L;EIF2S1;RPS20;RPS25
prerank,Reactome_2022__Ribosomal Scanning And Start Codon Recognition R-HSA-72702,0.16055734880491615,0.20899500476070731,0.9921259842519685,0.9982128591648479,1.0,23/56,35.50%,EIF4A2;RPS14;EIF3C;RPS27L;RPS27;EIF3A;EIF3M;EIF5;RPS2;EIF4A1;EIF3K;RPS23;EIF3E;RPS9;RPS4Y1;RPS15;EIF1AX;EIF3L;EIF2S1;RPS20;RPS25;EIF4H;RPS4X
prerank,Reactome_2022__Translation Initiation Complex Formation R-HSA-72649,0.1572306374829104,0.20863307097403716,0.9922480620155039,0.9980108036363516,1.0,23/56,35.50%,EIF4A2;RPS14;EIF3C;RPS27L;RPS27;EIF3A;EIF3M;RPS2;EIF4A1;EIF3K;RPS23;EIF3E;RPS9;RPS4Y1;PABPC1;RPS15;EIF1AX;EIF3L;EIF2S1;RPS20;RPS25;EIF4H;RPS4X
prerank,Reactome_2022__Peptide Chain Elongation R-HSA-156902,0.15220631465028014,0.20729122411613105,0.992,0.9980395098840044,1.0,30/84,31.95%,RPL15;RPL19;RPS14;RPL22;RPL13A;RPL23;RPS27L;RPL12;RPL18;RPS27;RPL34;RPL39L;RPL37A;RPL5;RPL26;RPL4;RPL27;RPL3L;RPS2;EEF2;RPL9;RPL31;MRPL13;RPS23;RPS9;RPS4Y1;RPL7;RPS15;RPS20;RPL22L1
prerank,GO_Biological_Process_2021__positive regulation of transcription initiation from RNA polymerase II promoter (GO:0060261),-0.14821710041557665,-0.20716346552546414,0.991869918699187,0.9965484741334028,1.0,8/22,34.14%,PSMC5;MED17;MED24;HNF1B;MED1;HNF1A;PSMC2;MED14
prerank,Elsevier_Pathway_Collection__Proteins Involved in Diffuse Large-B-Cell Lymphoma,-0.15493097192446725,-0.20692689342255569,0.984375,0.9962625380835868,1.0,19/54,30.28%,TCL1A;BCL3;ING1;IDO1;RIPK4;PRDM2;BCL6;IRF4;HDAC3;MET;TNFSF13B;CCAR1;TGFB1;GMCL1;MALT1;HDAC4;SPIB;ALK;HSP90AA1
prerank,GO_Biological_Process_2021__base-excision repair (GO:0006284),-0.15353055577968072,-0.2061750808564607,0.9821428571428571,0.9960881394242151,1.0,20/48,34.39%,POLG;DNA2;MPG;RPA2;POLD2;WRN;OGG1;PCNA;POLB;NEIL3;POLD4;POLQ;XPA;NEIL1;LIG3;ERCC6;NEIL2;PNKP;ADPRS;POLD3
prerank,Reactome_2022__Eukaryotic Translation Termination R-HSA-72764,0.14588573213776934,0.2042817382247289,1.0,0.998479569155576,1.0,32/88,32.37%,RPL15;RPL19;RPS14;RPL22;RPL13A;RPL23;RPS27L;RPL12;RPL18;RPS27;RPL34;RPL39L;RPL37A;GSPT2;RPL5;RPL26;RPL4;RPL27;RPL3L;RPS2;RPL9;RPL31;MRPL13;RPS23;N6AMT1;RPS9;RPS4Y1;RPL7;RPS15;RPS20;RPL22L1;APEH
prerank,Elsevier_Pathway_Collection__Microangiopathy in Diabetic Neuropathy,-0.14048384607037173,-0.2018124119381276,0.9920634920634921,0.9966466615729402,1.0,9/23,35.95%,ICAM1;MAP3K1;MAP2K2;TGFB1;RAF1;MAP2K1;NFKBIA;IL6;FOS
prerank,WikiPathway_2021_Human__Translation Factors WP107,0.15567227669503758,0.20150912413407632,0.991869918699187,0.9987504189378641,1.0,16/50,31.60%,EIF2AK1;EIF4A2;EIF3CL;EIF3C;EEF1B2;EIF3A;GSPT2;EIF5;EEF2;EIF4EBP2;EIF4A1;EIF3E;PABPC1;EIF4EBP1;EIF1AX;EIF2S1
prerank,Reactome_2022__Selenocysteine Synthesis R-HSA-2408557,0.14467090145864922,0.19996096418934814,1.0,0.9987278206653146,1.0,31/88,31.95%,RPL15;RPL19;RPS14;RPL22;RPL13A;RPL23;RPS27L;RPL12;RPL18;RPS27;RPL34;RPL39L;RPL37A;RPL5;SECISBP2;RPL26;RPL4;RPL27;RPL3L;RPS2;RPL9;RPL31;MRPL13;RPS23;RPS9;SARS1;RPS4Y1;RPL7;RPS15;RPS20;RPL22L1
prerank,Reactome_2022__mRNA 3-End Processing R-HSA-72187,0.1470979197427427,0.198927292345686,1.0,0.998637170161721,1.0,18/57,30.98%,SRRM1;MAGOHB;THOC6;CDC40;THOC7;SRSF5;CPSF3;DDX39A;CSTF1;CPSF7;CSTF2T;EIF4A3;CSTF3;PCF11;SLU7;THOC3;PABPN1;SYMPK
prerank,Elsevier_Pathway_Collection__NTSR1 Expression Targets,0.132729876985265,0.19543014655256202,1.0,0.9989064288620455,1.0,5/26,21.15%,MAPK1;ELK1;MAPKAPK2;GRB2;EGFR
prerank,Reactome_2022__Viral mRNA Translation R-HSA-192823,0.1442165208238625,0.19379500451285395,1.0,0.9988955785984869,1.0,31/88,31.95%,RPL15;RPL19;RPS14;RPL22;RPL13A;RPL23;RPS27L;RPL12;RPL18;RPS27;RPL34;RPL39L;RPL37A;DNAJC3;RPL5;RPL26;RPL4;RPL27;XK;RPL3L;RPS2;RPL9;RPL31;MRPL13;RPS23;RPS9;RPS4Y1;RPL7;RPS15;RPS20;RPL22L1
prerank,WikiPathway_2021_Human__Sleep regulation WP3591,0.13456259579157204,0.18950919561319254,0.9923664122137404,0.9992025317698103,1.0,9/28,34.07%,CACNA1I;TH;OXTR;ADA;UTS2R;GRIN2A;DRD1;GHRL;PTGDS
prerank,GO_Biological_Process_2021__maturation of SSU-rRNA (GO:0030490),0.14022880793894762,0.18778024434310886,0.9920634920634921,0.9991301526198536,1.0,4/34,7.90%,RPS14;NOB1;NOL10;TSR2
prerank,GO_Biological_Process_2021__regulation of stem cell population maintenance (GO:2000036),-0.13304369098250338,-0.1871028429330669,1.0,0.9985786082008273,1.0,6/19,32.98%,CNOT3;TAF6L;CNOT1;ZC3H13;ESRRB;WNT9B
prerank,GO_Biological_Process_2021__cotranslational protein targeting to membrane (GO:0006613),0.13004612528236567,0.1851398237177085,1.0,0.9991571510925434,1.0,12/94,10.60%,RPL15;RPL19;ARL6IP1;RPS14;RPL22;RPL13A;RPL23;SRP54;RPL12;RPL18;RPS27;RPL34
prerank,Elsevier_Pathway_Collection__N2 Neutrophils in Tumor-Promoting Inflammation and Tumor Progression,0.13832018099697166,0.18454496749794144,1.0,0.99892933395215,1.0,9/34,24.11%,SMAD4;CXCR4;STAT3;TYK2;CCL5;MYC;TGFBR2;AKT1;PIK3R1
prerank,Reactome_2022__SARS-CoV-2 Modulates Host Translation Machinery R-HSA-9754678,-0.13175075863272687,-0.1821760435300273,0.991869918699187,0.9987584668571027,1.0,16/46,33.59%,SNRPF;RPS6;RPS8;RPS15A;RPS17;RPS21;GEMIN7;RPS28;RPS10;SNRPG;RPS11;SNRPD2;DDX20;RPS3;SNRPB;RPS5
prerank,Reactome_2022__Response Of EIF2AK4 (GCN2) To Amino Acid Deficiency R-HSA-9633012,0.12987933577152105,0.1812050309984537,1.0,0.9989681316828959,1.0,32/96,31.95%,RPL15;RPL19;RPS14;RPL22;RPL13A;RPL23;RPS27L;RPL12;RPL18;RPS27;RPL34;RPL39L;RPL37A;RPL5;GDNF;RPL26;RPL4;RPL27;RPL3L;RPS2;RPL9;RPL31;MRPL13;RPS23;RPS9;RPS4Y1;RPL7;RPS15;EIF2S1;EIF2AK4;RPS20;RPL22L1
prerank,GO_Biological_Process_2021__cytoplasmic translation (GO:0002181),0.12755156372053547,0.18118136669655524,1.0,0.9986830419905846,1.0,33/93,33.24%,RPL15;EIF4A2;RPL19;RPS14;RPL22;RPL13A;RPL23;RPL12;RPL18;RPS27;RPL34;RPL37A;GSPT2;RPL5;RPL26;RPL4;RPL27;EIF3M;RPS2;EIF4A1;RPL9;RPL31;RPS23;TMA7;RPS9;RPS18;RPL7;RPS15;RPS20;RPL22L1;ZC3H15;RPL10;RPS25
prerank,Elsevier_Pathway_Collection__Contraction Due Vasospasm,0.1275412521937758,0.18044107061646206,0.9924812030075187,0.9984686164282338,1.0,9/36,25.79%,GNA15;RHOA;MAPK1;TBXA2R;ARHGEF1;EDNRB;EDN1;GNAI1;ADRA1B
prerank,WikiPathway_2021_Human__Cytoplasmic Ribosomal Proteins WP477,-0.1301902900282545,-0.17979347633030635,1.0,0.9985884281085187,1.0,23/88,26.09%,RPL39;RPS6;RPLP0;RPL28;RPS6KB2;RPS8;RPS15A;UBA52;RPL10A;RPS17;RPL23A;RPL30;RPL41;RPS21;RPL36;RPL13;RPL37;RPL8;RPL3;RPLP1;RPS28;RPS10;RPL21
